"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT04359303","Indirect Endovenous Systemic Ozone for New Coronavirus Disease (COVID19) in Non-intubated Patients","OzonoCOVID19","Not yet recruiting","No Results Available","COVID","Other: Systemic indirect endovenous ozone therapy","COVID19 clinical scale|Number of died patients|Oro/nasopharynx virus|Thorax imaging (0=none; 1=unilateral; 2=bilateral; 3=ground-glass opacification; 4=consolidation)|Days in hospital|Venous gas blood analysis","Javier Hidalgo Tallón|Sociedad Española de Ozonoterapia|Universidad Católica San Antonio de Murcia","All","18 Years and older   (Adult, Older Adult)","Phase 3","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","P.Inv. Ozono-COVID19 Ver.1.2","July 2020","November 2020","December 2020","April 24, 2020",,"June 23, 2020","SEOT, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT04359303"
2,"NCT04427254","Study of the Sars-Cov2 Neuroinvasiveness - COVID19","CORONEVRAXE","Not yet recruiting","No Results Available","COVID19","Drug: Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies","Percentage of patients with COVID-19 positive samples/biopsies","Fondation Ophtalmologique Adolphe de Rothschild","All","18 Years and older   (Adult, Older Adult)","Not Applicable","500","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","PBN_2020_16","June 2020","June 2022","June 2022","June 11, 2020",,"June 11, 2020","Fondation A de Rothschild, Paris, France",,"https://ClinicalTrials.gov/show/NCT04427254"
3,"NCT04377685","Prediction of Clinical Course in COVID19 Patients","COVID-CTPRED","Recruiting","No Results Available","COVID 19","Other: CT-Scan","diagnostic of COVID disease composite","Centre Hospitalier Universitaire de Saint Etienne|Institut National des Sciences Appliquées (INSA)|Institut National de la Santé Et de la Recherche Médicale, France|Centre National pour le Recherche Scientifique (CNRS)|Université de Lyon|Université Jean Monnet","All","18 Years and older   (Adult, Older Adult)",,"800","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","20CH109|IRBN652020/CHUSTE","March 1, 2020","September 30, 2020","September 30, 2020","May 6, 2020",,"May 18, 2020","Chu Saint-Etienne, Saint-Étienne, France",,"https://ClinicalTrials.gov/show/NCT04377685"
4,"NCT04386668","Let It Out (LIO) and COVID19: Testing an Online Emotional Disclosure-based Intervention During the COVID19 Pandemic","LIO-C","Not yet recruiting","No Results Available","COVID19","Other: Let It Out (LIO)-C|Other: Neutral writing control","Kessler Psychological Distress Scale (K10)|Perceived Stress Scale (PSS-10)|Pittsburgh Sleep Quality Index (PSQI)|Self-compassion scale (SCS)|UCLA Loneliness Scale (UCLA LS)|Uptake of existing mental health services (MHS)|Mood and meaning|Acceptability","University College, London","All","18 Years and older   (Adult, Older Adult)","Not Applicable","286","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other","15281/003","May 2020","September 2020","November 2020","May 13, 2020",,"May 15, 2020",,,"https://ClinicalTrials.gov/show/NCT04386668"
5,"NCT04396067","Combination With Inhibitor of Neutrophil Elastase (All-trans Retinoic Acid ) and Isotretinoin May Enhances Neutralizing Antibodies in COVID -19 Infected Patients Better Than COVID-19 Inactivated Vaccines","Antibodies","Not yet recruiting","No Results Available","COVID -19","Drug: Aerosolized 13 cis retinoic acid|Drug: Aerosolized All trans retinoic acid|Other: Placebo","lung injury score|Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon|Serum level of COVID19 RNA|d-dimers|Absolute lymphocyte counts|The immune correlates of protection against future exposure to SARS-CoV-2|Immunological profile|Total duration of mechanical ventilation, ventilatory weaning and curarisation|Occurrence of adverse event related to immunoglobulins|IgG, IgA and IgM against COVID-19|ACE2 expression in patients with COVID-19 infection|All cause mortality rate [|Ventilation free days|ICU free days","Kafrelsheikh University|Damietta University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","360","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID-19","June 2020","September 2020","November 2020","May 20, 2020",,"June 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04396067"
6,"NCT04379284","Risks of COVID19 in the Pregnant Population",,"Not yet recruiting","No Results Available","COVID19","Other: Biospecimen collection","Determine the prevalence of maternal fetal transmission of COVID19|Describe the outcomes of COVID19 positive pregnancies|Understand the placental impact of COVID19 in pregnancy at various gestational ages","Mayo Clinic","Female","18 Years to 45 Years   (Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","20-003251","May 5, 2020","April 30, 2021","July 31, 2021","May 7, 2020",,"May 11, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04379284"
7,"NCT04349371","Saved From COVID-19",,"Recruiting","No Results Available","COVID","Drug: Chloroquine|Drug: Placebo oral tablet","Number of symptomatic illness in at risk healthcare workers|Number of healthcare workers with symptomatic COVID infections|Number of severe illness in at risk healthcare workers|Number of sero-conversions in at risk healthcare workers|Percentage of patients with adverse events Grade 3 or higher|Percentage of patients with GI intolerance","Columbia University","All","18 Years and older   (Adult, Older Adult)","Phase 2","350","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","AAAS9992","April 2020","April 2021","April 2021","April 16, 2020",,"April 21, 2020","Columbia University Irving Medical Center/NYP, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04349371"
8,"NCT04346446","Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients",,"Completed","No Results Available","COVID","Drug: Convalescent Plasma Transfusion|Other: Supportive Care|Drug: Random Donor Plasma","Proportion of patients remaining free of mechanical ventilation in both groups|Mortality in both groups|Improvement in Pa02/Fi02 ratio in both groups|Improvement in SOFA score in both groups|Duration of hospital Stay in both group.|Duration of Intensive Care Unit stay in both groups.|Requirements of Vasopressor in both groups.|Days free of dialysis in both groups.","Institute of Liver and Biliary Sciences, India","All","18 Years and older   (Adult, Older Adult)","Phase 2","29","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ILBS-COVID-02","April 20, 2020","May 30, 2020","May 30, 2020","April 15, 2020",,"June 12, 2020","Maulana Azad medical College, New Delhi, Delhi, India|Institute of Liver and Biliary Sciences, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT04346446"
9,"NCT04449094","Emergence of the COVID 19 Epidemic in the City of Nice",,"Completed","No Results Available","COVID",,"Attack rate","Centre Hospitalier Universitaire de Nice","All","Child, Adult, Older Adult",,"200","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Retrospective","20dspcovid01","February 28, 2020","March 30, 2020","April 4, 2020","June 26, 2020",,"June 26, 2020","CHU de Nice, Nice, France",,"https://ClinicalTrials.gov/show/NCT04449094"
10,"NCT04388436","Post Covid-19 Cardiopulmonary and Immunological Changes","covid-19","Active, not recruiting","No Results Available","COVID",,"measurement of pulmonary function changes either obstructive or restrictive also lung diffusion and if there is remaining interstitial fibrosis|measurement for cardiac function and ejection fraction changes and if there is changes in pulmonary artery pressure|assessment of IGM and IGG level and if there is immunological changes","Mansoura University","All","Child, Adult, Older Adult",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20.05.67","May 11, 2020","July 10, 2021","October 10, 2021","May 14, 2020",,"May 19, 2020","Mansoura faculty of medicine, Mansoura, Dakahlia, Egypt",,"https://ClinicalTrials.gov/show/NCT04388436"
11,"NCT04433988","Efficacy of Pentoxifylline as Add on Therapy in COVID19 Patients",,"Not yet recruiting","No Results Available","COVID","Drug: Pentoxifylline|Drug: Placebo","Primary Outcome|Respiratory infection|Serious Adverse Events","Sadat City University","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","RC-6-2020","June 13, 2020","August 30, 2020","August 30, 2020","June 16, 2020",,"June 16, 2020","Faculty of Medicine, Shibīn Al Kawm, Egypt",,"https://ClinicalTrials.gov/show/NCT04433988"
12,"NCT04345419","A Real-life Experience on Treatment of Patients With COVID 19",,"Recruiting","No Results Available","COVID","Drug: Chloroquine|Drug: Favipiravir|Drug: Nitazoxanide|Drug: Ivermectin|Drug: Niclosamide|Drug: Other drugs","Number of patients with decreased viral load","Tanta University","All","Child, Adult, Older Adult","Phase 2|Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","COVID 19 treatment","June 16, 2020","December 2029","December 2029","April 14, 2020",,"June 18, 2020","Tanta university hospital, Tanta, Egypt",,"https://ClinicalTrials.gov/show/NCT04345419"
13,"NCT04334291","International COVID19 Clinical Evaluation Registry,","HOPE COVID 19","Recruiting","No Results Available","COVID 19","Combination Product: Observational (registry)","Death|In hospital stay.|Heart failure|Renal failure|Respiratory Insufficiency.|Upper respiratory tract involvement|Pneumonia|Sepsis|Systemic inflammatory response Syndrome.|Clinically relevant bleeding|Other complications.","IVAN J NUÑEZ GIL|St Carlos Hospital, Madrid, Spain","All","Child, Adult, Older Adult",,"6000","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","20/241-E|EUPAS34399","March 23, 2020","May 1, 2020","May 5, 2020","April 6, 2020",,"April 28, 2020","Hospital Lclinico San Carlos, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04334291"
14,"NCT04354753","AiM COVID for Covid 19 Tracking and Prediction",,"Completed","No Results Available","COVID 19","Other: No Intervention","Physical symptoms|Contact History|Travel History|Fever|Headache|Soar Throat|Runny nose|Cough|Shortness of breath|Nausea|Vomiting|Muscle pain|Joint pain|Diarrhoea|Other|Hospitalisation history|Co-morbid conditions","Aarogyam UK|University of Warwick|Igor Sikorsky Kyiv Polytechnic Institute|ClickMedix LLC","All","18 Years and older   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","AU12","March 28, 2020","April 14, 2020","April 17, 2020","April 21, 2020",,"April 21, 2020","Aarogyam (UK), Leicester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04354753"
15,"NCT04408157","A Research Study to Evaluate the Benefits of a Self-management Booklet to Promote Wellbeing During the COVID-19 Pandemic","SWitCh","Not yet recruiting","No Results Available","COVID","Behavioral: Self-management booklet (SWitCh: Stay well during COVID-19)","Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS): Tennant et al., 2007|Self-rated health status: Bombak, 2013|Brief Resilience Scale (BRS): Smith et al., 2008|Intolerance of Uncertainty Scale (IUS-12): Carleton et al., 2007|Positive Affect subscale of the Positive and Negative Affect Scale-X (PANAS-X): Watson & Clark, 1999|UCLA 3 item loneliness scale: Russell, 1996|Multidimensional Scale of Perceived Social Support (MSPSS): Zimet et al., 1988|Subjective Health Complaint Scale (SHC): Eriksen, Ihlebæk, & Ursin, 1999|Leeds Sleep Evaluation Questionnaire (LSEQ): Parrott & Hindmarch, 1980|Self-reported napping: Stone et al., 2018|Work and Social Adjustment Scale (WSAS): Mundt et al., 2002|International Physical Activity Questionnaire -short form (IPAQ-SF): Craig et al., 2003","King's College London","All","18 Years and older   (Adult, Older Adult)","Not Applicable","548","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","v1.1 06.05.2020","May 20, 2020","May 22, 2021","June 22, 2021","May 29, 2020",,"May 29, 2020",,,"https://ClinicalTrials.gov/show/NCT04408157"
16,"NCT04404218","The Açaí Berry COVID-19 Anti-Inflammation Trial","ACAI","Not yet recruiting","No Results Available","COVID","Dietary Supplement: Açaí palm berry extract - natural product|Other: Placebo","7-point ordinal symptom scale|The composite of all-cause mortality and need for mechanical ventilation|The composite of all-cause mortality and hospitalization|All-cause mortality|Need for mechanical ventilation|Need for hospitalization","University Health Network, Toronto|University of Toronto","All","40 Years and older   (Adult, Older Adult)","Phase 2","480","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CTO3176","May 2020","November 2020","May 2021","May 27, 2020",,"May 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04404218"
17,"NCT04347460","Establishing a COVID-19 Prospective Cohort for Identification of Secondary HLH","COVIDHLH","Recruiting","No Results Available","COVID",,"Presence of sHLH as determined by expert chart review by two independent reviewers|Determine the incidence of patients fulfilling HLH criteria in Covid 19 viral infection|Determine the incidence of patients fulfilling modified 2004 HLH diagnostic criteria (Ferritin > 10000 μg/L) in Covid 19 viral infection|Characterization and incidence of the hyper-inflammatory state in COVID-19|all cause mortality assesed on day 15|all cause mortality assesed on day 29|immunophenotpye","Technische Universität München","All","18 Years and older   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","161/20 S","March 27, 2020","July 1, 2020","August 31, 2020","April 15, 2020",,"April 15, 2020","Department of nephrology, Klinikum rechts der Isar, München, Bavaria, Germany",,"https://ClinicalTrials.gov/show/NCT04347460"
18,"NCT04366271","Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19","MESCEL-COVID19","Recruiting","No Results Available","COVID","Biological: Mesenchymal cells|Drug: Standard of care","Mortality due to lung involvement due to SARS-CoV-2 virus infection at 28 days of treatment|Mortality due to lung involvement due to SARS-CoV-2 virus infection at 14 days of treatment|Mortality from any cause at 28 days|Days without mechanical respirator and without vasopressor treatment for 28 days|Patients alive without mechanical ventilation and without vasopressors on day 28|Patients alive and without mechanical ventilation on day 14|Patients alive and without mechanical ventilation on day 28|Patients alive and without vasopressors on day 28|Days without vasopressors for 28 days|Patients cured at 15 days|Incidence of Treatment-Emergent Adverse Events","Hospital Infantil Universitario Niño Jesús, Madrid, Spain|Apices Soluciones S.L.","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 2","106","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MESCEL-COVID19|2020-001450-22","May 7, 2020","July 31, 2020","May 31, 2021","April 28, 2020",,"May 11, 2020","Hospital Universitario de Getafe, Getafe, Madrid, Spain|Hospital Universitario de Cruces, Barakaldo, Spain|Hospital Universitario de La Princesa, Madrid, Spain|Hospital Infantil Universitario Niño Jesus, Madrid, Spain|Hospital Ramón Y Cajal, Madrid, Spain|Complejo Universitario La Paz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04366271"
19,"NCT04373824","Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study",,"Recruiting","No Results Available","COVID","Drug: Ivermectin","effect of Ivermectin on eradication of virus.","Max Healthcare Insititute Limited","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MHC-COVID-19- INV- ACT-BHR","April 25, 2020","July 25, 2020","July 25, 2020","May 4, 2020",,"May 4, 2020","Max Super Speciality hospital, Saket (A unit of Devki Devi Foundation), New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT04373824"
20,"NCT04343092","Efficacy of Ivermectin as Add on Therapy in COVID19 Patients",,"Completed","No Results Available","COVID 19","Drug: Ivermectin (IVM)","Number of cured patients|Mean time to cure of the covid 19 patients","University of Baghdad","All","18 Years and older   (Adult, Older Adult)","Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PRO20040001","April 18, 2020","May 31, 2020","June 1, 2020","April 13, 2020",,"June 5, 2020","General Directorate of Medical City, Bagdad, Baghdad, Iraq",,"https://ClinicalTrials.gov/show/NCT04343092"
21,"NCT04338126","Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients","TCInpatient","Not yet recruiting","No Results Available","COVID19","Drug: Tranexamic acid|Drug: Placebo oral tablet","Admission to Intensive Care Unit","University of Alabama at Birmingham","All","19 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TXACOVID2","September 30, 2020","December 15, 2020","December 31, 2020","April 8, 2020",,"June 11, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT04338126"
22,"NCT04433039","COVID19 Versus H1N1: Radiological Challenge During Next Influenza Season Rising",,"Completed","No Results Available","COVID",,"COVID19 versus H1N1; radiological comparative study","Alexandria University","All","4 Years to 80 Years   (Child, Adult, Older Adult)",,"130","Other","Observational","Observational Model: Case-Crossover|Time Perspective: Retrospective","IRB (00012098), SN (0304669)","May 22, 2020","June 12, 2020","June 14, 2020","June 16, 2020",,"June 16, 2020","Faculty of Medicine, University of Alexandria, Alexandria, Egypt",,"https://ClinicalTrials.gov/show/NCT04433039"
23,"NCT04401098","Changing Of Egyptian Population Behaviour Towards COVID 19 Outbreak",,"Recruiting","No Results Available","COVID 19",,"awareness of Egyptian population","Damanhour University","All","Child, Adult, Older Adult",,"700","Other","Observational","Observational Model: Other|Time Perspective: Prospective","covid 19","May 2, 2020","October 1, 2020","April 1, 2021","May 26, 2020",,"May 26, 2020","Damanhour University, Damanhūr, Beheira, Egypt",,"https://ClinicalTrials.gov/show/NCT04401098"
24,"NCT04363008","COVID 19 Biomarkers",,"Recruiting","No Results Available","COVID 19","Diagnostic Test: serum inflammatory biomarkers","Inflammation|Oxygenation|Chronic Pulmonary outcomes|Pulmonary artery pressure using transthoracic echocardiography|Exertion|Quality of life assessment","University of British Columbia","All","Child, Adult, Older Adult",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","H20-00971","March 30, 2020","April 30, 2020","September 30, 2021","April 27, 2020",,"May 8, 2020","Vancouver General Hospital, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT04363008"
25,"NCT04379297","COvid-19 National Survey for Assessing VIral Spread by Nonaffected CarriErs (CON-VINCE)","CON-VINCE","Active, not recruiting","No Results Available","COVID19",,"Prevalence and dynamics of the SARS-COV 2 infection in Luxemburg|Collection of samples for research|Psycho-social evaluation","Luxembourg Institute of Health|Luxembourg National Research Funds|University of Luxembourg/ Luxembourg Centre for Systems Biomedicine|Centre Hospitalier du Luxembourg|TNS-Ilres|Laboratoires Réunis|BioneXt Lab|Ketterthill|Laboratoire National de santé","All","18 Years and older   (Adult, Older Adult)",,"1800","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CNER 202004/01|831x6ce0d|FNR/CON-VINCE","April 10, 2020","May 28, 2021","December 31, 2021","May 7, 2020",,"May 7, 2020","Luxembourg Institute of Health, Strassen, Luxembourg",,"https://ClinicalTrials.gov/show/NCT04379297"
26,"NCT04353154","The RAPID COVID TRIAGE Algorithm",,"Not yet recruiting","No Results Available","COVID","Diagnostic Test: Spartan Cube Point-of Care Covid-19 test","Sensitivity","Ottawa Heart Institute Research Corporation","All","18 Years and older   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20200228-01H","April 15, 2020","August 31, 2020","February 28, 2021","April 20, 2020",,"April 20, 2020",,,"https://ClinicalTrials.gov/show/NCT04353154"
27,"NCT04419610","RAS and Coagulopathy in COVID19",,"Not yet recruiting","No Results Available","COVID","Biological: TRV027|Other: sodium chloride 0.9%","Coagulopathy associated with COVID-19|Markers of dysregulation of coagulation system|Markers of dysregulation of RAS|Markers of Haemolysis/inflammation|Markers of Haemolysis/Inflammation|Markers of organ dysregulation - kidney|Markers of dysregulation of cardiovascular system|marker of dysregulation of endocrine system","Imperial College London","All","65 Years and older   (Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Health Services Research","283093","July 2020","August 2020","January 2021","June 5, 2020",,"June 17, 2020",,,"https://ClinicalTrials.gov/show/NCT04419610"
28,"NCT04359537","Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19","CHEER","Recruiting","No Results Available","COVID 19","Drug: Hydroxychloroquine Sulfate 200 MG|Other: Placebo","COVID-19-free survival in experimental arms compared to placebo|Incidence of confirmed SARS-COV-2 detection|Incidence of possible COVID-19 symptoms|Incidence of all-cause study medicine discontinuation|Ordinal Scale of COVID-19 Disease maximum severity if COVID-19 diagnosed at study end|Incidence of Hospitalization for COVID-19 or death|Incidence of study medication-related adverse events","Shaheed Zulfiqar Ali Bhutto Medical University","All","18 Years to 60 Years   (Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","F.1-1/2015/ERB/SZABMU/549","May 1, 2020","August 25, 2020","September 25, 2020","April 24, 2020",,"May 19, 2020","Shaheed Zulfiaqar Ali Bhutto Medical University, Islamabad, Federal Capital, Pakistan",,"https://ClinicalTrials.gov/show/NCT04359537"
29,"NCT04438863","Daily Home Spirometry for Early Detection of Pulmonary Complications in Patients With COVID19",,"Not yet recruiting","No Results Available","COVID 19","Diagnostic Test: home spirometry","Hospitalization","Sheba Medical Center","All","18 Years to 85 Years   (Adult, Older Adult)",,"90","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SHEBA-20-7022-SMC-LL-CTIL","September 1, 2020","September 1, 2021","September 1, 2021","June 19, 2020",,"June 19, 2020",,,"https://ClinicalTrials.gov/show/NCT04438863"
30,"NCT04407299","COVID-19 Impact on Rheumatic Patients",,"Completed","No Results Available","COVID","Behavioral: self-administered structured questionnaire","Score of five-item Brief Symptom Rating Scale (BSRS-5)","Cairo University","All","16 Years and older   (Child, Adult, Older Adult)",,"360","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","COVID-19Rheum","April 20, 2020","May 10, 2020","May 20, 2020","May 29, 2020",,"May 29, 2020","Kasr Alainy Hospital, Cairo, Non-US/Non-Canadian, Egypt",,"https://ClinicalTrials.gov/show/NCT04407299"
31,"NCT04381871","Potential Role of Gum Arabic as Immunomodulatory Agent Among COVID 19 Patients","GA&COVID19","Not yet recruiting","No Results Available","COVID 19","Dietary Supplement: Acacia Senegal|Dietary Supplement: Pectin","Mean change from baseline score of Immune Response to end of the trial ( Time Frame: up to 4 weeks )|Mortality rate|Determine viral load in each patient","Al-Neelain University|University of Khartoum","All","5 Years to 90 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GA& COVID19","June 1, 2020","August 1, 2020","September 1, 2020","May 11, 2020",,"May 12, 2020","Omdurman Teaching Hospital, Khartoum, Omdurman, Sudan|Jabra Hospital,, Khartoum, Sudan",,"https://ClinicalTrials.gov/show/NCT04381871"
32,"NCT04328272","Effectiveness of Hydroxychloroquine in Covid-19 Patients","Covid","Not yet recruiting","No Results Available","COVID19","Drug: Hydroxychloroquine 200 Mg Oral Tablet|Drug: Azithromycin 500Mg Oral Tablet|Dietary Supplement: Glucose tablets","National Early Warning Score equal to zero|C-reactive proteins|Lymphocyte Count|d-dimers","Prof. Dr. Umar Farooq|Ayub Medical College, Abbottabad","All","18 Years to 50 Years   (Adult)","Phase 3","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Ath/ct101/22/3","March 28, 2020","May 28, 2020","June 28, 2020","March 31, 2020",,"April 2, 2020","Ayub Teaching Institution, Abbottābād, K.p.k, Pakistan",,"https://ClinicalTrials.gov/show/NCT04328272"
33,"NCT04426344","Core Warming of COVID-19 Patients",,"Not yet recruiting","No Results Available","COVID 19","Device: ensoETM device","Viral load measured in tracheal aspirate 72 hours after initiation of core warming|PaO2/FiO2 ratio 72 hours after initiation of core warming|Duration of mechanical ventilation","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","202005150","June 2020","November 2020","November 2020","June 11, 2020",,"June 11, 2020","Barnes-Jewish Hospital, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04426344"
34,"NCT04345679","Anti COVID-19 Convalescent Plasma Therapy",,"Not yet recruiting","No Results Available","COVID 19","Biological: anti-SARS-CoV-2 convalescent plasma","Changing of viral load of SARS-CoV2|Changes in immunglobulin G COVID-19 antibody titer|Changes at the cytokine pattern|Intensive Care Unit Admission|Length of hospital stay|Duration of mechanical ventilation|Clinical Status|Mortality","Orthosera Kft.|Semmelweis University|University of Pécs|Hungarian National Blood Service|Humán Bioplazma Kft - Kedrion","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AntiCOVID19ORT","April 14, 2020","June 1, 2020","April 1, 2021","April 14, 2020",,"April 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04345679"
35,"NCT04365582","OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome","OUTCOV","Recruiting","No Results Available","COVID","Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Lopinavir 200Mg/Ritonavir 50Mg Tab","Hospital admission|Effect of treatment on Death at D20|Effect of treatment on Death at D60|Effect of treatment on Death due to COVID at D20|Effect of treatment on Death due to COVID at D60|Effect of treatment on need for ICU stay at D20|Effect of treatment on need for ICU stay at D60|Effect of treatment on duration of ICU stay at D20|Effect of treatment on duration of ICU stay at D60|Effect of treatment on need of mechanical ventilation at D20|Effect of treatment on need of mechanical ventilation at D60|Effect of treatment on duration of mechanical ventilation at D20|Effect of treatment on duration of mechanical ventilation at D60|Effect of treatment on time to hospitalization at D20|Effect of treatment on time to hospitalization at D60|Effect of treatment on Duration of Hospital stay et D20|Effect of treatment on Duration of Hospital stay et D60|Effect of treatment on Duration of symptoms at D20|Effect of treatment on Duration of symptoms at D60|Incidence of Treatment-Emergent Adverse Events","Groupe Hospitalier Paris Saint Joseph","All","50 Years and older   (Adult, Older Adult)","Phase 3","640","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OUTCOV","May 7, 2020","August 7, 2020","February 7, 2021","April 28, 2020",,"June 18, 2020","Hôpital Privé d'Antony, Antony, France|Hôpital Avicenne, Bobigny, France|Centre Hospitalier Intercommunal de Créteil, Créteil, France|Groupe Hospitalier Paris Saint-Joseph, Paris, France|Institut Mutualiste Montsouris, Paris, France",,"https://ClinicalTrials.gov/show/NCT04365582"
36,"NCT04349540","Role of Immune and Inflammatory Response in Recipients of Allogeneic Haematopoietic Stem Cell Transplantation (SCT) Affected by Severe COVID19","(COVID19_BMT)","Active, not recruiting","No Results Available","COVID19","Other: no intervention","Comparison of inflammatory/immunological biomarkers <72 hours after development of oxygen requirement|Overall survival at 30 and 100 days after development of oxygen requirement|Comparison of 30 and 100 day survival in SCT patients who are vs are not ongoing immunosuppression|Proportion of patients requiring mechanical ventilation|Incidence of secondary HLH (as defined by HS score)","Great Ormond Street Hospital for Children NHS Foundation Trust","All","3 Months and older   (Child, Adult, Older Adult)",,"40","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","20BO08","April 15, 2020","October 15, 2020","January 15, 2021","April 16, 2020",,"April 16, 2020","Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04349540"
37,"NCT04393402","Lung Ultrasound Score in Covid 19 Infectious Disease in Critical Care (LUS-COVID19)","LUS-COVID19","Recruiting","No Results Available","COVID","Procedure: lung ultrasound (LUS)","LUS applicability with COVID 19|Radiographic correlation (chest Xray and tomodensitometry)|LUS Mortality prediction|Prediction of Prone position response","Centre Hospitalier Universitaire de Nice","All","18 Years to 95 Years   (Adult, Older Adult)",,"14","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20reamedcovid03","March 20, 2020","December 31, 2020","December 31, 2020","May 19, 2020",,"May 19, 2020","CHU de Nice, Nice, France",,"https://ClinicalTrials.gov/show/NCT04393402"
38,"NCT04338906","Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19","CLOCC","Not yet recruiting","No Results Available","COVID","Drug: Camostat Mesilate|Drug: Placebo|Drug: Hydroxychloroquine","Not hospitalized|Time to improvement of 2 categories from admission on a 7-point ordinal scale|Proportion of participants in each group with normalization of fever|Proportion of participants in each group with oxygen saturation > 94% on room air for >24h|Time to fever normalization (if febrile at baseline)|Time to first negative SARS-CoV-2 PCR in NP swap (if pos. at baseline)|Time to first negative SARS-CoV-2 PCR in lower respiratory tract specimens (sputum, bronchoalveolar lavage, tracheal aspirate) (if positive at baseline)|Duration of oxygen therapy|Proportion of participants in each group with need for mechanical ventilation|Duration of hospitalization|All cause mortality","Heinrich-Heine University, Duesseldorf|Universitätsklinikum Hamburg-Eppendorf|University Hospital, Frankfurt|St. Georg Hospital Leipzig, Germany|Hospital Schwabing Munich, Germany|Missioklinik, Wuerzburg, Germany","All","18 Years and older   (Adult, Older Adult)","Phase 4","334","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLOCC-2020","June 1, 2020","June 1, 2021","December 31, 2021","April 8, 2020",,"April 8, 2020",,,"https://ClinicalTrials.gov/show/NCT04338906"
39,"NCT04359329","Estrogen Patch for COVID-19 Symptoms",,"Recruiting","No Results Available","COVID","Drug: Estradiol patch","Rate of Hospitalization|Rate of Transfer to Intensive Care Unit|Rate of Intubation|Rate of Death","Sharon Nachman|Stony Brook University","All","18 Years and older   (Adult, Older Adult)","Phase 2","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SBU-EstrogenPatch-COVID19","April 20, 2020","November 15, 2020","November 15, 2020","April 24, 2020",,"April 24, 2020","Stony Brook University Hospital, Stony Brook, New York, United States",,"https://ClinicalTrials.gov/show/NCT04359329"
40,"NCT04383626","Fear Among Dentists During COVID-19 Pandemic",,"Completed","No Results Available","COVID",,"fear among dentist during COVID 19 epidemic|practice modification among dentist during COVID 19 epidemic","Cairo University","All","20 Years and older   (Adult, Older Adult)",,"216","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","COVID-19 pandemic","March 2, 2020","April 5, 2020","May 5, 2020","May 12, 2020",,"May 12, 2020","Cairo University, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04383626"
41,"NCT04447469","Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation",,"Not yet recruiting","No Results Available","COVID","Drug: mavrilimumab|Other: Placebo","Cohort 1: Proportion of Participants Alive and Without Respiratory Failure at Day 15|Cohort 2: Mortality Rate at Day 15|Cohort 1: Time to Return to Room Air by Day 15|Cohort 1: Time to 2-point Clinical Improvement by Day 15|Cohort 1: Mortality Rate at Day 29|Cohort 1: Time to 1-Point Clinical Improvement by Day 15|Cohort 2: Mortality Rate at Day 29|Cohort 2: Proportion of Participants Alive and Without Respiratory Failure at Day 15|Cohorts 1 and 2: Proportion of Participants Alive and Without Respiratory Failure At Day 29|Cohorts 1 and 2: Time to Return to Room Air by Day 29|Cohort 2: Time to 2-point Clinical Improvement by Day 15|Cohorts 1 and 2: Time to 1-point Clinical Improvement by Day 29|Cohorts 1 and 2: Time to 2-point Clinical Improvement by Day 29|Cohort 1: Respiratory Failure-Free Survival by Day 15|Cohort 1: Respiratory Failure-Free Survival by Day 29|Cohort 1: Proportion of Participants Who Return to Room Air by Day 15|Cohorts 1 and 2: Proportion of Participants Who Return to Room Air by Day 29|Cohort 1: Mortality Rate at Day 15|Cohorts 1 and 2: Overall Survival by Day 29|Cohorts 1 and 2: Clinical Status Over Time|Cohorts 1 and 2: Number of Days Alive and Out of Hospital Through Day 90","Kiniksa Pharmaceuticals, Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","573","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","KPL-301-C203","June 2020","February 2021","April 2021","June 25, 2020",,"June 25, 2020","Tulane Medical Center, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT04447469"
42,"NCT04383548","Clinical Study for Efficacy of Anti-Corona VS2 Immunoglobulins Prepared From COVID19 Convalescent Plasma Prepared by VIPS Mini-Pool IVIG Medical Devices in Prevention of SARS-CoV-2 Infection in High Risk Groups as Well as Treatment of Early Cases of COVID19 Patients",,"Not yet recruiting","No Results Available","COVID19","Other: hyper immunoglobulins containing anti-Corona VS2 immunoglobulin","Efficacy of COVID19 hyper immunoglobulins for patients|Efficacy of COVID19 hyper immunoglobulins for high risk groups|Safety of anti-SARS-CoV-2 hyper immunoglobulins assessed by percentage of adverse events","Assiut University","All","21 Years to 50 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Mini-pooled IVIG in COVID19","June 1, 2020","December 1, 2020","January 1, 2021","May 12, 2020",,"May 12, 2020",,,"https://ClinicalTrials.gov/show/NCT04383548"
43,"NCT04407390","Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly","NR-COVID19","Recruiting","No Results Available","COVID","Dietary Supplement: Nicotinamide riboside|Dietary Supplement: Placebo","Hypoxic respiratory failure|Mortality|Sepsis|Circulatory failure|Days in hospital|NAD levels","University of Copenhagen|Bispebjerg Hospital|Elysium Health","All","70 Years and older   (Older Adult)","Phase 2","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H-20026601","June 1, 2020","May 1, 2021","May 1, 2022","May 29, 2020",,"June 2, 2020","Bispebjerg Hospital, Copenhagen NV, Denmark",,"https://ClinicalTrials.gov/show/NCT04407390"
44,"NCT04411446","Cholecalciferol to Improve the Outcomes of COVID-19 Patients","CARED","Not yet recruiting","No Results Available","COVID","Drug: Vitamin D|Drug: Placebo","Respiratory SOFA.|Need of a high dose of oxygen or mechanical ventilation.|Change in oxygen saturation.|Oxygen desaturation.|Change in Quick SOFA score.|Myocardial infarction.|Stroke.|Acute kidney injury.|Pulmonary thromboembolism.|Combined endpoint (stroke, myocardial infarction, acute kidney injury and pulmonary thromboembolism.|Admission to ICU.|Invasive Mechanical Ventilation.|Hospital Length of Stay.|ICU length of stay.|Death","Vitamin D Study Group|Ag Nac Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación","All","18 Years and older   (Adult, Older Adult)","Phase 4","1265","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","001","June 15, 2020","December 15, 2020","December 28, 2020","June 2, 2020",,"June 4, 2020","Hospital de Alta Complejidad en Red El Cruce, Florencio Varela, Buenos Aires, Argentina",,"https://ClinicalTrials.gov/show/NCT04411446"
45,"NCT04435795","Inhaled Ciclesonide for Outpatients With COVID19",,"Not yet recruiting","No Results Available","COVID 19","Drug: Ciclesonide","Improvement in dyspnea at day 7|Hospitalization at day 14|Oxygen Use|Mortality|Clinical status|Anxiety|Sleep Disturbance|Exercise capacity","McGill University Health Centre/Research Institute of the McGill University Health Centre","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","454","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2021-6696","June 25, 2020","February 25, 2021","March 25, 2021","June 17, 2020",,"June 17, 2020",,,"https://ClinicalTrials.gov/show/NCT04435795"
46,"NCT04428073","Therapeutic Vaccine Trial of COVID-19 for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection",,"Not yet recruiting","No Results Available","COVID","Biological: Covax-19™","To evaluate the safety of a therapeutic Covid-19 vaccine in participants by measuring the severity of local and systemic adverse events and laboratory abnormalities.|To evaluate the immunogenicity of a therapeutic Covid-19 vaccine in participants by measuring CD8+ T cells immune response|Virologic response after vaccination|Clinical outcome and progression after vaccinations","GeneCure Biotechnologies","All","18 Years to 60 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GC004","July 2020","July 2021","December 2021","June 11, 2020",,"June 11, 2020",,,"https://ClinicalTrials.gov/show/NCT04428073"
47,"NCT04444687","COVID 19: Is SARS-CoV-2 Contaminating Surgical Aerosols From Laparoscopy and Open Abdominal Surgery?","LapCoVIDSurg","Not yet recruiting","No Results Available","COVID","Diagnostic Test: Test for SARS-CoV-2","SARS-COV-2 RNA detection|Viral contamination of peritoneal cavity and fluid|Viral contamination of peritoneal cavity and fluid in open cases|Viral infection of members of the surgical team","University Hospital, Basel, Switzerland","All","18 Years and older   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","052020","August 2020","December 2020","February 2021","June 23, 2020",,"June 23, 2020",,,"https://ClinicalTrials.gov/show/NCT04444687"
48,"NCT04403828","Impact of COVID-19 on Personal Protection Among Dentist in Egypt",,"Active, not recruiting","No Results Available","COVID 19","Other: Survey","Personal protection measures|impact of Covid-19 pandemic on type of face masks used in dental clinic","Fayoum University","All","18 Years to 75 Years   (Adult, Older Adult)",,"323","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","PPE in COVID-19","May 20, 2020","June 1, 2020","June 15, 2020","May 27, 2020",,"June 9, 2020","Faculty of Dentistry, Fayoum, Egypt",,"https://ClinicalTrials.gov/show/NCT04403828"
49,"NCT04414657","USZ BioResource COVID",,"Recruiting","No Results Available","COVID19","Other: blood sampling for biobank","blood sampling for biobank","Regina Grossmann|University of Zurich","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CTC HFV2","April 9, 2020","April 30, 2022","April 30, 2022","June 4, 2020",,"June 4, 2020","University Hospital Zurich, Clinical Trials Center, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT04414657"
50,"NCT04397796","Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation",,"Not yet recruiting","No Results Available","COVID","Biological: BM-Allo.MSC|Biological: Placebo","Incidence of AEs|Mortality|Death|Number of ventilator-free days|Improvement of one category|7-point ordinal scale|NEWS|NEWS of ≤ 2|Sequential Organ Failure Assessment (SOFA)|Oxygen|Hospitalization|Incidence of SAEs","NantKwest, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","QUILT-COVID-19-MSC","June 2020","June 2021","June 2021","May 21, 2020",,"June 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04397796"
51,"NCT04348500","Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease",,"Recruiting","No Results Available","COVID19","Drug: Clazakizumab","Evaluate the safety of clazakizumab for the treatment of patients with COVID-19 disease and signs of pulmonary involvement|Patient survival at 28 days|Patient survival at 60 days|Number of patients requiring the dose of open-label clazakizumab|Reduced duration of intensive care unit stay|Reduced duration of hospital stay|Reduced need for ventilation","Cedars-Sinai Medical Center","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","00000644","April 24, 2020","December 31, 2020","March 31, 2021","April 16, 2020",,"June 5, 2020","Cedars-Sinai Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04348500"
52,"NCT04422574","COVID 19 Serology in Pulmonologists","Pneumoserocov","Completed","No Results Available","Covid 19",,"covid 19 serology|risk factors for positive serology testing","University Hospital, Montpellier","All","18 Years and older   (Adult, Older Adult)",,"97","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","RECHMPL20_0343","May 1, 2020","May 1, 2020","May 30, 2020","June 9, 2020",,"June 9, 2020","Uh Montpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04422574"
53,"NCT04335188","COVID-19 Registry Rhineland-Palatinate (Germany)",,"Recruiting","No Results Available","COVID","Other: Prospective oberservational registry","Chest x-ray|Chest CT|Supportive care - ICU|Supportive care - oxygen therapy|Supportive care - ventilation|Medication|Therapeutic strategies|Lab parameters|Intra-hospital complications|Vital status at discharge","IHF GmbH - Institut für Herzinfarktforschung|Ministerium für Soziales, Arbeit, Gesundheit und Demografie des Landes Rheinland-Pfalz","All","Child, Adult, Older Adult",,"4000","Other","Observational","Observational Model: Other|Time Perspective: Prospective","COVID-19 Registry","April 6, 2020","July 31, 2021","September 30, 2021","April 6, 2020",,"April 8, 2020","Klinikum der Stadt Ludwigshafen am Rhein GmbH, Klinik für Herzchirurgie, Ludwigshafen, RLP, Germany",,"https://ClinicalTrials.gov/show/NCT04335188"
54,"NCT04402944","Pulmozyme to Improve COVID-19 ARDS Outcomes",,"Not yet recruiting","No Results Available","COVID","Drug: Pulmozyme|Drug: Placebo","Ventilator-free days at 28 days|change in airway resistance|change in lung compliance|oxygenation (PaO2/FiO2 ratio)|length of stay (ICU and hospital)|rate of barotrauma|mortality.","Boston Children’s Hospital|Brigham and Women's Hospital","All","3 Years and older   (Child, Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","P00035140","June 18, 2020","May 31, 2021","December 31, 2021","May 27, 2020",,"June 12, 2020",,,"https://ClinicalTrials.gov/show/NCT04402944"
55,"NCT04374123","COVID-19 Serology Screening and Strict Protocol in the Endoscopy Unit",,"Recruiting","No Results Available","COVID","Diagnostic Test: Serological screening for IgG and IgM antibodies against COVID-19","Rate of COVID-19 nosocomial infection among the endoscopy staff at the end of the 30-days study.|Numbers of patients evaluated and treated during the COVID-19 outbreak in the endoscopy unit at the end of the 30-days study.|Technical success rate of endoscopic procedures during the 30-days study period.|IgG and IgM against COVID-19 in the endoscopy staff measured at the end of the study.|Adverse events rate of endoscopic procedures during the 30-days","Instituto Ecuatoriano de Enfermedades Digestivas","All","18 Years to 80 Years   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IECED-04-15-covid","April 20, 2020","May 20, 2020","June 1, 2020","May 5, 2020",,"May 5, 2020","Ecuadorian Institute of Digestive Diseases, Guayaquil, Guayas, Ecuador",,"https://ClinicalTrials.gov/show/NCT04374123"
56,"NCT04343976","Pegylated Interferon Lambda Treatment for COVID-19",,"Enrolling by invitation","No Results Available","COVID-19|COVID","Drug: Pegylated interferon lambda","Undetectable COVID PCR at day 7|Undetectable COVID PCR at day 3, 10 and 14|Percentage of subjects on Lambda vs placebo with symptomatic improvement|Percentage of subjects on Lambda vs placebo with improved clinical outcomes","Raymond Chung|Eiger BioPharmaceuticals|Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2020P001083","June 22, 2020","March 1, 2021","August 31, 2021","April 14, 2020",,"June 24, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04343976"
57,"NCT04392713","Efficacy of Ivermectin in COVID-19",,"Recruiting","No Results Available","COVID","Drug: Ivermectin 6 MG Oral Tablet (2 tablets)","Negative PCR|Need for mechanical ventilation","Combined Military Hospital, Pakistan","All","15 Years to 65 Years   (Child, Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IVE-COV","April 15, 2020","July 2020","July 2020","May 19, 2020",,"May 19, 2020","Combined Military Hospital Lahore, Lahore, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT04392713"
58,"NCT04357431","COVID-19 Among Egyptian Health Care Providers",,"Recruiting","No Results Available","COVID","Other: self-administered questionnaire","The percentage of knowledge regarding COVID-19 information","Assiut University","All","Child, Adult, Older Adult",,"600","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","COVIDQ","April 22, 2020","May 5, 2020","May 30, 2020","April 22, 2020",,"May 13, 2020","Ahmed Abbas, Assiut, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04357431"
59,"NCT04357444","Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19","LILIADE-COVID","Not yet recruiting","No Results Available","COVID 19","Drug: 1: ILT101|Drug: 2: Placebo Comparator","The PaO2/FiO2 ratio at D11|Changes in Tregs between Baseline and Day 7 (expressed in %)|Number of days alive with oxygen therapy within 28 days|Maximal oxygen rate within 28 days|Number of days alive free of invasive or non-invasive ventilation within 28 days|Number of days alive outside ICU within 28 days|Number of days alive outside hospital within 28 days|Time (in days) from randomization to death|Mortality rate at D28|Difference between CRP levels at randomization and at Day 7 (or at the time of discharge if occurs before Day 7)|Use of antibiotics for respiratory (proved or suspected) infection within 28 days|Number of prone positioning sessions|Changes in Tregs during the different visits between baseline and day 28|Cytokines analysis on plasma samples at Day 0, 7 and 14|Tregs numbers during induction period and throughout the follow up period at day 5, 7, 11, 14 and 28 compared to baseline before the first IL-2 injection.|Tregs percentages during induction period and throughout the follow up period at day 5, 7, 11, 14 and 28 compared to baseline before the first IL-2 injection.|Deep Immunophenotyping of Cellular components in blood samples at Day 0, 7, and 14|T cell repertoire on Treg, after sorting from blood at Day 7 and Day 14 and compared to baseline|T cell repertoire on Teff (CD4 and CD8) after sorting from blood at Day 7 and Day 14 and compared to baseline|Single cells sequencing will be performed in BAL at Day 7 and Day 14 and compared to baseline.","Assistance Publique - Hôpitaux de Paris|Iltoo Pharma","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","APHP200406|2020-001571-32","June 2020","July 2020","August 2020","April 22, 2020",,"June 9, 2020","Service Anesthésie Réanimation - Groupe Hospitalier Pitié-Salpêtrière, Paris, France",,"https://ClinicalTrials.gov/show/NCT04357444"
60,"NCT04352491","An Online Survey to Understand Feelings Related to COVID-19 Among ILBS Patients With Liver Disease",,"Completed","No Results Available","COVID 19","Other: No intervention","Assessment of the fear levels during the COVID-19 disease pandemic among patients with Liver disease (currently under treatment from ILBS)|Assessment of the anxiety levels during the COVID-19 disease pandemic among patients with Liver disease (currently under treatment from ILBS)|Assessment of the stress levels during the COVID-19 disease pandemic among patients with Liver disease (currently under treatment from ILBS)|Association between presence of Liver disease and fear levels|Association between presence of Liver disease and anxiety levels|Association between presence of Liver disease and stress levels|Correlation between Fear and Child-Turcotte-Pugh Score|Correlation between anxiety and Child-Turcotte-Pugh Score|Correlation between stress and Child-Turcotte-Pugh Score|Correlation between fear and Model for End Stage Liver Disease Score|Correlation between anxiety and Model for End Stage Liver Disease Score|Correlation between stress and Model for End Stage Liver Disease Score","Institute of Liver and Biliary Sciences, India","All","18 Years to 75 Years   (Adult, Older Adult)",,"347","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","ILBS-COVID-03","April 24, 2020","May 31, 2020","May 31, 2020","April 20, 2020",,"June 17, 2020","Institute of Liver and Biliary Sciences, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT04352491"
61,"NCT04445311","Ivermectin in Treatment of COVID-19",,"Recruiting","No Results Available","COVID","Drug: Ivermectin","time to be symptoms free|hospitalization|Mechanical ventilation|length of stay|mortality","Zagazig University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2|Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ZU-IRB#6151/31-5-2020","May 31, 2020","July 30, 2020","August 15, 2020","June 24, 2020",,"June 24, 2020","Waheed Shouman, Zagazig, Sharkia, Egypt",,"https://ClinicalTrials.gov/show/NCT04445311"
62,"NCT04430322","Covid-19 at the Regional Medical Center Metz-Thionville: a Descriptive Study","COMETE-19","Recruiting","No Results Available","COVID",,"ICU admission|Hospitalization|Length of stay at the ICU|Death|CT scan result|C reactive protein|Blood Count|Sodium|Urea|Troponine|Liver function|Coagulation test|Creatinine|Clearance|Potassium|Calcium|Gamma-glutamyl transpeptidase|Bilirubine|Alcaline phosphatase|Prothrombine","Centre Hospitalier Régional Metz-Thionville","All","Child, Adult, Older Adult",,"330","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","2020-02Obs-CHRMT","March 1, 2020","December 31, 2020","June 30, 2021","June 12, 2020",,"June 18, 2020","CHR Metz Thionville, Metz, France",,"https://ClinicalTrials.gov/show/NCT04430322"
63,"NCT04436458","Niclosamide In Moderate COVID-19",,"Not yet recruiting","No Results Available","COVID","Drug: Niclosamide Oral Tablet|Drug: Placebo","The primary endpoint is the rate of faecal SARS-CoV-2 virus clearance (rectal swab or stool sample) assessed by RT-PCR in the niclosamide group, compared to the placebo group","First Wave Bio, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FW-COV-002","August 2020","January 2021","February 2021","June 18, 2020",,"June 18, 2020",,,"https://ClinicalTrials.gov/show/NCT04436458"
64,"NCT04389294","HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists",,"Recruiting","No Results Available","COVID","Diagnostic Test: SARS-CoV2 serum antibody testing","Correlation between serology testing and clinical suspicion of COVID-19|Prevalence of SARS-CoV2 exposure|Correlation of pre-existing risk factors with results of serology testing|Number of asymptomatic participants with positive antibody serology|Proportion of antibody- positive participants who subsequently develop COVID-19|Proportion of participants who are eligible for in plasma donation","Hospital for Special Surgery, New York","All","21 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2020-0850","May 5, 2020","September 30, 2020","October 30, 2020","May 15, 2020",,"May 15, 2020","Hospital for Special Surgery, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04389294"
65,"NCT04403555","Ivermectin and Doxycycine in COVID-19 Treatment",,"Not yet recruiting","No Results Available","COVID","Drug: Ivermectin|Drug: Doxycycline|Drug: Chloroquine","The number of patients with resolved viral infection","Tanta University","All","Child, Adult, Older Adult","Phase 2|Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","tanta combo covid treatment","June 1, 2020","December 1, 2030","December 3, 2030","May 27, 2020",,"May 27, 2020","Sherief Abd-Elsalam, Tanta, Egypt",,"https://ClinicalTrials.gov/show/NCT04403555"
66,"NCT04420637","Impact of the Covid-19 Pandemic on Gastrointestinal and Liver Diseases","RetroCov","Not yet recruiting","No Results Available","COVID",,"liver disease|COVID infection in patients with chronic liver disease|decompensation of cirrhosis|Effect of Antiviral drugs on Covid-19 infection","Medical University of Graz","All","Child, Adult, Older Adult",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","RetroCov","June 15, 2020","December 2020","December 2021","June 9, 2020",,"June 9, 2020","Department of Internal Medicine, Medical University of Graz, Graz, Austria",,"https://ClinicalTrials.gov/show/NCT04420637"
67,"NCT04361786","Acral Cutaneous Thrombotic Vasculopathy and Covid-19 Infection",,"Recruiting","No Results Available","COVID 19",,"Biological acquired thrombophilia|Overexpression of interferon type I","University Hospital, Montpellier|Lyon Civil Hospitals - Lyon Sud Hospital Center|Marseille University Hospital - Assistance-Publique Hôpitaux de Marseille.","All","Child, Adult, Older Adult",,"10","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","RECHMPL20_0211","April 1, 2020","June 30, 2020","October 30, 2020","April 24, 2020",,"April 24, 2020","Uh Montpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04361786"
68,"NCT04383652","Collection of Coronavirus COVID-19 Outbreak Samples in New South Wales","COSiN","Recruiting","No Results Available","COVID","Other: Biological sample and clinical data collection","Coronavirus sequencing|Coronavirus culturing","Kirby Institute","All","Child, Adult, Older Adult",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","VISP2005","May 6, 2020","June 30, 2021","June 30, 2021","May 12, 2020",,"May 12, 2020","NSW Health Pathology, Randwick, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|Sydney Children's Hospital, Randwick, New South Wales, Australia|Blacktown Hospital, Blacktown, Australia|Royal Prince Alfred Hospital, Camperdown, Australia|St Vincent's Hospital, Darlinghurst, Australia|Northern Beaches Hospital, Frenchs Forest, Australia|Royal North Shore Hospital, Saint Leonards, Australia|Westmead Hospital, Westmead, Australia",,"https://ClinicalTrials.gov/show/NCT04383652"
69,"NCT04422561","Prophylactic Ivermectin in COVID-19 Contacts",,"Recruiting","No Results Available","COVID","Drug: Ivermectin Tablets","appearance of symptoms ( fever ,cough, sore throat, myalgia,diarrhea, shortness of breath)|development of COVID","Zagazig University","All","16 Years to 70 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ZU-IRB#6150/31-5-2020","May 31, 2020","June 2020","July 2020","June 9, 2020",,"June 23, 2020","Zagazig University, Zagazig, Sharkia, Egypt",,"https://ClinicalTrials.gov/show/NCT04422561"
70,"NCT04425720","Use of Remote Monitoring for COVID-19 Patient","RPM","Not yet recruiting","No Results Available","COVID","Device: LifeSignals Biosensor 1AX*|Other: Standard of Care","Monitored versus Non-Monitored in-patient admission|Emergency Department Visits|Length of stay|patient satisfaction|the incidence of mechanical ventilation and ECMO|serious adverse events","Montefiore Medical Center","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","pending","July 5, 2020","June 1, 2021","June 1, 2021","June 11, 2020",,"June 23, 2020","Montefiore Medical Center, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT04425720"
71,"NCT04351295","Efficacy of Faviprevir in COVID-19 Treatment",,"Not yet recruiting","No Results Available","COVID","Drug: Favipiravir|Drug: Placebos","Number of patients with viral cure","Tanta University","All","Child, Adult, Older Adult","Phase 2|Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","faviprevir covid","April 17, 2020","December 1, 2030","December 1, 2030","April 17, 2020",,"April 17, 2020","Tanta University, Tanta, Egypt",,"https://ClinicalTrials.gov/show/NCT04351295"
72,"NCT04409327","Phase 3 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes",,"Recruiting","No Results Available","COVID19","Drug: RTB101|Drug: Placebo","The percentage of subjects who develop laboratory-confirmed COVID-19: - with protocol-defined progressive symptoms OR - are hospitalized OR - die|The percentage of subjects who develop symptomatic laboratory-confirmed COVID-19 infection|Mortality rate in subjects who develop laboratory-confirmed COVID19|Percent of subjects who are hospitalized due to having one or more predefined COVID-19 symptoms and laboratory-confirmed SARS-CoV-2|Percent of subjects who require mechanical ventilation, noninvasive ventilation, high flow nasal canula oxygen delivery or ICU admission during the hospitalization for COVID19|Safety and tolerability will be assessed by report of AE/SAEs","Restorbio Inc.","All","65 Years and older   (Older Adult)","Phase 3","550","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","RTB101-210","May 2020","September 2020","October 2020","June 1, 2020",,"June 1, 2020","Nursing Home, Middletown, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT04409327"
73,"NCT04362969","COVID-EC Study: Clinical Characteristics of Patients With COVID-19 in Guayaquil, Ecuador",,"Not yet recruiting","No Results Available","COVID",,"Clinical characteristics of patients with COVID-19|Prognosis of patients, in terms of need for admission to intensive care, use of mechanical ventilation or death|Clinical characteristics of the patients with the worst prognosis|Relationship between the different treatments and the prognosis","Hospital San Carlos, Madrid|Universidad Catolica Santiago de Guayaquil","All","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","001","May 2020","May 2020","May 2020","April 27, 2020",,"May 7, 2020","GastroMuñoz, Guayaquil, Guayas, Ecuador",,"https://ClinicalTrials.gov/show/NCT04362969"
74,"NCT04345406","Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19",,"Not yet recruiting","No Results Available","COVID","Drug: ACEIs|Drug: Conventional treatment","number of patients with virological cure","Tanta University","All","Child, Adult, Older Adult","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACEIS COVID 19","April 15, 2020","December 1, 2029","December 1, 2029","April 14, 2020",,"April 14, 2020","Tanta University, Tanta, Egypt",,"https://ClinicalTrials.gov/show/NCT04345406"
75,"NCT04406038","Study of the Spread of COVID-19 in Saint Petersburg, Russia",,"Recruiting","No Results Available","COVID19",,"Prevalence of the SARS-COV-2 infection in Saint Petersburg, Russia|Prevalence odds ratios|Immune response dynamics|SARS-COV-2 antibodies dynamics","European University at St. Petersburg","All","18 Years and older   (Adult, Older Adult)",,"1550","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CDRU-001","May 27, 2020","October 28, 2020","October 28, 2020","May 28, 2020",,"May 29, 2020","Clinic ""Scandinavia"", Saint Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04406038"
76,"NCT04403607","Cardiac Imaging in SARS-CoV-2 (COVID-19)","CISCO-19","Recruiting","No Results Available","COVID",,"The primary cardiac outcome is the proportion of patients with a diagnosis of myocardial inflammation (myocarditis).|The primary cardio-pulmonary outcome is the proportion of patients with thrombosis|Myocardial injury|Myocardial stress|Systemic inflammation|Vascular injury|Endothelial activation and haemostasis|Fibrin lysis|Coagulation|Platelet count|Renal function|Quantify myocardial perfusion as a measure of coronary microvascular function|Association of the primary outcome according to a prior history of cardiovascular disease or no history of prior cardiovascular disease.|Patient reported outcome measures (PROMS) - health status|PROMS - functional capacity","NHS Greater Glasgow and Clyde|University of Glasgow","All","18 Years and older   (Adult, Older Adult)",,"180","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","GN20ID164","May 22, 2020","September 30, 2020","August 2021","May 27, 2020",,"June 2, 2020","Royal Alexandra Hospital, Paisley, Renfrewshire, United Kingdom|Royal Infirmary, Glasgow, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04403607"
77,"NCT04352400","Efficacy of Nafamostat in Covid-19 Patients (RACONA Study)","RACONA","Not yet recruiting","No Results Available","COVID19","Drug: Nafamostat Mesilate|Drug: Placebo","Time-to-clinical improvement|Responders|Critical or dead patients|pO2/FiO2 ratio|SOFA score over time|Hospitalization|Mechanical ventilation|Mechanical ventilation duration|Cardiovascular disease","University Hospital Padova|Yokohama City University|University of Zurich","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2|Phase 3","256","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RACONA Nafamostat","April 2020","December 2021","December 2021","April 20, 2020",,"April 20, 2020",,,"https://ClinicalTrials.gov/show/NCT04352400"
78,"NCT04359901","Sarilumab for Patients With Moderate COVID-19 Disease",,"Recruiting","No Results Available","COVID","Biological: SARILUMAB","Intubation or death","Westyn Branch-Elliman|VA Boston Healthcare System","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB 3305","April 10, 2020","April 2022","April 2023","April 24, 2020",,"June 4, 2020","VA Boston Healthcare System, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04359901"
79,"NCT04425915","Efficacy of Convalescent Plasma Therapy in Patients With COVID-19",,"Recruiting","No Results Available","COVID","Biological: Convalescent Plasma|Other: Standard of Care","Efficacy of convalescent plasma in severe COVID 19 patients in time to clinical improvement (Clinical improvement: Reduction of two points in ordinal scale or live discharge from the intensive care unit, whichever is earlier)|Proportion of patients in each category according to the ordinal scale|Duration of oxygen therapy in both groups|Duration of hospital stay in both groups|Proportion of patients on mechanical ventilation at day 7 in both groups|Mortality in both groups|Duration of Intensive Care Unit stay|Incidence of adverse effects in both groups|Presence of antibodies against SARS-CoV-2 in serum after plasma administration|Change in Cytokines in both groups|Change in acute phase reactants in both groups|Correlation of the titers in COVID-19 convalescent plasma donors with duration of illness, the severity of symptoms, duration of hospital stay, drugs used in therapy, duration between recovery, and donation.","Institute of Liver and Biliary Sciences, India","All","18 Years and older   (Adult, Older Adult)","Phase 3","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ILBS-COVID-04","June 9, 2020","May 30, 2021","May 30, 2021","June 11, 2020",,"June 11, 2020","Maulana Azad Medical College, New Delhi, Delhi, India|Institute of Liver & Biliary Sciences, New Delhi, Delhi, India|Rajiv Gandhi Super Speciality Hospital, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT04425915"
80,"NCT04365231","Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial","HASCOPT","Not yet recruiting","No Results Available","COVID19","Drug: Hydroxychloroquine and azithromycin treatment|Other: conventional management of patients","Percentage of patients with a negative RT-PCR test result to COVID-19|Maternal outcomes: Percentage of severe forms of the disease|Newborn outcomes: Rate of newborns hospitalized in intensive care or transferred to resuscitation unit","Hospital St. Joseph, Marseille, France","Female","18 Years and older   (Adult, Older Adult)","Phase 3","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HASCOPT2020","April 2020","June 2020","January 2021","April 28, 2020",,"April 28, 2020","Hopital Saint Joseph, Marseille, Paca, France",,"https://ClinicalTrials.gov/show/NCT04365231"
81,"NCT04338945","Impact of Pandemic COVID-19 on Surgical Specialities Residents in Italy",,"Completed","No Results Available","COVID","Behavioral: COVID-surgRES questionaire","Measure of the impact of COVID Emergency on surgical specialist training programs|Measure of impact of COVID Emergency on wellness of residents","Ospedale Policlinico San Martino","All","18 Years and older   (Adult, Older Adult)",,"800","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-ItaliansurgRES-SPIGC","March 15, 2020","April 15, 2020","May 1, 2020","April 8, 2020",,"May 20, 2020","U.O.C. Chirurgia Generale Universitaria ""V. Bonomo"", Bari, Italy|Ospedale Perrino Asl Brindisi, Brindisi, Italy|Dipartimento di scienze mediche e chirurgiche, Università di Catanzaro, Catanzaro, Italy|Ospedale Policlinico San Martino, Genova, Italy|Azienda Ospedaliera San Camillo-Forlanini, Roma, Italy|IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy|Ospedale Cristo re, Roma, Italy",,"https://ClinicalTrials.gov/show/NCT04338945"
82,"NCT04408040","Use of Convalescent Plasma for COVID-19",,"Not yet recruiting","No Results Available","COVID","Biological: Convalescent Plasma","Arms 1 & 2: number of critical and severe COVID-19 infected patients who are transfused with convalescent plasma result in lower death rates than the reported fatality rate|Arms 1 & 2: number of critical and severe COVID-19 infected patients who survive the infection|Arm 3: number of high risk COVID-19 infected patients who are transfused with convalescent plasma result in lower incidence of progression to severe or critical disease than the reported case rate|Arm 4: number of health care providers who are at risk to exposure to COVID-19 who are transfused with convalescent plasma result in lower incidence of developing COVID-19 infection than the reported case rate","Northside Hospital, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","700","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NSH 1281","June 2020","June 2022","June 2022","May 29, 2020",,"May 29, 2020","Northside Hospital, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04408040"
83,"NCT04351347","The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment",,"Recruiting","No Results Available","COVID","Drug: Ivermectin|Drug: Nitazoxanide with ivermectin|Drug: Ivermectin wth chloroquine","Number of patients with virological cure","Tanta University","All","Child, Adult, Older Adult","Phase 2|Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ivermecin covid","June 16, 2020","December 1, 2030","December 1, 2030","April 17, 2020",,"June 22, 2020","Tanta University, Tanta, Egypt",,"https://ClinicalTrials.gov/show/NCT04351347"
84,"NCT04346186","COVID-19: Investigation of Transmission and Immunisation Among Hospital Staff",,"Not yet recruiting","No Results Available","COVID","Diagnostic Test: IgM and IgG diagnostic kits to SARS-CoV-2|Diagnostic Test: Elisa-test for IgM and IgG to SARS-CoV-2","Positive IgM/IgG tests|Comparison of the point of care test and Elisa|Re-infection rate|IgM/IgG positive participants on follow-up test","Herlev Hospital|Nordsjaellands Hospital|Hvidovre University Hospital|Rigshospitalet, Denmark|Mental Health Services in the Capital Region, Denmark|University Hospital Bispebjerg and Frederiksberg","All","Child, Adult, Older Adult",,"30000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RegHCOVIDScreening","April 15, 2020","October 1, 2020","August 1, 2021","April 15, 2020",,"April 15, 2020","Herlev Hospital, Herlev, Region Hovedstaden, Denmark|Bispebjerg Hospital, København NV, Region Hovedstaden, Denmark|Psykiatrisk Center Ballerup, Ballerup, Denmark|Psykiatrisk Center København, Copenhagen, Denmark|Rigshospitalet, Copenhagen, Denmark|Psykiatrisk Center Amager, Copenhagen, Denmark|Psykiatrisk Center Stolpegaard, Gentofte, Denmark|Børne- og Ungdomspsykiatrisk Center, Glostrup, Denmark|Psykiatrisk Center Glostrup, Glostrup, Denmark|Nordsjaellands Hospital, Hillerød, Denmark|Psykiatrisk Center Nordsjælland, Hillerød, Denmark|Psykiatrisk Center Sankt Hans, Roskilde, Denmark|Bornholms Hospital, Rønne, Denmark|Psykiatrisk Center Bornholm, Rønne, Denmark",,"https://ClinicalTrials.gov/show/NCT04346186"
85,"NCT04394390","Do Vitamin D Levels Really Correlated With Disease Severity in COVID-19 Patients?","COVIDVIT","Enrolling by invitation","No Results Available","COVID","Dietary Supplement: vitamin d","laboratory measured vitamin D levels","Bursa City Hospital","All","Child, Adult, Older Adult",,"100","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","1","May 1, 2020","June 15, 2020","June 30, 2020","May 19, 2020",,"May 19, 2020","Bursa City Hospital, Bursa, Dogankoy, Turkey",,"https://ClinicalTrials.gov/show/NCT04394390"
86,"NCT04447534","Zinc With Chloroquine/Hydroxychloroquine in Treatment of COVID-19",,"Recruiting","No Results Available","COVID","Drug: Chloroquine|Drug: zinc","Number of patients with negative PCR","Tanta University","All","18 Years and older   (Adult, Older Adult)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","tanta zinc chloroquine","June 23, 2020","August 1, 2020","August 1, 2020","June 25, 2020",,"June 25, 2020","Tanta university hospital, Tanta, Egypt",,"https://ClinicalTrials.gov/show/NCT04447534"
87,"NCT04386850","Oral 25-hydroxyvitamin D3 and COVID-19",,"Recruiting","No Results Available","COVID 19","Drug: Oral 25-Hydroxyvitamin D3","COVID-19 (SARA-Cov-2) infection|Severity of COVID-19 (SARA-Cov-2) infection|Hospitalization|Disease duration|Death|Oxygen support|Type of oxygen support|Symptoms of COVID-19|Serum Levels of 25-hydroxyvitamin D3|Serum levels of calcium|Serum levels of phosphorus|Serum levels of creatinine|Serum levels of albumin|Serum levels of the blood urea nitrogen (BUN)|Serum levels of the parathyroid hormone (PTH)","Tehran University of Medical Sciences|Boston University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","1500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IRCT2020-0401046909N2|IRCT20200401046909N1","April 14, 2020","November 15, 2020","March 15, 2021","May 13, 2020",,"June 12, 2020","Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04386850"
88,"NCT04399746","Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19","IvAzCol","Recruiting","No Results Available","COVID","Drug: Ivermectin|Drug: Azithromycin|Drug: Cholecalciferol","Viral clearance|Symptoms duration|SpO2|SpO2/FiO2","Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IvAzCol","March 15, 2020","May 20, 2020","June 10, 2020","May 22, 2020",,"May 22, 2020","Outpatient treatment, Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT04399746"
89,"NCT04445467","An Adaptive Randomised Placebo Controlled Phase II Trial of Antivirals for COVID-19 Infection","VIRCO","Not yet recruiting","No Results Available","COVID","Drug: Favipiravir","Time to virological cure|Safety|Clinical improvement|Clinical symptoms|Biomarkers","Bayside Health","All","18 Years and older   (Adult, Older Adult)","Phase 2","190","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","66223","July 2020","November 2020","November 2020","June 24, 2020",,"June 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04445467"
90,"NCT04416061","The Role of a Private Hospital in Hong Kong Amid COVID-19 Pandemic","COVID-19","Active, not recruiting","No Results Available","COVID","Diagnostic Test: COVID 19 Diagnostic Test","Proportion of asymptomatic subjects|Proportion of subjects with recent contact history|Proportion of subjects with recent travel history","Hong Kong Sanatorium & Hospital","All","Child, Adult, Older Adult",,"2500","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","RC-2020-08","May 25, 2020","July 31, 2020","August 31, 2020","June 4, 2020",,"June 4, 2020","Hong Kong Sanatorium & Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04416061"
91,"NCT04420260","Primary Prevention of Infection by COVID-19 in Health Providers","PI-Covid-19","Not yet recruiting","No Results Available","COVID","Dietary Supplement: Group A: oropharygeal spray and immunostimulant|Dietary Supplement: Group B: Placebo oropharyngeal spray + Active principle immunostimulant|Dietary Supplement: Group C:Active principle oropharyngeal spray + Placebo taken PO|Dietary Supplement: Group D:Placebo oropharyngeal spray + Placebo taken PO","Seroconversion of IgM for COVID-19.|Seroconversion of IgG for COVID-19.","Unidad de Investigación Genética Molecular|Universidad de Antioquia","All","18 Years to 60 Years   (Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","UNIGEM PT-IC-02","July 2020","September 2020","September 2020","June 9, 2020",,"June 9, 2020",,,"https://ClinicalTrials.gov/show/NCT04420260"
92,"NCT04407169","Prevalence of Critical Forms of CoVid-19 in Patients With Chronic Respiratory Disease","CRITICoVid","Not yet recruiting","No Results Available","COVID","Other: no intervention","Percentage of patients who reached, during their hospitalization, a value greater than or equal to 6 on the WHO CoVid-19 infection progression scale|Determined potential predictive factors of critic form in patients with chronic lung diseases|Determined percentage of death|Determined duration of oxygen therapy|Determined duration of hospitalization|Determine mean values of the WHO CoVid-19 infection progression scale measured","Central Hospital, Nancy, France","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2020PI081","June 1, 2020","July 1, 2020","August 1, 2020","May 29, 2020",,"May 29, 2020",,,"https://ClinicalTrials.gov/show/NCT04407169"
93,"NCT04353180","Assessment the Activity Value of 13- Cis-Retinoic Acid (Isotretinoin) in the Treatment of COVID-19 (Randomized)","Isotretinoin","Not yet recruiting","No Results Available","COVID19","Drug: Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment|Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment|Drug: Standard treatment","lung injury score|Absolute lymphocyte counts|Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon|Serum level of COVID19 RNA|All cause mortality rate|Ventilation free days|ICU free days|d-dimers|Time to first negative SARS-CoV-2 PCR in NP swap|Angiotensin 1-7 (Ang 1-7) changes over time|Angiotensin 1-5 (Ang 1-5) changes over time|Renin changes over time|Aldosterone changes over time|Angiotensin-converting enzyme (ACE) changes over time|Frequency of adverse events and severe adverse events|Angiotensin II (Ang II) changes over time|Sequential organ failure assessment score(SOFA score) over time|Transe membrane protease ,serine II (TMPRSS2) changes over time|Testosterone levels changes over time|Dihydrotestosterone(DHT) levels changes over time|Cholesterol levels changes over time|Thrombin time (TT)","Kafrelsheikh University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Proposed by Mahmoud Elkazzaz","June 2020","August 2020","November 2020","April 20, 2020",,"June 26, 2020","Faculty of Medicine, Kafr El-sheikh University, Cairo, Kafr El-sheikh, Egypt|Faculty of Medicine, Kafr El-sheikh University, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04353180"
94,"NCT04420676","Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection","SynCov","Not yet recruiting","No Results Available","COVID","Dietary Supplement: Omnibiotic AAD|Dietary Supplement: Placebo","Diarrhea|Stool frequency|Stool consistency|Gastrointestinal symptoms|Duration of Covid-19 disease|Severity of Covid-19 disease|Stool Calprotectin|Stool Zonulin|Microbiome composition","Medical University of Graz","All","18 Years and older   (Adult, Older Adult)","Not Applicable","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SynCov","August 2020","December 2021","December 2022","June 9, 2020",,"June 9, 2020","Department of Internal Medicine, Medical University of Graz, Graz, Austria",,"https://ClinicalTrials.gov/show/NCT04420676"
95,"NCT04368871","Radiographic Findings and Their Temporal Changes in COVID-19 Positive Changes Patients: A Prospective Study",,"Recruiting","No Results Available","COVID",,"Radiographic findings and their temporal changes in COVID-19 positive patient: A Prospective study","Max Healthcare Insititute Limited","All","18 Years to 75 Years   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Covid-19/RFTC/MHC/2020","April 28, 2020","June 30, 2020","May 30, 2021","April 30, 2020",,"June 9, 2020","Max Super Speciality Hospital, A Unit of Devki Devi Foundation, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT04368871"
96,"NCT04371367","Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )","FORCE","Recruiting","No Results Available","COVID","Biological: avdoralimab|Other: Placebo","Number of patients alive and no longer hospitalized at D14|Number of ventilator-free days at Day 28 (VFD28)|Number of participants with treatment-related adverse events","Assistance Publique Hopitaux De Marseille|Innate Pharma","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","108","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2020-21","April 27, 2020","June 27, 2020","October 27, 2020","May 1, 2020",,"May 1, 2020","Assistance Publique Hôpitaux de Marseille, Marseille, France",,"https://ClinicalTrials.gov/show/NCT04371367"
97,"NCT04344535","Convalescent Plasma vs. Standard Plasma for COVID-19",,"Enrolling by invitation","No Results Available","COVID","Biological: Convalescent Plasma|Biological: Standard Donor Plasma","28 day ventilator free days|90 day all-cause mortality","Stony Brook University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SBU-COVID19-ConvalescentPlasma","April 8, 2020","April 30, 2021","August 31, 2021","April 14, 2020",,"April 17, 2020","Stony Brook University Hospital, Stony Brook, New York, United States",,"https://ClinicalTrials.gov/show/NCT04344535"
98,"NCT04359121","COVID-19 and the Developement of Phobic Fears of Disease",,"Recruiting","No Results Available","COVID19","Other: Questionnaires for specific phobia","Development of phobias","Medical University of Graz","All","18 Years to 90 Years   (Adult, Older Adult)",,"600","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","32-354 ex 19/20","April 15, 2020","April 15, 2023","April 15, 2024","April 24, 2020",,"May 6, 2020","Medical University of Graz, Graz, Styria, Austria",,"https://ClinicalTrials.gov/show/NCT04359121"
99,"NCT04363502","Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection",,"Recruiting","No Results Available","COVID","Drug: Clazakizumab|Drug: Placebo","Change in C-reactive protein (CRP) level","Johns Hopkins University","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB00247932","May 7, 2020","August 2020","August 2020","April 27, 2020",,"May 19, 2020","Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04363502"
100,"NCT04404361","PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer",,"Recruiting","No Results Available","COVID","Drug: Pacritinib|Drug: Placebo","Proportion of patients who progress to IMV and/or ECMO or death during the 28 days following randomization","CTI BioPharma","All","18 Years and older   (Adult, Older Adult)","Phase 3","358","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PAC319","May 22, 2020","July 31, 2020","October 31, 2021","May 27, 2020",,"June 17, 2020","Grady Memorial Hospital, Atlanta, Georgia, United States|St. Agnes Healthcare, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Ascension St. John Hospital, Grosse Pointe Woods, Michigan, United States|Ascension Providence Hospital- Novi Campus, Southfield, Michigan, United States|Providence Cancer Institute, Southfield, Michigan, United States|Atlantic Melanoma Center, Morristown, New Jersey, United States|Chilton Medical Center, Morristown, New Jersey, United States|Overlook Medical Center, Morristown, New Jersey, United States|Mount Sinai Medical Center, New York, New York, United States|The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, Cincinnati, Ohio, United States|St. John Medical Center, Tulsa, Oklahoma, United States|Rhode Island Hospital, Providence, Rhode Island, United States|The Miriam Hospital, Providence, Rhode Island, United States|Ascension All Saints, Racine, Wisconsin, United States|Ascension St. Francis Hospital, Racine, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04404361"
101,"NCT04391881","Oral Manifestation of COVID 19 Patient: A Cross Sectional Study on Egyptian Population",,"Not yet recruiting","No Results Available","Oral Health and COVID 19",,"Oral manifestation","Cairo University","All","18 Years to 60 Years   (Adult)",,"500","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","54678","May 30, 2020","June 30, 2020","June 30, 2020","May 18, 2020",,"May 18, 2020",,,"https://ClinicalTrials.gov/show/NCT04391881"
102,"NCT04371562","Predicting Death and ICU Admission in COVID-19 Patients in ED",,"Completed","No Results Available","COVID",,"7-day death|7-day ICU","Fondazione Policlinico Universitario Agostino Gemelli IRCCS","All","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","0017055/20","March 1, 2020","March 31, 2020","April 15, 2020","May 1, 2020",,"May 5, 2020","Marcello Covino, Roma, RM, Italy",,"https://ClinicalTrials.gov/show/NCT04371562"
103,"NCT04382924","Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Confirmed COVID-19 Infected Hospitalized Patients",,"Not yet recruiting","No Results Available","COVID","Drug: NP-120 (Ifenprodil)","Patient clinical status (on the WHO 7-point ordinal scale) at day 15 in IP versus SOC control group patients:|Status on an ordinal scale assessed daily while hospitalized and on days 15 and 28 in IP versus control group patients|NEWS assessed days 3, 5, 8 ,11 daily while hospitalized and on days 15 and 29 in IP versus control group patients|Rate of mechanical ventilation in IP versus control group patients|Duration of mechanical ventilation (if applicable) in IP versus control group patients|Duration of supplemental oxygen in IP versus control group patients|Time to return to room pressure (SpO2 > 94%) on room air|Duration in ICU (if applicable) in IP versus control group patients|Rate of Mortality in IP versus control group patients|Duration of hospitalization in IP versus control group patients|Time to discharge in IP versus control group patients|Effect on the rate of change of partial pressure of oxygen (PaO2) and PaO2/FiO2 ratio taken at baseline and measured once daily up to 2 weeks of treatment in IP versus control group patients","Algernon Pharmaceuticals|Novotech (Australia)","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","462","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AGN120-3","July 2020","January 2022","February 2022","May 11, 2020",,"May 11, 2020",,,"https://ClinicalTrials.gov/show/NCT04382924"
104,"NCT04367064","To Study the Clinical Characteristics and Treatment Outcome of COVID-19 Patients Admitted in Hospitals of Max Healthcare (SCOPe Study)","SCOPe","Recruiting","No Results Available","COVID",,"we will compare the clinical outcome of the COVID 19 patients with their age and gender|we will compare the effect of different treatments given to the COVID 19 patients at Max Hospital","Max Healthcare Insititute Limited","All","18 Years to 75 Years   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SCOPe/MHC/Covid-19/2020","April 25, 2020","June 25, 2020","July 25, 2020","April 29, 2020",,"April 29, 2020","Max Super Speciality hospital, Saket (A unit of Devki Devi Foundation), New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT04367064"
105,"NCT04399109","Evaluation of a Remote Monitoring Smartphone Application and Care Model of COVID-19 Patients in the Community (ReCOVER)","ReCOVER","Recruiting","No Results Available","COVID","Device: TCC-COVID mHealth solution","Rate of avoidable Emergency Department presentations per diagnosed COVID-19 case|All cause mortality per diagnosed COVID-19 case All-cause mortality rate at 30 days per diagnosed COVID-19 case|Rate of hospital admission per diagnosed COVID case|Rate of MBS claims for un-referred visits to general practitioners and analogous COVID-19 MBS telehealth items per diagnosed COVID case|Average length of stay (LOS) for admitted patients per diagnosed COVID case|Rate of admission to Intensive Care Unit (ICU) for admitted patients per diagnosed COVID case|Time from presentation to admission to ICU for patients admitted to ICU per diagnosed COVID case|Rate of intubation in admitted patients per diagnosed COVID case|Rate of readmission within 30 days of discharge in admitted patients per diagnosed COVID case|All-cause mortality at 90 days per diagnosed COVID case|Rate of avoidable Emergency Department presentations with COVID-19 diagnosis per 100,000 population, during trial period|Rate of hospital admission with COVID-19 diagnosis per 100,000 population, during trial period|Rate of admission to ICU with COVID-19 diagnosis per 100,000 population during trial period|Rate of mortality with COVID-19 cause of death per 100,000 population, during trial period|Qualitative assessment of TCC-COVID app usability via a subjective feedback questionnaire provided to all patients enrolled in the study.|Cost-effectiveness of TCC-COVID by measuring the incremental cost per death averted, per ICU admission averted and per length of stay in ICU|Rate of hospital bed days with COVID-19 diagnosis per 100,000 population, during trial period|Rate of ICU bed days with COVID-19 diagnosis per 100,000 population, during trial period|Qualitative assessment of KIOLA physician portal usability via a subjective feedback questionnaire","Dr Sze-Yuan Ooi|The University of New South Wales|The George Institute|South Eastern Sydney Local Health District|Prince of Wales Hospital, Sydney","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","PID00770","May 20, 2020","May 19, 2021","May 19, 2021","May 22, 2020",,"May 22, 2020","The Sutherland Hospital, Caringbah, New South Wales, Australia|St George Hospital, Kogarah, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT04399109"
106,"NCT04395768","International ALLIANCE Study of Therapies to Prevent Progression of COVID-19",,"Not yet recruiting","No Results Available","COVID19","Dietary Supplement: Vitamin C|Drug: Hydroxychloroquine|Drug: Azithromycin|Dietary Supplement: Zinc Citrate|Dietary Supplement: Vitamin D3|Dietary Supplement: Vitamin B12","Symptoms|Length of hospital stay|invasive mechanical ventilation or mortality|Mortality|mechanical ventilation|oxygen|ICU|days in hospital|days in ICU|renal replacement therapy|Extracorporeal support","National Institute of Integrative Medicine, Australia|Catholic Health Initiatives","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Alliance-COVID19","May 25, 2020","May 31, 2021","December 31, 2021","May 20, 2020",,"May 20, 2020",,,"https://ClinicalTrials.gov/show/NCT04395768"
107,"NCT04344548","Phase I / II Clinical Study of Immunotherapy Based on Adoptive Cell Transfer as a Therapeutic Alternative for Patients With COVID-19 in Colombia",,"Not yet recruiting","No Results Available","COVID","Biological: Allogeneic NK transfer","Adverse effects and Safety|NK transfer Immunogenicity","Universidad Nacional de Colombia|Fundación Salud de los Andes","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UNAL FSA COVID","April 13, 2020","June 10, 2020","November 10, 2020","April 14, 2020",,"April 14, 2020","Fundacion Salud De Los Andes, Bogotá, Bogotá Distrito Capital, Colombia|Universidad Nacional de Colombia, Bogota, Cundinamarca, Colombia",,"https://ClinicalTrials.gov/show/NCT04344548"
108,"NCT04365530","Become of Patients Infected or Suspected of Being Infected by Covid-19 and Supported by the GHPSJ and the Establishments of the Paris Plaisance Hospital City","COVIDGHPSJCite","Recruiting","No Results Available","COVID",,"Clinical consequences of a Covid-19 infection in the care population|Risk factors at M6|Risk factors at year 1|Risk factors at year 2|Impact of hospital reorganization on medical care at M6|Impact of hospital reorganization on medical care at Year 1|Impact of hospital reorganization on medical care at Year 2","Groupe Hospitalier Paris Saint Joseph","All","Child, Adult, Older Adult",,"2000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","Cohorte COVID GHPSJ CiteH","April 1, 2020","April 1, 2022","December 31, 2022","April 28, 2020",,"April 29, 2020","Hôpital Marie Lannelongue, Le Plessis-Robinson, France|AURA Paris Plaisance, Paris, France|Fondation Sainte-Marie, Paris, France|Groupe Hospitalier Paris Saint-Joseph, Paris, France|Hôpital Bellan, Paris, France",,"https://ClinicalTrials.gov/show/NCT04365530"
109,"NCT04351919","Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+)","COVID+PA","Not yet recruiting","No Results Available","Patients With COVID19","Drug: Hydroxychloroquine|Drug: Azithromycin","improvment or healing of clinical signs|Evolution of clinical signs","Abderrahmane Mami Hospital|Eshmoun Clinical Research Centre|Dacima Consulting","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","400","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ECC2020-04","May 5, 2020","July 15, 2020","July 15, 2020","April 17, 2020",,"May 5, 2020","Eshmoun Clinical Research Centre/ Hôpital Abderrahmen Mami-Ariana, Tunis, Tunisia",,"https://ClinicalTrials.gov/show/NCT04351919"
110,"NCT04355897","CoVID-19 Plasma in Treatment of COVID-19 Patients",,"Recruiting","No Results Available","COVID 19","Biological: Convalescent COVID 19 Plasma","Reduce mortality|Reduce requirement for mechanical ventilation.|Reduce the duration of mechanical ventilation.|Review of treatment related adverse events.","The Christ Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-23","April 28, 2020","July 2020","August 2020","April 21, 2020",,"May 20, 2020","The Christ Hospital, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04355897"
111,"NCT04382950","Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising COVID-19 Infection- and Lung Injury Preventing Drug Better Than Recombinant Human ACE2",,"Not yet recruiting","No Results Available","COVID","Combination Product: Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2) plus Aerosolized 13 cis retinoic acid","Time course of body temperature (fever)|Viral load over time|P/F ratio over time|Sequential organ failure assessment score(SOFA score) over time|Pulmonary Severity Index (PSI)|Image examination of chest over time|Proportion of subjects who progressed to critical illness or death|Time from first dose to conversion to normal or mild pneumonia|T-lymphocyte counts over time|C-reactive protein levels over time|Angiotensin II (Ang II) changes over time|Angiotensin 1-7 (Ang 1-7) changes over time|Angiotensin 1-5 (Ang 1-5) changes over time|Renin changes over time|Aldosterone changes over time|Angiotensin-converting enzyme (ACE) changes over time|Interleukin 6 (IL-6) changes over time|Soluble tumor necrosis factor receptor type II (sTNFrII) changes over time|Plasminogen activator inhibitor type-1 (PAI-1) changes over time|Von willebrand factor (vWF) changes over time|Tumor necrosis factor-α (TNF-α) changes over time|Soluble receptor for advanced glycation end products (sRAGE) changes over time|Surfactant protein-D (SP-D) changes over time|Frequency of adverse events and severe adverse events","Kafrelsheikh University","All","18 Years to 60 Years   (Adult)","Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COV-2019 Treatment This is","July 2020","November 2020","December 2020","May 11, 2020",,"June 4, 2020",,,"https://ClinicalTrials.gov/show/NCT04382950"
112,"NCT04369365","A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic",,"Recruiting","No Results Available","COVID","Drug: Azithromycin 500 milligram (mg) oral Tablet|Drug: Placebo","Cumulative number of severe acute respiratory syndrome corona virus 2 (SARS-COV-2) infections|Number of severe COVID-19 cases|Severity of COVID-19 cases|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Number of viral and bacterial infections|Number of participants with azithromycin-resistant bacterial strains in nasal swabs test","Prof. Dr. Matthias Preusser|Medical University of Vienna","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","OnCoVID-19 Trial","April 27, 2020","August 27, 2020","December 27, 2020","April 30, 2020",,"May 1, 2020","AKH Vienna, Department for Internal Medicine I, Oncology, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT04369365"
113,"NCT04366206","Factors Associated With Clinical Outcomes in Patients Hospitalized for Covid-19 in GHT-93 Est",,"Recruiting","No Results Available","COVID|SARS-CoV 2",,"Composite of death and mechanical ventilation|Need for mechanical ventilation|Death|Acute kidney injury|Acute respiratory distress syndrome|Cardiac arrhythmia and conduction disorder|60-days mortality|60-days mechanical ventilation","Centre Hospitalier Intercommunal Robert Ballanger|Groupe Hospitalier Pitie-Salpetriere","All","Child, Adult, Older Adult",,"143","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","GHTRB-2020-01","March 14, 2020","July 31, 2020","July 31, 2020","April 28, 2020",,"April 28, 2020","Centre Hospitalier Intercommunal Robert Ballanger, Aulnay-sous-Bois, France|Groupe Hospitalier Pitie Salpetriere, Paris, France",,"https://ClinicalTrials.gov/show/NCT04366206"
114,"NCT04354766","COVID-19 : Neutralizing Human Monoclonal Antibodies Against SARS-Cov-2","ANTI-COV-2","Recruiting","No Results Available","COVID","Other: Blood sample","Production of several human monoclonal antibodies capable of neutralizing the infection of a target cell by SARS-COV-2.","Hospices Civils de Lyon|Eurobio Scientific","All","18 Years and older   (Adult, Older Adult)",,"10","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","69HCL20_0340|2020-A01038-31","April 29, 2020","July 2020","July 2020","April 21, 2020",,"May 4, 2020","Hôpital de la Croix-Rousse, Lyon, France",,"https://ClinicalTrials.gov/show/NCT04354766"
115,"NCT04424004","MURDOCK Cabarrus County COVID-19 Prevalence and Immunity (C3PI) Study","C3PI","Not yet recruiting","No Results Available","COVID 19","Other: COVID-19 PCR and serology testing","Estimate the prevalence of COVID-19 infection based on responses to questionnaire items on symptoms and practices using a biweekly electronic survey.|Assess perceptions, concerns, and practices related to the COVID-19 pandemic and mitigation strategies|Estimate of the prevalence of active infection in Cabarrus County.|Estimate of the prevalence of exposure and potential immunity to COVID-19.","Duke University|North Carolina Department of Health and Human Services","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","Pro00105703","June 15, 2020","June 30, 2021","June 30, 2021","June 9, 2020",,"June 9, 2020",,,"https://ClinicalTrials.gov/show/NCT04424004"
116,"NCT04376580","Use of the Nasal Cannula During COVID-19",,"Enrolling by invitation","No Results Available","COVID 19",,"Number of physician using los flow nasal cannula during COVID 19 pandemia|Number of physician getting sick during Covid 19 pandemic","Tiva Group","All","Child, Adult, Older Adult",,"100","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","Nasal cannulas flow rate","April 30, 2020","July 31, 2020","September 30, 2020","May 6, 2020",,"May 21, 2020","Carolina Frederico, Buenos Aires, Caba, Argentina",,"https://ClinicalTrials.gov/show/NCT04376580"
117,"NCT04386239","Study on the Use of Sarilumab in Patients With COVID-19 Infection",,"Not yet recruiting","No Results Available","COVID19","Drug: Sarilumab Prefilled Syringe","Proportion of patients who show an improvement of the respiratory function|Evaluation of the time to resolution of fever|Evaluation of the viral load on blood and sputum for COVID-19|Evaluation of the plasma concentration of GM-CSF|Evaluation of the plasma concentration of Il-6|Evaluation of the plasma concentration of TNF-α|Evaluation of the rate of progression of White Blood Cell (WBC) fraction","ASST Fatebenefratelli Sacco","All","18 Years to 84 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID-SARI-001","May 2020","December 2020","December 2020","May 13, 2020",,"May 13, 2020",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT04386239/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04386239"
118,"NCT04392531","Clinical Trial to Assess Efficacy of cYclosporine Plus Standard of Care in Hospitalized Patients With COVID19",,"Recruiting","No Results Available","COVID19 Infection","Drug: Cyclosporine|Drug: Standard treatment","Severity Category|Mortality Rate|Number of Days in hospital|Number of days in ICU beds|Fio2 Needs|Adverse events rate|Change in CRP|Change in ferritin|Change in LDH|Change in CPK|Change in D Dimer|Change in IL-6|Change in KL-6|Change in Viral Load|Change specific antibodies","Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FJD-COVID19-20-01","April 16, 2020","July 2020","July 2020","May 19, 2020",,"May 19, 2020","Complejo Hospitalario Universitario La Coruña, La Coruña, Galicia, Spain|Hospital Quiron La Coruña, La Coruña, Galicia, Spain|Hospital Rey Juan Carlos, Mostoles, Madrid, Spain|Hospital Infanta Elena, Valdemoro, Madrid, Spain|Hospital General de Villalba, Villalba, Madrid, Spain|Fundacion Jimenez Diaz, Madrid, Spain|Clinica Universitaria de Navarra, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04392531"
119,"NCT04338828","Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED","NO COV-ED","Recruiting","No Results Available","COVID19","Drug: Nitric Oxide Gas|Other: Inhaled Supplemental Oxygen","Rates of return visits to the ED|Inpatient hospitalizations required|Rates of intubation|Rates of mortality","Massachusetts General Hospital|Department of Anesthesia, MGH","All","18 Years and older   (Adult, Older Adult)","Phase 2","260","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2019P00XXXX","April 18, 2020","April 2021","April 2022","April 8, 2020",,"May 20, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04338828"
120,"NCT04371952","DYNAMIC Study (DoxycYcliNe AMbulatoIre COVID-19)","DYNAMIC","Not yet recruiting","No Results Available","COVID19","Drug: Doxycycline|Drug: Placebo","Percentage of Patients with Clinical Respiratory Aggravation|Percentage of patients hospitalized|Percentage of patients requiring ventilatory assistance|Positive SARS-CoV-2 PCR Test|Duration of symptoms|Duration of hospitalization|Hospitalization intensive care or reanimation|Duration of mechanical ventilatory assistance|Percentage of deaths related to SARS-CoV-2|AE / SAE in both arms","Nantes University Hospital","All","46 Years and older   (Adult, Older Adult)","Phase 3","330","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RC20_0191","June 1, 2020","December 1, 2020","December 1, 2020","May 1, 2020",,"May 18, 2020","CHU Avicenne - APHP, Bobigny, France|CHU Bordeaux, Bordeaux, France|CHU Caen, Caen, France|CHU Dijon, Dijon, France|CHU Grenoble, Grenoble, France|CHU Nantes, Nantes, France",,"https://ClinicalTrials.gov/show/NCT04371952"
121,"NCT04438694","Use of Convalescent Plasma for Treatment of Patients With COVID-19 Infection","CP IN COVID19","Recruiting","No Results Available","COVID19","Drug: Convalescent Plasma","Duration of hospitalization/Recovery status","Cairo University","All","21 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","N39-2020","June 1, 2020","May 31, 2021","December 31, 2021","June 19, 2020",,"June 19, 2020","Cairo University Hospital, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04438694"
122,"NCT04379089","Neurologic Manifestations of COVID 19 in Children",,"Recruiting","No Results Available","COVID|Neurologic Manifestations","Other: Observational study only","Frequency of neurologic manifestations of COVID 19 among pediatric patients requiring hospital admission for confirmed or presumed COVID 19|Associations between prescription of empiric COVID-19 directed therapies and patient characteristics and outcomes among children with or without neurologic manifestations and confirmed or presumed COVID-19","University of Pittsburgh|University of Utah|Johns Hopkins University","All","up to 17 Years   (Child)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","STUDY20040154","April 29, 2020","December 31, 2021","December 31, 2022","May 7, 2020",,"May 7, 2020","UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04379089"
123,"NCT04338360","Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19",,"Available","No Results Available","COVID19","Biological: COVID-19 convalescent plasma",,"Mayo Clinic","All","18 Years and older   (Adult, Older Adult)",,,"Other","Expanded Access:Intermediate-size Population",,"20-003312",,,,"April 8, 2020",,"April 8, 2020","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic Health System in Albert Lea, Albert Lea, Minnesota, United States|Mayo Clinic Health System in Austin, Austin, Minnesota, United States|Mayo Clinic Health System in Cannon Falls, Cannon Falls, Minnesota, United States|Mayo Clinic Health System in Lake City, Lake City, Minnesota, United States|Mayo Clinic Health System in Mankato, Mankato, Minnesota, United States|Mayo Clinic Health System in Owatonna, Owatonna, Minnesota, United States|Mayo Clinic Health System in Red Wing, Red Wing, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|Mayo Clinic Health System - Eau Claire, Eau Claire, Wisconsin, United States|Mayo Clinic Health System - Franciscan Healthcare, La Crosse, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04338360"
124,"NCT04347538","Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19",,"Recruiting","No Results Available","COVID 19","Other: Saline Nasal Irrigation|Other: Saline with Baby Shampoo Nasal Irrigation","Change in SARS-CoV-2 mucosal immune response in the nasopharynx|Change in microbial load in the nasopharynx|Change in Viral Load in the nasopharynx over the course of COVID-19 infection|Symptom assessment|Temperature assessment","Vanderbilt University Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","200693","May 1, 2020","June 2021","June 2022","April 15, 2020",,"May 14, 2020","Vanderblt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04347538"
125,"NCT04377802","Safe Return to Regular Clinical Operation After COVID-19 Pandemic",,"Not yet recruiting","No Results Available","COVID 19","Diagnostic Test: molecular testing for virus RNA using RT-PCR","Health care provider safe return to work","King Fahad Specialist Hospital Dammam","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","400","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","KFSH-ONC-02","May 17, 2020","November 16, 2020","December 30, 2020","May 6, 2020",,"May 6, 2020","king Fahad specialist hospital, Dammam, Eastern Province, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT04377802"
126,"NCT04390464","mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)","TACTIC-R","Recruiting","No Results Available","COVID19","Drug: Ravulizumab|Drug: Baricitinib|Other: Standard of care","Time to incidence of the composite endpoint of: Death, Mechanical ventilation, ECMO, Cardiovascular organ support, or Renal failure|Change in clinical status as assessed on 7-point ordinal scale compared to baseline|Proportion of patients with adverse events of special interest in each treatment arm|Time to Sp02 >94% on room air|Time to first negative SARS-CoV2 PCR|Duration of oxygen therapy|Duration of hospitalisation|All cause mortality at day 28|Time to clinical improvement","Cambridge University Hospitals NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)","Phase 4","1167","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TACTIC-R","May 8, 2020","May 7, 2021","May 1, 2022","May 15, 2020",,"May 18, 2020","Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04390464"
127,"NCT04350320","Trial to Study the Benefit of Colchicine in Patients With COVID-19","COL-COVID","Recruiting","No Results Available","COVID19","Drug: Colchicine Tablets|Drug: Standard therapy for COVID-19 according to the stablished hospital protocols.","Changes in the patients' clinical status through the 7 points ordinal scale WHO R&D Blueprint expert group|Changes in IL-6 concentrations|Improvement in the clinical status|Changes in the score for the Sequential Organ Failure Assessment (SOFA score)|Changes in the punctuation in the National Early Warning Score|Number of days with invasive mechanical ventilation|Number of days with high flow oxygen therapy|Changes in other inflammatory markers|Changes in severity markers|Changes in myocardial damage|Time until reaching a virus negative status|Length of hospital stay|Number of days in the intensive care unit.|Mortality","Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia","All","18 Years and older   (Adult, Older Adult)","Phase 3","102","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IMIB-COLVID-2020-03","April 30, 2020","October 20, 2020","November 20, 2020","April 17, 2020",,"May 5, 2020","Virgen de la Arrixaca University Clinical Hospital, Murcia, Spain",,"https://ClinicalTrials.gov/show/NCT04350320"
128,"NCT04343794","Using Biovitals® Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19",,"Recruiting","No Results Available","COVID19","Device: BIOVITALS","Time to diagnosis of COVID-19 by RT-PCR in subjects|Compliance to complete the study|Sensitivity and specificity of Biovitals® Sentinel|Cross infection rate within the family cluster|Length of hospital stay of positive subjects|Length of ICU stay of positive patients|National Early Warning Score 2 rating of positive patients|Viral load of positive patients|Worsening of comorbidities|Mortality","The University of Hong Kong","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","COVID19_Biovitals_Protocol_1","April 1, 2020","December 31, 2021","January 31, 2022","April 13, 2020",,"April 15, 2020","The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04343794"
129,"NCT04334252","Descriptive Study Regarding Ambulant Screening During COVID-19 Pandemia",,"Recruiting","No Results Available","COVID 19","Other: Questionnaire","Prevalence of symptoms|Prevalence of positive Sars CoV-2 PCR|Prevalence of positive radiological findings|Prediction of symptoms","Jessa Hospital","All","18 Years and older   (Adult, Older Adult)",,"5000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","JessaH_COVID19_prescreening","April 17, 2020","December 20, 2020","December 20, 2020","April 6, 2020",,"May 19, 2020","Jessa hospital, Hasselt, Belgium",,"https://ClinicalTrials.gov/show/NCT04334252"
130,"NCT04437693","Post Exposure Prophylaxis in Healthcare Workers Exposed to COVID-19 Patients","HCQ-COVID19","Not yet recruiting","No Results Available","COVID 19","Drug: Hydroxychloroquine","Prevention of SARS-CoV-2 infection|Presence of any adverse effects related to HCQ|Incidence of COVID-19 related symptoms","Hamad Medical Corporation","All","18 Years to 60 Years   (Adult)","Phase 3","500","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","MRC-02-20-442","July 1, 2020","June 30, 2021","December 31, 2021","June 18, 2020",,"June 18, 2020",,,"https://ClinicalTrials.gov/show/NCT04437693"
131,"NCT04368260","Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic",,"Recruiting","No Results Available","COVID19","Device: Control swab|Device: Prototype swab","Number of subjects for which the prototype swab and the control swab provide the same COVID-19 PCR result","University of Virginia","All","up to 99 Years   (Child, Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","HSR200127","April 24, 2020","July 31, 2020","July 31, 2020","April 29, 2020",,"April 29, 2020","University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04368260"
132,"NCT04335097","Sensor Based Vital Signs Monitoring of Covid 19 Patients During Home Isolation","HSC19","Recruiting","No Results Available","COVID 19","Device: Biosensors","Stop home isolation|NEWS score|Clinic at hospitalization|Symptoms developed|Relative/peers evaluation of the patient|Serious of symptoms at admittance hospital","Lars Wik|University of Stavanger|Oslo University Hospital|Norwegian Telemedicine|University of Basque Country (UPV/EHU)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","214","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","127157","April 22, 2020","April 8, 2021","December 20, 2025","April 6, 2020",,"May 13, 2020","Lillestrom legevakt, Lillestrom, Norway",,"https://ClinicalTrials.gov/show/NCT04335097"
133,"NCT04341506","Non-contact ECG Sensor System for COVID19",,"Not yet recruiting","No Results Available","COVID-19","Device: Non-contact ECG","ECG changes associated with COVID-19","Northwestern Medicine","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-0407","April 15, 2020","July 15, 2020","September 15, 2020","April 10, 2020",,"April 10, 2020",,,"https://ClinicalTrials.gov/show/NCT04341506"
134,"NCT04354610","Cardiovascular and Renal Biomarkers to Predict Acute Heart or Kidney Injury in Severe Covid-19 Infection","Nancy-CovH-AKI","Recruiting","No Results Available","COVID 19","Procedure: Biological samples specific to research|Procedure: Clinical examination|Procedure: Telephone follow-up","Worsening of renal function by at least KDIGO grade 1 during hospitalization for Covid-19 infection|Troponin greater than 99th percentile during hospitalization for Covid-19 infection|AKI KDIGO grade 1 or higher in hospitalisation (approach with AND without a priori)|Elevation of troponin> 99th percentile in hospitalisation (approach with AND without a priori)|AKI KDIGO grade 1 or higher|Association with troponin elevation >99th|Association with elevation of serum creatinine >30%|With the onset of chronic renal failure (eDFG <60 ml / min / 1.73m2)|The occurrence of cardiovascular events (stroke, myocardial infarction, hospitalisation for heart failure, cardiovascular death) during hospitalisation and three months after discharge from hospital|The occurrence of death from any cause during hospitalisation and three months after discharge from hospital","Central Hospital, Nancy, France","All","18 Years and older   (Adult, Older Adult)","Not Applicable","57","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2020PI072","April 27, 2020","July 18, 2020","October 18, 2020","April 21, 2020",,"May 6, 2020","CHRU de Nancy, Nancy, France|CHRU de Nancy, Vandœuvre-lès-Nancy, France",,"https://ClinicalTrials.gov/show/NCT04354610"
135,"NCT04441710","Caregiver Serological Monitoring Extended Secondarily to Patients With the SARS-CoV-2 Coronavirus","CoVid3S","Not yet recruiting","No Results Available","COVID","Other: Questionnaire","Establishment of a reliable prediction model for the effectiveness of virus control","Hospices Civils de Lyon","All","Child, Adult, Older Adult",,"2500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","69HCL20_0395","July 2020","January 2022","January 2022","June 22, 2020",,"June 22, 2020","CHU de Grenoble - Hôpital Nord, La Tronche, France|Hôpital de la Croix Rousse, Lyon, France|Hôpital Henry Gabrielle, Saint-Genis-Laval, France|CHU de Saint Etienne, Saint-Étienne, France",,"https://ClinicalTrials.gov/show/NCT04441710"
136,"NCT04416347","COVID19 Clinical Predictors and Outcome",,"Recruiting","No Results Available","COVID|SARS-CoV 2","Other: SARS-CoV2 Infection","SARS-CoV-2 hospital mortality|SARS-CoV-2 mortality in critical care unit","St George's University Hospitals NHS Foundation Trust|St George's, University of London","All","18 Years and older   (Adult, Older Adult)",,"800","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2020.0115","June 15, 2020","April 30, 2022","April 30, 2022","June 4, 2020",,"June 19, 2020","St. George's University Hospitals Foundation Trust., London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04416347"
137,"NCT04399603","Mechanisms of Multi-organ Failure in COVID-19",,"Not yet recruiting","No Results Available","COVID","Other: no intervention-mechanistic study","Variation in inflammatory mediators in patients with multi-organ failure suffering from COVID-19|Correlation of inflammatory mediators in the bronchoalveolar lavage fluid with extent of lung injury (e.g. based upon oxygen requirement)|Correlation of circulating inflammatory mediators with renal and cardiovascular markers|Assess the role of inflammatory mediators obtained from patients in the development of renal injury using in vitro models (i.e. applying these inflammatory mediators isolated from these clinical samples on kidneys cells in a petri dish)","Imperial College London","All","18 Years to 90 Years   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Other|Time Perspective: Prospective","283783","May 18, 2020","November 17, 2021","November 17, 2021","May 22, 2020",,"May 22, 2020","Imperial College NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04399603"
138,"NCT04356677","Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19",,"Not yet recruiting","No Results Available","COVID19","Drug: 50 mg/mL Virazole|Drug: 100 mg/mL Virazole","Change in the clinical status severity (CSS) rating from the first dose date up to the completion of treatment|Time to recover gas exchange to a PaO2/FiO2 ≥300 for at least 24 hours.|Time to reach peripheral capillary oxygen saturation (Sp02) >94% for at least 24 hours.","Bausch Health Americas, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BHC-RIB-5401-HC","April 2020","April 2021","April 2021","April 22, 2020",,"April 22, 2020",,,"https://ClinicalTrials.gov/show/NCT04356677"
139,"NCT04348383","Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.","DEFACOVID","Recruiting","No Results Available","COVID19","Drug: Defibrotide 25 mg/kg 24 hours continuous infusion for 15 days|Drug: Placebo 250 cc 24 hours continuous infusion for 15 days","1. Mortality rate|Clinical improvement by WHO|Clinical improvement by NEWS2 scales|Biologic response|Radiological response|Collection and storage of biological samples","Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IMIB-DFC-2020-02","April 8, 2020","July 8, 2020","August 8, 2020","April 16, 2020",,"April 17, 2020","Virgen de la Arrixaca University Clinical Hospital, Murcia, Spain",,"https://ClinicalTrials.gov/show/NCT04348383"
140,"NCT04429334","Safety, Tolerability and Efficacy of Nangibotide in Mechanically Ventilated Patients With COVID-19 and Features of Systemic Inflammation",,"Not yet recruiting","No Results Available","COVID19","Drug: nangibotide|Drug: placebo","Adverse Events|Mortality","Inotrem","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MOT-C-204","June 2020","March 2021","March 2021","June 12, 2020",,"June 12, 2020","Réanimation Médicale, Hôpital Central, Nancy, France",,"https://ClinicalTrials.gov/show/NCT04429334"
141,"NCT04374487","A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications",,"Not yet recruiting","No Results Available","COVID 19","Drug: Convalescent Plasma|Other: Standard Care Therapy","The primary outcome is a composite measure of the avoidance of - 1. Progression to severe ARDS (P/F ratio 100) and 2. All-cause Mortality at 28 days|Time to symptom resolution-Fever,Shortness of Breath,Fatigue|Hospital length of stay|Change in SOFA pre and post transfusion|Duration of respiratory support required a. Duration of Invasive Mechanical Ventilation b. Duration of Non-Invasive|Radiological improvement|Adverse events (AE) associated with transfusion|To measure the change in RNA levels (Ct values) of SARS-CoV-2 from RT-PCR [Time Frame: Days 0, 1, 3, and 7 after transfusion]|Levels of bio-markers pre and post transfusion|Need of Vasopressor use","Max Healthcare Insititute Limited","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MHC-COVID-19-CP","May 9, 2020","May 9, 2021","May 9, 2021","May 5, 2020",,"May 5, 2020","Max Super Speciality hospital, Saket (A unit of Devki Devi Foundation), New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT04374487"
142,"NCT04355715","Combination of Chest Scanography and Nasal Viral Detection Test to Detect COVID-19 Positive Patients Before Surgical Intervention in a University Hospital During Coronavirus Pandemia","COVID-Scan","Active, not recruiting","No Results Available","COVID 19|SARS-Cov-2",,"Confirmed diagnosis of COVID-19 infection|Incidence of unexpected COVID-19 positive patients admitted to the hospital|Number of contaminating events avoided by the early detection of COVID-19 patients|Incidence of SARS-Cov-2 seroconversion","University Hospital, Montpellier","All","18 Years to 99 Years   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RECHMPL20_0223","April 1, 2019","October 1, 2020","October 20, 2020","April 21, 2020",,"April 27, 2020","Uh Montpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04355715"
143,"NCT04346329","Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19","Chloroquine UN","Not yet recruiting","No Results Available","COVID","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Adverse effects|Immune-score|COVID-19 prevention|Clinical response","Universidad Nacional de Colombia|Fundación Salud de los Andes","All","18 Years and older   (Adult, Older Adult)","Phase 3","86","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","UNAL-COVID-CP","April 20, 2020","June 1, 2020","October 1, 2020","April 15, 2020",,"April 15, 2020","Facultad de Medicina - Universidad Nacional de Colombia, Bogota, Cundinamarca, Colombia|Universidad Nacional de Colombia, Bogota, Cundinamarca, Colombia",,"https://ClinicalTrials.gov/show/NCT04346329"
144,"NCT04341207","Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients","ONCOVID","Recruiting","No Results Available","Cancer & COVID 19","Drug: Hydroxychloroquine|Drug: Azithromycin","Prevalence and the 3-months incidence of SARS-CoV-2 in cancer patients|Covid-19 disease-specific mortality rate in cancer patients treated by hydroxychloroquine and azithromycin","Gustave Roussy, Cancer Campus, Grand Paris","All","18 Years and older   (Adult, Older Adult)","Phase 2","1000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-001250-21|2020/3078","April 3, 2020","April 2022","April 2022","April 10, 2020",,"April 10, 2020","Gustave Roussy, Villejuif, Val De Marne, France",,"https://ClinicalTrials.gov/show/NCT04341207"
145,"NCT04443712","Screening for Patients Admitted to Ain-Shams University Hospitals for SARS-COV-2 (COVID19)",,"Recruiting","No Results Available","Coronavirus Disease 2019 (COVID19)",,"The incidence of the new COVID19 among hospitalized patients|Cost of screening hospitalized patients","Samia Girgis|Ain Shams University","All","Child, Adult, Older Adult",,"1900","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","FMASU P29 /2020","May 29, 2020","June 1, 2021","December 1, 2021","June 23, 2020",,"June 23, 2020","Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt",,"https://ClinicalTrials.gov/show/NCT04443712"
146,"NCT04343261","Convalescent Plasma in the Treatment of COVID 19",,"Enrolling by invitation","No Results Available","SARS-CoV-2|COVID|Coronavirus","Biological: Convalescent Plasma","Mortality|Viral Load|Serum Antibody Titers","Saint Francis Care","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","47","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SFH-20-23","April 10, 2020","December 1, 2020","April 1, 2021","April 13, 2020",,"June 17, 2020","Trinity Health Of New England, Hartford, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT04343261"
147,"NCT04363099","Multicentre Observational Study on Management COVID 19 Positive Outpatients in a French Cluster.","COVID AMBU 60","Recruiting","No Results Available","Covid-19","Other: observational","clinical description of covid 19 ambulatory cases.|Biological and radiological description of ambulatory cases|Prevalence of positive cases (PCR and/or serological positive)","Maison de Sante Pluridisciplinaire de Creil","All","up to 99 Years   (Child, Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","2020-A01059-30","March 1, 2020","June 30, 2020","December 31, 2020","April 27, 2020",,"April 27, 2020","Msp de Creil, Creil, France",,"https://ClinicalTrials.gov/show/NCT04363099"
148,"NCT04414410","Echocardiography in Critically-ill Patients With COVID-19 Pneumonia","ECHO-COVID","Enrolling by invitation","No Results Available","COVID|Sars-CoV2",,"Incidence of Left ventricular systolic dysfunction|Incidence of RV failure|Incidence of Vasoplegia|Incidence of Hypovolemia|Relation between plateau pressure and RV failure|Relation between tidal volume and RV failure|Relation between PaO2 and RV failure|Relation between PaCO2 and RV failure|Relation between PEEP and RV failure","Hospital Ambroise Paré Paris","All","Child, Adult, Older Adult",,"1500","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","RedCap19","May 12, 2020","September 30, 2020","September 30, 2020","June 4, 2020",,"June 4, 2020","University Hospital Ambroise Pare, Boulogne-Billancourt, Hauts De Seine, France",,"https://ClinicalTrials.gov/show/NCT04414410"
149,"NCT04434417","Validation of an Immunochromatographic Assay for IgG/IgM Antibodies to 2019- nCoV","I-GLOBAL","Recruiting","No Results Available","COVID","Device: 2019-nCoV IgG/IgM Rapid Test Cassette","Evaluation of the rate of SARS-CoV-2 positive cancer patients and health professionals in a comprehensive cancer center or in a cancer setting.|Evaluation of test accuracy|Interleukin-6 quantification|Interleukin-2 quantification|Interleukin-1 quantification|Tumor Necrosis Factor (TNF) quantification|Interferon gamma quantification","European Institute of Oncology|Azienda Socio-Sanitaria Territoriale di Cremona|Azienda Ospedaliera Niguarda Cà Granda|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|Papa Giovanni XXIII Hospital","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","I-GLOBAL","April 15, 2020","July 31, 2020","December 31, 2020","June 16, 2020",,"June 16, 2020","Papa Giovanni XXIII Hospital, Bergamo, Italy|Azienda Socio-Sanitaria Territoriale di Cremona, Cremona, Italy|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Milano, Italy|Azienda Ospedaliera Niguarda Cà Granda, Milano, Italy|European IO, Division of Early Drug Development for Innovative Therapies, Milan, Italy","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT04434417/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04434417"
150,"NCT04382469","Egyptian Initial Experience About 2019 Novel Corona Virus: Study of 48 Patients in Alexandria-Egypt Using Chest CT",,"Completed","No Results Available","COVID",,"Radiological pattern of initial presentation, disease progress, healing and recovery|Survey of co-morbid lung diseases","Alexandria University","All","Child, Adult, Older Adult",,"48","Other","Observational","Observational Model: Case-Crossover|Time Perspective: Retrospective","IRB (00012098), FWA (00018699)","February 1, 2020","April 30, 2020","May 1, 2020","May 11, 2020",,"May 12, 2020","Faculty of Medicine, University of Alexandria, Alexandria, Egypt",,"https://ClinicalTrials.gov/show/NCT04382469"
151,"NCT04416893","Part 2 on the Study Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children (COVILLE2 )","COVILLE2","Not yet recruiting","No Results Available","COVID19","Diagnostic Test: RT-PCR SARS-Cov2|Diagnostic Test: Sars-Cov2 serology","Proportion of asymptomatic children or children with mild respiratory symptoms|Cov2-SARS cases by age|Cov2-SARS cases by symptoms|Viral load|Presence of anti-SARS-CoV-2 antibodies (IgM and IgG) by the rapid serological test","Centre Hospitalier Intercommunal Creteil|Association Clinique Thérapeutique Infantile du val de Marne|GPIP|GFRUP","All","up to 15 Years   (Child)",,"630","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVILLE2","June 7, 2020","September 15, 2020","November 15, 2020","June 4, 2020",,"June 4, 2020",,,"https://ClinicalTrials.gov/show/NCT04416893"
152,"NCT04374838","Effect of COVID-19 Pandemic on Pediatric Cancer Care",,"Not yet recruiting","No Results Available","Covid19",,"pediatric cancer care pattern during COVID 19 pandemic","South Egypt Cancer Institute","All","Child, Adult, Older Adult",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","COVID-19 and Pediatric Cancer","May 15, 2020","December 15, 2020","May 15, 2021","May 5, 2020",,"May 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04374838"
153,"NCT04387292","Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic","SOCOVID","Recruiting","No Results Available","COVID19|Ophthalmopathy","Procedure: Ophthalmologic exam","Description of the ophthalmological problems observed","Fondation Ophtalmologique Adolphe de Rothschild","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","MMT_2020_12","June 2020","February 2021","February 2021","May 13, 2020",,"May 13, 2020","Fondation A de Rothschild, Paris, France",,"https://ClinicalTrials.gov/show/NCT04387292"
154,"NCT04441372","Prognostication of Oxygen Requirement in Non-severe SARS-CoV-2 (COVID-19) Respiratory Infection","PRIORITY","Not yet recruiting","No Results Available","Sars-CoV2|COVID",,"Clinical and biochemical prognostic markers|Performance of LMIC-friendly POC|Safe and ethical operational research","Medecins Sans Frontieres, Spain|Mahidol Oxford Tropical Medicine Research Unit|International Centre for Diarrhoeal Disease Research, Bangladesh","All","18 Years and older   (Adult, Older Adult)",,"850","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MSF0001","August 1, 2020","February 1, 2021","March 1, 2021","June 22, 2020",,"June 25, 2020","International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh",,"https://ClinicalTrials.gov/show/NCT04441372"
155,"NCT04372472","SQuISH-COVID: A Pilot Study",,"Active, not recruiting","No Results Available","Sepsis|COVID-19",,"To demonstrate the performance of the SeptiScan System as a diagnostic marker of life-threatening organ dysfunction caused by a dysregulated host immune response to infection.","Cytovale, Inc.|Biomedical Advanced Research and Development Authority","All","18 Years and older   (Adult, Older Adult)",,"300","Industry|U.S. Fed","Observational","Observational Model: Cohort|Time Perspective: Prospective","CV-CLN-003","April 7, 2020","May 29, 2020","May 29, 2020","May 4, 2020",,"May 4, 2020","Our Lady of the Lake Regional Medical Center, Baton Rouge, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT04372472"
156,"NCT04438070","COVID Screening Strategies in Homeless Shelters",,"Recruiting","No Results Available","COVID-19","Diagnostic Test: COVID-19 Swab","COVID-19 Detection Rate|Number of outbreaks|Enrollment over time","St. Joseph's Healthcare Hamilton|Timothy O'Shea|Marek Smieja|Lawrence Mbuagbaw","All","18 Years and older   (Adult, Older Adult)","Not Applicable","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","2020-10864-T","April 10, 2020","June 2020","June 2020","June 18, 2020",,"June 18, 2020","Various Homeless Shelters, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04438070"
157,"NCT04409886","Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients","HBOT","Not yet recruiting","No Results Available","COVID, Coronavirus","Device: Hyperbaric Chamber","Oxygenation index|SpO2|Symptoms level|Chest Xray","Maimonides Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","120-20-ASF","June 1, 2020","December 31, 2020","March 30, 2021","June 1, 2020",,"June 11, 2020",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT04409886/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04409886"
158,"NCT04380662","Risk Factors Worsening COVID19 for Out-patient With Home Monitoring","COVIDADOMEVA","Not yet recruiting","No Results Available","Covid19","Other: Risk factors","Identify the factors associated with the worsening of the COVID19|Describe the clinical care pathway of patients from Day 0 to Day 14|Describe the health status at Day 30|Describe the quality of life during the disease","University Hospital, Grenoble","All","Child, Adult, Older Adult",,"800","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","38RC20.135|2020-A01040-39","June 30, 2020","September 30, 2020","December 30, 2020","May 8, 2020",,"June 22, 2020","Grenoble University Hospital, Grenoble, France",,"https://ClinicalTrials.gov/show/NCT04380662"
159,"NCT04424771","Post-traumatic Stress Disease in Health Workers During COVID-19 Pandemia",,"Recruiting","No Results Available","COVID|Post Traumatic Stress Disorder","Behavioral: Maslach Burnout Inventory (MBI)","Number of patients with diagnosis of PTSD.","Ospedale Policlinico San Martino","All","18 Years to 70 Years   (Adult, Older Adult)",,"800","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PTSD-COVID-19","March 1, 2020","June 30, 2020","July 1, 2020","June 11, 2020",,"June 11, 2020","Ospedale Perrino Asl Brindisi, Brindisi, Italy|IRCCS Ospedale Policlinico San Martino, Genoa, Italy",,"https://ClinicalTrials.gov/show/NCT04424771"
160,"NCT04435522","Maraviroc in SARS-CoV-2",,"Not yet recruiting","No Results Available","COVID","Drug: Maraviroc","Safety and Tolerability|Time to clinical improvement, defined as time from enrollment to an improvement of two points on a seven-category ordinal scale (defined below) or live discharge from the hospital, whichever comes first.|Change in Biomarker Levels|Mortality|Time to Discharge|Days on mechanical ventilation","Rhode Island Hospital","All","18 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","16","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1611471-1","September 2020","December 2020","December 2020","June 17, 2020",,"June 17, 2020","Rhode Isand Hospital, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT04435522"
161,"NCT04342884","COVID-19 Community Research Partnership",,"Recruiting","No Results Available","Coronavirus|COVID",,"Seroprevalence of SARS-CoV-2 infection in the general population of North Carolina|Seroprevalence of SARS-CoV-2 infection among health care workers of North Carolina|Cumulative incidence of SARS-CoV-2 infection|Monthly incidence of SARS-CoV-2 infection|Stratified incidence of SARS-CoV-2 infection by age group|Stratified incidence of SARS-CoV-2 infection by sex|Stratified incidence of SARS-CoV-2 by season|Stratified incidence of SARS-CoV-2 infection by geographic area (zip code)|Stratified incidence of SARS-CoV-2 infection by preexisting comorbidities|Stratified incidence of SARS-CoV-2 infection by COVID-2 contacts|Stratified incidence of SARS-CoV-2 infection by use of personal protective equipment (PPE) by health workers|Relative risk of SARS-CoV-2 infection by age group|Relative risk of SARS-CoV-2 infection by sex|Relative risk of SARS-CoV-2 infection by season|Relative risk of SARS-CoV-2 infection by geographic area (zip code)|Relative risk of SARS-CoV-2 infection by preexisting comorbidities|Relative risk of SARS-CoV-2 infection by COVID-2 contacts|Relative risk of SARS-CoV-2 infection by use of PPE by health workers|Incidence of sequelae","Wake Forest University Health Sciences","All","Child, Adult, Older Adult",,"150000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00064912","April 8, 2020","December 2021","December 2021","April 13, 2020",,"June 11, 2020","Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04342884"
162,"NCT04360824","Covid-19 Associated Coagulopathy",,"Recruiting","No Results Available","COVID 19 Associated Coagulopathy","Drug: Intermediate dose thromboprophylaxis|Drug: Standard of Care thromboprophylaxis","Mortality|Major Bleeding|Arterial Thrombosis|Venous Thromboembolism|ICU admission, intubation/ventilation|Packed Red Blood Cell Transfusions|Platelet Transfusions|Fresh Frozen Plasma Transfusions|Cryoprecipitate Transfusions|Prothrombin Complex Concentrate Transfusions","University of Iowa","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 4","170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","202004235","May 6, 2020","April 16, 2021","April 16, 2021","April 24, 2020",,"June 19, 2020","University of Iowa, Iowa City, Iowa, United States|Gundersen Health System, La Crosse, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04360824"
163,"NCT04344756","Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort","CORIMMUNO-COAG","Not yet recruiting","No Results Available","COVID19 Pneumonia","Drug: Tinzaparin or unfractionated heparin","Survival without ventilation (VNI or mechanical ventilation)|ventilator free survival|World Health Organisation(WHO) progression scale ≤5|World Health Organisation(WHO) progression scale|overall survival|Length of hospital stay|Length of ICU stay|time to oxygenation supply independency|time to ventilator (non invasive or invasive)|rate of acute kidney injury|time to Renal Replacement Therapy (RRT) initiation|rate of clinically overt pulmonary embolism or proximal deep vein thrombosis|Rate of clinically overt arterial thrombosis|Rate of unscheduled central venous catheter replacement for catheter dysfunction|Rate of central venous catheter-related deep vein thrombosis (CVC-DVT)|Rate of unscheduled indwelling arterial catheter replacement for catheter dysfunction|Rate of acute clotting leading to the replacement the renal replacement therapy circuit stratified by regional citrate anticoagulation or not|Time to acute clot formation within the oxygenator (acute oxygenator thrombosis, AOT) leading to the exchange of an extracorporeal membrane oxygenation (ECMO) system|Time to acute clot formation within the pump head (pump head thrombosis, PHT) leading to the exchange of an extracorporeal membrane oxygenation (ECMO) system|Incidence of adverse events","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 2","808","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200389-6","April 20, 2020","July 31, 2020","September 30, 2020","April 14, 2020",,"April 15, 2020","Réanimation hôpital Louis Mourier, Colombes, Hauts De Seine, France|réanimation hôpital Cochin, Paris, France|Médecine vasculaire, Hôpital Européen Georges Pompidou, Paris, France",,"https://ClinicalTrials.gov/show/NCT04344756"
164,"NCT04401293","Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients",,"Recruiting","No Results Available","Sars-CoV2|COVID","Drug: Enoxaparin|Drug: Prophylactic/Intermediate Dose Enoxaparin","Composite outcome of arterial thromboembolic events, venous thromboembolic events and all-cause mortality at Day 30 ± 2 days.|Major bleeding|Composite outcome of arterial thromboembolic events, venous thromboembolic events and all-cause mortality at Hospital Day 10 + 4|Sepsis-induced coagulopathy (SIC) score|Progression to Acute Respiratory Distress Syndrome (ARDS)|Need for Intubation|Re-hospitalization","Northwell Health","All","18 Years and older   (Adult, Older Adult)","Phase 3","308","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20-0340","April 26, 2020","October 22, 2020","April 26, 2021","May 26, 2020",,"June 9, 2020","Beth Israel Newark, Newark, New Jersey, United States|Southside Hospital, Bay Shore, New York, United States|Huntington Hospital, Huntington, New York, United States|Lenox Hill Hospital, New York, New York, United States|Long Island Jewish Medical Center, Queens, New York, United States|Staten Island University Hospital, Staten Island, New York, United States",,"https://ClinicalTrials.gov/show/NCT04401293"
165,"NCT04344782","Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin®/Zeribev®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort","CORIMMUNO-BEVA","Not yet recruiting","No Results Available","COVID19 Pneumonia","Drug: Bevacizumab Injection","Proportion of surviving patients without need for intubation for respiratory support|Saturation of Oxygen in the blood (SaO2)|Arterial oxygen partial pressure (paO2)|Ratio of arterial oxygen partial pressure to fractional inspired oxygen (paO2/FiO2)|CT-scan score|dyspnea|overall survival|admissionn to the intensive care unit (ICU)|incidence of mechanical ventilation|hospital length of stay|incidence of adverse event|VEGF plasma concentration","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 2","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200389-7","April 15, 2020","September 30, 2020","November 30, 2020","April 14, 2020",,"April 17, 2020",,,"https://ClinicalTrials.gov/show/NCT04344782"
166,"NCT04361942","Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV)","COVID_MSV","Recruiting","No Results Available","COVID-19 Pneumonia","Biological: Mesenchymal Stromal Cells|Other: Placebo","Proportion of patients who have achieved withdrawal of invasive mechanical ventilation|Rate of mortality|Proportion of patients who have achieved clinical response|Proportion of patients who have achieved radiological responses","Red de Terapia Celular|Citospin|University of Valladolid|Castilla-León Health Service|Hospital del Río Hortega|Instituto de Salud Carlos III","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","TerCel_007|2020-001682-36","April 2020","November 30, 2020","December 31, 2020","April 24, 2020",,"April 29, 2020","Hospital Universitario Rio Hortega, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT04361942"
167,"NCT04362150","Long-term Impact of Infection With Novel Coronavirus (COVID-19)","LIINC","Recruiting","No Results Available","COVID",,"Participant age|Participant sex|Participant race/ethnicity|Proportion of participants previously hospitalized.","University of California, San Francisco","All","18 Years to 100 Years   (Adult, Older Adult)",,"800","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-30479","April 21, 2020","December 31, 2022","December 21, 2024","April 24, 2020",,"May 29, 2020","Zuckerberg San Francisco General Hospital (ZSFG), San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT04362150"
168,"NCT04339608","Max COVID19- Study",,"Recruiting","No Results Available","COVID-19",,"COVID-19 positive case","Max Healthcare Insititute Limited","All","18 Years and older   (Adult, Older Adult)",,"10000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Covid-19/MHC/2020","April 2, 2020","May 30, 2020","June 30, 2020","April 9, 2020",,"April 9, 2020","Max Super Speciality Hospital, A Unit of Devki Devi Foundation, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT04339608"
169,"NCT04372602","Duvelisib to Combat COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Duvelisib|Procedure: Peripheral blood draw","Overall survival|Length of hospital stay|Length of ICU stay|Duration of ventilator use|Duration of vasopressors use|Duration on renal replacement therapy|Viral kinetics as measured by virologic failure|Number of adverse events as measured by CTCAE v. 5.0","Washington University School of Medicine|Verastem, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","04-28-20-DiPersio","June 30, 2020","July 31, 2021","December 31, 2021","May 4, 2020",,"May 4, 2020","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04372602"
170,"NCT04366960","Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients","X-Covid 19","Recruiting","No Results Available","Covid19","Drug: Enoxaparin","Incidence of venous thromboembolism detected by imaging|In hospital major complications|Number of deep venous thrombosis events|Sequential organ failure assessment|C-reactive protein|Interleukin‐6|D-dimer|hs-troponin levels|Acute Respiratory Distress Syndrome|Hospital stay|Right ventricular function|Number of pulmonary embolism events","Niguarda Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 3","2712","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-001708-41","May 14, 2020","August 2020","November 2020","April 29, 2020",,"May 15, 2020","Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milano, Italy",,"https://ClinicalTrials.gov/show/NCT04366960"
171,"NCT04355052","Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to ""no Treatment"" in SARS CoV 2 Virus","COSTA","Recruiting","No Results Available","COVID - 19","Drug: hydroxychloroquine in combination with camostat mesylate|Drug: Hydroxychloroquine in combination of Azithromycin","clinical state as reflected by NEWS scoring|positive PCR|prevention of ICU|prevention of assisted ventilation|prevention of ECMO|death","Sheba Medical Center","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 3","250","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","7092-20-SMC","April 11, 2020","October 11, 2020","December 11, 2020","April 21, 2020",,"April 21, 2020","Sheba Medical Center, Ramat Gan, Israel|Sheba Medical Center, Tel HaShomer, Israel",,"https://ClinicalTrials.gov/show/NCT04355052"
172,"NCT04350073","Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID)",,"Recruiting","No Results Available","COVID-19","Device: Q-NRG Metobolic Cart Device|Device: MuscleSound Ultrasound|Device: Multifrequency Bioimpedance Spectroscopy","Metabolic and Nutritional Needs of COVID-19 Patients: Measured by Changes of Resting Energy expenditure(REE) over time, as measured by the indirect calorimetry Q-NRG device|Metabolic and Nutritional Needs of COVID-19 Patients:Changes of the Respiratory Exchange Ratio (RER) as measured by the indirect calorimetry Q-NRG device|Cardiac Output and Cardiac Measures (non-invasive) in COVID-19 patients|Muscle Mass and Quality Changes from COVID-19: Measured via Changes of Intramuscular Adipose Tissue (IMAT) Content From CT Scans of the Psoas at the Level of L3/Th3|Muscle Mass, Quality, Glycogen Changes in COVID-19: Via Metabolic/Muscle Imaging Derived From Muscle-Specific Ultrasound of Leg/Intercostal/Head Muscles|Body Composition in COVID-19 Patients: Measured via Multifrequency Bioimpedance Spectroscopy|Phase Angle in COVID-19 Patients: Measured via Multifrequency","Duke University","All","18 Years and older   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pro00105221","April 20, 2020","October 1, 2020","December 1, 2020","April 16, 2020",,"June 9, 2020","Duke University Medial Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04350073"
173,"NCT04407156","Epidemiology of Acute Kidney Injury in COVID19 Disease in United Kingdom",,"Not yet recruiting","No Results Available","COVID|AKI","Other: acute kidney injury","Incidence of Acute kidney injury in COVID-19|All-cause mortality in AKI patients","University Hospitals of Derby and Burton NHS Foundation Trust","All","18 Years to 110 Years   (Adult, Older Adult)",,"350","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","UHDB/2020/050","June 1, 2020","May 21, 2021","May 21, 2021","May 29, 2020",,"May 29, 2020","Derby Hospital NHS Foundation Trust, Derby, Derbyshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04407156"
174,"NCT04375670","COVID19-FOIE National Observatory",,"Recruiting","No Results Available","Liver Diseases|COVID19",,"Mortality rate related to Covid-19 in patients with a chronic liver disease|mortality rate according the stage of fibrosis and the cirrhotic status|mortality related to Covid-19 according an history of hepatocellular carcinoma, an immunosuppressive treatment and this type the etiology-ies of liver disease at the infection and comorbidities.|Incidence of liver complications","Assistance Publique - Hôpitaux de Paris|Association Française pour l’Etude du Foie (AFEF)","All","18 Years to 80 Years   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","IRB00006477","May 11, 2020","December 31, 2020","December 31, 2020","May 5, 2020",,"May 21, 2020","Ganne, Bondy, France",,"https://ClinicalTrials.gov/show/NCT04375670"
175,"NCT04350281","Double Therapy With IFN-beta 1b and Hydroxychloroquine",,"Recruiting","No Results Available","COVID","Drug: Interferon Beta-1B|Drug: Hydroxychloroquine","Time to negative NPS viral load|Time to NEWS 0|Length of Hospitalisation|Time to negative viral load in all clinical samples|Adverse events|Mortality|Inflammatory markers changes","The University of Hong Kong","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UW 20-211","April 9, 2020","March 31, 2022","July 31, 2022","April 17, 2020",,"April 17, 2020","The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04350281"
176,"NCT04364698","Observational Cohort of COVID-19 Patients at Raymond-Poincare","COVID-RPC","Recruiting","No Results Available","COVID-19",,"clinical, biological and radiological characteristics|patients' journey description|Treatments effects","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20SBS-COVID-RPC","May 7, 2020","June 2020","June 2020","April 28, 2020",,"May 14, 2020","Department of Infectiology, Raymond Poincaré Hospital, APHP, Garches, France",,"https://ClinicalTrials.gov/show/NCT04364698"
177,"NCT04346342","PRactice of VENTilation in COVID-19 Patients (PRoVENT-COVID)",,"Recruiting","No Results Available","COVID|Mechanical Ventilation|Acute Respiratory Failure",,"Ventilation Mode|Tidal volume set|Expiratory tidal volume|Positive end-expiratory pressure|Maximum airway pressure or plateau pressure (Pplateau) or peak pressure (Ppeak) (cm H2O);|Level of pressure support above PEEP|Inspired fraction of oxygen|Set and measured respiratory rate|Inspiration to expiration ratio|Number of ventilation-free days and alive at day 28|Duration of ventilation in survivors;|Use of prone positioning|Use of recruitment maneuvers|Incidence of acute kidney injury|Duration of ICU stay|Duration of hospital stay|ICU mortality|Hospital mortality|28-day mortality|90-day mortality","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","PRoVENT-COVID","March 6, 2020","May 2020","August 2020","April 15, 2020",,"April 15, 2020","Flevoziekenhuis, Almere, Netherlands|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Amsterdam, Netherlands|Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|Gelre hospitals, Apeldoorn, Netherlands|Rijnstate Hospital, Arnhem, Netherlands|Amphia Hospital, Breda, Netherlands|Reinier de Graaf Groep, Delft, Netherlands|Haga Hospital, Den Haag, Netherlands|Medical Center Haaglanden, Den Haag, Netherlands|Gelderse Vallei Hospital, Ede, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Maxima Medical Center, Eindhoven, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Spaarne Gasthuis, Haarlem, Netherlands|Dijklander Ziekenhuis, Hoorn, Netherlands|Medical Centre Leeuwarden, Leeuwarden, Netherlands|Maasstad Hospital, Rotterdam, Netherlands|Zuyderland Medical Centre, Sittard, Netherlands|UMC Utrecht, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT04346342"
178,"NCT04425707","Ivermectin In Treatment of COVID 19 Patients",,"Recruiting","No Results Available","Covid19","Drug: Ivermectin","to evaluate the role of Ivermectin as a line of treatment for COVID 19|To asses the rate of viral clearance in comparison to other treatment protocols.","Ministry of Health and Population, Egypt","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14-2020/3","June 9, 2020","July 1, 2020","September 1, 2020","June 11, 2020",,"June 11, 2020","isolation and referal hospitals for COVID 19 patients, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04425707"
179,"NCT04416113","Photodynamic Therapy for the Treatment of COVID-19",,"Not yet recruiting","No Results Available","Photodynamic Therapy& Low Level Laser in Management of COVID 19","Procedure: photobiomodulation and photodynamic therapy","Participants Achieving Either a Major Clinical Response or Partial Clinical Response (PCR) Defined by WHO","Cairo University","All","Child, Adult, Older Adult","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Cu-NILES/16/20","August 2020","December 2020","February 2021","June 4, 2020",,"June 5, 2020",,,"https://ClinicalTrials.gov/show/NCT04416113"
180,"NCT04329611","ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease",,"Suspended","No Results Available","COVID-19","Drug: Hydroxychloroquine","Composite of hospitalization, invasive mechanical ventilation or death within 30 days|mortality|Symptom duration|Disposition at 30 days defined as recovered, ongoing symptoms but not hospitalized, hospitalized, or deceased (categorical)","Dr. Michael Hill|Alberta Health Services|University of Alberta|University of Calgary|Calgary Health Trust|Alberta Innovates Health Solutions|Government of Alberta","All","18 Years and older   (Adult, Older Adult)","Phase 3","1660","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ABCOV-01 version 1.5","April 13, 2020","August 31, 2020","September 30, 2020","April 1, 2020",,"June 17, 2020","University of Calgary/Foothills Medical Centre, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT04329611"
181,"NCT04425538","A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).",,"Recruiting","No Results Available","COVID-19","Drug: Infliximab","Time to improvement in oxygenation|28-day mortality|Assessment of cytokine and inflammatory profile at baseline and at 48 hours after therapy|Qualitative and quantitative toxicity|incidence and duration of supplemental oxygen administration|Incidence and duration of non-invasive ventilation or by non-rebreather mask or high-flow nasal cannula|Incidence and duration of mechanical ventilation|Incidence and duration of vasopressor support|Incidence and duration of extracorporeal membrane oxygenation|Duration of fever|Correlation of cytokine profile to clinical outcomes specified in primary and secondary objectives|Duration of hospitalization|Secondary infections","Tufts Medical Center|National Institutes of Health (NIH)","All","18 Years and older   (Adult, Older Adult)","Phase 2","17","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00000564","June 1, 2020","September 2020","December 2020","June 11, 2020",,"June 11, 2020","Tufts Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04425538"
182,"NCT04360954","Evaluation of Antibody Tests for COVID-19",,"Recruiting","No Results Available","COVID|Coronavirus","Diagnostic Test: Diagnostic test","Test Sensitivity|Test Specificity","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","202004088","April 27, 2020","October 27, 2020","October 27, 2020","April 24, 2020",,"April 28, 2020","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04360954"
183,"NCT04376710","Surgical Telemedicine in the COVID-19 Pandemic Era",,"Not yet recruiting","No Results Available","COVID|Surgery","Other: Completion of pre-pandemic survey|Other: Completion of survey after peak of pandemic|Other: Completion of post telemedicine encounter survey","Evaluate surgeon perceptions to telemedicine and perceived barriers to implementation|Evaluate patient perceptions to telemedicine and perceived barriers to implementation","University of Colorado, Denver","All","31 Days to 18 Years   (Child, Adult)",,"100","Other","Observational","Observational Model: Other|Time Perspective: Prospective","20-1177","June 1, 2020","December 31, 2020","December 31, 2020","May 6, 2020",,"May 6, 2020","Children's Hospital Colorado, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT04376710"
184,"NCT04422444","Post Intensive Care Syndrome in COVID19 Patients","PICS-COVID19","Recruiting","No Results Available","COVID19|Post Intensive Care Unit Syndrome","Diagnostic Test: Questionnaires","Change from baseline Short Form 12 Health Survey (SF12) at 12 month|Change from baseline Lawton & Brody Instrumental activities of daily living scale at 12 months|Change from baseline Perceived Deficits Questionnaire (PDQ) at 12 months|Change from baseline Hospital Anxiety and Depression Scale (HADS) at 12 months|Change from baseline Davidson Trauma Scale (DTS) at 12 months","Corporacion Parc Tauli","All","18 Years to 90 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020/577","June 1, 2020","May 1, 2021","June 1, 2022","June 9, 2020",,"June 12, 2020","Corporació Parc Taulí, Sabadell, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04422444"
185,"NCT04399356","Niclosamide for Mild to Moderate COVID-19",,"Not yet recruiting","No Results Available","COVID (SARS-CoV-2)","Drug: Niclosamide|Drug: Placebo|Other: Telehealth monitoring","Change in respiratory viral clearance (by PCR)|Fecal viral clearance (by PCR)|Reduction (change) in viral shedding (by PCR)","Tufts Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","STUDY00000605","June 1, 2020","October 1, 2020","November 30, 2020","May 22, 2020",,"May 22, 2020",,,"https://ClinicalTrials.gov/show/NCT04399356"
186,"NCT04343183","Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection",,"Not yet recruiting","No Results Available","COVID-19","Device: Hyperbaric Oxygen Therapy","Decrease incidence of intubation by 30% or greater|Decrease renal injury","Ochsner Health System","All","18 Years and older   (Adult, Older Adult)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","STUDY00001051","April 2020","June 2020","June 2020","April 13, 2020",,"April 13, 2020","Ochsner Medical Center, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT04343183"
187,"NCT04375046","Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP Could be Promising COVID-19 Infection- and Lung Injury Preventing Drug Better Than Recombinant Human ACE2","Bacterial ACE2","Not yet recruiting","No Results Available","COVID-19","Drug: Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2)","Time course of body temperature (fever)|Viral load over time|P/F ratio over time|Sequential organ failure assessment score(SOFA score) over time|Pulmonary Severity Index (PSI)|Image examination of chest over time|Proportion of subjects who progressed to critical illness or death|Time from first dose to conversion to normal or mild pneumonia|T-lymphocyte counts over time|C-reactive protein levels over time|Angiotensin II (Ang II) changes over time|Angiotensin 1-7 (Ang 1-7) changes over time|Angiotensin 1-5 (Ang 1-5) changes over time|Renin changes over time|Aldosterone changes over time|Angiotensin-converting enzyme (ACE) changes over time|Angiotensin-converting enzyme 2 (ACE2) changes over time|Interleukin 6 (IL-6) changes over time|Interleukin 8 (IL-8) changes over time|Soluble tumor necrosis factor receptor type II (sTNFrII) changes over time|Plasminogen activator inhibitor type-1 (PAI-1) changes over time|Von willebrand factor (vWF) changes over time|Tumor necrosis factor-α (TNF-α) changes over time|Soluble receptor for advanced glycation end products (sRAGE) changes over time|Surfactant protein-D (SP-D) changes over time|Angiopoietin-2 changes over time|Frequency of adverse events and severe adverse events","Kafrelsheikh University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","proposed by Mahmoud kazazzaz","August 2020","September 2020","October 2020","May 5, 2020",,"May 11, 2020",,,"https://ClinicalTrials.gov/show/NCT04375046"
188,"NCT04412382","Covid-19: Possible Role of Neutrophil Extracellular Traps","NETSINCOVID","Not yet recruiting","No Results Available","Covid-19","Diagnostic Test: NETosis markers","NETOSIS AND MORTALITY|NETOSIS AND DCOVID-19 SEVERITY|NETOSIS AND INFLAMMATION|NETOSIS AND VENOUS THROMBOSIS","Azienda Ospedaliera Universitaria Integrata Verona","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","NETS IN COVID-19","June 1, 2020","December 31, 2020","December 31, 2021","June 2, 2020",,"June 2, 2020",,,"https://ClinicalTrials.gov/show/NCT04412382"
189,"NCT04374513","Community Pharmacists Behaviour During Covid-19",,"Recruiting","No Results Available","Covid19",,"community pharmacists facing covid-19","Damanhour University","All","Child, Adult, Older Adult",,"50","Other","Observational","Observational Model: Other|Time Perspective: Prospective","Pharmacists and covid-19","May 2, 2020","October 1, 2020","April 2021","May 5, 2020",,"May 19, 2020","Damanhour university, Beheira, Damanhour, Egypt|Damanhour universty, Alexandria, Egypt",,"https://ClinicalTrials.gov/show/NCT04374513"
190,"NCT04432987","Dornase Alpha for the Treatment of COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Pulmozyme","Response|Survival","Acibadem University|The Scientific and Technological Research Council of Turkey","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","8820","May 25, 2020","August 25, 2020","September 25, 2020","June 16, 2020",,"June 16, 2020","Acıbadem Altunizade Hospital, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04432987"
191,"NCT04333550","Application of Desferal to Treat COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Deferoxamine","Mortality rate|change in patients clinical manifestation|change in patients PaO2|Length of hospitalization|C-reactive protein|lymphocyte count|length of intensive care unit stay","Kermanshah University of Medical Sciences","All","3 Years to 99 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1398.1224","April 2020","September 2020","March 2021","April 3, 2020",,"May 4, 2020","Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran, Kermanshah, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04333550"
192,"NCT04375774","Verification of Alternative Do-it-yourself Equipment Respirators for the COVID-19 Personal Protective Equipment (PPE)","VADER","Recruiting","No Results Available","COVID","Device: FFP2|Device: Facial mask|Device: MFS","Evaluation of airtightness (Fit test)|User Comfort|Breathing easiness|Field of view quality|Ease of use","Cliniques universitaires Saint-Luc- Université Catholique de Louvain","All","18 Years to 60 Years   (Adult)","Not Applicable","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2020/15AVR/226","May 2020","May 2020","May 2020","May 5, 2020",,"May 5, 2020","Cliniques Universitaires Saint-Luc, Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT04375774"
193,"NCT04367714","Antibody Response Against SARS-CoV-2 in Dialysis Patients During COVID-19","COVCKD","Recruiting","No Results Available","COVID|Terminal Renal Insufficiency",,"AAntibody response","Region MidtJylland Denmark|Aarhus University Hospital|Central Jutland Regional Hospital|Aalborg University Hospital","All","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","FHM-1-2020","March 15, 2020","December 1, 2020","December 1, 2021","April 29, 2020",,"April 29, 2020","Godstrup Hospital, Herning, Denmark",,"https://ClinicalTrials.gov/show/NCT04367714"
194,"NCT04382053","Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia",,"Recruiting","No Results Available","COVID 19 Pneumonia, Impaired Respiratory Function","Drug: DFV890|Drug: Standard of Care (SoC)","APACHE II severity of disease score on Day 15 or on the day of discharge (whichever is earlier)|Serum C-reactive protein (CRP) levels|Clinical status over time|Proportion of participants not requiring mechanical ventilation for survival.|Proportion of participants with at least one-point improvement from baseline in clinical status","Novartis Pharmaceuticals|Novartis","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDFV890D12201|2020-001870-32","May 27, 2020","November 30, 2020","November 30, 2020","May 11, 2020",,"June 29, 2020","Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Hvidovre, Denmark|Novartis Investigative Site, Heidelberg, Baden-Württemberg, Germany|Novartis Investigative Site, Regensburg, Bavaria, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary",,"https://ClinicalTrials.gov/show/NCT04382053"
195,"NCT04342663","A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection","STOP COVID","Recruiting","No Results Available","COVID 19|Coronavirus","Drug: Fluvoxamine|Drug: Placebo","Time to clinical worsening|clinical deterioration on a Likert-type scale (1-6)|clinical deterioration measured by number of days|Symptomatic severity on a likert scale (0-10 where 0= none and 10=very severe)","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 2","152","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","202004023","April 10, 2020","August 1, 2020","September 1, 2020","April 13, 2020",,"May 19, 2020","BJC, Belleville, Illinois, United States|Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04342663"
196,"NCT04338074","TXA and Corona Virus 2019 (COVID19) in Outpatients","TCOutpatient","Recruiting","No Results Available","COVID-19","Drug: Tranexamic acid tablets|Drug: Placebo oral tablet","Hospitalization","University of Alabama at Birmingham","All","19 Years and older   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TXACOVID1","June 1, 2020","December 15, 2020","December 31, 2020","April 8, 2020",,"June 12, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT04338074"
197,"NCT04356534","Convalescent Plasma Trial in COVID -19 Patients",,"Recruiting","No Results Available","SARS-CoV 2|COVID-19","Other: plasma therapy using convalescent plasma with antibody against SARS-CoV-2|Other: Routine care for COVID-19 patients","Requirement for invasive ventilation|Change in viral clearance|Radiological change|Change in white cell count|C reactive protein measurement|lactate dehydrogenase measurement|Procalcitonin measurement|D Dimer measurement|Ferritin measurement|Troponin T measurement|Brain naturetic peptide measurement|Mortality rate","Royal College of Surgeons in Ireland - Medical University of Bahrain|Salmaniya Medical Complex|Bahrain Defence Force Royal Medical Services, Military Hospital|Mohammed Bin Khalifa Bin Sulman Al Khalifa Cardiac Centre, Awali","All","21 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BDF/R&REC/2020-423","April 19, 2020","June 30, 2020","June 30, 2020","April 22, 2020",,"June 18, 2020","Royal College of Surgeons in Ireland - Bahrain, Manama, Bahrain",,"https://ClinicalTrials.gov/show/NCT04356534"
198,"NCT04336904","Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19",,"Active, not recruiting","No Results Available","COVID-19","Drug: Favipiravir|Other: Placebo","Time from randomization to clinical recovery|Time from randomization to negativity in RT-PCR nucleic acid test|Incidence of deterioration/aggravation of pneumonia|Time from randomization to resolution of pyrexia|Time from randomization to relief of cough|Time from randomization to relief of dyspnoea|Rate of auxiliary oxygen therapy|ICU admission rate|Mortality","Giuliano Rizzardini|ASST Fatebenefratelli Sacco","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","HS216C17-PHASE III","March 25, 2020","July 2020","July 2020","April 7, 2020",,"April 8, 2020","Asst Fatebenefratelli Sacco, Milano, Italy",,"https://ClinicalTrials.gov/show/NCT04336904"
199,"NCT04345991","Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort","CORIPLASM","Recruiting","No Results Available","Covid19","Drug: Transfusion of COVID-19 convalescent plasma","Survival without needs of ventilator utilization or use of immunomodulatory drugs|WHO progression scale ≥6|Severe adverse events|WHO progression scale|Overall survival|Time from randomization to discharge|Time to oxygen supply independency|Survival without needs of ventilator utilization|Survival without use of immunomodulatory drugs","Assistance Publique - Hôpitaux de Paris|Etablissement Français du Sang","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200375-10|2020-001246-18","April 15, 2020","May 15, 2020","June 1, 2020","April 15, 2020",,"May 20, 2020","SMIT, Saint Antoine hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT04345991"
200,"NCT04445272","Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia",,"Recruiting","No Results Available","COVID-19","Drug: Tocilizumab","To calulate the time of intubation|To calculate the time with oxygen therapy|To calculate the time with Non-invasive mechanical ventilation|To evaluate mortality rate|To calculate respiratory function parameters|To evaluate radiological lung extension|To evaluate radiological evolution|To describe the duration of hospitalization and ICU use|To evaluate the requirement of additional organ support|To evaluate the effect of IV tocilizumab on the serum levels of inflammatory markers|To calculate the number of adverse events in patients with COVID-19 pneumonia treated with Tocilizumab|To assess time to reverse-transcriptase polymerase chain reaction (RT-PCR) virus negativity|To evaluate the effect of IV tocilizumab on the serum levels of inflammatory|To calculate the number of serious adverse events in patients with COVID-19 pneumonia treated with Tocilizumab|To calculate the number of adverse events of special interest in patients with COVID-19 pneumonia treated with Tocilizumab|To evaluate respiratory function","Fundacion SEIMC-GESIDA|Roche Pharma AG|Dynamic Science S.L.","All","18 Years and older   (Adult, Older Adult)","Phase 2","500","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BREATH-19 (FSG011-20)","May 22, 2020","August 22, 2020","August 22, 2020","June 24, 2020",,"June 24, 2020","Hospital Universitario de Cabueñes, Gijón, Asturias, Spain|Hospital Universitario Central Asturias, Oviedo, Asturias, Spain|Hospital Universitari de Bellvitge, L'Hospitalet De Llobregat, Barcelona, Spain|Hospital Sant Joan de Déu de Manresa, Manresa, Barcelona, Spain|Hospital de Mataró, Mataró, Barcelona, Spain|Hospital Universitario de Galdakao, Galdakao, Bizkaia, Spain|Hospital Universitario Marqués Valdecilla, Santander, Cantabria, Spain|Hospital Público General del Tomelloso, Tomelloso, Ciudad Real, Spain|Hospital Jerez de la Frontera, Jerez De La Frontera, Cádiz, Spain|Hospital Universitari Son Espases, Palma De Mallorca, Islas Baleares, Spain|Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain|Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain|Hospital Universitario de Getafe, Getafe, Madrid, Spain|Hospital Universitario de Getafe, Getafe, Madrid, Spain|Hospital Rey Juan Carlos, Móstoles, Madrid, Spain|Hospital Universitario Rey Juan Carlos, Móstoles, Madrid, Spain|Hospital Universitario Infanta Sofía, San Sebastián De Los Reyes, Madrid, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Nuestra Señora del Prado, Talavera De La Reina, Toledo, Spain|Complejo Hospitalario Universitario de Albacete, Albacete, Spain|Hospital Infanta Cristina, Badajoz, Spain|Hospital Clínic i Provincial Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital General Universitario de Ciudad Real, Ciudad Real, Spain|Hospital San Pedro Alcántara, Cáceres, Spain|Hospital Universitario Dr. Josep Trueta, Gerona, Spain|Hospital Universitario Clínico San Cecilio, Granada, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario HM Sanchinarro, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital Regional Universitario de Málaga, Málaga, Spain|Complexo Hospitalario Universitario de Ourense, Orense, Spain|Hospital Universitario Salamanca, Salamanca, Spain|Hospital Universitario Virgen de la Macarena, Sevilla, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Virgen de la Salud, Toledo, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital Universitari i Poliectenic La Fe, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT04445272"
201,"NCT04359095","Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia",,"Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir Pill|Drug: Azithromycin|Other: Standard treatment","Mortality|Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection|Time to death|Number of Participants that are transferred to the Intensive Care Unit (ICU)|Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.|Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray|Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection","Universidad Nacional de Colombia|Pontificia Universidad Javeriana|Clínica Universitaria Colombia|Hospital Universitario San Ignacio|Hospital Universitario Nacional de Colombia|Clínica Reina Sofía|Fundación Cardio Infantil|Hospital Universitario de Neiva","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","1600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","76968","May 11, 2020","October 11, 2020","October 31, 2020","April 24, 2020",,"April 24, 2020","Hospital Universitario de Neiva, Neiva, Huila, Colombia|Clínica Reina Sofía, Bogotá, Colombia|Fundacion Cardio Infantil, Bogotá, Colombia|Hospital Universitario San Ignacio, Bogotá, Colombia|Clinica Universitaria Colombia, Bogotá, Colombia|Hospital Universitario Nacional de Colombia, Bogotá, Colombia",,"https://ClinicalTrials.gov/show/NCT04359095"
202,"NCT04354831","A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection",,"Recruiting","No Results Available","COVID-19","Biological: anti-SARS-CoV-2 convalescent plasma","Overall Mortality within 60 days|Length of ICU stay during current admission for COVID","Medical College of Wisconsin|Froedtert Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","131","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO00037712","May 11, 2020","May 1, 2022","May 1, 2023","April 21, 2020",,"May 13, 2020","Froedtert Hospital, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04354831"
203,"NCT04358029","Cardiac Arrhythmias In Patients With Coronavirus Disease (COVID-19)",,"Recruiting","No Results Available","COVID 19 Cardiac|COVID 16 Arrhythmia|COVID 19 Death",,"Frequency of cardiac arrhythmias|Mode of death","Vivek Reddy|Icahn School of Medicine at Mount Sinai","All","Child, Adult, Older Adult",,"10000","Other","Observational","Observational Model: Case-Only|Time Perspective: Other","GCO 20-0931","April 9, 2020","May 2021","December 2021","April 22, 2020",,"May 13, 2020","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04358029"
204,"NCT04401072","Attitude of Egyptian Population Toward COVID 19 in Ramadan",,"Recruiting","No Results Available","Covid 19",,"Attitude of the Egyptian population during the COVID 19 pandemic in Ramadan","Damanhour University","All","Child, Adult, Older Adult",,"500","Other","Observational","Observational Model: Other|Time Perspective: Prospective","covid 19 in ramadan","April 24, 2020","May 22, 2020","October 2020","May 26, 2020",,"May 26, 2020","Damanhour University, Damanhūr, Beheira, Egypt",,"https://ClinicalTrials.gov/show/NCT04401072"
205,"NCT04351802","CORonavirus (COVID-19) Diagnostic Lung UltraSound Study","COR-DLUS","Not yet recruiting","No Results Available","COVID-19","Diagnostic Test: Lung ultrasound","Diagnosis of COVID-19 on lung ultrasound|Difference in diagnosis of COVID-19 on lung ultrasound vs. chest x-ray|Diagnosis of alternative condition to COVID-19 on lung ultrasound vs. chest x-ray|Ability of surveillance lung ultrasound to predict clinical trajectory / outcome in patients with COVID-19|Consistency of lung ultrasound interpretation in patients presenting with suspected COVID-19","University Hospital Plymouth NHS Trust","All","18 Years and older   (Adult, Older Adult)",,"180","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","282661","April 20, 2020","January 20, 2021","January 20, 2021","April 17, 2020",,"April 17, 2020",,,"https://ClinicalTrials.gov/show/NCT04351802"
206,"NCT04376879","Predicting the Need for Intubation in Hospitalised COVID-19 Patients (PRED ICU COVID19)",,"Recruiting","No Results Available","COVID-19","Other: Data monitoring for 48h within the first 12 hours of admission for COVID-19","the number of intubations in COVID-19 patients initially hospitalised in wards|the number of intubations in COVID-19 patients initially hospitalised in wards.","Central Hospital, Nancy, France","All","18 Years and older   (Adult, Older Adult)",,"384","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-A01076-33","May 16, 2020","November 2020","November 2020","May 6, 2020",,"May 27, 2020","Louis Mourier hospital (AP-HP), Colombes, France|Brabois Hospital (CHRU de Nancy), Vandœuvre-lès-Nancy, France",,"https://ClinicalTrials.gov/show/NCT04376879"
207,"NCT04445285","Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure","DAMPENCOVID","Recruiting","No Results Available","Covid19","Drug: Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase)|Drug: 0.9%sodium chloride","Mortality at 28 days|Systemic Therapeutic Response|Respiratory Response|Legnth of ICU Stay|Legnth of Hospital Stay|Pulmonary Function","Jon Simmons|University of South Alabama","All","18 Years and older   (Adult, Older Adult)","Phase 2","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","USAH 1002 000","April 28, 2020","July 31, 2020","July 31, 2020","June 24, 2020",,"June 29, 2020","University of South Alabama, Mobile, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT04445285"
208,"NCT04343742","Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19",,"Recruiting","No Results Available","COVID-19","Drug: chlorine dioxide 3000 ppm","negative testing of covid19","Genesis Foundation","All","Child, Adult, Older Adult",,"20","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","Genesis AKCOVID- FG-1","April 1, 2020","April 7, 2020","June 1, 2020","April 13, 2020",,"May 27, 2020","Hospital Fhsj, Bogota, Cundinamarca, Colombia|San Carlos Hospital, Bogota, Cundinamarca, Colombia",,"https://ClinicalTrials.gov/show/NCT04343742"
209,"NCT04414293","Low Dose Pulmonary Irradiation in Patients With COVID-19 Infection of Bad Prognosis","COVRTE-19","Not yet recruiting","No Results Available","COVID|Pneumonia, Viral","Radiation: Lung Low Dose Radiation","blood oxygen saturation level|Torax X-ray|Hospitalization|days free of assisted mechanical respiration|Mortality","Hospital Provincial de Castellon","All","65 Years and older   (Older Adult)","Not Applicable","41","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FHPCS-20-001","June 1, 2020","December 31, 2020","March 31, 2021","June 4, 2020",,"June 9, 2020","Hospital Provincial de Castellon, Castellón De La Plana, Castellon, Spain",,"https://ClinicalTrials.gov/show/NCT04414293"
210,"NCT04345848","Preventing COVID-19 Complications With Low- and High-dose Anticoagulation","COVID-HEP","Recruiting","No Results Available","COVID|Sars-CoV2","Drug: Enoxaparin","Composite outcome of arterial or venous thrombosis, disseminated intravascular coagulation and all-cause mortality|Arterial thrombosis|Venous thromboembolism|Disseminated intravascular coagulation|All-cause mortality|Sepsis-induced coagulopathy|Acute respiratory distress syndrome|Durations of hospital stay, ICU stay, ventilation|Sequential organ failure assessment score|Clinical deterioration","University Hospital, Geneva","All","18 Years and older   (Adult, Older Adult)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2020-00794","April 28, 2020","November 30, 2020","November 30, 2020","April 15, 2020",,"April 30, 2020","Geneva University Hospitals, Geneva, Switzerland",,"https://ClinicalTrials.gov/show/NCT04345848"
211,"NCT04345445","Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression",,"Not yet recruiting","No Results Available","COVID-19","Drug: Tocilizumab|Drug: Methylprednisolone","The proportion of patients requiring mechanical ventilation|Mean days of ventilation|The proportion of patients requiring ICU admission|Overall 28-day survival|Change in symptom severity assessed by the World Health Organization (WHO) Coronavirus Disease 2019 (COVID19) ordinal scale measured daily up to 7 days from baseline|Duration of hospital and ICU stay","University of Malaya","All","18 Years and older   (Adult, Older Adult)","Phase 3","310","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TVCS-COVID19","April 15, 2020","October 31, 2020","October 31, 2020","April 14, 2020",,"April 14, 2020","University Malaya Medical Centre, Kuala Lumpur, Malaysia",,"https://ClinicalTrials.gov/show/NCT04345445"
212,"NCT04347174","A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients",,"Recruiting","No Results Available","COVID-19","Drug: Suspension of heat killed (autoclaved) Mycobacterium w|Drug: Standard therapy of COVID-19","Sequential Organ Failure Assessment (SOFA) scores|7-category ordinal scale that ranges from 1 (not hospitalized with resumption of normal activities) to 7 (death)|All-cause mortality|Incidence of AE / SAE or event of clinical significance|SARS-CoV-2 detectable in nasal or oropharyngeal (OP) sample|ICU length of stay|Duration of mechanical ventilation|Duration of hospitalization|Clinical improvement|Time (in days) from treatment initiation to death","Cadila Pharnmaceuticals|Council of Scientific and Industrial Research, India","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CRSC20004","April 30, 2020","June 30, 2020","July 30, 2020","April 15, 2020",,"June 11, 2020","All India Institute of Medical Science, Raipur, Raipur, Chhattisgarh, India|All India Institute of Medical Sciences, Bhopal, Bhopal, Madhya Pradesh, India|Postgraduate Institute of Medical Education and Research, Chandigarh, India|All lndia Institute of Medical Science, Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT04347174"
213,"NCT04401241","How Routine Biomarkers and Blood Leucocytes Count Can Assist Diagnosis of COVID-19 in Emergency Department","MONACOVID","Completed","No Results Available","Covid19",,"routine biomarkers and blood cell count are discriminant to diagnose COVID-19|Probability of COVID-19 and CRP|Probability of COVID-19 and PCT|Probability of COVID-19 and Ddimers|Probability of COVID-19 and NTproBNP|Probability of COVID-19 and cTnT-HS|Probability of COVID-19 and blood cell counts|performance of combined routine biomarkers|Assess usual biomarkers and blood cell count","Centre Hospitalier Princesse Grace","All","18 Years and older   (Adult, Older Adult)",,"257","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","20-06","February 1, 2020","May 1, 2020","May 15, 2020","May 26, 2020",,"May 26, 2020","Centre Hospitalier Princesse Grace, Monaco, MON, Monaco",,"https://ClinicalTrials.gov/show/NCT04401241"
214,"NCT04358614","Baricitinib Therapy in COVID-19",,"Completed","No Results Available","COVID|Pneumonia","Drug: Baricitinib 4 MG Oral Tablet","To assess the safety of baricitinib combined with antiviral (lopinavir-ritonavir) in terms of serious or non-serious adverse events incidence rate.|To evaluate the impact of baricitinib in terms of clinical, laboratory, respiratory parameters.|ICU admission rate|Discharge rate.","Fabrizio Cantini|Hospital of Prato","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2|Phase 3","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HPrato-4","March 16, 2020","April 5, 2020","April 7, 2020","April 24, 2020",,"April 24, 2020","Fabrizio Cantini, Prato, Tuscany, Italy",,"https://ClinicalTrials.gov/show/NCT04358614"
215,"NCT04445376","Effect of Physical Therapy Exercises on Cardiorespiratory Fitness Level in COVID19 Patients After Recovery.",,"Not yet recruiting","No Results Available","Covid19","Other: Physical Exercises","6 minute walk test|Step test","Government College University Faisalabad","All","25 Years to 50 Years   (Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","313","June 25, 2020","July 20, 2020","August 15, 2020","June 24, 2020",,"June 25, 2020",,,"https://ClinicalTrials.gov/show/NCT04445376"
216,"NCT04409522","Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients",,"Recruiting","No Results Available","COVID-19","Drug: Melatonin|Drug: The usual treatment","Melatonin|Inflammatory cytokines|C-reactive protein (CRP)|Cough|Oxygen saturation of the blood|ESR|Radiological Treatment Response|Inflammatory route","Mohammad Sadegh Bagheri Baghdasht|Baqiyatallah Medical Sciences University","All","16 Years to 100 Years   (Child, Adult, Older Adult)","Not Applicable","55","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IR.BMSU.REC.1399.039","May 12, 2020","June 5, 2020","September 25, 2020","June 1, 2020",,"June 1, 2020","Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04409522"
217,"NCT04366739","Repurposing of Chlorpromazine in Covid-19 Treatment","reCoVery","Not yet recruiting","No Results Available","COVID-19","Drug: CHLORPROMAZINE (CPZ)|Combination Product: Standard of Care (SOC)","Time To Response (TTR)|Objective Response Rate (ORR)|All-cause mortality|Duration in days required for hospital discharge|Duration in days required for National Early Warning Score ≤ 2 maintained 24 hours|Number of days without oxygen therapy|Incidence of oxygen use, NIV or high flow oxygen therapy|Duration in days of oxygen prescription, NIV or high flow oxygen therapy|Biochemical response: rate of patients positive for SARS-CoV-2 PCR on a nasopharyngeal sample|Biochemical response: viral load of SARS-CoV-2 on a nasopharyngeal sample|Biochemical response: serum viral load of SARS-CoV-2|Biochemical response: C-reactive protein (CRP)|Biochemical response: blood test for lymphocytes (lymphopenia)|Parenchymal involvement (chest CT)|Define the optimal dose of CPZ and its tolerance: rates of serious adverse events|Define the optimal dose of CPZ and its tolerance: rates of non-serious side effects|Define the optimal dose of CPZ and its tolerance: anxiety assessment on Global Anxiety - Visual Analog Scale (GA-VAS)|Define the optimal dose of CPZ and its tolerance: Rates of drug discontinuation|Define the optimal dose of CPZ and its tolerance: biological anomalies|Define the optimal dose of CPZ and its tolerance: ECG abnormalities|Define the optimal dose of CPZ and its tolerance: plasma CPK assessment|Define the optimal dose of CPZ and its tolerance:plasma CPZ assessment|Define the optimal dose of CPZ and its tolerance: CPZ dose administered","Centre Hospitalier St Anne|Hôpital Cochin","All","18 Years and older   (Adult, Older Adult)","Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","D20-P016","April 29, 2020","August 30, 2020","September 30, 2020","April 29, 2020",,"April 29, 2020","Centre Hospitalier Sainte-Anne, Paris, France",,"https://ClinicalTrials.gov/show/NCT04366739"
218,"NCT04405310","Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial","CPC-SARS","Recruiting","No Results Available","COVID-19","Biological: Convalescent Plasma of patients with COVID-19|Other: placebo (hartmann plus albumine)","Death|Lenth of stay ICU|Days of Mechanical Ventilation|Suplemental Oxigen support|Viral Load by RT-PCR|Inflamatory biomarkers|SOFA (sequencial Organ Failure Assesment)","Grupo Mexicano para el Estudio de la Medicina Intensiva|Hospital General Naval de Alta Especialidad - Escuela Medico Naval|National Institute of Pediatrics, Mexico|Instituto Nacional de Enfermedades Respiratorias","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","DI/20/201/04/19","May 20, 2020","June 20, 2020","July 20, 2020","May 28, 2020",,"May 28, 2020","Hospital Nava de Alta Especialidad, Mexico City, Mexico|Hospital General de Mexico Dr Eduardo Liceaga, Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT04405310"
219,"NCT04437940","Evaluation of Vaginal Fluid for Covid-19 Positivity in Women With Positive Nasofarengeal Covid-19 Test",,"Recruiting","No Results Available","COVID|Sars-CoV2","Diagnostic Test: Vaginal fluid Covid-19 PCR test","Vaginal fluid Covid-19 PCR test result|becoming negative from positive","Acibadem University","Female","18 Years to 70 Years   (Adult, Older Adult)",,"35","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Acibadem Maslak Ob&Gyn","June 15, 2020","July 10, 2020","July 30, 2020","June 18, 2020",,"June 18, 2020","Acibadem Maslak Hospital, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04437940"
220,"NCT04321993","Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients",,"Recruiting","No Results Available","COVID-19","Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine sulfate|Drug: Baricitinib (janus kinase inhibitor)","Clinical status of subject at day 15 (on a 7 point ordinal scale).|Status on an ordinal scale assessed daily while hospitalized and on days 15 and 29 and 180.|Length of time to clinical improvement|Number of participants with normal pulmonary function and normal O2 saturation on days 11, 15 and 29|Number of participants that developed Acute Respiratory Distress Syndrome (ARDS) after treatment|Length of time to clinical progression|Cause of death (if applicable)|Sequential Organ Failure Assessment (SOFA) score, daily while hospitalized and on days 15 and 29. (Initial, highest, deltas and mean)|Length of time to normalization of fever|Length of time to normalization of oxygen saturation|Duration of supplemental oxygen (if applicable)|Duration of mechanical ventilation (if applicable)|Duration of hospitalization|Adverse events","Lisa Barrett|Nova Scotia Health Authority|Dalhousie University","All","18 Years and older   (Adult, Older Adult)","Phase 2","1000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SAIL-004","April 17, 2020","February 2022","March 2022","March 26, 2020",,"May 19, 2020","Nova Scotia Health Authority, Halifax, Nova Scotia, Canada",,"https://ClinicalTrials.gov/show/NCT04321993"
221,"NCT04355741","Gut Microbiota, ""Spark and Flame"" of COVID-19 Disease",,"Recruiting","No Results Available","COVID-19","Other: Exposure","Differences in gut microbiota composition between COVID-19 patients with different degrees of disease severity.|Differences in gut microbiota composition between COVID-19 patients in relation to mortality.|Differences in gut microbiota composition between COVID-19 patients in relation to length of stay in hospitals.|Differences in gut microbiota composition between COVID-19 patients in relation to duration of mechanical ventilation.","Universidade Nova de Lisboa|NOVA Medical School of Universidade NOVA de Lisboa|Hospital de São Francisco Xavier, Centro Hospitalar de Lisboa Ocidental|Centro Hospitalar Universitário São João|CUF Academic and Research Medical Center|Hospital CUF Infante Santo, S.A.|Centro de Medicina Laboratorial Germano de Sousa, S.A.|CINTESIS - Center for Health Technology and Services Research","All","18 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","COVID19_Microbiota","April 20, 2020","July 2020","December 2020","April 21, 2020",,"June 29, 2020","Hospital CUF Infante Santo, S.A., Lisbon, Portugal|Hospital de São Francisco Xavier, Lisbon, Portugal|Centro Hospitalar Universitário São João, Oporto, Portugal",,"https://ClinicalTrials.gov/show/NCT04355741"
222,"NCT04361422","Isotretinoin in Treatment of COVID-19","Randomized","Not yet recruiting","No Results Available","COVID-19","Drug: Isotretinoin Only Product in Oral Dose Form","Clinical clearance","Tanta University","All","18 Years to 40 Years   (Adult)","Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9469305c","April 21, 2020","June 2020","September 2020","April 24, 2020",,"April 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04361422"
223,"NCT04388683","Inhaled Nitric Oxide for Preventing Progression in COVID-19","NO-COVID-19","Recruiting","No Results Available","COVID-19","Drug: Nitric Oxide","Prevention of progressive systemic de-oxygenation, with escalation to higher levels of oxygen and ventilatory support or death, assessed using a 7-point severity scale.|Prevention of progression assessed by an alternate severity scale|Time to reaching maximal severity score|Proportion of patients in each stage at maximum severity|PaO2/FIO2 or SaO2/FIO2 ratio, measured daily|Length of hospital Stay (death assigned as worst case)|Frequency of Intubation, ECMO, or need to intubate with ""Do Not Resuscitate"" order|Mortality|IL6 level|TNF-alpha level|Fibrinogen level|CRP level|Ferritin Level|D-dimer level","Tufts Medical Center|Bellerophon","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","42","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00000554","May 12, 2020","April 30, 2021","July 31, 2021","May 14, 2020",,"May 18, 2020","Tufts Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04388683"
224,"NCT04449042","The PAWS-COVID-19 (Pediatric AirWay complicationS COVID-19) Registry",,"Recruiting","No Results Available","Airway Management|COVID19","Procedure: airway management during sedation or general anesthesia","airway complications|airway device|PPE|First pass success|induction techniques|failed intubation|complication risk factors","Boston Children’s Hospital|Children's Hospital of Philadelphia|Children's Hospital Colorado|Istituto Giannina Gaslini|The Hospital for Sick Children|Perth Children's Hospital of Western Austrailia|Lurie Children's Hospital of Chicago","All","up to 18 Years   (Child, Adult)",,"15000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB-P00035427","April 1, 2020","December 2025","December 2025","June 26, 2020",,"June 26, 2020","Boston Children's Hopsital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04449042"
225,"NCT04424056","A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease","INFLAMMACOV","Not yet recruiting","No Results Available","Covid19","Drug: Anakinra +/- Ruxolitinib (stages 2b/3)|Drug: Anakinra and Ruxolitinib (Advanced stage 3)|Drug: Tocilizumab +/- ruxolitinib (stages 2b/3)|Drug: Tocilizumab and Ruxolitinib (Advanced stage 3)|Other: Standard of care","Ventilation free days at D28","Assistance Publique Hopitaux De Marseille","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","216","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-23","September 1, 2020","September 30, 2022","November 1, 2022","June 9, 2020",,"June 23, 2020","Assistance Publique Hôpitaux de Marseille, Marseille, France",,"https://ClinicalTrials.gov/show/NCT04424056"
226,"NCT04401085","COVID-19: Herd Immunity Study in the Czech Republic","SARSCoV2CZPrev","Completed","No Results Available","COVID|SARS-CoV 2","Diagnostic Test: SARS-CoV-2 diagnostic rapid test|Diagnostic Test: Quantitative analysis of SARS-CoV-2 antibodies","Estimation of the actual prevalence of SARS-CoV-2 positive persons in the Czech Republic.|Estimation of the proportion of people with a subclinical course of the disease|Estimation of the cumulative prevalence of the disease and the proportion of people with a subclinical course differences between subcohorts according to demographic, social and clinically relevant stratifications.|Estimation of the proportion of persons suitable for the donation of convalescent plasma","Institute of Health Information and Statistics of the Czech Republic|Ministry of Health, Czech Republic|Faculty of Medicine, Palacky University|Faculty of Medicine, Masaryk University|Faculty of medicine, University of Ostrava|Faculty of Military Health Sciences, University of Defence in Brno|Faculty of Health Studies, J. E. Purkyně University in Ústí nad Labem|First Faculty of Medicine, Charles University, Czech Republic|Institute for Clinical and Experimental Medicine|General University Hospital, Prague|University Hospital Olomouc|Brno University Hospital|Krajská zdravotní, a.s., Ústí nad Labem Region Hospitals|Military University Hospital, Prague|Masaryk Memorial Cancer Institute|Institute Of Sociology, Czech Academy of Sciences|Czech Statistical Office|Faculty of Medicine in Hradec Králové, Charles University","All","8 Years to 89 Years   (Child, Adult, Older Adult)",,"27000","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","UZIS 2020/1","April 23, 2020","May 1, 2020","May 1, 2020","May 26, 2020",,"June 1, 2020","Institute of Health Information and Statistics of the Czech Republic, Prague, Czechia",,"https://ClinicalTrials.gov/show/NCT04401085"
227,"NCT04354597","Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID19 Patients","MOPHYDA","Not yet recruiting","No Results Available","COVID-19","Drug: HCQ & AZ","Effect of HCQ and AZ in preventing infection with COVID-19 among healthcare workers working with COVID-19 patients|Safety of HCQ and AZ|Oxygen requirement|ICU admission|Mortality rate","King Hussein Cancer Center","All","25 Years to 70 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","20 KHCC 67","May 1, 2020","August 15, 2020","October 15, 2020","April 21, 2020",,"May 5, 2020","King Hussein Cancer Center, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT04354597"
228,"NCT04377763","Developement and Evaluation of Serological Assays for COVID-19","SEROCOV","Not yet recruiting","No Results Available","COVID-19",,"Sensibility and specificity|Delay between the first symptoms and the positive serological result","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","20MWI-SEROCOV","May 2020","October 2020","October 2020","May 6, 2020",,"May 8, 2020","Laboratory of microbiology of hospital hygiene, Ambroise Paré Hospital, APHP, Boulogne-Billancourt, France",,"https://ClinicalTrials.gov/show/NCT04377763"
229,"NCT04374019","Novel Agents for Treatment of High-risk COVID-19 Positive Patients",,"Recruiting","No Results Available","COVID|Sars-CoV2","Drug: Hydroxychloroquine|Drug: Hydroxychloroquine and Azithromycin|Drug: Hydroxychloroquine and Ivermectin|Drug: Camostat Mesilate","Clinical Deterioration|Change in Viral Load|Rate of Organ Failure|Progression to ICU Care or Ventilation|Change in Clinical Status|Mortality|Rate of severe adverse events|Oxygen-free days|Ventilator-free days|Vasopressor-free days|ICU-free days|Hospital-free days|Patients meeting Hy's Law criteria|Liver Function|Heart Function","Susanne Arnold|University of Kentucky","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-20-COVID-01-PMC","May 1, 2020","May 2021","May 2021","May 5, 2020",,"May 7, 2020","University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT04374019"
230,"NCT04347915","The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Clevudine|Drug: Hydroxychloroquine","The rate of subjects tested as negative SARS-Coronavirus-2 (SARS-CoV-2)|The rate of subjects tested as negative SARS-Coronavirus-2 (SARS-CoV-2) in consecutive two days of Real-Time RT-PCR tests|The rate of subjects indicated by the improvement of lung invasive|The change of viral load","Bukwang Pharmaceutical","All","19 Years and older   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BK-CLV-201","May 6, 2020","September 30, 2020","December 31, 2020","April 15, 2020",,"May 11, 2020","Korea University Guro Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04347915"
231,"NCT04366167","Patient Recovery From Heart Surgery During the Covid-19 Pandemic","CardiacCovid","Recruiting","No Results Available","Cardiac Surgery|COVID","Other: Cardiac surgery","Change in Impact of Events scores|Survival|Morbidity|Change in Health-related quality of life scores|Change in Depression scores","Barts & The London NHS Trust|Queen Mary University of London","All","18 Years to 120 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","132127","April 18, 2020","April 19, 2021","December 31, 2021","April 28, 2020",,"April 28, 2020","St Bartholomew's Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04366167"
232,"NCT04428801","Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Biological: autologous adipose-derived stem cells","Tolerability and acute safety of AdMSC infusion by assessment of the total number of AEs/SAEs related and non-related with the medication|The overall proportion of subjects who develop any AEs/SAEs related and non-related with the AdMSC infusions as compared to the control group|COVID-19 incidence rates in both the study and control groups|The proportion of subjects who are infected by SARS-Cov-2 measured by PCR or other nuclear level-based SARS-Cov-2 virus testing in respiratory tract specimens (oropharyngeal samples) collected by oropharyngeal swab using the CDC standard method.|The proportion of subjects who are infected by SARS-Cov-2 virus develop symptoms including mild, classic, severe and critical sever cases between study group and control group.|Change of proportion of subjects who are infected by SARS-Cov-2 and develop IgM/IgG antibodies against SARS-Cov-2 between study group and control group.|Change of lymphocyte count in white blood cell counts from the baseline|Change of PaO2 arterial blood gases from the baseline|Compare the proportion of subjects who develop severe COVID-19 pneumonia cases for both study and control groups|COVID-19 mortality rates for both study and control groups|Change of C-reactive protein (CRP) (mg/L) from the baseline|Change of D-dimer (mg/L) from the baseline|Change of Procalcitonin (ug)/L from the baseline|Change of pro-type B natriuretic peptide (pro-BNP) (pg/mL) from the baseline|Change of Bilirubin (mg/dL) from the baseline|Change of Creatinine (mg/dL) from the baseline|Change in blood test values for cytokine panels (IL-1β, IL-6, IL-8, IL-10, TNFα) from the baseline|The proportion of subjects from SARS-CoV-2 RT-PCR positive to negativity in respiratory tract specimens (oropharyngeal samples) collected by oropharyngeal swab using the CDC standard method. as compared to control group|Quantifying viral RNA in stool for baseline and final follow-up.","Celltex Therapeutics Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","CTX0020-003","June 20, 2020","July 31, 2020","August 10, 2021","June 11, 2020",,"June 12, 2020",,,"https://ClinicalTrials.gov/show/NCT04428801"
233,"NCT04421534","Utility of Lactoferrin as an Adjunct Therapeutic Agent for COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Lactoferrin","Time to clinical improvement|Rate of virological cure","Cairo University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CUKA-001","June 2020","September 2020","November 2020","June 9, 2020",,"June 9, 2020",,,"https://ClinicalTrials.gov/show/NCT04421534"
234,"NCT04372979","Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients.","PLASCOSSA","Not yet recruiting","No Results Available","COVID-19","Drug: Transfusion of SARS-CoV-2 Convalescent Plasma.|Drug: Transfusion of standard Plasma.","Survival time without needs of a ventilator.|Morbidity|Mortality|Length of stay|Effect on viral pharyngeal specimen clearance|Effect on viral blood specimen clearance|Effect on hemostasis disorders|Kinetics of appearance of neutralizing antibodies|Transfusion endotheliopathy effect|Transfusion biological Inflammation effect|Transfusion hemovigilance|Decrease in the consumption of antibiotics","Direction Centrale du Service de Santé des Armées|University Hospital, Grenoble","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020-A01166-33","May 2020","October 2020","May 2021","May 4, 2020",,"May 15, 2020","HIA Percy, Clamart, France|HIA Laveran, Marseille, France|HIA Bégin, Saint-Mandé, France|HIA Sainte Anne, Toulon, France",,"https://ClinicalTrials.gov/show/NCT04372979"
235,"NCT04333407","Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.","C-19-ACS","Recruiting","No Results Available","COVID-19","Drug: Aspirin 75mg|Drug: Clopidogrel 75mg|Drug: Rivaroxaban 2.5 MG|Drug: Atorvastatin 40mg|Drug: Omeprazole 20mg","All-cause mortality at 30 days after admission|Absolute change in serum troponin from admission to peak value|Discharge Rate|Intubation Rate","Imperial College London","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","3170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20HH5868","April 3, 2020","March 30, 2021","March 30, 2021","April 3, 2020",,"April 9, 2020","Charing Cross Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04333407"
236,"NCT04387760","Favipiravir vs Hydroxychloroquine in COVID -19",,"Not yet recruiting","No Results Available","SARS-CoV 2|COVID-19","Drug: Hydroxychloroquine|Drug: Favipiravir|Other: Routine care for COVID-19 patients","Primary outcome measure will be time to viral clearance|Requirement of Escalation of Respiratory Support|Time until resolution of presenting symptoms|Adverse effects|Requirement of ICU Admission|Mortality rate|Serum lactate measurement|Serum Ferritin measurement|Serum D Dimer measurement|Serum procalcitonin measurement|Serum brain naturetic peptide measurement|Ratio of Lymphocyte to Neutrophil, measurement","Royal College of Surgeons in Ireland - Medical University of Bahrain|Bahrain Defence Force Royal Medical Services, Military Hospital|Ebrahim Khalil Kanoo Community Medical Center","All","21 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","40 / 07-May-2020","July 14, 2020","July 14, 2020","August 14, 2020","May 14, 2020",,"June 18, 2020","Royal College of Surgeons in Ireland - Bahrain, Manama, Bahrain",,"https://ClinicalTrials.gov/show/NCT04387760"
237,"NCT04321421","Hyperimmune Plasma for Critical Patients With COVID-19","COV19-PLASMA","Completed","No Results Available","COVID-19","Other: hyperimmune plasma","death|time to extubation|length of intensive care unit stay|time to CPAP weaning|viral load|immune response","Foundation IRCCS San Matteo Hospital|OSPEDALE CARLO POMA ASST MANTOVA","All","18 Years and older   (Adult, Older Adult)","Not Applicable","49","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRCCSSanMatteoH","March 17, 2020","April 28, 2020","May 7, 2020","March 25, 2020",,"May 28, 2020","Catherine Klersy, Pavia, PV, Italy|Ospedale Asst Carlo Poma Mantova, Mantova, Italy",,"https://ClinicalTrials.gov/show/NCT04321421"
238,"NCT04370288","Clinical Application of Methylene Blue for Treatment of Covid-19 Patients","Covid-19","Recruiting","No Results Available","Covid-19","Drug: MCN (Methylene blue, vitamin C, N-acetyl cysteine)","Proportion of patients remaining free of need for mechanical ventilation in both groups|Mortality rate in both groups|Improvement in Pa02/Fi02 ratio in both groups|Duration of hospital stay in both group.|Duration of Intensive Care Unit stay in both groups|Days free of dialysis in both groups|C-reactive proteins|WBC Count","Mashhad University of Medical Sciences","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IR.MUMS.REC.1399.122","April 19, 2020","September 20, 2020","September 21, 2020","April 30, 2020",,"May 4, 2020","Imam Reza Hospital, Mashhad, Razavi Khorasan, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04370288"
239,"NCT04431908","Validation of a Rapid Quantitative Test for Loss of Smell in COVID-19 Subjects",,"Not yet recruiting","No Results Available","COVID-19","Device: olfactory device","sensitivity, specificity and accuracy|repeatability|validation|asymptomatic sensitivity, specificity and accuracy","Yale University","All","18 Years and older   (Adult, Older Adult)",,"250","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2000028259","June 15, 2020","September 1, 2020","October 1, 2020","June 16, 2020",,"June 16, 2020",,,"https://ClinicalTrials.gov/show/NCT04431908"
240,"NCT04345653","Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers",,"Active, not recruiting","No Results Available","COVID19","Drug: Hydroxychloroquine Sulfate (HCQ)","Recruitment Feasibility|Recourse utilization|Safety as reflected on the number and severity of adverse events and serious adverse events|Early feasibility as reflected on the number of participants contracting COVID-19 (10% or less) in comparison to the expected 30% as per CDC.|Effect of basic inflammatory regulation","Hackensack Meridian Health","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","44","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Pro2020-0356","April 14, 2020","June 5, 2020","April 8, 2021","April 14, 2020",,"June 9, 2020","Hackensack Meridian Health - JFK Medical Center, Edison, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04345653"
241,"NCT04348396","Clinical and Biological Predictors of COVID-19 Disease in Older Patients",,"Not yet recruiting","No Results Available","COVID-19",,"Descriptive-epidemiological analysis of health conditions|Evaluation of frailty condition|Identification of biomarkers of inflammation|Assessment of functional capacity|Evaluation of drug consumption|Evaluation of inflamma-miRs","Istituto Nazionale di Ricovero e Cura per Anziani","All","65 Years and older   (Older Adult)",,"300","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","INRCA_01_2020","April 2020","December 2020","December 2020","April 16, 2020",,"April 16, 2020","IRCCS INRCA Hospital, Ancona, Italy",,"https://ClinicalTrials.gov/show/NCT04348396"
242,"NCT04390412","Low Dose Radiotherapy in COVID-19 Pneumonia",,"Recruiting","No Results Available","COVID|SARS (Severe Acute Respiratory Syndrome)","Radiation: Low Dose Radiotherapy","Change from baseline blood oxygenation|Number of Hospital stay days|Number of ICU stay days|Number of intubation events|WBC|Platelets|ESR|CRP|IL-6|Chest CT scan","Shahid Beheshti University of Medical Sciences","All","60 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","23568|IRCT20200509047366N1","May 4, 2020","August 2020","December 2020","May 15, 2020",,"May 15, 2020","Imam Hossein Hospital, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04390412"
243,"NCT04391712","Cold Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease",,"Recruiting","No Results Available","COVID-19","Device: MLS Laser|Other: Regular Inpatient Medical Care","Patient Disposition Post treatment|oxygenation|IL-6 levels|Chest Xray radiographic results|Brescia-COVID Respiratory Severity Scale|SMART-COP Score|PSI Score|CRP levels","Lowell General Hospital","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020.01","April 30, 2020","May 30, 2020","June 30, 2020","May 18, 2020",,"May 18, 2020","Lowell General Hospital, Lowell, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04391712"
244,"NCT04392973","FAvipiravir and HydroxyChloroquine Combination Therapy","FACCT","Recruiting","No Results Available","COVID19","Combination Product: Favipiravir and Hydroxychloroquine","Clinical Improvement|Viral shedding","King Abdullah International Medical Research Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","520","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RC20/174","May 21, 2020","November 2021","November 2021","May 19, 2020",,"June 23, 2020","King Abdulaziz Hospital, Hasa, Eastern Region, Saudi Arabia|AlMadina General Hospital, Al Madīnah, Saudi Arabia|King Abdulaziz Medical City, Jeddah, Saudi Arabia|King Abdulaziz Hospital, Mecca, Saudi Arabia|King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia|Imam Abdulrahman Alfaisal Hospital, Riyadh, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT04392973"
245,"NCT04382781","Immunosupressive Treatment in COVID-19 Patients","SAM-COVID","Recruiting","No Results Available","COVID-19 Infection","Drug: NO-Immunosuppressive|Drug: Immunosuppressive|Drug: Immunoglubulins","Invasive ventilation or death|Ventilation|Death|Secondary infections|Digestive tract hemorrhage|Change in 7 points scale","Spanish Network for Research in Infectious Diseases|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","FIS-INM-2020-03","May 2020","May 2020","May 2020","May 11, 2020",,"May 12, 2020","Hospital Virgen Macarena, Sevilla, Spain","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT04382781/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04382781"
246,"NCT04323514","Use of Ascorbic Acid in Patients With COVID 19",,"Recruiting","No Results Available","Hospitalized Patients With Covid-19 Pneumonia","Dietary Supplement: Vitamin C","In-hospital mortality|PCR levels|Lactate clearance|Hospital stay|Symptoms|Positive swab|Tomography imaging","University of Palermo","All","Child, Adult, Older Adult","Not Applicable","500","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3143","March 13, 2020","March 13, 2021","March 13, 2021","March 26, 2020",,"March 26, 2020","A.R.N.A.S. Civico - Di Cristina - Benfratelli, Palermo, Italy","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT04323514/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04323514"
247,"NCT04412486","COVID-19 Convalescent Plasma (CCP) Transfusion",,"Recruiting","No Results Available","COVID-19","Biological: COVID Convalescent Plasma","Change in PaO2/FiO2 after CCP transfusion.|Change in pulse oximetry status after CCP transfusion.|Change in aO2 after CCP transfusion.|Change in respiratory rate after CCP transfusion.|Change in intubation status after CCP transfusion.|Change in Sequential Organ Failure Assessment (SOFA).|Change in 8-point ordinal clinical deterioration scale.|Length of ICU/hospital stay.|Development of plasma transfusion reactions.|Development of immune complex disorders.|Change in anti CoV-2 IgM and IgG levels.","Gailen D. Marshall Jr., MD PhD|University of Mississippi Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-0137","June 1, 2020","May 31, 2022","May 31, 2022","June 2, 2020",,"June 2, 2020","University of Mississippi Medical Center, Jackson, Mississippi, United States",,"https://ClinicalTrials.gov/show/NCT04412486"
248,"NCT04406389","Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)","IMPACT","Not yet recruiting","No Results Available","COVID-19","Drug: Enoxaparin sodium|Drug: Unfractionated heparin|Drug: Fondapariniux|Drug: Argatroban","30-day mortality|Length of Intensive Care Unit (ICU) Stay in Days|Number of documented venous thromboembolism (VTE), arterial thrombosis (stroke, myocardial infarction, other) and microthrombosis events|Number of major and clinically relevant non-major bleeding events","Weill Medical College of Cornell University","All","18 Years and older   (Adult, Older Adult)","Phase 4","186","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-04021936","June 2020","December 2020","June 2021","May 28, 2020",,"May 28, 2020","Weill Cornell Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04406389"
249,"NCT04291053","The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Huaier Granule","Mortality rate|Clinical status assessed according to the official guideline|The differences in oxygen intake methods|Duration (days) of supplemental oxygenation|Duration (days) of mechanical ventilation|The mean PaO2/FiO2|Length of hospital stay (days)|Length of ICU stay (days)|Pulmonary function","Tongji Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","550","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TJ-IRB20200205","April 1, 2020","August 1, 2020","September 1, 2020","March 2, 2020",,"March 17, 2020",,,"https://ClinicalTrials.gov/show/NCT04291053"
250,"NCT04371406","Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients","MG-COVID","Not yet recruiting","No Results Available","Covid-19","Drug: Hydroxychloroquine and Azithromycin|Dietary Supplement: Azinc","Rate of patients with occurrence of an unfavorable outcome between randomization and day 14|Primary outcome of ancillary virological study : evolution of viral load between day 0 and day 14|The all-cause mortality rate at day 14|The all-cause mortality rate at day 28|Rate of patients with occurrence of an unfavorable outcome between randomization and day 28|The rate of use of mechanical ventilation at day 14|The rate of use of mechanical ventilation at day 28|The Intensive Care Unit admission rate at day 14|The Intensive Care Unit admission rate at day 28|Number of days of hospitalization for any cause between day 0 and day 14|Number of days of hospitalization for any cause between day 0 and day 28|The time to resolution of all COVID symptoms at day 14|The time to resolution of all COVID symptoms atday 28|The rate of use of oxygen therapy at day 14|The rate of use of oxygen therapy at day 28|The rate of use of secondary antibiotic therapy (after day 2) at day 14|The rate of use of secondary antibiotic therapy (after day 2) at day 28|Clinical status at day 14|Clinical status at day 28|number of serious adverse events at day 14|number serious adverse events at day 28|number of adverse events at day 14|number of adverse events at day 28|The rate of patients with treatment withdrawal|Ancillary virological study : rate of patients with negative viral load at day 8|Ancillary virological study : rate of patients with negative viral load at day 14","Assistance Publique - Hôpitaux de Paris","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","2770","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200447|2020-001702-35","May 2, 2020","August 2, 2020","September 2, 2020","May 1, 2020",,"May 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04371406"
251,"NCT04365725","Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections","REMDECO-19","Recruiting","No Results Available","COVID-19","Drug: Remdesivir","Clinical course on Day 15.|Clinical course on Day 3.|Clinical course on Day 8|Clinical course on Day 11.|Clinical course on Day 29.|Duration of treatment|Sepsis-related Organ Failure Assessment score|Duration without mechanical ventilation|Mortality|cumulative incidence of grade 3 and 4 adverse events (AEs).","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","APHP200522","May 5, 2020","June 2020","June 2020","April 28, 2020",,"May 13, 2020","Hôpital Cochin, Paris, France",,"https://ClinicalTrials.gov/show/NCT04365725"
252,"NCT04401423","TXA COVID-19 Clinical Trial",,"Not yet recruiting","No Results Available","COVID-19","Drug: TXA127|Drug: Placebo","Incidence of acute kidney injury|Incidence of respiratory failure|Mortality|Renal failure|Vasoplegic shock|Inflammatory markers, specifically IL-6 levels|Reduction in supplemental oxygen requirements","Columbia University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","AAAT0535","June 2020","June 2021","December 2021","May 26, 2020",,"May 26, 2020",,,"https://ClinicalTrials.gov/show/NCT04401423"
253,"NCT04380961","A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19",,"Recruiting","No Results Available","Severe or Critical Confirmed Coronavirus Disease (COVID)-19","Drug: Sirukumab|Drug: Placebo|Other: Standard of Care (SOC)","Time to Improvement of at Least 2 Categories Relative to Baseline on the 6-Point Ordinal Clinical Recovery Scale|Percentage of Participants with an Improvement of at Least 2 Categories Relative to Baseline on the 6-Point Ordinal Clinical Recovery Scale on Day 28|Percentage of Participants with Serious Adverse Events (SAEs)|Percentage of Participants with Related Adverse Events|Percentage of Participants with Severe or Life Threatening Bacterial, Invasive Fungal, Viral or Opportunistic Infections|Percentage of Participants with Grade 3 and 4 Neutropenia|Percentage of Participants with Grade 3 and 4 Lymphocytopenia|Percentage of Participants with Increased Alanine Aminotransferase (ALT) Greater than or equal to 3 Times Upper Limit of Normal (ULN) Combined with Increased Bilirubin > 2 Times ULN|Time to Improvement of at least 1 Category Relative to Baseline on the 6-Point Ordinal Clinical Recovery Scale|Percentage of Participants with an Improvement of at Least 1 Category Relative to Baseline on the 6-Point Ordinal Clinical Recovery Scale on Day 28|Time from Study Intervention to end of Oxygen Supplementation|Time from Study Intervention to Hospital Discharge Among the Surviving Participants|Total Length of Hospitalization|Percentage of Participants with All-cause Mortality|Number of Ventilation Free Days|Participant's Clinical Status at Day 7, 14, 21, 28 as Assessed by 6-Point Ordinal Clinical Recovery Scale|Total Time on Invasive Mechanical Ventilation|Percentage of Participants with a Worse Category Relative to Baseline on the 6-Point Ordinal Clinical Recovery Scale over Time|Percentage of Participants on Extracorporeal Membrane Oxygenation (ECMO) Over Time|Total Time on ECMO|Percentage of Alive Participants at Day 28, Week 8 and Week 16|Percentage of Alive Participants that Required Readmission at Week 8 and Week 16","Janssen Pharmaceutica N.V., Belgium","All","18 Years to 84 Years   (Adult, Older Adult)","Phase 2","270","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CR108820|CNTO136COV2001","April 24, 2020","June 25, 2020","September 16, 2020","May 8, 2020",,"June 11, 2020","Loyola University Medical Center, Maywood, Illinois, United States|University of Illinois College of Medicine at Peoria, Peoria, Illinois, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States|Wayne State University/Detroit Medical Center, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Beaumont Health Systems, Royal Oak, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercury Street Medical Group, PLLC, Butte, Montana, United States|Saint Michael's Medical Center - Infectious Disease, Newark, New Jersey, United States|SUNY Upstate Medical University, Syracuse, New York, United States|East Carolina University, Greenville, North Carolina, United States|Baylor Scott & White Research Institute, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04380961"
254,"NCT04392427","New Antiviral Drugs for Treatment of COVID-19",,"Not yet recruiting","No Results Available","COVID|Drug Effect","Drug: Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :","negative test result for COVID-19","Mansoura University","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","20.05.69","May 2020","May 2022","May 2022","May 18, 2020",,"May 18, 2020","Mansoura University, Mansoura, Select A State Or Province, Egypt",,"https://ClinicalTrials.gov/show/NCT04392427"
255,"NCT04342637","COVID-19 Endoscopy Survey","COVID-19 Endo","Completed","No Results Available","COVID-19","Other: Practice details","Effect of GI societies recommendations on prevention of SARS-CoV-2 infection|To measure the percentage change in performed endoscopic procedure in response to COVID-19|Effect of COVID-19 precautions on procedure time|Effect of COVID-19 precautions on time of disinfection|Effect of COVID-19 precautions on procedure success|Effect of COVID-19 precautions on complications|Effect of COVID-19 precautions on working time|Effect of COVID-19 precautions on staff number","Al-Azhar University","All","30 Years to 70 Years   (Adult, Older Adult)",,"163","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","WES-2","April 10, 2020","April 25, 2020","May 1, 2020","April 13, 2020",,"May 20, 2020","Kings County Hospital Center, Brooklyn, NY, USA, Albertson, New York, United States|Faculty of Medicine, Zagazig University, Zagazig, Sharkia, Egypt|Al-Azhar Univerisity, Cairo, Egypt|Ahvaz Imam hospital, Ahvaz, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04342637"
256,"NCT04401033","Increased Risk of SARS-CoronaVirus-2 (SARS-CoV-2) Infection Associated With Endoscopy (DECORE Study)","DECORE","Recruiting","No Results Available","SARS-CoV 2|COVID","Behavioral: Telephonic medical visit|Procedure: Gastrointestinal endoscopy|Procedure: Abdominal ultrasound","SARS-CoV-2 infection in patients|SARS-CoV-2 infection in HCW","Hospital del Río Hortega","All","18 Years and older   (Adult, Older Adult)",,"450","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","003","May 11, 2020","June 30, 2020","June 30, 2020","May 26, 2020",,"May 27, 2020","Hospital Rio Hortega, Valladolid, Spain","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT04401033/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04401033"
257,"NCT04347993","A Prospective ""Universal"" Observational Database for COVID-19",,"Recruiting","No Results Available","COVID-19",,"Need for hospitalization|Duration of hospitalization|Need for ICU/Ventilator Support|Duration of ICU/Ventilator Support|Overall Survival","Hackensack Meridian Health","All","Child, Adult, Older Adult",,"5000","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","Pro2020-0342","March 27, 2020","April 2021","April 2021","April 15, 2020",,"April 24, 2020","Hackensack Meridian Health - John Theurer Cancer Center, Hackensack, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04347993"
258,"NCT04331509","COVID-19 Symptom Tracker",,"Recruiting","No Results Available","COVID-19","Other: No Intervention","Physical health symptoms|Lack of physical health symptoms|Fever","King's College London|Zoe Global Limited|Massachusetts General Hospital|Harvard School of Public Health|Stanford University","All","18 Years and older   (Adult, Older Adult)",,"10000000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-19 Symptom tracker","March 23, 2020","March 23, 2022","March 23, 2022","April 2, 2020",,"April 7, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States|King's College London, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04331509"
259,"NCT04427345","Predictive Factors COVID-19 Patients","MI-COVID","Recruiting","No Results Available","covid19","Other: Predictive factors for clinical response in patients with COVID-19.","Identify risk factors for intra-hospital mortality.|Identify risk factors to build a prognostic score.|Predictive factors for the hospitalization duration.|Predictive factors for clinical status patients based on ""Ordinal Scale for Clinical Improvement""|Describe the anti-viral therapies used commonly in this emergency in terms of efficacy|Describe the anti-viral therapies used commonly used in this emergency in terms of safety|Monitor the clinical course of the disease in discharged patients.","University of Milano Bicocca","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","MI-COVID","March 1, 2020","June 2020","May 31, 2021","June 11, 2020",,"June 11, 2020","ASST Monza-Ospedale San Gerardo, Monza, Italy",,"https://ClinicalTrials.gov/show/NCT04427345"
260,"NCT04345523","Convalescent Plasma Therapy vs. SOC for the Treatment of COVID19 in Hospitalized Patients","ConPlas-19","Recruiting","No Results Available","COVID-19","Other: Blood and derivatives.|Drug: Standard of Care","Category Changes in Ordinal Scale|Time to category 5, 6 or 7 of the ordinal scale|Mortality of any cause at 15 days|Mortality of any cause at 29 days|Oxygenation free days|Ventilator free days|Incidence of Treatment-Emergent Adverse Events|Antibodies levels in CP donors recovered from COVID-19|Viral load","Cristina Avendaño Solá|Puerta de Hierro University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","278","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ConPlas-19","April 3, 2020","July 2020","July 2020","April 14, 2020",,"April 15, 2020","Hospital Clínico Universitario Lozano Blesa, Zaragoza, Aragón, Spain|Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Hospital Universitario Príncipe de Asturias, Meco, Madrid, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04345523"
261,"NCT04358835","Keto-diet for Intubated Critical Care COVID-19","KICC-COVID19","Not yet recruiting","No Results Available","COVID-19","Dietary Supplement: Ketogenic diet|Other: standard of care","Change in the partial pressure of carbon dioxide (PaCO2)|Change in minute ventilation|Change in respiratory system compliance|Change in driving pressure|Change in ventilator synchrony|Change in mean arterial pressure|Change in the fraction of inspired oxygen percentage of oxygen (FiO2)|Change in the partial pressure of carbon dioxide (PaO2) to the fraction of inspired oxygen percentage of oxygen (FiO2) ratio|Change in hydrogen ion activity (pH)|Change in Bicarbonate (HCO3)|Change in red blood cell count|Change in white blood cell count|Change in white cell differential|Change in hemoglobin levels|Change in hematocrit|Change in mean cell volume|Change in mean cell hemoglobin|Change in mean cell hemoglobin concentration|Change in platelet count|Change in red cell distribution width|Change in blood albumin level|Change in serum alkaline phosphatase level|Change in serum aspartate transaminase level|Change in serum alanine aminotransferase level|Change in blood urea nitrogen levels|Change in serum calcium level|Change in serum chloride level|Change in serum potassium level|Change in serum creatinine level|Date patient is re-intubated or need mechanical ventilation for a second time|Length of intensive care unit stay|The total hospital stay|Disposition at discharge|Change in heart rate|Change in the dosage of vasopressor medication","Johns Hopkins University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00247383","September 1, 2020","September 1, 2021","December 31, 2021","April 24, 2020",,"June 17, 2020",,,"https://ClinicalTrials.gov/show/NCT04358835"
262,"NCT04353323","COVID 19-Caregivers IGg Seroconversion","CoSigS","Not yet recruiting","No Results Available","Infection, COVID-19","Other: Blood sampling","Seroconversion","University Hospital, Limoges","All","18 Years and older   (Adult, Older Adult)",,"130","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","87RI20_0016/CoSigS","May 25, 2020","June 25, 2020","December 25, 2020","April 20, 2020",,"May 11, 2020","CHU de Limoges, Limoges, France",,"https://ClinicalTrials.gov/show/NCT04353323"
263,"NCT04355871","Characteristics and Outcomes of Hospitalized Patients With COVID-19 in Spain","COVID19@Spain","Completed","No Results Available","Covid19",,"Overall mortality|Mechanical ventilation","Fundacion SEIMC-GESIDA","All","Child, Adult, Older Adult",,"4035","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","COVID-19/SEIMC-FSG","March 18, 2020","April 15, 2020","April 17, 2020","April 21, 2020",,"May 11, 2020","Comp. Hosp. Univ. A Coruña, A Coruña, Spain|H. Quiron A Coruña, A Coruña, Spain|H. de Alcaniz, Alcañiz, Spain|H. Gral Univ. de Alicante, Alicante, Spain|H. Univ. San Juan de Alicante, Alicante, Spain|H. Univ. de la Ribera, Alzira, Spain|H. Santos Reyes, Aranda De Duero, Spain|H. Dr. Jose Molina Orosa, Arrecife, Spain|Consorcio Sanitari Integral (CAIDM), Barcelona, Spain|H. Clinic, Barcelona, Spain|H. del Mar, Barcelona, Spain|H. Parc Sanitari Sant Joan de Deu, Barcelona, Spain|H. Santa Creu y Sant Pau, Barcelona, Spain|H. Univ. de Bellvitge, Barcelona, Spain|H. Vall d'Hebron, Barcelona, Spain|Hospital CIMA-Sanitas, Barcelona, Spain|SCIAS H. de Barcelona, Barcelona, Spain|H. Clinica de Benidorm, Benidorm, Spain|H. de Cruces, Bilbao, Spain|H. San Eloy_Barakaldo, Bilbao, Spain|H. Univ. de Basurto, Bilbao, Spain|H. Urduliz-Alfredo Espinosa, Bilbao, Spain|H. Gral de La Palma, Breña Alta, Spain|H. de Puerto Real, Cadiz, Spain|H. de Calahorra, Calahorra, Spain|H. Sant Jaume de Calella, Calella, Spain|H. Univ Santa Lucia, Cartagena, Spain|H. Univ de Henares, Coslada, Spain|Hospital Marina Salud de Dénia, Denia, Spain|Hospital Don Benito-Villanueva de la Serena, Don Benito, Spain|H. Gral Univ. de Elche, Elche, Spain|H. Univ. del Vinalopo, Elche, Spain|Comp. Hospt. Univ. de Ferrol, Ferrol, Spain|H. Francesc de Borja, Gandia, Spain|H. de Figueres, Gerona, Spain|H. Comarcal de Blanes, Girona, Spain|H. Josep Trueta, Girona, Spain|H. Clinico San Cecilio, Granada, Spain|Hospital HLA Inmaculada, Granada, Spain|H. de Guadalajara, Guadalajara, Spain|H. de Guadarrama, Guadarrama, Spain|H. Juan Ramón Jiménez, Huelva, Spain|H. Riotinto, Huelva, Spain|H. Can Misses, Ibiza, Spain|H. Universitario de Jaén, Jaén, Spain|H. Univ. de Jerez de la Frontera, Jerez De La Frontera, Spain|H. Univ Insular de Gran Canaria, Las Palmas De Gran Canaria, Spain|H. Universitario de Gran Canaria Dr. Negrin, Las Palmas De Gran Canaria, Spain|H. Univ. Severo Ochoa, Leganés, Spain|H. San Pedro, Logroño, Spain|H. Univ. Menez Rafael Mendez, Lorca, Spain|H. Lucus Augusti, Lugo, Spain|H. 12 de Octubre, Madrid, Spain|H. Clinica Univ. de Navarra_ Campus Madrid, Madrid, Spain|H. Clinico San Carlos, Madrid, Spain|H. Fundacion Jiménez Díaz, Madrid, Spain|H. Gral de la Defensa Gomez Ulla, Madrid, Spain|H. HLA Univ. Moncloa, Madrid, Spain|H. HM Sanchinarro, Madrid, Spain|H. Puerta de Hierro, Madrid, Spain|H. Univ HM Madrid, Madrid, Spain|H. Univ Principe de Asturias, Madrid, Spain|H. Univ. de Alcorcón, Madrid, Spain|H. Univ. de Getafe, Madrid, Spain|H. Univ. de Móstoles, Madrid, Spain|H. Univ. Gregorio Marañon, Madrid, Spain|H. Univ. HM Monteprincipe, Madrid, Spain|H. UNiv. HM Puerta del Sur, Madrid, Spain|H. Univ. Infanta Leonor, Madrid, Spain|H. Univ. La Paz, Madrid, Spain|H. Univ. La Princesa, Madrid, Spain|H. Univ. Ramón y Cajal, Madrid, Spain|H. Univ. Rey Juan Carlos, Madrid, Spain|H. Costa del Sol, Marbella, Spain|H. de Mataro, Mataró, Spain|H. de Melilla, Melilla, Spain|H. de Mendaro, Mendaro, Spain|Hospital Alto Deba, Mondragón, Spain|H. Virgen de la Arrixaca, Murcia, Spain|H. Marbella Internacional, Málaga, Spain|H. Virgen de la Victoria, Málaga, Spain|H. Vega Baja, Orihuela, Spain|H. Univ. Central de Asturias, Oviedo, Spain|H. de Palamos, Palamós, Spain|H. Son Espases, Palma De Mallorca, Spain|H. Son Llatzer, Palma De Mallorca, Spain|H. Clinica Univ. Navarra, Pamplona, Spain|H. Virgen del Puerto, Plasencia, Spain|H. El Bierzo, Ponferrada, Spain|H. Do Salnes, Pontevedra, Spain|H. UNiv. Los Arcos del Mar Menor, Pozo Aledo, Spain|H. Santa Barbara, Puertollano, Spain|H. Parc Tauli, Sabadell, Spain|Complejo Asist. Univ. de Salamanca, Salamanca, Spain|H. Infanta Sofia, San Sebastián De Los Reyes, Spain|H. de Donostia, San Sebastián, Spain|H. de l'Esperit Sant, Santa Coloma De Gramenet, Spain|H. Univ. Marques de Valdecilla, Santander, Spain|H. Clinico Univ. Santiago de Compostela, Santiago De Compostela, Spain|H. Univ de Valme, Sevilla, Spain|H. Univ. Virgen del Rocio, Sevilla, Spain|H. Univ. Virgen Macarena, Sevilla, Spain|H. Virgen Macarena, Sevilla, Spain|H. Univ Joan XXIII, Tarragona, Spain|H. U. de Canarias, Tenerife, Spain|H. Univ. Nuestra Sra. de la Candelaria, Tenerife, Spain|H. Mutua de Terrasa, Terrassa, Spain|Complejo Hospitalario Virgen de la Salud, Toledo, Spain|H. Univ. HM Torrelodones, Torrelodones, Spain|H. Quiron Salud Torrevieja, Torrevieja, Spain|H. Virgen de la Cinta, Tortosa, Spain|H. Reina Sofia de Tudela, Tudela, Spain|H. Arnau de Vilanova-Lliria, Valencia, Spain|H. Clinico Univ. de Valencia, Valencia, Spain|H. de Sagunto, Valencia, Spain|H. Univ. y Polit. La Fe, Valencia, Spain|H. Clin. Univ. de Valladolid, Valladolid, Spain|H. Rio Hortega, Valladolid, Spain|H. Alvaro Cunqueiro, Vigo, Spain|H. de Viladecans, Viladecans, Spain|H. de la Marina Baixa, Villajoyosa, Spain|Hospital de la Plana, Villareal, Spain|H. Univ de Alava, Vitoria, Spain|H. Virgen de la Concha, Zamora, Spain|H. Lozano Blesa, Zaragoza, Spain|H. Miguel Servet, Zaragoza, Spain|H. Ntra. Sra. de Gracia, Zaragoza, Spain|Complejo Asistencial de Avila, Ávila, Spain",,"https://ClinicalTrials.gov/show/NCT04355871"
264,"NCT04399889","hCT-MSCs for COVID19 ARDS",,"Recruiting","No Results Available","COVID|Corona Virus Infection|COVID19","Biological: human cord tissue mesenchymal stromal cells","Safety of the Investigational Product|Describe the potential for MSC therapy to favorably alter the course of COVID-ARDs","Joanne Kurtzberg, MD|The Marcus Foundation|Duke University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pro00105410","June 18, 2020","April 1, 2021","July 31, 2021","May 22, 2020",,"June 22, 2020","Duke Hospital, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04399889"
265,"NCT04365257","Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)","PREVENT","Recruiting","No Results Available","COVID-19","Drug: Prazosin|Other: Standard of care","Death|Hospitalized, requiring mechanical ventilation and/or high flow nasal cannula and/or ICU/CCU admission (or equivalent) and/or ECMO|Hospitalized, requiring supplemental oxygen, not requiring ICU/CCU level care (or interventions listed under Outcome 2)|Cumulative incidence of grade 3 and 4 adverse events|Number of participants with serious adverse events|Incidence of symptomatic hypotension or hypotension requiring cessation of prazosin|Number of participants with laboratory abnormalities in peripheral blood|Duration of laboratory abnormalities in peripheral blood|Number of participants with laboratory abnormalities in plasma|Duration of laboratory abnormalities in plasma","Johns Hopkins University|Fast Grants","All","45 Years to 85 Years   (Adult, Older Adult)","Phase 2","220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00246659|COV2001","May 13, 2020","December 2020","December 2020","April 28, 2020",,"May 15, 2020","Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04365257"
266,"NCT04366232","Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation (JAKINCOV)","JAKINKOV","Not yet recruiting","No Results Available","Covid-19","Drug: Anakinra alone (stages 2b/3)|Drug: Anakinra and Ruxolitinib (overcome stage 3)|Other: Standard of care","Biological criteria|Duration of oxygen therapy (days)|Number of intensive care units admissions|Number of days in intensive care units|Mortality rate|Total number of days in hospital|Organ failure score modification (Sepsis-related Organ Failure Assessment (SOFA) score)|Number of bacterial and/or fungal sepsis","Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer|Hopital d'instruction des Armees Sainte-Anne|Assistance Publique Hopitaux De Marseille","All","18 Years and older   (Adult, Older Adult)","Phase 2","54","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-CHITS-003|2020-001963-10","June 2020","August 31, 2020","August 31, 2020","April 28, 2020",,"June 9, 2020","AP-HM, Hôpital de la Conception, Marseille, Bouches-du-Rhône, France|Hôpital Sainte-Musse, Toulon, VAR, France|Sainte Anne Teaching Military Hospital, Toulon, Var, France",,"https://ClinicalTrials.gov/show/NCT04366232"
267,"NCT04434248","An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19",,"Active, not recruiting","No Results Available","COVID-19","Drug: Favipiravir|Drug: Standard of Care","Rate of viral elimination by Day 10 [pilot stage, dose selection]|Time to viral elimination [pivotal stage]|Time to clinical improvement [pivotal stage]|Rate of viral elimination|Time to normalization of clinical symptoms|Duration of oxygen therapy|Change in the level of lung damage according to CT|Rate of transfer to the intensive care unit|Rate of the use of non-invasive lung ventilation|Rate of the use of mechanical ventilation|Mortality|Peak plasma concentration (Cmax)|Time to peak plasma concentration (Tmax)|Area under the plasma concentration versus time curve (AUC0-t)|Trough plasma concentration (Ctrough)","Chromis LLC|Chemical Diversity Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","330","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID-FPR-01","April 23, 2020","July 2020","July 2020","June 16, 2020",,"June 16, 2020","Republican Clinical Hospital, Makhachkala, Russian Federation|""K+31"" Clinic, Moscow, Russian Federation|""Khaven"" Llc, Moscow, Russian Federation|Central Clinical Hospital with Polyclinic, Moscow, Russian Federation|Central Research Institute of Epidemiology, Moscow, Russian Federation|City Clinical Hospital n.a. O.M. Filatov, Moscow, Russian Federation|City Clinical Hospital named after S.S. Yudin, Moscow, Russian Federation|City Clinical Hospital No. 24, Moscow, Russian Federation|City Clinical Hospital No. 51, Moscow, Russian Federation|First Moscow State Medical University n.a. I.M. Sechenov, Moscow, Russian Federation|Moscow State University n.a. M. V. Lomonosov, Moscow, Russian Federation|National Medical and Surgical Center named after N.I. Pirogov, Moscow, Russian Federation|City Hospital № 33 of the Leninsky region of Nizhny Novgorod, Nizhny Novgorod, Russian Federation|Infectious clinical hospital No.2 of Nizhny Novgorod, Nizhny Novgorod, Russian Federation|Ryazan State Medical University named after I.P. Pavlov, Ryazan, Russian Federation|Military Medical Academy named after S.M. Kirova, Saint Petersburg, Russian Federation|Saratov State Medical University named after V.I. Razumovsky, Saratov, Russian Federation|Clinical hospital No.1, Smolensk, Russian Federation|Regional Clinic Hospital, Tver, Russian Federation|Bashkir State Medical University, Ufa, Russian Federation|Yakutsk City Clinical Hospital, Yakutsk, Russian Federation|Yaroslavl Regional Clinical Hospital for War Veterans, Yaroslavl, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04434248"
268,"NCT04336462","Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19","COVID-19","Recruiting","No Results Available","COVID-19","Device: oxyhydrogen|Device: Oxygen","Recovery time|Clinical Symptom Remission time|fever duration|Leicester cough questionaire (LCQ)|minimum oxygen|Negative conversion rate|white blood cell(WBC)|Red blood cells(RBC)|Hemoglobin(Hb )|Platelets(PLT)|Lymphocyte count|The percentage of lymphocyte|neutrophils|C-reactive protein (CRP)|Myocardial enzyme|liver function|Renal function|Muscle enzyme","Shanghai Asclepius Meditec Inc.|Shanghai Public Health Clinical Center|Henan Provincial People's Hospital|Shenzhen Third People's Hospital|The First People's Hospital of Yunnan|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Shanghai 6th People's Hospital|Guangdong Provincial Hospital of Traditional Chinese Medicine","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","100","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","JT202002LZ","February 15, 2020","February 21, 2020","August 1, 2020","April 7, 2020",,"April 7, 2020","First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04336462"
269,"NCT04386512","Clinical Epidemiology and Characteristics Of Covid-19 Cases Occurred In A Lymphoma Setting In The First Epidemic Phase (LymphoCov1)","LymphoCov1","Not yet recruiting","No Results Available","COVID|Lymphoma",,"mortality|transfer to ICU","Versailles Hospital","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","P20/12_LymphoCov","May 15, 2020","June 1, 2020","July 15, 2020","May 13, 2020",,"May 13, 2020",,,"https://ClinicalTrials.gov/show/NCT04386512"
270,"NCT04389658","Contagiousness and Immunogenicity Status of COVID-19 in Asymptomatic Population (COVID-19 CONDITION)","CONDITION","Recruiting","No Results Available","COVID-19",,"Prevalence of contagiousness in asymptomatic individuals by PCR|Ratio of asymptomatic immunized (IgA/IgM and IgG) population|Description of demographic characteristics","Igenomix","All","Child, Adult, Older Adult",,"1000","Industry","Observational","Observational Model: Other|Time Perspective: Retrospective","IGX1-COV-XS-20-01","May 7, 2020","June 2020","August 2020","May 15, 2020",,"May 18, 2020","Igenomix, Paterna, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT04389658"
271,"NCT04393038","ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19","Mir-Age","Recruiting","No Results Available","COVID-19","Drug: ABX464|Drug: Placebo","Rate of patients with no invasive or non-invasive mechanical ventilation (IMV and NIV, respectively), but excluding simple nasal/mask oxygen supplementation, and who are alive|Rate of patients hospitalized|Percentage of patients reporting each severity rating on a 7-point ordinal scale|Change from enrolment in inflammatory markers in plasma and in immune phenotype and assessment of cell-activation markers in PBMCs|Rate of patients requiring oxygen supplementation|Time to hospitalization|Time to assisted ventilation and oxygen supplementation|Change from baseline in microRNA-124 levels|Change from baseline in CRP, Troponin I & T and D-dimer|SARS-CoV-2 viral load|Number and rates of participants with Treatment Emergent Adverse Event","Abivax S.A.","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","1034","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ABX464-401","May 1, 2020","December 30, 2020","April 30, 2021","May 19, 2020",,"May 19, 2020","Centre Hospitalier Universitaire de Nice, Nice, France",,"https://ClinicalTrials.gov/show/NCT04393038"
272,"NCT04381052","Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection",,"Not yet recruiting","No Results Available","COVID-19","Drug: Clazakizumab|Other: Placebo","Cumulative incidence of serious adverse events associated with clazakizumab or placebo|Cumulative Incidence of Intubation|Time to Extubation|Length of Intensive Care Unit (ICU) stay|Number of Patients who Present a Decrease in C-reactive protein (CRP)|Number of Patients with Acute Kidney Injury (AKI)|Number of Patients with a Need for Renal Replacement Therapy (RRT)|Duration of Renal Replacement Therapy (RRT)|Patient Survival|Number of Patients with Hemodialysis|Number of Patients with Continuous Renal Replacement Therapies (CRRT)|Number of Patients with Peritoneal Dialysis","Columbia University|NYU Langone Health|Vitaeris INC","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AAAT0142","May 2020","August 1, 2020","August 1, 2020","May 8, 2020",,"May 8, 2020","Columbia University Medical Center / New York Presbyerian Hospital, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04381052"
273,"NCT04368390","Neuroradiolological Analysis of COVID-19 Patients","COVID-19BRAIN","Recruiting","No Results Available","Covid-19",,"Neuroradiological analysis of patients brain MRI","University Hospital, Strasbourg, France","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Other","7759","April 3, 2020","April 2021","April 2021","April 29, 2020",,"April 29, 2020","Service d'Imagerie 2 - Neuroradiologie, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT04368390"
274,"NCT04404179","Setting up a COVID-19 Care Facility at a Prison in Pakistan",,"Completed","No Results Available","COVID-19","Other: COVID-19 FACILITY","Recovery|Mortality|ICU admission","Services Institute of Medical Sciences, Pakistan","All","Child, Adult, Older Adult",,"69","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CovJ","March 27, 2020","May 2, 2020","May 2, 2020","May 27, 2020",,"May 29, 2020","Camp Jail / COVID-19 CARE FACILITY/ SIMS, Lahore, Pakistan",,"https://ClinicalTrials.gov/show/NCT04404179"
275,"NCT04314232","Mechanisms for Covid-19 Disease Complications","COVID MECH","Recruiting","No Results Available","COVID|Coronavirus Infection",,"Number of participants with ICU admission or death|Number of participants with ICU admission|Number of participants with death from all causes|Total duration of ICU stay|Total duration of hospital stay","University Hospital, Akershus","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","117589","March 18, 2020","December 31, 2021","December 31, 2021","March 19, 2020",,"June 26, 2020","Akershus University Hospital, Lørenskog, Norway",,"https://ClinicalTrials.gov/show/NCT04314232"
276,"NCT04333732","CROWN CORONATION: Chloroquine RepurpOsing to healthWorkers for Novel CORONAvirus mitigaTION","CROWN CORONA","Not yet recruiting","No Results Available","COVID 19","Drug: Low-dose chloroquine|Drug: Mid-dose chloroquine|Drug: High-dose chloroquine|Drug: Placebo","Symptomatic COVID-19|Peak severity of COVID-19 over the study period","Washington University School of Medicine|Bill and Melinda Gates Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 3","55000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","202004099","May 2020","February 2021","February 2021","April 3, 2020",,"May 7, 2020","Washington University School of Medicine, Saint Louis, Missouri, United States|Population Health Resarch Institute, Hamilton, Ontario, Canada|University of Toronto, Toronto, Ontario, Canada|St James's Hospital, Dublin, Leinster, Ireland|Universitas Academic Hospital, Bloemfontein, Free State, South Africa|Wits RHI, University of the Witwatersrand, Johannesburg, Gauteng, South Africa|Steve Biko Academic Hospital, Pretoria, Gauteng, South Africa|Tygerberg Hospital, Cape Town, Western Cape, South Africa|Groote Schuur Hospital, Cape Town, Western Cape, South Africa|University College London, London, United Kingdom|Levy Mwanawasa University Teaching Hospital, Lusaka, Zambia|Centre for Infectious Disease Research in Zambia [CIDRZ], Lusaka, Zambia",,"https://ClinicalTrials.gov/show/NCT04333732"
277,"NCT04401410","Anti-SARS Cov-2 T Cell Infusions for COVID 19","BAT IT","Not yet recruiting","No Results Available","SARS-CoV 2|Viral Infection|COVID 19","Biological: Partially HLA-matched Virus Specific T cells (VSTs)","Safety of administering partially HLA-matched SARS-CoVSTs to hospitalized COVID19 patients with high risk of progression to mechanical ventilation.|Efficacy of anti-COVID19 of administering banked partially HLA-matched SARS-CoVSTs to hospitalized COVID19 patients.","Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital System|AlloVir","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-47739 BAT IT","July 30, 2020","August 15, 2021","August 15, 2021","May 26, 2020",,"May 26, 2020","Houston Methodist Hospital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04401410"
278,"NCT04363346","Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia",,"Recruiting","No Results Available","COVID-19","Drug: FT516","Number of participants with Dose Limiting Toxicity Events|The time in days from the 1st FT516 infusion to the elimination of viral shedding in nasal pharyngeal and stool samples|The time in days from the 1st FT516 infusion to discontinued need for supplemental oxygen|The time in days from the 1st FT516 infusion to hospital discharge","Masonic Cancer Center, University of Minnesota","All","18 Years to 76 Years   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IDIM-2020-28708|2020LS083","May 14, 2020","January 2022","January 2022","April 27, 2020",,"May 18, 2020","University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04363346"
279,"NCT04333420","Open-label, Randomized Study of IFX-1 in Patients With Severe COVID-19 Pneumonia","PANAMO","Recruiting","No Results Available","COVID-19 Pneumonia","Drug: Best supportive Care (BSC) + IFX-1|Drug: Best supportive care only","Change in PaO2/FiO2|Patients achieving early response","InflaRx GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","130","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IFX-1-P2.9","March 31, 2020","October 31, 2020","December 31, 2020","April 3, 2020",,"April 16, 2020","University Amsterdam, Amsterdam, Netherlands|University Amsterdam, Amsterdam, Netherlands|University Maastricht, Maastricht, Netherlands",,"https://ClinicalTrials.gov/show/NCT04333420"
280,"NCT04438239","Rehabilitation Needs After COVID-19 Hospital Treatment","REACT","Not yet recruiting","No Results Available","Covid-19","Other: none, this study is observational","number of participants with considerable dyspnea: Medical Research Council (MRC, 0-4, lower score better outcome)|number of participants with fatigue|number of participants with anxiety|number of participants with depression|level of independence in B-ADL|level of participation in social|description of qualitative data about patients' experience","Azienda Unità Sanitaria Locale Reggio Emilia","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Other|Time Perspective: Prospective","428/2020/OSS/AUSLRE","June 30, 2020","December 31, 2020","December 31, 2020","June 18, 2020",,"June 18, 2020",,,"https://ClinicalTrials.gov/show/NCT04438239"
281,"NCT04342689","The Role of Resistant Starch in COVID-19 Infection",,"Recruiting","No Results Available","COVID-19","Drug: Dietary Supplement containing resistant starch|Dietary Supplement: Placebo Starch","Rates of hospitalization for a COVID-19 related complication|Time to clinical recovery (TTCR)|Symptom Severity Score","Yale University|University of Michigan|University of Minnesota","All","19 Years and older   (Adult, Older Adult)","Phase 3","1500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2000027887","June 3, 2020","June 1, 2021","June 1, 2021","April 13, 2020",,"June 17, 2020","Yale University, New Haven, Connecticut, United States|University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT04342689"
282,"NCT04382794","Sitagliptin Treatment in Diabetic COVID-19 Positive Patients","SIDIACO-RETRO'","Completed","No Results Available","Covid19","Drug: Retrospective case-control analysis","Clinical parameter of acute lung disease|Death|Biochemical parameter of acute lung disease","University of Milan|Papa Giovanni XXIII Hospital|IRCCS Policlinico S. Matteo|Humanitas Hospital, Italy|Ospedale dell'Angelo, Venezia-Mestre|University of Pavia","All","18 Years and older   (Adult, Older Adult)",,"319","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","5/2020","May 14, 2020","June 15, 2020","June 15, 2020","May 11, 2020",,"June 17, 2020","ASST FBF-Sacco P.O. Sacco, Milan, MI, Italy|Papa Giovanni XXIII Hospital, Bergamo, Italy|Ospedale dell'Angelo, Venezia-Mestre, Mestre, Italy|Humanitas Hospital, Milan, Italy|University of Pavia, Pavia, Italy|IRCCS Policlinico S. Matteo, Pavia, Italy",,"https://ClinicalTrials.gov/show/NCT04382794"
283,"NCT04351516","Test and Treat COVID 65plus+","COVID65plus","Recruiting","No Results Available","SARS-CoV 2|COVID-19","Drug: Hydroxychloroquine|Other: Placebo","● Rate of hospitalization or death at day 7 after study inclusion","University Hospital Tuebingen","All","65 Years and older   (Older Adult)","Phase 2|Phase 3","350","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COVID65plus|2020-001482-37","April 21, 2020","December 31, 2020","May 1, 2021","April 17, 2020",,"May 27, 2020","Uniklinikum Tuebingen, Tuebingen, Germany|Uniklinikum Ulm, Ulm, Germany",,"https://ClinicalTrials.gov/show/NCT04351516"
284,"NCT04343144","Trial Evaluating Efficacy and Safety of Nivolumab (Optivo®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort.","CORIMUNO-NIVO","Not yet recruiting","No Results Available","COVID19- Infection With SARS-CoV-2 Virus","Drug: Nivolumab Injection","Time to clinical improvement|Overall survival|Cumulative incidence of ICU admission|Length of hospital stay|Positive nasal PCR|Incidence of adverse events|Incidence of grade 3-4 adverse events|World Health Organisation (WHO) progression scale","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 2","92","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200389-5","April 15, 2020","July 31, 2020","September 30, 2020","April 13, 2020",,"April 14, 2020","Pneumologie hôpital Tenon, Paris, France",,"https://ClinicalTrials.gov/show/NCT04343144"
285,"NCT04381962","A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2)","ATOMIC2","Recruiting","No Results Available","COVID-19","Drug: Azithromycin Capsule","Proportion progressing to respiratory failure or death (all clinically-diagnosed participants)|Proportion progressing to respiratory failure or death (SARS-CoV-2 PCR positive)|All cause mortality|Proportion progressing to pneumonia.|Proportion progressing to severe pneumonia|Peak severity of illness|Safety and tolerability","University of Oxford|Pfizer","All","19 Years and older   (Adult, Older Adult)","Phase 3","800","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATOMIC2|2020-001740-26|282892|20/HRA/2105","May 29, 2020","September 13, 2020","October 13, 2020","May 11, 2020",,"June 9, 2020","Horton General Hospital, Banbury, Oxfordshire, United Kingdom|John Radcliffe Hospital, Oxford, Oxfordshire, United Kingdom|Ninewells Hospital, Dundee, Scotland, United Kingdom|Birmingham City Hospital, Birmingham, United Kingdom|Sandwell General Hospital, West Bromwich, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04381962"
286,"NCT04343755","Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection",,"Recruiting","No Results Available","COVID-19","Biological: Convalescent Plasma","For patients hospitalized for COVID-19 but not intubated|Primary objective for patients with COVID-19 already intubated|Duration of hospitalization|Duration of mechanical ventilation|Time to symptoms resolution|Overall survival|Rate of virologic clearance by nasopharyngeal swab at day 10|Impact of donor titers level on efficacy|Impact of donor titers level on safety|Recipient Anti-SARS-CoV2 titer assessment on days 0 (pre-infusion),3,10,30, 60","Hackensack Meridian Health","All","18 Years and older   (Adult, Older Adult)","Phase 2","55","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro2020-0375","April 9, 2020","April 2021","April 2021","April 13, 2020",,"April 17, 2020","Hackensack University Medical Center, Hackensack, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04343755"
287,"NCT04369820","C5a Receptor Expression - COVID-19 (C5-COV)","C5-COV","Recruiting","No Results Available","COVID-19","Other: draw blood","Show an overexpression of C5a receptor in patients with ARDS secondary to COVID-19 compared to control patients (patients with COVID-19 without respiratory distress and healthy volunteers).","Assistance Publique Hopitaux De Marseille|Innate Pharma","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2020-14|IDRCB","March 31, 2020","September 2020","November 2020","April 30, 2020",,"May 4, 2020","Assistance Publique Hôpitaux de Marseille, Marseille, France",,"https://ClinicalTrials.gov/show/NCT04369820"
288,"NCT04432298","Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Patients With Acute COVID-19 Disease",,"Recruiting","No Results Available","COVID-19","Drug: Pamrevlumab|Drug: Placebo","Proportion of subjects who never received mechanical ventilation and/or ECMO and alive|Proportion of subjects alive, discharged home, and not on supplemental oxygen|Time to recovery based on a Modified 8-Point Ordinal Scale|Days in ICU/CCU (either on or off mechanical ventilation and/or ECMO)|Days on mechanical ventilation and/or ECMO|Time to death from any cause|Changes in PaO2/FiO2 ratio, both as categorical and continuous variable|Change in (non-invasive) oxygen supplementation requirements","FibroGen","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 2","130","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FGCL-3019-098","June 20, 2020","December 2020","January 2021","June 16, 2020",,"June 24, 2020","Research Center, Greensboro, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04432298"
289,"NCT04324489","DAS181 for Severe COVID-19: Compassionate Use",,"Completed","No Results Available","COVID-19","Drug: DAS181","Improved clinical status|Return to room air|SARS-CoV-2 RNA|Discharge|Death","Renmin Hospital of Wuhan University|Ansun Biopharma, Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","4","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DAS181-SARS-CoV-2","March 6, 2020","April 16, 2020","April 30, 2020","March 27, 2020",,"May 5, 2020","Renmin Hospital of Wuhan University, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04324489"
290,"NCT04427332","Smell and Taste Disorders in COVID-19 Patients","COVID-19 ORL","Recruiting","No Results Available","covid19","Other: Investigation of smell and taste disorders","Identification of demographic and clinical factors in covid19 patients.|Description of the disturbances of smell and taste|Description of factors that influence smell and taste","University of Milano Bicocca","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-19 ORL","May 15, 2020","June 30, 2020","September 30, 2020","June 11, 2020",,"June 11, 2020","ASST Monza-Ospedale San Gerardo, Monza, Italy",,"https://ClinicalTrials.gov/show/NCT04427332"
291,"NCT04449965","Povidone-Iodine Rinses in the Management of COVID-19",,"Not yet recruiting","No Results Available","Covid19","Drug: Povidone-iodine|Drug: Placebo","Change in SARS-CoV-2 positivity in the saliva|Change in the SAR-CoV-2 viral load in the saliva|Change in Wisconsin Upper Respiratory Symptom Survey (WURSS-44)|Change Sino nasal Outcome Test (SNOT-22)|Change in clinical condition","St. Paul's Hospital, Canada","All","19 Years and older   (Adult, Older Adult)","Early Phase 1","81","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Betadine COVID-19","July 1, 2020","November 1, 2020","December 1, 2020","June 29, 2020",,"June 29, 2020",,,"https://ClinicalTrials.gov/show/NCT04449965"
292,"NCT04392141","Colchicine Plus Phenolic Monoterpenes to Treat COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Standard Treatment|Drug: Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions","Mortality rate|Change in patients clinical manifestation|Length of hospitalization|C-reactive protein|lymphocyte count|serum lactate dehydrogenase|serum Interleukin-6|erythrocyte sedimentation rate","Kermanshah University of Medical Sciences","All","10 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1399.062","April 1, 2020","June 1, 2020","October 1, 2020","May 18, 2020",,"May 18, 2020","Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran, Kermanshah, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04392141"
293,"NCT04418284","Online Learning of Veterinary Anatomy During COVID-19 Pandemic",,"Enrolling by invitation","No Results Available","COVID-19","Other: survey","Measure the students' interest in studying anatomy on-line.","South Valley University","All","17 Years to 35 Years   (Child, Adult)",,"400","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","2-2020","June 5, 2020","July 5, 2020","July 5, 2020","June 5, 2020",,"June 16, 2020","South Valley University, Qinā, Egypt",,"https://ClinicalTrials.gov/show/NCT04418284"
294,"NCT04449718","Vitamin D Supplementation in Patients With COVID-19",,"Recruiting","No Results Available","COVID-19","Dietary Supplement: Vitamin D|Dietary Supplement: Placebo","Length of hospitalization|Mortality|Number of cases admitted to Intensive Care Unit (ICU)|Length of use of mechanic ventilator|Number and severity of symptoms|Inflammatory markers|C-reactive protein|Vitamin D|Creatinine|Calcium|Physical activity","University of Sao Paulo","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","30959620.4.0000.0068","June 1, 2020","November 30, 2020","November 30, 2020","June 29, 2020",,"June 29, 2020","Clinical Hospital of the School of Medicine, University of Sao Paulo, Sao Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04449718"
295,"NCT04408326","Efficacy and Safety of Angiotensin II Use in Coronavirus Disease(COVID)-19 Patients With Acute Respiratory Distress Syndrome","ACES","Recruiting","No Results Available","COVID|Acute Respiratory Distress Syndrome","Drug: Angiotensin II|Drug: Interleukin-1 receptor antagonist","Proportions of patients with mean arterial pressure ≥ 65 mmHg or an increase of mean arterial pressure ≥10 mmHg at 3 hours|Noradrenaline dose|Sequential Organ Failure Assessment (SOFA) score|RRT-free days|RRT discontinuation|Serum creatinine|PaO2/FiO2 ratio|Mortality|Adverse events|Change in serum C-reactive protein|Change in serum ferritin","Guy's and St Thomas' NHS Foundation Trust|Australian and New Zealand Intensive Care Research Centre|Monash University|Royal Surrey County Hospital NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","283005","June 1, 2020","May 1, 2021","May 1, 2021","May 29, 2020",,"June 5, 2020","Guy's & St Thomas' Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04408326"
296,"NCT04323878","Early CPAP in COVID Patients With Respiratory Failure. A Prospective Cohort Study.","EC-COVID-PCS","Not yet recruiting","No Results Available","Early CPAP Ventilation in COVID-19 Patients",,"Death or need of intubation|30-day mortality","Mario Negri Institute for Pharmacological Research","All","18 Years and older   (Adult, Older Adult)",,"3000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EC-COVID-PCS-Fenice","April 6, 2020","October 5, 2020","November 9, 2020","March 27, 2020",,"March 31, 2020",,,"https://ClinicalTrials.gov/show/NCT04323878"
297,"NCT04337190","Impact of Angiotensin II Receptor Blockers Treatment in Patients With COVID 19 (COVID-ARA2)","COVID-ARA2","Recruiting","No Results Available","COVID|Acute Respiratory Distress Syndrome","Biological: blood sampling","ACE2 level change over time|ACE2 activity over time|Mortality at day 28|ARDS severity|Duration of mechanical ventilation|Need for prone positionning|Need for extracorporeal membran oxygenation|Use of paralytic agents|Need for renal replacement therapy|Need for vasoactive drugs (norepinephrine, dobutamine,epinephrine)|Sequential Organ Failure Assessment (SOFA) score|Number of session(s) of prone positionning|Duration of extracorporeal membran oxygenation treatment|Type of vasoactive drugs|Duration of vasoactive treatment","University Hospital, Angers","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-ARA2","April 3, 2020","October 6, 2020","December 6, 2020","April 7, 2020",,"April 10, 2020","University Hospital Angers, Angers, France",,"https://ClinicalTrials.gov/show/NCT04337190"
298,"NCT04347681","Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19",,"Recruiting","No Results Available","Convalescent Plasma for COVID 19","Other: convalescent plasma from recovered COVID 19 donor","ICU length of stay|Safety of convalescent plasma & Serious adverse reactions.|Number of days on mechanical ventilation|30 days of mortality|Days to clinical recovery .","King Fahad Specialist Hospital Dammam|King Fahad Medical City|King Faisal Specialist Hospital And Research Center|King Abdulaziz Medical City|King Fahad University Hospital|John Hopkins Aramco Healthcare|Taibah University|King Saud University|King Khaled University Hospital|King Fahad Military Medical Complex|Qatif Central Hospital","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HAEM0321","April 18, 2020","December 31, 2020","April 11, 2021","April 15, 2020",,"May 19, 2020","John Hopkins Aramco Healthcare, Dhahran, Eastern Provence, Saudi Arabia|Dammam Medical Complex, Dammam, Saudi Arabia|Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia|king Fahad specialist hospital, Dammam, Saudi Arabia|DHahran Military Medical Complex, Dhahran, Saudi Arabia|International Medical Center, Jeddah, Saudi Arabia|Madinah General Hospital, Medina, Saudi Arabia|Ohud Hospital, Medina, Saudi Arabia|Taibah University, Medina, Saudi Arabia|Qatif Central Hospital, Qatif, Saudi Arabia|King Abdulaziz Medical City, Riyadh, Saudi Arabia|King Fahad Medical City, Riyadh, Saudi Arabia|King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia|King Khalid University Hospital, Riyadh, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT04347681"
299,"NCT04448119","Control of COVID-19 Outbreaks in Long Term Care",,"Not yet recruiting","No Results Available","COVID-19|SARS-CoV-2","Drug: Favipiravir|Drug: Favipiravir Placebo","Control of Outbreak|Mortality (Residents)|COVID-19 Infection (Residents)|COVID-19 Infection (Staff)|Hospitalization (Residents)|Medication Discontinuation (Residents)|Medication Discontinuation (Staff)|COVID-19 in new LTCH Units (a)|COVID-19 in new LTCH Units (b)|COVID-19 in new LTCH Units (c)","Appili Therapeutics Inc.|MOUNT SINAI HOSPITAL|Applied Health Research Centre|Sunnybrook Health Sciences Centre|University Health Network, Toronto|University of Toronto","All","65 Years and older   (Older Adult)","Phase 2","760","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CONTROL-COVID-Favipiravir-1","June 2020","March 2021","March 2021","June 25, 2020",,"June 25, 2020",,,"https://ClinicalTrials.gov/show/NCT04448119"
300,"NCT04382586","Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants",,"Recruiting","No Results Available","COVID-19 Pulmonary Complications|COVID-19","Drug: Zanubrutinib|Drug: Supportive Care|Drug: Placebo","Respiratory failure-free survival rate at day 28|Median reduction in days spent on supplemental oxygen|All-cause mortality|Proportion of participants experiencing respiratory failure or death|Mechanical ventilation-free survival|Days on mechanical ventilation|Duration of hospitalization|Time to discharge|PaO2:FiO2 and/or oxygenation index|Change from Baseline to Day 14 in WHO - 8 Point Ordinal Scale","BeiGene","All","18 Years and older   (Adult, Older Adult)","Phase 2","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BGB-3111-219","June 2020","July 2020","September 2020","May 11, 2020",,"June 29, 2020","MedStar Heath Research Institute/ MedStar Washington Hospital Center, Washington, District of Columbia, United States|Loyola University Medical Center, Maywood, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham And Women's Hospital, Boston, Massachusetts, United States|Atlantic Health System Inc. / Morristown Medical Center, Morristown, New Jersey, United States|Rutgers University Hospital, Newark, New Jersey, United States|Overlook Medical Center, Summit, New Jersey, United States|Covenant Health System, Lubbock, Texas, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04382586"
301,"NCT04370262","Multi-site Adaptive Trials for COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: SOC + Intravenous Famotidine|Drug: SOC + Placebo","Mortality|Virologic response to study treatment detected in blood|Virologic clearance in nasal swab and/or lower respiratory secretions|Clinical Severity","Northwell Health","All","18 Years and older   (Adult, Older Adult)","Phase 3","942","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20-0268","April 7, 2020","September 7, 2020","April 7, 2021","April 30, 2020",,"June 16, 2020","Southside Hospital, Bay Shore, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Northern Westchester Hospital, Mount Kisco, New York, United States|Lenox Hill Hospital, New York, New York, United States|Long Island Jewish Medical Center, Queens, New York, United States",,"https://ClinicalTrials.gov/show/NCT04370262"
302,"NCT04341168","Clinical and Immunological Characterisation of COVID-19 in Children, Adolescents and Adults",,"Not yet recruiting","No Results Available","COVID-19|SARS-CoV-2","Other: this study is non- interventional","Clinical course of COVID-19|Analysis of development of antibodies to SARS-CoV-2|Estimation of viral load|Detection of viral coinfections|Measurement of cytokine and chemokine response|Characterisation of virus-host-interaction|Identification of disease patterns in proteome|Analysis of change in lymphocyte subtypes|Analysis of histological changes in severe lung disease|Detection of bacterial coinfections","University Hospital of Cologne|Clinic for Internal Medicine I, University Hospital Cologne, Germany|Institute of Virology, University Hospital Cologne, Germany|Center for Molecular Medicine Cologne (CMMC) Cologne, Germany","All","Child, Adult, Older Adult",,"160","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","KICC19","April 2020","October 2020","October 2020","April 10, 2020",,"April 14, 2020","University Hospital Cologne, Cologne, NRW, Germany",,"https://ClinicalTrials.gov/show/NCT04341168"
303,"NCT04359862","Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection","SEVO-COVID19","Recruiting","No Results Available","Acute Respiratory Distress Syndrome|COVID19 Infection","Drug: Sevoflurane|Drug: Propofol","PaO2/FiO2|TNFα|IL-1b|IL-6|IL-8|Mortality","Fundación para la Investigación del Hospital Clínico de Valencia","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 4","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SEVO-COVID19","April 16, 2020","August 16, 2020","September 16, 2020","April 24, 2020",,"April 29, 2020","Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT04359862"
304,"NCT04377646","A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers","COVID-Milit","Not yet recruiting","No Results Available","Sars-CoV2|COVID19","Drug: Hydroxychloroquine|Drug: Hydroxychloroquine (placebo)|Drug: Zinc|Drug: Zinc (Placebo)","SARS CoV2 infection|COVID-19 symptoms description|Adverse Events","Military Hospital of Tunis|UR17DN02 : Autoimmune Diseases Research Unit|Dacima Consulting","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","660","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","UR17DN02-001|TN2020-NAT-INS-38","May 4, 2020","May 24, 2020","July 31, 2020","May 6, 2020",,"May 6, 2020","Military Hospital of Tunis, Tunis, Tunisia",,"https://ClinicalTrials.gov/show/NCT04377646"
305,"NCT04385810","Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19","DOCOV","Recruiting","No Results Available","Covid19|Sars-CoV2","Procedure: Ophthalmologic exam","Describe ophthalmologic damage to the cornea with direct exam at day 0|Describe ophthalmologic damage to the cornea with direct exam at day 7|Describe ophthalmologic damage to the cornea with direct exam at day 14|Describe ophthalmologic damage to the cornea with direct exam at discharge of hospital|Describe ophthalmologic damage to the cornea with slit lamp exam at day 0|Describe ophthalmologic damage to the cornea with slit lamp exam at day 7|Describe ophthalmologic damage to the cornea with slit lamp exam at day 14|Describe ophthalmologic damage to the cornea with slit lamp exam at discharge of hospital|Describe tear film anomalies at day 0|Describe tear film anomalies at day 7|Describe tear film anomalies at day 14|Describe tear film anomalies at discharge of hospital|Describe ophthalmologic damage to the retina at day 0|Describe ophthalmologic damage to the retina at day 7|Describe ophthalmologic damage to the retina at day 14|Describe ophthalmologic damage to the retina at discharge of hospital|Describe ophthalmologic damage to the optic nerve at day 0|Describe ophthalmologic damage to the optic nerve at day 7|Describe ophthalmologic damage to the optic nerve at day 14|Describe ophthalmologic damage to the optic nerve at discharge of hospital","Fondation Ophtalmologique Adolphe de Rothschild","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","JDS_2020_13","April 27, 2020","October 2020","October 2020","May 13, 2020",,"May 13, 2020","Fondation Adolphe de Rothschild, Paris, France",,"https://ClinicalTrials.gov/show/NCT04385810"
306,"NCT04335123","Study of Open Label Losartan in COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Losartan","Number of participants with treatment-related adverse events as assessed by protocol definition of AE|Number of days on supplemental oxygen in respiratory failure due to COVID-19|Incidence of mechanical ventilation use|Days on mechanical ventilation|Incidence of non-invasive positive pressure ventilation or heated high flow nasal cannula use|Days on non-invasive positive pressure ventilation or high flow nasal cannula|Incidence of transfer to ICU from non-ICU hospital bed|ICU length of stay (days)|30-day mortality rate|Hospital length of stay (days)|Cumulative incidence of severe adverse events|Cumulative incidence of adverse events|Change from baseline in oxygenation|Incidence of medications with possible antiviral activity (hydroxychloroquine, lopinavir/ritonavir, ribavirin or remdesivir) or adjunctive therapy use (e.g., tocilizumab)|Incidence (and length in days) of extracorporeal membrane oxygenation use|Incidence (and length in days) of renal replacement therapy use|Intolerance of high dose (50mg) losartan after tolerating 25mg","University of Kansas Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00145514","March 25, 2020","September 2020","October 2020","April 6, 2020",,"April 24, 2020","University of Kansas Medical Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT04335123"
307,"NCT04351659","Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19",,"Recruiting","No Results Available","COVID-19","Other: Blood donation from convalescent donor","Success rate in production of SARS-CoV-2 specific T cells from convalescent donor","KK Women's and Children's Hospital|Singapore General Hospital|National University Hospital, Singapore","All","21 Years to 65 Years   (Adult, Older Adult)",,"8","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-T 1.0","April 2020","August 2020","August 2020","April 17, 2020",,"April 17, 2020","National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT04351659"
308,"NCT04403581","Egyptian Doctors Stresses, Knowledge and Attitude During COVID-19 Pandemic",,"Not yet recruiting","No Results Available","Covid-19","Other: Questionnaire","Cross-sectional descriptive study: Egyptian Doctors Stresses, Knowledge and Attitude during COVID-19 Pandemic","Ain Shams University","All","23 Years to 55 Years   (Adult)",,"384","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","Egyptian doctors in COVID-19","May 2020","June 2020","June 2020","May 27, 2020",,"May 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04403581"
309,"NCT04344912","Impact of COVID19 Outbreak in Cardiac Acute Care","CCU-COVID19","Recruiting","No Results Available","Acute Coronary Syndrome|Heart Failure|COVID","Other: Data collection","Incidence of recurrent Major Cardiovascular Events (MACE) and urgent rehospitalization","Assistance Publique - Hôpitaux de Paris|Action, France","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Other","APHP200524|0522070420","March 20, 2020","June 2020","August 2020","April 14, 2020",,"April 28, 2020","Unité de Soins Intensifs de Cardiologie, Pitié Salpêtrière Hospital, AP-HP, Paris, France",,"https://ClinicalTrials.gov/show/NCT04344912"
310,"NCT04420182","COVID-19 Virtual Care at Home",,"Not yet recruiting","No Results Available","Covid-19","Other: Virtual Care at Home","28 Day Patient Satisfaction Questionnaire|Emergency Department Visits|28 Day EQ-5D-5L Scores","Lawson Health Research Institute|Cardiac Arrhythmia Network of Canada","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2000","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTO 3210","June 8, 2020","June 30, 2021","December 31, 2021","June 9, 2020",,"June 9, 2020","London Health Sciences Centre, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04420182"
311,"NCT04323228","Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19","ONSCOVID19","Not yet recruiting","No Results Available","COVID-19","Dietary Supplement: oral nutrition supplement (ONS) enriched in eicosapentaenoic acid, gamma-linolenic acid and antioxidants|Dietary Supplement: isocaloric/isonutrigenous ONS","Change from baseline score of Nutrition risk screening-2002 (NRS-2002) at end of the trial|Change from baseline Serum ferritin level at end of the trial|Change from baseline serum Interleukin-6 concentration at end of the trial|Change from baseline serum C-reactive protein concentration at end of the trial|Change from baseline serum Tumor necrosis factor-α concentration at end of the trial|Change from baseline serum monocyte chemoattractant protein 1 (MCP-1) at end of the trial|Change from baseline Weight at end of the trial|Height|Change from baseline BMI at end of the trial|Change from baseline mid arm circumference at end of the trial|Change from baseline triceps skin-fold thickness at end of the trial|Change from baseline MAMA at end of the trial|Change from baseline percentage of peripheral O2 saturation at end of the trial|Change from baseline degree of body temperature at end of the trial|Change from baseline count the total leukocyte at end of the trial|Change from baseline differential lymphocytic count at end of the trial|Change from baseline Neutrophil count at end of the trial|Change from baseline neutrophil to lymphocyte ratio at end of the trial","King Saud University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","ONS_COVID-19","July 1, 2020","October 1, 2020","October 30, 2020","March 26, 2020",,"June 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04323228"
312,"NCT04420468","Descriptive and Retrospective Analysis of Acute Myocarditis Associated With Pandemic COVID-19 in Children","HEART-COVID","Not yet recruiting","No Results Available","COVID-19",,"Acute myocarditis|Multi-systemic inflammatory syndrome|Kawasaki disease|Results of SARS-CoV-2","Assistance Publique - Hôpitaux de Paris","All","up to 17 Years   (Child)",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","APHP200632","June 2020","December 2020","December 2020","June 9, 2020",,"June 9, 2020","Hôpital Bicêtre, Le Kremlin-Bicêtre, France|Hôpital Armand Trousseau, Paris, France|Hôpital Necker-Enfants Malades, Paris, France|Hôpital Robert Debré, Paris, France",,"https://ClinicalTrials.gov/show/NCT04420468"
313,"NCT04421625","Patients and Health Staff of Cancer Centres During the Covid-19 Pandemic","PAPESCO-19","Not yet recruiting","No Results Available","COVID-19","Diagnostic Test: Diagnostic test for SARS-Cov2 for patients and health staff","Establishment of a clinical basis for to describe the number and severity of Covid-19 infections in Cancer centres staff and patients.|Establishment of a biological basis for to describe the number and severity of Covid-19 infections in Cancer centres staff and patients.|Dosage of IgM and IgG anti SARS-CoV2|Evaluate the diagnostic performance of the minute test for IgM|Evaluate the quantification of IgG in long term (M12) in the Cancer Centres populations|Evaluate the frequency of reinfections among the persons who have developed IgG|Evaluate the threshold of protective IgG among the subjects who have developed IgG|Evaluate the influence of polymorphisms of receptor of IgG Fc-gamma low-affinity (FcδIIA, FcδIIIa) on the humoral immune response|Evaluate the severity of Covid-19 infection (invisible, visible, prolonged, severe and fatal) by age group|Evaluate the frequency of reinfection by Covid-19 (recurrence of evocative clinical symptoms and positive viral PCR or positive IgM serology) during follow-up|Evaluate the risk factors (clinical and therapeutic) to develop severe forms of Covid-19 infection in patients|Evaluate the changes in health care practice|Evaluate the resources associated with organizational changes|Evaluate the allocated resources|Evaluate the incidence of Covid-19 infections|Evaluate the distribution of risk factors for contamination in patients and in the general population|Evaluate the anxiety state over time|Evaluate the depression over time|Evaluate the post-traumatic developments|Evaluate the change in health care change frequency|Evaluate the number of patients concerned by health care changes|Evaluate the rate of morbidity|Evaluate the rate of mortality","Institut Cancerologie de l'Ouest","All","18 Years and older   (Adult, Older Adult)","Not Applicable","12000","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","ICO-2020-16","June 15, 2020","June 15, 2022","June 15, 2022","June 9, 2020",,"June 9, 2020","Institut de Cancerologie de l'Ouest, Angers, France",,"https://ClinicalTrials.gov/show/NCT04421625"
314,"NCT04386759","COVID-19 Infection in Healthcare Workers","HOP-COVID","Not yet recruiting","No Results Available","COVID-19","Other: Cohort","SARS-COV-2 infection|Individual factors|Hospital ward level","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)",,"6000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","APHP200483","May 2020","October 2020","October 2020","May 13, 2020",,"May 13, 2020","Assistance Publique Hôpitaux de Paris - CHU Henri Mondor, Créteil, France",,"https://ClinicalTrials.gov/show/NCT04386759"
315,"NCT04341870","Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO","CORIMUNO-VIRO","Suspended","No Results Available","COVID19|SARS-CoV-2 Infection","Drug: Sarilumab|Drug: Azithromycin|Drug: Hydroxychloroquine","Need for ventilation (including invasive and non invasive ventilation), intensive care or death|Early improvement: OMS progression scale <= 5|OMS progression scale|Survival|ICU-free days alive|Ventilation-free days alive|Hospital-free days alive|Oxygen therapy-free days alive|Time to negative viral excretion|Immunophenotyping and multiplex cytokines","Assistance Publique - Hôpitaux de Paris","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","27","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200375-3","April 11, 2020","May 8, 2020","August 2020","April 10, 2020",,"May 6, 2020","AP-HP Hôpital Avicenne, Bobigny, France|AP-HP Hôpital Ambroise Paré, Boulogne-Billancourt, France|AP-HP Hôpital Beaujon, Clichy, France|AP-HP Hôpital Pitié Salpétrière, Paris, France|AP-HP Hôpital Saint Antoine, Paris, France",,"https://ClinicalTrials.gov/show/NCT04341870"
316,"NCT04376788","Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19","COVID-19","Not yet recruiting","No Results Available","COVID-19","Biological: exchange blood transfusion from normal donor|Biological: plasma from convalescent patients with COVID-19|Drug: Methylene Blue 5 MG/ML","improvement of condition|change in organs function with PFS and OS","Ain Shams University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FMASU P22/2020","May 5, 2020","June 1, 2020","June 1, 2020","May 6, 2020",,"May 6, 2020","Ain Shams University, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04376788"
317,"NCT04366882","Minimal Invasive Autopsies to Investigate Changes in Deceased COVID-19 Patients","MIA-COVID-19","Recruiting","No Results Available","COVID-19","Procedure: CT-scan with minimal invasive autopsy","Determination of cause of death and contributing factors based on clinical, radiological, microbiological and histopathological data of the deceased patient|Detailed description of the postmortem radiological changes induced by COVID-19|Detailed description of the postmortem histopathological changes induced by COVID-19|Postmortem quantity of viral RNA|Postmortem disease mechanisms at cellular level","Jessa Hospital|Hasselt University|University Hospital, Antwerp","All","Child, Adult, Older Adult","Not Applicable","45","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","JessaH_COVID-19_MIA","April 14, 2020","December 2020","December 2020","April 29, 2020",,"April 29, 2020","Jessa Hospital, Hasselt, Belgium",,"https://ClinicalTrials.gov/show/NCT04366882"
318,"NCT04360356","Ivermectin and Nitazoxanide Combination Therapy for COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Combination Product: Ivermectin plus Nitazoxanide|Other: Standard Care","Number of Patients with COVID-19-negative PCR|Number of patients with improved respiratory rate|Number of patients with improved PaO2|Number of patients with normalized Serum IL6|Number of patients with normalized Serum TNFα|Number of patients with normalized Serum iron|Number of patients with normalized Serum ferritin|Number of patients with normalized International normalized ratio ""INR"" for prothrombin time|Number of patients with normalized complete blood count ""CBC""|The Mortality rate among treated patients","Tanta University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IVR/NTZ","May 2020","October 2020","December 2020","April 24, 2020",,"April 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04360356"
319,"NCT04370223","Ozone Auto-hemotherapy for COVID-19 Pneumonia","COVID-OZONE","Not yet recruiting","No Results Available","COVID-19 Pneumonia","Biological: Ozone auto-hemotherapy","Rate of patients achieving improvement in clinical condition at day 14 after recruitment|Mortality at day 28|Rate of patients achieving improvement in clinical condition at day 28 after recruitment|Rate of patients achieving improvement in clinical condition at day 7 after recruitment|Time to clinical improvement or hospital discharge|Number of ventilator-free days at 28 days|Hospital length of stay|Time to a 2-fold decrease in ferritin|Time to a 2-fold decrease in C-protein reactive|Time to a 2-fold decrease in Dimer-D|Time to a 2-fold decrease in Lactate Dehydrogenase|Time to a 2-fold decrease in Neutrophils to Lymphocytes ratio","Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta|Clinica Nuestra Senora del Rosario","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 3","208","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID-19 Networking group","May 25, 2020","October 25, 2020","December 25, 2020","April 30, 2020",,"June 9, 2020","Hospital Universitari Dr Josep Trueta, Girona, Spain|Clinica Nuestra Señora del Rosario, Ibiza, Spain|Hospital Quirón Rey Juan Carlos I, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario Príncipe de Asturias de Alcalá de Henares, Madrid, Spain|Fundació Althaia de Manresa, Manresa, Spain|Hospital Vithas Valencia Consuelo, Valencia, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, Spain|Clinica Claro, Vigo, Spain",,"https://ClinicalTrials.gov/show/NCT04370223"
320,"NCT04366180","Evaluation of the Probiotic Lactobacillus Coryniformis K8 on COVID-19 Prevention in Healthcare Workers",,"Recruiting","No Results Available","Covid-19","Dietary Supplement: Probiotic|Dietary Supplement: Control","Incidence of SARS CoV-2 infection in healthcare workers|Incidence of hospital admissions caused by SARS-CoV-2 infection|Incidence of ICU admissions caused by SARS-CoV-2 infection|Incidence of pneumonia caused by SARS-CoV-2 infection|Incidence of oxygen support requirement caused by SARS-CoV-2 infection|Incidence of gastrointestinal symptoms caused by SARS-CoV-2 infection|Days with body's temperature > 37.5 ºC|Days with cough|Days with fatigue|Medical treatment","Biosearch S.A.","All","20 Years and older   (Adult, Older Adult)","Not Applicable","314","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","P054","April 24, 2020","June 2020","October 2020","April 28, 2020",,"April 30, 2020","Raquel Rodriguez Blanque, Granada, Spain",,"https://ClinicalTrials.gov/show/NCT04366180"
321,"NCT04382235","Non-invasive Ventilatory Support of Patients Affected by COVID-19","WARd-COVID","Active, not recruiting","No Results Available","Covid-19","Device: Non-invasive ventilatory support","The number of patients treated with non-invasive ventilation devices.|Incidence of patients requiring mechanical ventilation|Incidence of organ failure|Duration of hospitalization|Clinical outcome at hospital discharge","University of Milano Bicocca","All","18 Years and older   (Adult, Older Adult)",,"900","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","WARd-COVID","March 26, 2020","May 31, 2020","June 30, 2020","May 11, 2020",,"May 11, 2020","Policlinico San Marco - Ospedale Zingonia, Zingonia, BG, Italy|ASST Papa Giovanni XXIII - Bergamo, Bergamo, Italy|Azienda Ospedaliera - Universitaria di Bologna, Policlinico S. Orsola Malpighi, Bologna, Italy|ASST Spedali Civili - Brescia, Brescia, Italy|ASST Valle Olona - Ospedale di Busto Arsizio, Busto Arsizio, Italy|ASST Lariana - Ospedale Sant'Anna, Como, Italy|ASST Crema - Ospedale Maggiore di Crema, Crema, Italy|ASST Cremona - Ospedale di Cremona, Cremona, Italy|Istituto Clinico Humanitas Gavazzeni, Cremona, Italy|ASST Garda - Presidio di Desenzano del Garda, Desenzano Del Garda, Italy|ASST Monza - Desio, Desio, Italy|ASST Spedali Civili -Ospedale di Gardone Val Trompia, Gardone Val Trompia, Italy|ASST Lecco - Ospedale ""A. Manzoni"", Lecco, Italy|ASST Ovest milanese - Ospedale di Legnano, Legnano, Italy|ASST Lodi - Ospedale Maggiore di Lodi, Lodi, Italy|ASST OVEST Milanese - Ospedale di Magenta, Magenta, Italy|ASST Garda - Ospedale di Manerbio, Manerbio, Italy|ASST Mantova - Ospedale Carlo Poma, Mantova, Italy|ASST Melegnano e della Martesana - Presidio di Melzo-Gorgonzola, Melzo, Italy|ASST Fatebenefratelli - Presidi Fatebenefratelli & M. Melloni, Milano, Italy|ASST Fatebenefratelli - Sacco, Milano, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy|Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy|Ospedale San Giuseppe, Milano, Italy|ASST Spedali Civili -Presidio Ospedaliero di Montichiari, Montichiari, Italy|ASST Monza - Ospedale San Gerardo, Monza, Italy|Fondazione IRCCS Policlinico San Matteo - Pavia, Pavia, Italy|Policlinico San Pietro, Ponte San Pietro, Italy|Istituto Clinico Humanitas Rozzano, Rozzano, Italy|ASST Valle Olona - Ospedale di Saronno, Saronno, Italy|ASST Bergamo OVEST - Ospedale ""Treviglio-Caravaggio"" di Treviglio, Treviglio, Italy|Ospedale di Circolo e Fondazione Macchi - Varese, Varese, Italy|ASST Vimercate - Ospedale di Vimercate, Vimercate, Italy|ASST Melegnano e della Martesana - Ospedale di Vizzolo Predabissi, Vizzolo Predabissi, Italy",,"https://ClinicalTrials.gov/show/NCT04382235"
322,"NCT04347850","A Cohort of Patients With Possible or Confirmed SARS-CoV-2 (COVID-19)","COVIDothèque","Recruiting","No Results Available","SARS-CoV-2|COVID-19","Other: blood sample","Number of confirmed COVID-19|Number of severe COVID-19","University Hospital, Montpellier","All","Child, Adult, Older Adult",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RECHMPL20_0185","February 1, 2020","December 1, 2022","December 30, 2022","April 15, 2020",,"April 16, 2020","Uh Montpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04347850"
323,"NCT04350593","Dapagliflozin in Respiratory Failure in Patients With COVID-19","DARE-19","Recruiting","No Results Available","COVID-19","Drug: Dapagliflozin 10 MG|Drug: Placebo","Time to first occurrence of either death from any cause or new/worsened organ dysfunction through 30 days of follow up, defined as at least one of the following:|Hierarchical composite outcome measures including time to death from any cause, time to new/worsened organ dysfunction, clinical status at day 30 and time to hospital discharge|Time to hospital discharge|Total number of days alive, out of hospital, and/or free from mechanical ventilation|Total number of days alive, not in the ICU, and free from mechanical ventilation (as defined in the primary outcome measure)|Time to death from any cause|Time to new/worsened organ dysfunction|Time to acute kidney injury (defined as doubling of s-Creatinine compared to baseline)","Saint Luke's Health System|AstraZeneca|George Clinical Pty Ltd","All","18 Years and older   (Adult, Older Adult)","Phase 3","900","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1690C00081|ESR-20-20653","April 22, 2020","October 2020","December 2020","April 17, 2020",,"June 18, 2020","NorthShore University HealthSystem, Evanston, Illinois, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Saint Luke's Mid America Heart Institute, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Jacobi Medical Center, Bronx, New York, United States|St. Francis Hospital, Roslyn, New York, United States|Sentara Healthcare, Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04350593"
324,"NCT04425629","Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult Patients With COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: REGN10933+REGN10987 combination therapy|Drug: Placebo","Proportion of patients with treatment-emergent serious adverse events (SAEs)|Proportion of patients with infusion-related reactions|Proportion of patients with hypersensitivity reactions|Time-weighted average change from baseline in viral shedding as measured by quantitative reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples|Time-weighted average change from baseline in viral shedding as measured by RT-qPCR in saliva samples|Proportion of patients with at least one COVID-19 related medically attended visit|Time-weighted average change from baseline in viral shedding measured by RT-qPCR in nasal swab samples|Time to negative RT-qPCR in all tested samples with no subsequent positive RT-qPCR in any tested samples|Change from baseline in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral shedding as measured by RT-qPCR in NP swabs|Change from baseline in SARS-CoV-2 viral shedding as measured by RT-qPCR in saliva samples|Change from baseline in SARS-CoV-2 viral shedding as measured by RT-qPCR in nasal swabs|Proportion of patients with at least two COVID-19 related medically attended visits|Total number of COVID-19 related medically-attended visits|Proportion of patients admitted to a hospital due to COVID-19|Proportion of patients admitted to an intensive care unit (ICU) due to COVID-19|Proportion of patients at least 1 outpatient or telemedicine visit due to COVID-19|Proportion of patients requiring mechanical ventilation due to COVID-19|Serum concentration of REGN10933 over time|Serum concentration of REGN10987 over time|Assessment of pharmacokinetic (PK) parameter: maximum serum concentration observed (Cmax) of REGN10933|Assessment of PK parameter: maximum serum concentration observed (Cmax) of REGN10987|Assessment of PK parameter: Cmax-to-dose ratio (Cmax/dose) of REGN10933|Assessment of PK parameter: Cmax-to-dose ratio (Cmax/dose) of REGN10987|Assessment of PK parameter: Time to Cmax (tmax) for REGN10933|Assessment of PK parameter: Time to Cmax (tmax) for REGN10987|Assessment of PK parameter: Area Under the Curve (AUC) computed from time zero to the time of the last positive concentration (AUClast) for REGN10933|Assessment of PK parameter: AUC computed from time zero to the time of the last positive concentration (AUClast) for REGN10987|Incidence of anti-drug antibodies (ADA) to REGN10933|Incidence of anti-drug antibodies (ADA) to REGN10987|Number of days of hospitalization due to COVID-19|Number of deaths due to any cause (All-Cause Mortality)","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","1054","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R10933-10987-COV-2067","June 16, 2020","November 21, 2020","November 21, 2020","June 11, 2020",,"June 25, 2020","Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, Tyler, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04425629"
325,"NCT04287686","Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19",,"Withdrawn","No Results Available","COVID-19","Drug: Recombinant human angiotensin-converting enzyme 2 (rhACE2)","Time course of body temperature (fever)|Viral load over time|P/F ratio over time|Sequential organ failure assessment score(SOFA score) over time|Pulmonary Severity Index (PSI)|Image examination of chest over time|Proportion of subjects who progressed to critical illness or death|Time from first dose to conversion to normal or mild pneumonia|T-lymphocyte counts over time|C-reactive protein levels over time|Angiotensin II (Ang II) changes over time|Angiotensin 1-7 (Ang 1-7) changes over time|Angiotensin 1-5 (Ang 1-5) changes over time|Renin changes over time|Aldosterone changes over time|Angiotensin-converting enzyme (ACE) changes over time|Angiotensin-converting enzyme 2 (ACE2) changes over time|Interleukin 6 (IL-6) changes over time|Interleukin 8 (IL-8) changes over time|Soluble tumor necrosis factor receptor type II (sTNFrII) changes over time|Plasminogen activator inhibitor type-1 (PAI-1) changes over time|Von willebrand factor (vWF) changes over time|Tumor necrosis factor-α (TNF-α) changes over time|Soluble receptor for advanced glycation end products (sRAGE) changes over time|Surfactant protein-D (SP-D) changes over time|Angiopoietin-2 changes over time|Frequency of adverse events and severe adverse events","The First Affiliated Hospital of Guangzhou Medical University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GIRH-APN01","February 2020","April 2020","April 2020","February 27, 2020",,"March 17, 2020","GCP Office of The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04287686"
326,"NCT04361318","Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Combination Product: Hydroxychloroquine plus Nitazoxanide|Other: Standard care","Number of patients with COVID-19-negative PCR|Number of patients with improved respiratory rate|Number of patients with improved PaO2|Number of patients with normalized Serum IL6|Number of patients with normalized Serum TNFα|Number of patients with normalized Serum iron|Number of patients with normalized Serum ferritin|Number of patients with normalized International normalized ratio ""INR"" for prothrombin time|Number of patients with normalized complete blood count ""CBC""|The Mortality rate among treated patients","Tanta University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","HCQ/NTZ","May 2020","October 2020","December 2020","April 24, 2020",,"April 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04361318"
327,"NCT04344171","CovidDB: The Covid-19 Inpatient Database",,"Recruiting","No Results Available","COVID-19",,"Outcome comparison between different antiviral therapies|Outcome comparisons between ventilation types|Identification of risk factors|Number of days in hospital vs. clinical classification","ClarData","All","Child, Adult, Older Adult",,"5000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CovidDB","March 30, 2020","December 31, 2022","June 30, 2023","April 14, 2020",,"April 21, 2020","RoMed - Klinikum Bad Aibling, Bad Aibling, Germany|DONAUISAR Klinikum Deggendorf, Deggendorf, Germany|DONAUISAR Klinikum Dingolfing, Dingolfing, Germany|RoMed - Klinikum Prien am Chiemsee, Prien, Germany|RoMed - Klinikum Rosenheim, Rosenheim, Germany|Universitätsklinikum Ulm, Ulm, Germany|RoMed - Klinikum Wasserburg Am Inn, Wasserburg Am Inn, Germany|Klinikum Altmühlfranken, Weißenburg, Germany|Timiş County Emergency Clinical Hospital, Timisoara, Romania",,"https://ClinicalTrials.gov/show/NCT04344171"
328,"NCT04338100","Point Of Care UltraSonography for Risk-stratification of COVID-19 Patients","POCUSCO","Not yet recruiting","No Results Available","COVID|Coronavirus Infection","Procedure: Follow-up at 14 days","Risk of unfavourable outcome at D14|Risk of unfavourable outcome over time|Risk-stratification threshold values|Adding value of POCUS score to previous risk-stratification clinical rules|POCUS score and patient clinical status at D14|POCUS and CT scan correlation|POCUS versus CT scan risk-stratification performances|POCUS score evolution performances","University Hospital, Angers","All","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2020-A00782-37","April 6, 2020","December 29, 2020","January 29, 2021","April 8, 2020",,"April 8, 2020",,,"https://ClinicalTrials.gov/show/NCT04338100"
329,"NCT04354857","Qualitative and Quantitative Evaluation of Anosmia Over Time in Clinically Symptomatic Patients Tested for COVID-19 Infection","Anosmie-COVID","Recruiting","No Results Available","COVID-19","Other: olfactory and gustatory tests","SARS-CoV-2 infection status|Olfactory and gustatory loss|Ability to detect odor|Ability to detect salty taste|Ability to detect sweet taste|Severity of infection according to hospitalization rate","Centre Hospitalier Universitaire de Nīmes","All","18 Years and older   (Adult, Older Adult)",,"454","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB: 20.04.09","March 27, 2020","July 2020","November 2020","April 21, 2020",,"April 21, 2020","CHU de Nimes, Nîmes, France",,"https://ClinicalTrials.gov/show/NCT04354857"
330,"NCT04363489","The CEDiD Study (COVID-19 Early Diagnosis in Doctors)","CEDiD","Not yet recruiting","No Results Available","Covid19","Device: Wearable Medical Device (Empatica E4)","COVID-19","King's College London|Empatica, Inc.","All","18 Years and older   (Adult, Older Adult)",,"30","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CEDiD Study STH","April 27, 2020","May 27, 2020","May 27, 2020","April 27, 2020",,"April 28, 2020",,,"https://ClinicalTrials.gov/show/NCT04363489"
331,"NCT04336774","CAPTION AI to Minimize Risk of COVID Exposure","CAPTION AI","Recruiting","No Results Available","COVID-19","Device: Caption AI","Percent of patient echos that are not interpretable|Percent of patient echos that provide an automated (AI) LVEF (left ventricular ejection fraction)|Time to acquire images as measured by time stamps|Percent of agreement between AI calculate LVEF and LVEF read by physician","Duke University|Caption Health, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","500","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","pro00105212","May 2020","November 1, 2020","November 9, 2020","April 7, 2020",,"May 8, 2020","Duke Health, Durham, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04336774"
332,"NCT04420299","Clinical Trial on the Efficacy and Safety of Bemiparin in Patients Hospitalized Because of COVID-19",,"Recruiting","No Results Available","Covid-19","Drug: Bemiparin","Proportion of patients that worsen|Mortality from any cause at day 28|Proportion of subjects that requires admission to the ICU|Proportion of subjects requiring non-invasive mechanical ventilation|Proportion of subjects requiring invasive mechanical ventilation.|Proportion of subjects with some organ failure|Proportion of patients who have modified their oxygen therapy requirements between treatment assessment visit and baseline|Proportion of subjects with pathological angioTAC|Proportion of subjects with improvement in chest radiography|Proportion and median hospital discharge between patients in both groups.|Titration score|Ferritin score|D-dimer modification score|Adverse events (total and serious).|Related adverse events (total and serious).|Clinically relevant major and non major hemorrhages.","Fundación de investigación HM|Syntax for Science, S.L","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","BEMICOVID-19|2020-001548-24","June 4, 2020","March 31, 2021","March 31, 2021","June 9, 2020",,"June 11, 2020","Hospital Universitario HM Montepríncipe, Boadilla Del Monte, Madrid, Spain|Hospital Universitario HM Puerta del Sur, Móstoles, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04420299"
333,"NCT04392128","Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE)","HYACINTHE","Not yet recruiting","No Results Available","COVID19|Hematologic Malignancy","Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil]|Drug: Azithromycin 250 MG Oral Capsule|Drug: Placebo oral tablet|Drug: Placebo oral capsule","Evaluation of the efficacy of hydroxychloroquine and azithromyncine on the viral load drop at day 5.|Clinical evolution|Proportion of patients progressing to a severe form|Mortality|Evaluation of viral load drop|Tolerance of study treatment|Evaluation of the seroconversion|NK immunological study|Hospitalisation duration|Impact of the study treatment on the treatment of the hematological disease|Monitoring of the QT space|Dosage of residual concentration of azithromycine and hydroxychloroquine.|T immunological study","Institut de Cancerologie Strasbourg Europe","All","18 Years and older   (Adult, Older Adult)","Phase 2","114","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020-005|2020-002002-45","May 12, 2020","December 31, 2020","January 31, 2021","May 18, 2020",,"May 20, 2020","Institut de Cancérologie Strasbourg Europe, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT04392128"
334,"NCT04356833","Nebulised Rt-PA for ARDS Due to COVID-19","PACA","Recruiting","No Results Available","COVID","Drug: nebulised recombinant tissue-Plasminogen Activator (rt-PA)","treatment efficacy - Percentage change in PaO2/FiO2 ratio|Safety as measured by bleeds|Safety as measured by other (non-bleed related) adverse events|Safety as measured by fibrinogen levels|Absolute change in PaO2/FiO2 ratio|Changes in respiratory compliance|Clinical status as determined by a 7 point ordinal scale|Sequential Organ Failure Assessment (SOFA) score|Follow up period - oxygen free days|Follow up period - ventilator free days|Follow up period - intensive care stay|New oxygen via ventilation use - incidence|New oxygen via ventilation use - duration|Incidence of new mechanical ventilation use|Duration of new mechanical ventilation use|In hospital mortality","University College, London","All","16 Years to 70 Years   (Child, Adult, Older Adult)","Phase 2","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","132151","April 22, 2020","January 14, 2021","January 14, 2021","April 22, 2020",,"April 30, 2020","The Royal Free Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04356833"
335,"NCT04412278","Impact of COVID-19 Pandemic on Perceived Exercise Benefits and Barriers",,"Completed","No Results Available","COVID|Isolation, Social","Other: Online Survey","Exercise Benefits and Barriers Scale|Sociodemographic information|International Physical Activity Questionairre","Okan University","All","15 Years to 65 Years   (Child, Adult, Older Adult)",,"392","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","500600127","June 1, 2020","June 8, 2020","June 8, 2020","June 2, 2020",,"June 11, 2020","Istanbul Okan University, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04412278"
336,"NCT04400448","Acceptance of Telemedicine During the COVID-19 Pandemic",,"Not yet recruiting","No Results Available","Covid-19",,"Acceptance of telemedicine|Patient satisfaction","Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","TELECOVID","June 1, 2020","August 31, 2020","October 31, 2020","May 22, 2020",,"May 28, 2020",,,"https://ClinicalTrials.gov/show/NCT04400448"
337,"NCT04364022","Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland","COPEP","Recruiting","No Results Available","Prevention of COVID-19","Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil]|Drug: Lopinavir/ritonavir","21-day incidence of COVID-19 in individuals exposed to SARS-CoV- 2 who are asymptomatic at baseline (intent-to-treat (ITT) analysis).|21-day incidence of COVID-19 in individuals exposed to SARS-CoV- 2 who are asymptomatic, PCR-confirmed SARS-CoV-2 negative and have negative SARS-CoV-2 serology at baseline (modified ITT)|21-day incidence of SARS-CoV-2 infection in individuals exposed to SARS-CoV-2 who are asymptomatic, PCR-confirmed SARS-CoV-2 negative and have negative SARS-CoV-2 serology at baseline (modified ITT)|Severity of clinical COVID-19 on a 7-point ordinal scale","Calmy Alexandra|University Hospital, Geneva","All","18 Years and older   (Adult, Older Adult)","Phase 3","420","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CCER 2020-00864","April 2020","October 2020","October 2020","April 27, 2020",,"April 27, 2020","Universitätsspital Basel and SwissTPH, Basel, Switzerland|Hôpitaux Universitaires de Genève, Geneva, Switzerland",,"https://ClinicalTrials.gov/show/NCT04364022"
338,"NCT04352933","PROLIFIC ChemoprophylaxisTrial (COVID-19)",,"Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine - Daily dosing|Drug: Hydroxychloroquine - Weekly Dosing|Other: Matched Placebo Hydroxychloroquine","Time to positive COVID-19 disease|Number of COVID-19 test positive cases|Number of COVID-19 serological test positive cases|Severity of COVID-19 disease between each arm|Number of common COVID-19 complications between each arm","Cambridge University Hospitals NHS Foundation Trust","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PROLIFIC2020 (A095583)","May 11, 2020","October 31, 2020","April 2021","April 20, 2020",,"May 13, 2020","Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04352933"
339,"NCT04375202","Colchicine in COVID-19: a Pilot Study","COLVID-19","Recruiting","No Results Available","COVID-19","Drug: Colchicine 1 MG Oral Tablet","Rate of entering the critical stage|Trend of White blood cell count|Change of the ""Sequential Organ failure Assessment"" (SOFA)|Rate of biochemical criterion (CK, ALT, ferritin) recovery|Rate of disease remission|Toxicity of Colchicine","University Of Perugia","All","18 Years and older   (Adult, Older Adult)","Phase 2","308","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-001475-33","April 18, 2020","June 30, 2020","October 31, 2020","May 5, 2020",,"May 5, 2020","Associazione Italiana Pneumologi Ospedalieri, Milan, Italy|Società Italiana di Reumatologia, Milan, Italy",,"https://ClinicalTrials.gov/show/NCT04375202"
340,"NCT04347889","Preventing COVID-19 in Healthcare Workers With HCQ: A RCT",,"Not yet recruiting","No Results Available","Covid-19","Drug: Hydroxychloroquine|Other: Vitamin C","COVID-19 Seroconversion rate|Admission for Covid-19","Stony Brook University","All","18 Years and older   (Adult, Older Adult)","Phase 2","1212","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","IRB2020-00222","April 20, 2020","December 30, 2020","December 30, 2020","April 15, 2020",,"April 17, 2020",,,"https://ClinicalTrials.gov/show/NCT04347889"
341,"NCT04395599","Risk of Air Contamination During Visceral Surgery in COVID19 Patients","COELIOCOVID","Not yet recruiting","No Results Available","Sars-CoV2|Surgery|COVID","Other: Cartography of air contamination, environment contamination and biological fluid by Sars-Cov2 during visceral surgery in COVID19 patients.","Air contamination|Environment contamination|Surgical approach|Opening of the digestive tract|Biological fluids|Pneumoperitoneum","University Hospital, Lille","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2020_44|2020-A01461-38","May 2020","October 2020","October 2020","May 20, 2020",,"May 20, 2020",,,"https://ClinicalTrials.gov/show/NCT04395599"
342,"NCT04418557","COVID-19 and Obstetric Transmission","COVIDOB","Recruiting","No Results Available","COVID|Pregnancy Complications","Diagnostic Test: RT-PCR and antibody testing","Presence of COVID-19 virus|Presence of antibodies to COVID-19 virus","University Hospitals Cleveland Medical Center|Cuyahoga County Board of Health|The Cleveland Clinic|MetroHealth Medical Center|Case Western Reserve University","Female","18 Years to 50 Years   (Adult)",,"200","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","20200479","April 28, 2020","July 31, 2021","July 31, 2021","June 5, 2020",,"June 9, 2020","University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04418557"
343,"NCT04399733","EMPOWER - BAME vs COVID",,"Not yet recruiting","No Results Available","COVID-19, SARS-CoV 2 Infection|Health Disparities",,"Identify COVID-19 specific host-defence (""protective"") or predisposing (""susceptibility"") genetic biomarkers|Epidemiological profiles of COVID-19 infections in different UK ethnic populations","Future Genetics Limited","All","6 Years and older   (Child, Adult, Older Adult)",,"12800","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EMPOWER-BAME vs COVID","July 1, 2020","July 1, 2022","October 1, 2022","May 22, 2020",,"June 16, 2020","Future Genetics Limited, Birmingham, West Midlands, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04399733"
344,"NCT04445610","Measles Vaccine: Is There a Protective Role in COVID 19 Pandemic?",,"Not yet recruiting","No Results Available","Coronavirus (COVID-19)",,"Viral clearance","Ain Shams University","All","Child, Adult, Older Adult",,"60","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","FMASU P31a/ 2020","July 1, 2020","September 1, 2020","November 1, 2020","June 24, 2020",,"June 26, 2020","Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt",,"https://ClinicalTrials.gov/show/NCT04445610"
345,"NCT04379310","Evaluation of Clinical Parameters on Admission and Medications in Covid-19 Pneumonia (Corona Virus Disease 2019)","Covid-19","Completed","No Results Available","Covid-19","Drug: ACE Inhibitors and Calcium Channel Blockers","extend of lung involvement|oxygen saturation on admission","Nisantasi University","All","18 Years to 99 Years   (Adult, Older Adult)",,"54","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","20200504441","May 1, 2020","May 5, 2020","May 8, 2020","May 7, 2020",,"June 5, 2020","Vital Hospital, Bahcelievler, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04379310"
346,"NCT04405102","COVID-19 Ozanimod Intervention Study","COZI","Not yet recruiting","No Results Available","COVID-19","Drug: Ozanimod|Other: Standard of care","The mean oxygen flow required to maintain the oxygen saturation (SpO2) target at 92%|Daily Patient progression assessed with the World Health Organization-adapted 6-points ordinal scale|Rate of non invasive ventilation (NIV) / high flow nasal therapy (HFNT) use|Rate of intubation|Ventilator-free days at day 28|Rate of ICU admission/length of stay/mortality|Severity index measurement","François Lellouche|Celgene|Bristol-Myers Squibb|Laval University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","48","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2021-3474","July 6, 2020","January 6, 2022","July 6, 2022","May 28, 2020",,"May 28, 2020",,,"https://ClinicalTrials.gov/show/NCT04405102"
347,"NCT04412265","Frailty in Elderly Patients With COVID-19","FRA-COVID","Recruiting","No Results Available","Covid19","Other: Relation between frailty and clinical outcomes in elderly patients with COVID-19.","Development of a tool to measure frailty|A ""proxy"" variable of the fragility index can be built on the basis of regional administrative databases only.|Give elements to focus the screening policies for COVID19.|Give the prevention of contagion at the elderly population level.","University of Milano Bicocca","All","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","FRA-COVID","March 1, 2020","June 2020","March 1, 2021","June 2, 2020",,"June 9, 2020","ASST Monza-Ospedale San Gerardo, Monza, Italy",,"https://ClinicalTrials.gov/show/NCT04412265"
348,"NCT04325633","Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection","ENACOVID","Not yet recruiting","No Results Available","COVID-19","Drug: 1: Naproxen|Drug: 2: Standard of care","Mortality all causes at day30|Number of days alive free of mechanical ventilation|Number of days alive outside|Number of days alive outside hospital|Maximal changes in Sofa score|Time to negativation of virus titer in the nasopharyngeal aspirate (NPA)","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 3","584","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200387","April 13, 2020","May 13, 2021","July 13, 2021","March 27, 2020",,"April 14, 2020",,,"https://ClinicalTrials.gov/show/NCT04325633"
349,"NCT04368884","Observational Study to Assess the Seroconversion Status of Health Care Workers and Suspected or Confirmed Cases of COVID-19 Patients",,"Recruiting","No Results Available","Covid-19",,"Development of antibodies","Max Healthcare Insititute Limited","All","18 Years to 80 Years   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Covid-19/MHC-2/2020","April 22, 2020","June 30, 2020","July 30, 2020","April 30, 2020",,"April 30, 2020","Max Super Speciality Hospital, A Unit of Devki Devi Foundation, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT04368884"
350,"NCT04427098","Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients","INHIXACOV19","Recruiting","No Results Available","COVID-19","Drug: Enoxaparin 40 Mg/0.4 mL Injectable Solution|Drug: Enoxaparin","To investigate the efficacy of enoxaparin in improving the clinical outcome of hospitalized patients with moderate-severe COVID-19.|To analyse the safety of enoxaparin in hospitalized patients with moderatesevere COVID-19.|To describe the rates and the types of thromboembolic events among hospitalized patients with confirmed diagnosis of COVID-19.","Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","300","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-001308-40","May 22, 2020","October 30, 2020","October 30, 2020","June 11, 2020",,"June 17, 2020","Policlinico S. Orsola Malpighi Dipartimento Malattie Infettive, Bologna, Emilia Romagna, Italy|Azienda Ospedaliero-Universitaria di Parma Anestesia e Rianimazione Dipartimento di Medicina e Chirurgia, Parma, Emilia Romagna, Italy|I.R.C.C.S. ""Casa Sollievo della Sofferenza"", San Giovanni Rotondo (FG) UOVD Emostasi e trombosi- Poliambulatorio Giovanni Paolo II Viale Padre Pio n.7 San Giovanni Rotondo (FG), San Giovanni Rotondo, Foggia, Italy|Fondazione Poliambulanza Chirurgia Vascolare, Brescia, Italy|Piazzale Spedali Civili, 1, 25123 Brescia BS Medicina Interna UniBS 2° Medicina ASST Spedali Civili, Brescia, Italy|Azienda Ospedaliero-Universitaria ""Policlinico - V. Emanuele"", Catania Anestesia e Rianimazione UO Malattie Infettive, Catania, Italy|ASST Cremona Unità Operativa di Chirurgia Vascolare Dipartimento di Medicina di Laboratorio e di Radiologia- Centro Emostasi e Trombosi, Cremona, Italy|Ospedale Morgagni Pierantoni U.O.C. Malattie Infettive, Forlì, Italy|Ospedale Carlo Poma di Mantova MALATTIE INFETTIVE Padiglione 37 Str. Lago Paiolo, 10, 46100 Mantova, Mantova, Italy|AZIENDA OSPEDALIERA Regionale S CARLO POTENZA Struttura Complessa Interaziendale ""Malattie Infettive"", Matera, Italy|Ospedale San Raffaele Unità Funzionale dell'Unità Operativa di Malattie Infettive Osp. San Raffaele, Milano, Italy|Ospedale Amedeo di Savoia Torino Università di Torino Malattie Infettive, Torino, Italy|Azienda Ospedaliera Universitaria Integrata Verona UOC Malattie Infettive e Tropicali, Verona, Italy","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT04427098/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04427098"
351,"NCT04432324","Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19)",,"Not yet recruiting","No Results Available","COVID-19","Biological: Intravenous Immune Globulin|Drug: Standard Medical Treatment","Percentage of Participants Dying or Requiring ICU Admission|Percentage of Participants Who are Dependent on High Flow Oxygen Devices or Invasive Mechanical Ventilation|Change from Baseline in National Early Warning Score (NEWS)|Time to Clinical Response as Assessed by: NEWS ≤ 2 Maintained for 24 hours|Time to Hospital Discharge|Duration of ICU Stay|Duration of Any Oxygen Use|Duration of Mechanical Ventilation|Absolute Value and Mean Change from Baseline in Ordinal Scale|Percentage of Participants in Each Severity Category of the 7-point Ordinal Scale|Time to Sustained Normalization of Temperature|Percentage of Participants with Normalization of Fever|Number of Participants who Develop Acute Respiratory Distress Syndrome (ARDS)|Length of Time to Clinical Progression","Instituto Grifols, S.A.|Grifols Therapeutics LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GC2004|2020-001696-32","June 2020","July 2020","December 2020","June 16, 2020",,"June 16, 2020","Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04432324"
352,"NCT04382066","Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19","APLICOV-PC","Recruiting","No Results Available","COVID-19","Drug: Plitidepsin 1.5 mg/day|Drug: Plitidepsin 2.0 mg/day|Drug: Plitidepsin 2.5 mg/day","Frequency of occurrence of Neutropenia ≥ grade 3|Frequency of occurrence of Thrombocytopenia ≥ grade 3|Frequency of occurrence of Anemia ≥ grade 3|Frequency of occurrence of Lymphopenia ≥ grade 3|Frequency of occurrence of CPK increase ≥ grade 3|Frequency of occurrence of Increase ALT and / or AST ≥ grade 3|Frequency of occurrence of Increase total bilirubin or direct bilirubin ≥ grade 3|Frequency of occurrence of Neurotoxicity ≥ grade 3|Frequency of occurrence of QT-QTc interval extension ≥ grade 3|Frequency of occurrence of Other adverse events ≥ grade 3|Percentage of patients in whom treatment cannot be completed.|Percentage of patients with adverse events.|Percentage of patients with serious adverse events.|Percentage of patients with ECG abnormalities.|Change in the viral load of SARS-CoV-2|Time to negative PCR test for COVID-19|Mortality|Percentage of patients requiring invasive mechanical ventilation and / or ICU admission|Percentage of patients requiring non-invasive mechanical ventilation|Percentage of patients requiring oxygen therapy","PharmaMar|Apices Soluciones S.L.","All","18 Years and older   (Adult, Older Adult)","Phase 1","27","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APL-D-002-20|2020-001993-31","May 12, 2020","November 2020","November 2020","May 11, 2020",,"June 4, 2020","Hospital Universitario Hm Montepríncipe, Boadilla Del Monte, Madrid, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Ciudad Real, Ciudad Real, Spain|Hospital La Princesa, Madrid, Spain|Hospital Ramón Y Cajal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04382066"
353,"NCT04408456","Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19","PEP-Q","Recruiting","No Results Available","CoVID-19","Drug: HCQ|Other: Standard therapy","Incidence confirmed case of COVID-19|Incidence of probable case of COVID-19|Incidence of adverse drug reaction (ADR)","Postgraduate Institute of Medical Education and Research","All","18 Years and older   (Adult, Older Adult)","Phase 3","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IEC-04/2020-1624","March 1, 2020","June 30, 2020","June 30, 2020","May 29, 2020",,"June 2, 2020","Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India|Post Graduate Institute of Medical Education and Research, Chandigarh, India",,"https://ClinicalTrials.gov/show/NCT04408456"
354,"NCT04355884","Opportunistic Screening for Asymptomatic Left Ventricular Dysfunction in Coronavirus Disease 2019 (COVID19) Survivors",,"Not yet recruiting","No Results Available","COVID-19","Diagnostic Test: Standard 12-lead ECG, NT-proBNP, echocardiography","New-onset cardiac arrhythmia|Elevation of NT-proBNP|Left ventricular dysfunction","The University of Hong Kong","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID_LVD_SCREEN","April 20, 2020","May 1, 2020","May 1, 2020","April 21, 2020",,"April 24, 2020","The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04355884"
355,"NCT04387929","Detection of Anti-COVID-19 Antibody Levels in an Hospital Population",,"Recruiting","No Results Available","COVID-19","Diagnostic Test: Detection of anti-COVID-19 antibody level","SARS-CoV-2 levels of IgG antibodies|SARS-CoV-2 viral load in nasopharyngeal swab of IgG positive subjects|Epidemiology correlations","Istituto Clinico Humanitas","All","18 Years to 90 Years   (Adult, Older Adult)",,"6000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1374 IgG COVID-19 HUMANITAS","May 4, 2020","May 30, 2021","May 30, 2021","May 14, 2020",,"May 15, 2020","Humanitas Rozzano/San Pio X, Rozzano, Lombardia, Italy",,"https://ClinicalTrials.gov/show/NCT04387929"
356,"NCT04390178","Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19)",,"Active, not recruiting","No Results Available","COVID-19","Biological: SARS-CoV-2 convalescent plasma","Disease progression|Adverse events (AE)|Time ro resolution of fever and symptoms|Clearance of viraemia|Inflammatory parameters|Antibody response to SARS-CoV-2","Joakim Dillner|Danderyd Hospital|Karolinska Institutet|Karolinska University Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CP1","April 10, 2020","June 2020","December 2020","May 15, 2020",,"May 15, 2020","Danderyd Hospital, Danderyd, Sweden",,"https://ClinicalTrials.gov/show/NCT04390178"
357,"NCT04432103","Treatment of Severe and Critical COVID-19 Pneumonia With Convalescent Plasma",,"Not yet recruiting","No Results Available","Covid-19","Biological: Anti SARS-CoV 2 Convalescent Plasma in severe COVID-19 patients|Biological: Anti SARS-CoV 2 Convalescent Plasma in critical COVID-19 patients","INCIDENCE OF CRITICAL PNEUMONIA|MORTALITY RATE AMONG CRITICAL PNEUMONIA PATIENTS|INCIDENCE OF MECHANICAL VENTILATION|DAYS OF MECHANICAL VENTILATION","Centro Medico ABC","All","18 Years and older   (Adult, Older Adult)","Phase 3","36","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABC-20-14","June 19, 2020","July 30, 2020","September 30, 2020","June 16, 2020",,"June 17, 2020",,,"https://ClinicalTrials.gov/show/NCT04432103"
358,"NCT04344925","Non Invasive Positive Pressure Ventilation to Minimize Aerosolization for COVID 19",,"Recruiting","No Results Available","COVID-19","Device: Aerosol-reducing Mask|Device: Standard Mask","Total Leak Volume of Non Invasive Ventilation Mask|Glasgow Coma Scale(GCS)|Respiratory Rate|Heart Rate|Metabolic Data: Blood Gas Measurements|Metabolic Data: Bicarbonate (HC03)|Metabolic Data: Partial Pressure of Carbon Dioxide (PaC02)|Metabolic Data: Partial Pressure of Oxygen (Pa02)","Lawson Health Research Institute","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","137654","April 18, 2020","August 2020","September 2020","April 14, 2020",,"June 11, 2020","London Health Science Centre, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04344925"
359,"NCT04306497","TCM Differentiation and Treatment Protocol of COVID-19","TDATPOC","Completed","No Results Available","COVID-19","Drug: TCM prescriptions","The relief of main symptoms/ disappearance rate of time|Chest CT absorption|Evaluation standard of comprehensive curative effect|Virus antigen negative conversion rate|The number of severe and critical conversion cases|Incidence of complications|Traditional Chinese Medicine Syndrome Score","Jiangsu Famous Medical Technology Co., Ltd.","All","18 Years to 80 Years   (Adult, Older Adult)",,"340","Industry","Observational","Observational Model: Cohort|Time Perspective: Other","JSZYJ202001","January 22, 2020","April 30, 2020","May 30, 2020","March 13, 2020",,"June 4, 2020","Huai'an fourth people's Hospital, Huaian, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT04306497"
360,"NCT04445233","COVID-19 Household Transmission Study","CO-HOST","Recruiting","No Results Available","COVID-19",,"Secondary household infection rate|Secondary household infection rate - risk factors|Sensitivity of self-collected nasal swabs","University of North Carolina, Chapel Hill|North Carolina Translational and Clinical Sciences Institute","All","1 Year and older   (Child, Adult, Older Adult)",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-0982|550KR242023","April 29, 2020","December 2020","December 2020","June 24, 2020",,"June 24, 2020","University of North Carolina Health Care, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04445233"
361,"NCT04415086","Treatment of Patients With COVID-19 With Convalescent Plasma","COOPCOVID-19","Recruiting","No Results Available","COVID-19","Biological: convalescent plasma","Time elapsed until clinical improvement or hospital discharge|acute adverse events|Clinical Status|Duration of clinical events|SARS-CoV-2 in nasopharyngeal swab|IgG, IgM and IgA titers for SARS-CoV-2|Neutralizing antibodies","University of Sao Paulo General Hospital|Ministério da Ciência, Tecnologia, Inovações e Comunicações|Faculty of Medicine of Ribeirão Preto (FMRP-USP)|Hospital de Clínicas, Faculdade de Medicina Universidade Estadual de Campinas|Hospital Sirio-Libanes|Hospital Israelita Albert Einstein","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COOP-COVID-19-MCTIC","June 1, 2020","April 20, 2022","May 22, 2022","June 4, 2020",,"June 9, 2020","University of Sao Paulo - General Hospital, São Paulo, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT04415086"
362,"NCT04380532","Tableted COVID-19 Therapeutic Vaccine","COVID-19","Active, not recruiting","No Results Available","Covid19","Biological: V-SARS","Effect on CBC as per CTCAE v4.0|Effect on biochemistry parameters as per CTCAE v4.0|Lack of adverse events as per CTCAE v4.0","Immunitor LLC|Immunitor Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Imm24","May 15, 2020","May 15, 2021","June 15, 2021","May 8, 2020",,"May 27, 2020","Immunitor Inc, Vancouver, BC - British Columbia, Canada|Aldar Bourinbayar, Ulaanbaatar, BZD, 3-khoroo, Mongolia",,"https://ClinicalTrials.gov/show/NCT04380532"
363,"NCT04427566","Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise","VENTED","Recruiting","No Results Available","COVID-19","Radiation: Radiation therapy","Mortality rate of subjects treated with whole lung low-dose radiation|Survival rate of subjects treated with whole lung low-dose radiation|Change in number of Intensive care unit days|Change in number of days using supplemental oxygen|Change in oxygenation index/oxygen saturation index for 14 days post treatment or until extubated|Quantitation of Lung Involvement using Chest CT|Quantitation of Lung Opacities using Chest CT|SARS-CoV2 viral titers|Incidence of adverse events, including severity and duration, for administration of low dose radiation to lungs|Change in performance status after low dose radiation to lungs","Ohio State University Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VENTED","June 11, 2020","December 31, 2021","December 31, 2021","June 11, 2020",,"June 23, 2020","Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04427566"
364,"NCT04385043","Hyperimmune Plasma in Patients With COVID-19 Severe Infection","COV2-CP","Recruiting","No Results Available","COVID-19","Other: plasma hyperimmune|Drug: standard therapy","decrease in mortality|lymphocytes|PCR levels vs control|PCR levels vs before treatment|AB levels and clinical improvement|Inflammatory cytokines vs controls|Inflammatory cytokines vs before treatment","University of Catanzaro|Azienda Ospedaliera Policlinico ""Mater Domini""|Azienda Sanitaria Provinciale Di Catanzaro|Annunziata Hospital, Cosenza, Italy|Azienda Ospedaliera Bianchi-Melacrino-Morelli","All","18 Years to 60 Years   (Adult)","Phase 2|Phase 3","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Covid-19 convalescent plasma","May 1, 2020","October 15, 2020","May 15, 2021","May 12, 2020",,"May 12, 2020","Azienda Ospedaliera Policlinico Mater Domini, Catanzaro, Italy|Azienda Ospedaliera Pugliese Ciaccio Catanzaro, Catanzaro, Italy|Azienda Ospedaliera Annunziata, Cosenza, Italy|Azienda Sanitaria Provinciale, Crotone, Italy|Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy|Azienda Sanitaria Provinciale, Vibo Valentia, Italy",,"https://ClinicalTrials.gov/show/NCT04385043"
365,"NCT04352348","Cohort of Patients Infected With SARS-CoV2 (COVID-19) or Suspected of Being","COVIDeF","Recruiting","No Results Available","COVID-19","Other: blood samples","Identification of prognostic factors for progression to a severe form of COVID-19 infection|Clinical aggravation of the infection|Discharge of hospitalization|Death|Description of clinical manifestations|Description of biological manifestations|Description of radiological manifestations|Description of physiological manifestations|Patient-related prognostic factors|Virus-related risk factors|Comparison of the results of different diagnosis tests","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","APHP200382|2020-A00754-35","March 31, 2020","May 31, 2021","March 31, 2022","April 20, 2020",,"May 12, 2020","GH Pitié-Salpêtrière / Service d'Accueil des Urgences, Paris, Ile-de-France, France",,"https://ClinicalTrials.gov/show/NCT04352348"
366,"NCT04323332","Traditional Chinese Medicine for Severe COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Traditional Chinese Medicine Prescription","Length of hospital stay (days)|Duration (days) of supplemental oxygenation|CT imaging changes|Mortality rate|Time to Clinical Improvement (TTCI)|The pneumonia severity index scores|Time to COVID-19 nucleic acid testing negativity in throat swab|Blood immune cell count|Serum inflammatory markers|Erythrocyte sedimentation rate|Platelet and D-dimer changes|Creatinine changes|Muscle enzymes changes|Usage of antibiotics|Usage of glucocorticoids|Frequency of adverse events","Xiyuan Hospital of China Academy of Chinese Medical Sciences","All","up to 85 Years   (Child, Adult, Older Adult)","Phase 3","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020XLA015-1","March 2020","March 2020","April 2020","March 26, 2020",,"March 26, 2020","Hao Li, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04323332"
367,"NCT04412252","Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy",,"Not yet recruiting","No Results Available","COVID-19","Drug: Tofacitinib|Other: Placebo","Clinical status using ordinal scale|Status of alive and not using mechanical ventilation or extracorporeal membrane oxygenation (ECMO)|Status of discharged or not requiring supplemental oxygen|Mortality","Pfizer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","A3921377","June 4, 2020","September 16, 2020","October 18, 2020","June 2, 2020",,"June 11, 2020","University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04412252"
368,"NCT04317092","Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)","TOCIVID-19","Recruiting","No Results Available","COVID-19 Pneumonia","Drug: Tocilizumab Injection","One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","National Cancer Institute, Naples","All","Child, Adult, Older Adult","Phase 2","400","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TOCIVID-19|2020-001110-38","March 19, 2020","December 19, 2020","December 19, 2022","March 20, 2020",,"April 7, 2020","Azienda Ospedaliera ""SS. Antonio e Biagio e C. Arrigo"" (Dipartimento Internistico SSD Reumatologia), Alessandria, Italy|Ospedale di Busto Arsizio ASST Valle Olona (U.O.C. Malattie Infettive), Busto Arsizio, Italy|A.O.U. Policlinico V. Emanuele (U.O. di Malattie infettive, U.O. di Anestesia e Rianimazione, U.O. di Medicina d'Urgenza), Catania, Italy|AOE Cannizzaro di Catania (U.O. di Malattie Infettive, U.O. di Anestesia e Rianimazione, U.O., Catania, Italy|Ospedale Annunziata Azienda Ospedaliera di Cosenza (U.O.C. Malattie Infettive), Cosenza, Italy|ASST OVEST MILANESE presidi Legnano - Magenta, Magenta, Italy|Azienda Ospedaliero-Universitaria di Modena, Modena, Italy|A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione I), Modena, Italy|A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione II), Modena, Italy|A.O.U. di Modena (Dipartimento Medicine Specialistiche - Struttura Complessa Malattie Infettive), Modena, Italy|Dipartimento Medicine Specialistiche - Struttura Complessa Malattie dell'Apparato Respiratorio, Modena, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Oncologia), Naples, Italy|National Cancer Institute, Naples, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Anestesia Rianimazione e terapia intensiva), Naples, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Malattie Infettive ad indirizzo respiratorio), Naples, Italy|A.O. Ospedali Riuniti Marche Nord - Presidio Ospedaliero San Salvatore di Pesaro (UOC Pronto Soccorso e Medicina d'Urgenza), Pesaro, Italy|Denominazione: UOC di Medicina e Chirurgia d'Accettazione e d'Urgenza dell'Ospedale Santa Maria delle Grazie di Pozzuoli, Pozzuoli, Italy|Ospedale Santa Maria delle Croci, AUSL della Romagna (U.O. Anestesia e Rianimazione), Ravenna, Italy|Grande Ospedale Metropolitano, Reggio Calabria, Reggio Calabria, Italy|Ospedale Infermi, AUSL della Romagna (U.O. Malattie Infettive), Rimini, Italy|Policlinico Gemelli (U.O.C. Dipartimento Scienze di Laboratorio e Infettivologiche), Rome, Italy|ASST Sette Laghi (Dipartimento di Medicina Interna), Varese, Italy|ASST Sette Laghi (Dipartimento Emergenze ed Urgenze), Varese, Italy|ASST Sette Laghi (U.O.C. Anestesia e Rianimazione Neurochirurgica e Generale), Varese, Italy|ASST Sette Laghi (U.O.C. Malattie Infettive e Tropicali), Varese, Italy|A.O.U. Integrata di Verona (Dip. Malattie Infettive), Verona, Italy|Ospedale Magalini (U.O. Malattie Infettive), Villafranca Di Verona, Italy",,"https://ClinicalTrials.gov/show/NCT04317092"
369,"NCT04444310","Antibody Responses in Contacts of COVID-19 Patients",,"Active, not recruiting","No Results Available","COVID-19",,"Measure level of Abs in asymptomatic close contacts of COVID 19 patients.","Assiut University","All","18 Years to 80 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Assiut13","June 15, 2020","June 18, 2020","September 30, 2020","June 23, 2020",,"June 23, 2020","AssiutU, Assiut, Egypt",,"https://ClinicalTrials.gov/show/NCT04444310"
370,"NCT04357808","Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID)","SARCOVID","Recruiting","No Results Available","Covid-19","Drug: Sarilumab|Other: Standar of care","Mean change in clinical status assessment using the 7-point ordinal scale at day 7 after randomisation|Duration of hospitalisation (days)|Death|Time to become afebrile (days)|Time to non-invasive mechanical ventilation (days)|Time to invasive mechanical ventilation (days)|Time to independence from supplementary oxygen therapy (days)|Mean change in clinical status assessment using the 7-point ordinal scale at day 14 after randomisation","Maria del Rosario Garcia de Vicuña Pinedo|Instituto de Investigación Sanitaria Hospital Universitario de la Princesa|Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SARCOVID|2020-001634-36","April 13, 2020","June 2020","June 2020","April 22, 2020",,"April 22, 2020","Hospital Universitario de la Princesa, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04357808"
371,"NCT04408014","Seroepidemiological Study of SARS-CoV-2 (COVID-19) Infection in Population Subgroups in the State of São Paulo",,"Not yet recruiting","No Results Available","COVID|SARS-CoV 2","Diagnostic Test: Serological test|Diagnostic Test: Nasopharyngeal Swab|Diagnostic Test: Oropharyngeal Swab","Prevalence of antibodies against SARS-CoV-2 through serological testing|Frequency of participants with a positive RT-PCR test result for SARS-CoV-2","Butantan Institute","All","6 Months to 100 Years   (Child, Adult, Older Adult)",,"18901","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","COVID-19-Epi-01","June 1, 2020","July 15, 2020","July 30, 2020","May 29, 2020",,"May 29, 2020",,,"https://ClinicalTrials.gov/show/NCT04408014"
372,"NCT04382729","Neuromuscular Electrical Stimulation in Patients With COVID19 Associated Pneumonia",,"Recruiting","No Results Available","COVID-19 Pneumonia","Other: Neuromuscular Electrical Stimulation|Other: Physical Therapy Exercise","Short Physical Performance Battery (SPPB) Score|Functional Independence Measure (FIM) Scale Score|Fatigue Severity Scale Score|Muscle Strength|Two Step Test Length|Six Minutes Walking Test Distance|Muscle Thickness","University of Turin, Italy|San Luigi Gonzaga Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","ESC270320","April 17, 2020","July 2020","July 2020","May 11, 2020",,"May 11, 2020","San Luigi Gonzaga Hospital, Orbassano, TO, Italy",,"https://ClinicalTrials.gov/show/NCT04382729"
373,"NCT04339660","Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia",,"Recruiting","No Results Available","COVID-19","Biological: UC-MSCs|Other: Placebo","The immune function (TNF-α 、IL-1β、IL-6、TGF-β、IL-8、PCT、CRP)|Blood oxygen saturation|Rate of mortality within 28-days|Size of lesion area by chest imaging|CD4+ and CD8+ T cells count|Peripheral blood count recovery time|Duration of respiratory symptoms (fever, dry cough, difficulty breathing, etc.)|COVID-19 nucleic acid negative time","Puren Hospital Affiliated to Wuhan University of Science and Technology|Shanghai University|Qingdao Co-orient Watson Biotechnology group co. LTD|Basic Medical Sciences, Chinese Academy of Medical Sciences","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Pr20200402","February 1, 2020","June 30, 2020","June 30, 2020","April 9, 2020",,"April 9, 2020","Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04339660"
374,"NCT04366856","PROne Positioning in coVID-19 Oxygeno-dependent Patients in Spontaneous Ventilation (PROVID Study)","PROVID","Not yet recruiting","No Results Available","COVID|ARDS","Behavioral: 1: Prone positioning|Behavioral: 2: No instruction regarding positioning","Proportion of patients who meet one or both following criteria: need for intubation (for mechanical ventilation), occurrence of death during hospital stay.|Proportion of patients admitted to ICU (for patients included out of ICU)|Days alive and free from non invasive ventilation (NIV) or high flow nasal canula oxygen delivery (HFNC) (for those neither under NIV or HFNC at the time of study inclusion)|Days alive and out of ICU|Days alive and out of hospital|Maximum oxygenotherapy rate during hospital stay [Time Frame: At day28]","Assistance Publique - Hôpitaux de Paris","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200504","April 2020","May 2020","July 2020","April 29, 2020",,"April 29, 2020","Département d'Anesthésie Réanimation - Kremlin Bicêtre, Le Kremlin-Bicêtre, France",,"https://ClinicalTrials.gov/show/NCT04366856"
375,"NCT04372368","Convalescent Plasma for the Treatment of Patients With COVID-19",,"Available","No Results Available","COVID-19|SARS-CoV 2","Biological: COVID-19 Convalescent Plasma",,"University of Colorado, Denver","All","18 Years and older   (Adult, Older Adult)",,,"Other","Expanded Access:Treatment IND/Protocol",,"20-0990",,,,"May 4, 2020",,"May 4, 2020","Children's Hospital Colorado, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|UCHealth Memorial Hospital North, Colorado Springs, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|UCHealth Poudre Valley Hospital, Fort Collins, Colorado, United States|UCHealth Highlands Ranch Hospital, Highlands Ranch, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT04372368"
376,"NCT04336956","Covid-19 Pediatric Observatory","PANDOR","Recruiting","No Results Available","COVID-19","Other: hospitalized children with Covid19","Percentage of children with severe or critical form.|Percentage of children requiring intensive care support|Clinical symptoms of children|Biological results of children|CT chest of children|Pulmonary echography|nasopharynx SARScov2 PCR|nasopharynx sarscov2 load|nasopharynx multiplex PCR|number of hospital days","Centre Hospitalier Intercommunal Creteil|Association Clinique Thérapeutique Infantile du val de Marne|GPIP|Société Française de Pédiatrie|GFRUP","All","up to 18 Years   (Child, Adult)",,"250","Other","Observational","Observational Model: Cohort|Time Perspective: Other","PANDOR","April 7, 2020","June 30, 2021","June 30, 2021","April 7, 2020",,"May 22, 2020","Chu Felix Guyon, Saint Denis, La Réunion, France|Ch St Esprit, Agen, France|Ch General Aix En Provence -, Aix-en-Provence, France|CHU Angers, Angers, France|CH d'ANGOULEME, Angoulème, France|Pringy - Ch D'Annecy, Annecy, France|CH Argenteuil, Argenteuil, France|Ch Armentieres, Armentières, France|CH Arpajon, Arpajon, France|Ch Auxerre, Auxerre, France|CH GENERAL Henri Duffaut, Avignon, France|CHU de BESANCON, Besançon, France|Hopital Femme Enfant, Caen, France|Ch de Pontoise, Cergy-Pontoise, France|Ch W. Morey, Chalon-sur-Saône, France|CH de CHAMBERY, Chambéry, France|Ch Hotel Dieu, Chartres, France|Centre Hospitalier intercommunal de Creteil, Creteil, France|Ch de Dax, Dax, France|Hopital D'Enfants Chu Dijon, Dijon, France|CH Louviers Val de Reuil, Elbeuf, France|CH Gonesse, Gonesse, France|CH d'HYERES, Hyères, France|Ch de Marne La Vallee, Jossigny, France|Chru de Grenoble, La Tronche, France|CHGénéral du HAVRE, Le Havre, France|Hopital Roger Salengro - Lille, Lille, France|Hopital Saint Vincent de Paul, Lille, France|Ch de Longjumeau, Longjumeau, France|Lorient - Ch de Bretagne Sud, Lorient, France|Hopital Femme Mere Enfant-Bron, Lyon, France|Hopital Nord Enfants, Marseille, France|Hopital de Meaux, Meaux, France|CH de Montargis, Montargis, France|CH de MONTBRISON, Montbrison, France|CHRU de Nancy, Nancy, France|Nantes - Hopital Mere Enfant, Nantes, France|Ch de Neuilly Sur Seine, Neuilly-sur-Seine, France|Hopital Lenval, Nice, France|CHU Nimes Caremeau, Nîmes, France|Assistance Publique Hôpitaux de Paris, Paris, France|POISSY - CH de POISSY, Poissy, France|QUIMPER - CH de Cornouaille, Quimper, France|RANG du FLIERS - C.H.A.M., RANG du FLIERS, France|Hopital Américain CHU REIMS, Reims, France|CH RODEZ, Rodez, France|Chu Rouen, Rouen, France|Hopital Charles-Nicolle, Rouen, France|Chu St Etienne, Saint Etienne, France|Ch de Saint Denis, Saint-Denis, France|Ch de Saint Malo, Saint-Malo, France|Ch Du Pays Du Mont Blanc, Sallanches, France|Chg Salon de Provence, Salon de Provence, France|CH Tarbes, Tarbes, France|CH Bel Air, Thionville, France|Hopital Sainte Musse, Toulon, France|CHU Toulouse-hôpital des Enfants, Toulouse, France|CH de TROYES, Troyes, France|Ch Bretagne Atlantique, Vannes, France|Ch Le Chesnay, Versailles, France|Hopital de Villeneuve Saint Georges, Villeneuve-Saint-Georges, France",,"https://ClinicalTrials.gov/show/NCT04336956"
377,"NCT04425460","A Multi-center,Randomized,Double-blind,Placebo-controlled,Phase 3 Study Evaluating Favipiravir in Treatment of COVID19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Favipiravir|Other: Placebo","Time from randomization to clinical recovery|Negativity in RT-PCR nucleic acid test|Time from randomization to resolution of pyrexia|Time from randomization to relief of cough|Incidence of deterioration/aggravation of pneumonia|Time from randomization to relief of dyspnoea|Rate of auxiliary oxygen therapy or non-invasive ventilation|ICU admission rate within 28 days of randomization|All-cause mortality within 28 days of randomization.","Zhejiang Hisun Pharmaceutical Co. Ltd.|Opera CRO, a TIGERMED Group Company","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","256","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","HS216C17(MRCT)","June 2020","August 2020","September 2020","June 11, 2020",,"June 11, 2020","The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Shangcheng District, China|Peking University First Hospital, Beijing, Xicheng District, China|Department of Internal Medicine Pneumology and infectious diseases Neukölln Clinic, Berlin, Germany|Medical clinic and polyclinic IV Hospital of the University of Munich, München, Germany|Infectious Diseases Hospital Cluj-Napoca, Cluj-Napoca, Cluj, Romania|National Institute of Infectious Diseases ""Prof.Dr.Matei Bals"", Bucharest, Ilfov, Romania|""Dr.Victor Babes"" Infectious Diseases and Pneumoftiziology Clinical Hospital Timisoara, Timisoara, Timis, Romania|""Dr.Victor Babes"" Infectious Diseases and Pneumoftiziology Clinical Hospital Timisoara, Timişoara, Timis, Romania|Dr.Victor Babes Infectious Diseases and Pneumoftiziology Clinical Hospital Timisoara, Timişoara, Timis, Romania|Emergency County Hospital ""Pius Brinzeu""Timisoara, Timişoara, Timis, Romania",,"https://ClinicalTrials.gov/show/NCT04425460"
378,"NCT04390503","Convalescent Plasma for COVID-19 Close Contacts",,"Recruiting","No Results Available","SARS-CoV 2|COVID-19","Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma)|Biological: Control (albumin 5%)","Rate of Severe Disease|Rate of measurable anti-SARS-CoV-2 titers|Rate of SARS-CoV-2 PCR Positivity|Duration of SARS-CoV-2 PCR Positivity|Levels of SARS-CoV-2 RNA","Columbia University","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","AAAT0052","May 2020","April 2021","April 2021","May 15, 2020",,"May 15, 2020","Columbia University Irving Medical Center/NYP, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04390503"
379,"NCT04444115","Loneliness During Strict and Lifted Social Distancing Protocols Against the COVID-19 Pandemic",,"Not yet recruiting","No Results Available","Loneliness During COVID-19",,"UCLA Loneliness Scale-8 (ULS-8)|Patient Health Questionnaire-9 (PHQ-9)|Generalized Anxiety Disorder-7 (GAD-7)","Modum Bad|University of Oslo","All","18 Years and older   (Adult, Older Adult)",,"10084","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","802810-1","June 22, 2020","July 13, 2020","July 13, 2020","June 23, 2020",,"June 23, 2020",,,"https://ClinicalTrials.gov/show/NCT04444115"
380,"NCT04365595","SARS-CoV-2 Associated Respiratory Failure Recovery (COVID-19 CAir)",,"Recruiting","No Results Available","SARS-CoV 2|COVID","Other: Questionnaires, spirometry","Health-related quality-of-life|Anxiety and depression|Symptom burden|Spirometry","University of Zurich","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2020-00745","June 3, 2020","December 2020","December 2020","April 28, 2020",,"June 11, 2020","University Hospital Zurich, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT04365595"
381,"NCT04348071","Safety and Efficacy of Ruxolitinib for COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Ruxolitinib","Phase 2: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 2: Cumulative incidence of serious adverse events (SAEs)|Phase 2: Changes in white blood cell count (CBC) through Day 15|Phase 2: Changes in hemoglobin through Day 15|Phase 2: Changes in platelets through Day 15|Phase 2: Changes in creatinine through Day 15|Phase 2: Changes in glucose through Day 15|Phase 2: Changes in prothrombin time (PT) through Day 15|Phase 2: Changes in total bilirubin through Day 15|Phase 2: Changes in ALT through Day 15|Phase 2: Changes in AST through Day 15|Phase 2: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 2: Changes in hemoglobin through End of Study (EOS)|Phase 2: Changes in platelets through End of Study (EOS)|Phase 2: Changes in creatinine through End of Study (EOS)|Phase 2: Changes in glucose through End of Study (EOS)|Phase 2: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 2: Changes in total bilirubin through End of Study (EOS)|Phase 2: Changes in ALT through End of Study (EOS)|Phase 2: Changes in AST through End of Study (EOS)|Phase 3: Percentage of patients reporting each severity on an 8-point ordinal scale at Day 15|Phase 2: Change in the 8-point ordinal scale|Phase 2: Change in National Early Warning Score (NEWS)|Phase 3: Change in the 8-point ordinal scale|Phase 3: Change in National Early Warning Score (NEWS)|Phase 3: Time to an improvement of one category using the 8-point ordinal scale|Phase 3: Time to an improvement of two categories using the 8-point ordinal scale|Phase 3: Time to discharge or to a NEWS ≤2 and maintained for 24 hours, whichever occurs first|Phase 3: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 3: Cumulative incidence of serious adverse events (SAEs)|Phase 3: Duration of hospitalization|Phase 3: Duration of new oxygen use|Phase 3: Duration of new ventilator or ECMO use|Phase 3: Incidence of discontinuation or temporary suspension of drug for any reason|Phase 3: Incidence of new oxygen use|Phase 3: Incidence of new ventilator use|Phase 3: Number of oxygen free days|Phase 3: Number of ventilator or ECMO free days|Phase 3: 14 day mortality rate|Phase 3: 28 day mortality rate|Phase 3: Changes in white blood cell count (CBC) through Day 15|Phase 3: Changes in hemoglobin through Day 15|Phase 3: Changes in platelets through Day 15|Phase 3: Changes in creatinine through Day 15|Phase 3: Changes in glucose through Day 15|Phase 3: Changes in prothrombin time (PT) through Day 15|Phase 3: Changes in total bilirubin through Day 15|Phase 3: Changes in ALT through Day 15|Phase 3: Changes in AST through Day 15|Phase 3: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 3: Changes in hemoglobin through End of Study (EOS)|Phase 3: Changes in platelets through End of Study (EOS)|Phase 3: Changes in creatinine through End of Study (EOS)|Phase 3: Changes in glucose through End of Study (EOS)|Phase 3: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 3: Changes in total bilirubin through End of Study (EOS)|Phase 3: Changes in ALT through End of Study (EOS)|Phase 3: Changes in AST through End of Study (EOS)","University of Colorado, Denver","All","18 Years to 89 Years   (Adult, Older Adult)","Phase 2|Phase 3","80","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-0869","June 2020","August 2020","October 2020","April 15, 2020",,"May 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04348071"
382,"NCT04355338","Assessment of Incidence of SARS-CoV-2 Infection and COVID-19 in Brazil (AVISA)","AVISA","Not yet recruiting","No Results Available","COVID-19",,"Incidence of SARS-CoV-2 infection|Incidence of COVID-19|Incidence of hospitalization due to COVID-19|Level of neutralizing antibodies|Previous SARS-CoV-2 infection","Butantan Institute","All","Child, Adult, Older Adult",,"4100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COV-01-IB","May 15, 2020","November 30, 2020","May 15, 2022","April 21, 2020",,"April 28, 2020",,,"https://ClinicalTrials.gov/show/NCT04355338"
383,"NCT04340232","Safety and Efficacy of Baricitinib for COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Baricitinib","Phase 2: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 2: Cumulative incidence of serious adverse events (SAEs)|Phase 2: Changes in white blood cell count (CBC) through Day 15|Phase 2: Changes in hemoglobin through Day 15|Phase 2: Changes in platelets through Day 15|Phase 2: Changes in creatinine through Day 15|Phase 2: Changes in glucose through Day 15|Phase 2: Changes in prothrombin time (PT) through Day 15|Phase 2: Changes in total bilirubin through Day 15|Phase 2: Changes in ALT through Day 15|Phase 2: Changes in AST through Day 15|Phase 2: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 2: Changes in hemoglobin through End of Study (EOS)|Phase 2: Changes in platelets through End of Study (EOS)|Phase 2: Changes in creatinine through End of Study (EOS)|Phase 2: Changes in glucose through End of Study (EOS)|Phase 2: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 2: Changes in total bilirubin through End of Study (EOS)|Phase 2: Changes in ALT through End of Study (EOS)|Phase 2: Changes in AST through End of Study (EOS)|Phase 3: Percentage of patients reporting each severity on an 8-point ordinal scale at Day 15|Phase 2: Change in the 8-point ordinal scale|Phase 2: Change in National Early Warning Score (NEWS)|Phase 3: Change in the 8-point ordinal scale|Phase 3: Change in National Early Warning Score (NEWS)|Phase 3: Time to an improvement of one category using the 8-point ordinal scale|Phase 3: Time to an improvement of two categories using the 8-point ordinal scale|Phase 3: Time to discharge or to a NEWS ≤2 and maintained for 24 hours, whichever occurs first|Phase 3: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 3: Cumulative incidence of serious adverse events (SAEs)|Phase 3: Duration of hospitalization|Phase 3: Duration of new oxygen use|Phase 3: Duration of new ventilator or ECMO use|Phase 3: Incidence of discontinuation or temporary suspension of drug for any reason|Phase 3: Incidence of new oxygen use|Phase 3: Incidence of new ventilator use|Phase 3: Number of oxygen free days|Phase 3: Number of ventilator or ECMO free days|Phase 3: 14 day mortality rate|Phase 3: 28 day mortality rate|Phase 3: Changes in white blood cell count (CBC) through Day 15|Phase 3: Changes in hemoglobin through Day 15|Phase 3: Changes in platelets through Day 15|Phase 3: Changes in creatinine through Day 15|Phase 3: Changes in glucose through Day 15|Phase 3: Changes in prothrombin time (PT) through Day 15|Phase 3: Changes in total bilirubin through Day 15|Phase 3: Changes in ALT through Day 15|Phase 3: Changes in AST through Day 15|Phase 3: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 3: Changes in hemoglobin through End of Study (EOS)|Phase 3: Changes in platelets through End of Study (EOS)|Phase 3: Changes in creatinine through End of Study (EOS)|Phase 3: Changes in glucose through End of Study (EOS)|Phase 3: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 3: Changes in total bilirubin through End of Study (EOS)|Phase 3: Changes in ALT through End of Study (EOS)|Phase 3: Changes in AST through End of Study (EOS)","University of Colorado, Denver","All","18 Years to 89 Years   (Adult, Older Adult)","Phase 2|Phase 3","80","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-0738","June 2020","August 2020","October 2020","April 9, 2020",,"May 6, 2020","University of Colorado, Denver, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT04340232"
384,"NCT04382092","Co-infection Management in COVID-19 Critically Ill",,"Completed","No Results Available","COVID-19","Diagnostic Test: FilmArray Pneumonia","% of COVID-19 co-infections|% of antibiotic switches following FA results","Cliniques universitaires Saint-Luc- Université Catholique de Louvain|BioMérieux","All","18 Years and older   (Adult, Older Adult)","Not Applicable","32","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2019/14MAR/124","March 23, 2020","April 24, 2020","April 24, 2020","May 11, 2020",,"May 11, 2020","Cliniques Universitaires Saint-Luc, Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT04382092"
385,"NCT04385108","Predictive Immune Biomarkers for COVID-19 Pathogenesis","COVIDBioToul","Not yet recruiting","No Results Available","COVID-19","Biological: Blood collection on admission and longitudinally|Biological: Blood collection on their first consultation and 10 to 14 days later","Immune signature|Dosage of cytokines and chemokines in plasma samples|Analysis of the early dynamics of SARS-CoV-2-specific humoral immunity","University Hospital, Toulouse","All","18 Years and older   (Adult, Older Adult)","Not Applicable","170","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","RC31/20/0162","May 12, 2020","December 31, 2021","December 31, 2021","May 12, 2020",,"May 12, 2020","Purpan University Hospital, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT04385108"
386,"NCT04355793","Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection",,"Available","No Results Available","COVID-19","Drug: Ruxolitinib",,"Incyte Corporation","All","12 Years and older   (Child, Adult, Older Adult)",,,"Industry","Expanded Access:Treatment IND/Protocol",,"INCB 18424-MA-COVID-19-301",,,,"April 21, 2020",,"April 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04355793"
387,"NCT04329832","Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19","HAHPS","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin","COVID Ordinal Outcomes Scale at 14 days|Hospital-free days at 28 days (number of days patient not in hospital)|Ventilator-free days at 28 days (number of days patient not on a ventilator)|ICU-free days at 28 days (number of days patient not in an ICU)|Time to a 1-point decrease in the WHO ordinal recovery score","Intermountain Health Care, Inc.|University of Utah","All","18 Years and older   (Adult, Older Adult)","Phase 2","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1051355","March 30, 2020","December 31, 2020","December 31, 2021","April 1, 2020",,"June 2, 2020","Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04329832"
388,"NCT04346602","A Study on the Clinical and Psychological Characteristics of Patients With COVID-2019",,"Recruiting","No Results Available","COVID-2019","Other: all treatment about COVID-2019","fever|cough|diarrhea|anxiety|insomnia|depression","Jilin University","All","1 Year to 80 Years   (Child, Adult, Older Adult)",,"132","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","130004","February 1, 2020","June 1, 2020","December 1, 2020","April 15, 2020",,"April 15, 2020","the First Hospital of Jilin University, Chang chun, Jilin, China",,"https://ClinicalTrials.gov/show/NCT04346602"
389,"NCT04388410","Safety and Efficacy of Convalescent Plasma Transfusion for Patients With COVID-19","EPCOvid-1","Not yet recruiting","No Results Available","COVID-19","Biological: convalescent plasma","Severity and death|Adverse events that require study treatment interruption|Time to clinical improvement|Antibodies against SARS-CoV-2|Disease progression 1|Disease progression 2|Time on mechanical ventilation|Number of days with fever|Adverse events attributed to the study intervention","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Hospital San Jose Tec de Monterrey|Instituto Nacional de Enfermedades Respiratorias|Instituto Nacional de Cardiologia Ignacio Chavez|Hospital General Dr. Manuel Gea González|Instituto Nacional de Cancerologia, Columbia|Hospital Regional de Alta Especialidad del Bajio","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3380","June 1, 2020","October 31, 2020","December 31, 2020","May 14, 2020",,"May 15, 2020",,,"https://ClinicalTrials.gov/show/NCT04388410"
390,"NCT04361916","Home Care for Patients With COVID-19: Active Monitoring in Two Italian Health Units (Casale Monferrato and Torino)","Mon-Covid","Recruiting","No Results Available","COVID-19","Other: home care monitoring","SpO2|in-hospital mortality|need of intubation|feasibility of active monitoring","Mario Negri Institute for Pharmacological Research","All","18 Years and older   (Adult, Older Adult)","Not Applicable","425","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","Mon-Covid","April 21, 2020","October 31, 2020","December 31, 2020","April 24, 2020",,"April 24, 2020","Asl Alessandria, Casale Monferrato, Alessandria, Italy",,"https://ClinicalTrials.gov/show/NCT04361916"
391,"NCT04350450","Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore",,"Withdrawn","No Results Available","COVID|Coronavirus|COVID-19","Drug: Hydroxychloroquine","Time to resolution of symptoms|Number of days from onset of illness to symptom resolution|Number of days to return to work|Rate of hospital admission in treated and untreated healthcare workers|Adverse effect of HCQ during treatment","Montefiore Medical Center","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-11445","April 2020","August 2020","August 2020","April 17, 2020",,"May 27, 2020","Montefiore Medical Center, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT04350450"
392,"NCT04348877","Plasma Rich Antibodies From Recovered Patients From COVID19","PRA-001","Not yet recruiting","No Results Available","Coronavirus Disease (COVID-19)","Other: Antibody-Rich Plasma from COVID-19 recovered patients","viral COVID-19 clearance|Decrease of radiological abnormalities|Clinical improvement","Ain Shams University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FMASU P15/ 2020","April 20, 2020","October 2020","December 2020","April 16, 2020",,"April 20, 2020","Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt",,"https://ClinicalTrials.gov/show/NCT04348877"
393,"NCT04359654","Nebulised Dornase Alfa for Treatment of COVID-19","COVASE","Not yet recruiting","No Results Available","COVID19|Hypoxia","Drug: Dornase Alfa Inhalation Solution [Pulmozyme]","Measuring the change in inflammation|Number of patients that are alive at 28 days|Amount of days that patient requires oxygen|Average oxygenation index|Days patient admitted to hospital|Percentage of patients that need mechanical ventilation","University College, London","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","132333","May 1, 2020","August 1, 2020","November 1, 2020","April 24, 2020",,"April 30, 2020","University College London Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04359654"
394,"NCT04362085","Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care",,"Recruiting","No Results Available","COVID-19","Drug: Therapeutic Anticoagulation","Composite outcome of ICU admission (yes/no), non-invasive positive pressure ventilation (yes/no), invasive mechanical ventilation (yes/no), or all-cause death (yes/no) up to 28 days.|All-cause death|Composite outcome of ICU admission or all-cause death|Major bleeding|Number of participants who received red blood cell transfusion|Number of participants with transfusion of platelets, frozen plasma, prothrombin complex concentrate, cryoprecipitate and/or fibrinogen concentrate.|Number of hospital-free days alive up to day 28|Number of ICU-free days alive up to day 28|Number of ventilator-free days alive up to day 28|Number of participants with venous thromboembolism|Number of participants with arterial thromboembolism|Number of participants with heparin induced thrombocytopenia|Changes in D-dimer up to day 3","St. Michael's Hospital, Toronto|University of Vermont Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 3","462","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RAPID COVID-COAG","May 11, 2020","November 2020","December 2020","April 24, 2020",,"May 15, 2020","St. Michael's Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04362085"
395,"NCT04344145","Exhaustion and Needs in Frontline COVID-19 Healthcare Workers: Cross-sectional Study in a Belgian Population",,"Completed","No Results Available","COVID-19",,"Burnout|Emotional Distress|Insomnia|Needs and difficulties in work situations","Université Libre de Bruxelles","All","18 Years and older   (Adult, Older Adult)",,"693","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","PSY-ENCOVID19","April 16, 2020","May 25, 2020","May 29, 2020","April 14, 2020",,"June 11, 2020","Hôpital de Warquignies, Boussu, Hainaut, Belgium|Hôpital de Jolimont, Haine-Saint-Paul, Hainaut, Belgium|Hôpital de Lobbes, Lobbes, Hainaut, Belgium|Hôpital de Mons, Mons, Hainaut, Belgium|Erasme Hospital CUB, Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT04344145"
396,"NCT04409847","COVID-19 Blood Pressure Endothelium Interaction Study (OBELIX)","OBELIX","Not yet recruiting","No Results Available","COVID|Hypertension","Diagnostic Test: ABPM|Diagnostic Test: ECG|Diagnostic Test: FMD|Diagnostic Test: PWV|Diagnostic Test: Rarefaction","ABPM systolic blood pressure|24-hr ABPM DBP|day ABPM SBP|day ABPM DBP|night ABPM SBP|night ABPM DBP|dipping status|morning surge|24 hour ABPM HR|day ABPM HR|night ABPM HR","NHS Greater Glasgow and Clyde|University of Glasgow","All","30 Years to 60 Years   (Adult)",,"70","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","GN20CA245","June 1, 2020","December 31, 2020","May 31, 2021","June 1, 2020",,"June 1, 2020","NHS Greater Glasgow and Clyde, Glasgow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04409847"
397,"NCT04362865","Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection",,"Recruiting","No Results Available","COVID-19",,"Characterize immune response|B- and T-cell arm immune response|Immune response and outcome","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"150","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","200103|20-C-0103","April 27, 2020","December 1, 2023","December 1, 2024","April 27, 2020",,"June 23, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04362865"
398,"NCT04426695","Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: REGN10933+REGN10987 combination therapy|Drug: Placebo","Proportion of patients with treatment-emergent Serious Adverse Events (SAEs)|Proportion of patients with infusion-related reactions|Proportion of patients with hypersensitivity reactions|Time-weighted average change from baseline viral shedding as measured by quantitative reverse transcription polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples|Time-weighted average change from baseline viral shedding as measured by RT-qPCR in saliva samples|Proportion of patients with at least 1-point improvement on a 7-Point Ordinal Scale in clinical status|Time-weighted average change from baseline viral shedding as measured by RT-qPCR in nasal samples|Time to negative RT-qPCR in all tested samples with no subsequent positive RT-qPCR in any tested samples|Change from baseline in SARS-CoV-2 viral shedding as measured by RT-qPCR in NP swabs|Change from baseline in SARS-CoV-2 viral shedding as measured by RT-qPCR in saliva samples|Change from baseline in SARS-CoV-2 viral shedding as measured by RT-qPCR in nasal swabs|Proportion of patients with at least 2-point improvement on a 7-Point Ordinal Scale in clinical status|Time to no longer requiring oxygen supplementation|Number of days of supplemental oxygen use|Proportion of patients initiating high-intensity oxygen therapy|Number of days of high-intensity oxygen therapy|Proportion of patients initiating mechanical ventilation|Number of days of mechanical ventilation|Number of Ventilator-free days|Number of days of hospitalization|Proportion of patients re-admitted to hospital after discharge through the end of study|Number of deaths due to any cause (All-Cause Mortality)|Overall Survival|Serum concentration of REGN10933 over time|Serum concentration of REGN10987 over time|Incidence of anti-drug antibodies (ADA) to REGN10933|Incidence of anti-drug antibodies (ADA) to REGN10987|Assessment of pharmacokinetic (PK) parameter: maximum serum concentration observed (Cmax) of REGN10933|Assessment of PK parameter: maximum serum concentration observed (Cmax) of REGN10987|Assessment of PK parameter: Cmax-to-dose ratio (Cmax/dose) for REGN10933|Assessment of PK parameter: Cmax-to-dose ratio (Cmax/dose) for REGN10987|Assessment of PK parameter: Time to Cmax (tmax) for REGN10933|Assessment of PK parameter: Time to Cmax (tmax) for REGN10987|Assessment of PK parameter: Area Under the Curve (AUC) computed from time zero to the time of the last positive concentration (AUClast) for REGN10933|Assessment of PK parameter: AUC computed from time zero to the time of the last positive concentration (AUClast) for REGN10987|Assessment of PK parameter: AUC from time zero extrapolated to infinity (AUCinf) for REGN10933|Assessment of PK parameter: AUC from time zero extrapolated to infinity (AUCinf) for REGN10987|Assessment of PK parameter: AUCinf-to-dose ratio (AUCinf/dose) of REGN10933|Assessment of PK parameter: AUCinf-to-dose ratio (AUCinf/dose) of REGN10987|Assessment of PK parameter: Observed terminal half-life [t1/2] for REGN10933|Assessment of PK parameter: Observed terminal half-life [t1/2] of REGN10987|Assessment of PK parameter: Clearance (CL) for REGN10933|Assessment of PK parameter: Clearance (CL) of REGN10987|Assessment of PK parameter: Volume of distribution at steady state (Vss) of REGN10933|Assessment of PK parameter: Volume of distribution at steady state (Vss) of REGN10987|Assessment of PK parameter: Mean residence time (MRT) of REGN10933|Assessment of PK parameter: Mean residence time (MRT) of REGN10987","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","1860","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R10933-10987-COV-2066","June 10, 2020","March 3, 2021","March 3, 2021","June 11, 2020",,"June 26, 2020","Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Saint Louis, Missouri, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Tyler, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04426695"
399,"NCT04370808","VITACOV: Vitamin D Polymorphisms and Severity of COVID-19 Infection","VITACOV","Not yet recruiting","No Results Available","COVID-19","Other: Exposure","Differences in vitamin D blood levels between COVID-19 patients with different degrees of disease severity.|Differences in genetic variants in vitamin D-related genes between COVID-19 patients with different degrees of disease severity.|Differences in vitamin D blood levels between COVID-19 patients in relation to mortality.|Differences in vitamin D blood levels between COVID-19 patients in relation to length of stay in hospitals.|Differences in vitamin D blood levels between COVID-19 patients in relation to duration of mechanical ventilation.|Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to mortality.|Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to length of stay in hospitals.|Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to duration of mechanical ventilation.","University of Lisbon|Cardiovascular Centre of Universidade de Lisboa (CCUL)|Faculty of Medicine of Universidade de Lisboa (FMUL)|Centro Hospitalar Universitário Lisboa Norte (CHULN)|Centro Hospitalar Universitário São João (CHUSJ)|CINTESIS - Center for Health Technology and Services Research|NOVA Medical School of Universidade NOVA de Lisboa|HeartGenetics, Genetics and Biotechnology SA|Instituto Gulbenkian de Ciência (IGC)","All","18 Years and older   (Adult, Older Adult)",,"500","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","VITACOV","June 2020","October 2020","March 2021","May 1, 2020",,"May 19, 2020","Cardiovascular Center at Universidade de Lisboa, Lisbon, Lisboa, Portugal|Centro Hospitalar Universitário Lisboa Norte, Lisbon, Lisboa, Portugal|Centro Hospitalar de São João, Oporto, Portugal",,"https://ClinicalTrials.gov/show/NCT04370808"
400,"NCT04394026","Imaging Feature of SARS-CoV2 Infection","COVID19IF","Recruiting","No Results Available","Viral Pneumonia|COVID",,"Describe qualitative and quantitative variables|Ability of imaging to predict disease progression|Ability of imaging to predict disease evolution|Imaging findings and demographic data|Imaging findings and laboratory exams","Francesco De Cobelli|IRCCS San Raffaele","All","Child, Adult, Older Adult",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Other","COVID-19 IF","April 16, 2020","August 31, 2020","October 1, 2020","May 19, 2020",,"May 19, 2020","Deaprtment of Radiology, IRCCS Ospedale San Raffaele, Milano, Italy",,"https://ClinicalTrials.gov/show/NCT04394026"
401,"NCT04329650","Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia",,"Recruiting","No Results Available","COVID-19","Drug: Siltuximab|Drug: Methylprednisolone","Proportion of patients requiring ICU admission at any time within the study period.|Days of stay in the ICU during the study period.|Days until resolution of fever defined as body temperature (axillary ≤ 36.6 ° C, oral ≤ 37.2 ° C, or rectal or tympanic ≤ 37.8 ° C) for at least 48 hours, without administration of antipyretics or until hospital discharge.|Proportion of patients with a worsening requirement of supplemental oxygen at 29 days. days.|Days with hypoxemia (SpO2 <93% in ambient air or requiring oxygen supplemental or mechanical ventilation support) at 29 days.|Proportion of patients using mechanical ventilation at 29 days.|Days with use of mechanical ventilation at 29 days.|Days until the start of use of mechanical ventilation, non-invasive ventilation or use of high flow nasal cannula (if the patient have not previously required these interventions at the inclusion of the study) at 29 days.|Days of hospitalization among survivors at 29 days.|Mortality rate from any cause at 29 days.|Proportion of patients with serious adverse events at 29 days.|Proportion of patients with invasive bacterial or fungal infections clinically significant or opportunistic with grade 4 neutropenia (count neutrophil absolute <500 / mm3) at 29 days.|Proportion of patients with invasive bacterial or fungal infections clinically significant or opportunistic at 29 days.|Proportion of patients with grade 2 or higher adverse reactions related to the infusion of the sudy treatments at 29 days.|Proportion of patients with hypersensitivity reactions of grade 2 or higher related to the administration of the study treatments at 29 days.|Proportion of patients with gastrointestinal perforation at 29 days.|Proportion of patients with secondary severe infections confirmed by laboratory or worsening of existing infections at 29 days.|Changes from baseline in plasma leukocyte levels at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma hemoglobin levels at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma platelet at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma creatinine levels at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma total bilirubin levels at days 1, 3, 5, 7 and 9.|Proportion of patients with ALT≥ 3 times ULN (for patients with initial values normal) or> 3 times ULN AND at least 2 times more than the initial value (for patients with abnormal initial values) at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma biomarkers (PCR, lymphocytes, ferritin, d-dimer and LDH) at days 1, 3, 5, 7 and 9.|Changes from baseline in chest Rx at days 1, 3 and 5.","Judit Pich Martínez|Fundacion Clinic per a la Recerca Biomédica","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SILCOR-COVID-19","April 15, 2020","May 20, 2020","May 20, 2020","April 1, 2020",,"April 17, 2020","Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitari Mútua de Terrassa, Terrassa, Spain",,"https://ClinicalTrials.gov/show/NCT04329650"
402,"NCT04434157","Association of the Neutrophil/Lymphocyte Ratio With Clinical Complications and Mortality in COVID-19 Patients",,"Completed","No Results Available","Covid-19",,"Clinical complications and Mortality|Neutrophil-Lymphocyte and Lymphocyte-Platelet ratio","Hospital Regional de Alta especialidad de Ixtapaluca|Hospital General de México Dr. Eduardo Liceaga","All","Child, Adult, Older Adult",,"221","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","NR-09-2020","March 28, 2020","May 5, 2020","May 5, 2020","June 16, 2020",,"June 16, 2020","Hospital Regional de Alta Especialidad de Ixtapaluca, Ixtapaluca, State Of Mexico, Mexico",,"https://ClinicalTrials.gov/show/NCT04434157"
403,"NCT04384497","Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study",,"Recruiting","No Results Available","COVID-19","Biological: SARS-CoV-2 convalescent plasma","Number and proportion of patients with progression to ventilation or sustained requirement of supplementary oxygen therapy|Adverse events|Dose of plasma needed to clear viremia|Clearance of viremia|Fever and symptoms|Inflammatory parameters|Antibody response to SARS-CoV-2","Joakim Dillner|Danderyd Hospital|Karolinska University Hospital|Karolinska Institutet","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CP2","May 7, 2020","June 2020","December 2020","May 12, 2020",,"May 27, 2020","Danderyd Hospital, Danderyd, Stockholm, Sweden|Karolinska University Hospital, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT04384497"
404,"NCT04443270","Chloroquine Phosphate Prophylactic Use in Health Personnel Exposed to COVID-19 Patients",,"Not yet recruiting","No Results Available","COVID-19","Drug: Chloroquine phosphate","Negative Polymerase Chain Reaction assay at day 0|Polymerase Chain Reaction assay at day 60|Clinical improvement related to COVID-19|Heart rhythm negative adverse event related to the Chloroquine Phosphate Prophylactic Use|Heart rhythm negative adverse event related to the Chloroquine Phosphate Prophylactic|COVID-19 symptomatic onset rate","CMN ""20 de Noviembre""","All","18 Years to 59 Years   (Adult)","Phase 1","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","01","June 22, 2020","August 31, 2020","November 30, 2020","June 23, 2020",,"June 23, 2020","Centro Médico Nacional ""20 de Noviembre"", Mexico City, Benito Juárez, Mexico",,"https://ClinicalTrials.gov/show/NCT04443270"
405,"NCT04354389","DAS181 for STOP COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: DAS181|Drug: Placebo","COVID-19 Clinical Classification (CCC)|Return to room air (RTRA)|Improved COVID-19 Clinical Classification|Return To Room Air (RTRA)|Death (all cause)|SARS-CoV-2 RNA undetectable|Percent of subjects discharged|Clinical Deterioration","Ansun Biopharma, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","82","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DAS181-3-02-EU|2020-001874-30","May 25, 2020","June 30, 2020","October 31, 2020","April 21, 2020",,"May 11, 2020","Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milano, Italy|A.O.U Policlinico Di Modena, Modena, Italy",,"https://ClinicalTrials.gov/show/NCT04354389"
406,"NCT04410354","Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Merimepodib|Drug: Matching Placebo|Drug: Remdesivir","Number of subjects not hospitalized or, if hospitalized, free of respiratory failure|Adverse Events|National Institute of Allergy and Infectious Disease (NIAID) 8-Point Ordinal Scale|Temperature|Death|Mechanical ventilation|Vasopressor Support|Oxygen Therapy|Cessation of Viral Shedding|Change in Oxygen Saturation/Fraction of Inspired Oxygen","ViralClear Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","VC-02-01","June 16, 2020","July 2020","August 2020","June 1, 2020",,"June 18, 2020","Mayo Clinic in Arizona, Phoenix, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States|Atlantic Health System / Morristown Medical Center, Morristown, New Jersey, United States|Atlantic Health System / Overlook Medical Center, Summit, New Jersey, United States|St. David's South Austin Medical Center, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04410354"
407,"NCT04374279","Trial to Promote Recovery From COVID-19 With Ivermectin or Endocrine Therapy","RECOVER","Not yet recruiting","No Results Available","COVID-19|SARS-CoV 2","Drug: Bicalutamide 150 Mg Oral Tablet|Drug: Ivermectin 3Mg Tab","Number of participants who have clinical improvement at day 7 after randomization|All-cause mortality|Duration of hospitalization|Percentage of patients needing upgrade to the intermediate care unit (IMC)|Duration of IMC stay|Percentage of patients needing upgrade to the intensive care unit (ICU)|Duration of ICU stay|Number of participants requiring mechanical ventilation|Duration of mechanical ventilation|Number of participants experiencing adverse events","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COV2003|IRB00249425","June 2020","June 2021","June 2021","May 5, 2020",,"May 5, 2020","Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04374279"
408,"NCT04407585","Testing the Accuracy of a Digital Test to Diagnose Covid-19",,"Recruiting","No Results Available","Covid-19","Diagnostic Test: Covid-19 swab PCR test","SARS-CoV-2 infection","King's College London|Zoe Global Limited|Department of Health, United Kingdom","All","18 Years and older   (Adult, Older Adult)",,"1000000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Covid-19 Validation Study","June 1, 2020","May 10, 2021","May 10, 2021","May 29, 2020",,"June 24, 2020","King's College London, London, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT04407585/SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04407585"
409,"NCT04402892","COVID-19: SARS-CoV-2 Specific Memory B and T-CD4+ Cells","MEMO-COV2","Not yet recruiting","No Results Available","COVID-19|SARS-CoV-2 Infection","Other: 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients )|Other: 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (cured Patients)","Immunological memory: resolution of COVID-19 after SARS-CoV2 infection.","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","APHP200551","June 1, 2020","March 1, 2021","March 1, 2021","May 27, 2020",,"May 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04402892"
410,"NCT04324996","A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19",,"Recruiting","No Results Available","COVID-19","Biological: NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells","Clinical response|Side effects in the treatment group","Chongqing Public Health Medical Center|Chongqing Sidemu Biotechnology Technology Co.,Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ChongqingPublicHMC","March 21, 2020","May 31, 2020","September 30, 2020","March 27, 2020",,"March 27, 2020","Chongqing Public Health Medical Center, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT04324996"
411,"NCT04360733","Precision Immunology to Determine the Immune Response in Patients With COVID-19",,"Recruiting","No Results Available","SARS-CoV 2|COVID","Other: Blood draw","Immune response","University of Bonn","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Other|Time Perspective: Prospective","BOST-03","April 20, 2020","April 2022","September 2022","April 24, 2020",,"April 24, 2020","University Hospital Bonn, Bonn, Germany",,"https://ClinicalTrials.gov/show/NCT04360733"
412,"NCT04433013","A Randomized Controlled Trial Assessing the Efficacy of Lianhua Qingwen as an Adjuvant Treatment in Patients With Mild Symptoms of COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Lianhua Qingwen|Drug: Placebo","Proportion of participants who test negative for COVID-19|Time taken in days for relief of clinical symptoms|Proportion of participants with mild symptoms of COVID-19 progressing to moderate or severe illness|Proportion of participants who test positive for COVID-19 with Ct value>30","Nanyang Technological University|Ministry of Health, Singapore","All","21 Years and older   (Adult, Older Adult)","Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","IRB-2020-05-029","July 2020","December 2020","February 2021","June 16, 2020",,"June 17, 2020",,,"https://ClinicalTrials.gov/show/NCT04433013"
413,"NCT04359290","Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS","RuXoCoil","Not yet recruiting","No Results Available","ARDS, Human|COVID","Drug: Ruxolitinib administration","Overall survival|Assessment of the duration of ventilation support|cytokine storm|time on ICU|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|time frame for seroconversion under ruxolitinib treatment (SARS-Co-19- IgG)|pulmonary function assessed by a CT scan|overall survival","Philipps University Marburg Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KKS-278","May 2020","September 2020","November 2020","April 24, 2020",,"April 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04359290"
414,"NCT04380688","Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.","CALAVI US","Not yet recruiting","No Results Available","COVID-19","Drug: Acalabrutinib","Occurrence of Adverse Events and Serious Adverse Events|Subject alive and free of respiratory failure|Proportion of subjects alive and free of respiratory failure|Percent change from baseline in CRP|Change from baseline in ferritin|Change from baseline in absolute lymphocyte counts|All cause mortality|Proportion of subjects alive and discharged from ICU|Time from randomization to first occurrence of respiratory failure or death on study due to any cause|Number of days alive and free of respiratory failure|Number of days with respiratory failure|Number of days hospitalized|Number of days in ICU (length of stay)|Number of days alive outside of hospital|Relative change from baseline in oxygenation index (PaO2/FiO2)|Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862 (Cmax)|Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862 (Tmax)|Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862 (AUC)","AstraZeneca|Acerta Pharma B.V.","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 2","60","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D822FC00003","May 12, 2020","September 30, 2020","September 30, 2020","May 8, 2020",,"May 8, 2020","Research Site, Washington, District of Columbia, United States|Research Site, Louisville, Kentucky, United States|Research Site, Baltimore, Maryland, United States|Research Site, Bethesda, Maryland, United States|Research Site, Bethesda, Maryland, United States|Research Site, Hackensack, New Jersey, United States|Research Site, Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT04380688"
415,"NCT04346199","Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.","CALAVI","Not yet recruiting","No Results Available","COVID-19","Drug: Acalabrutinib","Subject alive and free of respiratory failure|Proportion of subjects alive and free of respiratory failure|Percent change from baseline in CRP|Change from baseline in ferritin|Chnage from baseline in absolute lymphocyte counts|All cause mortality|Proportion of subjects alive and discharged from ICU|Time from randomization to first occurrence of respiratory failure or death on study due to any cause|Number of days alive and free of respiratory failure|Number of days with respiratory failure|Number of days hospitalized|Number of days in ICU (length of stay)|Number of days alive outside of hospital|Relative change from baseline in oxygenation index (PaO2/FiO2)|Occurrence of Adverse Events and Serious Adverse Events|Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862 (Cmax)|Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862 (Tmax)|Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862 (AUC)","AstraZeneca|Acerta Pharma B.V.","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 2","140","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D822FC00001","May 11, 2020","November 30, 2020","November 30, 2020","April 15, 2020",,"May 11, 2020","Research Site, Bobigny, France|Research Site, Villejuif Cedex, France|Research Site, Bologna, Italy|Research Site, Firenze, Italy|Research Site, Milano, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Fuenlabrada, Spain|Research Site, Madrid, Spain|Research Site, Mérida, Spain|Research Site, Pozuelo de Alarcón, Spain",,"https://ClinicalTrials.gov/show/NCT04346199"
416,"NCT04381884","Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19",,"Recruiting","No Results Available","COVID-19 Drug Treatment","Drug: IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.","Reduction in SARS-CoV-2 viral load|Number of patients with partial or complete response in COVID-19 clinical symptoms|Number of patients with worsening in the clinical condition|Number of patients with adverse events as a measure of safety and tolerability|Ivermectin concentrations measured in plasma|Evaluation of reactivity of the antibodies against SARS-CoV-2","Laboratorio Elea Phoenix S.A.|Universidad Nacional de Salta|Centro de Investigación Veterinaria Tandil CIVETAN|Hospital de Pediatría Prof Dr. Juan P. Garrahan|Universidad Nacional de Quilmes","All","18 Years to 69 Years   (Adult, Older Adult)","Phase 2","45","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IVM-AR-1","May 18, 2020","June 30, 2020","June 30, 2020","May 11, 2020",,"May 27, 2020","Centro de Educación Médica e Investigaciones Clínicas ""Norberto Quirno"" CEMIC, Buenos Aires, Ciudad De Buenos Aires, Argentina",,"https://ClinicalTrials.gov/show/NCT04381884"
417,"NCT04397822","COVID-19: Study of INFLAmmasome and PLAtelets Functions","CO-QUETTES","Recruiting","No Results Available","COVID-19","Biological: Blood samples","Activation of platelet NLRP3 inflammasome","University Hospital, Toulouse","All","18 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RC31/20/0142","April 16, 2020","October 2020","April 2021","May 21, 2020",,"May 21, 2020","CHU Toulouse, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT04397822"
418,"NCT04409184","Whole Blood Collection From Individuals in the Convalescent Phase of SARS-CoV-2 Infection",,"Not yet recruiting","No Results Available","COVID|Sars-CoV2",,"Characterization of specific T cell responses in peripheral blood isolated from patients that have been exposed to SARS-CoV-2.","Medical College of Wisconsin|Versiti","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","PRO00037957","May 2020","May 2021","May 2021","June 1, 2020",,"June 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04409184"
419,"NCT04367896","COVID-19 OUTBREAK AND SOLID ORGAN TRANSPLANTATION (SOT) : AN INTERNATIONAL WEB-BASED SURVEY",,"Completed","No Results Available","COVID-19 OUTBREAK AND SOLID ORGAN TRANSPLANTATION","Other: Survey Group","Management of Solid Organ Transplant during COVID-19 pandemic|Equity of resource distribution|Equity rank of resource distribution","Fondazione Policlinico Universitario Agostino Gemelli IRCCS",,"Child, Adult, Older Adult",,"1819","Other","Observational","Observational Model: Other|Time Perspective: Prospective","Covid-19_V1","March 24, 2020","April 17, 2020","April 17, 2020","April 29, 2020",,"April 29, 2020","Fondazione Policlinico Universitario ""Agostino Gemelli"", Rome, Italy",,"https://ClinicalTrials.gov/show/NCT04367896"
420,"NCT04346797","CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort","CORIMUNO19-ECU","Recruiting","No Results Available","SARS-CoV-2|COVID19","Drug: Eculizumab","Survival without needs of intubation at day 14|Change in organ failure at day 3|Intubation free survival at day 14|WHO progression scale at days 4, 7 and 14|Survival at 14, 28 and 90 days|Time to discharge|Time to oxygen supply independency|Time to negative viral excretion|Incidence of secondary infections|Vasopressor-free survival|Ventilator-free survival|28-day ventilator-free days|Incidence of dialysis|PaO2/FiO2 ratio|Rate of respiratory acidosis at day 4|Time to ICU discharge","Assistance Publique - Hôpitaux de Paris","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200375-4","April 16, 2020","September 30, 2020","December 31, 2020","April 15, 2020",,"April 27, 2020","Saint Louis, Paris, Ile De France, France|Réanimation médicale, Paris, France|saint Louis, Paris, France",,"https://ClinicalTrials.gov/show/NCT04346797"
421,"NCT04421404","Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients","CAPRI","Recruiting","No Results Available","COVID-19|Sars-CoV2","Biological: COVID-19 Convalescent Plasma (CCP)|Biological: Placebo","Severe Hypoxemic Respiratory Failure Endpoint|8-Point Ordinal Scale Endpoint","Priscilla Hsue, MD|Blood Systems Research Institute|San Francisco General Hospital|University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20-30794","June 8, 2020","April 30, 2021","April 30, 2021","June 9, 2020",,"June 16, 2020","San Francisco General Hospital, San Francisco, California, United States|UCSF Medical Center at Mount Zion, San Francisco, California, United States|University of California, San Francisco Medical Center (Parnassus Campus), San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT04421404"
422,"NCT04352582","COVID-19 and Vaccination Attitudes","VACAT","Recruiting","No Results Available","COVID-19","Other: Survey","How vaccination and other attitudes are affected by COVID","University Hospital, Geneva|University of Zurich|University of Lausanne","All","Child, Adult, Older Adult",,"1000","Other","Observational","Observational Model: Other|Time Perspective: Prospective","VACAT","April 14, 2020","April 30, 2020","April 30, 2020","April 20, 2020",,"April 20, 2020","Survey, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04352582"
423,"NCT04449588","Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS",,"Recruiting","No Results Available","COVID-19 Pneumonia","Drug: BDB-001 Injection|Other: Conventional treatment","Time to recovery of peripheral capillary oxygen saturation (SpO2) from baseline|28-day all-cause mortality rate|Percentage of subjects achieving recovery in SpO2|Mean change of PaO2/FiO2|Mechanical ventilation time|Time of oxygen therapy|Lymphocyte count|Change in inflammation indicators (CRP or IL-6) from baseline|Improvement in body temperature|Mean change from baseline in the clinical improvement based on ordinal scale recommended by the WHO R&D Blueprint during treatment period|Improvement at Day3, 7, 11 & Day14 based on ordinal scale recommended by the WHO R&D Blueprint during treatment period|Time to get categories 1 to 4 in the 8-points ordinal scale|Time to attain an improvement of 1 point on the ordinal scale","Staidson (Beijing) Biopharmaceuticals Co., Ltd|Beijing Defengrui Biotechnology Co. Ltd","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","368","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STS-BDB001-04","July 10, 2020","August 7, 2021","August 7, 2022","June 29, 2020",,"June 29, 2020","Southwest Hospital Chongqing, Chongqing, Chongqing, China|RSUP Persahabatan(Persahabatan General Hospital), East Jakarta, Jakarta, Indonesia|RSUD Pasar Minggu(Pasar Minggu General Hospital), South Jakarta, Jakarta, Indonesia|RSUD Cengkareng(Cengkareng General Hospital), West Jakrata, Jakrata, Indonesia",,"https://ClinicalTrials.gov/show/NCT04449588"
424,"NCT04433000","Reliability of a Pocket Sized Ultrasound Scanner in the Evaluation Covid-19 Pneumonia","USCovid","Recruiting","No Results Available","Covid-19 Pneumonia","Diagnostic Test: Butterfly","Bland-Altman estimate of bias and Limits of Agreement (LoA) of patient mean scores obtained with the two instruments","University of Siena","All","Child, Adult, Older Adult",,"34","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","USCovid","March 15, 2020","June 10, 2020","June 10, 2020","June 16, 2020",,"June 16, 2020","Azienda Ospedaliera Universitaria Senese, Siena, Si, Italy",,"https://ClinicalTrials.gov/show/NCT04433000"
425,"NCT04351646","Diagnostics of COVID-19/DARTS (Development and Assessment of Rapid Testing for SARS-CoV-2 Outbreak)",,"Not yet recruiting","No Results Available","COVID-19",,"Antibody titres to SARS-CoV-2","St George's, University of London","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020.0075","April 15, 2020","April 15, 2022","April 15, 2022","April 17, 2020",,"April 17, 2020","St. Georges Hospital Foundation Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04351646"
426,"NCT04362345","Clinical Features and Risk Factors Associated With Worse Outcome in Patients Hospitalized for Covid-19 Pneumonia",,"Recruiting","No Results Available","Covid-19",,"Identification of risk factors for severity (death or transfer to resuscitation) of Covid-19 infection","University Hospital, Strasbourg, France","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Other","7773","April 9, 2020","May 17, 2020","May 17, 2020","April 24, 2020",,"April 30, 2020","Service des Maladies Infectieuses et Tropicales, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT04362345"
427,"NCT04328012","COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2","COVIDMED","Recruiting","No Results Available","SARS-CoV-2 Infection","Drug: lopinavir/ritonavir|Drug: Hydroxychloroquine Sulfate|Drug: Losartan|Drug: Placebos","National Institute of Allergy and Infectious Diseases COVID-19 Ordinal Severity Scale (NCOSS)|Hospital length of stay (LOS)|Intensive care unit level LOS|Mechanical ventilation|survival","Bassett Healthcare","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","4000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1581969","April 6, 2020","January 1, 2021","April 1, 2021","March 31, 2020",,"April 8, 2020","Bassett Medical Center, Cooperstown, New York, United States",,"https://ClinicalTrials.gov/show/NCT04328012"
428,"NCT04418375","Establishment of a Biological Collection During COVID-19 Serological Screening in APHP Professionals (COVID-HOP)","COVID-HOP","Not yet recruiting","No Results Available","COVID-19",,"Identification of markers associated with asymptomatic COVID + status (results of the serological test) versus symptomatic COVID + status through a questionnaire (medical history, work environment, lifestyle) and a biological collection|Identification of markers associated with a positive or a negative serology through a questionnaire (medical history, work environment, lifestyle) and a biological collection|Description of the serological status according to the professional risk of exposure to the virus|Description of the clinical manifestations of COVID-19 infection in hospital professionals|Identification of risk factors associated with the loss of anti SARS-CoV-2 immunity through a questionnaire (medical history, work environment, lifestyle) and a biological collection|Identification of markers associated with symptomatic COVID-19 infection during follow-up despite the presence of anti SARS-CoV-2 antibodies through a questionnaire (medical history, work environment, lifestyle) and a biological collection|Correlation between the serology result and the PCR result (swabs) for people who have been tested as part of routine care.|Identification of potential therapeutic targets to avoid developing a symptomatic form|Identification of potential therapeutic targets to promote the maintenance of an anti SARS-CoV2 protective immunity|Creation of COVIDneg and COVID + asymptomatic control groups for other COVID-19 biological collections.","Assistance Publique - Hôpitaux de Paris|Fondation Université de Paris|Fondation Hôpitaux de Paris-Hôpitaux de France","All","18 Years and older   (Adult, Older Adult)",,"4000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","APHP200609|2020-A01364-35","June 2020","February 2021","March 2022","June 5, 2020",,"June 5, 2020",,,"https://ClinicalTrials.gov/show/NCT04418375"
429,"NCT04333355","Safety in Convalescent Plasma Transfusion to COVID-19",,"Recruiting","No Results Available","COVID-19","Biological: Convalescent Plasma","Side effects|Heart Failure|Pulmonary Edema|Allergic Reaction|Viral load of SARS-CoV-2","Hospital San Jose Tec de Monterrey|Tecnologico de Monterrey","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PC-TecSalud Fase I","May 25, 2020","December 20, 2020","April 30, 2021","April 3, 2020",,"May 8, 2020","Hospital San José, Monterrey, Nuevo Leon, Mexico",,"https://ClinicalTrials.gov/show/NCT04333355"
430,"NCT04359615","Favipiravir in Hospitalized COVID-19 Patients","FIC","Not yet recruiting","No Results Available","COVID-19","Drug: Favipiravir|Drug: Hydroxychloroquine","Time to clinical improvement|Mortality|oxygen saturation by pulse oximetry (SpO2) Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events","Shahid Beheshti University of Medical Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Favipiravir in COVID-19","April 20, 2020","May 3, 2020","May 5, 2020","April 24, 2020",,"April 28, 2020","Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04359615"
431,"NCT04411147","A Longitudinal Study of COVID-19 Sequelae and Immunity",,"Recruiting","No Results Available","COVID-19",,"Medical Sequelae in COVID- 19 Survivors|Risk Factors for Medical Sequelae in COVID-19 Survivors|Antibody and cell-mediated immune responses to SARSCoV-2|Antibody and cell-mediated immune responses to SARSCoV-2 over time|Incidence of reinfection with COVID-19|Incidence of clinical silent infection|Mental health status in COVID-19 survivors and contacts","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"900","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","200123|20-I-0123","June 17, 2020","December 31, 2025","December 31, 2027","June 2, 2020",,"June 29, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04411147"
432,"NCT04344015","COVID-19 Plasma Collection",,"Recruiting","No Results Available","COVID-19","Other: Plasma Donation","Number of patients who screen eligible for donation|Number of patients who consent to plasma donation|Number of plasma donations received|Safety of donation procedures","Thomas Jefferson University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2000","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","20D.346","April 13, 2020","April 12, 2021","April 12, 2021","April 14, 2020",,"May 11, 2020","Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04344015"
433,"NCT04364828","NGS Diagnostic in COVID-19 Hosts - Genetic Cause Relating to the Course of Disease Progression","COVID-19 NGS","Not yet recruiting","No Results Available","COVID-19","Genetic: Whole Genome Analysis|Genetic: T-cell receptor (TCR) repertoire|Genetic: SARS-CoV-2 viral composition","Viral evolution|Immune response|Disease severity","University Hospital Tuebingen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","COVID-19 NGS","April 2020","April 2021","August 2021","April 28, 2020",,"May 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04364828"
434,"NCT04364815","The University of the Philippines Hydroxychloroquine PEP Against COVID-19 Trial",,"Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine plus standard preventive measures|Drug: Placebo plus standard preventive measures","Efficacy of HCQ Prophylaxis in Preventing COVID-19 infection|Efficacy of study drug as post-exposure prophylaxis in preventing COVID-19 related symptoms (to be reported as absolute number and frequency of events)|Time to COVID-19 infection in patients receiving study drug (in days)|Safety and tolerability of study drug (to be reported as absolute number and frequency of events)","University of the Philippines","All","18 Years to 59 Years   (Adult)","Phase 3","960","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","RGAO-2020-0339","May 2020","May 2021","May 2021","April 28, 2020",,"May 5, 2020",,,"https://ClinicalTrials.gov/show/NCT04364815"
435,"NCT04355936","Telmisartan for Treatment of COVID-19 Patients",,"Recruiting","No Results Available","COVID-19 Drug Treatment","Drug: Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.","C reactive protein|Number of opacified quadrants on lung Rx|Occurrence of mechanical ventilation|Intensive care unit admission|Death|LDH|Troponin|Time to mechanical ventilation","Laboratorio Elea Phoenix S.A.|Carlos R. Rojo, MD","All","18 Years and older   (Adult, Older Adult)","Phase 2","400","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-001","May 19, 2020","October 1, 2020","October 1, 2020","April 21, 2020",,"June 4, 2020","Hospital de Clínicas 'José de San Martín', Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Ciudad De Buenos Aires, Argentina",,"https://ClinicalTrials.gov/show/NCT04355936"
436,"NCT04392245","Proctologic Practice and Covid-19","PROCTOLOCK","Completed","No Results Available","Proctologic Practice During COVID-19",,"Predictive power of respondents' and hospitals' demographics on the change of status of proctologic surgical and outpatient activities","Societa Italiana di Chirurgia ColoRettale|Gaetano Gallo|Alessandro Sturiale|Veronica De Simone|Gian Luca Di Tanna|Iacopo Giani|Ugo Grossi","All","Child, Adult, Older Adult",,"1050","Other","Observational","Observational Model: Other|Time Perspective: Prospective","1.0","April 15, 2020","April 26, 2020","April 26, 2020","May 18, 2020",,"May 18, 2020","Gallo Gallo, Catanzaro, Italy",,"https://ClinicalTrials.gov/show/NCT04392245"
437,"NCT04359316","Azithromycin in Hospitalized COVID-19 Patients","AIC","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin","Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events","Shahid Beheshti University of Medical Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Azithromycin in COVID-19","April 20, 2020","May 3, 2020","May 5, 2020","April 24, 2020",,"April 24, 2020","Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04359316"
438,"NCT04358809","Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically Ill",,"Not yet recruiting","No Results Available","COVID-19","Drug: Suspension of heat killed (autoclaved) Mycobacterium w|Other: Placebo","Number of patients with increased disease severity|Incidence of adverse events and serious adverse events (Safety)|Number of COVID-19 patients discharged from hospital|Number of COVID-19 patients transfer to ICU|Number of COVID-19 patients with reduction in disease severity by 1 ordinal scale|Number of of symptom free patients","Cadila Pharnmaceuticals|Council of Scientific and Industrial Research, India","All","18 Years and older   (Adult, Older Adult)","Phase 3","480","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CRSC20006","April 30, 2020","February 28, 2021","April 30, 2021","April 24, 2020",,"April 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04358809"
439,"NCT04428008","Thymosin Alpha 1 to Prevent COVID-19 Infection in Elderly Renal Dialysis Patients","Ta1","Not yet recruiting","No Results Available","COVID-19","Drug: Thymalfasin","Reduction in documented infection with COVID-19 Reduction in infection with COVID-19|Need for hospitalization|Hospital length of stay|Need for ICU admission|ICU length of stay|Need for mechanical ventilation|Duration of mechanical ventilation|Recovery time from COVID-19|Change in any existing comorbidities or occurrence of newly diagnosed disease|Incidence of non-COVID-19 infections|Change in lymphocyte subsets (CD4, CD8)|Mortality|Treatment-emergent adverse events|Treatment-emergent changes in vital signs|Treatment-emergent laboratory parameters","Inova Health System|Nephrology Associates of Northern Virginia, Inc.|Davita Clinical Research","All","60 Years and older   (Adult, Older Adult)","Phase 2","240","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ACW-1221958-1","June 2020","January 2021","June 2021","June 11, 2020",,"June 17, 2020",,,"https://ClinicalTrials.gov/show/NCT04428008"
440,"NCT04343768","An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial","COVIFERON","Completed","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir|Drug: Interferon Beta-1A|Drug: Interferon Beta-1B","Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization","Shahid Beheshti University of Medical Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Different Interferons in COVID","April 9, 2020","April 27, 2020","April 27, 2020","April 13, 2020",,"May 5, 2020","Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04343768"
441,"NCT04382846","Novel Regimens in COVID-19 Treatment",,"Not yet recruiting","No Results Available","COVID|Corona Virus Infection","Drug: Nitazoxanide|Drug: Ivermectin|Drug: Chloroquine|Drug: Azithromycin","Number of patients with virological cure","Tanta University","All","18 Years and older   (Adult, Older Adult)","Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","tanta covid treatment","May 8, 2020","December 1, 2030","December 1, 2030","May 11, 2020",,"May 11, 2020",,,"https://ClinicalTrials.gov/show/NCT04382846"
442,"NCT04349592","Qatar Prospective RCT Of Therapy Eliminating Covid Transmission","Q-PROTECT","Not yet recruiting","No Results Available","Covid19","Drug: Hydroxychloroquine + Azithromycin|Drug: Hydroxychloroquine + Placebo|Other: Placebo + Placebo","Proportion of virologically cured (no virus detected) cases at day 6|The dichotomous virologic shedding endpoint as assessed at two weeks after study entry|Quantitative viral load (assessed with each virology testing set)","Hamad Medical Corporation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","456","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MRC-05-001","April 14, 2020","May 14, 2020","May 30, 2020","April 16, 2020",,"April 16, 2020",,,"https://ClinicalTrials.gov/show/NCT04349592"
443,"NCT04358536","Classification of COVID-19 Infection in Posteroanterior Chest X-rays",,"Completed","No Results Available","COVID-19","Device: CovX","Identification of COVID-19","Dascena","All","18 Years and older   (Adult, Older Adult)",,"230","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","04202002","April 1, 2020","April 17, 2020","April 17, 2020","April 24, 2020",,"April 24, 2020","Dascena, Oakland, California, United States",,"https://ClinicalTrials.gov/show/NCT04358536"
444,"NCT04252118","Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19",,"Recruiting","No Results Available","COVID-19","Biological: MSCs","Size of lesion area by chest radiograph or CT|Side effects in the MSCs treatment group|Improvement of Clinical symptoms including duration of fever and respiratory|Time of nucleic acid turning negative|Rate of mortality within 28-days|CD4+ and CD8+ T celll count|Alanine aminotransferase|C-reactive protein|Creatine kinase","Beijing 302 Hospital|Innovative Precision Medicine Group (IPM), Hangzhou, China.|Huoshenshan Hospital|Tianjin Haihe Hospital|VCANBIO CELL & GENE ENGINEERING CORP.,LTD, China|Shenzhen Third People's Hospital|Fifth Affiliated Hospital, Sun Yat-Sen University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020003D","January 27, 2020","December 2020","December 2021","February 5, 2020",,"April 15, 2020","Beijing 302 Military Hospital of China, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04252118"
445,"NCT04359953","Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19","COVID-Aging","Not yet recruiting","No Results Available","COVID-19 Infection","Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Telmisartan","Two-weeks survival rate|Rate of undetectable RT-PCR of SARS-CoV-2|Rate of death|Hypotension|Hypothermia and hyperthermia|Pneumonia severity according to WHO|Pneumonia severity according to PSI (Hung et al 2017)|Rate of no cough|Rate of no dyspnea|Rate of no fever|Rate of no requiring supplemental oxygen|Rate of SARS-Cov-2 undetectable|Recovery time|Critical admission rate|Mechanical ventilation rate|Changes in Activity of Daily Living (ADL) Activity of Daily Living)|Changes in Activity of Daily Living IADL (Instrumental Activity of Daily Living)|The number and dose of added corticosteroids, immonumodulators or immunosuppressants","University Hospital, Strasbourg, France","All","60 Years and older   (Adult, Older Adult)","Phase 3","1600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","7747","April 24, 2020","June 1, 2021","June 1, 2021","April 24, 2020",,"April 24, 2020","CHU de Strasbourg, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT04359953"
446,"NCT04280705","Adaptive COVID-19 Treatment Trial (ACTT)",,"Recruiting","No Results Available","COVID-19","Other: Placebo|Drug: Remdesivir","Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","800","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20-0006","February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",,"May 7, 2020","University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States|University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States|University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States|University of California Irvine Medical Center - Infectious Disease, Orange, California, United States|VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States|University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States|Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States|Cedars Sinai Medical Center, West Hollywood, California, United States|Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States|University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States|Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases, New Orleans, Louisiana, United States|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Annapolis, Maryland, United States|Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States|University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States|University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States|Hospital of the University of Pennsylvania - Infectious Diseases, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States|University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States|Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States|The University of Washington - Virology Research Clinic, Seattle, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States|University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases, Copenhagen, Denmark|Universitatsklinikum Bonn, Medizinische Klinik I - Bereich Infektiologie/HIV der Medizinischen Klinik, Bonn, Nordrhein-Westfalen, Germany|Universitatsklinikum Koeln Klinik I fur Innere Medizin Klinisches Studienzentrum fur Infektiologie I, Cologne, Germany|Universitätsklinikum Frankfurt -Medizinische Klinik II - Infektiologie, Frankfurt, Germany|AHEPA University Hospital - 1st Department of Internal Medicine, Thessaloniki, Central Macedonia, Greece|Medical School of Athens University - Evangelismos Hospital - Department of Critical Care and Pulmonary Services, Athens, Greece|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan|Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán - Departamento de Infectologia, Mexico City, Mexico|Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cosío Villegas, Mexico City, Mexico|National Centre for Infectious Diseases (NCID), Singapore, Singapore|Hospital Clinic Barcelona, Servicio de Salud Internacional, Barcelona, Cataluña, Spain|Hospital Germans Trias i Pujol - Servei Malalties Infeccioses, Barcelona, Cataluña, Spain|Royal Sussex County Hospital - Department of Intensive Care Medicine, East Sussex, Brighton, United Kingdom|Saint Thomas' Hospital - Directorate of Infection, London, London, City Of, United Kingdom|Royal Victoria Infirmary - Department of Infectious Diseases, Level 6, Ward 19, Newcastle Upon Tyne, United Kingdom|St. James's University Hospital - Infectious Diseases, Leeds, West Yorkshire, United Kingdom|John Radcliffe Hospital, Headington, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04280705"
447,"NCT04401579","Adaptive COVID-19 Treatment Trial 2 (ACTT-II)",,"Recruiting","No Results Available","COVID-19","Other: Placebo|Drug: Remdesivir|Drug: Baricitinib","Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","1032","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20-0006 ACTT-II","May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",,"June 22, 2020","University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States|University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States|University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States|University of California Irvine Medical Center - Infectious Disease, Orange, California, United States|VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States|University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States|Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States|Cedars Sinai Medical Center, West Hollywood, California, United States|Rocky Mountain Regional Veteran Affairs Medical Center - Department of Infectious Diseases, Aurora, Colorado, United States|Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States|Georgetown University Medical Center - Division of Infectious Diseases, Washington, District of Columbia, United States|University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine, Gainesville, Florida, United States|University of Miami Miller School of Medicine - Infectious Diseases, Miami, Florida, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Atlanta VA Medical Center - Infectious Diseases Clinic, Decatur, Georgia, United States|Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States|University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States|Indiana University School of Medicine - Infectious Diseases, Indianapolis, Indiana, United States|Ochsner Medical Center - Kenner - Department of Infectious Diseases, Kenner, Louisiana, United States|Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases, New Orleans, Louisiana, United States|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States|Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States|University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|University of New Mexico Clinical and Translational Science Center, Albuquerque, New Mexico, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States|University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States|University of Pennsylvania Perelman School of Medicine - Penn Institute for Immunology, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center - Internal Medicine - Infectious Diseases, Dallas, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States|University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States|Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan|Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán - Departamento de Infectologia, Mexico City, Mexico|Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cosío Villegas, Mexico City, Mexico|National University Health System - Division of Infectious Diseases, Singapore, Singapore|National Centre for Infectious Diseases (NCID), Singapore, Singapore|Changi General Hospital - Clinical Trials and Research Unit (CTRU), Singapore, Singapore|Ng Teng Fong General Hospital - Infectious Disease Service, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT04401579"
448,"NCT04348656","CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)","CONCOR-1","Recruiting","No Results Available","COVID-19","Biological: Convalescent plasma","Intubation or death in hospital|Need for Intubation|Time to intubation|Ventilator-free days|In-hospital death|Time to in-hospital death|Death at 30 days|Length of stay in intensive care unit (ICU)|Length of stay in hospital|Need for extracorpeal membrane oxygenation (ECMO)|Need for renal replacement therapy|Development of myocarditis|Adverse events and serious adverse events|CCP transfusion-associated adverse events (AE)","Hamilton Health Sciences Corporation|Canadian Blood Services|Héma-Québec|University of Toronto|Université de Montréal|Weill Cornell Medicine/New York-Presbyterian|New York Blood Centre|McMaster University","All","16 Years and older   (Child, Adult, Older Adult)","Phase 3","1200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CONCOR-1","May 14, 2020","October 31, 2020","December 31, 2020","April 16, 2020",,"June 9, 2020","Brooklyn Hospital, Brooklyn, New York, United States|Lower Manhattan Hospital, New York, New York, United States|Weill Cornell Medical Center, New York, New York, United States|Hamilton General Hospital, Hamilton, Ontario, Canada|Juravinski Hospital, Hamilton, Ontario, Canada|Grand River Hospital, Kitchener, Ontario, Canada|London Health Sciences Centre - University Hospital, London, Ontario, Canada|Trillium Health Partners, Mississauga, Ontario, Canada|Trillium Health Partners - Credit Valley, Mississauga, Ontario, Canada|Ottawa Hospital - General Campus, Ottawa, Ontario, Canada|Ottawa Hospital - Civic Campus, Ottawa, Ontario, Canada|Scarborough Health Network - Centenary Hospital, Scarborough, Ontario, Canada|Scarborough Health Network - General Hospital, Scarborough, Ontario, Canada|Scarborough Health Network - Birchmount Hospital, Scarborough, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Unity Health St. Michael's Hospital, Toronto, Ontario, Canada|Sinai Health System, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Windsor Regional Hospital - Metropolitan Campus, Windsor, Ontario, Canada|Windsor Regional Hospital - Ouellette Campus, Windsor, Ontario, Canada|Hôpital de la Cité-de-la-Santé, Laval, Quebec, Canada|Hotel Dieu Hospital of Lévis, Lévis, Quebec, Canada|Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada|Centre hospitalier de l'Université de Montréal, Montréal, Quebec, Canada|Centre hospitalier universitaire Sainte-Justine, Montréal, Quebec, Canada|Jewish General Hospital, Montréal, Quebec, Canada|McGill University Health Centre, Montréal, Quebec, Canada|Hôpital du Sacré-Coeur de Montreal, Montréal, Quebec, Canada|Ciussse De L'Estrie CHUS, Sherbrooke, Quebec, Canada|Centre hospitalier affilié universitaire régional de Trois-Rivières, Trois-Rivières, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04348656"
449,"NCT04438980","Glucocorticoids in COVID-19 (CORTIVID)","CORTIVID","Recruiting","No Results Available","Covid-19 Pneumonia","Drug: Methylprednisolone|Other: Placebo","Proportion of patients developing treatment failure|Mortality at day 28|Proportion of patients requiring ICU admission|Proportion of patients requiring rescue-therapy with tocilizumab|Length of hospital stay|Proportion of severe adverse events|Proportion of bacterial, fungal or opportunistic infections|Evolution of inflammatory biomarkers related to COVID-19|Proportion of SARS-CoV-2 clearance.","Fundacion Miguel Servet|Complejo Hospitalario de Navarra|Hospital Sant Joan Despí Moisès Broggi","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CORTIVID","May 15, 2020","December 2020","February 2021","June 19, 2020",,"June 22, 2020","Hospital Sant Joan Despí Moisès Broggi, Sant Joan Despí, Barcelona, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain",,"https://ClinicalTrials.gov/show/NCT04438980"
450,"NCT04374422","COVID-19 Pandemic and Female Sexual Behavior",,"Completed","No Results Available","Sexual Behavior|COVID","Behavioral: fsfi survey","FSFI (Female Sexual Function Index)SCORE difference","Acibadem University","Female","18 Years and older   (Adult, Older Adult)",,"58","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AcibademU cov","April 10, 2020","April 12, 2020","April 12, 2020","May 5, 2020",,"May 5, 2020","Haseki Training and Research Hospital, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04374422"
451,"NCT04367792","Cardiac Injury in COVID-19: a Pathology Study",,"Recruiting","No Results Available","COVID-19",,"Cardiac pathological findings from series of >= 50 patients dying from COVID-19 disease|viral load in cardiac tissues and the extent of damage|Co-localize the SARS-CoV-2 using RNAscope in situ hybridization, with its entry receptor ACE2 and serine protease TMPRSS2 in different cell types found in the heart","A.O. Ospedale Papa Giovanni XXIII|CVPath Institute Inc. Renu Virmani, Aloke Finn|A.O. Ospedale Papa Giovanni XXIII, Anatomia Patologica, Dr Andrea Gianatti, co-PI","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","56/20","April 2020","October 2020","March 2021","April 29, 2020",,"May 1, 2020","ASST Ospedale Papa Giovanni XXIII, Bergamo, Italy",,"https://ClinicalTrials.gov/show/NCT04367792"
452,"NCT04299724","Safety and Immunity of Covid-19 aAPC Vaccine",,"Recruiting","No Results Available","Treat and Prevent Covid-19 Infection","Biological: Pathogen-specific aAPC","Frequency of vaccine events|Frequency of serious vaccine events|Proportion of subjects with positive T cell response|28-day mortality|Duration of mechanical ventilation if applicable|Proportion of patients in each category of the 7-point scale|Proportion of patients with normalized inflammation factors|Clinical improvement based on the 7-point scale if applicable|Lower Murray lung injury score if applicable","Shenzhen Geno-Immune Medical Institute|Shenzhen Third People's Hospital|Shenzhen Second People's Hospital","All","6 Months to 80 Years   (Child, Adult, Older Adult)","Phase 1","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GIMI-IRB-20002","February 15, 2020","July 31, 2023","December 31, 2024","March 9, 2020",,"March 9, 2020","Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04299724"
453,"NCT04406324","COVID-19: Respiratory and Sleep Follow-up","Co-SURVIVORS","Not yet recruiting","No Results Available","COVID-19","Other: No intervention","Diffusion Capacity for Carbon Monoxide (CO) 3 months after COVID diagnosis|Prevalence of Sleep Disordered Breathing (SDB) 3 months after COVID diagnosis|Prevalence of sleep disorders 3 months after COVID diagnosis|Prevalence of ventilatory muscle function impairments, 3 months after COVID diagnosis|Prevalence of cardiac impairments 3 months after COVID diagnosis|Follow-up of pulmonary diffusion capacity of carbon monoxide|Follow-up of sleep disorders treatment compliance|Follow-up of sleep disorders treatments efficacy|HLA alleles aspect of COVID clinical presentation|KIR loci aspect of COVID clinical presentation|metabolomic aspect of COVID clinical presentation","University Hospital, Grenoble","All","18 Years and older   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","38RC20.157","June 5, 2020","March 5, 2021","March 5, 2026","May 28, 2020",,"May 28, 2020","Hôpital Avicenne, Bobigny, France|Centre Hospitalier Henri Mondor, APHP, Créteil, France|CHU Grenoble Alpes, Grenoble, France|CHRU Nancy, Nancy, France",,"https://ClinicalTrials.gov/show/NCT04406324"
454,"NCT04449731","Changes in Dietary Behaviours During the COVID-19 Outbreak Confinement in the Adult Population (COVIDiet_Int)","COVIDiet_Int","Recruiting","No Results Available","COVID-19",,"Adherence to the Mediterranean diet before and during the COVID-19 confinement|Eating behaviours|Level of physical activity during the COVID-19 confinement|Weight gain during the COVID-19 confinement","Universidad de Granada|University of Athens|University of Zagreb|University of Belgrade|Institute of Technology, Sligo|University of Sarajevo|Lithuanian University of Health Sciences|Jozef Stefan Institute|University of Southern Denmark|Institut Za Javno Zdeavlje|University of Skopje|Poznan University of Life Sciences|Bezmialem Vakif University|Centro Hospitalar e Universitário de Coimbra, E.P.E.|Kuwait University","All","18 Years and older   (Adult, Older Adult)",,"30000","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","1526/CEIH/2020","March 20, 2020","August 30, 2020","June 30, 2021","June 29, 2020",,"June 29, 2020","Universidad de Granada, Granada, Spain",,"https://ClinicalTrials.gov/show/NCT04449731"
455,"NCT04412460","Echocardiography in Patients With Covid-19",,"Recruiting","No Results Available","COVID|ARDS, Human",,"ICU Mortality|ICU length-of stay|ICU ventilator free days|Hospital length-of-stay","University Hospital Tuebingen","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CovidEcho","March 20, 2020","December 31, 2021","December 31, 2021","June 2, 2020",,"June 2, 2020","University Hospital Tubingen, Tubingen, BW, Germany",,"https://ClinicalTrials.gov/show/NCT04412460"
456,"NCT04425044","AiM Covid Self Monitoring",,"Completed","No Results Available","Covid19","Other: Other","Fever|Shortness of Breath|Cough|Sore Throat|Headache|Muscle/ Joint Pain|Diarrhoea|Vomiting/ Nausea|Runny Nose|Loss of Smell/Taste|Other symptoms","Aarogyam UK|University of Warwick|NMP Medical Research Institute|Mothers Touch Foundation","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Au015","April 12, 2020","May 18, 2020","May 28, 2020","June 11, 2020",,"June 11, 2020","Mothers Touch Foundation, Mumbai, Maharashtra, India|NMP Medical Research Institite, Jaipur, Rajasthan, India",,"https://ClinicalTrials.gov/show/NCT04425044"
457,"NCT04441385","Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).","MARACOVID","Not yet recruiting","No Results Available","COVID-19","Drug: Maraviroc 300 mg|Other: Standard care therapy","Proportion of patients developing severe ARDS.|All-cause mortality.|Percentage of patients requiring tracheal intubation, use of Non-invasive Ventilation NIV or High Flow Nasal Cannula (HFNC) devices during the study period|Percentage of patients who progress to severe ARDS, death or ICU admission.|Differences in Time to Clinical Improvement|Change in clinical status of subject on a 7-point ordinal scale.|Percentage of patients requiring immunosuppressive/immunomodulatory treatment as a rescue medication.|Proportion of patients developing adverse effects, serious adverse reactions, laboratory or physical examination findings, EKG abnormalities acquired during the trial, death and adverse events leading to early discontinuation of treatment.","Hospital Universitario Infanta Leonor|Hospital Clínic de Barcelona|ViiV Healthcare","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MARACOVID|2020-002011-21","June 26, 2020","November 30, 2020","December 20, 2020","June 22, 2020",,"June 22, 2020","Hospital Clínic, Barcelona, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04441385"
458,"NCT04331171","Epidemiological Observation From a Smartphone Self-monitoring Application for Suspected COVID-19 Patients' Triage","COVID CALL 15","Recruiting","No Results Available","COVID-19","Device: Web application users","To assess of the evolution of the number of calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/|To assess of the evolution of the proportion of relevant calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/|To assess the evolution over time of the COVID 19 epidemic|To assess the evolution over space of the COVID 19 epidemic|To assess symptoms|To assess the users population","Weprom|Institut Pasteur|Assistance Publique - Hôpitaux de Paris|DOCAPOST|Direction Générale de l'Offre de Soins","All","18 Years and older   (Adult, Older Adult)",,"3000000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","WP-2020-02","March 17, 2020","March 31, 2020","July 31, 2020","April 2, 2020",,"April 17, 2020","All French Emergency services, Le Mans, France",,"https://ClinicalTrials.gov/show/NCT04331171"
459,"NCT04330586","A Trial of Ciclesonide in Adults With Mild COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Ciclesonide Metered Dose Inhaler [Alvesco]|Drug: Hydroxychloroquine","Rate of SARS-CoV-2 eradication at day 14 from study enrollment|Rate of SARS-CoV-2 eradication at day 7 from study enrollment|Time to SARS-CoV-2 eradication (days)|Viral load area-under-the-curve (AUC) reduction versus control|Time to clinical improvement (days)|Proportion of clinical failure","Korea University Guro Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","141","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KUMC-COVID-19","April 1, 2020","June 30, 2020","September 30, 2020","April 1, 2020",,"April 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04330586"
460,"NCT04397328","COVID-19 PEP- High-risk Individuals in Long-term and Specialized Care - Canada",,"Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Placebo","Incidence of symptomatic fever >37.8, dry cough, or shortness of breath (resident/patient report or nurse observation) respiratory infection with confirmed PCR+ result for SARS-CoV-2.|Requirement for admission to acute care hospital and/or ICU admission or death|Asymptomatic PCR+ SARS-CoV-2 test result|Time to clinical recovery (TTCR).","Lawson Health Research Institute","All","40 Years and older   (Adult, Older Adult)","Phase 3","336","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","9881","May 19, 2020","April 30, 2021","April 30, 2021","May 21, 2020",,"May 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04397328"
461,"NCT04427358","RT-PCR SARS-CoV-2 at 1 Month of COVID-19 Infection in the Geriatric Population","COVID-19GAOM","Recruiting","No Results Available","Covid-19",,"Analysis of the rate of RT-PCR SARS-CoV-2 positive at 1 month of COVID infection","University Hospital, Strasbourg, France","All","70 Years and older   (Older Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","7838","May 7, 2020","August 2020","August 2020","June 11, 2020",,"June 11, 2020","Service SSR Gériatrique, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT04427358"
462,"NCT04377308","Fluoxetine to Reduce Intubation and Death After COVID19 Infection",,"Recruiting","No Results Available","COVID-19|Cytokine Storm","Drug: Fluoxetine","Hospitalizations|Intubation|Death|Number of days of illness|PHQ-9 score for depressive symptoms,|generalized anxiety Disorder-7 scale","University of Toledo Health Science Campus","All","18 Years and older   (Adult, Older Adult)","Phase 4","2000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FRIDA COVID19","May 1, 2020","April 20, 2021","October 20, 2021","May 6, 2020",,"May 6, 2020","University of Toledo, Toledo, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04377308"
463,"NCT04397380","COVID-19 Thales Thermography Triage : Thermal Camera Feasibility Study","COVID3T","Not yet recruiting","No Results Available","Pyrexia|COVID","Device: Thermography|Device: Tympanic Temperature","Temperature","NHS Greater Clyde and Glasgow","All","16 Years and older   (Child, Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","INGC20AE209","May 20, 2020","June 3, 2020","July 1, 2020","May 21, 2020",,"May 22, 2020","Queen Elizabeth University Hospital, Glasgow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04397380"
464,"NCT04418505","Vielight RX Plus for the Treatment of COVID-19 Respiratory Symptoms","COVIDLight","Not yet recruiting","No Results Available","COVID-19","Device: Vielight RX Plus","Time to recovery|Time to elimination of COVID-19 related symptoms|Mean number of days with mild COVID-19 related symptoms|Mean number of days with mild overall respiratory symptoms|Time to symptom reduction|Time to elimination of symptoms|Average number of days with mild respiratory symptoms|Oxygen saturation|Hospitalization rate|Mortality","Vielight Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","280","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VL-2020-02","July 1, 2020","January 1, 2021","January 1, 2021","June 5, 2020",,"June 9, 2020","Dr. Michael Zahavi, Oshawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04418505"
465,"NCT04372199","SEVERITY SCORE FOR COVID-19 PNEUMONIA",,"Recruiting","No Results Available","COVID|Pneumonia",,"To identify the best predictors of critical coronavirus pneumonia and to realize a simple severity score able to early classify high-risk individuals admitted to Internal Medicine Department for COVID-19 disease, needing an intensive approach","Fondazione Policlinico Universitario Agostino Gemelli IRCCS","All","18 Years and older   (Adult, Older Adult)",,"248","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","3112","April 29, 2020","May 27, 2020","May 27, 2020","May 1, 2020",,"May 1, 2020","Massimo Montalto, Roma, Italy","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT04372199/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04372199"
466,"NCT04394884","Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND)",,"Recruiting","No Results Available","COVID-19",,"To characterize the immunologic mechanisms by which BTK inhibition may ameliorate hyper- inflammatory responses in patients with COVID-19.|1. Characterization of TLR3 and TLR7/8-dependent immunologic phenotypes in COVID-19 patients before and after BTK inhibition.|2. Evaluation of mechanisms of immune cell-specific activation, cytokine production, exhaustion and apoptosis in COVID-19 patients before and after BTK inhibition.|3. Transcriptional, chromatin, and epigenetic profiling of immune cells at the single cell level in COVID-19 patients before and after BTK inhibition.|4. Longitudinal evaluation of TCR and BCR repertoire development in COVID-19 patients before and after BTK inhibition.|5. Characterization of SARS- CoV-2 serological responses in COVID-19 patients with and without BTK inhibition.|6. Characterization of genetic variants that correlate with disease severity and/or response to BTK inhibition treatment.|7. Evaluation of soluble biomarkers as surrogate markers of hyper- inflammation/prognosis and of response to BTK inhibition therapy in COVID-19 patients","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"160","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","999920114|20-I-N114","July 2, 2020","April 30, 2023","April 30, 2023","May 20, 2020",,"June 29, 2020","Johns Hopkins Hospital, Baltimore, Maryland, United States|Walter Reed National Medical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04394884"
467,"NCT04425252","Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19","CRISIS","Recruiting","No Results Available","COVID-19","Drug: Brequinar|Other: Standard of Care","Safety/tolerability measured by rates of post randomization adverse events and hematology/chemistry safety labs.|Hospitalization status|Duration of hospitalization|NEWS2 Score|Mortality|SARS-CoV-2 nasopharyngeal viral load|Inflammatory markers|DHO Concentration|Brequinar Concentration","Clear Creek Bio, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CCB-CRISIS-01","June 25, 2020","September 2020","October 2020","June 11, 2020",,"June 29, 2020","Hartford Hospital, Hartford, Connecticut, United States|University of South Florida/Tampa General, Tampa, Florida, United States|Temple University, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04425252"
468,"NCT04373161","Home Pulse Oximeter Use in Patients With COVID-19",,"Completed","No Results Available","Sars-CoV2|COVID-19|COVID","Device: Home Pulse Oximetry Monitoring","Hospitalization in COVID-19 patients with low home SpO2|Trend in resting home pulse oximetry readings|Timing of SpO2 <92%|Home pulse oximeter use effect on subsequent ED visits|Reason for return to the Emergency Department|Hospitalization outcome - morbidity|Hospitalization outcome - mortality|Median Length of Stay","Swedish Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","209","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2020032301","March 20, 2020","April 22, 2020","April 22, 2020","May 4, 2020",,"May 6, 2020","Swedish Hospital, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04373161"
469,"NCT04344249","Cohort of Patients With Inflammatory Bowel Disease During COVID-19 Pandemic","IBD-COVID-19","Recruiting","No Results Available","IBD|COVID",,"IgG and IgM anti SARS-CoV-2|Clinical factors and severity of COVID-19 infection|demographic factors and severity of COVID-19 infection|pharmacologic factors and severity of COVID-19 infection","Nantes University Hospital","All","18 Years to 100 Years   (Adult, Older Adult)",,"850","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RC20_0150","April 10, 2020","September 30, 2020","September 1, 2021","April 14, 2020",,"April 30, 2020","Chu Nantes, Nantes, France",,"https://ClinicalTrials.gov/show/NCT04344249"
470,"NCT04350671","Interferon Beta 1a in Hospitalized COVID-19 Patients","IB1aIC","Enrolling by invitation","No Results Available","COVID-19","Drug: Interferon Beta-1A|Drug: Lopinavir / Ritonavir|Drug: Single Dose of Hydroxychloroquine","Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events","Shahid Beheshti University of Medical Sciences","All","50 Years and older   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Interferon Beta 1a in COVID-19","April 15, 2020","April 20, 2020","April 24, 2020","April 17, 2020",,"April 20, 2020","Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04350671"
471,"NCT04374695","Renin-Angiotensin-Aldosterone System Inhibitors, Hypertension, and COVID-19","COVHYP","Not yet recruiting","No Results Available","COVID-19",,"Prior treatment by ACEi|Prior treatment by ARB|Baseline characteristics and comorbidities|Major Clinical Adverse Events","Versailles Hospital|Bernard LIVAREK, MD, Cardiology department, Versailles Hospital|Jean-Paul BERESSI, MD, Department of diabetology, Versailles Hospital|Mehrsa KOUKABI FRADELIZZI, MD, Emergency department, Versailles Hospital|Floriane GILLES, MD, Cardiology department, Versailles Hospital|Alisson BERTRAND, Cardiology department, Versailles Hospital|Marie DE TOURNEMIRE, Cardiology department, Versailles Hospital|Victorien MONGUILLON, Cardiology department, Versailles Hospital|Maeva PASQUALINI, Cardiology department, Versailles Hospital|Alix PREVOT, Cardiology department, Versailles Hospital|Guillaume ROGER, Cardiology department, Versailles Hospital|Joseph SABA, Cardiology department, Versailles Hospital|Joséphine SOLTANI, Cardiology department, Versailles Hospital|Jean-François PROST, Cardiology department, Versailles Hospital|Cécile LAUREANA, Department of medical information, Versailles Hospital","All","18 Years and older   (Adult, Older Adult)",,"700","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","P20/11_COVHYP","May 1, 2020","June 1, 2020","July 1, 2020","May 5, 2020",,"May 5, 2020",,,"https://ClinicalTrials.gov/show/NCT04374695"
472,"NCT04395781","Pediatric Acute and Critical Care COVID-19 Registry of Asia","PACCOVRA","Not yet recruiting","No Results Available","COVID|Pediatric Disorder",,"Overall severity of illness|Respiratory complications|Other complications|Mortality","KK Women's and Children's Hospital|King Chulalongkorn Memorial Hospital|Ramathibodi Hospital|Postgraduate Institute of Medical Education and Research, Chandigarh|Rumah Sakit Anak dan Bunda Harapan Kita|National University Hospital, Singapore|St. Marianna University School of Medicine|Tokyo Metropolitan Children's Medical Center, Japan|Aichi Children's Health and Medical Center, Japan|General Hospital H. Adam Malik|Children's Hospital of Chongqing Medical University|Zhengzhou Children's Hospital, China|Universiti Kebangsaan Malaysia Medical Centre|Penang Hospital, Malaysia|Vicente Sotto Memorial Medical Center|Hyogo Prefectural Kobe Children’s Hospital|Singapore Clinical Research Institute","All","up to 21 Years   (Child, Adult)",,"2000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","2020/2094","May 18, 2020","December 31, 2022","December 31, 2023","May 20, 2020",,"May 26, 2020",,,"https://ClinicalTrials.gov/show/NCT04395781"
473,"NCT04374071","Early Short Course Corticosteroids in COVID-19",,"Completed","No Results Available","COVID|Pneumonia, Viral","Drug: Methylprednisolone","Transfer to Intensive care unit (ICU)|Need for Mechanical Ventilation|Mortality|Development and Severity of ARDS|Length of hospital stay (LOS).","Henry Ford Health System","All","18 Years and older   (Adult, Older Adult)",,"250","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","HFH IRB # 13739","March 12, 2020","March 27, 2020","April 30, 2020","May 5, 2020",,"May 5, 2020","Henry Ford Hospital, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT04374071"
474,"NCT04400890","Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of Resveratrol for COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Resveratrol|Dietary Supplement: Vitamin D3","Hospitalization rates for COVID-19|ICU Admission Rates|Invasive Ventilation Rates","Marvin McCreary, MD|Mount Carmel Health System","All","45 Years and older   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","McCreary2020","June 2020","September 2020","November 2020","May 26, 2020",,"May 26, 2020",,,"https://ClinicalTrials.gov/show/NCT04400890"
475,"NCT04379479","Clinical Effect of Dialyzable Leukocyte Extract in Suspected or Confirmed Cases of COVID-19 (FUTURE-T)","FUTURE-T","Not yet recruiting","No Results Available","COVID-19|SARS-CoV-2 Infection","Drug: Dialyzable Leukocyte Extract|Drug: Placebo oral","Change in the score of the ""Contingency scale to assess the severity of acute respiratory disease in cases suspected/confirmed by COVID-19""|Clinical deterioration|Duration of the clinical status","National Polytechnic Institute, Mexico","All","18 Years and older   (Adult, Older Adult)","Phase 2","562","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IC-20-001|SH-001-2020","May 2020","August 2020","December 2020","May 7, 2020",,"May 7, 2020","Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT04379479"
476,"NCT04414098","Ruxolitinib in the Treatment of Covid-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: INC424 / Ruxolitinib","Evaluate the efficacy of ruxolitinib in the treatment of COVID-19 severe acute respiratory syndrome|Evaluate the median duration of hospitalization.|Evaluate the evolution of systemic inflammation parameters.|Evaluate COVID-19 mortality rate|Evaluate the proportion of the requirement of mechanical ventilation.|Evaluate ruxolitinib adverse reactions|Evaluate the proportion of secondary infections during the treatment with ruxolitinib","Marcelo Iastrebner|Novartis|Clinica Zabala","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CZabala","June 1, 2020","August 15, 2020","September 15, 2020","June 4, 2020",,"June 4, 2020",,,"https://ClinicalTrials.gov/show/NCT04414098"
477,"NCT04395456","A Phase 2 Study of the C3 Inhibitor AMY-101 in Patients With ARDS Due to COVID-19 (SAVE)","SAVE","Not yet recruiting","No Results Available","Acute Respiratory Distress Syndrome Due to SARS-CoV-2 Infection (Severe COVID19)","Drug: AMY-101|Other: WFI 5% glucose","The proportion of patients who are alive, without evidence of ARDS (i.e. PaO2/FIO2 >300 mm Hg), who do not require any oxygen support (in room air).|The proportion of patients assigned to each category, of a six-category ordinal scale.|Proportion of patients surviving|Proportion of respiratory failure-free survival|Cumulative incidence of resolution of ARDS (defined as PaO2/FiO2 ≥200 in room air)|Cumulative incidence of freedom from oxygen requirement|Proportion of patients requiring invasive mechanical ventilation due to worsening of ARDS|Proportion of patients requiring non-invasive mechanical ventilation (NIV) due to worsening of ARDS|Proportion of patients developing thrombotic microangiopathies|Changes in PaO2 and PaO2/FIO2|Changes in quick Sequential Organ Failure Assessment Score (qSOFA: respiratory rate, systolic blood pressure, Glasgow Coma Scale (GCS)|Changes in maximal and minimal cardiovascular parameters: Respiratory rate|Changes in maximal and minimal cardiovascular parameters: Heart Rate|Changes in levels of biomarkers of inflammation (CBC, CRP, Ferritin, Procalcitonin, D-dimers, LDH)|Length of stay in ICU|Cumulative incidence of discharge from hospital|Number of adverse events|Changes in levels of anti-drug antibodies|Changes in levels of biomarkers of complement activity: C3, C3a, C5a, sC5b-9|Changes in levels of biomarkers of cytokine release syndrome: IL-1, IL-6, IL-12|Changes in levels of Club Cell protein CC16 (biomarker of lung damage )|Changes in levels of AMY-101 plasma level","Amyndas Pharmaceuticals S.A.","All","18 Years and older   (Adult, Older Adult)","Phase 2","144","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","AMY-101_SAVE","July 2020","January 2021","March 2021","May 20, 2020",,"May 20, 2020",,,"https://ClinicalTrials.gov/show/NCT04395456"
478,"NCT04384029","The Geneva Covid-19 CVD Study",,"Active, not recruiting","No Results Available","COVID|CVD","Other: Covid-19 + patients","mobidity discharge|mobidity at 30 days|mobidity 1 year after hospitalization|mortality discharge|mortality 30 days after hospitalization|mortality 1 year after hospitalization|Clinical outcomes according to medication at admission|Clinical outcomes related to preexisting cardiovascular risk factors at admission|New onset of CVD induced by COVID-19 disease|Cost of hospital stay|Clinical follow up at 30 days (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis).|Clinical follow up at 1 year (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis).","François MACH|University Hospital, Geneva","All","18 Years and older   (Adult, Older Adult)",,"7000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","CCER-2020-00610","March 24, 2020","March 31, 2021","March 31, 2022","May 12, 2020",,"May 12, 2020","Geneva University Hospital (HUG), Geneva, Switzerland",,"https://ClinicalTrials.gov/show/NCT04384029"
479,"NCT04355624","Kidney Involvement in COVID-19 Disease (COVKID)","COVKID","Recruiting","No Results Available","COVID|Kidney Injury",,"Kidney involvement in COVID-19 disease|Physiopathologic mechanism of kidney involvement in SARS-CoV-2 infection|To identify risk factors for kidney involvement in in SARS-CoV-2 infection|To evaluate the impact of kidney involvement in SARS-CoV-2 infection|To assess the long-term health effect of kidney injury on survivors of SARS-CoV-2 infection in case of AKI KDIGO 2 or 3","Centre Hospitalier Universitaire de Nice","All","18 Years and older   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20reamedcovid02","April 15, 2020","April 30, 2020","July 30, 2020","April 21, 2020",,"May 13, 2020","Centre hospitalier d'Antibes Juan les pins, Antibes, France|Centre hospitalier de Cannes, Cannes, France|Centre hospitalier de Grasse, Grasse, France|CHU de Nice, Nice, France",,"https://ClinicalTrials.gov/show/NCT04355624"
480,"NCT04313322","Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells",,"Recruiting","No Results Available","Use of Stem Cells for COVID-19 Treatment","Biological: WJ-MSCs","Clinical outcome|CT Scan|RT-PCR results","Stem Cells Arabia","All","18 Years and older   (Adult, Older Adult)","Phase 1","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID-19","March 16, 2020","June 30, 2020","September 30, 2020","March 18, 2020",,"March 18, 2020","Stem Cells Arabia, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT04313322"
481,"NCT04438993","The COVID-19 Disease and CARdiac Events Study","COVICARE","Recruiting","No Results Available","COVID|Coronavirus",,"Cardiac abnormalities in COVID-19 disease in-patients|Biomarkers","NHS Lanarkshire","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVI-RW-2020","May 29, 2020","October 2020","November 2020","June 19, 2020",,"June 19, 2020","University Hospital Hairmyres, Glasgow, Scotland, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04438993"
482,"NCT04395807","Helmet CPAP Versus HFNC in COVID-19","COVID HELMET","Recruiting","No Results Available","COVID|Acute Hypoxemic Respiratory Failure","Device: Helmet CPAP|Device: HFNC","Ventilator-Free Days (VFD)|SpO2/FiO2-ratio|Patient comfort|Frequency of endotracheal intubation|Frequency of carbon dioxide rebreathing|Days alive within","Lund University|Region Skane","All","18 Years and older   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","COVID HELMET","June 3, 2020","December 31, 2020","May 2021","May 20, 2020",,"June 5, 2020","Helsingborg's Hospital, Helsingborg, Region Skane, Sweden",,"https://ClinicalTrials.gov/show/NCT04395807"
483,"NCT04376593","PET/CT Imaging in COVID-19 Patients",,"Enrolling by invitation","No Results Available","COVID-19|SARS-CoV-2 Infection","Drug: 18F-αvβ6-BP","Administration of 18F-αvβ6-BP|Determine whether 18F-αvβ6-BP demonstrates accumulation in lung damage","University of California, Davis","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","1592298","May 2020","May 2021","May 2022","May 6, 2020",,"May 6, 2020","University of California Davis, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT04376593"
484,"NCT04407494","Diagnostic Value of Patient - Reported and Clinically Verified Olfactory Disorders (COVID-19)","COVID-OLFA","Completed","No Results Available","COVID-19","Biological: Reporting of anosmia, ageusia and other clinical symptoms","Diagnostic values of anosmia and ageusia for COVID-19|Diagnostic values of CODA","University Hospital, Montpellier","All","18 Years and older   (Adult, Older Adult)",,"809","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RECHMPL20_0176","March 1, 2020","April 1, 2020","April 30, 2020","May 29, 2020",,"June 1, 2020","Uhmontpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04407494"
485,"NCT04365439","Convalescent Plasma for COVID-19",,"Not yet recruiting","No Results Available","Blood Plasma Therapy|COVID","Biological: Blood plasma","Titers of anti-SARS-CoV-2 antibodies in the plasma derived from convalescent donors|Change in titers of anti-SARS-CoV-2 antibodies in patients' plasma|Change in inflammatory cytokines concentration (e.g. IL-6, HMGB1)|Viral load decay in the recipient after plasma transfusion with semiquantitative assessment of nasopharyngeal swabs|Number of patients with improvement in the 7-points Ordinal Scale|Proportion of patients with adverse events, severity of adverse events","Enos Bernasconi|Ente Ospedaliero Cantonale, Bellinzona","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-00895","April 27, 2020","May 30, 2020","June 30, 2020","April 28, 2020",,"April 28, 2020",,,"https://ClinicalTrials.gov/show/NCT04365439"
486,"NCT04346160","A Study to Assess the Virus RNA, and miRNA Levels Related to Viral Infection, and Inflammatory Response in Tears of Patients Affected by COVID-19 Disease",,"Not yet recruiting","No Results Available","COVID|Conjunctivitis","Diagnostic Test: Schirmer Test I","virus molecular analysis|host molecular analysis|Epidemiologic data","G. d'Annunzio University","All","18 Years and older   (Adult, Older Adult)",,"25","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","UChieti03","April 14, 2020","April 30, 2020","April 30, 2020","April 15, 2020",,"April 20, 2020","Ophtalmology Clinic, G.d'Annunzio University, Chieti, Italy",,"https://ClinicalTrials.gov/show/NCT04346160"
487,"NCT04328285","Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers","COVIDAXIS","Active, not recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Placebo of Hydroxychloroquine|Drug: Lopinavir and ritonavir|Drug: Placebo of LPV/r Tablets","Occurrence of an symptomatic or asymptomatic SARS-CoV-2 infection among healthcare workers (HCWs)|Evaluation of the occurrence of adverse events in each arm,|Evaluation of the discontinuation rates of the investigational drug in each arm,|Evaluation of the adherence of participants to study drug,|Evaluation of the incidence of symptomatic cases of SARS-CoV-2 infection in each arm,|Evaluation of the incidence of asymptomatic cases of SARS-CoV-2 infection in each arm|Evaluation of the incidence of severe cases of SARS-CoV-2 infection in each arm.|corrected QT interval (ms)","Centre Hospitalier Universitaire de Saint Etienne|Institut Pasteur","All","18 Years and older   (Adult, Older Adult)","Phase 3","1200","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","20PH061|2020-001188-96","April 14, 2020","November 30, 2020","November 30, 2020","March 31, 2020",,"June 23, 2020","CHU d'Angers, Angers, France|CHU de Bordeaux, Bordeaux, France|CHU de Clermont-Ferrand, Clermont-ferrand, France|CHU de Montpellier, Montpellier, France|CHU de Nancy, Nancy, France|CHU de Nantes, Nantes, France|AP-HP - Hôpital Bichat, Paris, France|CHU de Rennes, Rennes, France|CHU de Rouen, Rouen, France|CHU de Saint-Etienne, Saint-Étienne, France",,"https://ClinicalTrials.gov/show/NCT04328285"
488,"NCT04362943","Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults","COVID-AGE","Recruiting","No Results Available","COVID-19","Drug: Baricitinib or Anakinra","Mortality|X-ray changes|Disability changes|Ambulation changes|lymphocyte count changes|C-Reactive Protein changes|Ferritin changes|D-Dimer changes","Complejo Hospitalario Universitario de Albacete","All","70 Years and older   (Older Adult)",,"576","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","PAS-BAR-2020-04","April 20, 2020","May 15, 2020","July 31, 2020","April 27, 2020",,"April 27, 2020","Complejo Hospitalario Universitario de Albacete, Albacete, Spain",,"https://ClinicalTrials.gov/show/NCT04362943"
489,"NCT04390594","Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal","SEN-CoV-Fadj","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + Azithromycin","SARS-CoV-2 viral load level|Vital status|Proportion of patients with serious adverse events reported during the clinical trial.|Length of hospitalization|Length of hospitalization in a resuscitation unit|Duration of oxygen therapy|Maximum quick SOFA (qSOFA) score during hospitalisation","Institut Pasteur de Dakar|Fann Hospital, Senegal|Ministry of Health, Senegal|Diamniadio Children Hospital, Senegal|Dalal Jamm Hospital, Senegal","All","15 Years and older   (Child, Adult, Older Adult)","Phase 3","258","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-002","June 1, 2020","December 1, 2020","June 1, 2021","May 15, 2020",,"May 27, 2020","Infectious and Tropical Diseases Department, Fann Hospital, Dakar, Senegal|Diamniadio Children Hospital, Diamniadio, Senegal|Dalal Jamm Hospital, Guédiawaye, Senegal",,"https://ClinicalTrials.gov/show/NCT04390594"
490,"NCT04376853","CoronaWatch - Early Detection of Cardiovascular Risks in COVID-19 Via SmartWatch","CoronaWatch","Recruiting","No Results Available","COVID-19","Device: Apple Watch Series 5","Biomarker|Protective factors|SmartWatch compliance|Arrhythmias|QT time changes|Longitudinal risk models","University Hospital Heidelberg|The German Heart Foundation|Klaus Tschira Stiftung|Freunde und Förderer der Kardiologie Heidelberg","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CoronaWatch","April 15, 2020","June 2020","July 2020","May 6, 2020",,"May 6, 2020","Department III of Internal Medicine, University Hospital Heidelberg, Heidelberg, Baden-Württemberg, Germany",,"https://ClinicalTrials.gov/show/NCT04376853"
491,"NCT04398303","ACT-20 in Patients With Severe COVID-19 Pneumonia",,"Not yet recruiting","No Results Available","COVID-19 Pneumonia","Biological: ACT-20-MSC|Biological: ACT-20-CM|Biological: Placebo","Mortality at day 30|Ventilated Subjects - Ventilator Free Days|Ventilated Subjects - Improvement in Ventilator Settings|High-Flow O2 Support Subjects - Step-Down O2 Therapy|High Flow O2 Support Subjects - Respiration Rate|Both Ventilated and High-Flow O2 Support Subjects - ICU-Free Days|Both Ventilated and High-Flow O2 Support Subjects - Pulmonary Function Improvement|Both Ventilated and High-Flow O2 Support Subjects - Increased Berlin Score","Aspire Health Science","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AHS 20-03","May 2020","October 2020","October 2020","May 21, 2020",,"May 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04398303"
492,"NCT04416048","Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19","COVID-PREVENT","Not yet recruiting","No Results Available","COVID-19","Drug: Rivaroxaban|Other: Standard Of Care (SOC)","Composite endpoint of venous thromboembolism (DVT and/or fatal or non-fatal PE), arterial thromboembolism, new myocardial infarction, non-hemorrhagic stroke, all-cause mortality or progression to intubation and invasive ventilation|Development of disseminated intravascular coagulation (DIC) according to the ISTH criteria|Number of days requiring invasive ventilation|Number of days requiring non-invasive ventilation|Improvement on a seven-category ordinal scale recommended by the WHO as clinical improvement scale for patients with respiratory infections","Charite University, Berlin, Germany|Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","400","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","COVID-PREVENT|2020-002282-33","June 15, 2020","April 30, 2021","May 30, 2021","June 4, 2020",,"June 4, 2020","Kardiologie und Angiologie I Universitätsherzzentrum Freiburg, Freiburg, Baden-Württemberg, Germany|Clinic for Gastroenterology, Infectology and Poisoning Universitäsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany|Cardiology and Pneumology Clinic Klinikum Garmisch-Partenkirchen, Garmisch-Partenkirchen, Bayern, Germany|Medical Clinic and Polyclinic I. L. Ludwigs-Maximilians-University Clinic, Munich, Munich, Bayern, Germany|Cardiology, Pneumology and Intensive Care Clinic, München Klinik Neuperlach, München, Bayern, Germany|Internal Medicine and Cardiology Klinik Henningsdorf. Oberhavel Kliniken, Hennigsdorf, Brandenburg, Germany|Clinic for Cardiology, Angiology und Nephrology Universitätsklinikum Frankfurt, Goethe-Universität, Frankfurt am Main, Hessen, Germany|Clinic and Polyclinic Internal Medicine Universitätsmedizin Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany|Cardiology and Pneumology Clinic Universitätsmedizin Göttingen, Göttingen, Niedersachsen, Germany|Clinic for Cardiology and Intensive Care - Klinikum Bielefeld, Bielefeld, Nordrhein-Westfalen, Germany|Medical Clinic I. Marien Hospital, Universitätsklinikum der Ruhr Universität Bochum, Herne, Herne, Nordrhein-Westfalen, Germany|Pneumology, Allergology, Sleep-and Respiratory Medicine Clinic Helios Universitätsklinikum Wupperthal, Wuppertal, Nordrhein-Westfalen, Germany|Center for Cardiology, University Medicine Mainz, Mainz, Rheinland-Pfalz, Germany|Clinic for Vascular Medicine, Städtisches Krankenhaus Dresden, Dresden, Sachsen, Germany|Medical Clinic I. Universitätsklinikum Carl Gustav Carus, Dresden, Dresden, Sachsen, Germany|Cardiology, Pneumology and Intensive Care Clinic Helios Klinikum Pirna, Dresden, Pirna, Sachsen, Germany|Medical Clinic II, University Clinic Schleswig-Holstein - Campus Lübeck, Lübeck, Schleswig-Holstein, Germany|Department of Pneumology and Infectology Charité University Medicine Berlin, Campus Mitte, Berlin, Germany|Internal Medicine II, Cardiology, Sana Klinikum, Lichtenberg. Berlin, Berlin, Germany|Medical Clinic II. St. Joseph Hospital Berlin, Berlin, Germany|Department of Cardiology Charité University Medicine Berlin, Campus Benjamin Franklin, Berlin, Germany|Internal Medicine, Hospital Bethel Berlin in Lichterfelde, Berlin, Germany|Internal Medicine/Cardiology department Unfallkrankenhaus Berlin, Berlin, Germany|Department of Cardiology Charité University Medicine Berlin, Campus Virchow, Berlin, Germany|Internal Medicine, Cardiology and Intensive Care Clinic Vivantes Humboldt Klinikum, Berlin, Berlin, Germany|Intensive Care and Cardiology, Hospital Havelhöhe, Berlin, Germany|Internal Medicine Deparment Hospital Waldfriede, Berlin, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT04416048"
493,"NCT04315298","Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Sarilumab|Drug: Placebo","Percent change in C-reactive protein (CRP) levels in patients with serum IL-6 level greater than the upper limit of normal|Proportion of patients with at least 1-point improvement in clinical status using the 7-point ordinal scale in patients with critical COVID-19 receiving mechanical ventilation at baseline|Proportion of patients with at least 1-point improvement in clinical status using the 7-point ordinal scale in patients with COVID-19 receiving mechanical ventilation at baseline|Proportion of patients with at least 1-point improvement in clinical status using the 7-point ordinal scale in patients with COVID-19 not on mechanical ventilation but on high-intensity oxygen therapy* at baseline|Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale in severe or critical patients with serum IL-6 levels greater than the upper limit of normal|Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale reporting in severe or critical patients with all IL-6 levels|Time to resolution of fever for at least 48 hours without antipyretics in patients with documented fever|Time to resolution of fever for at least 48 hours without antipyretics by clinical severity|Time to resolution of fever for at least 48 hours without antipyretics by baseline IL-6 levels|Time to improvement in oxygenation for at least 48 hours|Time to improvement in oxygenation for at least 48 hours by clinical severity|Time to improvement in oxygenation for at least 48 hours by baseline IL-6 levels|Time to resolution of fever and improvement in oxygenation for at least 48 hours|Mean change in the 7-point ordinal scale|Percentage of patients in each clinical status category using the 7-point ordinal scale|Time to discharge or to a National Early Warning Score 2 (NEWS2) of ≤2 and maintained for 24 hours|Change from baseline in NEWS2 scoring system|Number of days with fever|Proportion of patients alive, off oxygen|Number of days of resting respiratory rate >24 breaths/min|Number of days with hypoxemia|Number of days of supplemental oxygen use|Time to saturation ≥94% on room air|Number of ventilator free days in the first 28 days|Number of patients requiring initiation of mechanical ventilation|Number of patients requiring non-invasive ventilation|Number of patients requiring the use of high flow nasal cannula|Number of patients admitted into an intensive care unit (ICU)|Number of days of hospitalization among survivors|Number of deaths due to any cause|Proportion of patients with at least 1-point improvement in clinical status using the 7-point ordinal scale|Proportion of patients who recover|Proportion of deaths|Proportion of patients alive not receiving mechanical ventilation|Proportion of patients alive not requiring extracorporeal membrane oxygenation (ECMO)|Proportion of patients with a 2-point improvement in clinical status on the 7-point ordinal scale|Time to at least 1-point improvement in clinical status assessment on the 7-point ordinal scale|Time to at least 2-point improvement in clinical status assessment on the 7-point ordinal scale|Proportion of patients receiving mechanical ventilation|Proportion of patients receiving ECMO|Proportion of patients discharged and alive|Time to recovery|Time to death due to any cause|Number of ventilator free days|Proportion of patients with serious adverse events|Proportion of patients with Grade 4 neutropenia (ANC <500/mm3)|Proportion of patients with severe or life-threatening bacterial, invasive fungal, or opportunistic infection|Proportion of patients with severe or life-threatening bacterial, invasive fungal, or opportunistic infection in patients with Grade 4 neutropenia (ANC <500/mm3)|Proportion of patients with hypersensitivity reactions|Proportion of patients with infusion reactions|Proportion of patients with gastrointestinal perforation|White blood cell count|Hemoglobin levels|Platelet count|Creatinine levels|Total bilirubin level|Alanine aminotransferase (ALT) level|Aspartate aminotransferase (AST) level","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","2500","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","6R88-COV-2040","March 18, 2020","May 20, 2021","July 20, 2021","March 19, 2020",,"June 9, 2020","Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Santa Monica, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Denver, Colorado, United States|Regeneron Study Site, New Haven, Connecticut, United States|Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, Coral Gables, Florida, United States|Regeneron Study Site, Gainesville, Florida, United States|Regeneron Study Site, Orlando, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Decatur, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Ann Arbor, Michigan, United States|Regeneron Study Site, Rochester, Minnesota, United States|Regeneron Study Site, Edison, New Jersey, United States|Regeneron Study Site, Hackensack, New Jersey, United States|Regeneron Study Site, Livingston, New Jersey, United States|Regeneron Study Site, Morristown, New Jersey, United States|Regeneron Study Site, Neptune, New Jersey, United States|Regeneron Study Site, Newark, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site 1, Bronx, New York, United States|Regeneron Study Site 2, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Brooklyn, New York, United States|Regeneron Study Site, Buffalo, New York, United States|Regeneron Study Site, Elmhurst, New York, United States|Regeneron Study Site 1, Manhasset, New York, United States|Regeneron Study Site 2, Manhasset, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site 1, New York, New York, United States|Regeneron Study Site 2, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Stony Brook, New York, United States|Regeneron Study Site, Valhalla, New York, United States|Regeneron Study Site, Tulsa, Oklahoma, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Danville, Pennsylvania, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Scranton, Pennsylvania, United States|Regeneron Study Site, Wilkes-Barre, Pennsylvania, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Murray, Utah, United States|Regeneron Study Site, Falls Church, Virginia, United States|Regeneron Study Site, Richmond, Virginia, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site, Renton, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04315298"
494,"NCT04432922","Perceptions, Representations and Experiences of Septic Isolation of Hospitalized Patients for COVID-19 Infection",,"Not yet recruiting","No Results Available","COVID19","Other: Hospitalized Patients for COVID-19 Infection","To highlight the perceptions, representations and experiences of septic isolation of patients hospitalized for COVID-19 infection|to identify key elements to improve the medical discourse on septic isolation among patients","Centre Hospitalier Intercommunal Creteil","All","18 Years and older   (Adult, Older Adult)",,"15","Other","Observational","Observational Model: Other|Time Perspective: Prospective","ISOCOV","July 1, 2020","July 15, 2020","July 15, 2020","June 16, 2020",,"June 22, 2020","Centre hospitalier intercommunal de Villeneuve St Georges, Villeneuve St Georges, France",,"https://ClinicalTrials.gov/show/NCT04432922"
495,"NCT04424017","Sero-prevalence of Coronavirus Disease 2019 (COVID-19) in Healthcare Workers",,"Not yet recruiting","No Results Available","COVID|Corona Virus Infection","Biological: Specific anti-SARS-CoV-2 antibodies","Describe the serological status of individuals in the study by presence of specific anti-SARS-CoV-2 antibodies","Egyptian Center for Research and Regenerative Medicine|Cairo University|National Research Center, Egypt|Academy of Scientific Research and Technology, Egypt","All","28 Years to 60 Years   (Adult)",,"726","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","COVID-19\004","June 16, 2020","September 30, 2020","September 30, 2020","June 9, 2020",,"June 11, 2020","Egypt Center for Research and Regenerative Medicine, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04424017"
496,"NCT04350684","Umifenovir in Hospitalized COVID-19 Patients","UAIIC","Enrolling by invitation","No Results Available","COVID-19","Drug: Umifenovir|Drug: Interferon-β 1a|Drug: Lopinavir / Ritonavir|Drug: Single Dose of Hydroxychloroquine|Drug: Standards of Care","Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events","Shahid Beheshti University of Medical Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Umifenovir in COVID-19","April 15, 2020","April 22, 2020","April 24, 2020","April 17, 2020",,"April 20, 2020","Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04350684"
497,"NCT04351581","Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With COVID-19","RASCOVID-19","Recruiting","No Results Available","Covid-19","Other: Discontinuation of ACEi/ARB|Other: Continuation of ACEi/ARB","Days alive and out of hospital within 14 days after recruitment|Key-secondary composite endpoint: Occurrence of worsening of COVID-19|Occurrence and time to occurrence of each of the components of the key-secondary composite endpoint|Kidney function assessed by plasma creatinine|Duration of index hospitalisation|30-day mortality|Number of days alive during the intervention period|Number of participants not yet discharged at day 30|Number of readmissions after 30 days.|Kidney function as assessed by eGFR","University Hospital, Gentofte, Copenhagen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","215","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","H-20026484|2020-001544-26","May 18, 2020","December 2020","December 2020","April 17, 2020",,"June 5, 2020","Department of Medicine, Gentofte Hospital, University of Copenhagen, Hellerup, Capital Region Of Denmark, Denmark|Department of Medicine, Herlev Hospital, University of Copenhagen, Herlev, Capital Region Of Denmark, Denmark",,"https://ClinicalTrials.gov/show/NCT04351581"
498,"NCT04346420","Impact of the Double-Trunk Mask on Oxygenation Titration in COVID-19",,"Completed","No Results Available","COVID|Hypoxemia","Other: Standard interface|Device: Double-Trunk Mask","Change in O2 output|Comfort with the interfaces|Changes in PaO2|Changes in PaCO2|Changes in pH|Changes in respiratory rate","Cliniques universitaires Saint-Luc- Université Catholique de Louvain","All","18 Years and older   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","DTM-001","April 9, 2020","May 1, 2020","May 1, 2020","April 15, 2020",,"June 9, 2020","Cliniques universitaires Saint-Luc, Brussels, Brussels Capital, Belgium",,"https://ClinicalTrials.gov/show/NCT04346420"
499,"NCT04418518","A Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness","CONCOR-1","Not yet recruiting","No Results Available","COVID-19","Biological: Convalescent plasma","Intubation or death in hospital|Need for Intubation|Time to intubation|Ventilator-free days|In-hospital death|Time to in-hospital death|Death at 30 days|Length of stay in intensive care unit (ICU)|Length of stay in hospital|Need for extracorpeal membrane oxygenation (ECMO)|Need for renal replacement therapy|Development of myocarditis|Adverse events and serious adverse events|CCP transfusion-associated adverse events (AE)","Weill Medical College of Cornell University|Hamilton Health Sciences Corporation","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","1200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-04021981","June 2020","June 2021","December 2021","June 5, 2020",,"June 5, 2020","Weill Cornell Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04418518"
500,"NCT04389359","PROphylaxis for paTiEnts at Risk of COVID-19 infecTion","PROTECT","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine Sulfate 200 MG","Time to confirmed diagnosis of COVID-19|All-cause mortality|Severity of COVID-19 disease|Incidence of COVID-19 complications","Cambridge University Hospitals NHS Foundation Trust|University of Cambridge","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","1500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","A095590","May 2020","August 2021","August 2025","May 15, 2020",,"May 15, 2020",,,"https://ClinicalTrials.gov/show/NCT04389359"
501,"NCT04363372","A Study for Efficacy and Safety of Live Biotherapeutic MRx4DP0004 to Treat COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: MRx-4DP0004|Drug: Placebo","Change in mean clinical status score in each treatment arm|Number of adverse events in each treatment arm|Number of patients with an improvement in clinical status score in each treatment arm|Number of patients with a deterioration in clinical status score in each treatment arm|Number of patients with at least 95% oxygen saturation on room air in each treatment arm|Time to patients with at least 95% oxygen saturation on room air in each treatment arm|Number of patients with an improvement in the National Early Warning Score (NEWS) 2 in each treatment arm|Number of patients with an deterioration in the National Early Warning Score (NEWS) 2 in each treatment arm|Number of patients requiring Continuous Positive Airway Pressure in each treatment arm|Number of patients requiring Intermittent Positive Pressure Ventilation in each treatment arm|Time to patients requiring Continuous Positive Airway Pressure in each treatment arm|Time to patients requiring Intermittent Positive Pressure Ventilation in each treatment arm|Time to discharge in each treatment arm|Number of deaths in each treatment arm","4D pharma plc","All","18 Years and older   (Adult, Older Adult)","Phase 2","90","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MRx-4DP0004-II-001","May 2020","August 2020","September 2020","April 27, 2020",,"April 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04363372"
502,"NCT04399681","The Utility of Bedside Lung Ultrasonography on Diagnosis of COVID-19",,"Recruiting","No Results Available","COVID|Pneumonia, Viral","Device: Bedside lung ultrasound","Presence of viral pneumonia caused by COVID 19","Kanuni Sultan Suleyman Training and Research Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","KSSEAH--","May 10, 2020","August 10, 2020","September 10, 2020","May 22, 2020",,"May 22, 2020","Istanbul Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04399681"
503,"NCT04344561","Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation","UPSAT","Recruiting","No Results Available","COVID|Hypoxic Respiratory Failure","Other: Postural Positioning","Incidence of Mechanical Ventilation|Number of participants with supplemental oxygen requirements|Mean oxyhemoglobin saturation|Mean Nocturnal Oxyhemoglobin Saturation|Heart Rate|Respiratory Rate|Percentage of time in the assigned position","Johns Hopkins University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00246834","May 25, 2020","May 1, 2021","May 1, 2021","April 14, 2020",,"June 24, 2020","Johns Hopkins Bayview Hospital, Baltimore, Maryland, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04344561"
504,"NCT04385160","Myeloproliferative Neoplasms (MPN) and COVID-19","MPN-COVID","Recruiting","No Results Available","Myeloproliferative Neoplasm|COVID",,"pulmonary embolism (PE)|fatal or non fatal thrombotic event|Continuous Positive Airway Pressure (CPAP)|invasive ventilation|admission in Intensive Care Unit (ICU)|death|treatments and interventions applied for MPN|treatments and interventions applied for COVID-19|thrombotic events association to patients characteristic and treatments","Fondazione per la Ricerca Ospedale Maggiore|European Leukemia Net","All","18 Years and older   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Cohort|Time Perspective: Other","FROM - O-MPN-COVID-2020","May 13, 2020","July 15, 2020","September 1, 2020","May 12, 2020",,"June 11, 2020","Mount Sinai Health System, New York, New York, United States|New York-Presbyterian/Weill Cornell Medical Center, New York, New York, United States|Zealand University Hospital, Køge, Denmark|Hopital Saint-Louis, Paris, France|University Medical Center RWTH, Aachen, Germany|University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center, Minden, Germany|Ospedale San Gerardo di Monza, Monza, Monza Brianza, Italy|A.S.O. SS. Antonio e Biagio e C.Arrigo di Alessandria, Alessandria, Italy|Asl AT - Ospedale ""Cardinal Massaia"" di Asti, Asti, Italy|ASST-Papa Giovanni XXIII, Bergamo, Italy|Policlinico S.Orsola-Malpighi, Bologna, Italy|ASST-Spedali Civili, Brescia, Italy|AOU Ospedale Careggi, Firenze, Italy|Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy|Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy|IRCCS Ospedale San Raffaele, Milano, Italy|Azienda Ospedaliero Universitaria Maggiore della Carità, Novara, Italy|IRCCS Policlinico San Matteo, Pavia, Italy|Policlinico Universitario Fondazione Agostino Gemelli, Roma, Italy|A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy|Ospedale Policlinico ""G.B. Rossi"" Borgo Roma, Verona, Italy|Ospedale San Bortolo, Vicenza, Italy|Hospital Clínic De Barcelona, Barcelona, Barcellona, Spain|Hospital del Mar, Barcelona, Barcellona, Spain|Institut Català d' Oncologia - Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain|ICO L'Hospitalet - Hospital Moisès Broggi, Sant Joan Despí, Barcelona, Spain|Hospital Universitario Príncipe de Asturias, Alcalá De Henares, Madrid, Spain|Hospital General de La Palma, Breña Alta, Santa Cruz De Tenerife, Spain|Servicio de Hematología Hospital General Universitario de Albacete, Albacete, Spain|Hospital General de Elche, Alicante, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|ICO Girona Hospital Josep Trueta Servei d'hematologia, Girona, Spain|FEA Hematología Hospital Universitario de Móstoles, Madrid, Spain|Hospital 12 de octubre, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Gregorio Marañón, Madrid, Spain|Hospital Moncloa, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Clínico Universitario, Valencia, Spain|Guy's and St. Thomas' NHS Foundation Trust., London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04385160"
505,"NCT04379466","Effector and Regulatory T Cell Receptor Repertoire Analyses in Patients Affected by COVID-19","CovRep","Not yet recruiting","No Results Available","COVID-19",,"A list of COVID-19 specific TCR sequences|One or more measures from peripheral blood immunophenotyping that is/are associated with COVID-19 outcome|Group of COVID-19 specific TCR sequences that is associated with COVID-19 outcome","Assistance Publique - Hôpitaux de Paris","All","18 Years to 75 Years   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","APHP200544|2020-A01245-34","May 2020","July 2020","November 2020","May 7, 2020",,"May 7, 2020",,,"https://ClinicalTrials.gov/show/NCT04379466"
506,"NCT04408365","Endothelial Function, Inflammation and Organ Dysfunction in COVID-19",,"Not yet recruiting","No Results Available","COVID|Shock",,"Plasma bio-adrenomedullin, proenkephalin, dipeptidyl peptidase-3, renin and angiotensin II|Duration of vasodilatory shock|Acute kidney injury|Need for renal replacement therapy|Duration of ventilation|Duration of extracorporeal membrane oxygenation|Mortality","Guy's and St Thomas' NHS Foundation Trust|King's College Hospital NHS Trust","All","18 Years and older   (Adult, Older Adult)",,"82","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","282930","June 1, 2020","May 31, 2021","May 31, 2021","May 29, 2020",,"May 29, 2020",,,"https://ClinicalTrials.gov/show/NCT04408365"
507,"NCT04377750","The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation",,"Recruiting","No Results Available","Covid19 Pneumonia","Drug: Tocilizumab","Survival","Hadassah Medical Organization|Sheba Medical Center|Wolfson Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0224-20-HMO-CTIL","April 8, 2020","April 29, 2020","May 8, 2021","May 6, 2020",,"May 6, 2020","Hadassah Medical Orginisation, Jerusalem, Please Select:, Israel|Barzilai Medical Center, Ashkelon, Israel|Wolfson Medical Center, H̱olon, Israel|Sheba Medical Center, Ramat Gan, Israel",,"https://ClinicalTrials.gov/show/NCT04377750"
508,"NCT04408339","COVID-19 in Cancer Patients: Evaluation of Clinical Course and Impact on Oncological Care Including Biobanking","COVIDHELP","Recruiting","No Results Available","Cancer|COVID","Other: No Intervention","Rate of hospitalization|Duration of hospitalization|Rate of admission to intensive care unit|Length of stay in intensive care unit|Need of mechanical ventilation|Duration of mechanical ventilation|Disease-specific mortality rate|Rate of patients, whose oncologic treatment had to be modified due to COVID-19|Cellular and humoral immune response to COVID-19 infection","Universitätsklinikum Hamburg-Eppendorf|University of Schleswig-Holstein, Campus Lübeck|Universitätsklinikum Schleswig-Holstein, Campus Kiel","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PV7313","April 15, 2020","April 14, 2021","April 14, 2022","May 29, 2020",,"June 16, 2020","University Hospital Hamburg Eppendorf, Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT04408339"
509,"NCT04377620","Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)",,"Recruiting","No Results Available","COVID-19","Drug: Placebo|Drug: Ruxolitinib","Proportion of participants who have died due to any cause|Number of Ventilator free days|Number of ICU free days|Oxygen free days|Vasopressor free days|Hospital free days|Improvement in the COVID-19 ordinal scale|Change in SOFA Score|Number of treatment-related adverse events","Incyte Corporation","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","500","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","INCB 18424-369","May 24, 2020","September 29, 2020","September 29, 2020","May 6, 2020",,"June 16, 2020","Georgetown University Hospital, Washington, District of Columbia, United States|Tampa General Hospital, Tampa, Florida, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|Boston Medical Center, Boston, Massachusetts, United States|Lahey Clinic Inc., Burlington, Massachusetts, United States|UMass MMC - University Campus, Worcester, Massachusetts, United States|Duke University Medical Center, Durham, North Carolina, United States|Jefferson Hospital, Philadelphia, Pennsylvania, United States|West Penn Hospital, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04377620"
510,"NCT04347954","PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)",,"Recruiting","No Results Available","COVID-19","Drug: Povidone-Iodine 2%|Drug: Povidone-Iodine 0.5%|Drug: Isotonic saline 0.9%","Mean change in viral titers of SARS-CoV-2|Frequency of adverse effects of interest after nasal sprays|Frequency of symptoms related to SARS-CoV-2|Compliance with study drug administration|Change from baseline in University of Pennsylvania Smell Identification Test (UPSIT)","Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB-56134","June 11, 2020","September 2020","October 2020","April 15, 2020",,"June 18, 2020","Stanford Health Care, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04347954"
511,"NCT04412291","A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study",,"Recruiting","No Results Available","Covid-19","Drug: Anakinra Prefilled Syringe|Drug: Tocilizumab Prefilled Syringe|Drug: Standard-of-care treatment","Time to recovery|Mortality|Number of Days on mechanical ventilation|Number of days of supplemental oxygen use|Number of patients requiring initiation of mechanical ventilation|Time to improvement in oxygenation for at least 48 hours|Mean change in the 8-point ordinal scale|Proportion of patients on level e-h on the 8-point ordinal scale at day 15|Time to improvement in one category from admission using the 8-point ordinal scale|Mean change in Sequential organ failure assessment score (SOFA)|Time to resolution of fever for at least 48 hours by clinical severity|Time to change in National Early Warning Score 2 (NEWS2) scoring system|Time to score of <2 maintained for 24 hours in NEWS2 scoring system (National Early Warning Score)|Mean change in NEWS2 scoring system (National Early Warning Score)|Number of days with fever|Number of days of resting respiratory rate >24 breaths/min|Time to saturation ≥94% on room air|Incidence of serious adverse events|Incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infection|Incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infection in patients with grade 4 neutropenia|Incidence of hypersensitivity reactions|Incidence of infusion reactions|Number of ventilator free days in the first 28 days|Number of patients requiring non-invasive ventilation|Number of patients requiring the use of high flow nasal cannula|Number of patients requiring Extracorporeal membrane oxygenation (ECMO)|Number of patients that have been admitted into an intensive care unit (ICU)|Number of days of hospitalization in survivors|Number of deaths due to any cause","Karolinska University Hospital|Karolinska Institutet","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-001748-24","June 11, 2020","August 2020","February 2021","June 2, 2020",,"June 26, 2020","Karolinska University Hospital, Huddinge, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT04412291"
512,"NCT04348461","BAttLe Against COVID-19 Using MesenchYmal Stromal Cells",,"Not yet recruiting","No Results Available","COVID|Respiratory Distress Syndrome","Drug: Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells","Efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Survival Rate)|Safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Adverse Event Rate","Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|Instituto de Investigación Sanitaria y Biomédica de Alicante|Hospital General Universitario Gregorio Marañon|Clinica Universidad de Navarra, Universidad de Navarra|Hospital Universitario de Salamanca|Hospital General Universitario de Alicante|Hospital Clínico Universitario Virgen de la Arrixaca","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BALMYS-19","April 6, 2020","September 15, 2020","September 30, 2020","April 16, 2020",,"April 16, 2020",,,"https://ClinicalTrials.gov/show/NCT04348461"
513,"NCT04406493","Monitoring COVID-19 Patients' Lung Fluid Using Impedance Technique",,"Recruiting","No Results Available","ARDS|COVID","Diagnostic Test: Lung impedance technique","Correlation between impudence deterioration to clinical conditions and hospitalization period","Hillel Yaffe Medical Center","All","18 Years to 95 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","0059-20-HYMC","April 28, 2020","April 28, 2021","April 28, 2021","May 28, 2020",,"May 28, 2020","Hillel Yaffe MC,, Hadera, Israel",,"https://ClinicalTrials.gov/show/NCT04406493"
514,"NCT04354714","Ruxolitinib to Combat COVID-19",,"Withdrawn","No Results Available","COVID-19","Drug: Ruxolitinib|Procedure: Peripheral blood draw","Overall survival|Length of hospital stay|Length of ICU stay|Duration of ventilator use|Duration of vasopressors use|Duration on renal replacement therapy|Viral kinetics as measured by virologic failure|Number of adverse events as measured by CTCAE v. 5.0|Proportion of participants with detectable virus","Washington University School of Medicine|Incyte Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","04-13-20-DiPersio","June 30, 2020","July 31, 2021","December 31, 2021","April 21, 2020",,"May 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04354714"
515,"NCT04363060","Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit","AziA","Not yet recruiting","No Results Available","COVID-19 Pneumonia","Combination Product: Azithromycin with amoxicillin/clavulanate|Drug: amoxicillin/clavulanate","Rate of positive SARS-CoV-2 RT-PCR|Clinical evolution on the World Health Organization Ordinal Scale for Clinical Improvement for COVID-19|Total duration of antibiotic treatment during the 30 days following inclusion|Number of all-cause mortality during the 30 days following inclusion|Number of in-hospital mortality during the 30 days following inclusion|Number of patients transferred to intensive care unit during the 30-day follow-up|Number of days without mechanical ventilation during the 30 days following inclusion|adverse events attributable to antibiotic treatment during the 30 days following inclusion|Hospital length of stay during the 30 days following inclusion","Nantes University Hospital","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","104","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RC20_0168","April 30, 2020","July 30, 2020","July 30, 2020","April 27, 2020",,"April 29, 2020","Chu Angers, Angers, France|CHD Vendée, La Roche-sur-Yon, France|CHU Poitiers, Poitiers, France",,"https://ClinicalTrials.gov/show/NCT04363060"
516,"NCT04338698","Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT","PROTECT","Not yet recruiting","No Results Available","COVID 19","Drug: Hydroxychloroquine|Drug: Oseltamivir|Drug: Azithromycin","Laboratory Result|Clinical Outcome","Shehnoor Azhar|Federal Task Force on Science & Technology notified by Government of Pakistan|University of Health Sciences Lahore","All","18 Years and older   (Adult, Older Adult)","Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12(06)/2016-Coord","April 7, 2020","September 1, 2020","November 30, 2020","April 8, 2020",,"April 10, 2020",,,"https://ClinicalTrials.gov/show/NCT04338698"
517,"NCT04361123","Atrium COVID-19 Syndromic and Serologic Surveillance",,"Enrolling by invitation","No Results Available","Coronavirus|COVID","Other: daily syndromic surveillance|Diagnostic Test: monthly serologic IgM/G test","Seroprevalence of SARS-CoV-2 infection in the general population of North Carolina|Seroprevalence of SARS-CoV-2 infection among health care workers of North Carolina|Cumulative incidence of SARS-CoV-2 infection|Monthly incidence of SARS-CoV-2 infection|Stratified incidence of SARS-CoV-2 infection by age group|Stratified incidence of SARS-CoV-2 infection by sex|Stratified incidence of SARS-CoV-2 by season|Stratified incidence of SARS-CoV-2 infection by geographic area (zip code)|Stratified incidence of SARS-CoV-2 infection by preexisting comorbidities|Stratified incidence of SARS-CoV-2 infection by COVID-2 contacts|•Stratified incidence of SARS-CoV-2 infection by use of personal protective equipment (PPE) by health workers|Relative risk of SARS-CoV-2 infection by age group|Relative risk of SARS-CoV-2 infection by sex|Relative risk of SARS-CoV-2 infection by season|Relative risk of SARS-CoV-2 infection by geographic area (zip code)|Relative risk of SARS-CoV-2 infection by preexisting comorbidities|Relative risk of SARS-CoV-2 infection by COVID-2 contacts|Relative risk of SARS-CoV-2 infection by use of PPE by health workers|Incidence of sequelae","Michael Runyon, MD|Atrium Health","All","18 Years and older   (Adult, Older Adult)",,"450000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","04-20-11A","April 2020","December 2021","December 2021","April 24, 2020",,"April 30, 2020","Atrium Health, Charlotte, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04361123"
518,"NCT04275947","The COVID-19 Mobile Health Study (CMHS)","CMHS","Recruiting","No Results Available","COVID-19","Other: nCapp, a cell phone-based auto-diagnosis system","Accuracy of nCapp COVID-19 risk diagnostic model","Chinese Alliance Against Lung Cancer|Shanghai Respiratory Research Institution","All","18 Years to 90 Years   (Adult, Older Adult)",,"450","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CAALC-008-CMHS","February 14, 2020","April 30, 2020","May 31, 2020","February 19, 2020",,"February 19, 2020","Renmin Hospital of Wuhan University, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04275947"
519,"NCT04406532","Home-Based Covid-19 Rehabilitation Program",,"Not yet recruiting","No Results Available","Covid-19","Behavioral: PT-Pal|Behavioral: Self-guided exercises","Change in pulmonary function (St George's Respiratory questionnaire: SGRQ)|Change in physical function (Activity Measure for Post-Acute Care: AM-PAC)|Change in pulmonary function (Sabrasez single breath count)|Change in pulmonary function (Peak flow tests)|Change in physical function (5 times site to stand test)|Health events (emergency room visits and hospitalizations)|Change in psychological measures (Beck Anxiety Inventory: BAI)|Change in psychological measures (Center for Epidemiologic Studies Depression Scale: CES-D)|Feasibility (Adherence)|Feasibility (Acceptability)","Albert Einstein College of Medicine","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2020-11535","July 1, 2020","January 1, 2021","March 1, 2021","May 28, 2020",,"May 28, 2020",,,"https://ClinicalTrials.gov/show/NCT04406532"
520,"NCT04363866","A Pilot Study to Assess Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19)",,"Not yet recruiting","No Results Available","COVID-19|SARS-CoV-2","Drug: Hydroxychloroquine|Drug: Placebo","Clinical Status at Day 5 Assessed by a 6-Point Ordinal Scale|Number of Participants with Detectable SARS-CoV-2 Virus from Day 0 to Day 28 and at Day 5|Toxicity of Study Drug Assessed by Incidence of Adverse Events","Oregon Health and Science University|OHSU Knight Cancer Institute","All","18 Years and older   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","STUDY00021303","May 2020","December 2020","June 2021","April 27, 2020",,"April 27, 2020","Oregon Health and Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT04363866"
521,"NCT04353206","Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure",,"Recruiting","No Results Available","Covid-19|Sars-CoV2","Biological: Multiple Doses of Anti-SARS-CoV-2 convalescent plasma","Proportion of subjects who consent to the study and receive at least one dose of convalescent plasma.|Overall survival of patients in the ICU receiving at least once dose of convalescent plasma for Covid-19-induced respiratory failure.","Noah Merin|Johns Hopkins University|Cedars-Sinai Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Acute Care CP Consortium Trial","May 2020","May 2021","May 2021","April 20, 2020",,"May 14, 2020","8700 Beverly Blvd., Los Angeles, California, United States|Johns Hopkins University, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04353206"
522,"NCT04382625","Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial",,"Not yet recruiting","No Results Available","SARS-CoV-2 Pneumonia|COVID-19","Drug: Hydroxychloroquine","Change from Baseline Oxygenation on Day 1 to Day 5|Change from Baseline Oxygenation at Day 5|Intensive Care length of stay|Required Mechanical Ventilation|Required Oxygen supplementation|Hospitalization length of Stay|Mortality|Cardiac Arrhythmia - Polymorphic Ventricular Tachycardia|Cardiac Arrhythmia - Ventricular Tachycardia|Cardiac Arrhythmia - Lengthening QTc","Kootenai Health|Washington State University","All","18 Years and older   (Adult, Older Adult)","Phase 4","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18244","May 2020","January 1, 2022","June 1, 2022","May 11, 2020",,"May 11, 2020","Kootenai Health, Coeur d'Alene, Idaho, United States",,"https://ClinicalTrials.gov/show/NCT04382625"
523,"NCT04371965","Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With COVID-19","KILLER","Not yet recruiting","No Results Available","COVID-19","Drug: Povidone-Iodine","Change from baseline naso-pharyngeal viral load quantified by RT-PCR at Day7|Delay between inclusion and negativation of SARS-CoV-2 nasopharyngeal carriage|Delay between inclusion and negativation of SARS-CoV-2 nasopharyngeal cell cultures|Thyroid tests at Day0 and Day7|Patient satisfaction at Day7 using a numerical comfort scale, graduated from 0 (any discomfort) to 10 (maximum possible discomfort)|Daily presence of clinical signs in favour of COVID-19, including respiratory distress using NYHA scale, chest pain, anosmia, agueusia, tiredness, cough, stiffness, nasal congestion, dysphagia and diarrhea|Need for ward or intensive care hospitalization","Poitiers University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KILLER","May 1, 2020","July 1, 2020","August 1, 2020","May 1, 2020",,"May 1, 2020","University Hospital of Poitiers, Poitiers, France",,"https://ClinicalTrials.gov/show/NCT04371965"
524,"NCT04386369","Evaluation of Airway Pressure Release Ventilation in COVID-19 ARDS","APRV-COVID19","Completed","No Results Available","ARDS|COVID19","Other: Airway pressure release ventilation","Proportion of patients improving PaO2/FiO2 ratio at 6 hours of APRV|Number of interventions on ventilator settings|Change in mean blood pressure|Change in heart rate|Changes in catecholamine doses|Changes in static compliance at the end of 6 hours of APRV|Variations of minute ventilation|Changes in static compliance 4 hours after stopping APRV|Proportion of patients with a decrease of the PaO2/FiO2 ratio","Central Hospital, Nancy, France","All","18 Years and older   (Adult, Older Adult)",,"17","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2020PI076","April 15, 2020","June 1, 2020","June 1, 2020","May 13, 2020",,"June 11, 2020","Centre Hospitalier Régional Universitaire de Nancy, Nancy, France",,"https://ClinicalTrials.gov/show/NCT04386369"
525,"NCT04435184","Crizanlizumab for Treating COVID-19 Vasculopathy","CRITICAL","Not yet recruiting","No Results Available","COVID-19","Drug: Crizanlizumab|Other: 0.9% saline","Soluble P-selectin level|D-dimer level|VWF level|CRP level|Change in clinical status as assessed by the World Health Organization (WHO) Ordinal Scale for COVID-19 Trials|Time to hospital discharge|Safety of Crizanlizumab as assessed by adverse events","Johns Hopkins University|Novartis|Socar Research SA|Brigham and Women's Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00249874","June 2020","October 2020","October 2020","June 17, 2020",,"June 17, 2020","Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04435184"
526,"NCT04330638","Treatment of COVID-19 Patients With Anti-interleukin Drugs","COV-AID","Recruiting","No Results Available","COVID-19","Other: Usual Care|Drug: Anakinra|Drug: Siltuximab|Drug: Tocilizumab","Time to Clinical Improvement|Time to improvement in oxygenation|Mean change in oxygenation|Number of days with hypoxia|Number of days of supplemental oxygen use|Time to absence fever for more than 48h without antipyretics|Number of days with fever|Time to halving of CRP levels compared to peak value during trial|Time to halving of ferritin levels compared to peak value during trial|Incidence of AEs (Adverse Events)|Incidence of SAEs (Serious Adverse Events)|Duration of hospital stay|Duration of hospital stay in survivors|Mean change in clinical sign score between day 1 and day 7|Mean change in clinical sign score between day 1 and day 15|Time to clinical sign score <6 maintained for 24h|Mean change of SOFA score (Sequential Organ Failure Assessment) between day 1 and day 7|Mean change of SOFA score between day 1 and day 15|Mean change NEWS2 (National Early Warning) score between day 1 and day 7|Mean change NEWS2 score between day 1 and day 15|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-1|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-6|Incidence of nosocomial bacterial or invasive fungal infection|incidence of secondary haemophagocytic lymphohistiocytosis|Incidence of secondary haemophagocytic lymphohistiocytosisscore in relation to serum IL-1|Incidence of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6|Time to first use of high-flow oxygen devices, non-invasive or invasive mechanical ventilation in non-ventilated patients|Time to first use of salvage systemic steroids in ventilated patients|Number of ventilator free days|Duration of mechanical ventilation in ventilated patients|Duration of ICU stay in patients that enrolled in trial while already on invasive or non-invasive mechanical ventilation|Time to progression to ARDS in ventilated patients|Time to progression to ARDS in ventilated patients according to IL-1|Time to progression to ARDS in ventilated patients according to IL-6|All-cause mortality rate (excluding group that entered during ventilation)|Percentage of patients in clinical status on 6-point Ordinal Scale|Incidence of lung function abnormalities|Incidence of lung fibrosis on chest CT scan|All-cause mortality rate","University Hospital, Ghent|Belgium Health Care Knowledge Centre","All","18 Years and older   (Adult, Older Adult)","Phase 3","342","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COV-AID","April 2020","September 2020","December 2020","April 1, 2020",,"April 24, 2020","AZ Sint-Jan Brugge, Brugge, Belgium|University Hospital Saint-Pierre, Brussels, Belgium|Erasmus University Hospital, Brussels, Belgium|University Hospital Saint-Luc, Brussels, Belgium|University Hospital Antwerp, Edegem, Belgium|Ziekenhuis Oost-Limurg, Genk, Belgium|AZ Sint-Lucas, Gent, Belgium|University Hospital Ghent, Gent, Belgium|Jessa ZH, Hasselt, Belgium|University Hospital Brussels, Jette, Belgium|CHU Tivoli, La Louvière, Belgium|CHR de la Citadelle, Liège, Belgium|University Hospital Liège, Liège, Belgium|Cliniques Saint-Pierre Ottignies, Ottignies-Louvain-la-Neuve, Belgium|AZ Delta, Roeselare, Belgium",,"https://ClinicalTrials.gov/show/NCT04330638"
527,"NCT04416256","COVID-19 Pandemic and Worldwide Organ Procurement","COVID","Recruiting","No Results Available","COVID-19",,"Organ transplantation activity during COVID-19 pandemic|Further analysis on organ transplantation with stratification","Paris Translational Research Center for Organ Transplantation|Agence de La Biomédecine|Eurotransplant|United Network for Organ Sharing|Deutsche Stiftung Organtransplantation|Centro Nazionale Trapianti|Brazilian Organ Transplant Association|The Canadian Association of Transplantation|Scandiatransplant|Nederlandse Transplantatie Vereniging|Austrotransplant|Centro Nacional de Trasplantes|Instituto Nacional de Donación y Trasplante de Células, Tejidos y Órganos|Donor Network of Croatia|Instituto Nacional Central Único Coordinador de Ablación e Implante|Corporación Nacional de Trasplantes de Chile|Australian Organ and Tissue Donation and Transplantation Authority|Organización Nacional de Trasplantes|Autoridade Para Services de Sangue e Transplantacáo","All","Child, Adult, Older Adult",,"230000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID/W.W.","February 1, 2020","February 2022","February 2022","June 4, 2020",,"June 4, 2020","Paris Transplant Group, Paris, France",,"https://ClinicalTrials.gov/show/NCT04416256"
528,"NCT04436471","An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac"" Vaccine Against COVID-19",,"Recruiting","No Results Available","Preventive Immunization COVID-19","Biological: Gam-COVID-Vac","Changing ofantibody levels against the SARS-CoV-2 glycoprotein S in 42 days|Number of Participants With Adverse Events|Changing of of virus neutralizing antibody titer|Changing of antigen-specific cellular immunity level","Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation|Acellena Contract Drug Research and Development","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","38","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","02-Gam-COVID-Vac-2020","June 17, 2020","August 5, 2020","August 15, 2020","June 18, 2020",,"June 22, 2020","Main military clinical hospital named after academician N. N. Burdenko, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04436471"
529,"NCT04368923","Management of Covid-19 Patients During Home Isolation",,"Active, not recruiting","No Results Available","Covid 19","Device: Oxygen Therapy|Procedure: Physical Therapy","Arterial Blood Gases (ABG): Partial Pressure of Oxygen and Carbon Dioxide|Arterial Blood Gases (ABG): Acidity Potential Hydrogen (pH)|Vital Signs (Temprature)|Vital Signs (Respiratory Rate)|Vital Signs (Oxygen Saturation)|Vital Signs (Heart Rate)|Vital Signs (Blood Pressure)","Cairo University","All","21 Years to 40 Years   (Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","REC/012-2020","March 15, 2020","June 21, 2020","June 23, 2020","April 30, 2020",,"June 23, 2020","M. Sedky, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04368923"
530,"NCT04344431","Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19)","OHB10cov","Recruiting","No Results Available","Covid-19","Combination Product: Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device)","Time to normalize the oxygen requirement (oxygeno-dependence)|Days of hospitalization between the HBO group and the control group.|Oxygen flow values to obtain a saturation by pulse oximetry greater than or equal to 92% values between the HBO group and the control group.|Days on invasive mechanical ventilation|Mortality","Direction Centrale du Service de Santé des Armées","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2|Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2020PPRC03","April 14, 2020","April 2021","May 2021","April 14, 2020",,"April 21, 2020","Sainte Anne Military Teaching Hospital, Toulon, France",,"https://ClinicalTrials.gov/show/NCT04344431"
531,"NCT04404062","Validation of COVID-19 Tests",,"Active, not recruiting","No Results Available","COVID-19","Diagnostic Test: Covid-19 Rapid Test Kit (RAPG-COV-019)|Diagnostic Test: Quantitative IgG Test","Identification of asymptomatic carriers of SARS-CoV-2|Validation of the ability of the immunoassay kit to detect antibodies to SARS-CoV-2|Development of a quantitative laboratory reference test for the measurement of SARS-CoV-2|Exploration of SARS-CoV-2 epidemiology","Richmond Pharmacology Limited","All","18 Years to 70 Years   (Adult, Older Adult)",,"500","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","C20010","March 16, 2020","August 2020","August 2020","May 27, 2020",,"May 27, 2020","Richmond Pharmacology Ltd. 1a Newcomen St, London Bridge, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04404062"
532,"NCT04425837","Effectiveness and Safety of Convalescent Plasma in Patients With High-risk COVID-19",,"Not yet recruiting","No Results Available","Sars-CoV2|Covid-19","Biological: SARS-CoV-2 convalescent plasma treatment|Other: Standard care","Mortality|Adverse events|ICU admission|Mechanical ventilation|ICU length|Reduction of D Dimer|LDH reduction|Reduction of Troponin level|Decrease in ferritin level|Decrease in procalcitonin level|Decrease in CRP|Increase in lymphocyte count|Increase in PaO2 / Fio2|Decrease in Sequential Organ failure assessment (SOFA ) score|Extracorporeal membrane oxygenation (ECMO)|Lung infiltration","Fundación Santa Fe de Bogota","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","236","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","PLASMA COVID-19","July 2020","February 2021","February 2021","June 11, 2020",,"June 11, 2020","Fundación Santa Fe de Bogotá, Bogotá, Cundinamarca, Colombia",,"https://ClinicalTrials.gov/show/NCT04425837"
533,"NCT04385940","Vitamin D and COVID-19 Management",,"Not yet recruiting","No Results Available","COVID-19","Dietary Supplement: Ddrops® products, 50,000 IU, Oral|Dietary Supplement: Vitamin D3","Symptoms recovery|Hospitalization|Blood white blood cell count (WBC)|Duration of mechanical ventilation|Duration of hospitalization|Intensive care unit (ICU) admission|Duration of ICU stay|Blood C-reactive protein (CRP)|Blood Lymphocyte count|Blood Ferritin|Blood platelet count|Blood interleukin-6 (IL-6)|Blood Tumor Necrosis Factor alpha (TNF)","University of Alberta","All","17 Years and older   (Child, Adult, Older Adult)","Phase 3","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","00100606","June 2020","August 2020","December 2020","May 13, 2020",,"June 5, 2020",,,"https://ClinicalTrials.gov/show/NCT04385940"
534,"NCT04347824","Predict Adverse Events by Covid-19 Nephritis",,"Recruiting","No Results Available","Covid-19",,"Time to Disease-Aggravation|Complications|Resources|Blood-test","University Hospital Goettingen|Universitätsklinikum Hamburg-Eppendorf|University Hospital, Aachen|Transplantationszentrum Köln-Merheim","All","Child, Adult, Older Adult",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","UMG_Co19-Nephritis","April 27, 2020","December 31, 2020","December 31, 2021","April 15, 2020",,"June 4, 2020","University Medical Center Goettingen, Göttingen, Germany",,"https://ClinicalTrials.gov/show/NCT04347824"
535,"NCT04308317","Tetrandrine Tablets Used in the Treatment of COVID-19","TT-NPC","Enrolling by invitation","No Results Available","Corona Virus Disease 2019,COVID-19","Drug: Tetrandrine","Survival rate|body temperature","Henan Provincial People's Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TT-NPC","March 5, 2020","March 1, 2021","May 1, 2021","March 16, 2020",,"March 16, 2020","Tetrandrine Tablets, Jinhua, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT04308317"
536,"NCT04341688","A Clinical Trial of Gargling Agents in Reducing Intraoral Viral Load Among COVID-19 Patients","GARGLES","Not yet recruiting","No Results Available","Covid-19","Drug: Gargle/Mouthwash","Intraoral viral load|Salivary cytokine profile","Aga Khan University|University of Karachi","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","2020-Sur-ERC-4926","August 1, 2020","January 31, 2021","March 31, 2021","April 10, 2020",,"June 26, 2020",,,"https://ClinicalTrials.gov/show/NCT04341688"
537,"NCT04408066","COVID-19: A POC Test Under Research & Evaluation","CAPTURE","Recruiting","No Results Available","COVID-19","Diagnostic Test: Sample Collection/Performance Evaluation (A)|Diagnostic Test: Sample Collection/Performance Evaluation (B)","Performance of the LumiraDx Assay versus reference methods with regards to clinical sensitivity and specificity for the detection of the SARS-COV-2 IgG/IgM and viral antigen in patient samples.","LumiraDx UK Limited","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2000","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","S-CLIN-PROT-00028","April 30, 2020","April 30, 2022","April 30, 2022","May 29, 2020",,"June 4, 2020","Barts Health NHS Trust, London, United Kingdom|Homerton University Hospital NHS Foundation Trust, London, United Kingdom|University College London Hospitals NHS Foundation Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04408066"
538,"NCT04337996","Dynamic Evaluation of COVID-19 Diagnostic Tests","TRODVID-19","Not yet recruiting","No Results Available","COVID-19","Diagnostic Test: COVID-19 diagnostic test","Comparison of the proportion of patients classified as COVID-19 positive according to the 2 strategies|Positive or negative Covid-19 test|Positive or negative character of the antibodies test|Biological parameters|medical-economic comparison","Tourcoing Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","165","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","RIPH_2020_6","June 2020","December 2020","December 2020","April 8, 2020",,"June 12, 2020",,,"https://ClinicalTrials.gov/show/NCT04337996"
539,"NCT04394117","Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease","CLARITY","Recruiting","No Results Available","SARS-Cov-2|COVID-19","Drug: Angiotensin Receptor Blockers","7-Point National Institute of Health Clinical Health Score|Mortality|Intensive Care Unit Admission|Respiratory Failure|Dialysis Requirement|Hospitalisation Days|Ventilator-Free Days|Dialysis Days|Acute Kidney Injury|Hypotension Requiring Vasopressors","The George Institute","All","18 Years and older   (Adult, Older Adult)","Phase 4","605","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","11052020","June 19, 2020","January 30, 2021","April 30, 2021","May 19, 2020",,"June 18, 2020","Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Canterbury Hospital, Campsie, New South Wales, Australia|Concord Hospital, Concord, New South Wales, Australia|St George Hospital, Kogarah, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT04394117"
540,"NCT04394442","Hydroxychloroquine in COVID-19 Patients",,"Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine","time to viral clearance|% of mortality|Length of stay|time to be afebrile|need for mechanical ventilation","Samah Lutfy|Zagazig University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SNH1352020","March 21, 2020","August 2020","August 2020","May 19, 2020",,"May 19, 2020","SNH, Mecca, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT04394442"
541,"NCT04361253","Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy","(ESCAPE)","Recruiting","No Results Available","COVID|Infectious Disease","Biological: High-Titer COVID-19 Convalescent Plasma (HT-CCP)|Biological: Standard Plasma (FFP)","Modified WHO Ordinal Scale (MOS) score","Brigham and Women's Hospital","All","12 Months and older   (Child, Adult, Older Adult)","Phase 3","220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2020P001215","April 30, 2020","June 2021","December 2021","April 24, 2020",,"May 18, 2020","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04361253"
542,"NCT04367545","Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic","MolCOVID","Recruiting","No Results Available","COVID|RT-ddPCR Multiplex","Diagnostic Test: Saliva collection","Number of positive patient using saliva method compared to number of positive patient using standard method|Number of negative patient using saliva method compared to number of negative patient using standard method","University Hospital, Rouen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2020/0094/OB","April 16, 2020","July 2020","July 2020","April 29, 2020",,"June 9, 2020","Rouen University Hospital, Rouen, France",,"https://ClinicalTrials.gov/show/NCT04367545"
543,"NCT04369742","Treating COVID-19 With Hydroxychloroquine (TEACH)",,"Suspended","No Results Available","COVID-19","Drug: Hydroxychloroquine (HCQ)|Other: Pacebo: Calcium citrate","Cumulative incidence of SAEs through day 30|Cumulative incidence of grade 3 or 4 AEs through day 30|Incidence of discontinuation of therapy (for any reason)|Severe disease progression composite outcome|Cumulative incidence of events|Hospital length of stay|Days of fever|Days of non-invasive ventilator use|Days of non-rebreather mask oxygen supplementation|Score on Cytokine Release Syndrome (CRS) Grading Scale|Percentage of subjects reporting each severity score on 8 point ordinal scale Day 1 and EOT (End of Treatment - Day 6)|Percentage of subjects with qTC prolongation at EOT|Cumulative Incidence of mortality|Cumulative Incidence of ICU admission|Cumulative Incidence of Invasive mechanical ventilation|Cumulative Incidence of ECMO|Cumulative Incidence of hypotension requiring vasopressor support|SARS-CoV-2 viral eradication from nasopharyngeal specimens at EOT|Change in Alanine Aminotransferase (ALT) levels|Change in Aspartate Aminotransferase (AST) levels|Change in Creatinine levels|Change in Glucose levels|Change in White Blood Cell (WBC) count|Change in Hemoglobin levels|Change in Platelet count|Change in total bilirubin levels|Change in Lactate Dehydrogenase (LDH) levels|Change in C-Reactive Protein (CRP) levels|Change in Interleukin 6 (IL-6) levels","NYU Langone Health|State University of New York - Downstate Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","626","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","20-00463","April 15, 2020","June 2020","June 2020","April 30, 2020",,"June 19, 2020","State University of New York (SUNY) Downstate Medical Center, Brooklyn, New York, United States|NYU Langone Health, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04369742"
544,"NCT04368234","Duke COVID-19 Shared Data and Specimen Repository",,"Recruiting","No Results Available","COVID-19",,"Development of data repository to provide a secure, centralized storage location for COVID-19 related specimens","Duke University","All","Child, Adult, Older Adult",,"100000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pro00105316","May 5, 2020","April 30, 2025","April 30, 2025","April 29, 2020",,"April 29, 2020","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04368234"
545,"NCT04422509","Lanadelumab for Treatment of COVID-19 Disease","COVID_LAN","Not yet recruiting","No Results Available","COVID-19","Biological: lanadelumab|Other: regular care","oxygen|adverse events","Radboud University|Takeda","All","16 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","80","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UMCN-AKF20.04","June 25, 2020","June 1, 2021","August 1, 2021","June 9, 2020",,"June 9, 2020","Jereoen Bosch hospital, 's-Hertogenbosch, Netherlands|Amsterdam UMC, Amsterdam, Netherlands|Rijnstate hospital, Arnhem, Netherlands|Tergooi ziekenhuizen, Blaricum, Netherlands|Amphia hospital, Breda, Netherlands|Haga hospital, Den Haag, Netherlands|Radboudumc, Nijmegen, Netherlands|Elisabeth-Tweesteden ziekenhuis, Tilburg, Netherlands|UMC Utrecht, Utrecht, Netherlands|Isala klinieken, Zwolle, Netherlands",,"https://ClinicalTrials.gov/show/NCT04422509"
546,"NCT04348942","A COVID-19 Symptom, Exposure and Immune Response Registry",,"Recruiting","No Results Available","COVID-19",,"Registry Data","ObvioHealth","All","18 Years and older   (Adult, Older Adult)",,"10000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","OBVIO-OBV-001","May 29, 2020","May 1, 2021","May 1, 2021","April 16, 2020",,"June 9, 2020","ObvioHealth, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04348942"
547,"NCT04347278","Observational Study of Follow-up of Hospitalized Patients Diagnosed With COVID-19 to Evaluate the Effectiveness of the Drug Treatment Used to Treat This Disease. COVID-19 Registry","RegCOVID19","Recruiting","No Results Available","SARS-CoV-2","Drug: Patients with the treatment agains COVID19","Effectiveness of current drug treatments for hospitalized patients with SARS-CoV-2 infection (COVID-19 patients) in routine clinical practice|Risk factors or modifiers of pharmacological effect such as demographic characteristics, comorbidity or underlying pathology, concomitant medication.|Information on the patterns of use of these drugs (dose, duration of treatment,|Adverse events|Time of hospital admission and/or stay in ICU and maximum severity reached.|Treatments for SARS-CoV-2 positive patients not described in the protocol|healthy survey for patients after their recovery/discharge from hospital.","Instituto de Investigación Marqués de Valdecilla|Hospital Universitario Marqués de Valdecilla|Hospital Universitario de Canarias|Hospital San Pedro de Alcántara","All","1 Year to 100 Years   (Child, Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Other|Time Perspective: Other","IDI-REM-2020-1","April 22, 2020","October 15, 2020","January 1, 2021","April 15, 2020",,"June 2, 2020","Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain",,"https://ClinicalTrials.gov/show/NCT04347278"
548,"NCT04380519","Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)",,"Recruiting","No Results Available","COVID-19","Biological: RPH-104 80 mg|Drug: Olokizumab 64 mg|Drug: Placebo","Proportion of patients, responded to the study therapy, in each of the treatment groups|Changes of patients' clinical status on a 6 points ordinal scale over time|Mortality rate over the follow-up period|Improvement of the patient's clinical status by at least 2 points on a 6-point ordinal scale in the absence of tocilizumab or sarilumab administration.|Proportion of patients received tocilizumab or sarilumab due to COVID-19","R-Pharm International, LLC|Data Management 365 LLC|K-Research, LLC|R-Pharm","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2|Phase 3","372","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CL04041078","April 23, 2020","October 15, 2020","November 15, 2020","May 8, 2020",,"May 8, 2020","Federal State Budget Institution ""National Medical Surgery Center named after N.I. Pirogov"" of Ministry of Health of Russian Federation, Moscow, Russian Federation|State Budget Healthcare Institution ""City Clinical Hospital № 15 named after O.M. Filatov"" of Moscow City Healthcare Department, Moscow, Russian Federation|Federal State Budgetary Institution ""Federal Center for Cerebrovascular Pathology and Stroke"" of the Ministry of Health of the Russian Federation, Moscow, Russian Federation|Federal State Autonomous Education Insitution of High Education the First Moscow State Medical University named after I.M. Sechenov of Ministry of Healthcare of Russian Federation (Sechenov University), Moscow, Russian Federation|Federal State Budget Institution ""National Medicine Research Center on Cardiology"" By Ministry of Healthcare of Russian Federation, Moscow, Russian Federation|State Budget Institution of Healthcare ""City Clinical Hospital #52"", Moscow City Healthcare Department, Moscow, Russian Federation|Moscow State Budget Institution of Healthcare ""Scientific Research Institute of Emergency Medicine named after N.V. Sklifosovsky of Moscow Department of Healthcare"", Moscow, Russian Federation|State Budget Healthcare Institution ""City Clinical Hospital #40"", Moscow City Healthcare Department, ""Communarca"" Division, Moscow, Russian Federation|АО ""State Company ""Medsi"" based on Clinical Hospital №1"", Moscow, Russian Federation|Saint Petersburg State Budget Institution of Healthcare ""Clinical infectious diseases hospital named after S.P. Botkin"", Saint Petersburg, Russian Federation|Saint-Petersburg State Budget Institution of Healthcare ""City Hospital №40"", Saint Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04380519"
549,"NCT04405544","Determination of Acute Encephalopathy Predictors in Patients With COVID-19",,"Recruiting","No Results Available","Encephalopathy|COVID","Diagnostic Test: CT-scan|Diagnostic Test: EEG|Diagnostic Test: EP|Diagnostic Test: Pulse oximetry|Diagnostic Test: Blood tests","The percentage of patients who have developed encephalopathy","State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia","All","18 Years to 60 Years   (Adult)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NMSC-01-20","May 22, 2020","July 22, 2020","October 22, 2020","May 28, 2020",,"June 1, 2020","N.I. Pirogov National Medical and Surgical Center, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04405544"
550,"NCT04413045","Novel COVID-19, A National Analysis",,"Recruiting","No Results Available","COVID-19","Other: Prevalence of COVID-19","Patient Prognosis Score|Oxygen Saturation|Laboratory Data|Radiological Features|Hospital Stay|Liver Function|Kidney Function","Assiut University","All","Child, Adult, Older Adult",,"50","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","Novel COVID-19 Prevalence","May 20, 2020","June 2020","June 2020","June 2, 2020",,"June 2, 2020","Assiut University Hospitals, Assiut, Egypt",,"https://ClinicalTrials.gov/show/NCT04413045"
551,"NCT04359797","COVID-19 Patient Positioning Pragmatic Trial",,"Enrolling by invitation","No Results Available","COVID-19","Other: Prone|Other: Usual Care","Modified WHO Ordinal Scale|FIO2","Vanderbilt University Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","200727","April 27, 2020","April 2021","June 2021","April 24, 2020",,"June 29, 2020","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04359797"
552,"NCT04343690","COPING With COVID-19( CWC-19)",,"Not yet recruiting","No Results Available","COVID-19","Behavioral: Crisis management coaching","Change in stress level as measured by survey|Change wellness as measured by survey","Duke University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","Pro00105319","April 13, 2020","June 30, 2020","June 30, 2020","April 13, 2020",,"April 13, 2020","Duke University, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04343690"
553,"NCT04389567","Famotidine Outpatient COVID-19 Treatment Study",,"Completed","No Results Available","COVID-19","Drug: Famotidine","Symptomatic improvement|Peripheral blood oxygen saturation","Northwell Health|Cold Spring Harbor Laboratory","All","18 Years and older   (Adult, Older Adult)",,"10","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","1605914-1","May 12, 2020","May 25, 2020","May 25, 2020","May 15, 2020",,"June 4, 2020","Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, United States",,"https://ClinicalTrials.gov/show/NCT04389567"
554,"NCT04387214","COVID-19 Pandemic and Academic Performance of Veterinary Students",,"Completed","No Results Available","COVID-19","Other: survey","Measure the effect of COVID-19 pandemic on the academic performance of veterinary medical students|Measure the average studying time|Evaluate on-line education during COVID-19 pandemic lockdown|Evaluate on-line education in practical lessons during COVID-19 pandemic lockdown","South Valley University","All","17 Years to 60 Years   (Child, Adult)",,"857","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","1-2020","April 13, 2020","May 31, 2020","May 31, 2020","May 13, 2020",,"June 16, 2020","South Valley University, Qinā, Egypt",,"https://ClinicalTrials.gov/show/NCT04387214"
555,"NCT04361214","Leflunomide in Mild COVID-19 Patients",,"Recruiting","No Results Available","COVID-19","Drug: Leflunomide","Tolerability of high dose leflunomide as measured by leflunomide dose modifications|Tolerability of high dose leflunomide as measured by discontinuation of leflunomide|Tolerability of high dose leflunomide as measured by Adverse Events|Rate of hospitalization due to COVID-19 as measured by number of patients hospitalized|Time to defervescence as measured in days while on treatment protocol|Resolution of other COVID-19 symptoms measured in days while on treatment protocol","University of Chicago","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB20-0622","May 5, 2020","July 2020","July 2020","April 24, 2020",,"May 20, 2020","University of Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04361214"
556,"NCT04337762","Beat COVID-19 - Observational Trial","JUPITER","Recruiting","No Results Available","COVID-19",,"Health Outcomes","Beat COVID LLC","All","18 Years to 110 Years   (Adult, Older Adult)",,"100000","Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","20200835","April 6, 2020","December 2020","July 2021","April 8, 2020",,"April 9, 2020","Beat COIVD, LLC, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04337762"
557,"NCT04380935","Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome",,"Not yet recruiting","No Results Available","COVID|Acute Respiratory Distress Syndrome","Biological: Convalescent plasma|Drug: Standard of care","All-cause mortality|Length of stay in intensive care unit|Duration of mechanical ventilation|Body temperature (degree in Celsius)|The Sequential Organ Failure Assessment (SOFA) Score|PAO2/FIO2 ratio|C-Reactive Protein (CRP) in mg/L|D-Dimer in ng/mL|Procalcitonin in ng/mL|Interleukin 6 (IL-6) in pg/mL|Allergic/ anaphylaxis transfusion reaction|Hemolytic transfusion reaction|Transfusion Related Acute Lung Injury|Transfusion associated Circulatory Overload","Indonesia University|Dr Cipto Mangunkusumo General Hospital|Fakultas Kedokteran Universitas Indonesia","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","convalescent plasma RSCM-FKUI","May 11, 2020","August 31, 2020","August 31, 2020","May 8, 2020",,"May 8, 2020","Dr. Cipto Mangunkusumo General Hospital, Jakarta, DKI Jakarta, Indonesia|St. Carolus Hospital, Jakarta, DKI Jakarta, Indonesia|PELNI Hospital, Jakarta, DKI Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT04380935"
558,"NCT04389411","The COvid-19 Symptom MOntelukast Trial","COSMO","Not yet recruiting","No Results Available","COVID-19","Drug: Montelukast 10mg","Emergency Room Visits and Hospitalizations|Emergency room visit count|Hospitalization admission count|Time to ER Visit|Time to hospitalization|All-cause mortality|Inpatient Length of stay|Time to ICU admission|Time to intubation|Time to other serious COVID-19 complications","McGill University|Lady Davis Institute","All","40 Years and older   (Adult, Older Adult)","Phase 3","600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","443807","July 2020","February 2021","June 2021","May 15, 2020",,"June 23, 2020",,,"https://ClinicalTrials.gov/show/NCT04389411"
559,"NCT04448743","Role of Microparticles in Covid-19 Infection","MICO","Not yet recruiting","No Results Available","COVID-19","Other: Blood sample","Western blot measurement of ACE2 receptor expression in porcine cells","University Hospital, Strasbourg, France","All","18 Years and older   (Adult, Older Adult)",,"175","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","7829","June 2020","November 2021","November 2021","June 26, 2020",,"June 26, 2020",,,"https://ClinicalTrials.gov/show/NCT04448743"
560,"NCT04364594","COVID-19 Search in Conjunctival Cells","COVID-T","Active, not recruiting","No Results Available","COVID 19|Pulmonary Disease","Diagnostic Test: conjunctival swab","Conjunctival swab results based on RT-PCR|Conjunctival swab positivity in relation to Pulmonary and blood abnormalities","Fondazione Policlinico Universitario Agostino Gemelli IRCCS","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","0013008/20","March 26, 2020","May 24, 2020","May 30, 2020","April 28, 2020",,"May 27, 2020","Maria Cristina Savastano, Roma, Italy",,"https://ClinicalTrials.gov/show/NCT04364594"
561,"NCT04353596","Stopping ACE-inhibitors in COVID-19","ACEI-COVID","Recruiting","No Results Available","SARS-CoV-2|COVID-19","Drug: ACE inhibitor, angiotensin receptor blocker","Combination of maximum Sequential Organ Failure Assessment (SOFA) Score and death|Composite of admission to an intensive care unit (ICU), the use of mechanical ventilation, or all-cause death|Maximum and median maximum Sequential Organ Failure Assessment (SOFA) Score|Rates of non-invasive ventilation|Rates of renal replacement therapies|Change of viral burden|Change of C-reactive protein (CRP), interleukin 6 (IL-6), D-Dimer, IL-6, hochsensitives Troponin (hsTN), NT-pro-brain natriuretic peptide (NT-pro BNP)|Number of patients with systolic/diastolic blood pressure > 180/120 mmHg|Hospitalisation due to cardiac decompensation|Rates of mechanical ventilation|Rates of clonal hematopoiesis of indeterminate potential (CHIP)","Medical University Innsbruck|Ludwig-Maximilians - University of Munich|Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)","All","18 Years and older   (Adult, Older Adult)","Phase 4","208","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","EudraCT 2020-001206-35","April 15, 2020","May 15, 2021","May 15, 2022","April 20, 2020",,"June 11, 2020","Medical University Innsbruck, University Hospital of Internal Medicine III, Innsbruck, Tyrol, Austria|Landeskrankenhaus Hall, Hall In Tirol, Austria|Medical University Innsbruck, Intensive Care and Emergency Medicine Department, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine II, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine IV, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine I, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine V, Innsbruck, Austria|Klinikum Klagenfurt, Klagenfurt, Austria|Bezirkskrankenhaus Kufstein, Kufstein, Austria|Bezirkskrankenhaus St. Johann, Sankt Johann In Tirol, Austria|Bezirkskrankenhaus Schwaz, Schwaz, Austria|Krankenhaus St. Vinzenz Zams, Zams, Austria|LMU Klinikum, Medizinische Klinik I, Munich, Bavaria, Germany|Asklepios Stadtklinik Bad Tölz, Bad Tölz, Germany|Klinikum Landkreis Erding, Erding, Germany|Klinikum Memmingen, Memmingen, Germany|Deutsches Herzzentrum München, Munich, Germany|Klinikum rechts der Isar, Medizinische Klinik und Poliklinik I, Munich, Germany|LMU Klinikum, Medizinische Klinik III, Munich, Germany|LMU Klinikum, Medizinische Klinik II, Munich, Germany|LMU Klinikum, Medizinische Klinik IV, Munich, Germany|München Klinik Bogenhausen und Schwabing, Munich, Germany|Universitätsklinik der Paracelsus Medizinischen Privatuniversität, Nürnberg, Germany|Klinikum Starnberg, Starnberg, Germany|Klinik für Innere Medizin Weilheim, Weilheim, Germany",,"https://ClinicalTrials.gov/show/NCT04353596"
562,"NCT04423978","Implications of Covid-19 on the Lifestyle Changes",,"Recruiting","No Results Available","COVID-19",,"The ratio of individuals living in the province of Reggio Emilia who completed the survey|The ratio of individuals who changed the lifestyles during the lock-down|The number and the type of support services used the most by participants","Azienda Unità Sanitaria Locale Reggio Emilia","All","18 Years and older   (Adult, Older Adult)",,"1500","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","ICOLS_CovidStyle","May 4, 2020","June 22, 2020","June 22, 2020","June 9, 2020",,"June 19, 2020","Elisa Mazzini, Reggio Emilia, Italy",,"https://ClinicalTrials.gov/show/NCT04423978"
563,"NCT04389450","Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19",,"Recruiting","No Results Available","COVID|ARDS","Biological: PLX-PAD|Biological: Placebo","Number of ventilator free days|All-cause mortality|Duration of mechanical ventilation","Pluristem Ltd.","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 2","140","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PLX-COV-01","June 4, 2020","September 2020","September 2021","May 15, 2020",,"June 9, 2020","Holy Medical Center, Teaneck, New Jersey, United States|Maimonides Medical Center, New York, New York, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04389450"
564,"NCT04326920","Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)","SARPAC","Recruiting","No Results Available","COVID-19","Drug: Sargramostim|Other: Control","Improvement in oxygenation at a dose of 250 mcg daily during 5 days improves oxygenation in COVID-19 patients with acute hypoxic respiratory failure|Incidence of AE (Adverse Event)|Incidence of SAEs (Serious Adverse Event)|Clinical Status using 6-point ordinal scale|Clinical Status using Clincal sign score|Clinical Status using SOFA score (Sequential Organ Failure Assessment score),|Clinical Status using NEWS2 score (National Early Warning Score)|incidence of severe or life-threatening bacterial, invasive fungal or opportunistic infection|number of patients requiring initiation of mechanical ventilation|Number of deaths due to any cause at 4 weeks|Number of deaths due to any cause at 20 weeks|number of patients developing features of secondary haemophagocytic lymphohistiocytosis|long term Clinical status defined by 6-point ordinal scale|long term Clinical status defined by chest X-ray|long term Clinical status defined lung function","University Hospital, Ghent|Flanders Institute of Biotechnology","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SARPAC","March 24, 2020","October 31, 2020","December 31, 2020","March 30, 2020",,"April 24, 2020","AZ Sint Jan Brugge, Brugge, Belgium|University Hospital Ghent, Gent, Belgium|UZ Brussel, Jette, Belgium|AZ Delta Roeselare, Roeselare, Belgium",,"https://ClinicalTrials.gov/show/NCT04326920"
565,"NCT04434118","Hydroxychloroquine May Reduce Risk of COVID-19 Infection in Rheumatoid Arthritis Patients:",,"Enrolling by invitation","No Results Available","Rheumatoid Arthritis|COVID","Drug: Traditional antirheumatic drugs","The risk of COVID-19 infection among RA patients|The incidence of hospitalization for Covid-19 patients.","Sadat City University","All","18 Years to 60 Years   (Adult)",,"600","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","IRB: RC-5-2020","March 20, 2020","June 20, 2020","June 20, 2020","June 16, 2020",,"June 16, 2020","Faculty of Medicine, Shibīn Al Kawm, Egypt",,"https://ClinicalTrials.gov/show/NCT04434118"
566,"NCT04355767","Convalescent Plasma in Outpatients With COVID-19","C3PO","Not yet recruiting","No Results Available","COVID-19","Biological: Convalescent Plasma|Biological: Saline","Number of patients with disease progression|Worst severity rating on the WHO COVID Ordinal Scale for Clinical Improvement during the 30 days following randomization|Time to disease progression|Number of Hospital-free days during the 30 days following randomization|All-cause mortality","Stanford University|National Heart, Lung, and Blood Institute (NHLBI)|Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network","All","18 Years and older   (Adult, Older Adult)","Phase 3","600","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","C3PO","July 2020","December 2022","December 2022","April 21, 2020",,"June 26, 2020","Stanford University, Stanford, California, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04355767"
567,"NCT04369300","Anxiety And Depression During COVID-19 IN INDIA",,"Not yet recruiting","No Results Available","COVID-19","Behavioral: Registery Data Collection","Prevalence (magnitude) of anxiety of general adult population during COVID-19|prevalence (magnitude) of depression and anxiety of general adult population during COVID 19","Max Healthcare Insititute Limited","All","18 Years to 90 Years   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","Covid-19/MHC/PSYCH/20-10","April 24, 2020","November 24, 2020","February 24, 2021","April 30, 2020",,"April 30, 2020",,,"https://ClinicalTrials.gov/show/NCT04369300"
568,"NCT04445337","Stellate Ganglion Blockade in COVID-19 Positive Patients",,"Not yet recruiting","No Results Available","COVID 19|ARDS","Procedure: Stellate Ganglion Block","Evaluate the safety of a new modified stellate ganglia block (SGB) in ARDS|Evaluate the efficacy of a new modified stellate ganglia block (SGB) in ARDS","University of Nebraska","All","19 Years to 85 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","603.20.FB","July 2020","July 2021","July 2021","June 24, 2020",,"June 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04445337"
569,"NCT04420286","Study of the Increase in ICU Beds Capacity During COVID-19 Pandemic in France","FRENCH ICU","Recruiting","No Results Available","Coronavirus Infections|COVID19 Outbreak in France",,"origin of the ICU beds created during the COVID-19 outbreak in France.|Human Resources","Centre Hospitalier Universitaire de Nīmes","All","Child, Adult, Older Adult",,"9000","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","30RC20_0117","May 6, 2020","June 5, 2020","June 5, 2020","June 9, 2020",,"June 9, 2020","CHU de Nîmes, Hôpital Universitaire Carémeau, Nimes, France",,"https://ClinicalTrials.gov/show/NCT04420286"
570,"NCT04420390","Low Dose Radiotherapy for COVID-19 Pneumonitis","LOWRAD-Cov19","Recruiting","No Results Available","Covid19","Radiation: Radiotherapy","Radiological response|Remission of respiratory symptoms|SPO2 and PaO2/FiO2|Adverse events|Hospitalization|Overall survival|Ferritin value|blood cell count|C-reactive protein|D-dimer|LDH levels","Hospital San Carlos, Madrid","All","60 Years and older   (Adult, Older Adult)","Not Applicable","41","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LOWRAD-Cov19","May 1, 2020","July 31, 2020","September 8, 2020","June 9, 2020",,"June 9, 2020","Servicio de Oncología Radioterápica. Hospital Clínico San Carlos, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04420390"
571,"NCT04429724","Health Professional Exposure Assessment to Covid-19","SERODRON","Not yet recruiting","No Results Available","COVID-19","Diagnostic Test: Diagnostic test Covid-19","Number of contaminated personnel|Number of symptomatic staff by occupational category and service|Number of contaminated personnel with effective protection|comparison of socio-demographic characteristics and co-morbidities between patients losing their antibodies and those maintaining their antibodies","Tourcoing Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","6000","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","RIPH_2020_8","June 2020","December 2020","December 2020","June 12, 2020",,"June 12, 2020",,,"https://ClinicalTrials.gov/show/NCT04429724"
572,"NCT04446377","A Study of LAM-002A for the Prevention of Progression of COVID-19",,"Not yet recruiting","No Results Available","COVID-19 Disease","Drug: Apilimod Dimesylate Capsule|Other: Placebo","Viral Load Change|Viral Load AUC|Safety and Tolerability","AI Therapeutics, Inc.|Yale University","All","18 Years and older   (Adult, Older Adult)","Phase 2","142","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LAM-002A-CVD-CLN01","June 29, 2020","December 31, 2020","January 31, 2021","June 24, 2020",,"June 24, 2020","Yale University, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT04446377"
573,"NCT04377477","COVID-19 Pneumonitis Low Dose Lung Radiotherapy (COLOR-19)","COLOR-19","Recruiting","No Results Available","COVID-19","Radiation: Single fraction whole lung radiotherapy","Lenght of hospital stay (days)|Number of Intensive Care Unit admissions|Variation of the Brescia COVID-19 Respiratory Severity Scale after treatment|Occurence of CTCAE 5.0 adverse events|Variation of the chest X-ray radiological findings according to Brixia scoring system","Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","All","50 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NP 4097","May 10, 2020","May 10, 2021","July 23, 2022","May 6, 2020",,"May 8, 2020","Radiation Oncology Department, ASST SpedaliCivili, Brescia, Brescia, Italy",,"https://ClinicalTrials.gov/show/NCT04377477"
574,"NCT04304313","A Pilot Study of Sildenafil in COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Sildenafil citrate tablets","Rate of disease remission|Rate of entering the critical stage|Time of entering the critical stage|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of C-reactive protein (CRP) recovery|Rate of Biochemical criterion (CK, ALT, Mb) recovery|Rate of undetectable viral RNA (continuous twice)|Time for hospitalization|Rate of adverse event","Tongji Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 3","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GST-G1","February 9, 2020","March 1, 2020","November 9, 2020","March 11, 2020",,"March 17, 2020","Department and Institute of Infectious Disease, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04304313"
575,"NCT04443881","Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS)","ANA-COVID-GEAS","Recruiting","No Results Available","COVID-19 Pnemonia","Drug: Anakinra 149 MG/ML Prefilled Syringe [Kineret]","Treatment success, defined as number of patients not requiring mechanical ventilation to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia.|Number of patients not requiring mechanical ventilation to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia.|Time to mechanical ventilation to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia.|Time to oxygen saturation normalization to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia.|Stay in ICU and hospitalization to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia.|Total mortality rate to assess the effect of anakinra in addition to standard treatment on mortality in patients with severe COVID-19 and CSS pneumonia.|Mortality 48 hours, 7 days, in ICU and hospital to assess the effect of anakinra in addition to standard treatment on mortality in patients with severe COVID-19 and CSS pneumonia.|Viral clearance / viral shedding to assess the effect of anakinra in addition to standard treatment on mortality in patients with severe COVID-19 and CSS pneumonia.|To assess the effect of anakinra in addition to standard treatment on mortality in patients with severe COVID-19 and CSS pneumonia.","Fundacion Miguel Servet","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ANA-COVID-GEAS","May 8, 2020","December 2020","March 2021","June 23, 2020",,"June 23, 2020","Hospital Clinic, Barcelona, Cataluña, Spain|Hospital Universitario Vall d´Hebron, Barcelona, Cataluña, Spain|Complexo Hospitalario Universitario de Santiago, Santiago De Compostela, Galicia, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Mallorca, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario y Politecnico La Fe, Valencia, Spain|Complejo Hospitalario Universitario de Vigo, Vigo, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT04443881"
576,"NCT04422379","COVID-19 and Liver Injury in Patients With or Without Underlying Liver Disease: A Multi-centre Retrospective-prospective Observational Study",,"Not yet recruiting","No Results Available","COVID-19",,"COVID-19 Positive Case","Max Healthcare Insititute Limited","All","18 Years to 75 Years   (Adult, Older Adult)",,"314","Other","Observational","Observational Model: Cohort|Time Perspective: Other","COVID 19/LI/2020","June 7, 2020","July 30, 2020","August 30, 2020","June 9, 2020",,"June 9, 2020","Max Super Speciality Hospital, Saket (A Unit Of Devki Devi Foundation), New Delhi, Dlelhi, India",,"https://ClinicalTrials.gov/show/NCT04422379"
577,"NCT04393233","Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation","RHUMACOVID","Recruiting","No Results Available","Rheumatoid Arthritis|COVID",,"Reduction or discontinuation of the DMARD therapy in relation to the Covid-19 sanitary crisis","University Hospital, Brest","All","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RHUMACOVID ( 29BRC20.0110)","April 23, 2020","May 23, 2020","May 23, 2020","May 19, 2020",,"May 29, 2020","CHRU de Brest, Brest, France",,"https://ClinicalTrials.gov/show/NCT04393233"
578,"NCT04382755","Zilucoplan® in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure","ZILU-COV","Not yet recruiting","No Results Available","COVID-19","Drug: Zilucoplan®|Drug: Placebo","Mean change in oxygenation|Median change in oxygenation|number of AE's (Adverse Events)|number of SAE's (Serious Adverse Events)|mean change in 6-point ordinal scale change|Time since randomization until improvement in oxygenation|Number of days with hypoxia|Number of days of supplemental oxygen use|Time to absence of fever (defined as 37.1°C or more) for more than 48h without antipyretic|Number of days with fever|Time to halving of CRP levels to peak value during trial|Time to halving of ferritin levels compared to peak value during trial|Incidence of AE's|Incidence of SAE's|Incidence of SUSAR's (Suspected Unexpected Serious Adverse Reaction)|Incidence of SAR's (Serious Adverse Reaction)|Duration of hospital stay|Duration of hospital stay in survivors|Mean change in clinical sign score between day 1 and day 6|Mean change in clinical sign score between day 1and day 15 (or on discharge, whichever is first)|Mean change in clinical sign score between day 1 and day 28 (or on discharge, whichever is first)|Mean change of SOFA score between day 1 and day 6 (or on discharge, whichever is first)|Mean change of SOFA score between day 1 and day 15 or on discharge, whichever is first)|Mean change NEWS2 (National Early Warning) score between day 1 and day 6|Mean change NEWS2 (National Early Warning) score between day 1 and day 15|Percentage of patients reporting each severity rating on a 6-point ordinal scale at randomization, day 6 and 15 (or discharge, whichever comes first) and day 28 (phone call)|6-point Ordinal Scale at 6 and 15 days (or discharge whichever comes first) and day 28 (phone call), in relation to serum D-dimers and complement C5a levels at randomization|Incidence of nosocomial bacterial or invasive fungal infection for 28 days (phone call) after enrolment in trial|incidence of secondary haemophagocytic lymphohistiocytosis in relation to serum D-dimers and complement C5a at randomization|Time since randomization until first use of high-flow oxygen devices in non-ventilated patients|Time since randomization until first use of non-invasive mechanical ventilation in non-ventilated patients|Time since randomization until first use of invasive mechanical ventilation in non-ventilated patients|Time since to first use of salvage systemic steroids in ventilated patients|Number of ventilator-free days|Duration of invasive and non-invasive mechanical ventilation in ventilated patients|Duration of ICU stay in patients that enrolled in trial on invasive or non-invasive mechanical ventilation for less than 24h prior to or after randomization|Time since randomization to progression to ARDS (Acute Respiratory Distress Syndrome) in ventilated patients|Time to progression to ARDS in ventilated patients according to D-dimers at randomization|Time to progression to ARDS in ventilated patients according to complement C5a at randomization|All-cause mortality rate (excluding group that entered during ventilation)|All-cause mortality rate (including group that entered during ventilation)|Percentage of patients in clinical status on 6-point Ordinal Scale|Mean change in clinical sign score between day 1 and follow up 12-22 weeks|Incidence of lung function abnormalities at follow|Incidence of lung fibrosis on chest CT scan|All cause mortality for the entire study population","University Hospital, Ghent|UCB Pharma","All","18 Years and older   (Adult, Older Adult)","Phase 2","81","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ZILU-COV","May 2020","May 2021","September 2021","May 11, 2020",,"May 11, 2020","OLVZ Aalst, Aalst, Belgium|AZ Sint Jan Brugge, Brugge, Belgium|Erasmus University Hospital, Brussels, Belgium|AZ Sint-Lucas, Gent, Belgium|University Hospital Ghent, Gent, Belgium|Jan Yperman Ziekenhuis Ieper, Ieper, Belgium|University Hospital Liège, Liège, Belgium|AZ Delta, Roeselare, Belgium|AZ Vesalius, Tongeren, Belgium",,"https://ClinicalTrials.gov/show/NCT04382755"
579,"NCT04363034","Arkansas Expanded Access COVID-19 Convalescent Plasma Treatment Program",,"Available","No Results Available","COVID-19","Biological: Convalescent Plasma",,"University of Arkansas","All","18 Years and older   (Adult, Older Adult)",,,"Other","Expanded Access:Intermediate-size Population",,"260944",,,,"April 27, 2020",,"April 29, 2020",,,"https://ClinicalTrials.gov/show/NCT04363034"
580,"NCT04332081","Hyperbaric Oxygen for COVID-19 Patients",,"Terminated","No Results Available","COVID-19","Device: hyperbaric oxygen therapy (HBOT)","Mortality|Need for mechanical ventilation|Days on invasive mechanical ventilation","NYU Langone Health","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","s20-00399","April 6, 2020","May 29, 2020","May 29, 2020","April 2, 2020",,"June 4, 2020","NYU Winthrop Hospital, Mineola, New York, United States",,"https://ClinicalTrials.gov/show/NCT04332081"
581,"NCT04344587","Awake Prone Position for Early Hypoxemia in COVID-19","APPEX-19","Enrolling by invitation","No Results Available","COVID-19","Other: Self-prone position recommendation|Other: Usual care","Change in respiratory status|Length of time participant spends in the prone position|Length of time participant spends in the supine position|Length of time participant spends lying on side|Length of time participant spends sitting up|Length of time participant spends standing or walking|Dyspnea or difficult/labored breathing|Discomfort with proning|Length of hospital stay|Invasive mechanical ventilation|Loss of IV access as a consequence of turning in bed|Acute respiratory distress syndrome (ARDS) diagnosis|Hospital mortality","Boston University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","560","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","H-40070","April 23, 2020","December 2020","December 2020","April 14, 2020",,"June 18, 2020","MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Piedmont Atlanta, Atlanta, Georgia, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Boston Medical Center, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Creighton University, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT04344587"
582,"NCT04355247","Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm",,"Recruiting","No Results Available","Covid-19","Drug: MethylPREDNISolone 80 Mg/mL Injectable Suspension","Clinical complete response criteria|Clinical Partial Response criteria|Secondary response criteria","Auxilio Mutuo Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CCAM 20-01","April 14, 2020","July 31, 2020","April 30, 2021","April 21, 2020",,"April 21, 2020","San Juan City Hospital / Puerto Rico Medical Center, San Juan, Puerto Rico|Hospital Auxilio Mutuo Cancer Center, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT04355247"
583,"NCT04337541","Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System",,"Recruiting","No Results Available","COVID-19","Other: Surgical facial mask","Reduction in COVID-19 infection frequency|Antibody-screening","Rigshospitalet, Denmark|Nordsjaellands Hospital|Hvidovre University Hospital|Herlev Hospital|Technical University of Denmark","All","18 Years and older   (Adult, Older Adult)","Not Applicable","6000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2020-04-02","April 2, 2020","July 1, 2020","July 1, 2020","April 7, 2020",,"April 7, 2020","Rigshospitalet, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT04337541"
584,"NCT04362813","Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia","CAN-COVID","Recruiting","No Results Available","Pneumonia and Cytokine Release Syndrome (Covid-19)","Drug: Canakinumab|Drug: Placebo","Number of patients with clinical response|COVID-19-related death rate during the 4-week period after study treatment|Ratio to baseline in the C-reactive protein (CRP)|Ratio to baseline in the serum ferritin|Ratio to baseline in the D-dimer|Number of participants with Adverse Event (AE), serious adverse events (SAE), clinically significant changes in laboratory measures, and vital signs","Novartis Pharmaceuticals|Novartis","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","450","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CACZ885D2310|2020-001370-30","April 30, 2020","July 31, 2020","November 6, 2020","April 27, 2020",,"June 11, 2020","Novartis Investigative Site, Glendale, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Brooklyn, New York, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Lyon cedex 04, Rhone, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Nantes Cedex 1, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Toulouse Cedex 4, France|Novartis Investigative Site, Lubeck, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Sestroretsk, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, San Sebastian de los Reyes, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Barnet, United Kingdom|Novartis Investigative Site, Coventry, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04362813"
585,"NCT04441996","Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity",,"Not yet recruiting","No Results Available","COVID-19","Biological: Therapeutic plasma exchange (TPE)|Other: Standard of care","Change in Plasma Viscosity|All Cause Mortality|Bleeding and Thromboembolic Complications|Time to Treatment Failure|Duration of ICU Stay|Duration of Hospital Stay|Discharge Disposition|Change in Clinical Status|Change in Body Temperature|Change in Systolic Blood Pressure|Change in Diastolic Blood Pressure|Change in Heart Rate|Change in Respiratory Rate|Change in Ventilator Days|Change in Ventilator Oxygen Percent (FiO2)|Change in Positive End-Expiratory Pressure (PEEP)|Change in Vasopressor Requirements|Change in Need for Treatment from a Registered Respiratory Therapist (RRT)|Change in Sequential Organ Failure Assessment (SOFA) Score|Change in Partial Pressure of Arterial Oxygen (PaO2)/Percentage of Inspired Oxygen (FiO2) Ratio|Change in Ventilatory Ratio|Change in White Blood Count (WBC)|Change in Hemoglobin (Hb)|Change in Hematocrit (Hct)|Change in Platelet Count|Change in Mean Platelet Volume (MVP)|Change in Blood Urea Nitrogen (BUN)|Change in Creatinine|Change in Bilirubin|Change in Total Protein|Change in Albumin|Change in C-reactive Protein (CRP)|Change in Interleukin 6 (IL-6)|Change in Prothrombin Time (PT)|Change in International Normalized Ratio (INR)|Change in Activated Partial Thromboplastin Time (aPTT)|Change in Anti-factor Xa (anti-Xa)|Change in Fibrinogen|Change in D-dimer","Emory University","All","18 Years and older   (Adult, Older Adult)","Phase 4","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00000949","July 2020","October 2020","October 2020","June 22, 2020",,"June 22, 2020","Emory Saint Joseph's Hospital, Atlanta, Georgia, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04441996"
586,"NCT04389710","Convalescent Plasma for the Treatment of COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Convalescent Plasma","Number of patients who receive COVID-19 convalescent plasma transfusions in acute care facilities infected with SARS-CoV-2|Number and type of adverse events associated with COVID-19 convalescent plasma in patients with COVID-19|Length of hospital stay|Length of Intensive Care Unit stay|Length of intubation|Survival to discharge|Changes in complete blood count in patients after receiving convalescent plasma|Abnormal changes in Basic Metabolic Panel (BMP) measures in patients after receiving convalescent plasma|Changes in C-Reactive Protein (CRP) in patients after receiving convalescent plasma|Changes in d-dimer in patients after receiving convalescent plasma|Changes in fibrinogen in patients after receiving convalescent plasma|Changes in prothrombin time (PT) in patients after receiving convalescent plasma|Changes in partial thromboplastin time (PTT) in patients after receiving convalescent plasma","Thomas Jefferson University","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20D.379","April 15, 2020","April 14, 2021","April 14, 2021","May 15, 2020",,"June 25, 2020","Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04389710"
587,"NCT04381845","Immunity and Infections in the Psychiatric Population","COVIDIMMUNOPSY","Not yet recruiting","No Results Available","COVID|Psychiatric Disorders","Diagnostic Test: COVID19 immunization testing","Number of COVID-positive patients","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","APHP200553","May 10, 2020","June 10, 2020","June 25, 2020","May 11, 2020",,"May 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04381845"
588,"NCT04347070","Implementation of Physiotherapy on COVID-19 Patients in ICU","PHYSIO-COVID","Recruiting","No Results Available","Sars-CoV2|COVID-19","Other: Phsyiotherapy","Time of physiotherapy|Type of physiotherapy implemented","University Hospital, Montpellier|Société espagnole de pneumologie (SEPAR)|Societe française de kinésithérapie en réanimation (SKR)","All","18 Years and older   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","RECHMPL20_0175","April 1, 2017","September 1, 2020","December 1, 2022","April 15, 2020",,"April 16, 2020","Uhmontpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04347070"
589,"NCT04344002","LunG canceR pAtients coVId19 Disease (GRAVID)","GRAVID","Recruiting","No Results Available","Covid-19|Lung Cancer",,"Clinical data of lung cancer patients with COVID-19 diagnoses|Diagnosis data|Treatments received|Prognostic factors","Spanish Lung Cancer Group","All","Child, Adult, Older Adult",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Other","GECP 20/02_GRAVID","April 21, 2020","September 15, 2020","December 15, 2020","April 14, 2020",,"May 14, 2020","Complejo Hospitalario Universitario de Ferrol, Ferrol, A Coruña, Spain|H. Clínica Benidorm, Benidorm, Alicante, Spain|Hospital de Elche, Elche, Alicante, Spain|Hospital General Universitario de Elda, Elda, Alicante, Spain|Hospital de Torrevieja, Torrevieja, Alicante, Spain|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Cetir Centre Mèdic, Esplugues De Llobregat, Barcelona, Spain|Hospital General de Granollers, Granollers, Barcelona, Spain|Hospital Universitario de Galdakao, Galdakao, Bizkaia, Spain|Complejo Hospitalario de la Coruña, La Coruña, Coruña, Spain|H. Insular de Gran Canarias, Las Palmas De Gran Canaria, Gran Canarias, Spain|Hospital San Pedro, Logroño, La Rioja, Spain|Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain|Hospital Severo Ochoa, Leganés, Madrid, Spain|Hospital Universitario de Móstoles, Móstoles, Madrid, Spain|Hospital de Manacor, Manacor, Mallorca, Spain|Hospital Costa del Sol, Marbella, Málaga, Spain|Clínica Universidad de Navarra, Pamplona, Navarra, Spain|Clínica Universitaria de Navarra, Pamplona, Navarra, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Instituto Onkologikoa, San Sebastián, País Vasco, Spain|Hospital Sant Joan de Reus, Reus, Tarragona, Spain|Hospital Verge de la Cinta, Tortosa, Tarragona, Spain|H. Universitario de Canarias, La Laguna, Tenerife, Spain|Hospital Universitario de La Ribera, Alzira, Valencia, Spain|Hospital de Manises, Manises, Valencia, Spain|Hospital de Cruces, Baracaldo, Vizcaya, Spain|Hospital de Basurto, Bilbao, Vizcaya, Spain|H. Gen. Universitario Alicante, Alicante, Spain|H. Universitario Quirón Dexeus, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|H. Duran i Reynals-ICO, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital La Mancha Centro, Ciudad Real, Spain|Hospital Virgen de la Luz, Cuenca, Spain|Hospital Universitario de Puerto Real, Cádiz, Spain|Hospital Dr. Josep Trueta, Girona, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital de Guadalajara, Guadalajara, Spain|Complejo Asistencial Universitario de León, León, Spain|Hospital San Millan Y San Pedro, Logroño, Spain|Hospital Universitario Lucus Augusti, Lugo, Spain|MD Anderson, Madrid, Spain|H.U. Puerta de Hierro, Madrid, Spain|Fundación Jimenez Diaz, Madrid, Spain|Hospital Universitario Infanta Sofía, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital de Sanchinarro, Madrid, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario de Fuenlabrada, Madrid, Spain|Hospital Universitario del Henares, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital General Universitario Morales Meseguer, Murcia, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Santa María Naí, Ourense, Spain|Hospital Son Espases, Palma de Mallorca, Spain|H. Son Llàtzer, Palma de Mallorca, Spain|Hospital Clinico de Salamanca, Salamanca, Spain|Hospital General de Segovia, Segovia, Spain|Hospital Virgen del Rocío, Sevilla, Spain|Hospital Sant Pau i Santa Tecla, Tarragona, Spain|Hospital universitario Nuestra Señora Candelaria, Tenerife, Spain|H. General U. de Valencia, Valencia, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Dr. Peset, Valencia, Spain|Hospital Politècnic i Universitari La Fe, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Instituto Valenciano de Oncología, Valencia, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, Spain|H. Miguel Servet, Zaragoza, Spain|Hospital Ntra. Sra. Sónsoles, Ávila, Spain|Hospital Universitario de Áraba, Vitoria, Áraba, Spain",,"https://ClinicalTrials.gov/show/NCT04344002"
590,"NCT04436484","Immune Biomarkers of Outcome From COVID-19","IBOC","Recruiting","No Results Available","COVID-19","Diagnostic Test: Peripheral blood sampling","Mortality|Disease severity","University Hospital Plymouth NHS Trust","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20/HEP/381","April 29, 2020","August 28, 2020","October 28, 2020","June 18, 2020",,"June 22, 2020","University Hospitals Plymouth NHS Trust, Plymouth, Devon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04436484"
591,"NCT04373486","Incidence of Acute Pulmonary Embolism in Covid-19 Patients on CT Angiography and Relationship to D-dimer Levels","COVID-APE","Recruiting","No Results Available","Covid-19 With Positive RT-PCR",,"Rate of positivity for Acute Pulmonary Embolism","University Hospital, Strasbourg, France","All","18 Years and older   (Adult, Older Adult)",,"160","Other","Observational","Observational Model: Case-Only|Time Perspective: Other","7840","March 3, 2020","April 30, 2020","May 1, 2020","May 4, 2020",,"May 4, 2020","Service de Radiologie B - NHC, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT04373486"
592,"NCT04379440","Geriatric Population COVID-19 Observational Study (GEROCOVIDobs)","GEROCOVIDobs","Recruiting","No Results Available","COVID-19",,"Health status (WHO classification)|Incidence of Serious Adverse Events|COVID-19 prevalent symptoms at onset|COVID-19 Prognostic Factors|Incidence of COVID-19 in the RSA cohort|Affective/mood state change from baseline in the "" At home "" cohort|Cognitive function in the ""Dementia"" and ""At home "" cohorts|Daily Life Function in the ""Dementia"" and ""At home "" cohorts|Instrumental Daily Life function in the ""Dementia"" and ""At home "" cohorts|Residual signs and symptoms in the "" Outcomes "" cohort|Incidence of outcomes in the "" Outcomes "" cohort per Frailty Status|Incidence of outcomes in the "" Outcomes "" cohort per Comorbidity burden at baseline","Raffaele Antonelli Incalzi|Italian Society of Gerontology and Geriatrics|BLUECOMPANION FRANCE|BLUECOMPANION LTD|Campus Bio-Medico University","All","60 Years and older   (Adult, Older Adult)",,"1500","Other","Observational","Observational Model: Cohort|Time Perspective: Other","GC01-Obs","April 25, 2020","September 30, 2020","November 30, 2020","May 7, 2020",,"May 7, 2020","RSA La Quiete, Castiglione Cosentino, Calabria, Italy|ASP Catanzaro, Catanzaro Lido, Calabria, Italy|AOU Ferrara, Ferrara, Emilia Romagna, Italy|Policlinico Campus Bio-Medico, Rome, Roma, Italy|AOU Careggi, Firenze, Toscana, Italy|AOU Pisana Geriatria, Pisa, Toscana, Italy|Ospedale di Comunita' ULSS 6 Euganea- COVID Center, Camposampiero, Veneto, Italy",,"https://ClinicalTrials.gov/show/NCT04379440"
593,"NCT04445935","Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial",,"Recruiting","No Results Available","Anticoagulation in COVID-19 ARDS","Drug: Bivalirudin Injection|Drug: Standard treatment","P/F ratio|Kidney function","Hamad Medical Corporation","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 4","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","MRC-05-082","June 28, 2020","September 28, 2020","March 28, 2021","June 24, 2020",,"June 24, 2020","Hamad Medical Corporation, Doha, Qatar",,"https://ClinicalTrials.gov/show/NCT04445935"
594,"NCT04395664","Arrhythmias in Patients With COVID-19","ACOVID","Recruiting","No Results Available","COVID-19","Device: C3+ Holter Monitor","In-hospital mortality during hospitalization and a confirmed COVID-19 diagnosis|Incident intensive care unit admission during hospitalization and a confirmed COVID-19 diagnosis|Incident pulmonary embolism during hospitalization and a confirmed COVID-19 diagnosis|Incident cardiac arrest during hospitalization and a confirmed COVID-19 diagnosis|Incident hypoxic respiratory failure during hospitalization and a confirmed COVID-19 diagnosis","Herlev and Gentofte Hospital","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","H-20021500","April 16, 2020","August 2020","April 1, 2021","May 20, 2020",,"May 20, 2020","Department of Cardiology, Herlev & Gentofte Hospital, Copenhagen, Hellerup, Denmark",,"https://ClinicalTrials.gov/show/NCT04395664"
595,"NCT04365699","Cardiovascular Effects of COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: AT-001","Proportion of subjects with decreased left ventricular ejection fraction ≥10% from baseline at time of hospitalization|Incidence of Adverse Events for patients receiving AT-001|Change in left ventricular ejection fraction|Change in left ventricular end-diastolic diameter|Change in left ventricular end-systolic diameter|Change in biomarkers of cardiac injury|Frequency of atrial fibrillation|Frequency of heart block|Frequency of non-sustained ventricular tachycardia|Frequency of sustained ventricular tachycardia|Frequency of ventricular fibrillation|Proportion of subjects requiring mechanical ventilation|Proportion of subjects with decrease in left ventricular ejection fraction ≥10% from baseline at time of hospitalization","NYU Langone Health","All","18 Years and older   (Adult, Older Adult)","Phase 2","500","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-00416","April 8, 2020","December 31, 2020","December 31, 2020","April 28, 2020",,"April 28, 2020","NYU Langone Health, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04365699"
596,"NCT04399317","Flow Controlled Ventilation in ARDS Associated With COVID-19",,"Recruiting","No Results Available","ARDS Associated With COVID-19","Device: Flow controlled ventilation (Evone-ventilator)","arterial oxygen partial pressure (PaO2)","Hamad Medical Corporation","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","MRC-05-018","May 28, 2020","July 2020","August 2020","May 22, 2020",,"June 25, 2020","Hamad Medical Corporation, Doha, Qatar",,"https://ClinicalTrials.gov/show/NCT04399317"
597,"NCT04407533","Dietary Intake and Eating Habits During the COVID-19 Pandemic","COVIDiet","Recruiting","No Results Available","COVID-19","Other: Diet tracking and survey","Dietary intake|Diet quality|Eating habits","McGill University","All","18 Years and older   (Adult, Older Adult)",,"1920","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","20-04-064","May 25, 2020","August 31, 2022","August 31, 2022","May 29, 2020",,"May 29, 2020","McGill University - School of Human Nutrition, Montréal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04407533"
598,"NCT04359277","A Randomized Trial of Anticoagulation Strategies in COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Enoxaparin Higher Dose|Drug: Lower-dose prophylactic anticoagulation","Composite incidence of: all-cause mortality, cardiac arrest, symptomatic deep venous thrombosis, pulmonary embolism, arterial thromboembolism, myocardial infarction, stroke, or shock|Score on WHO Ordinal Scale|Incidence of acute kidney injury (KDIGO criteria for Acute Kidney Injury (AKI))|Requirement of invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)|Cardiac injury|Hypercoagulability|Disseminated Intravascular Coagulation (DIC) Score|Length of Hospital Stay","NYU Langone Health","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","s20-00479","April 21, 2020","April 21, 2021","April 21, 2021","April 24, 2020",,"June 23, 2020","NYU Langone Health, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04359277"
599,"NCT04405908","SCB-2019 as COVID-19 Vaccine",,"Recruiting","No Results Available","COVID-19","Biological: SCB-2019|Biological: SCB-2019 with AS03 adjuvant|Biological: SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant","Incidence of solicited adverse events (AEs) after vaccination|Incidence of unsolicited AEs after vaccination|Immunogenicity(Anti-SCB-2019 Antibody Titers)|Incidence of serious AEs (SAEs) and adverse events of special interest (AESIs)|Immunogenicity( serum anti SARS-CoV-2 neutralizing antibody titers (ACE2 receptor-based) )|Immunogenicity(serum anti SARS-CoV-2 neutralizing antibody titers (cell based) )|Immunogenicity(serum anti SARS-CoV-2 whole virus antibody titers)|Antibody kinetics of each SCB 2019 vaccine formulation after first and second doses","Clover Biopharmaceuticals AUS Pty Ltd","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CLO-SCB-2019-001","June 19, 2020","October 20, 2020","March 30, 2021","May 28, 2020",,"June 23, 2020","Linear Clinical Research Ltd, Nedlands, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT04405908"
600,"NCT04400812","Attitude and Perception Towards COVID-19 Pandemic",,"Enrolling by invitation","No Results Available","COVID-19","Other: questionnaire","Knowledge about COVID-19 by questionnaire|Perception about COVID-19 by questionnaire|Attitude towards COVID-19 by questionnaire","Zagazig University","All","16 Years to 70 Years   (Child, Adult, Older Adult)",,"5000","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","ZU#IRB#6138-17-5-2020","May 19, 2020","June 2020","August 2020","May 26, 2020",,"May 26, 2020","Zagazig University, Zagazig, Sharkia, Egypt",,"https://ClinicalTrials.gov/show/NCT04400812"
601,"NCT04354805","Administration of Chlorpromazine as a Treatment for COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Chlorpromazine","Clinical improvement","Cairo University","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Medical","July 1, 2020","August 2020","September 2020","April 21, 2020",,"June 19, 2020","Cairo University, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04354805"
602,"NCT04422340","Senior-COVID-Rea Multicentric Survey","SeniorCOVIDRea","Recruiting","No Results Available","COVID-19 Disease, Severe Form","Other: Group1","Evaluation of the impact of age on mortality at 30 days after admission to intensive care","Hospices Civils de Lyon","All","60 Years and older   (Adult, Older Adult)",,"185","Other","Observational","Observational Model: Cohort|Time Perspective: Other","69HCL20_0386","April 1, 2020","August 15, 2020","August 15, 2020","June 9, 2020",,"June 16, 2020","Resuscitation unit at Hospital Emile Roux, Le Puy-en-Velay, France|- Resuscitation unit of the Groupement Hospitalier Nord - Hospices Civils de Lyon, Lyon, France|- Resuscitation unit of the Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France|Resuscitation unit of the Groupement Hospitalier Centre - Hospices Civils de Lyon, Lyon, France|Resuscitation unit of the Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France|Service de Réanimation de l'Hôpital Nord Ouest, Villefranche-sur-Saône, France|Medipole Resuscitation unit, Villeurbanne, France",,"https://ClinicalTrials.gov/show/NCT04422340"
603,"NCT04351763","Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms","ReCOVery-SIRIO","Recruiting","No Results Available","COVID-19","Drug: Amiodarone|Drug: Verapamil","Clinical improvement|Mean change in the 7-point ordinal scale|Mortality|Time to resolution of fever|Clinical improvement or fever resolution|Tachyarrhythmias|Mortality or tachyarrhythmias|Time to clinical improvement from admission using the 7-point ordinal scale|Change in NEWS2 score|Duration of hospitalization|PO2/FIO2","Nicolaus Copernicus University","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2|Phase 3","804","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","NCU-COVID19","April 27, 2020","March 2, 2021","April 10, 2021","April 17, 2020",,"April 17, 2020","Nicolaus Copernicus University, Bydgoszcz, Poland",,"https://ClinicalTrials.gov/show/NCT04351763"
604,"NCT04353284","Camostat Mesylate in COVID-19 Outpatients",,"Recruiting","No Results Available","COVID-19","Drug: Camostat Mesilate|Other: Placebo","Change in SARS-COV-2 viral load|Change in positive COVID-19 status|Change in COVID-19 symptom severity|Change in COVID-19 symptom frequency|Change in body temperature","Yale University","All","18 Years and older   (Adult, Older Adult)","Phase 2","114","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2000027971","June 19, 2020","May 31, 2021","May 31, 2021","April 20, 2020",,"June 22, 2020","Yale University, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT04353284"
605,"NCT04380402","Atorvastatin as Adjunctive Therapy in COVID-19","STATCO19","Not yet recruiting","No Results Available","COVID-19","Drug: Atorvastatin","Proportion of patients that progress to severe or critical requiring ICU admission and/or emergency salvage therapy, or death|Overall score of patients in each arm on Day 7 based on WHO Ordinal Scale for Clinical Improvement|Overall score of patients in each arm on Day 30 based on WHO Ordinal Scale for Clinical Improvement|Proportions of patients in each arm who test negative for SARS-CoV-2 on Day 7","Mount Auburn Hospital","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MountAuburn","May 20, 2020","December 31, 2021","May 8, 2022","May 8, 2020",,"May 22, 2020",,,"https://ClinicalTrials.gov/show/NCT04380402"
606,"NCT04388527","COVID-19 Convalescent Plasma for Mechanically Ventilated Population",,"Recruiting","No Results Available","Covid-19","Biological: COVID-19 Convalescent Plasma","Participants with serious adverse events.|Time to clinical improvement.|Clinical status assessment, using 8-point ordinal scale, of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Clinical status assessment using the National Early Warning Score (NEWS) of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Incidence of new oxygenation use up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Duration of new oxygen use up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Oxygen-free days of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Non-invasive ventilation/high flow oxygen days up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Incidence of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Duration of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Ventilator/ECMO free days to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Incidence of new mechanical ventilation or ECMO use of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Duration of new mechanical ventilation or ECMO use of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Duration of hospitalization of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006|Mortality of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006|Cumulative incidence of SAEs through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Cumulative incidence of Grade 3 and Grade 4 clinical and/or laboratory adverse events through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in WBC with differential through day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in hemoglobin measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in platelets measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006..|Changes in creatinine measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006..|Changes in glucose measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in bilirubin measurement through Day 29 of convalescent plasma administration as compared to matched participants form the control arm of DMID Protocol No. 20-0006..|Changes in ALT measurement laboratory adverse events through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in AST measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in PT measurement laboratory adverse events through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Phase 1","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","842996 (PennCCP-01)","April 30, 2020","August 30, 2020","September 30, 2020","May 14, 2020",,"May 29, 2020","Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04388527"
607,"NCT04340544","Hydroxychloroquine for the Treatment of Mild COVID-19 Disease","COMIHY","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Placebo","Difference in time to resolution of clinical signs and symptoms of mild COVID-19 treated with hydroxychloroquine or placebo as assessed by daily self-assessment|Difference between hydroxychloroquine- and placebotreated patients on an ordinal outcome scale until Day 28 (death, admission to intensive care, hospitalization, continuing disease, recovered)|All-cause mortality within 28 days","University Hospital Tuebingen|Robert Bosch Medical Center|Universitätsklinikum Hamburg-Eppendorf|Bernhard Nocht Institute for Tropical Medicine","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","2700","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COMIHY","April 22, 2020","November 30, 2021","September 30, 2022","April 9, 2020",,"May 11, 2020","Institute for Tropical Medicine, Tübingen, Germany",,"https://ClinicalTrials.gov/show/NCT04340544"
608,"NCT04374903","Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients","COVID19-HOPE","Not yet recruiting","No Results Available","COVID-19 Patients","Drug: HCQ & AZ vs HCQ+SIR","Time to Clinical improvement (TTCI)|Clinical failure defined as death or need for Intubation and mechanical ventilation|Adverse effects|QT interval prolongation|Failure to continue assigned therapy|Time to viral clearance","King Hussein Cancer Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","58","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20 KHCC 74","May 1, 2020","August 1, 2020","September 1, 2020","May 5, 2020",,"May 5, 2020","King Hussein Cancer Center, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT04374903"
609,"NCT04377035","The Role of Ultrasound in COVID-19",,"Recruiting","No Results Available","COVID-19",,"In-hospital mortality during hospitalization and a confirmed COVID-19 diagnosis|Incident ARDS (Adult Respiratory Distress Syndrome) and intensive care unit admission during hospitalization and a confirmed COVID-19 diagnosis|Incident hypoxic respiratory failure during hospitalization and a confirmed COVID-19 diagnosis|Incident pulmonary embolism during hospitalization and a confirmed COVID-19 diagnosis|Incident cardiac arrest during hospitalization and a confirmed COVID-19 diagnosis|Death from any cause after hospital admission with a confirmed COVID-19 diagnosis at follow-up|Incident stroke after hospital admission with a confirmed COVID-19 diagnosis at follow-up|Incident heart failure after hospital admission with a confirmed COVID-19 diagnosis at follow-up|Incident myocardial infarction after hospital admission with a confirmed COVID-19 diagnosis at follow-up","University Hospital, Gentofte, Copenhagen","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","H-20021500","March 31, 2020","May 1, 2020","March 1, 2021","May 6, 2020",,"May 8, 2020","Cardiovascular Non-Invasive Imaging Research Laboratory, department of Cardiology, Herlev & Gentofte Hospital, Hellerup, Denmark",,"https://ClinicalTrials.gov/show/NCT04377035"
610,"NCT04395391","Home Usability Study of the SARS-CoV-2 (COVID-19) Test",,"Active, not recruiting","No Results Available","COVID-19","Diagnostic Test: SARS-CoV-2","Valid SARS-CoV-2 Test","Exact Sciences Corporation","All","18 Years and older   (Adult, Older Adult)",,"30","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-06","May 18, 2020","May 21, 2020","June 2020","May 20, 2020",,"May 28, 2020","Exact Sciences, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04395391"
611,"NCT04348422","Evaluating the Immune Response for COVID-19","COVIDIMMUNE","Not yet recruiting","No Results Available","COVID-19","Diagnostic Test: COVID-19 RT-PCR|Diagnostic Test: COVID-19 Serology|Other: Symptoms questionnare","Proportion of symptomatic patients with immune response (IgM/IgG/IgA)|Proportion of Asymptomatic patients with immune response (IgM/IgG/IgA)|Time to IgM|Time to IgG|Time to IgA|Serology kits inter-observer agreement","Assaf-Harofeh Medical Center","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","105-20-ASF","April 20, 2020","December 1, 2020","December 31, 2020","April 16, 2020",,"April 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04348422"
612,"NCT04338958","Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation","RuxCoFlam","Recruiting","No Results Available","Covid-19","Drug: Ruxolitinib","overall response rate in reversal of hyperinflammation","University of Jena","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RuxCoFlam","April 22, 2020","January 31, 2021","August 31, 2021","April 8, 2020",,"May 1, 2020","Universitätsmedizin Göttingen - Klinik für Hämatologie und Onkologie, Göttingen, Germany|University Hospital Jena, Jena, Germany|Klinikum der Landeshauptstadt Stuttgart gKöR, Stuttgart, Germany|Universitätsklinikum Ulm, Ulm, Germany|Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH, Villingen-Schwenningen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany",,"https://ClinicalTrials.gov/show/NCT04338958"
613,"NCT04384900","Accelerated Prone Position Ventilation of Patients With COVID-19","PROVENT-COVID","Recruiting","No Results Available","COVID-19","Procedure: Prone position ventilation","Days alive without respiratory life support (invasive mechanical ventilation) at day 28.|Days alive and out of hospital on day 28 after randomisation.|Days alive at day 28 without life support (vasopressor/inotropic support, invasive mechanical ventilation or renal replacement therapy).|Number of participants with one or more SARs as described in section 6.1 plus incidence of new persistent nerve injury or grade 3 or 4 (full-thickness skin loss or worse) pressure wounds.|28-days all-cause mortality.","Nordsjaellands Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","H-20027361","May 11, 2020","November 2020","December 2020","May 12, 2020",,"May 14, 2020","Nordsjællands Hospital, Hillerød, Region Hovedstanden, Denmark",,"https://ClinicalTrials.gov/show/NCT04384900"
614,"NCT04369807","Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection","COVERSCAN","Recruiting","No Results Available","COVID-19","Diagnostic Test: Outpatient MRI","Characterise prevalence and severity of organ volume change and damage (heart, kidneys and liver)|Characterise prevalence and severity of organ volume change and damage (lung, pancreas and spleen)|Change from Baseline in liver-specific biomarkers: volume, iron corrected T1(cT1), fat content and T2star|Change from Baseline in organ-specific biomarkers characterising organ volume change in the heart and spleen along with organ volume and damage in the kidney, liver and pancreas assessed by volume, iron corrected T1 (cT1) and fat infiltration|Change in patient reported outcome measured by the Dyspnea-12 questionnaire|Change in patient reported outcome measured by the St. George's Respiratory questionnaire (SGRQ)|Change in patient reported outcome measured by the EQ-5D-5L questionnaire|Degree of change in liver MR-derived biomarkers","Perspectum Diagnostics Ltd","All","18 Years and older   (Adult, Older Adult)",,"507","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20/SC/0185","April 21, 2020","May 31, 2023","May 31, 2023","April 30, 2020",,"April 30, 2020","Mayo Clinic Healthcare, London, United Kingdom|Gemini, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04369807"
615,"NCT04375124","Treatment of Angiotensin Peptide (1-7) for COVID-19",,"Recruiting","No Results Available","COVID-19","Biological: Biological/Vaccine: Angiotensin peptide (1-7) derived plasma","mortality","Kanuni Sultan Suleyman Training and Research Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KSSEAH--0059","April 25, 2020","August 31, 2020","September 30, 2020","May 5, 2020",,"May 15, 2020","Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04375124"
616,"NCT04381351","Noncoding RNAs in COVID-19 and COVID-19 Related Kidney Dysfunction","MiRCOVID","Recruiting","No Results Available","COVID-19",,"predicitive value of noncoding RNAs in COVID-19 associated organ dysfunction","Heinrich-Heine University, Duesseldorf","All","18 Years to 90 Years   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1","April 16, 2020","March 1, 2021","July 31, 2021","May 8, 2020",,"May 27, 2020","Klinik für Anästhesiologie, Düsseldorf, Germany",,"https://ClinicalTrials.gov/show/NCT04381351"
617,"NCT04377789","Effect of Quercetin on Prophylaxis and Treatment of COVID-19",,"Recruiting","No Results Available","COVID-19","Dietary Supplement: Quercetin Prophylaxis|Dietary Supplement: Quercetin Treatment","Prevalence of COVID-19 calculated using a questionnaire|Standardized Mortality rate|Morbidity rate","Kanuni Sultan Suleyman Training and Research Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","KSSEAH--0058","March 20, 2020","July 31, 2020","August 31, 2020","May 6, 2020",,"May 15, 2020","Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04377789"
618,"NCT04371822","Efficacy of Sunlight Activated Synthetic Porphyrin in COVID-19 Infected Patients","SnPPIX","Not yet recruiting","No Results Available","COVID-19","Drug: SnPP Protoporphyrin plus Sunlight exposure|Drug: Sulfonatoporphyrin(TPPS) plus Sunlight exposure.|Other: placebo","lung injury score|Serum ferritin|Absolute lymphocyte counts|Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon|Serum level of COVID19 RNA|All cause mortality rate|Ventilation free days|ICU free days|d-dimers|Time to first negative SARS-CoV-2 PCR in NP swap","Kafrelsheikh University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","56","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Proposed by Mahmoud Elkazz","August 2020","October 2020","November 2020","May 1, 2020",,"June 24, 2020","Kafr El-sheikh University, Cairo, Kafr El-sheikh, Egypt",,"https://ClinicalTrials.gov/show/NCT04371822"
619,"NCT04338347","CAP-1002 in Severe COVID-19 Disease",,"Available","No Results Available","COVID-19","Biological: CAP-1002 Allogeneic Cardiosphere-Derived Cells",,"Capricor Inc.","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Intermediate-size Population|Treatment IND/Protocol",,"CAP-1002-COVID-19",,,,"April 8, 2020",,"May 27, 2020","Cedars-Sinai Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04338347"
620,"NCT04443725","Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine , Sofosbuvir, daclatasvir|Drug: Standard of care treatment","Virological cure","Cairo University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CUKA-003","July 2020","October 2020","December 2020","June 23, 2020",,"June 25, 2020",,,"https://ClinicalTrials.gov/show/NCT04443725"
621,"NCT04356690","Etoposide in Patients With COVID-19 Infection",,"Recruiting","No Results Available","COVID-19","Drug: Etoposide","Change in pulmonary status|Change in ferritin levels|Change in C-reactive protein levels|Change in d-dimer levels|Change in white blood cell count|Incidence of serious adverse events|Overall survival|Length of hospitalization|Duration of ventilation|Ventilator free days|Improvement in arterial oxygen partial pressure (PaO2) to fractional inspired oxygen (FiO2)","Boston Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","H-40102","May 8, 2020","December 2020","December 2021","April 22, 2020",,"May 11, 2020","Boston Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04356690"
622,"NCT04415151","Tofacitinib for Treatment of Moderate COVID-19","I-TOMIC","Not yet recruiting","No Results Available","COVID-19","Drug: Tofacitinib 10 mg|Drug: Placebo","Disease Severity|Clinical improvement|Time to recovery|Time to clinical improvement|Clinical status|Mortality|Mechanical Ventilatory Support|Mechanical Ventilatory Support Duration|Freedom from mechanical ventilation|Adverse events|Additional intervention|Viral titer","Yale University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2000027848","June 30, 2020","March 31, 2021","March 31, 2021","June 4, 2020",,"June 4, 2020",,,"https://ClinicalTrials.gov/show/NCT04415151"
623,"NCT04366115","Evaluating AVM0703 for Treatment of COVID-19","AVM0703","Not yet recruiting","No Results Available","COVID-19","Drug: AVM0703|Drug: Placebo|Drug: hydrocortisone","Dose-Limiting Toxicities|28 day all-cause mortality will be a primary end point for Phase 1 and 2","AVM Biotechnology LLC|Medpace, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","126","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AVM0703-101","June 2020","June 2022","June 2023","April 28, 2020",,"May 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04366115"
624,"NCT04383002","High Dose Inhaled Nitric Oxide for COVID-19 (ICU Patients)",,"Not yet recruiting","No Results Available","COVID-19","Drug: Nitric Oxide","COVID-19 PCR status at completion of treatment (day 3) from tracheal aspirate","University Health Network, Toronto","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-5449","May 2020","December 2020","December 2020","May 11, 2020",,"May 11, 2020",,,"https://ClinicalTrials.gov/show/NCT04383002"
625,"NCT04395976","Ayurveda as Prophylaxis for Suspected COVID-19 Patients",,"Not yet recruiting","No Results Available","Covid-19","Other: Ayurveda","Clinical confirmation of Covid-19","British Ayurvedic Medical Council|All Party Parliamentary Group - Indian Traditional Sciences|University of Warwick","All","18 Years and older   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","BAMC01","June 10, 2020","September 10, 2020","October 1, 2020","May 20, 2020",,"May 20, 2020","British Ayurvedic Medical Council, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04395976"
626,"NCT04376398","Survey: COVID-19 Patients Managed in the Operating Theatre of Belgian Hospitals","COVID","Recruiting","No Results Available","COVID-19",,"Global evaluation of the implication of the Belgian anesthesiologists during COVID-19 pandemic|If any compare our results with other countries","Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Society for Anesthesia and Resuscitation of Belgium","All","up to 100 Years   (Child, Adult, Older Adult)",,"200","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","COVID-ANESTHESIO","April 6, 2020","June 30, 2020","September 30, 2020","May 6, 2020",,"May 6, 2020","Cliniques Universitaires Saint Luc, Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT04376398"
627,"NCT04327674","The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19",,"Recruiting","No Results Available","COVID-19",,"FLUS findings and respiratory failure|FLUS findings and chest x-ray.|FLUS findings and admission to intensive care.|FLUS findings and SAR-CoV-2 PCR-test result.","University of Aarhus","All","18 Years and older   (Adult, Older Adult)",,"375","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-FLUS","March 14, 2020","May 15, 2020","May 15, 2020","March 31, 2020",,"March 31, 2020","Lungemedicinsk Forskningsafdeling. Aarhus University Hospital, Aarhus, Denmark|Regionshospitalet Horsens., Horsens, Denmark",,"https://ClinicalTrials.gov/show/NCT04327674"
628,"NCT04412785","Cyclosporine in Patients With Moderate COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Cyclosporine","Safety-oxygen, ICU transfer and ventilation|Safety-changes in absolute lymphocyte count|Safety-changes in creatinine clearance|Safety-secondary bacterial infections|Laboratory measurements of safety and antiviral efficacy related to COVID-19-SARS-CoV-2 by measuring the clearance of SARS-CoV-2 from respiratory secretions|Laboratory measurements-D-dimer levels|Laboratory measurements-ferritin|Laboratory measurements- IL-6","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","842998","June 22, 2020","September 2020","December 2020","June 2, 2020",,"June 29, 2020","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04412785"
629,"NCT04412369","Multi-modality Imaging & Immunophenotyping of COVID-19 Related Myocardial Injury","MIIC-MI","Not yet recruiting","No Results Available","COVID19|Cardiovascular Diseases","Diagnostic Test: Non-invasive cardiac imaging","Number of participants with a diagnosis of COVID-19 related myocarditis, Type 1 or 2 myocardial infarction and/or other mechanism of cardiac injury confirmed by multi-modality imaging.|Comparison of a panel of inflammatory cytokines and immune cell profiles in patients categorized by cardiac diagnosis after imaging|Comparison of a panel of blood coagulation markers in patients categorized by cardiac diagnosis after imaging","University of Cambridge|Cambridge University Hospitals NHS Foundation Trust|British Heart Foundation|Wellcome Trust","All","18 Years to 99 Years   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","A09565","June 2020","June 2021","June 2021","June 2, 2020",,"June 2, 2020","Cambridge Univeristy Hospitals NHS Foundation Trust, Cambridge, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04412369"
630,"NCT04361981","Influence of COVID-19 Infection in Thromboembolic Venous Disease: National Cohort Study","TVP-COVID-RIV","Not yet recruiting","No Results Available","COVID-19","Other: Deep Venous Disease Diagnostic","Deep Venous Disease Incidence|30-days mortality|ICU admission|Anticoagulant treatment","Sociedad Espanola de Angiologia y Cirugia Vascular","All","Child, Adult, Older Adult",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RIV-R3","April 2020","August 31, 2020","December 31, 2020","April 24, 2020",,"April 27, 2020","Red de Investigacion Vascular (SEACV), Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04361981"
631,"NCT04445207","Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19",,"Available","No Results Available","COVID|Sars-CoV2|Corona Virus Infection","Biological: Convalescent Plasma",,"Jonathan Gerber|University of Massachusetts, Worcester","All","12 Years and older   (Child, Adult, Older Adult)",,,"Other","Expanded Access:Treatment IND/Protocol",,"H000020420",,,,"June 24, 2020",,"June 24, 2020","UMass Medical School, Worcester, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04445207"
632,"NCT04409483","Evaluation of Additional Treatments for COVID-19: a Randomized Trial in Niger","TRASCOV","Withdrawn","No Results Available","Covid-19","Drug: Lopinavir-Ritonavir Drug Combination|Combination Product: Standard Care","Hospitalization or death|All-cause mortality|Time to hospitalization|Length of hospitalization|Admission to intensive care|Adverse events|Serious adverse events","Epicentre|Université Abdou Moumouni|Centre de Recherche Médicale et Sanitaire|Ministry of Public Health, Republic of Niger","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Trascov","June 1, 2020","December 31, 2020","December 31, 2021","June 1, 2020",,"June 29, 2020",,,"https://ClinicalTrials.gov/show/NCT04409483"
633,"NCT04411602","Feasibility Study of Anti-SARS-CoV-2 Plasma Transfusions in COVID-19 Patients With SRD",,"Recruiting","No Results Available","Severe Acute Respiratory Syndrome|COVID","Drug: SARS-CoV-2 plasma","Transfusion of patients in the ICU with convalescent plasma for COVID-19-induced respiratory failure.|Ventilatory free days|Patient mortality (including death from any cause)","Ascension South East Michigan","All","18 Years and older   (Adult, Older Adult)","Phase 1","90","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1589349","April 7, 2020","December 31, 2020","December 31, 2020","June 2, 2020",,"June 2, 2020","Ascension Providence Hospital, Novi Campus, Novi, Michigan, United States|Ascension Providence Hospital, Southfield Campus, Southfield, Michigan, United States|Ascension Macomb-Oakland Hospital, Warren Campus, Warren, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT04411602"
634,"NCT04445415","Diagnostic Value of New COVID-19 Antibodies Testing Among Laboratory Healthcare Workers",,"Not yet recruiting","No Results Available","COVID-19","Diagnostic Test: COVID-19 antibodies testing","diagnostic value of COVID-19 antibodies testing|Role of COVID -19 Antibodies testing in treatment of Patients|Assement of COVID -19 prevalence among healthcare workers","Assiut University","All","Child, Adult, Older Adult",,"250","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","COVID-19 antibodies testing","July 1, 2020","June 1, 2021","September 1, 2021","June 24, 2020",,"June 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04445415"
635,"NCT04424797","Prone Positioning on Admission for Hospitalized COVID-19 Pneumonia Protocol",,"Recruiting","No Results Available","COVID-19","Other: Prone Positioning|Other: Supine Positioning","Incidence of intubation|Maximum oxygen requirement|Length of Stay|Ventilator-free days|Treatment failure of prone positioning due to worsening SpO2 status while prone|Mortality","Poudre Valley Health System","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-6034","June 2020","December 2020","December 2020","June 11, 2020",,"June 11, 2020","UCHealth Poudre Valley Hospital, Fort Collins, Colorado, United States|UCHealth Greeley Hospital, Greeley, Colorado, United States|UCHealth Medical Center of the Rockies, Loveland, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT04424797"
636,"NCT04387643","Protecting Health Care Workers During the COVID-19 Outbreak",,"Completed","No Results Available","Covid-19","Dietary Supplement: Ayurvedic Kadha","Physical Health|Psychological Health|Coping with distress|Self-Help","Aarogyam UK|Samta Ayurveda Prakoshtha, India","All","18 Years to 60 Years   (Adult)",,"52","Other","Observational","Observational Model: Other|Time Perspective: Prospective","AU/SA/01","March 1, 2020","April 2, 2020","April 2, 2020","May 14, 2020",,"May 14, 2020","Samta Ayurveda Prakoshtha, Jaipur, Rajasthan, India",,"https://ClinicalTrials.gov/show/NCT04387643"
637,"NCT04368065","Registry to Study Factors That May Impact COVID-19 Occurrence and Severity",,"Recruiting","No Results Available","COVID-19",,"COVID-19 symptom occurrence and severity|COVID-19 treatments|Hospitalization","Iqvia Pty Ltd","All","18 Years and older   (Adult, Older Adult)",,"100000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","IQVIA_COVIDREGISTRY_2020","April 2, 2020","December 31, 2021","June 1, 2022","April 29, 2020",,"April 29, 2020","IQVIA, Cambridge, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04368065"
638,"NCT04438850","COVidIVERmectin: Ivermectin for Treatment of Covid-19","COVER","Not yet recruiting","No Results Available","Covid19","Drug: Ivermectin|Other: Placebo","SADR|Viral load|Trend viral load|Clinical resolution|Viral clearance|Virological clearance|hospitalization rate|Severity score","IRCCS Sacro Cuore Don Calabria di Negrar|Istituto Di Ricerche Farmacologiche Mario Negri","All","18 Years and older   (Adult, Older Adult)","Phase 2","102","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","cover_1","June 2020","August 2020","October 2020","June 19, 2020",,"June 19, 2020","IRCCS Sacro Cuore Don Calabria hospital, Negrar, Verona, Italy|Policlinico S. Orsola, Bologna, Italy|Ospedale Luigi Sacco, Milan, Italy|Ospedale di Rovereto, Rovereto, Italy|Ospedale Amedeo di Savoia, Turin, Italy|Hospital Clinic/ISGlobal, Barcelona, Spain|Hospital La Paz-Carlos III, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04438850"
639,"NCT04435041","Remote-by-Default Care in the COVID-19 Pandemic",,"Active, not recruiting","No Results Available","COVID-19",,"RECAP Early warning score","University of Oxford|University of Plymouth|Nuffield Trust","All","Child, Adult, Older Adult",,"1","Other","Observational","Observational Model: Other|Time Perspective: Other","283196","June 1, 2020","May 31, 2021","November 30, 2021","June 17, 2020",,"June 17, 2020","University of Oxford, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04435041"
640,"NCT04434144","A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh",,"Completed","No Results Available","Ivermectin|Hydroxychloroquine|COVID19","Drug: Ivermectin + Doxycycline|Drug: Hydroxychloroquine + Azithromycin","Number of participants with ""treatment success"" determine by a negative RT PCR for COVID19.|Number of participants with ""adverse effects"" determined by the existence of the pharmacological side effects of the particular drug during treatment.","Upazila Health & Family Planning Officer's (UHFPO) Office, Chakoria, Cox's Bazar","All","16 Years to 80 Years   (Child, Adult, Older Adult)",,"116","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","10000918","May 2, 2020","June 5, 2020","June 5, 2020","June 16, 2020",,"June 16, 2020","Chakoria Upazilla Health Complex, Cox's Bazar, Bangladesh",,"https://ClinicalTrials.gov/show/NCT04434144"
641,"NCT04355026","Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia",,"Recruiting","No Results Available","Covid-19","Drug: Bromhexine Oral Tablet and/or hydroxychloroquine tablet","Duration of hospitalization|Duration of disease|Hospital-aquired pneumonia|ICU stay duration|Oxygene therapy duration|Mechanical ventilatory support duration","General and Teaching Hospital Celje","All","19 Years and older   (Adult, Older Adult)","Phase 4","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SBCebromhexinCovid-19","April 10, 2020","June 30, 2020","July 31, 2020","April 21, 2020",,"April 21, 2020","SB Celje, Celje, Slovenia",,"https://ClinicalTrials.gov/show/NCT04355026"
642,"NCT04341675","Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia","SCOPE","Recruiting","No Results Available","COVID-19","Drug: Sirolimus|Drug: Placebo","Proportion of patients who are alive and free from advanced respiratory support measures at day 28.|Proportion of patients who require escalation in care|Change over time in study-specific biomarkers (LDH, Ferritin, D-dimer, lymphocyte count)|Proportion of patients surviving to hospital discharge|Drug safety profile|Duration of advanced respiratory support|Duration of hospital stay|Time from treatment initiation to death|Time to resolution of fever|Proportion of patients who require initiation of off-label therapies","University of Cincinnati","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020-0337","April 24, 2020","July 2020","September 2020","April 10, 2020",,"May 20, 2020","Loyola University Medical Center, Chicago, Illinois, United States|University of Cincinnati, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04341675"
643,"NCT04444271","Mesenchymal Stem Cell Infusion for COVID-19 Infection",,"Recruiting","No Results Available","COVID-19","Drug: Mesenchymal stem cells|Other: Placebo","Overall survival|Clinical improvement|Time of COVID19 PCR negativity|Radiological improvement (day 15 and day 30 assessment)|days required to discharge from hospital","Zaineb Akram|Armed Forces Bone Marrow Transplant Center, Rawalpindi, Pakistan","All","10 Years and older   (Child, Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NIBMT-MSc-COVID-2020","May 1, 2020","August 30, 2020","September 30, 2020","June 23, 2020",,"June 29, 2020","NIBMT, Rawalpindi, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT04444271"
644,"NCT04407286","Vitamin D Testing and Treatment for COVID 19",,"Recruiting","No Results Available","Covid 19|Vitamin D Deficiency","Dietary Supplement: Vitamin D3","Vitamin D levels|severity of COVID 19 symptoms","Arizona State University|Southwest College of Naturopathic Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 1","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00011960","May 19, 2020","August 18, 2020","May 18, 2021","May 29, 2020",,"May 29, 2020","Arizona State University, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT04407286"
645,"NCT04366050","Ramipril for the Treatment of COVID-19","RAMIC","Not yet recruiting","No Results Available","COVID-19","Drug: Ramipril 2.5 MG Oral Capsule|Drug: Placebo oral capsule","Composite of mortality or need for ICU admission or ventilator use","University of California, San Diego|Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 2","560","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","RAMIC Trial","April 2020","April 2021","April 2021","April 28, 2020",,"April 28, 2020",,,"https://ClinicalTrials.gov/show/NCT04366050"
646,"NCT04400058","Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression",,"Recruiting","No Results Available","Covid-19","Biological: Octagam 10%|Other: Placebo","Stabilization or Improvement in Clinical Status|Oxygen saturation|Modified Borg Dyspnea scale|Quality of Life MQoL-SIS (McGill Quality of Life Single-Item Scale)|Time to intubation|Time to extubation|Time to mechanical ventilation|Time to cessation of mechanical ventilation|Time to change of modality for oxygenation|Time to death|Imaging findings (chest CT/chest X-ray)|Blood glucose|Blood calcium|Sodium|Potassium|Carbon dioxide|Chloride|Albumin|Total protein|Alkaline phosphatase|Alanine transaminase|Aspartate aminotransferase|Bilirubin|Blood urea nitrogen|D-dimer|Fibrinogen|PT|PTT|INR|hsCRP|Ferritin|LDH|IgG|IgM|IgA|IFE|Troponin|Red blood cell count|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean corpuscular hemoglobin|Mean corpuscular hemoglobin concentration|Red cell distribution width|White blood cell count|White blood cell differential|Platelet count|Mean platelet volume|Platelet distribution width|Frequency of adverse events|Frequency of serious adverse events","Octapharma","All","18 Years and older   (Adult, Older Adult)","Phase 3","208","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","GAM10-10","June 1, 2020","December 30, 2020","December 30, 2020","May 22, 2020",,"June 29, 2020","Octapharma Research Site, Loma Linda, California, United States|Octapharma Research Site, Iowa City, Iowa, United States|Octapharma Research Site, Covington, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT04400058"
647,"NCT04446104","A Preventive Treatment for Migrant Workers at High-risk of Covid-19",,"Recruiting","No Results Available","Covid-19","Drug: Hydroxychloroquine Sulfate Tablets|Drug: Ivermectin 3Mg Tab|Drug: Zinc|Drug: Povidone-Iodine|Dietary Supplement: Vitamin C","Incidence of acute respiratory illness in treatment arms (hydroxycholorquine, ivermectin, zinc and povidone iodine)|Incidence of febrile respiratory illness in treatment arms (hydroxycholorquine, ivermectin, zinc and povidone iodine)|Rate of hospitalization for COVID-19 and non-COVID-19 related indications in treatment arms (hydroxycholorquine, ivermectin, zinc and povidone iodine)|Rate of oxygen supplementation and mechanical ventilation in treatment arms (hydroxycholorquine, ivermectin, zinc and povidone iodine)|Duration of oxygen supplementation and mechanical ventilation in treatment arms (hydroxycholorquine, ivermectin, zinc and povidone iodine)|Length of hospital stay in treatment arms (hydroxycholorquine, ivermectin, zinc and povidone iodine)|Rate of laboratory-confirmed COVID-19 in treatment arms (hydroxycholorquine, ivermectin, zinc and povidone iodine)|Incidence of adverse events and serious adverse events in control arm (Vitamin C)|Incidence of drug discontinuation due to adverse events in control arm (Vitamin C)","National University Hospital, Singapore","Male","21 Years to 60 Years   (Adult)","Phase 3","5000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2020/00561","May 13, 2020","July 2020","July 2020","June 24, 2020",,"June 24, 2020","Tuas South Dormitory, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT04446104"
648,"NCT04329923","The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)","PATCH","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine Sulfate 400 mg twice a day|Drug: Hydroxychloroquine Sulfate 600 mg twice a day|Drug: Hydroxychloroquine Sulfate 600 mg once a day|Drug: Placebo oral tablet","Median release from quarantine time|Rate of hospital discharge|Rate of infection|Rate of housemate infection|Rate of hospitalization|Cohort 1 adverse event rate|Time to condition appropriate for discharge|Rate of ICU admission|Time to PCR negativity|Cohort 2 adverse events|Scheduled shifts missed|Cohort 3 adverse events","Ravi Amaravadi, MD|University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Phase 2","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","842838","April 9, 2020","April 1, 2021","December 1, 2021","April 1, 2020",,"April 28, 2020","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04329923"
649,"NCT04394416","Trial of Imatinib for Hospitalized Adults With COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Imatinib|Drug: Placebo oral tablet","The proportion of patients with a two-point change using the 8-category ordinal scale|All-Cause mortality|Time to a 2-point clinical change|Hospitalization|Duration of ECMO or invasive mechanical ventilation|Duration of ICU stay|SARS-CoV-2 negative|Negative oropharyngeal or nasopharyngeal swab|Serious adverse events (SAEs)|Discontinuation due to adverse events","University of Maryland, Baltimore","All","18 Years and older   (Adult, Older Adult)","Phase 3","204","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2038GCCC","June 2, 2020","June 1, 2022","June 1, 2023","May 19, 2020",,"June 4, 2020","University of Maryland Medical Center, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04394416"
650,"NCT04374461","A Study of N-acetylcysteine in Patients With COVID-19 Infection",,"Recruiting","No Results Available","Covid-19","Drug: N-acetylcysteine|Other: Peripheral Blood","Arm A: number of patients who are successfully extubated and/or transferred out of critical care due to clinical improvement|Arm B: number of patients who are discharged from the hospital due to clinical improvement","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","86","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-168","May 1, 2020","May 2021","May 2021","May 5, 2020",,"June 1, 2020","Memorial Sloan Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04374461"
651,"NCT04341142","Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER","COVID-SER","Recruiting","No Results Available","Covid19","Diagnostic Test: Serological tests will be applied on patients blood sampling","The positivity (Yes/No) of the serological test.","Hospices Civils de Lyon","All","18 Years and older   (Adult, Older Adult)","Not Applicable","130","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","69HCL20_0329","April 9, 2020","September 9, 2020","September 9, 2020","April 10, 2020",,"June 4, 2020","Hôpital Lyon Sud,Sainte Eugénie bat 4M,5, Chemin du Grand Revoyet, Pierre-Bénite cedex, France",,"https://ClinicalTrials.gov/show/NCT04341142"
652,"NCT04397757","COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.",,"Recruiting","No Results Available","COVID-19","Biological: COVID-19 Convalescent Plasma","Participants with serious adverse events.|Comparison of clinical severity score between patients on the experimental versus control arms;|Clinical status assessment, using 8-point ordinal scale, of convalescent plasma administration by comparing treatment vs control arms|Clinical status assessment using the National Early Warning Score (NEWS) of convalescent plasma administration by comparing treatment vs control arms|Oxygen-free days of convalescent plasma administration by comparing treatment vs control arms|Incidence of new oxygenation use up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Duration of new oxygen use up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Non-invasive ventilation/high flow oxygen days up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Incidence of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Duration of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Ventilator/ECMO free days to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Incidence of new mechanical ventilation or ECMO use of convalescent plasma administration by comparing treatment vs control arms|Duration of new mechanical ventilation or ECMO use of convalescent plasma administration by comparing treatment vs control arms|Duration of hospitalization of convalescent plasma administration by comparing treatment vs control arms|Mortality of convalescent plasma administration by comparing treatment vs control arms|Cumulative incidence of SAEs through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Cumulative incidence of Grade 3 and Grade 4 clinical and/or laboratory adverse events through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in WBC with differential through day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in hemoglobin measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in platelets measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in creatinine measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in glucose measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in bilirubin measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in ALT measurement laboratory adverse events through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in AST measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in PT measurement laboratory adverse events through Day 29 of convalescent plasma administration by comparing treatment vs control arms","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","843003 (PennCCP-02)","May 13, 2020","September 13, 2020","November 13, 2020","May 21, 2020",,"June 2, 2020","Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04397757"
653,"NCT04361643","Low-dose Lenalidomide for Non-severe COVID-19 Treatment Trial","GETAFE","Not yet recruiting","No Results Available","COVID-19","Drug: Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5.|Drug: Placebo","Clinical improvement|Immune-inflammatory improvement|Mortality","Hospital Universitario Getafe","All","60 Years and older   (Adult, Older Adult)","Phase 4","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COVID19-EC01","April 27, 2020","August 31, 2020","December 31, 2020","April 24, 2020",,"April 29, 2020","Hospital Universitario de Getafe, Getafe, Spain",,"https://ClinicalTrials.gov/show/NCT04361643"
654,"NCT04318418","ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19","CODIV-ACE","Not yet recruiting","No Results Available","COVID-19",,"Severe COVID-19|Death","Neuromed IRCCS","All","Child, Adult, Older Adult",,"5000","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","DEP_012020","March 23, 2020","April 10, 2020","April 30, 2020","March 24, 2020",,"March 24, 2020","IRCCS Neuromed, Department of Epidemiology and Prevention, Pozzilli, Italy",,"https://ClinicalTrials.gov/show/NCT04318418"
655,"NCT04285801","Critically Ill Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort Study",,"Completed","No Results Available","COVID-19",,"28 day mortality|vasopressor days|days on mechanical ventilation|sequential organ function assessment score|ECMO use|percentage nitric oxide use|percentage free from oxygen supplement","Chinese University of Hong Kong","All","18 Years and older   (Adult, Older Adult)",,"8","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","2020.059","February 14, 2020","February 25, 2020","February 25, 2020","February 26, 2020",,"March 10, 2020","Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04285801"
656,"NCT04333628","Chloroquine for Mild Symptomatic and Asymptomatic COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: chloroquine|Other: standard care","change in virus duration (viral shedding)|change in the number of patients going from asymptomatic to moderately disease","HaEmek Medical Center, Israel|T MAY BIOPHARMA LTD.","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","210","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EMC 0045-20","April 2020","April 2021","December 2021","April 3, 2020",,"April 14, 2020",,,"https://ClinicalTrials.gov/show/NCT04333628"
657,"NCT04330599","Longitudinal Population-based Observational Study of COVID-19 in the UK Population","COVIDENCE UK","Not yet recruiting","No Results Available","COVID-19",,"Incidence of confirmed COVID-19|Incidence of probable or suspected COVID-19|Incidence of COVID-19 requiring hospitalisation|Incidence of COVID-19 requiring ventilatory support|Incidence of fatal COVID-19|Symptom duration per COVID-19 episode|Symptom severity per COVID-19 episode|Incidence of seroconversion to SARS-CoV-2|Incidence of recurrent COVID-19|EQ-5D-3L health-related quality of life score|Health care costs associated with incident COVID-19|Impact of the COVID-19 pandemic and the societal response on participants' financial status|Incidence of COVID-19 on participant's physical health|Impact of COVID-19 on participants' mental health|Impact of COVID-19 on physical health of offspring born to participants during follow-up","Queen Mary University of London|King's College London|London School of Hygiene and Tropical Medicine|University of Edinburgh|Swansea University|Queen's University, Belfast|Barts Charity","All","16 Years and older   (Child, Adult, Older Adult)",,"12000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVIDENCE UK","May 5, 2020","April 1, 2025","April 1, 2025","April 1, 2020",,"April 28, 2020",,,"https://ClinicalTrials.gov/show/NCT04330599"
658,"NCT04365738","Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection",,"Completed","No Results Available","COVID-19","Other: Rehabilitation","Dyspnea|Chest expansion|Fatigue severity|Visual Analog Scale for pain|Hospital anxiety and depression scale","Istanbul Bilgi University","All","28 Years to 45 Years   (Adult)","Not Applicable","270","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","PR COVID-19","March 11, 2020","April 10, 2020","April 26, 2020","April 28, 2020",,"April 28, 2020","Istanbul Bilgi University, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04365738"
659,"NCT04372628","Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19","TREAT NOW","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Lopinavir/ritonavir 400 mg/100 mg|Other: Placebo","Modified COVID Ordinal Outcomes Scale: Study Day 15|Modified COVID Ordinal Outcome Scale: Study Day 8|Modified COVID Ordinal Outcome Scale: Study Day 29|Proportion of patients hospitalized: Day 1 to 29|Time to hospitalization Day 1 to Day 29|Time to symptom resolution: Day 1 to Day 29|All-cause, all-location mortality: Day 1 to Day 29|Oxygen-free days: Day 1 to Day 29|Fever-free days: Day 1 to Day 29|Ventilator-free days: Day 1 to Day 29|ICU-free days: Day 1 to Day 29|Hospital-free days: Day 1 to Day 29","Vanderbilt University Medical Center|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","900","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","200827","May 31, 2020","December 1, 2020","May 1, 2021","May 4, 2020",,"May 19, 2020","University of Colorado School of Medicine, Aurora, Colorado, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04372628"
660,"NCT04429763","Safety and Efficacy of Mesenchymal Stem Cells in the Management of Severe COVID-19 Pneumonia","CELMA","Not yet recruiting","No Results Available","COVID-19","Biological: Umbilical cord derived mesenchymal stem cells|Biological: Placebo","Clinical deterioration or death","Trustem|Fundación Universitaria de Ciencias de la Salud|Hospital de San Jose|Hospital Infantil Universitario de San Jose","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 2","30","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","202001","July 2020","September 2020","November 2020","June 12, 2020",,"June 12, 2020",,,"https://ClinicalTrials.gov/show/NCT04429763"
661,"NCT04410328","Aggrenox To Treat Acute Covid-19","ATTAC-19","Not yet recruiting","No Results Available","Covid19","Drug: Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally|Other: Standard of care","Covid (Coronavirus Disease-19) Ordinal Scale|Mortality|Supplemental Oxygen|Invasive-ventilator|ICU stay|Hospital stay|Inflammatory markers|Thromboembolic complications|COVID ordinal scale","Rutgers, The State University of New Jersey|Boehringer Ingelheim","All","19 Years and older   (Adult, Older Adult)","Phase 3","132","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro2020001399","June 21, 2020","December 15, 2020","December 15, 2021","June 1, 2020",,"June 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04410328"
662,"NCT04418206","Validating an ELISpot for Early Detection of an Active Immune Response Against COVID-19","EliSpot","Not yet recruiting","No Results Available","Covid 19","Other: patients COVID 19","IgA specific cells of SARS|OMS progression scale","Centre Hospitalier Universitaire de Nice","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","20-PP-10","June 1, 2020","December 1, 2020","June 1, 2021","June 5, 2020",,"June 5, 2020","CH Antibes, Antibes, Alpes Maritimes, France|Ch Cannes, Pneumologie, Cannes, Alpes Maritimes, France|Ch Grasse, Grasse, Alpes Maritimes, France|CHU de nice, Nice, Alpes-Maritimes, France",,"https://ClinicalTrials.gov/show/NCT04418206"
663,"NCT04427865","Utility of Lactoferrin as a Preventive Agent for Healthcare Workers Exposed to COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: prophylactic lactoferrin daily","Incidence of SARS-CoV-2|Severity of disease in confirmed infected participants","Cairo University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CUKA-002","July 2020","September 2020","November 2020","June 11, 2020",,"June 16, 2020",,,"https://ClinicalTrials.gov/show/NCT04427865"
664,"NCT04276896","Immunity and Safety of Covid-19 Synthetic Minigene Vaccine",,"Recruiting","No Results Available","Pathogen Infection Covid-19 Infection","Biological: Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs","Clinical improvement based on the 7-point scale|Lower Murray lung injury score|28-day mortality|Duration of mechanical ventilation|Duration of hospitalization|Proportion of patients with negative RT-PCR results|Proportion of patients in each category of the 7-point scale|Proportion of patients with normalized inflammation factors|Frequency of vaccine/CTL Events|Frequency of Serious vaccine/CTL Events","Shenzhen Geno-Immune Medical Institute|Shenzhen Third People's Hospital|Shenzhen Second People's Hospital","All","6 Months to 80 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GIMI-IRB-20001","March 24, 2020","July 31, 2023","December 31, 2024","February 19, 2020",,"March 19, 2020","Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China|Shenzhen Second People's Hospital, Shenzhen, Guangdong, China|Shenzhen Third People's Hospital, Shenzhen, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04276896"
665,"NCT04304053","Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention","HCQ4COV19","Active, not recruiting","No Results Available","COVID-19","Drug: Treatment and prophylaxis|Other: Standard Public Health measures","Clinical and virological outcome in exposed contacts|Transmission of SARS-CoV-2 in exposed contacts|Virological outcome in index cases|Clinical outcome in index cases","Fundacio Lluita Contra la SIDA|Germans Trias i Pujol Hospital|Department of Health, Generalitat de Catalunya|FUNDACIÓN FLS DE LUCHA CONTRA EL SIDA, LAS ENFERMEDADES INFECCIOSAS Y LA PROMOCIÓN DE LA SALUD Y LA CIENCIA|Laboratorios Gebro Pharma SA|Laboratorios Rubió|Institut Catala de Salut","All","18 Years and older   (Adult, Older Adult)","Phase 3","2250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HCQ4COV19|2020-001031-27","March 18, 2020","June 15, 2020","June 15, 2020","March 11, 2020",,"June 24, 2020","Departament de Salut, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04304053"
666,"NCT04421027","A Study of Baricitinib (LY3009104) in Participants With COVID-19","COV-BARRIER","Recruiting","No Results Available","COVID-19","Drug: Baricitinib|Drug: Placebo","Percentage of Participants who Die or Require Non-Invasive Ventilation/High-Flow Oxygen or Invasive Mechanical Ventilation (including extracorporeal membrane oxygenation [ECMO])|Percentage of Participants with at Least 1-Point Improvement on NIAID-OS or Live Discharge from Hospital|Number of Ventilator-Free Days|Time to Recovery|Overall Improvement on the NIAID-OS|Duration of Hospitalization|Percentage of Participants with a Change in Oxygen Saturation from <94% to ≥94% from Baseline|Mortality|Duration of Stay in the Intensive Care Unit (ICU) in Days|Time to Clinical Deterioration (one-category increase on the NIAID-OS)|Time to Resolution of Fever, in Participants with Fever at Baseline|Mean Change from Baseline on the National Early Warning Score (NEWS)|Time to Definitive Extubation|Time to Independence from Non-Invasive Mechanical Ventilation|Time to Independence from Oxygen Therapy in Days|Number of Days with Supplemental Oxygen Use|Number of Days of Resting Respiratory Rate <24 Breaths per Minute","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","17830|I4V-MC-KHAA|2020-001517-21","June 12, 2020","September 1, 2020","September 1, 2020","June 9, 2020",,"June 22, 2020","Chandler Regional Medical Center, Chandler, Arizona, United States|Mercy Gilbert Medical Center, Gilbert, Arizona, United States|Valleywise Health, Phoenix, Arizona, United States|St Josephs Hospital and Medical Center, Phoenix, Arizona, United States|Sharp Healthcare, San Diego, California, United States|San Francisco VA Medical Center, San Francisco, California, United States|Morehouse School of Medicine, Atlanta, Georgia, United States|Community Hospital South, Indianapolis, Indiana, United States|White Oak Medical Center, Adventist Healthcare, Silver Spring, Maryland, United States|South Shore Hospital, Weymouth, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|SUNY Downstate, Brooklyn, New York, United States|Oregon Health and Science University, Portland, Oregon, United States|Temple University School of Medicine, Philadelphia, Pennsylvania, United States|Swedish Medical Center, Seattle, Washington, United States|Multicare Health System, Tacoma, Washington, United States|Hospital Z.G.A.D ""Evita Pueblo"", Berazategui, Buenos Aires, Argentina|Sanatorio de la Trinidad Mitre, Caba, Buenos Aires, Argentina|Fundacion Sanatorio Guemes, Caba, Buenos Aires, Argentina|Hospital Central de San Isidro ""Dr. Melchor Ángel Posse"", San Isidro, Buenos Aires, Argentina|Clinica Central S.A., Villa Regina, Rio Negro, Argentina|Hospital San Roque, Cordoba, Argentina|Hospital Felício Rocho, Belo Horizonte, Minas Gerais, Brazil|CEPETI Centro de Ensino e Pesquisa em Terapia Intensiva, Curitiba, Paraná, Brazil|CPCLIN, Natal, Rio Grande Do Norte, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil|Pesquisare, Santo Andre, Sao Paulo, Brazil|Upeclin - Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu - UNESP, Botucatu, São Paulo, Brazil|Hospital PUC-CAMPINAS, Campinas, São Paulo, Brazil|Real e Benemerita Associação Portuguesa de Beneficiencia, São Paulo, Brazil|Hospital Alemão Oswaldo Cruz, São Paulo, Brazil|Universidade Federal de São Paulo - Escola Paulista de Medicina, São Paulo, Brazil|Hospital Santa Paula, São Paulo, Brazil|Casa de Saude Santa Marcelina - Centro de Pesquisa Clinica, São Paulo, Brazil|Universitätsklinikum Erlangen, Erlangen, Bayern, Germany|Universitätsklinikum Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Ospedale Clinicizzato SS Annunziata, Chieti Scalo, Chieti, Italy|INMI Lazzaro Spallanzani, Roma, Rome, Italy|ASST Fatebenefratelli - Ospedale Luigi Sacco, Milano, Italy|Ospedale Niguarda Ca Granda, Milano, Italy|Nuovo Ospedale di Prato S. Stefano, Prato, Italy|Medica Sur, Mexico, DF, Mexico|Instituto Nacional de Cardiologia Ignacio Chavez, Mexico, DF, Mexico|Instituto Nacional de Cancerologia, Mexico City, FD, Mexico|ITESM Campus Monterrey, Monterrey, Nuevo Leon, Mexico|Hospital Universitario ""Dr. Jose Eleuterio Gonzalez"", Monterrey, Nuevo León, Mexico|Infectious Clinical Hospital #2, Moscow, Russian Federation|City Clinical Hospital #15 named after O.M. Filatov, Moscow, Russian Federation|City Clinical Hospital #64, Moscow, Russian Federation|Saint-Petersburg City Pokrovskaya Hospital, Saint-Petersburg, Russian Federation|Hospital Txagorritxu, Vitoria, Alava, Spain|Hospital Universitario Infanta Leonor-INTERNAL MED, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Royal Cornwall Hospital, Truro, Cornwall, United Kingdom|St. George'S Healthcare Nhs Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04421027"
667,"NCT04380792","Prevalence of DVT or PE in Patients Infected With COVID-19 Admitted to Hospital","SCREENING","Recruiting","No Results Available","COVID-19",,"VTE events and complications","Manuel Monreal|Foundation for the study of VTE diseases. (FUENTE)","All","Child, Adult, Older Adult",,"5000","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","SCREENING042020","April 13, 2020","April 13, 2025","June 30, 2025","May 8, 2020",,"May 8, 2020","Manuel Monreal, Badalona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04380792"
668,"NCT04361500","Registry of COVID-19 Patients Treated With the Seraph 100 Microbind Affinity Blood Filter","COSA","Recruiting","No Results Available","COVID-19","Device: Seraph 100","Survival|Length of ICU stay|Length of Hospital stay|Length of ventilator therapy|Adverse events","Hannover Medical School|Medical Clinic V Nephrology, Academic Teaching Hospital Brunswick","All","18 Years to 99 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","COSA-8998","April 15, 2020","October 1, 2020","October 1, 2021","April 24, 2020",,"April 24, 2020","Academic Teaching Hospital Brunswick, Brunswick, Lower Saxony, Germany|Hannover Medical School, Hannover, Germany",,"https://ClinicalTrials.gov/show/NCT04361500"
669,"NCT04355143","Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19)","COLHEART-19","Recruiting","No Results Available","COVID-19","Drug: Colchicine Tablets|Other: Current care per UCLA treating physicians","Composite of all-cause mortality, need for mechanical ventilation, or need for mechanical circulatory support (MCS)|Delta (peak minus baseline) troponin level|Delta (baseline to peak) brain natriuretic peptide (BNP) level|Change in left ventricular ejection fraction (LVEF) on echocardiography|Delta (peak minus baseline) C-Reactive protein (CRP) inflammatory biomarker level|Delta (peak minus baseline) D-Dimer inflammatory biomarker level|Time (days) to primary endpoint|Number of participants requiring mechanical ventilation|Number of participants requiring mechanical circulatory support (MCS)|Re-hospitalization at 90 days|All-cause mortality","University of California, Los Angeles","All","18 Years and older   (Adult, Older Adult)","Phase 2","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-000685","May 1, 2020","April 25, 2021","April 25, 2021","April 21, 2020",,"May 21, 2020","UCLA Ronald Reagan Medical Center, Los Angeles, California, United States|UCLA Santa Monica Hospital, Santa Monica, California, United States",,"https://ClinicalTrials.gov/show/NCT04355143"
670,"NCT04363385","Collection of Biological Samples With Clinical Characterization of Covid-19 Patients",,"Recruiting","No Results Available","Covid-19","Biological: Biological test","Phenotype/genotype correlation research modulating the severity of Covid-19 disease|Phenotype/transcriptomic correlation research modulating the severity of Covid-19 disease|Phenotype/biomarker correlation research modulating the severity of Covid-19 disease|Development of clinical-biological scores in the severity of Covid-19 disease|Development of predictive imaging scores in the severity of Covid-19 disease|Identification of pathophysiological pathways to susceptibility to Covid-19 disease|Identification of genetic markers for treatment response|Identification of transcriptomic markers for treatment response|Identification of proteomic for treatment response","Centre Hospitalier Intercommunal Creteil","All","Child, Adult, Older Adult","Not Applicable","500","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","COVIGENET","May 15, 2020","December 15, 2020","December 15, 2020","April 27, 2020",,"June 16, 2020","Centre hospitalier intercommunal de Créteil, Créteil, France",,"https://ClinicalTrials.gov/show/NCT04363385"
671,"NCT04359459","Nasal Epithelial Genetic and Single Cell RNA COVID-19 Study","CIPOLLINI","Not yet recruiting","No Results Available","COVID-19",,"Nasal epithelial transcriptional response to SARS-CoV2|ACE2-AngII system","University Medical Center Groningen","All","18 Years and older   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CIPOLLINI","June 2020","June 2022","June 2022","April 24, 2020",,"April 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04359459"
672,"NCT04394000","Impact of an Intensified Thromboprofylaxis Protocol in COVID-19",,"Completed","No Results Available","COVID19|Thromboembolism","Other: thromboprofylaxis protocol|Other: standard protocol","2 week mortality|incidence of venous thromboembolism|1 week mortality|3 week mortality|1 month mortality|incidence of kidney failure|incidence of continuous renal replacement therapy (CRRT)|lowest PaO2/FiO2 (P/F) ratio|highest Sequential Organ Failure Assessment (SOFA) score|length of stay|highest bilirubin|highest ( AST|highest Aspartaat-Amino-Transferase (ALT)","Jessa Hospital","All","18 Years and older   (Adult, Older Adult)",,"72","Other","Observational","Observational Model: Cohort|Time Perspective: Other","Jessa_20.48","May 4, 2020","May 15, 2020","May 15, 2020","May 19, 2020",,"May 19, 2020","Jessa hospital, Hasselt, Belgium",,"https://ClinicalTrials.gov/show/NCT04394000"
673,"NCT04351620","High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine","Tolerability of high dose HCQ as measured by HCQ dose modification|Tolerability of high dose HCQ as measured by discontinuation of HCQ|Tolerability of High Dose HCQ as measured by Adverse Events|Rate of hospitalization due to COVID-19 as measured by number of patients hospitalized|Time to defervescence as measured in days while on treatment protocol|Resolution of other COVID-19 symptoms measured in days while on treatment protocol","University of Chicago","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB20-0572","April 2020","June 2020","June 2020","April 17, 2020",,"April 17, 2020","University of Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04351620"
674,"NCT04372004","Comparison of the Efficacy of Rapid Tests to Identify COVID-19 Infection (CATCh COVID-19)","CATCH COVID-19","Not yet recruiting","No Results Available","COVID-19","Diagnostic Test: diagnostic tests for COVID-19 infection","Compare the efficacy of detection of viral infection using serology and viral-RNA detection kits|Define the temporal trend of antibodies in blood","Texas Cardiac Arrhythmia Research Foundation","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","TCAI_CATCH COVID-19","May 2020","May 2021","June 2021","May 1, 2020",,"May 8, 2020",,,"https://ClinicalTrials.gov/show/NCT04372004"
675,"NCT04319315","Social Media Effect on Knowledge Dissemination During COVID-19 Virus Outbreak",,"Recruiting","No Results Available","COVID-19","Other: survey","Number of physicians affected by social media measured by online survey designed to measure the influence of social media on medical practice","Assiut University","All","25 Years to 65 Years   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Other|Time Perspective: Prospective","AssiutU-3-2020","March 11, 2020","April 1, 2020","April 16, 2020","March 24, 2020",,"April 7, 2020","Assiut University Hospitals, Assiut, Egypt",,"https://ClinicalTrials.gov/show/NCT04319315"
676,"NCT04360278","Plasma Collection From Convalescent and/or Immunized Donors for the Treatment of COVID-19",,"Recruiting","No Results Available","COVID-19",,"Collection of convalescent plasma","National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"1500","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","200092|20-CC-0092","April 21, 2020","April 14, 2030","April 14, 2030","April 24, 2020",,"June 11, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04360278"
677,"NCT04384588","COVID19-Convalescent Plasma for Treating Patients With Active Symptomatic COVID 19 Infection (FALP-COVID)","FALP-COVID","Recruiting","No Results Available","COVID-19 Infection|Cancer Patients|General Population","Biological: Convalescent Plasma from COVID-19 donors","in-hospital mortality secondary to COVID-19 among patients treated with convalescent plasma|safety of the use of convalescent plasma drom COVID 19 donors|Mortality at 30 days, 90 days, 6 months and 1 year|in-hospital Mortality COVID-19 related compared with non-treated population according to Chilean official reports|Number of days of hospitalization in high complexity facilities after convalescent plasma use|Number of days of hospitalization in intensive care unit after convalescent plasma use|Number of days of mechanical ventilatory support in patients after convalescent plasma use|Total number of days of mechanical ventilatory support|Total number of hospitalization days in patients treated with convalescent plasma|Number of hospitalization days in patients after treatment with convalescent plasma|Viral load measuring|Immunological response in treated patients (COVID19-Immunoglobulin M and Immunoglobulin G, neutralizing antibodies)|Negativization of COVID 19 load since convalescent plasma use|Negativization of COVID 19 load since hospitalization|Negativization of COVID 19 load since first reported symptoms COVID-19 related|Donor Interferon Gamma profile characterization|Donor Granulocyte Macrophage Colony Stimulating Factor characterization|Donor Tumor Necrosis Factor Alfa characterization|Donor Interleukin -1 beta characterization|Donor Interleukin-2 characterization|Donor Interleukin-4 characterization|Donor Interleukin-6 characterization|Donor Interleukin-8 characterization|Donor Interleukin-10 characterization|Receptor Interferon Gamma profile characterization|Receptor Granulocyte Macrophage Colony Stimulating Factor characterization|receptor Tumor Necrosis Factor Alfa characterization|receptor Interleukin -1 beta characterization|Receptor Interleukin-2 characterization|Receptor Interleukin-4 characterization|Receptor Interleukin-6 characterization|Receptor Interleukin-8 characterization|Receptor Interleukin-10 characterization","Fundacion Arturo Lopez Perez|Confederación de la Producción y del Comercio (CPC)|Bolsa de Santiago","All","15 Years and older   (Child, Adult, Older Adult)","Phase 2|Phase 3","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FALP 001-2020","April 7, 2020","April 6, 2021","April 6, 2021","May 12, 2020",,"May 12, 2020","Fundacion Arturo Lopez Perez, Providencia, Santiago, Chile",,"https://ClinicalTrials.gov/show/NCT04384588"
678,"NCT04363216","Pharmacologic Ascorbic Acid as an Activator of Lymphocyte Signaling for COVID-19 Treatment",,"Not yet recruiting","No Results Available","COVID-19","Drug: Ascorbic Acid","Clinical Improvement|Patient status upgraded to ICU level [Clinical decline]|Oxygen supplementation|Days with fever|Days to discharge|SAEs","Thomas Jefferson University","All","18 Years and older   (Adult, Older Adult)","Phase 2","66","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JT#15681","May 2020","May 2021","May 2021","April 27, 2020",,"May 5, 2020",,,"https://ClinicalTrials.gov/show/NCT04363216"
679,"NCT04373889","COVID-19 Among Healthcare Workers in Belgian Hospitals","COVHECBEHO","Recruiting","No Results Available","SARS-CoV-2|COVID-19",,"Change of prevalence of COVID-19 infection among Belgian active hospital healthcare workers (HCW)|Change of seroprevalence of SARS-CoV-2 among Belgian active hospital HCW|Change in new cases (incidence) of COVID-19 among Belgian hospital HCW|Change in SARS-CoV-2 seroconversion among Belgian hospital HCW|Sensitivity and specificity of serological tests|Sensitivity and specificity of saliva sampling method (sampling with Oracol or equivalent)|Validate the nasal swab against the standard|Potential risk factors for the infection|The proportion of asymptomatic cases among new cases that develop during a period of 5 months|The presence of virus shedding in urine, feces and sperm as well as cellular immune response","Sciensano|Institute of Tropical Medicine Antwerp","All","18 Years and older   (Adult, Older Adult)",,"800","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Sciensano","April 22, 2020","September 27, 2020","September 27, 2020","May 5, 2020",,"May 5, 2020","Sciensano, Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT04373889"
680,"NCT04433026","BNP, Serum Troponin and D-dimer as Risk Factors in Patients With COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Diagnostic Test: N terminal pro B type natriuretic peptide (NTproBNP), D-Dimer, and serum Tropinin - I","Measurement of N-terminal pro-B type natriuretic peptide, troponin-I and D-dimer in COVID-19 patients|Cardiac complications in COVID-19 patients associated with more adverse effects","Assiut University","All","Child, Adult, Older Adult",,"90","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","Cardiac markers in COVID-19","July 1, 2020","July 1, 2021","September 1, 2021","June 16, 2020",,"June 17, 2020",,,"https://ClinicalTrials.gov/show/NCT04433026"
681,"NCT04339426","Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection",,"Recruiting","No Results Available","Covid19","Drug: Atovaquone/Azithromycin","Virology Cure Rate|Incidence of GI adverse events|Cardiac Toxicity","HonorHealth Research Institute","All","18 Years to 95 Years   (Adult, Older Adult)","Phase 2","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HRI-COVID-19-Anti-Malarial-001","April 20, 2020","October 2020","April 2021","April 9, 2020",,"June 9, 2020","HonorHealth, Scottsdale, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT04339426"
682,"NCT04403386","Prospective Natural History Study of Smoking, Immune Cell Profiles, Epigenetics and COVID-19",,"Recruiting","No Results Available","COVID-19",,"Levels of senescent CD16+CD8+ T cells prior to COVID-19 disease and time to COVID-19 disease morbidity (antibody positvity).","National Institute of Environmental Health Sciences (NIEHS)|National Institutes of Health Clinical Center (CC)","All","30 Years to 55 Years   (Adult)",,"200","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","200108|20-E-0108","June 1, 2020","May 31, 2022","May 31, 2022","May 27, 2020",,"June 18, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States|NIEHS Clinical Research Unit (CRU), Research Triangle Park, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04403386"
683,"NCT04375761","COVID-19: Human Epidemiology and Response to SARS-CoV-2","HEROS","Enrolling by invitation","No Results Available","Coronavirus Disease 2019 (COVID-19)|SARS-CoV-2","Procedure: Collection of Biological Samples|Procedure: Symptom and Exposure Surveys","Cumulative Incidence of SARS-CoV-2 RNA Detection in Nasal Samples Among Index Participants and Their Household Contacts Over the Study/Surveillance Period|Percent of Index Participants and Their Household Contacts with Detectable SARS-CoV-2-Specific Antibodies in Serum Over the Study/Surveillance Period|Cumulative Incidence of SARS-CoV-2 Detection in Nasal Samples Among Index Participants with Asthma and Other Atopic Disease Compared to Index Participants without Atopic Disease Over the Study/Surveillance Period|Percent of Index Participants with Asthma and Other Atopic Disease with Detectable SARS-CoV-2-Specific Antibodies in Serum Compared to Index Participants without Atopic Disease Over the Study/Surveillance Period|Changes in the Nasal Transcriptome Associated with Detection of SARS-CoV-2 in Nasal Samples Among Index Participants and Their Household Contacts Over the Study/Surveillance Period|Changes in the Nasal Transcriptome Associated with Detection of SARS-CoV-2 in Nasal Samples Among Index Participants with Asthma and Other Atopic Disease Compared to Index Participants without Atopic Disease Over the Study/Surveillance Period|Symptoms Associated with Detection of SARS-CoV-2 in Nasal Samples Among Index Participants and Their Household Contacts Over the Study/Surveillance Period|Cumulative Incidence of SARS-CoV-2 Detection in Nasal Samples Among Index Participants using Topical Steroids Compared to Index Participants that are Not Using Topical Steroids Over the Study/Surveillance Period|Cumulative Incidence of SARS-CoV-2 Detection in Nasal Samples Among Index Participants Using Topical, Oral, or Inhaled Steroids Compared to Index Participants that are Not Using Topical, Oral, or Inhaled Steroids During the Study/Surveillance Period|Analysis of Factors, Baseline and Prior History, for Possible Association with the Cumulative Incidence of SARS-COV-2 Detection in Nasal Samples: Index Participants and Their Household Contacts Over the Study/Surveillance Period","National Institute of Allergy and Infectious Diseases (NIAID)|Rho, Inc.","All","Child, Adult, Older Adult",,"8000","NIH|Industry","Observational","Observational Model: Family-Based|Time Perspective: Prospective","DAIT-COVID-19-001","May 1, 2020","December 2020","December 2020","May 5, 2020",,"June 25, 2020","Children's Hospital Colorado: Inner City Asthma Consortium (ICAC) Site, Aurora, Colorado, United States|Children's Hospital Colorado: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages (OMEGA) Site, Aurora, Colorado, United States|Children's National Medical Center: Inner City Asthma Consortium (ICAC) Site, Washington, District of Columbia, United States|Ann & Robert H. Lurie Children's Hospital of Chicago: Food Allergy Outcomes Related to White and African American Racial Differences (FORWARD) and Improving Technology-Assisted Recording of Asthma Control in Children (iTRACC) Site, Chicago, Illinois, United States|Massachusetts General Hospital:Childhood Microbiome (CHIME) and Wheezing Index (WIND) Site, Boston, Massachusetts, United States|Boston Children's Hospital: School Inner-City Asthma Study (SICAS-2), Environmental Assessment of Sleep in Youth (EASY), Severe Asthma Research Program (SARP) and Preventing Asthma in High Risk Kids (PARK) Site, Boston, Massachusetts, United States|Boston Medical Center: Inner City Asthma Consortium (ICAC) Site, Boston, Massachusetts, United States|Henry Ford Health System: Childhood Allergy Study (CAS) Site, Detroit, Michigan, United States|Henry Ford Health System: Inner City Asthma Consortium (ICAC) Site, Detroit, Michigan, United States|Henry Ford Health System: Microbes, Asthma, Allergy and Pets (MAAP) and Wayne County Health, Environment, Allergy, and Asthma Longitudinal Study (WHEALS) Site, Detroit, Michigan, United States|St. Louis Children's Hospital: Inner City Asthma Consortium (ICAC) Site, Saint Louis, Missouri, United States|Columbia University Medical Center: Inner City Asthma Consortium (ICAC) Site, New York, New York, United States|Cincinnati Children's Hospital Medical Center: Greater Cincinnati Pediatric Clinic Repository (GCPCR) and Mechanisms of Progression of Atopic Dermatitis to Asthma in Children (MPAACH) Site, Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center: Inner City Asthma Consortium (ICAC) Site, Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages (OMEGA) Site, Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center:Cincinnati Childhood Allergy & Air Pollution Study (CCAAPS) Site, Cincinnati, Ohio, United States|Vanderbilt University Medical Center: Infant Susceptibility to Pulmonary Infections and Asthma Following RSV Exposure Study (INSPIRE) Site, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center: Inner City Asthma Consortium (ICAC) Site, Dallas, Texas, United States|University of Wisconsin Hospital and Clinics: Childhood Origins of Asthma (COAST) Site, Madison, Wisconsin, United States|University of Wisconsin Hospital and Clinics: Wisconsin Infant Study Cohort (WISC) Site, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04375761"
684,"NCT04368156","Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms","SAVIOR","Recruiting","No Results Available","Covid-19","Device: gammaCore® (Vagus nerve stimulation)","Need for mechanical ventilation|Supplemental oxygen requirements|Mortality|Delay onset of ventilation|Cytokine levels","Carlos Tornero|Hospital Clínico Universitario de Valencia","All","18 Years and older   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SAVIOR","April 20, 2020","July 31, 2020","July 31, 2020","April 29, 2020",,"April 29, 2020","Hospital Clínico Universitario de Valencia, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT04368156"
685,"NCT04412772","A RCT - Safety & Efficacy of Tocilizumab - Tx of Severe COVID-19: ARCHITECTS","ARCHITECTS","Recruiting","No Results Available","COVID-19","Drug: Tocilizumab|Drug: Placebo","Clinical status (on a 7-point ordinal scale) at day 28|Clinical improvement|Mechanical Ventilation|Oxygenation","Queen's Medical Centre","All","18 Years to 95 Years   (Adult, Older Adult)","Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RA-2020-019","June 1, 2020","December 31, 2021","December 31, 2021","June 2, 2020",,"June 2, 2020","Queen's Medical Center, Honolulu, Hawaii, United States",,"https://ClinicalTrials.gov/show/NCT04412772"
686,"NCT04334382","Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19","HyAzOUT","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin","Hospitalization within 14 days of enrollment|Duration of COVID-19-attributable symptoms|Hospital-free days at 28 days|Ventilator-free days at 28 days|ICU-free days at 28 days","Intermountain Health Care, Inc.|University of Utah|Utah Department of Health","All","45 Years and older   (Adult, Older Adult)","Phase 3","1550","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1051360","April 2, 2020","December 31, 2020","December 31, 2021","April 6, 2020",,"April 9, 2020","Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04334382"
687,"NCT04424849","Thorax Computed Tomography Severity Score and Outcome in COVID-19 Patients",,"Recruiting","No Results Available","COVID-19","Diagnostic Test: CT-Scan","Invasive respiratory support in patients with COVID-19|Mortality in patients with COVID-19","Tepecik Training and Research Hospital","All","18 Years and older   (Adult, Older Adult)",,"40","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2020/5-4","March 15, 2020","June 15, 2020","July 15, 2020","June 11, 2020",,"June 11, 2020","Tepecik Training and Research Hospital, Izmir, Izmir, Konak, Turkey",,"https://ClinicalTrials.gov/show/NCT04424849"
688,"NCT04345536","Prospective Quality Register of Patients With Confirmed Covid-19 at Oslo University Hospital","CovidRegOUH","Recruiting","No Results Available","COVID-19",,"Mortality|Severe disease","Oslo University Hospital","All","Child, Adult, Older Adult",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CovidRegOUH","March 15, 2020","January 1, 2021","May 1, 2021","April 14, 2020",,"April 14, 2020","Oslo University Hospital, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT04345536"
689,"NCT04438057","Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Biological: CCP","Time to Resolution of Symptoms|SAEs within 24 hours of plasma infusion|Decrease in Inflammatory Markers|Hospitalization within 28 days","Metro Infectious Disease Consultants","All","18 Years and older   (Adult, Older Adult)","Phase 2","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MIDC-CCP","July 6, 2020","July 6, 2021","July 6, 2021","June 18, 2020",,"June 22, 2020","Metro Infectious Disease Consultants, Burr Ridge, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04438057"
690,"NCT04380987","Luxembourg Cohort of Positive Patients for COVID-19: a Stratification Study to Predict Patient Prognosis","Predi-COVID","Recruiting","No Results Available","Covid19","Biological: Biological sampling","Description of clinical manifestations|Clinical aggravation of the infection|Discharge of hospitalization|Death|Description of biological manifestations|Patient-related prognostic factors|Virus-related prognostic factors|Vocal biomarker of Covid-19 related respiratory complications","Luxembourg Institute of Health|Centre Hospitalier du Luxembourg|Hopitaux Robert Schuman (Luxembourg)|Laboratoire National de Santé (Luxembourg)|University of Luxembourg","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Predi-Covid","May 4, 2020","July 31, 2021","December 31, 2021","May 8, 2020",,"May 8, 2020","Luxembourg Institute of Health, Luxembourg, Luxembourg",,"https://ClinicalTrials.gov/show/NCT04380987"
691,"NCT04342182","Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study)","ConCoVid-19","Recruiting","No Results Available","COVID-19","Biological: Convalescent plasma","Overall mortality until discharge from the hospital or a maximum of 60 days after admission whichever comes first|Impact of 300ml convP therapy on hospital days|Impact of 300ml convP on weaning from oxygen therapy|Impact of 300ml convP on overall mortality in patients admitted to the ICU within 24 hours after admission|Difference in the effect of convP on mortality in patients with a duration of symptoms less or more the median duration of symptoms in the study population|Impact of 300ml convP therapy on ICU days in patients admitted to the ICU within 24 hours after admission|Impact of plasma therapy on the decrease in SARS-CoV2 shedding from airways|Impact of CTL and NK cell immunity on the likelihood of being protected from immune serum transfer|Safety of convP therapy|Change of the 8-point WHO COVID19 disease severity scale on day 15|Change of the 8-point WHO COVID19 disease severity scale on day 30|Change of the 8-point WHO COVID19 disease severity scale on day 15 in the subgroup of patients with a baseline neutralizing antibody titer (PRNT50) <80.|Impact of plasma therapy on risk of long-term structural lung damage and lung function","Erasmus Medical Center|Sanquin Plasma Products BV","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","426","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NL73489.078.20","April 8, 2020","July 1, 2020","July 1, 2020","April 10, 2020",,"May 18, 2020","Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands|NoordWest Ziekenhuisgroep, Alkmaar, Netherlands|Onze Lieve Vrouwen Gasthuis, Amsterdam, Netherlands|Rijnstate Ziekenhuis, Arnhem, Netherlands|Reinier de Graaf Gasthuis, Delft, Netherlands|Haaglanden Medisch Centrum, Den Haag, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Medisch Spectrum Twente, Enschede, Netherlands|Groene Hart Ziekenhuis, Gouda, Netherlands|Martini Hospital, Groningen, Netherlands|Spaarna Gasthuis, Haarlem, Netherlands|Alrijne Ziekenhuis, Leiderdorp, Netherlands|Sint Antonius Ziekenhuis, Nieuwegein, Netherlands|Canisius-Wilhelmina Hospital, Nijmegen, Netherlands|Maasstad Ziekenhuis, Rotterdam, Netherlands|ZorgSaam Hospital, Terneuzen, Netherlands|Bernhoven Hospital, Uden, Netherlands|VieCuri, Venlo, Netherlands",,"https://ClinicalTrials.gov/show/NCT04342182"
692,"NCT04343001","Coronavirus Response - Active Support for Hospitalised Covid-19 Patients","CRASH-19","Not yet recruiting","No Results Available","Covid-19","Drug: Aspirin|Drug: Losartan|Drug: Simvastatin","Death|Myocardial infarction|Congestive cardiac failure|Severe cardiac arrythmia|Myocarditis|Respiratory failure including ARDS|Viral pneumonitis|Acute renal failure|Sepsis|Stroke|Gastrointestinal bleeding|Receipt of non invasive or mechanical ventilation|Ability to self care at hospital discharge","London School of Hygiene and Tropical Medicine","All","40 Years and older   (Adult, Older Adult)","Phase 3","10000","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-KEP-420","April 2020","April 2021","August 2021","April 13, 2020",,"April 20, 2020","University College Hospital, Ibadan, Oyo, Nigeria|Shifa Tameer-e-Millat University, Rawalpindi, Pakistan",,"https://ClinicalTrials.gov/show/NCT04343001"
693,"NCT04367662","Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19","COVID'HEMOS","Completed","No Results Available","COVID-19","Procedure: blood sampling","Clinical worsening (yes/no) of the patient during hospitalization|D-DIMERS plasma levels in blood|Fibrin monomers plasma levels in blood|Antithrombin plasma levels in blood|Prothrombin Fragment 1 plasma levels in blood|Prothrombin Fragment 2 plasma levels in blood|Thrombin generation test plasma levels in blood|Microvesicles of platelet plasma levels in blood|Cross-linked platelets plasma levels in blood|Willebrand Factor plasma levels in blood|Factor VIII plasma levels in blood","University Hospital, Rouen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","99","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2020/0104/OB","April 9, 2020","May 14, 2020","May 14, 2020","April 29, 2020",,"June 9, 2020","Rouen University Hospital, Rouen, France",,"https://ClinicalTrials.gov/show/NCT04367662"
694,"NCT04418245","CT Biomarkers Identification by Artificial Intelligence for COVID-19 Prognosis","COVID 19-IA","Active, not recruiting","No Results Available","Covid-19","Diagnostic Test: Imaging by thoracic scanner","Vital status|Patient requiring more than 3 liters of oxygen to maintain a saturation >95% (intensive care unit or resuscitation department)|Percentage of lung affected on CT|Percentage of lung affected by ground glass opacity on scan|Percentage of lung affected by condensation on scan|Length of hospitalization|rehospitalization|Duration of intubation|Software operating time|C-reactive protein levels|lactate dehydrogenase|lymphocytemia|D Dimers level|Time until onset of symptoms|Time between RT-PCR positive results and first scan|Age|BMI> 30|Medical history of cardiovascular disease|Diabetes|Medical history of respiratory disease|Medical history of immunosuppressed condition|Current or previous history of smoking|Calculate a prognostic score from clinical, biological and CT parameters|Calculate a prognostic score from clinical and biological parameters only|Compare receiver operating curves of prognostic scores with and without CT parameters","Centre Hospitalier Universitaire de Nīmes","All","Child, Adult, Older Adult",,"1000","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","NIMAO/2020/COVID 19-IA/JF-01","March 1, 2020","June 2020","July 2020","June 5, 2020",,"June 5, 2020","CHU la Timone, Marseille, France|CHU Montpellier, Montpellier, France|CHU de Nimes, Nîmes, France|CHU Poitiers, Poitiers, France|CHU Strasbourg, Strasbourg, France|CHU Martinique, Fort-de-France, Martinique",,"https://ClinicalTrials.gov/show/NCT04418245"
695,"NCT04410159","Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients","GARGLES","Recruiting","No Results Available","COVID-19","Drug: Povidone-Iodine|Drug: Essential oils|Other: Tap water","Early Viral Clearance|Late viral clearance|Symptoms progression|Disease Progression|Disease Progression 2","Universiti Sains Islam Malaysia|Universiti Kebangsaan Malaysia Medical Centre","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","USIMalaysia","June 22, 2020","July 15, 2020","August 15, 2020","June 1, 2020",,"June 25, 2020","Universiti Kebangsaan Malaysia Medical Centre, Bandar Tun Razak, Wilayah Persekutuan Kuala Lumpur, Malaysia",,"https://ClinicalTrials.gov/show/NCT04410159"
696,"NCT04357990","Kerecis Oral and Nasal Spray for Treating the Symptoms of COVID-19","KONS-COVID-19","Recruiting","No Results Available","COVID-19","Device: Kerecis Oral and Nasal Spray|Other: Placebo","Number of days until complete resolution of symptoms per group|Number of hospital admissions per group|Number of days until a reduction in symptoms per group|Number of adverse events per group","Kerecis Ltd.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","81","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KS-0470","May 1, 2020","July 2020","July 2020","April 22, 2020",,"May 6, 2020","National Hospital of Iceland (Landspítali), Reykjavík, Iceland",,"https://ClinicalTrials.gov/show/NCT04357990"
697,"NCT04368013","Host-pathogen Interactions, Immune Response, and Clinical Prognosis at COVID-19 - the CoVUm Trial","CoVUm","Not yet recruiting","No Results Available","COVID-19","Procedure: Extended sampling and procedures","Mortality","Johan Normark|Umeå University|Västerbotten County Council","All","15 Years to 100 Years   (Child, Adult, Older Adult)","Not Applicable","400","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","CoVUm","April 28, 2020","April 14, 2026","April 14, 2026","April 29, 2020",,"April 29, 2020","Incectious Diseases Clinic, Umeå, Västerbotten, Sweden",,"https://ClinicalTrials.gov/show/NCT04368013"
698,"NCT04368221","Characterization of Fungal Infections in COVID-19 Infected and Mechanically Ventilated Patients in ICU","MY-CO-VID","Not yet recruiting","No Results Available","Covid-19",,"Opportunistic fungal co-infections.|Median time|Time between diagnosis and targeted treatment|Preventive strategies","Rennes University Hospital","All","18 Years and older   (Adult, Older Adult)",,"250","Other","Observational","Observational Model: Cohort|Time Perspective: Other","35RC20_8885_MY_CO_VID","May 2020","May 2021","May 2021","April 29, 2020",,"May 13, 2020","CHU Angers, Angers, France|CHU de Brest, Brest, France|CHU de Dijon, Dijon, France|CHU Grenoble, Grenoble, France|CHU Lille, Lille, France|CHU Lyon, Lyon, France|CHU Marseille, Marseille, France|CHU Nantes, Nantes, France|CHU de Nice, Nice, France|CHU Paris - Avicenne, Paris, France|CHU Paris - Bichat, Paris, France|CHU Paris - HEGP, Paris, France|CHU Paris - Mondor, Paris, France|CHU Paris - Tenon, Paris, France|Hôpital Lariboisière/ St Louis, Paris, France|Hôpital Necker-Enfants Malades, Paris, France|Hôpital Pitié-Salpêtrière, Paris, France|CHU Poitiers, Poitiers, France|CHU Rennes, Rennes, France|CHU Strasbourg, Strasbourg, France|CHU Toulouse, Toulouse, France|CHU Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT04368221"
699,"NCT04393311","Ulinastatin for the Treatment of COVID-19 in Hospitalized Patients",,"Not yet recruiting","No Results Available","COVID-19","Drug: Ulinastatin|Drug: Placebo","Time to recovery|COVID-19 disease severity scale score on Day 8|COVID-19 disease severity scale score on Day 15|COVID-19 disease severity scale score on Day 22|COVID-19 disease severity scale score on Day 29|Incidence of mortality at Day 29|Incidence of in-hospital mortality|Number of days alive and not on mechanical ventilator or ECMO in the 28 days following first dose|Number of patients with resolution of symptoms defined as score of 8 on the 8-point ordinal scale at Day 29|Number of patients alive and free of respiratory failure defined as score of 4, 5, 6, 7, or 8 on the 8-point ordinal scale at Day 29|Duration of mechanical ventilation|Duration of ECMO|Duration of noninvasive ventilation|Duration of ICU stay|Duration of hospital stay|Change in oxygen saturation","Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","56639","July 2020","January 2021","January 2021","May 19, 2020",,"June 26, 2020","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04393311"
700,"NCT04392414","Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease",,"Recruiting","No Results Available","COVID-19","Biological: COVID-19 convalescent hyperimmune plasma|Biological: Non-convalescent fresh frozen plasma (Standard plasma)","The number and proportion of patients with the normal body temperature (≤37.2 C) at the day 1, 2, 3, 4, 5, 6, 7 after the start of therapy|Days before mechanical ventilation|Days of need for oxygen therapy|Days of stay in the ICU|Days of hospitalization|Changes of the titer of the SARS-CoV-2 antibodies in the blood plasma of patients|Dynamics of the cytokine profile|Incidence of the cytokine storm development and the need of administering cytokine storm inhibitors|Dynamics of the level of C-reactive protein|30-day mortality rate","Federal Research Clinical Center of Federal Medical & Biological Agency, Russia","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CovPlas-Covid19","May 1, 2020","August 1, 2020","September 15, 2020","May 18, 2020",,"June 4, 2020","Federal Research Clinical Center of Federal Medical & Biological Agency, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04392414"
701,"NCT04442191","Convalescent Plasma as a Possible Treatment for COVID-19",,"Recruiting","No Results Available","COVID-19","Biological: Convalescent plasma|Biological: Placebo","Oxygen supplementation|28-day and in-hospital mortality rate|Number of participants transferred to the Intensive Care Unit (ICU)|Number of participants intubated|Length of hospital stay in days|Type of respiratory support|C-reactive Protein (CRP)|Lymphocyte count|Length or respiratory support required, in days|Lactate dehydrogenase (LDH)|Ferritin|D-Dimer|White Blood Cell (WBC) Count","University of Illinois at Chicago","All","40 Years and older   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020-0441","May 5, 2020","May 5, 2021","May 5, 2021","June 22, 2020",,"June 22, 2020","University of Illinois at Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04442191"
702,"NCT04358211","Expanded Access to Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19",,"Available","No Results Available","COVID-19","Biological: Biological: COVID-19 convalescent plasma",,"Nakhle Saba, MD|Tulane University","All","18 Years and older   (Adult, Older Adult)",,,"Other","Expanded Access:Intermediate-size Population|Treatment IND/Protocol",,"2020-595",,,,"April 24, 2020",,"April 24, 2020","Tulane Medical Center, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT04358211"
703,"NCT04373096","Enhanced Hood PPE to Minimize COVID-19 Transmission to Front-line Health Care Workers",,"Not yet recruiting","No Results Available","Covid19","Device: current IPAC-UHN PPE|Device: modified IPAC-UHN PPE","Incidence of contamination of any part of the base clothing or exposed skin of the upper body|1) Number of body areas contaminated|2) Number of discrete areas of contamination of <1 cm2 and >1 cm2|3) Visibility during the simulated procedure|4) Ease of intubation procedures when wearing PPE|5) Ease of breathing while wearing PPE|6) Thermal comfort while wearing the PPE|7) Incidence of breaching of doffing procedures","University Health Network, Toronto","All","20 Years to 75 Years   (Adult, Older Adult)","Not Applicable","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","20-5448","June 1, 2020","August 31, 2020","August 31, 2020","May 4, 2020",,"May 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04373096"
704,"NCT04360980","The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection",,"Recruiting","No Results Available","COVID-19","Drug: Colchicine Tablets","CRPxN/R ratio change|Clinical deterioration by the WHO definition|PCR Viral Load|CT severity involvement index|LDH change","Shahid Beheshti University of Medical Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SBMU.IR.REC.165423","March 20, 2020","May 20, 2020","May 30, 2020","April 24, 2020",,"April 27, 2020","SBMU, Tehran, Iran, Islamic Republic of|Nooshin Dalili, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04360980"
705,"NCT04378920","A Study of Trans Crocetin in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 Disease (LEAF-4L7520/4L6715)","LEAF-4L6715","Recruiting","No Results Available","COVID19|Acute Respiratory Distress Syndrome","Drug: LEAF-4L6715|Drug: LEAF-4L7520","proportion of patients showing an increase of at least 25% of PaO2/FiO2 ratio|proportion of patients with a PaO2/FiO2 ratio above 200 mm Hg|all cause mortality","Institut de Cancerologie Strasbourg Europe|LEAF4Life LLC","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","180","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-003|2020-001393-30|2020-A00900-39","April 14, 2020","July 31, 2020","October 31, 2020","May 7, 2020",,"May 14, 2020","Hôpitaux Universitaires de Strasbourg, Strasbourg, France|Institut de Cancerologie Strasbourg Europe, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT04378920"
706,"NCT04335136","Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19","APN01-COVID-19","Recruiting","No Results Available","COVID-19","Drug: RhACE2 APN01|Drug: Physiological saline solution","Cause of death or invasive mechanical ventilation|LDH level|Mortality|VFD|Time to death","Apeiron Biologics","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","APN01-01-COVID19","April 30, 2020","September 2020","November 2020","April 6, 2020",,"June 16, 2020","Medizinische Universität Innsbruck, Innsbruck, Austria|Kaiser Franz Josef Spital, 4. Medizinische Abteilung mit Infektions- und Tropenmedizin, Wien, Austria|Medizinische Universität Wien, Wien, Austria|The National University Hospital, Rigshospitalet, Copenhagen, Denmark|Herlev Gentofte Hospital, Herlev, Denmark|Nordsjællands Hospital, Hillerød, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Klinikum rechts der Isar, Technische Universität München, München, Germany",,"https://ClinicalTrials.gov/show/NCT04335136"
707,"NCT04331366","Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19","GO2 PEEP","Recruiting","No Results Available","COVID-19","Device: GO2 PEEP MOUTHPIECE","Change in Oxygen Saturation by Pulse Oximetry|Change in Respiratory Rate|Change in Heart Rate|Change in Blood Pressure|Change in Subjective Work of Breathing|Change in Partial Pressure of Oxygen (PaO2)|Change in Partial Pressure of Carbon Dioxide (PaCO2)|Change in pH|Change in Bicarbonate (HCO3)|Change in Oxygen Saturation (O2Sat) by Arterial Blood Gas Test","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","STUDY00000381","April 8, 2020","August 2020","August 2020","April 2, 2020",,"June 19, 2020","Emory University Hospital, Atlanta, Georgia, United States|Emory St. Joseph's Hospital, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04331366"
708,"NCT04391127","Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection",,"Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Ivermectin|Drug: Placebo","Mean days of hospital stay|Rate of Respiratory deterioration, requirement of invasive mechanical ventilation or dead|Mean of oxygenation index delta|Mean time to viral PCR negativization","Centenario Hospital Miguel Hidalgo","All","16 Years to 90 Years   (Child, Adult, Older Adult)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","2020-A-09","May 4, 2020","August 30, 2020","September 30, 2020","May 18, 2020",,"June 12, 2020","Jose Manuel Arreola Guerra, Aguascalientes, Mexico",,"https://ClinicalTrials.gov/show/NCT04391127"
709,"NCT04389645","Interferon Gamma Induced Protein 10 (IP-10) in a Clinical Decision Support Protocol in COVID-19 Patients",,"Completed","No Results Available","COVID-19","Diagnostic Test: IP-10 in CDS protocol","IP-10 levels","MeMed Diagnostics Ltd.","All","18 Years and older   (Adult, Older Adult)",,"52","Industry","Observational",,"MM-5000-BV","April 7, 2020","May 12, 2020","May 12, 2020","May 15, 2020",,"May 15, 2020","Rabin Medical Center, Petach Tikva, Israel",,"https://ClinicalTrials.gov/show/NCT04389645"
710,"NCT04371679","Changes in Cardiac and Pulmonary Hemodynamics as Predictor of Outcome in Hospitalized COVID-19 Patients","COVID-HO","Recruiting","No Results Available","Covid-19","Other: No interventions planned","Death (all-cause mortality) or discharge from ICU (limit of 4 months)","Hasselt University","All","Child, Adult, Older Adult",,"40","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","Covid-HO","April 1, 2020","October 1, 2020","December 1, 2020","May 1, 2020",,"May 1, 2020","Jessa Hospital, Hasselt, Belgium",,"https://ClinicalTrials.gov/show/NCT04371679"
711,"NCT04362189","Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: HB-adMSC|Drug: Placebo","D-dimer|Interleukin-6|C Reactive protein|Oxygenation|PCR test SARS-CoV-2|EKG qt interval|Leukocyte differential|TNF alpha|Glucose|Calcium|Albumin|Total protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Total bilirubin|White blood cells|Red blood cells|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean corpuscular hemoglobin|Mean corpuscular hemoglobin concentration|Red cell distribution width|Neutrophils|Lymphs|Monocytes|Eosinophils|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute eosinophils|Absolute basophils|Immature granulocytes|Platelets|Prothrombin time|INR|NK cell surface antigen (CD3-CD54+)|CD4+/CD8+ ratio|IL-10|VEGF|Myoglobin|Troponin|Creatinine kinase|Serum ferritin|Adverse events|7-point ordinal scale","Hope Biosciences|Advanced Diagnostics Healthcare|Hope Biosciences Stem Cell Research Foundation","All","Child, Adult, Older Adult","Phase 2","100","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allogeneic Treatment COVID-19","May 15, 2020","October 31, 2020","October 31, 2020","April 24, 2020",,"May 22, 2020","River Oaks Hospital and Clinics, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04362189"
712,"NCT04330690","Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial","CATCO","Recruiting","No Results Available","COVID-19","Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: remdesivir","Efficacy of Interventions as assessed by all-cause mortality|Time to improvement of one category from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs)","Sunnybrook Health Sciences Centre|AbbVie|Apotex Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","2900","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2114","March 18, 2020","March 18, 2022","May 18, 2022","April 1, 2020",,"June 24, 2020","Peter Lougheed Centre, Calgary, Alberta, Canada|Foothills Medical Centre, Calgary, Alberta, Canada|Rockyview General Hospital, Calgary, Alberta, Canada|South Health Campus, Calgary, Alberta, Canada|Royal Alexandra Hospital, Edmonton, Alberta, Canada|University of Alberta Hopsital, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver Coastal Health, Univeristy of British Columbia, Vancouver, British Columbia, Canada|St Paul's Hospital, Vancouver, British Columbia, Canada|Island Health - Royal Jubilee Hospital, Victoria, British Columbia, Canada|Island Health - Victoria General Hospital, Victoria, British Columbia, Canada|William Osler Health System - Brampton Civic Hospital, Brampton, Ontario, Canada|William Osler Health System - Etobicoke General Hospital, Etobicoke, Ontario, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|Grand River Hospital, Kitchener, Ontario, Canada|St.Joseph's Health Care, London, Ontario, Canada|University Hospital, London, Ontario, Canada|Victoria Hospital, London, Ontario, Canada|Trillium Health Partners -Mississauga Site, Mississauga, Ontario, Canada|Trillium Health Partners-Credit Valley Hospital, Mississauga, Ontario, Canada|The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada|Hôpital Montfort, Ottawa, Ontario, Canada|The Ottawa Hospital - Civic Campus, Ottawa, Ontario, Canada|Queensway Carleton Hospital, Ottawa, Ontario, Canada|Thunder Bay Regional Health Sciences Centre, Thunder Bay, Ontario, Canada|North York General Hospital, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Quebec, Canada|McGill University Health Centre-Glen Site Royal Victoria Hospital, Montréal, Quebec, Canada|CHU de Québec - Université Laval, Québec, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Québec- Université Laval, Québec, Quebec, Canada|Centre Intégré Universitaire de Santé et de Services Sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04330690"
713,"NCT04370236","XPro1595 for the Treatment of Pulmonary Complications From COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: XPro1595|Drug: Placebo","Proportion of participants with disease progression from randomization to 28 days post-randomization|Proportion of participants with all-cause mortality|Proportion of participants who transfer to ICU level care by Day 28 (ICU level care is defined as a hospital setting where patient to nurse ratio is < 4);|Proportion of participants with a new onset of neurologic disease (requiring medical intervention), including stroke by Day 28;|Proportion of participants with evidence of new CHF or new MI requiring medical intervention by Day 28;|Proportion of participants with a new onset embolus or thrombus by Day 28;|Proportion of participants who develop a need for renal replacement therapy (defined as need for any type of dialysis including intermittent or continuous peritoneal or hemodialysis) by Day 28;|Proportion of participants with an increase in the WHO Ordinal Scale of Clinical Improvement score at any time during the study;|Length of hospital stay defined as the number of days in hospital from time of randomization to time of discharge or death, whichever occurs first;|Change from baseline in inflammation markers over time.","Inmune Bio, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","366","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","XPro1595-COVID-19","July 2020","February 2021","February 2021","April 30, 2020",,"June 2, 2020",,,"https://ClinicalTrials.gov/show/NCT04370236"
714,"NCT04359511","Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia","CORTICOVIDHUGO","Not yet recruiting","No Results Available","COVID-19","Drug: Prednisone|Drug: Hydrocortisone","Clinical improvement defined by the improvement of 2 points on a 7-category ordinal scale, at 14 days.|Proportion of patients free of oxygen at day 14 and 28|Proportion of patients discharged alive from hospital at day 14 and 28|Time to discharge for patients alive|Proportion of patients that were hospitalized to ICU or who died at day 14 and 28|14 and 28 day mortality rate|The time until weaning from oxygen therapy|The proportion of patients with clinical degradation of at least 1 point on the ordinal scale to 7 categories on D14 and D28","University Hospital, Tours","All","18 Years and older   (Adult, Older Adult)","Phase 3","210","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CORTI-COVID-19-HUGO|DR200136","June 2020","December 2020","December 2020","April 24, 2020",,"June 4, 2020",,,"https://ClinicalTrials.gov/show/NCT04359511"
715,"NCT04331795","Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis","COVIDOSE","Completed","No Results Available","COVID-19","Drug: Tocilizumab","Clinical response|Biochemical response|Overall survival|Survival to hospital discharge|Progression of COVID-19 pneumonitis|Rate of non-elective mechanical ventilation|Duration of mechanical ventilation|Time to mechanical ventilation|Rate of vasopressor/inotrope utilization|Duration of vasopressor/inotrope utilization|Time to vasopressor or inotropic utilization|Number of ICU days|Duration of Increased Supplemental Oxygen Requirement from Baseline","University of Chicago","All","18 Years and older   (Adult, Older Adult)","Phase 2","32","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB20-0515","April 4, 2020","June 5, 2020","June 5, 2020","April 2, 2020",,"June 9, 2020","University of Chicago Medicine, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04331795"
716,"NCT04435717","Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19 (COVITOZ-01)","COVITOZ-01","Recruiting","No Results Available","Covid19","Drug: Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1|Drug: Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 (2 doses)","Change in IL-12 values in the 3 study groups from the start of treatment (D0) and on days D + 1 and D + 3.|Progression of pneumonia|PaO2/FiO2|cause mortality to 28 days after started treatment|Length of hospital stay|patients requiring Intensive Care Unit admission|evolution of inflammatory parameters IL12|evolution of inflammatory parameters IL-10, IL-1, IL-6, IL-17 and IFN-gamma|evolution of inflammatory parameters Procalcitonin (PCT),|evolution of inflammatory parameters C-reactive protein (PCR),|evolution of inflammatory parameters D-dimer|evolution of inflammatory parameters and ferritin|pharmacokinetics of tocilizumab Cmin|pharmacokinetics of tocilizumab Cmax|pharmacokinetics of tocilizumab Cmedia|pharmacokinetics of tocilizumab Tmax|pharmacokinetics of tocilizumab AUC|Adverse event|Adverse event to cause the treatment interruption.|Adverse event Abnormalities in laboratory","Hospital Universitario Ramon y Cajal","All","18 Years and older   (Adult, Older Adult)","Phase 2","78","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVITOZ-01","May 4, 2020","August 4, 2020","August 4, 2020","June 17, 2020",,"June 17, 2020","Hospital Universitario Ramón y Cajal, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04435717"
717,"NCT04396106","Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19)",,"Not yet recruiting","No Results Available","COVID-19","Drug: AT-527|Other: Placebo","Proportions (active vs. placebo) of subjects who progress to respiratory failure|Proportions (active vs. placebo) of subjects experiencing treatment-emergent adverse events|Time to clinical recovery","Atea Pharmaceuticals, Inc.","All","45 Years to 80 Years   (Adult, Older Adult)","Phase 2","180","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","AT-03A-001","May 2020","July 2020","August 2020","May 20, 2020",,"May 20, 2020","Atea Study Site, Sacramento, California, United States|Atea Study Site, San Diego, California, United States|Atea Study Site, Chicago, Illinois, United States|Atea Study Site, Baltimore, Maryland, United States|Atea Study Site, Boston, Massachusetts, United States|Atea Study Site, Saint Louis, Missouri, United States|Atea Study Site, Cincinnati, Ohio, United States|Atea Study Site, Cleveland, Ohio, United States|Atea Study Site, Columbus, Ohio, United States|Atea Study Site, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04396106"
718,"NCT04333225","Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers",,"Active, not recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine","Rate of COVID-19 positive conversion|Time-to-first clinical event","Baylor Research Institute","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","228","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","020-132","April 3, 2020","July 30, 2020","July 30, 2020","April 3, 2020",,"May 5, 2020","Baylor University Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04333225"
719,"NCT04405843","Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Ivermectin Oral Product|Drug: Placebo","Time to event|Clinical condition on day 2|Clinical condition on day 5|Clinical condition on day 8|Clinical condition on day 11|Clinical condition on day 15|Clinical condition on day 21|Proportion of subjects with additional care|Proportion of subjects who die|Duration of additional care|Adverse events|Proportion of subjects who discontinue intervention","Centro de Estudios en Infectogía Pediatrica","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ScDi823","June 2020","October 2020","November 1, 2020","May 28, 2020",,"May 28, 2020",,,"https://ClinicalTrials.gov/show/NCT04405843"
720,"NCT04351724","Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)","ACOVACT","Recruiting","No Results Available","COVID-19","Drug: Chloroquine or Hydroxychloroquine|Drug: Lopinavir/Ritonavir|Other: Best standard of care|Drug: Rivaroxaban|Drug: Thromboprophylaxis|Drug: Candesartan|Drug: non-RAS blocking antihypertensives|Drug: Clazakizumab|Drug: placebo for clazakizumab","sustained improvement (>48h) of one point on the WHO Scale|Time to improvement on WHO Scale|Mean change in the ranking on an ordinal scale from baseline|time to discharge or a National Early Warning Score (NEWS) ≤2 (maintained for 24h), whichever occurs first|change from baseline in National Early Warning Score (NEWS)|Oxygenation free days|Incidence of new oxygen use during the trial|duration of oxygen use during the trial|Ventilator free days until day 29|Incidence of new mechanical ventilation use during the trial|duration of mechanical ventilation use during the trial|Viral load/viral clearance|Duration of Hospitalization|Mortality|Obesity - mortality|Obesity - duration of hospitalization|Obesity - ICU admission|Obesity - new oxygen use|Drug-drug interactions with lopinavir/ritonavir|Renin Angiotensin System (RAS) fingerprint","Medical University of Vienna|Kaiser Franz Josef Hospital|SMZ-Ost Donauspital|Otto Wagner Hospital|Hospital Hietzing|Wilhelminenspital Vienna|Medical University Innsbruck","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2|Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACOVACT","April 16, 2020","December 1, 2020","December 31, 2020","April 17, 2020",,"April 24, 2020","Medical University of Innsbruck, Innsbruck, Tirol, Austria|Medical University of Vienna, Vienna, Austria|Wilhelminenspital, Vienna, Austria|SMZ Süd Kaiser Franz Josef Spital, Vienna, Austria|KH Hietzing, Vienna, Austria|SMZ Baumgartner Höhe Otto Wagner Spital, Vienna, Austria|SMZ Ost Donauspital, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT04351724"
721,"NCT04393246","mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms",,"Not yet recruiting","No Results Available","COVID-19","Drug: EDP1815|Drug: Dapagliflozin|Drug: Ambrisentan|Other: Standard of care","Time to incidence of the composite endpoint of: Death, Mechanical ventilation, ECMO, Cardiovascular organ support, or Renal failure|Change in biomarkers thought to be associated with progression of COVID-19 compared to baseline: IL-6|Change in biomarkers thought to be associated with progression of COVID-19 compared to baseline: ferritin|Change in biomarkers thought to be associated with progression of COVID-19 compared to baseline: c-reactive protein (CRP)|Change in biomarkers thought to be associated with progression of COVID-19 compared to baseline: D-dimer|Change in biomarkers thought to be associated with progression of COVID-19 compared to baseline: neutrophil/lymphocyte ratio|Change in biomarkers thought to be associated with progression of COVID-19 compared to baseline: lactate dehydrogenase (LDH)|Change in clinical status as assessed on 7-point ordinal scale compared to baseline|Time to each of the individual endpoints of the composite primary outcome measure|Proportion of patients with adverse events of special interest in each treatment arm|Time to Sp02 >94% on room air|Time to first negative SARS-CoV2 PCR|Duration of oxygen therapy|Duration of hospitalisation|All-cause mortality at day 28|Time to clinical improvement","Cambridge University Hospitals NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","1407","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TACTIC-E","June 15, 2020","February 15, 2021","June 15, 2021","May 19, 2020",,"June 4, 2020","Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04393246"
722,"NCT04344444","Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease","RCT","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin","Most severe outcome","LCMC Health","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 3","600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID 2020-001","April 10, 2020","April 10, 2021","December 10, 2021","April 14, 2020",,"April 14, 2020","University Medical Center New Orleans, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT04344444"
723,"NCT04429867","Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease",,"Active, not recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Placebo","Impact of hydroxychloroquine in hospitalized patients with COVID-19 and risk factors for severe/critical disease.|Hospital length of stay|30-Day Mortality|Resolution of Symptoms|Incidence of QTc >500ms after initiation of therapy|Incidence of discontinuation of therapy","WellStar Health System","All","18 Years and older   (Adult, Older Adult)","Phase 4","700","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1604885","May 7, 2020","December 7, 2020","December 7, 2020","June 12, 2020",,"June 16, 2020","Wellstar Kennestone Hospital, Marietta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04429867"
724,"NCT04359264","Direct Income SupporT and Advice Negating Spread of Epidemic COVID-19: a Randomized Controlled Trial","DISTANSE COVID","Active, not recruiting","No Results Available","COVID-19","Other: Cash transfer","Symptoms consisent with COVID-19|Number of close contacts|Number of participants with positive test for COVID-19|Self-reported health based on the single question: ""In general, would you say your health is..""|Ability to make ends meet based on the single question: ""At the end of the month, are you able to make ends meet?""","St. Michael's Hospital, Toronto","All","18 Years and older   (Adult, Older Adult)","Not Applicable","392","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","20-081","April 20, 2020","May 29, 2020","June 30, 2020","April 24, 2020",,"May 27, 2020","Municipality of Assiginack Family Health Team, Assiginack, Ontario, Canada|St Michael's Hospital Academic Family Health Team, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04359264"
725,"NCT04344080","Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19","CYTOCOV-19","Recruiting","No Results Available","COVID-19","Device: CytoSorb-Therapy","Percentage of patients with a significant stabilization of hemodynamics for at least 24 hours|Change in organ dysfunction|Lactate clearance|Renal replacement therapy|Extracorporeal Membrane Oxygenation|ICU length of stay|Time on mechanical ventilation|Cumulative catecholamine dose|Overall and ICU mortality|Change of plasma Interleukin-6 (IL6) level|Change of plasma Interleukin-10 (IL10) level|Change of plasma Procalcitonin (PCT) level|Change of HLA-DR level|Change of TNF alpha level after ex-vivo stimulation","Universitätsklinikum Hamburg-Eppendorf","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CYTOCOV-19|U1111-1250-2078|DRKS00021199","April 1, 2020","December 2020","February 2021","April 14, 2020",,"April 14, 2020","University Medical Center Hamburg-Eppendorf, Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT04344080"
726,"NCT04377659","Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection",,"Recruiting","No Results Available","COVID-19","Drug: Tocilizumab","Progression of respiratory failure or death","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-185","May 1, 2020","May 1, 2021","May 1, 2021","May 6, 2020",,"May 29, 2020","Memorial Sloan Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04377659"
727,"NCT04425772","A Clinical Trial for Azvudine in the Treatment of Novel Coronavirus Pneumonia (COVID-19）",,"Not yet recruiting","No Results Available","COVID-19","Drug: FNC+Standard of Care|Drug: FNC dummy tablet+Standard of Care","Change (reduction) in viral load from baseline|proportion of subjects change from mild or moderate type to severe type|proportion of subjects change from severe type to critical type|novel coronavirus nucleic acid conversion rate|Novel coronavirus nucleic acid negative conversion time|The time and proportion of improvement in pulmonary imaging|Time and proportion of temperature return to normal|time and rate of improvement of respiratory symptoms and signs (lung rhones, cough, sputum, sore throat, etc.)|time and rate of improvement of diarrhea, myalgia, fatigue and other symptoms|Changes of blood oxygen detection index|Frequency of requirement for supplemental oxygen or non-invasive ventilation|Frequency of adverse events","HeNan Sincere Biotech Co., Ltd","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","342","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FNC-Hope4","June 12, 2020","August 12, 2020","August 12, 2020","June 11, 2020",,"June 11, 2020",,,"https://ClinicalTrials.gov/show/NCT04425772"
728,"NCT04352465","Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 Patients",,"Not yet recruiting","No Results Available","COVID-19","Drug: Methotrexate","Change in clinical conditions|Change of Clinical symptoms - respiratory rate|Hypoxia|Changes of blood oxygen|Inflammatory parameters|Evolution of Acute Respiratory Syndrome|Hospital discharge|ICU discharge|Rate of mortality","Azidus Brasil|InCor Heart Institute|Hospital Santa Marcelina|PREVENT SENIOR PRIVATE OPERADORA DE SAÚDE LTDA","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","42","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LDE-MTX_COVID19","May 1, 2020","June 30, 2020","November 30, 2020","April 20, 2020",,"April 29, 2020","Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04352465"
729,"NCT04380779","Prevalence of Severe Bleeding in COVID-19 Patients Treated With Higher Than Recommended Thromboprophylaxis Doses","BLEEDING","Recruiting","No Results Available","COVID-19",,"Bleeding events and complications","Manuel Monreal|Foundation for the study of VTE diseases. (FUENTE)","All","Child, Adult, Older Adult",,"5000","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","BLEEDING042020","April 13, 2020","April 13, 2025","June 13, 2025","May 8, 2020",,"May 8, 2020","Manuel Monreal, Badalona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04380779"
730,"NCT04352751","Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020",,"Recruiting","No Results Available","Covid-19","Other: convalescent plasma","Change in COVID-19 severity status","Hilton Pharma","All","18 Years to 55 Years   (Adult)","Not Applicable","2000","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","PIPK- 0000 /NIBD-0000/2020","May 1, 2020","April 2021","April 2021","April 20, 2020",,"May 15, 2020","National Institute of Blood Diseases and Bone Marrow Transplantation (NIBD), Karachi, Sindh, Pakistan",,"https://ClinicalTrials.gov/show/NCT04352751"
731,"NCT04435314","Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19",,"Not yet recruiting","No Results Available","covid19","Drug: Nitazoxanide|Drug: Placebo","The proportion of subjects with laboratory-confirmed COVID-19 identified after start of treatment and before the end of the study|Incidence of Treatment-Emergent Adverse Events|The proportion of subjects with symptomatic laboratory-confirmed COVID-19 identified after start of treatment and before the end of the study|The proportion of subjects with asymptomatic laboratory-confirmed COVID identified after the start of treatment and before the end of the study|Treatment adherence|Disease complication|Incidence of subjects that underwent unscheduled visit","Azidus Brasil|Farmoquimica S.A.","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","NITFQM0620OR","June 2020","August 2020","August 2020","June 17, 2020",,"June 17, 2020",,,"https://ClinicalTrials.gov/show/NCT04435314"
732,"NCT04348448","Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia",,"Not yet recruiting","No Results Available","COVID-19","Drug: Canakinumab 150 MG/ML [Ilaris]","intensive care treatment|ICU stay times|% died after 1 month after treatment|hospitalization|adverse event","AUSL Romagna Rimini","All","18 Years to 100 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CANASCOV","April 2020","July 2020","September 2020","April 16, 2020",,"April 16, 2020",,,"https://ClinicalTrials.gov/show/NCT04348448"
733,"NCT04365816","NutriCovid30 : Nutritional Evaluation for Covid-19 Infection at D30",,"Not yet recruiting","No Results Available","COVID-19","Other: Interview","Evaluation of food intake at 1 month after discharge from hospital for COVID|Weight variation during the infection|Clinical signs limiting food intake|Factors limiting food intake|Implemented nutritional strategy|Pre-existing chronic disorders|Covid-19 repercussions","University Hospital, Grenoble|University Grenoble Alps","All","18 Years and older   (Adult, Older Adult)",,"600","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-A01120-39","May 2020","July 2020","November 2020","April 28, 2020",,"May 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04365816"
734,"NCT04389801","Use of Desferal for Prevention of ARDS in Hospitalised Cases Documented With Covid 19 Infection",,"Not yet recruiting","No Results Available","Covid 19","Drug: Desferal 500 MG Injection","Mortality rate|Duration of severe symptoms","Hesham Al-Inany|Cairo University","All","Child, Adult, Older Adult","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","0012","June 1, 2020","September 30, 2020","December 31, 2020","May 15, 2020",,"May 15, 2020",,,"https://ClinicalTrials.gov/show/NCT04389801"
735,"NCT04397718","Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization","HITCH","Not yet recruiting","No Results Available","CoVID19","Drug: Degarelix|Other: Saline","A composite endpoint of mortality, ongoing need for hospitalization, or requirement for mechanical ventilation/extracorporeal membrane oxygenation (ECMO) at Day 15 after randomization.|Time to clinical improvement|Inpatient mortality|Duration of hospitalization|Duration of intubation for mechanical ventilation.|Time to normalization of temperature.|Maximum severity of COVID19 illness.","VA Office of Research and Development","Male","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","198","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","COVID19-8900-15","July 1, 2020","November 1, 2020","November 1, 2020","May 21, 2020",,"June 17, 2020","VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States|Brooklyn Campus of the VA NY Harbor Healthcare System, Brooklyn, NY, Brooklyn, New York, United States|Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY, New York, New York, United States|VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04397718"
736,"NCT04427501","A Study of LY3819253 (LY-CoV555) in Participants With Early Mild to Moderate COVID-19 Illness","BLAZE-1","Recruiting","No Results Available","COVID-19","Drug: LY3819253|Drug: Placebo","Change from Baseline to Day 11 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) Viral Load|Change from Baseline to Day 11 in SARS-CoV-2 Viral Load Among Participants Enrolled with Recent Symptoms Prior to Randomization|Pharmacokinetics (PK): Mean Concentration of LY3819253|Percentage of Participants Who Experience COVID-Related Hospitalization, COVID-Related Emergency Room (ER) Visit, or Death","Eli Lilly and Company|AbCellera Biologics Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","400","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","17947|J2W-MC-PYAB","June 13, 2020","September 15, 2020","September 15, 2020","June 11, 2020",,"June 26, 2020","Long Beach Clinical Trials LLC, Long Beach, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|Zion Medical Center, San Diego, California, United States|Kaiser Permanente - San Diego Medical Center, San Diego, California, United States|Georgetown University School of Medicine, Washington, District of Columbia, United States|Northwestern University, Chicago, Illinois, United States|John H. Stroger Hospital of Cook County, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Franciscan Health Hammond, Hammond, Indiana, United States|Community Hospital South, Indianapolis, Indiana, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital, Chelsea, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Mount Sinai Morningside, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State Univ College Of Medicine, Columbus, Ohio, United States|Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, United States|Temple University School of Medicine, Philadelphia, Pennsylvania, United States|Baylor Scott & White Cancer Center, Dallas, Texas, United States|CARE ID, Annandale, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04427501"
737,"NCT04367402","COST (COvid STudio) ACTION: Study for the Evaluation of Specific Antibodies Anti Covid-19 Linked to Covid-19 Infection, Symptoms and Genetic Expression of ACE2 Polymorphisms in Patients (COST ACTION)","COST ACTION","Recruiting","No Results Available","COVID-19","Other: BioMedomics COVID-19 IgM-IgG Rapid Test","Retrospective study on individuals with or without symptoms to verify the reliability of a prognostic/diagnostic test based on IgM/IgG analysis.|ACE2 expression in patients with COVID-19 infection","Azienda Ospedaliera San Paolo","All","18 Years and older   (Adult, Older Adult)",,"600","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","2020/ST/057","March 30, 2020","April 24, 2020","September 2020","April 29, 2020",,"April 30, 2020","AO San Paolo, Milan, IT, Italy",,"https://ClinicalTrials.gov/show/NCT04367402"
738,"NCT04328441","Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine","BCG-CORONA","Recruiting","No Results Available","COVID-19","Drug: BCG Vaccine|Drug: Placebo","Health Care Workers absenteeism|the cumulative incidence of documented COVID-19|the cumulative incidence of Hospital Admission due to documented COVID-19|the number of days of unplanned absenteeism, because of documented COVID-19|the cumulative incidence of self-reported acute respiratory symptoms or fever|the cumulative incidence of death due to documented COVID-19|the cumulative incidence of Intensive Care Admission due to documented COVID-19|the number of days of absenteeism, because of imposed quarantine as a result of exposure to COVID-19|the number of days of absenteeism, because of imposed quarantine as a result of having acute respiratory symptoms, fever or documented COVID-19|the number of days of unplanned absenteeism because of self-reported acute respiratory symptoms|the number of days of self-reported fever (≥38 gr C)|the cumulative incidence of self-reported fever (≥38 gr C)|the number of days of self-reported acute respiratory symptoms|the cumulative incidence of self-reported acute respiratory symptoms|the cumulative incidence of death for any reason|the cumulative incidence of Intensive Care Admission for any reason|the cumulative incidence of Hospital Admission for any reason|• the cumulative incidence and magnitude of plasma/serum antibodies (IgA,M,G) and SARS-CoV-2-specific antibodies at 12 weeks after vaccination and at the end of the study period","UMC Utrecht|Radboud University","All","18 Years and older   (Adult, Older Adult)","Phase 3","1500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","NL73249.041.20","March 25, 2020","October 25, 2020","December 25, 2020","March 31, 2020",,"April 29, 2020","Jeroen Bosch ziekenhuis, Den Bosch, Brabant, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Gelderland, Netherlands|Radboud UMC, Nijmegen, Gelderland, Netherlands|Sint Maartenskliniek, Nijmegen, Gelderland, Netherlands|Noordwest Ziekenhuisgroep locatie Alkmaar, Alkmaar, Noord Holland, Netherlands|Hagaziekenhuis, Den Haag, Zuid-Holland, Netherlands|Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands|Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT04328441"
739,"NCT04432961","Natural Language Processing (NLP) Analysis of Free Text Notes to Investigate Coronavirus (COVID-19)",,"Not yet recruiting","No Results Available","COVID-19",,"research database of EHR records from COVID-19 patients processed using NLP tools for named entity recognition and linking adapted to CUH EMR data to identify variables of interest|A set of annotation guidelines to produce human-expert (gold) labelled data for a subset of the EHR|A comparison of the NLP output to terms in the structured problem list to identify missing terms in the structured problem list","Cambridge University Hospitals NHS Foundation Trust|University of Cambridge","All","18 Years to 100 Years   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","A095625","July 2020","September 2020","July 2021","June 16, 2020",,"June 16, 2020",,,"https://ClinicalTrials.gov/show/NCT04432961"
740,"NCT04391920","Registry of CytoSorb Therapy in COVID-19 ICU Patients","CTC REGISTRY","Not yet recruiting","No Results Available","COVID-19","Device: CytoSorb 300 mL device","ICU mortality|Duration of ECMO after start of CytoSorb|Duration of mechanical ventilatory support after start of CytoSorb|Duration of pharmacologic hemodynamic support after start of CytoSorb|Change in serum concentrations of inflammatory biomarkers after start of CytoSorb","CytoSorbents, Inc","All","18 Years and older   (Adult, Older Adult)",,"1000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-001|FDA EUA","May 2020","May 2021","August 2021","May 18, 2020",,"May 18, 2020",,,"https://ClinicalTrials.gov/show/NCT04391920"
741,"NCT04437875","An Open Study of the Safety, Tolerability and Immunogenicity of ""Gam-COVID-Vac Lyo"" Vaccine Against COVID-19",,"Recruiting","No Results Available","Preventive Immunization COVID-19","Biological: Gam-COVID-Vac Lyo","The changing of antibody levels against the SARS-CoV-2 glycoprotein S at 42 days|Number of Participants With Adverse Events|The changing of virus neutralizing antibody titer|The changing of antigen-specific cellular immunity level","Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation|Acellena Contract Drug Research and Development","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","38","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","03-Gam-COVID-Vac Lyo-2020","June 17, 2020","August 5, 2020","August 15, 2020","June 18, 2020",,"June 22, 2020","Sechenov First Moscow State Medical University, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04437875"
742,"NCT04432766","A Phase 1 Study to Assess BAT2020 in Hospitalized Patients Infected With SARS-CoV-2 (COVID-19)",,"Not yet recruiting","No Results Available","COVID-19","Drug: BAT2020","Incidence of adverse events (AEs)|Duration of survival and free of respiratory failure|Percentage of patients reporting each severity rating on an 8-point ordinal scale|Change in National Early Warning Score (NEWS) from baseline|Frequency of respiratory progression|Number of participants with treatment-related adverse events as assessed by oropharyngeal swabs, nasopharyneal and blood samples for virology|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Grade 4 AEs are defined as events that are potentially life threatening|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Number of non-invasive ventilation/high flow oxygen free days|Number of oxygenation free days|Ventilator/extracorporeal membrane oxygenation (ECMO) free days|Subject 28-day mortality|viral load change from baseline","Bio-Thera Solutions","All","Child, Adult, Older Adult","Phase 1","174","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BAT2020-001-CR","July 20, 2020","October 3, 2020","January 18, 2021","June 16, 2020",,"June 16, 2020",,,"https://ClinicalTrials.gov/show/NCT04432766"
743,"NCT04365634","A Single-center Retrospective Study to Find Prediction Factors Related to Mortality of COVID-19 Patients.",,"Completed","No Results Available","COVID-19",,"Find the prediction factors associated with hospitalized death of patients with COVID-19 by univariate and multivariate analysis|Demographics and clinical characteristics|Laboratory parameters and radiography image features|Treatment, complications and clinical outcomes","Tongji Hospital","All","Child, Adult, Older Adult",,"306","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","TJ20200202","February 2, 2020","March 15, 2020","April 1, 2020","April 28, 2020",,"April 28, 2020","Tongji Hospital, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04365634"
744,"NCT04429711","Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Ivermectin Oral Product","Viral clearance at day 6|Viral shedding duration|Symptoms clearance time","Sheba Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SHEBA-20-7156-ES-CTIL","May 12, 2020","September 30, 2020","October 31, 2020","June 12, 2020",,"June 16, 2020","Sheba Medical Center, Ramat-Gan, Israel",,"https://ClinicalTrials.gov/show/NCT04429711"
745,"NCT04307693","Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)",,"Terminated","No Results Available","COVID-19","Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine sulfate","Viral load|Viral load change|Time to clinical improvement (TTCI)|Percentage of progression to supplemental oxygen requirement by day 7|Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hours by day 7|Time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission|Rate of switch to Lopinavir/ritonavir or hydroxychloroquine by day 7|adverse effects|Concentration of Lopinavir/ritonavir and hydroxychloroquine","Asan Medical Center","All","16 Years to 99 Years   (Child, Adult, Older Adult)","Phase 2","65","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S2020-0472-0001","March 11, 2020","April 30, 2020","April 30, 2020","March 13, 2020",,"May 27, 2020","Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04307693"
746,"NCT04344236","Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Saline oral/nasal rinse|Drug: 0.5% Povidone/Iodine oral/nasal rinse|Drug: 0.12% Chlorhexidine oral/nasal rinse","Viral load (and/or cycle time to PCR as a proxy for quantitative viral load) in the nasopharynx and oropharynx|Oxygen requirement of the patient|Oxygen saturation of the patient","NYU Langone Health","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 2","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","s20-00444","April 9, 2020","May 1, 2020","May 9, 2020","April 14, 2020",,"April 14, 2020","NYU Langone Health, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04344236"
747,"NCT04385849","Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Biological: N-803|Other: Saline","Preliminary safety and efficacy evaluation of N-803 by adverse event (AE) incidence|Preliminary safety and efficacy evaluation of N-803 by subject clinical status using a the 7-point ordinal scale.|Preliminary safety and efficacy evaluation of N-803 by changes in lymphocyte counts|Further evaluate efficacy of N-803 using changes to the National Early Warning Score (NEWS)|Further evaluate the safety of N-803 using change from baseline in hemoglobin|Further evaluate the safety of N-803 using change from baseline in platelets|Further evaluate the safety of N-803 using change from baseline in white blood cell count","ImmunityBio, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","QUILT-COVID-19","June 1, 2020","July 11, 2020","July 11, 2020","May 13, 2020",,"June 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04385849"
748,"NCT04400461","Short-term Physical Function Outcomes in Severe COVID-19 Patients Admitted to ICU for Invasive Mechanical Ventilation",,"Recruiting","No Results Available","COVID-19","Other: Data collection and clinical testing of subjects","Medical Research Council sum score (MRC- SS).|The Functional Status Score for the ICU (FSS-ICU)|Age|Sex|Body Mass Index|Baseline mobility|APACHE II score|Length of stay in ICU|Number of days on mechanical ventilation|Polyneuropathy diagnosis|Number of days on Neuromuscular Blockers|Episodes of prone positioning|Length of stay in hospital|Continuation of care","Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","All","18 Years to 80 Years   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","165/20","May 15, 2020","September 30, 2020","November 15, 2020","May 22, 2020",,"May 22, 2020","Medical ICU. Hospital Universitario Ramón y Cajal, Madrid, Spain|Surgical ICU. Hospital Universitario Ramón y Cajal, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04400461"
749,"NCT04363814","Clinical Impact of BACTEK-R in Subject With Mild Pneumonia Due to COVID-19 Infection",,"Not yet recruiting","No Results Available","COVID-19","Biological: Bactek-R","Clinical recovery|Clinical worsening|Clinical severity|Time to symptoms remission|Medication Use|Hospitalization time|Blood routine test|Heart rate|Blood pressure|Cardiac auscultation|Oxygen saturation|Adverse events","Inmunotek S.L.|BioClever 2005 S.L.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","100","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MV130-SLG-35","June 10, 2020","July 1, 2020","July 31, 2020","April 27, 2020",,"May 22, 2020",,,"https://ClinicalTrials.gov/show/NCT04363814"
750,"NCT04345692","A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients","OAHU-COVID19","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine","i. Clinical status|Oxygenation|Mechanical Ventilation|Hospitalization|Mortality","Queen's Medical Centre","All","18 Years to 95 Years   (Adult, Older Adult)","Phase 3","350","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RA-2020-018","March 26, 2020","December 31, 2021","December 31, 2021","April 14, 2020",,"June 4, 2020","Queen's Medical Center, Honolulu, Hawaii, United States",,"https://ClinicalTrials.gov/show/NCT04345692"
751,"NCT04364763","A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)",,"Not yet recruiting","No Results Available","COVID-19","Drug: RBT-9 (90 mg)|Drug: 0.9% sodium chloride (normal saline)","Evaluate the effect of RBT-9 versus placebo on clinical status of COVID-19 patients as measured using the 8-point World Health Organization (WHO) Ordinal Clinical Scale|Time to first occurrence of death from any cause or new/worsened organ dysfunction|All-cause survival|Oxygen saturation (SpO2)/fraction of inspired oxygen (FiO2) ratio|Fever incidence|Acute kidney injury (AKI) incidence|New or worsening congestive heart failure (HF)|Hospitalization status|Ventricular tachycardia or fibrillation lasting at least 30 seconds and/or associated with hemodynamic instability or pulseless electrical activity, or resuscitated cardiac arrest|Oxygen-free days|Intensive care unit (ICU) status|Days on ventilator|Time to and duration of vasopressor or inotrope utilization|Dialysis status","Renibus Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","252","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","REN-005","June 25, 2020","June 30, 2021","December 31, 2021","April 28, 2020",,"June 23, 2020",,,"https://ClinicalTrials.gov/show/NCT04364763"
752,"NCT04397562","A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19","CORONA","Active, not recruiting","No Results Available","COVID-19","Drug: Levilimab|Drug: Placebo","Mortality rate|7-point Ordinal Scale|Duration of hospital stay|Rate of subjects required ICU stay|Duration of ICU Stay|Rate of subjects with COVID-19 progression to critical (respiratory failure required invasive ventilation or septic shock or multiple organ failures|Rate of subjects requiring the rescue therapy|Duration of oxygen supplementation|Rate of subjects requiring the invasive ventilation|Duration of invasive ventilation","Biocad","All","18 Years and older   (Adult, Older Adult)","Phase 3","204","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BCD-089-4","April 29, 2020","April 2021","April 2021","May 21, 2020",,"June 11, 2020","State Budgetary Healthcare Institution Kaluga region ""Kaluga Regional Clinical Hospital"", Kaluga, Russian Federation|State Budget Institution of the Republic of Dagestan ""Republican Clinical Hospital"", Machačkala, Russian Federation|A.N. Bakulev National Medical Research Center of Cardiovascular Surgery, Moscow, Russian Federation|City Clinical Hospital No. 40 of the Department of Health of the city of Moscow, Moscow, Russian Federation|City Clinical Hospital No.52, Moscow, Russian Federation|City Clinical Hospital № 15 named. O.M. Filatov, Moscow, Russian Federation|City Clinical Hospital №1 named after N.I. Pirogov, Moscow City Health Department, Moscow, Russian Federation|Federal State Budgetary Institution ""Central Clinical Hospital with Clinic"", Office of the President of the Russian Federation, Moscow, Russian Federation|I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation|Pirogov Russian National Research Medical University, Moscow, Russian Federation|Railway clinical hospital named after N.A. Semashko, Moscow, Russian Federation|Almazov National Medical Research Centre, Saint Petersburg, Russian Federation|Clinical Infectious Disease Hospital named after S.P. Botkin, Saint Petersburg, Russian Federation|North-western State Medical University named after I.I.Mechnikov, Saint Petersburg, Russian Federation|Federal State Budgetary Educational Institution of Higher Education ""Bashkir State Medical University"" of the Ministry of Healthcare of the Russian Federation, Ufa, Russian Federation|Federal State Budgetary Educational Institution of Higher Education ""North Ossetian State Medical Academy"" of the Ministry of Health of the Russian Federation (FSBEI HE SOGMA of the Ministry of Health of Russia), Vladikavkaz, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04397562"
753,"NCT04433910","A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19","CAPSID","Recruiting","No Results Available","COVID-19","Drug: Convalesscent Plasma","Composite endpoint of survival and no longer fulfilling criteria of severe COVID-19.|Time to clinical improvement|Frequency and severity of adverse events by CTCAE v5.0, (Key secondary endpoint)|Case fatality rate|Length of hospital stay Length of hospital stay (if applicable)|Length of stay in ICU|Duration of ventilation support / ECMO|Time until negative SARS-CoV-2 PCR (nasopharyngeal sample)|Predictive value of comorbidities|Predictive value of coagulation markers|Predictive value of inflamation|Percentage of former COVID-19 patients willing to donate qualifying for plasma donation.|Amount of Plasma Units that could be collected for the clinical trial|Titer of anti-SARS-CoV-2 in transfused plasma units|Impact of donor characteristics on anti-SARS-CoV-2 humoral response|Course of anti-SARS-CoV-2 titer in both patient groups at different time points related to transfusion of convalescent plasma|Correlation of anti-SARS-CoV-2 titer in transfused plasma units and primary and key secondary outcomes.|Effect of timing of plasma transfusions","Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","106","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAPSID2020-DRK-BSD|2020-001310-38","June 2020","December 2020","February 2021","June 16, 2020",,"June 23, 2020","University Hospital Ulm, Ulm, Baden-Württmberg, Germany|University Hopsital Frankfurt, Frankfurt, Hessia, Germany|Saarland University Hospital, Homburg, Saarland, Germany",,"https://ClinicalTrials.gov/show/NCT04433910"
754,"NCT04331899","Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19","COVID-Lambda","Recruiting","No Results Available","COVID-19","Drug: Peginterferon Lambda-1a|Other: Placebo","Duration of Viral shedding of SARS-CoV-2 by qRT-PCR","Stanford University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","55619","April 24, 2020","May 31, 2021","May 31, 2022","April 2, 2020",,"June 18, 2020","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04331899"
755,"NCT04411680","Study of Sargramostim in Patients With COVID-19","iLeukPulm","Not yet recruiting","No Results Available","COVID-19|Sars-CoV2","Drug: Sargramostim|Drug: Standard of care","Change in oxygenation parameter of P(A-a)O2 gradient by Day 6|Percent of patients who have been intubated by Day 14|Change in ordinal scale|All cause 28-day mortality|Number of patients with treatment-emergent serious adverse events or clinically significant adverse drug reactions (ADRs)","Partner Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTX-001-002","June 2020","October 2020","January 2021","June 2, 2020",,"June 2, 2020",,,"https://ClinicalTrials.gov/show/NCT04411680"
756,"NCT04411628","A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: LY3819253|Drug: Placebo","Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration|Pharmacokinetics (PK): Area Under the Concentration-time Curve (AUC) of LY3819253|Pharmacodynamics (PD): Change from Baseline to Day 29 in Viral Load","Eli Lilly and Company|AbCellera Biologics Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","40","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","17823|J2W-MC-PYAA","May 28, 2020","August 23, 2020","August 23, 2020","June 2, 2020",,"June 26, 2020","Cedars Sinai Medical Center, Los Angeles, California, United States|Veterans Affairs Medical Center San Diego, San Diego, California, United States|Emory University, Atlanta, Georgia, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Quality Clinical Research, Inc., Omaha, Nebraska, United States|Alexandria Center for Life - NYC/ NYCEDC, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Temple University School of Medicine, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04411628"
757,"NCT04362332","Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19","ARCHAIC","Terminated","No Results Available","COVID-19","Drug: Chloroquine Sulfate|Drug: Hydroxychloroquine|Other: Standard supportive care","Composite endpoint with disease progression defined as a NEWS2score ≥ 7 within 14 days or resulting in admission to Intensive/Medium Care unit or resulting in death within 14 days.|Side effects","UMC Utrecht|ZonMw: The Netherlands Organisation for Health Research and Development","All","18 Years to 110 Years   (Adult, Older Adult)","Phase 4","25","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NL73529.041.20 versie 3","April 14, 2020","June 8, 2020","June 8, 2020","April 24, 2020",,"June 19, 2020","UMCU, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT04362332"
758,"NCT04384614","Covid-19 In Tunisia: An Observational Cross-Sectional Registry Study","CONNAITRE","Not yet recruiting","No Results Available","Covid 19|BCG Vaccination","Diagnostic Test: Test PCR|Genetic: TDR|Other: Clinical Examination","Differences related to epidemiological demographic characteristics","Direction des Soins de Santé de Base|Eshmoun Clinical Research Centre|Dacima Consulting","All","18 Years to 80 Years   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","ECC2020-07","May 15, 2020","July 15, 2020","July 15, 2020","May 12, 2020",,"May 13, 2020","Eshmoun Clinical Research Centre, Tunis, Tunisia",,"https://ClinicalTrials.gov/show/NCT04384614"
759,"NCT04441398","Efficacy and Safety of Nitazoxanide 600 mg to Treat Mild Ambulatory COVID-19 Patients",,"Not yet recruiting","No Results Available","covid19","Drug: Nitazoxanide|Drug: Placebo","Change in signs and symptoms scale|Incidence of Treatment-Emergent Adverse Events|The proportion of subjects hospitalized after start of treatment and before the end of the study|The proportion of subjects that need mechanical ventilation after start of treatment and before the end of the study|Duration of symptoms|Rate of mortality within 21-days","Azidus Brasil|Farmoquimica S.A.","All","50 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NITFQM0720OR","July 2020","September 2020","September 2020","June 22, 2020",,"June 22, 2020",,,"https://ClinicalTrials.gov/show/NCT04441398"
760,"NCT04323631","Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death",,"Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Other: The control group will not receive hydroxychloroquine","Number patients developing severe infection or death","Rambam Health Care Campus|Rabin Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","1116","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0154-20-RMB","March 2020","December 2020","December 2020","March 26, 2020",,"March 26, 2020",,,"https://ClinicalTrials.gov/show/NCT04323631"
761,"NCT04329507","Non-invasive Detection of Pneumonia in Context of Covid-19 Using Gas Chromatography - Ion Mobility Spectrometry (GC-IMS)",,"Not yet recruiting","No Results Available","COVID-19|Respiratory Disease","Diagnostic Test: Breath test","To perform a study in patients with clinical features of pneumonia/chest infection to identify a signature of Covid-19 pneumonia in patients exposed to SARS-CoV-2, compared to unexposed patients or those without.|Detection of markers of Covid-19 pneumonia in non-invasive breath samples.|Relationship of this biomarker signature to the presence of SARS-CoV-2 in nasal and throat swabs.|Subsequently, the signature's relationship to other biomarkers of SARS-CoV-2 infection which are currently being explored|In a smaller group of participants, ideally daily non-invasive breath samples will be collected to determine if there are changes between SARS-CoV-2 positive patients and those that are negative until hospital discharge or undue participant burden .","NHS Lothian","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","282014","March 25, 2020","March 25, 2020","March 25, 2020","April 1, 2020",,"April 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04329507"
762,"NCT04434131","Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Convalescent Plasma","Correlation between the NAb dose titer in the convalescent plasma and change or lack of change when comparing pre-treatment and day one NAb titers to inpatients with documented COIVD-19 infection|Rapid deterioration as evidenced by increase in ordinal or news score within 4 hours of transfusion|Number of participants with clearance of viral shedding of SARSCoV-2 in nasopharyngeal or nasal samples","University of New Mexico","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","20-227","April 28, 2020","April 28, 2021","April 28, 2025","June 16, 2020",,"June 16, 2020","University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT04434131/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04434131"
763,"NCT04331834","Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic","PrEP_COVID","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Placebos","Confirmed cases of a COVID-19|SARS-CoV-2 seroconversion|Occurrence of any adverse event related with hydroxychloroquine treatment|Incidence of SARS-CoV-2 infection and COVID-19 among healthcare workers|Risk ratio for the different clinical, analytical and microbiological conditions to develop COVID-19|COVID-19 Biobank","Barcelona Institute for Global Health|Hospital Clinic of Barcelona|Laboratorios Rubió","All","18 Years and older   (Adult, Older Adult)","Phase 3","440","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PrEP_COVID","April 3, 2020","October 3, 2020","October 30, 2020","April 2, 2020",,"April 7, 2020","ISGlobal, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04331834"
764,"NCT04331470","Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Levamisole Pill + Budesonide+Formoterol inhaler|Drug: Lopinavir/Ritonavir + hydoxychloroquine","Clear chest CT-scan|PCR test|Physical statues of patient","Fasa University of Medical Sciences","All","15 Years to 100 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","97548","April 4, 2020","April 20, 2020","May 20, 2020","April 2, 2020",,"April 13, 2020","Vali-Asr Hospital, Fasa, Fars, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04331470"
765,"NCT04440007","Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With SOC Versus SOC in Subjects With COVID-19","SOC","Not yet recruiting","No Results Available","Covid-19","Drug: Abivertinib|Other: Standard of Care","Proportion of subjects alive and free of respiratory failure at Day 14|Incidence of treatment-emergent adverse events (safety and tolerability of STI-5656)|Proportion of subjects alive and free of respiratory failure at Day 28|Change in clinical status|Discharge from ICU|Time to respiratory failure or death","Sorrento Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STI-5656-2001","August 2020","January 2021","March 2021","June 19, 2020",,"June 25, 2020",,,"https://ClinicalTrials.gov/show/NCT04440007"
766,"NCT04371926","Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk","PREVENT","Withdrawn","No Results Available","COVID-19","Drug: Hydroxychloroquine Sulfate","Time to reach normal body temperature|Development of COVID-19 symptoms during HCQ preventive therapy in staff|COVID-19 test result at follow-up in patients|Worsening of symptoms in COVID-19 patients","Texas Cardiac Arrhythmia Research Foundation","All","18 Months to 85 Years   (Child, Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","TCAI_PREVENT","June 2020","June 2021","July 2021","May 1, 2020",,"June 4, 2020",,,"https://ClinicalTrials.gov/show/NCT04371926"
767,"NCT04443803","Characterizing the Perioperative Epidemiology of SARS-CoV-2 (COVID-19) Spread for Quality Improvement of Perioperative Infection Control Program",,"Not yet recruiting","No Results Available","COVID-19",,"Perioperative transmission of SARS-CoV-2","Randy Loftus|University of Iowa","All","18 Years to 120 Years   (Adult, Older Adult)",,"9","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","202005391","July 1, 2020","August 31, 2020","August 31, 2020","June 23, 2020",,"June 23, 2020",,,"https://ClinicalTrials.gov/show/NCT04443803"
768,"NCT04423861","Efficacy and Safety of Nitazoxanide 600 mg TID for the Treatment of Hospitalized Patients With COVID-19",,"Not yet recruiting","No Results Available","covid19","Drug: Nitazoxanide|Drug: Placebo","Viral load|Evolution of acute respiratory syndrome|Change in Clinical Condition|Hospital discharge|Rate of mortality within 21-days|Need of mechanical ventilation","Azidus Brasil|Farmoquimica S.A.|Hospital Casa de Saúde - Vera Cruz - Campinas - SP - Brazil","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NITFQM0520OR","July 2020","August 2020","August 2020","June 9, 2020",,"June 9, 2020",,,"https://ClinicalTrials.gov/show/NCT04423861"
769,"NCT04386252","Phase Ib-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults",,"Not yet recruiting","No Results Available","COVID-19","Biological: AV-COVID-19","Confirm safety|Suggestion of efficacy|Optimal dose of SARS-CoV-2 antigen|Advantage of administering vaccine admixed with GM-CSF|Frequency of detecting IgG against SARS-CoV-2 in blood after vaccination","Aivita Biomedical, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","180","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CL-COV-P01-US","July 2020","December 2020","March 2021","May 13, 2020",,"June 24, 2020","Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT04386252"
770,"NCT04312464","Myocardial Damage in COVID-19",,"Enrolling by invitation","No Results Available","COVID-19|Cardiovascular Diseases","Other: non","The myocardial injury incidence|The risk factors analysis for the death|Clinical characteristics|Clinical course|Cardiovascular comorbidity|Analysis of causes of death","Wuhan Union Hospital, China","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","MD-COVID-19","January 1, 2020","March 15, 2020","March 18, 2020","March 18, 2020",,"March 18, 2020","Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04312464"
771,"NCT04313023","The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2",,"Recruiting","No Results Available","COVID-19","Drug: PUL-042 Inhalation Solution|Drug: Placebo","Severity of COVID-19|Incidence of SARS-CoV-2 infection|ICU admission|Mechanical ventilation|Mortality","Pulmotect, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PUL-042-501","June 9, 2020","September 2020","October 2020","March 18, 2020",,"June 19, 2020","University of California Irvine, Orange, California, United States|Clinical Research of South Florida Alliance for Multispecialty Research, Coral Gables, Florida, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|Willis-Knighton Physcian Network, Bossier City, Louisiana, United States|Englewood Health, Englewood, New Jersey, United States|Ascension St. John, Tulsa, Oklahoma, United States|MD Anderson Cancer Center, Houston, Texas, United States|Next Level Urgent Care, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04313023"
772,"NCT04336254","Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients",,"Recruiting","No Results Available","COVID-19","Biological: allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC)|Other: Intravenous saline injection (Placebo)","TTCI|Lung lesion|Immune function|Time of SARS-CoV-2 clearance|Blood test|SPO2|RR|Body temperature|Side effects in the treatment group|C-reactive protein (mg/L)","Renmin Hospital of Wuhan University|Beijing SH Bio-Tech Corporation, Beijing (CN)|Utooth Biological Technology Co., Ltd. Hubei (CN)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020K-G005|hDPSC-CoVID-2019-02-2020","April 6, 2020","December 31, 2020","March 31, 2021","April 7, 2020",,"April 7, 2020","Renmin Hospital of Wuhan University (East Campus), Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04336254"
773,"NCT04292899","Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)",,"Active, not recruiting","No Results Available","COVID-19","Drug: Remdesivir|Drug: Standard of Care","The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events","Gilead Sciences","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","6000","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-540-5773|2020-000841-15","March 6, 2020","June 2020","June 2020","March 3, 2020",,"June 2, 2020","Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States|Alta Bates Summit Medical Center, Berkeley, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|Eden Medical Center, Castro Valley, California, United States|Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States|Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States|St Joseph Hospital Eureka, Fortuna, California, United States|Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States|Mission Hospital Regional Medical Center, Mission Viejo, California, United States|Kaiser Permanente Los Angeles Medical Center, 27300 Iris Avenue, Moreno Valley, California, United States|El Camino Hospital, Mountain View, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Kaiser Permanente Oakland Medical Center, Oakland, California, United States|Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States|The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States|Kaiser Permanente Los Angeles Medical Center, 13651 Willard Street, Panorama City, California, United States|Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Riverside, California, United States|Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States|Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States|Kaiser Permanente Oakland Medical Center, 1200 El Camino Real, San Francisco, California, United States|California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 2425 Geary Blvd, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 250 Hospital Parkway, Suite 850, San Jose, California, United States|Kaiser Permanente Oakland Medical Center, 2500 Merced St, San Leandro, California, United States|Kaiser Permanente Oakland Medical Center, 700 Lawrence Expressway, Santa Clara, California, United States|Providence St. Johns Medical Center, Santa Monica, California, United States|Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States|Stanford Hospital, Stanford, California, United States|University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States|SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States|SCL Health St. Joseph Hospital, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States|Yale-New Haven Hospital, New Haven, Connecticut, United States|Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States|John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Tulane University, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Hennepin Healthcare, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States|Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States|St. Joseph's University Medical Center, Paterson, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|James J. Peters Veterans Administration Medical Center, Bronx, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Danbury Hospital, Lagrangeville, New York, United States|North Shore University Hospital, Manhasset, New York, United States|North Shore University Hospital, 270-05 76th Ave, New Hyde Park, New York, United States|Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center-New York Presbyterian Hospital, New York, New York, United States|New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Kaiser Sunnyside Medical Center, Portland, Oregon, United States|Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|Prisma Health Richland Hospital, Columbia, South Carolina, United States|Prisma Health Richland Hospital, 701 Grove Road, Greenville, South Carolina, United States|The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States|Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States|Virginia Hospital Center, Arlington, Virginia, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States|VCU Health Medical Center, Richmond, Virginia, United States|Providence Regional Medical Center Everett, Everett, Washington, United States|Kadlec Regional Medical Center, Kennewick, Washington, United States|Providence St. Peter Hospital, Olympia, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Center for Comprehensive Care, Seattle, Washington, United States|MultiCare Deaconess Hospital, Spokane, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|St Joseph Medical Center, Tacoma, Washington, United States|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|CHU Pellegrin, Bordeaux, France|CHU de Montpellier-Hopital Gui de Chauliac, Montpelier Cedex 5, France|CHU de Nantes-Hotel Dieu, Nantes, France|Hopital Saint-Louis, Paris, France|Hopital Saint Antoine, Paris, France|Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie, Berlin, Germany|Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Germany|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany|Klinik für Hämatologie, Onkologie, Immunologie, München, Germany|Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP), Stuttgart, Germany|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|UOC Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, Italy|ASST degli Spedali Civili di Brescia, Brescia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy|UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy|Dipartimento di Malattie Infettive, Malattie Infettive I- Malattie Infettive III, AssT Fatebenefratelli Sacco Ospedale Luigi Sacco, Milano, Italy|UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy|UOC Medicina Di Laboratorio, Azienda Ospedaliera di Padova, Padova PD, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|UOC Malattie Infettive I, Fondazione IRCCS Policlinio San Matteo, Pavia, Italy|Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy|UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy|Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy|Yokohama Municipal Citizen's Hospital, Kanagawa, Japan|Nagoya City East Medical Center, Nagoya, Japan|Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|Amsterdam University Medical Centre - Location AMC, Amsterdam, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Erasmus Medical Centre, Rotterdam, Netherlands|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore|Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Cruces, Bizkaia, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario de Málaga, Málaga, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden|SUS (Skanes University Hospital), Malmo, Sweden|Karolinska University Hospital, Stockholm, Sweden|Hopitaux Universitaires de Genève, Genève 14, Switzerland|Ospedale Regionale di Locarno La Carità, Lugano, Switzerland|Universitätsspital Zürich, Zürich, Switzerland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Imperial College Healthcare NHS Trust, London, Greater London, United Kingdom|Royal Infirmary of Edinburgh, Edinburgh, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom|Royal Lancaster Hospital, Lancaster, United Kingdom|Liverpool University Hospital, Liverpool, United Kingdom|Northwick Park Hospital, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom|King's College Hospital NHS Trust, London, United Kingdom|University College London, London, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Sheffield Teaching Hospitals, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04292899"
774,"NCT04416139","Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19","COVID-19","Recruiting","No Results Available","Covid 19","Biological: Infusion IV of Mesenchymal Stem cells","Functional Respiratory changes: PaO2 / FiO2 ratio|Clinical cardiac changes: Heart rate per minute|Clinical Respiratory Changes: Respiratory rate per minute|Changes in body temperature|General biochemical changes in Leukocytes|General biochemical changes on lymphocytes|General biochemical changes on platelets|General biochemical changes on fibrinogen|General biochemical changes on pocalcitonin|General biochemical changes on ferritin|General biochemical changes on D-dimer|Changes on inflammatory C-reactive protein|Cahnges on Inflammatory cytokine TNFa|Changes on Inflammatory cytokine IL10|Changes on Inflammatory cytokine IL1|Changes on Inflammatory cytokine IL6|Changes on Inflammatory cytokine IL 17|Changes on VEGF|Radiological Changes|Immunological changes on T cell|Immunological changes on Dendritic cells|Immunological changes on CD4+ T|Immunological changes on CD8+ T|Immunological changes on NK cell|Adverse events|RNA detection by SARS-Cov2 PCR","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCI-3354-20-21-1","May 1, 2020","April 30, 2021","May 1, 2021","June 4, 2020",,"June 4, 2020","Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT04416139"
775,"NCT04332094","Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19","TOCOVID","Recruiting","No Results Available","COVID-19","Drug: Tocilizumab|Drug: Hydroxychloroquine|Drug: Azithromycin","In-hospital mortality|Need for mechanical ventilation in the Intensive Care Unit","Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Instituto de Salud Carlos III","All","18 Years and older   (Adult, Older Adult)","Phase 2","276","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIBSP-COV-2020-23","April 2, 2020","September 2020","October 2020","April 2, 2020",,"April 7, 2020","Hospital de la Santa Creu i Sant Pau, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04332094"
776,"NCT04346615","Safety and Efficacy Trial of Zavegepant Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen",,"Recruiting","No Results Available","COVID-19 Infection","Drug: Vazegepant (BHV-3500)|Drug: Placebo","To evaluate efficacy of vazegepant (BHV-3500) compared with placebo in subjects hospitalized with COVID-19 infection requiring supplemental oxygen, using a 6-point ordinal scale.|The number of unique subjects alive and off of oxygen. These are subjects in categories 5 or 6 of the 6-point ordinal scale being used as the primary endpoint.|A subject requiring initiation of invasive mechanical ventilation, non-invasive ventilation, or a high flow nasal cannula is a subject that has any eCRF showing the use of any such device on any day.|The number of unique subjects admitted to an ICU verse those not admitted.|Subjects are alive and respiratory-failure free if they are categorized as being in categories 3, 4, 5 or 6 of the 6-point ordinal scale being used as the primary endpoint.|Subjects are alive and free of either invasive mechanical ventilation or non-invasive ventilation if they are categorized as being in categories 4, 5 or 6 of the 6-point ordinal scale being used as the primary endpoint.|Efficacy on Day 29 will be evaluated using the same 6-point severity scales that is used at Day 15.|Time to improvement of one category on the 6-point severity scale will be determined as the number of days from baseline to the first day that an eCRF indicates a one category improvement in the scale.|A 48-hour improvement in SpO2/FiO2 ratio consists of two consecutive days where the case report forms show a clinically meaningful increase from baseline.|The time to improvement in the in the NEWS2 scale will be determined as the number of days from baseline to the first eCRF that shows an improvement.|A score < 2 for 24 hours on the NEWS2 scale consists of a day where all of the reported NEWS2 scores are < 2.|The change in NEWS2 scores will be determined as the change from baseline at Day 15 and at Day 29.|The number of unique subjects alive and off of oxygen.|The percentage of subjects discharged to home on supplemental oxygen will determined from the unique number of subjects have eCRF pages indicating they were discharged to home while still on supplemental oxygen.|A day with a resting respiratory rate > 24 is a day in which all eCRFs collected for a subject indicate observed respiratory rates > 24 breaths per minute.|A day with supplemental oxygen is one in which any case report form collected on that day indicates the use of any amount of supplemental oxygen.|Time to saturation greater than or equal to 90% on room air is measured by the number of days from baseline to the first day on which an eCRF indicates saturation greater than or equal to 90% without any supplemental oxygenation.|A ventilator free day is a day in which all of the eCRFs collected indicate that the subject was not using a ventilator.|SOFA scores will be determined from eCRFs. Values will be determined for subjects at admission to an ICU and for all subjects still in an ICU at the end of the study (Day 29).|The number of days of hospitalization will be determined from eCRFs. A hospitalization day is any day that it is shown that a subject spent at least spent part of the day in a hospital.|Time to fever resolution, without antipyretics, during two contiguous days .|The number of deaths, SAEs, severe AEs and Grade 3 or 4 laboratory abnormalities will be tabulated as the number of unique subjects meeting those criteria.|The incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infections will be tabulated as the number of unique subjects, reported in eCRFs, as having these conditions at any point in the study|The incidence of intranasal administration reactions will be tabulated, from eCRFs, as the number of unique subjects having such a condition at any point in the study.|The percentage of subjects who develop significant renal disease.","Biohaven Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BHV3500-203","April 25, 2020","December 2020","December 2020","April 15, 2020",,"June 29, 2020","Georgetown University Medical Center, Washington, District of Columbia, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04346615"
777,"NCT04312997","The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection",,"Recruiting","No Results Available","COVID-19","Drug: PUL-042 Inhalation Solution|Drug: Placebo","Severity of COVID-19|SARS-CoV-2 infection|Severity of COVID-19 over 14 days|Severity of COVID-19 symptoms|ICU admission|Mechanical Ventilation|Mortality","Pulmotect, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PUL-042-502","June 16, 2020","September 2020","October 2020","March 18, 2020",,"June 19, 2020","University of California Irvine, Orange, California, United States|Clinical Research of South Florida Alliance for Multispecialty Research, Coral Gables, Florida, United States|St. Elizabeth Healthcare, Edgewood, Kentucky, United States|Ascension St. John, Tulsa, Oklahoma, United States|MD Anderson Cancer Center, Houston, Texas, United States|Next Level Urgent Care, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04312997"
778,"NCT04385264","#StayHome: Early Hydroxychloroquine to Reduce Secondary Hospitalisation and Household Transmission in COVID-19","#StayHome","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Mannitol","Proportion of poor outcomes (in index cases)|Secondary household attack rate (in household contacts)|Subjective disease severity (in index cases)|Rate of acute respiratory distress syndrome (in index cases)|Severity of radiological lung pathology (in index cases)|Objective disease severity (in index cases)|Safety: Unintended toxic HCQ accumulation (in index cases)|Safety: Adverse events (in index cases)|Social distancing knowledge, attitudes and practices amongst index cases and household contacts","Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","800","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Unisante","May 12, 2020","August 2020","October 2020","May 12, 2020",,"May 12, 2020","Unisanté, Lausanne, Vaud, Switzerland",,"https://ClinicalTrials.gov/show/NCT04385264"
779,"NCT04370782","Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting",,"Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Zinc Sulfate|Drug: Doxycycline","Time to Resolution of Symptoms relative to baseline (day 1 of trial)|Number of participants hospitalized and/or requiring repeat ER visits|ICU Length of Stay|Ventilator|Severity of symptoms|Number of participants with adverse events due to drug regimen|Number of participants with QTc prolongation >500ms","St. Francis Hospital, New York","All","30 Years and older   (Adult, Older Adult)","Phase 4","750","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-21","April 28, 2020","September 30, 2020","December 31, 2020","May 1, 2020",,"May 18, 2020","St Francis Hospital, Roslyn, New York, United States",,"https://ClinicalTrials.gov/show/NCT04370782"
780,"NCT04345510","Testing for COVID-19 Infection in Asymptomatic Persons",,"Not yet recruiting","No Results Available","COVID-19 Infection",,"COVID-19 infection","German Cancer Research Center","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-19-1.0-DKFZ","April 20, 2020","May 31, 2020","December 31, 2020","April 14, 2020",,"April 14, 2020",,,"https://ClinicalTrials.gov/show/NCT04345510"
781,"NCT04334980","Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Biological: bacTRL-Spike|Other: Placebo","Frequency of Adverse Events|Immune response against SARS-CoV-2 Spike protein|Incidence of COVID-19 infection|bacTRL-Spike in stool post-vaccination|Seroconversion of circulating anti-Spike IgG antibodies & stability of serum IgG titers|Effectiveness of intestinal colonization of the probiotic-based bacTRL-Spike oral vaccine","Symvivo Corporation","All","19 Years and older   (Adult, Older Adult)","Phase 1","112","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","bacTRL-Spike-1","July 2020","August 31, 2021","December 31, 2021","April 6, 2020",,"June 29, 2020","University of California, San Diego (UCSD), Antiviral Research Center (AVRC), San Diego, California, United States|Vaccine Evaluation Center, BC Children's Hospital Research Institute, University of British Columbia., Vancouver, British Columbia, Canada|Canadian Center for Vaccinology Dalhousie University, IWK Health Centre, Halifax, Nova Scotia, Canada",,"https://ClinicalTrials.gov/show/NCT04334980"
782,"NCT04352764","ANTIBODY BASED TESTS FOR SARSCoV-2 COVID-19) - Evaluation of Patients and Healthcare Providers in the Confines of Healthcare Settings",,"Recruiting","No Results Available","Covid19","Diagnostic Test: CoronaCideTM COVID-19 IgM/IgG Rapid Test and Premier Biotech COVID-19 IgM/IgG Rapid Test","prevalence of COVID-19 exposure|correlation between the test results with the presence or lack of COVID-19 symptoms or illness|correlate pre-existing risk factors with test results and baseline symptoms|correlate subsequent healthcare utilization with test results and baseline symptoms","Texas Cardiac Arrhythmia Research Foundation","All","Child, Adult, Older Adult",,"5000","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","TCAI_COVID-19","March 27, 2020","December 31, 2020","January 31, 2021","April 20, 2020",,"April 27, 2020","St. David's Medical Center, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04352764"
783,"NCT04417335","Reducing COVID-19 Related Hospital Admission in Elderly by BCG Vaccination",,"Active, not recruiting","No Results Available","COVID-19","Biological: BCG vaccine|Biological: Placebo","SARS-CoV-2 related hospital admission|the duration of hospital admission due to documented COVID-19|the cumulative incidence of documented SARS-CoV-2 infection|the cumulative incidence of self-reported acute respiratory symptoms or fever|the cumulative incidence of death due to documented SARS-CoV-2 infection|the cumulative incidence of hospital admission for any reason|the cumulative incidence of Intensive Care Admission due to documented SARS-CoV-2 infection","Radboud University","All","60 Years and older   (Adult, Older Adult)","Phase 4","2014","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","NL73430.091.20|2020-001591-15","April 16, 2020","May 2021","May 2021","June 4, 2020",,"June 4, 2020","Radboud University, Nijmegen, Gelderland, Netherlands|UMC Utrecht, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT04417335"
784,"NCT04348409","Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Nitazoxanide Tablets|Drug: Placebo","Viral load|Evolution of acute respiratory syndrome|Change in Clinical Condition|Hospital discharge|Rate of mortality within 21-days|Need of mechanical ventilation","Azidus Brasil|Farmoquimica S.A.|Hospital Vera Cruz|Hospital Casa de Saúde - Vera Cruz - Campinas - SP - Brazil|Centro de Genomas - UNIFESP|Emilio Ribas Institute of Infectious Diseases","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NITFQM0320OR","May 25, 2020","July 31, 2020","July 31, 2020","April 16, 2020",,"June 9, 2020","Hospital Vera Cruz, Campinas, São Paulo, Brazil|Centro de Genomas, São Paulo, Brazil|Hospital Emílio Ribas, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04348409"
785,"NCT04377711","A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients",,"Recruiting","No Results Available","COVID-19","Drug: Ciclesonide|Drug: Placebo","Percentage of patients hospital admission or death by day 30|All-cause mortality by day 30|COVID-19-related mortality by day 30|Percentage of patients with subsequent emergency department visit or hospital admission for reasons attributable to COVID 19 by day 30|Time to hospital admission or death|Time to alleviation of COVID-19-related symptoms of cough, dyspnea, chills, and feeling feverish, defined as symptom-free for a continuous period of more than 24 hours (ie, > 3 AM/PM assessments)|Change from baseline in oxygen saturation levels|Change from baseline in COVID-19 viral load in nasopharyngel sample nasal secretions at day 30|Safety will be assessed based on adverse events.","Covis Pharma S.à.r.l.","All","12 Years to 100 Years   (Child, Adult, Older Adult)","Phase 3","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ALV-020-001","June 8, 2020","September 1, 2020","December 1, 2020","May 6, 2020",,"June 11, 2020","University of Buffalo, Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT04377711"
786,"NCT04353518","Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Suspension of heat killed (autoclaved) Mycobacterium w|Other: Placebo","Number of subject acquiring COVID-19 infection|Incidence of Adverse Event and Serious Adverse Event (safety and tolerability)|Number of subject developing Upper Respiratory Tract Infection (URTI) symptoms|Number of subject developing severe COVID-19 infection based on ordinal scale","Cadila Pharnmaceuticals|Council of Scientific and Industrial Research, India","All","18 Years and older   (Adult, Older Adult)","Phase 3","4000","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CRSC20005","April 30, 2020","March 30, 2021","May 30, 2021","April 20, 2020",,"April 22, 2020",,,"https://ClinicalTrials.gov/show/NCT04353518"
787,"NCT04371744","QT-Logs : Artificial Intelligence for QT Interval Analysis of ECG From Smartwatches in Patient Receiving Treatment for Covid-19","QT-Logs","Completed","No Results Available","COVID-19",,"Corrected QT (QTc) interval measurement","Assistance Publique Hopitaux De Marseille","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CIL 2020-52","April 17, 2020","June 4, 2020","June 5, 2020","May 1, 2020",,"June 9, 2020","Assistance Publique Hôpitaux de Marseille, Marseille, France",,"https://ClinicalTrials.gov/show/NCT04371744"
788,"NCT04360551","Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients",,"Not yet recruiting","No Results Available","COVID-19","Drug: Telmisartan 40mg|Drug: Placebo","Maximum clinical severity of disease|Incidence of treatment emergent adverse events|Renin angiotensin system peptides|Plasma biomarkers","University of Hawaii","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","H051","July 1, 2020","June 30, 2021","June 30, 2021","April 24, 2020",,"April 24, 2020","University of Hawaii - Manoa, John A Burns School of Medicine UH Clinics at Kakaako, Honolulu, Hawaii, United States",,"https://ClinicalTrials.gov/show/NCT04360551"
789,"NCT04343989","A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection",,"Recruiting","No Results Available","COVID-19","Drug: Clazakizumab 25 mg|Drug: Clazakizumab 12.5 mg|Other: Placebo","Cumulative incidence of serious adverse events associated with clazakizumab or placebo|Cumulative incidence of intubation|Time to extubation|Length of ICU stay|Number of patients who present a decrease in C-reactive protein|Patient Survival","NYU Langone Health","All","18 Years and older   (Adult, Older Adult)","Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","s20-00392","March 31, 2020","July 1, 2020","July 1, 2020","April 14, 2020",,"May 6, 2020","New York University School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04343989"
790,"NCT04348474","Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19",,"Suspended","No Results Available","Covid-19","Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin Tablets","Change in Clinical Condition|Hospitalization|Rate of mortality within 28-days|Change in Clinical Condition related to comorbidity","Azidus Brasil","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","200","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HIAPRE0420OR","April 20, 2020","June 30, 2020","July 31, 2020","April 16, 2020",,"April 22, 2020","Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04348474"
791,"NCT04391686","Resting Energy Expenditure of the COronaVirus (COVID19) Patient in Reanimation Context","RECOVERY","Not yet recruiting","No Results Available","COVID-19|Obesity","Diagnostic Test: indirect calorimetry","The resting energy expenditure (in Kcal / 24h) measured by indirect calorimetry during the stay in intensive care.","Centre Hospitalier Arras","All","18 Years and older   (Adult, Older Adult)",,"90","Other","Observational","Observational Model: Cohort|Time Perspective: Other","2020-04","June 1, 2020","December 31, 2020","December 31, 2020","May 18, 2020",,"May 18, 2020","Arras general hospital, Arras, France",,"https://ClinicalTrials.gov/show/NCT04391686"
792,"NCT04445493","EPISODE-PS-COVID: hEad Pulse for Ischemic StrOke DEtection Prehospital Study During the COVID-19 Pandemic ( EPISODEPSCOVID )","EPISODE-PH-COV","Not yet recruiting","No Results Available","Stroke, Acute|COVID-19","Device: MindRhythm Harmony","Prevalence of COVID-19 infection in suspected stroke population|Quality head pulse recordings","MindRhythm, Inc.|Wayne State University","All","18 Years and older   (Adult, Older Adult)",,"250","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EPISODE-PH-COVID","July 2020","December 2020","June 2021","June 24, 2020",,"June 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04445493"
793,"NCT04328493","The Vietnam Chloroquine Treatment on COVID-19","VICO","Recruiting","No Results Available","SARS-CoV-2 Infection|COVID-19","Drug: Chloroquine phosphate","Viral clearance time|Lengh of hospital stay|Ventilator free days|Oxygene free days|Time to death|Adverse events|fever clearance time|Ordinal outcome scale|Development of ARDS","Oxford University Clinical Research Unit, Vietnam|Ministry of Health, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam|Cu Chi COVID Hospital, Vietnam|Can Gio COVID Hospital, Vietnam|Cho Ray Hospital|National Hospital for Tropical Diseases, Hanoi, Vietnam|Department of Health, Ho Chi Minh city","All","18 Years and older   (Adult, Older Adult)","Phase 2","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID","April 7, 2020","April 1, 2021","April 1, 2022","March 31, 2020",,"May 29, 2020","National Hospital for Tropical Diseases, Hanoi, Vietnam|Can Gio COVID Hospital, Ho Chi Minh City, Vietnam|Cho Ray Hospital, Ho Chi Minh City, Vietnam|Cu Chi COVID Hospital, Ho Chi Minh City, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam",,"https://ClinicalTrials.gov/show/NCT04328493"
794,"NCT04348435","A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19",,"Enrolling by invitation","No Results Available","COVID-19","Drug: HB-adMSCs|Drug: Placebos","Incidence of hospitalization for COVID-19|Incidence of symptoms associated with COVID-19|Absence of upper/lower respiratory infection|Leukocyte differential|C Reactive protein|TNF alpha|IL-6|IL-10|Glucose|Calcium|Albumin|Total protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Total bilirubin|white blood cells|red blood cells|hemoglobin|hematocrit|mean corpuscular volume|mean corpuscular hemoglobin|mean corpuscular hemoglobin concentration|red cell distribution width|neutrophils|Lymphs|Monocytes|Eosinophils|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute eosinophils|Absolute basophils|Immature granulocytes|Platelets|Prothrombin time|INR|SF-36|PHQ-9","Hope Biosciences|Hope Biosciences Stem Cell Research Foundation","All","Child, Adult, Older Adult","Phase 2","100","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Allogeneic COVID-19 Protection","April 23, 2020","December 31, 2020","April 30, 2021","April 16, 2020",,"April 30, 2020","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04348435"
795,"NCT04329572","Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19",,"Suspended","No Results Available","COVID-19","Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin Tablets","Evolution of acute respiratory syndrome, oxygen saturation hemodynamic stability|Viral load|Change in Clinical Condition|Evolution of Acute Respiratory Syndrome|Hospital discharge|Rate of mortality within 28-days","Azidus Brasil","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","400","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HIAPRE0320OR","April 23, 2020","May 31, 2020","June 30, 2020","April 1, 2020",,"April 22, 2020","Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04329572"
796,"NCT04393727","Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19","TSUNAMI","Recruiting","No Results Available","COVID|SARS-CoV 2","Biological: CONVALESCENT PLASMA","Need of invasive mechanical ventilation|Mortality rates|Time to invasive mechanical ventilation|Time to virologic cure|Length of hospital stay|Adverse events","Azienda Ospedaliero, Universitaria Pisana","All","18 Years and older   (Adult, Older Adult)","Phase 2","126","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TSUNAMI","May 1, 2020","September 30, 2020","October 30, 2020","May 19, 2020",,"May 20, 2020","Azienda Ospedaliero Universitaria Pisana, Pisa, Italy",,"https://ClinicalTrials.gov/show/NCT04393727"
797,"NCT04383613","Prone Positioning for Patients on General Medical Wards With COVID19","COVID-PRONE","Recruiting","No Results Available","Covid-19|ARDS","Other: Prone positioning","Composite outcome of in-hospital all-cause mortality, invasive or non-invasive mechanical ventilation, or need for FiO2 of 60% or more|Length of hospitalization|Adverse events of prone positioning (i.e., venous thromboembolism, pneumonia)|In-hospital all-cause mortality|Invasive or non-invasive mechanical ventilation|Need for FiO2 of 60% or more|Ventilator-free days (i.e., the number of days in hospital the patient was not on a ventilator)|Composite outcome of in-hospital all-cause mortality, invasive or non-invasive mechanical ventilation, or need for FiO2 of 60% or more assessed at 30 days, 90 days and 1 year|Time spent in prone positioning among patients achieving the composite outcome of in-hospital all-cause mortality, invasive or non-invasive mechanical ventilation, or need for FiO2 of 60% or more","St. Michael's Hospital, Toronto|Sunnybrook Health Sciences Centre|Sinai Health System|Toronto General Hospital|University Health Network, Toronto|William Osler Health System","All","18 Years and older   (Adult, Older Adult)","Not Applicable","350","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Other","2020-1","May 15, 2020","December 11, 2020","December 11, 2020","May 12, 2020",,"June 17, 2020","William Osler Health System, Brampton, Ontario, Canada|William Osler Health System, Etobicoke, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Sinai Health System, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04383613"
798,"NCT04447131","Effect of COVID-19 on Platelet Aggregation",,"Recruiting","No Results Available","COVID-19|SARS-CoV-2","Other: venipuncture in peripheral vein","Platelet aggregation analyzed by Multiplate-ADP|Platelet aggregation by Multiplate-ASPI and Multiplate-TRAP in patients hospitalized for COVID-19 versus healthy controls.|Reticulated platelet fraction in patients hospitalized for COVID-19 versus healthy controls.|Platelet aggregation for COVID-19 versus patients hospitalized for respiratory symptoms but negative for Influenza and COVID-19 research.|Reticulated platelet fraction in patients hospitalized for COVID-19 versus patients hospitalized for respiratory symptoms but negative for influenza or COVID-19 research.|Platelet aggregation in patients hospitalized for COVID-19 versus patients hospitalized for Influenza.|Reticulated platelet fraction in patients hospitalized for COVID-19 versus patients hospitalized for Influenza.|Platelete aggreggation versus composite outcome of death from any cause, thrombotic events, need for ICU, need for intubation during hospitalization|Reticulated platelet fraction versus composite outcome of death from any cause, thrombotic events, need for ICU, need for intubation during hospitalization|Platelet aggregation versus time (days) of total hospitalization and in the ICU|Reticulated platelet fraction versus time (days) of total hospitalization and in the ICU|Platelet aggregation versus WHO ordinal scale of outcomes for COVID-19","University of Sao Paulo|Fundação de Amparo à Pesquisa do Estado de São Paulo","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","SDC 5089/20/118","April 29, 2020","July 30, 2020","December 30, 2020","June 25, 2020",,"June 25, 2020","Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04447131"
799,"NCT04371471","Covid-19 Pandemic Triage Score","STC-19","Completed","No Results Available","Sars-CoV2|Covid19","Diagnostic Test: STC-19 score","STC-19 score","Groupe Hospitalier de la Rochelle Ré Aunis|Numa Health International","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2020/P04/288","March 1, 2020","April 30, 2020","April 30, 2020","May 1, 2020",,"June 25, 2020","Groupe Hospitalier de la Rochelle Ré Aunis, La Rochelle, France",,"https://ClinicalTrials.gov/show/NCT04371471"
800,"NCT04292730","Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment",,"Active, not recruiting","No Results Available","COVID-19","Drug: Remdesivir|Drug: Standard of Care","The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events","Gilead Sciences","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","1600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-540-5774|2020-000842-32","March 15, 2020","June 2020","June 2020","March 3, 2020",,"June 2, 2020","Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States|Alta Bates Summit Medical Center, Berkeley, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|Eden Medical Center, Castro Valley, California, United States|Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States|Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States|St Joseph Hospital Eureka, Fortuna, California, United States|Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States|Mission Hospital Regional Medical Center, Mission Viejo, California, United States|Kaiser Permanente Los Angeles Medical Center,27300 Iris Avenue, Moreno Valley, California, United States|El Camino Hospital, Mountain View, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Kaiser Permanente Oakland Medical Center, Oakland, California, United States|Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States|The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States|Kaiser Permanente Los Angeles Medical Center,13651 Willard Street, Panorama City, California, United States|Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Riverside, California, United States|Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States|Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States|Kaiser Permanente Oakland Medical Center, 1200 El Camino Real, San Francisco, California, United States|California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 2425 Geary Blvd, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 250 Hospital Parkway, Suite 850, San Jose, California, United States|Kaiser Permanente Oakland Medical Center, 2500 Merced St, San Leandro, California, United States|Kaiser Permanente Oakland Medical Center, 700 Lawrence Expressway, Santa Clara, California, United States|Providence St. Johns Medical Center, Santa Monica, California, United States|Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States|Stanford Hospital, Stanford, California, United States|University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States|SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States|SCL Health St. Joseph Hospital, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States|Yale University, New Haven, Connecticut, United States|Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States|Cook County General Hospital, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Tulane University, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States|Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Hennepin Healthcare, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States|Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States|Hackensack Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States|St. Joseph's University Medical Center, Paterson, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|James J. Peters Veterans Administration Medical Center, Bronx, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Danbury Hospital, Lagrangeville, New York, United States|North Shore University Hospital, Manhasset, New York, United States|North Shore University Hospital, 270-05 76th Ave, New Hyde Park, New York, United States|Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Irving Medical Center, New York, New York, United States|Weill Cornell Medical College/NYU Presbyterian Hospital, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Kaiser Sunnyside Medical Center, Portland, Oregon, United States|Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|Prisma Health Richland Hospital, Columbia, South Carolina, United States|Prisma Health Richland Hospital, 701 Grove Road, Greenville, South Carolina, United States|The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States|Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States|Virginia Hospital Center, Arlington, Virginia, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|VCU Health Medical Center, Richmond, Virginia, United States|Providence Medical Research Center, Everett, Washington, United States|Kadlec Regional Medical Center, Kennewick, Washington, United States|Providence St. Peter Hospital, Olympia, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Center for Comprehensive Care, Seattle, Washington, United States|MultiCare Deaconess Hospital, Spokane, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|St Joseph Medical Center, Tacoma, Washington, United States|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|CHU Pellegrin, Bordeaux, France|CHU de Montpellier-Hopital Gui de Chauliac, Montpelier Cedex 5, France|CHU de Nantes-Hotel Dieu, Nantes, France|Hopital Saint-Louis, Paris, France|Hopital Saint Antoine, Paris, France|Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie, Berlin, Germany|Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Germany|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany|Klinik für Hämatologie, Onkologie, Immunologie, München, Germany|Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP), Stuttgart, Germany|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|UOC Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, Italy|ASST degli Spedali Civili di Brescia, Brescia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy|UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy|ASST Fatebenefratelli Sacco, Milano, Italy|UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy|UOC Malattie Infettive e Tropicali, Azienda Ospedaliera di Padova, Padova PD, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|Malattie Infettive I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy|UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy|Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy|Yokohama Municipal Citizen's Hospital, Kanagawa, Japan|Nagoya City East Medical Center, Nagoya, Japan|Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|Amsterdam University Medical Centre - Location AMC, Amsterdam, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Erasmus Medical Centre, Rotterdam, Netherlands|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore|Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Cruces, Bizkaia, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario de Málaga, Málaga, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden|SUS (Skanes University Hospital), Malmo, Sweden|Karolinska University Hospital, Stockholm, Sweden|Hopitaux Universitaires de Genève, Genève 14, Switzerland|Ospedale Regionale di Locarno La Carità, Lugano, Switzerland|Universitätsspital Zürich, Zürich, Switzerland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Imperial College NHS Trust, London, Greater London, United Kingdom|NHS Lothian, Royal lnfirmary of Edinburgh, Edinburgh, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom|Royal Lancaster Hospital, Lancaster, United Kingdom|Liverpool University Hospital, Liverpool, United Kingdom|Northwick Park Hospital, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom|King's College Hospital NHS Trust, London, United Kingdom|University College London, London, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Sheffield Teaching Hospitals, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04292730"
801,"NCT04381312","Direct and Indirect Impact of COVID-19 In Older Populations","COVID-OLD","Recruiting","No Results Available","Risk Factors for COVID-19 Outcomes in Elderly Populations",,"mortality|Risk factors for death|Describe clinical symptoms specific to old population|describe specific and non-specific treatments used for COVID 19|describe all acute complications|functional decline|Rehospitalisation|medical complications|Admission in nursing home|risk factors for 3-month functional decline, acute complication and admission to nursing home","University Hospital, Grenoble","All","70 Years and older   (Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","38RC20.118|2020-A00846-33","April 9, 2020","July 9, 2021","October 9, 2021","May 8, 2020",,"May 8, 2020","Chu Grenoble Alpes, Grenoble Cedex 9, Grenoble, France",,"https://ClinicalTrials.gov/show/NCT04381312"
802,"NCT04431453","Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants From Birth to < 18 Years of Age With Coronavirus Disease 2019 (COVID-19)","CARAVAN","Not yet recruiting","No Results Available","COVID-19","Drug: Remdesivir","Proportion of Participants Experiencing any Treatment-Emergent Adverse Events|Proportion of Participants Experiencing any Treatment-Emergent Graded Laboratory Abnormalities|Plasma Concentrations of Remdesivir (RDV) and Metabolites|Change From Baseline in Oxygenation Use|Change From Baseline in the Use of Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO)|Clinical Improvement on a 7-point Ordinal Scale|Time (days) to Discharge From Hospital|Days to First Confirmed Negative Polymerase Chain Reaction (PCR) Result|Change From Baseline in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Viral Load|Bilirubin Concentrations in < 14-day-old Participants|Clinical Improvement Based on Scoring Using the Pediatric Early Warning Score (PEWS) Improvement Scale|Plasma Concentrations of Sulfobutylether β-cyclodextrin Sodium (SBECD)|Proportion of Participants With Concomitant Use of Medications other than RDV for Treatment of Coronavirus Disease 2019 (COVID-19)","Gilead Sciences","All","up to 18 Years   (Child, Adult)","Phase 2|Phase 3","52","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-540-5823|2020-001803-17","June 2020","December 2020","December 2020","June 16, 2020",,"June 29, 2020",,,"https://ClinicalTrials.gov/show/NCT04431453"
803,"NCT04358549","Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Favipiravir + Standard of Care|Drug: Standard of Care","Time to viral clearance|Status of clinical recovery as measured by the study-specific 6-point ordinal scale on Day 15|Clinical effect of favipiravir + SOC compared to SOC measured by the National Early Warning Score 2 (NEWS2)|Characterize the pharmacokinetics (PK) of favipiravir in plasma: Cmax)|Characterized the pharmacokinetics (PK) of favipiravir in plasma: Cmin|Characterized the pharmacokinetics (PK) of favipiravir in plasma: AUC","Fujifilm Pharmaceuticals U.S.A., Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FAVI-COV-US201","April 17, 2020","August 2020","December 2020","April 24, 2020",,"June 29, 2020","HonorHealth, Scottsdale, Arizona, United States|Boston Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|UMass Memorial Health Care, Worcester, Massachusetts, United States|Atlantic Health System / Morristown Medical Center, Morristown, New Jersey, United States|Houston Methodist Hospital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04358549"
804,"NCT04367168","Colchicine Twice Daily During 10 Days as an Option for the Treatment of Symptoms Induced by Inflammation in Patients With Mild and Severe Coronavirus Disease","ColchiVID","Recruiting","No Results Available","COVID","Drug: Colchicine|Drug: Placebo oral tablet","Number of patients with improvement in body temperature, myalgia, arthralgia, total lymphocyte count, D-dimer, fibrinogen and ferritin levels|Progression to severe disease","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","174","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","337420-21-1","May 27, 2020","April 27, 2021","April 27, 2021","April 29, 2020",,"May 28, 2020","Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT04367168"
805,"NCT04374149","Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS",,"Not yet recruiting","No Results Available","Cytokine Release Syndrome|COVID19","Procedure: Therapeutic Plasma Exchange|Drug: Ruxolitinib","Overall Response Rate","Prisma Health-Upstate","All","12 Years to 80 Years   (Child, Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PHU COVID-19-001","April 30, 2020","September 1, 2020","April 30, 2021","May 5, 2020",,"May 5, 2020",,,"https://ClinicalTrials.gov/show/NCT04374149"
806,"NCT04357834","WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories","WAVE","Not yet recruiting","No Results Available","COVID|COVID 19|SARS-CoV 2","Other: Equipment with smartwatch throughout hospital stay on the general ward","Diagnostic accuracy of smartwatch data in predicting ICU requirement in COVID-19 contracted inpatients quantified as the area under the receiver operator characteristics curve (AUC ROC > 0.85).|Diagnostic accuracy of routine physiological data in predicting ICU requirement in COVID-19 contracted in-patients quantified as the area under the receiver operator characteristics curve (AUC ROC > 0.85).|Diagnostic accuracy of predicting hospital discharge without ICU admission in COVID-19 contracted in-patients quantified as area under the receiver operator characteristics curve|Change of heart rate from baseline (hospitalization) to ICU admission|Change of heart rate variability from baseline (hospitalization) to ICU admission|Change of skin temperature from baseline (hospitalization) to ICU admission|Change of blood oxygen saturation from baseline (hospitalization) to ICU admission|Change of respiration rate from baseline (hospitalization) to ICU admission|Change of physical activity from baseline (hospitalization) to ICU admission|Change of stress level from baseline (hospitalization) to ICU admission|Change of sleep pattern from baseline (hospitalization) to ICU admission|Change of steps per day from baseline (hospitalization) to ICU admission|Change of systolic blood pressure from baseline (hospitalization) to ICU admission|Change of diastolic blood pressure from baseline (hospitalization) to ICU admission|Change of body temperature from baseline (hospitalization) to ICU admission|Change of oxygen partial pressure (pO2) from baseline (hospitalization) to ICU admission|Change of CO2 partial pressure (pCO2) from baseline (hospitalization) to ICU admission|Change of blood pH from baseline (hospitalization) to ICU admission|Change of bicarbonate from baseline (hospitalization) to ICU admission|Change of base excess from baseline (hospitalization) to ICU admission|Change of oxygen flow rate from baseline (hospitalization) to ICU admission","University Hospital Inselspital, Berne|ETH Zurich","All","18 Years to 120 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Other|Time Perspective: Prospective","WAVE","May 1, 2020","July 31, 2020","July 31, 2020","April 22, 2020",,"April 24, 2020","Emergency Department, University Hospital Bern, Inselspital, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT04357834"
807,"NCT04373759","Cardiac Arrest Incidence and Outcome Among Patients With COVID-19 in French ICUs","ACICOVID","Recruiting","No Results Available","Sars-CoV2|Covid-19","Other: Cardiopulmonary resuscitation|Other: Modified Rankin score","Incidence of unexpected cardiac arrest|Charlson score|Organ failure score at ICU admission and/or before unexpected in-ICU cardiac arrest|Etiology retained to explain cardiac arrest occurrence|Modified Rankin score (mRS) at ICU discharge, at hospital discharge and at 3 months","Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-CHITS-004","May 2, 2020","September 2020","December 2020","May 4, 2020",,"June 24, 2020","CHU Felix Guyon, Saint-Denis, La Reunion, France|CHU Amiens Picardie, Amiens, France|CH Angoulème, Angoulême, France|CH Argenteuil, Argenteuil, France|CH Bethune, Beuvry, France|CHU Ambroise Paré AP-HP, Boulogne-Billancourt, France|CH Brive, Brive-la-Gaillarde, France|CHU Caen, Caen, France|Hôpital Privé St Martin, Caen, France|CH Cahors, Cahors, France|CHU Antoine Béclère AP-HP, Clamart, France|CH Louis Mourier AP-HP, Colombes, France|CHU Henri Mondor AP-HP, Créteil, France|CHU Dijon, Dijon, France|CH de la Dracénie, Draguignan, France|CHI Frejus St Raphael, Fréjus, France|Grand Hôpital de l'Est Francilien, Jossigny, France|CH La Rochelle, La Rochelle, France|CHU Grenoble-Alpes, La Tronche, France|CH Versailles, Le Chesnay, France|CHU Kremlin Bicêtre, Le Kremlin-Bicêtre, France|CH Lens, Lens, France|CHRU Roger Salengro, Lille, France|CH Sambre Avesnois, Maubeuge, France|CHU Meaux, Meaux, France|Groupe Hospitalier Sud Ile de France, Melun, France|CHU Montpellier, Montpellier, France|CHR Orléans, Orléans, France|CHU Lariboisière AP-HP, Paris, France|CHU Saint Louis AP-HP, Paris, France|CHU St Antoine, Paris, France|Groupe Hospitalier Saint Joseph, Paris, France|CHU Necker Enfants Malades, Paris, France|Groupe Hospitalier Diaconesse Croix Saint-Simon, Paris, France|Hôpital Privé Claude Galien, Quincy-sous-Sénart, France|CHU Rouen, Rouen, France|Centre Hospitalier Intercommunal Toulon La Seyne sur Mer, Toulon, France|Hôpital Nord Franche Comté, Trévenans, France|Institut Gustave Roussy, Villejuif, France|CH Etampes, Étampes, France|CHU Martinique - Fort de France, Fort-de-France, Martinique",,"https://ClinicalTrials.gov/show/NCT04373759"
808,"NCT04359992","Study of Hemostasis in Case of Severe COVID-19","THROMBOVID","Not yet recruiting","No Results Available","COVID-19 Infection","Other: Extra blood sample","Platelet activation intensity with the occurrence of clinical thrombotic complications","University Hospital, Strasbourg, France","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","7774","April 17, 2020","April 17, 2021","May 1, 2021","April 24, 2020",,"April 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04359992"
809,"NCT04428021","Standard or Convalescent Plasma in Patients With Recent Onset of COVID-19 Respiratory Failure","PLACO-COVID","Not yet recruiting","No Results Available","COVID-19","Drug: Standard Therapy Protocol (STP)|Other: STP + Standard Plasma (SP)|Other: STP + COVID-19 Convalescent Plasma (CP)","30-days survival|Ventilator free survival|6-months survival|Incidence of complications|Days in intensive care units (ICU)|Positivity for Immunoglobulin G to SARS-Cov-2|Clearance of viral load|Sequential Organ Failure Assessment (SOFA) score|Any variation from Standard Therapy Protocol","Azienda Ospedaliera Città della Salute e della Scienza di Torino","All","18 Years and older   (Adult, Older Adult)","Phase 2","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","CS3/33","June 15, 2020","June 15, 2021","December 15, 2021","June 11, 2020",,"June 11, 2020",,,"https://ClinicalTrials.gov/show/NCT04428021"
810,"NCT04401228","Predictive Models for Intensive Care Admission and Death of COVID-19",,"Active, not recruiting","No Results Available","COVID19|Pneumonia, Viral|Inflammatory Response","Other: predict admission of covid-19 patients to ICU and death with routine and quickly avalaible clinical, biological and radiological variables?","admission to ICU|death","Clinique Saint Pierre Ottignies","All","18 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","0410508057","March 1, 2020","May 1, 2020","January 1, 2021","May 26, 2020",,"May 26, 2020","Clinique Saint-Pierre, Ottignies, Brabant Wallon, Belgium",,"https://ClinicalTrials.gov/show/NCT04401228"
811,"NCT04411784","PROTECT-ASUC: Covid-19 Pandemic Response Of assessmenT, EndosCopy and Treatment in Acute Severe Ulcerative Colitis","PROTECT-ASUC","Active, not recruiting","No Results Available","Inflammatory Bowel Diseases|COVID",,"Primary outcome measure: The need for in-hospital colectomy or rescue therapy|2.1: Duration and type/route of steroid use|2.2: 30 day colectomy free survival rates|2.3: Covid-19 infection rates|2.4: Rate of Rescue therapy use|2.5: Duration of hospital stay|2.6: Admission severity scoring|2.7: Readmission rates","Hull University Teaching Hospitals NHS Trust","All","16 Years to 100 Years   (Child, Adult, Older Adult)",,"200","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","284030","May 20, 2020","July 2020","July 2020","June 2, 2020",,"June 2, 2020","Gastroenterology, Hull Royal Infirmary, Hull University Teaaching Hospitals NHS Trust, Hull, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04411784"
812,"NCT04374591","Home-based Treatment of Computed Tomography and Clinically Suspected Novel COVID-19 With Adjuvant Inhalable Sodium Bicarbonate: A Preliminary Case Series",,"Active, not recruiting","No Results Available","Pneumonia|Covid19","Drug: Sodium Bicarbonate","Time to clinical recovery|Pulmonary recovery status","Mansoura University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Sodium Bicarbonate COVID-19","April 1, 2020","June 1, 2020","June 1, 2020","May 5, 2020",,"May 27, 2020","Gomhoria Street, Mansoura, Outside U.S./Canada, Egypt",,"https://ClinicalTrials.gov/show/NCT04374591"
813,"NCT04368728","Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults",,"Recruiting","No Results Available","SARS-CoV-2 Infection|COVID-19","Biological: BNT162a1|Biological: BNT162b1|Biological: BNT162b2|Biological: BNT162c2|Other: Placebo","Percentage of participants reporting local reactions|Percentage of participants reporting systemic events|Percentage of participants reporting adverse events|Percentage of participants reporting serious adverse events|Percentage of sentinel cohort participants with abnormal hematology and chemistry laboratory values|Percentage of sentinel cohort participants with grading shifts in hematology and chemistry laboratory assessments|SARS-CoV-2-specific WT serum neutralizing antibody levels, expressed as GMTs|GMFR in SARS-CoV-2-specific WT serum neutralizing titers from before vaccination to each subsequent time point|Proportion of participants achieving a greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2-specific WT serum neutralizing antibody levels|SARS-CoV-2--spike protein-specific binding antibody levels and RBD-specific binding antibody levels, expressed as GMCs|Proportion of participants achieving a greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2--spike protein-specific binding antibody levels and RBD-specific binding antibody levels|GMFR in SARS-CoV-2-spike protein-specific binding antibody levels and RBD-specific binding antibody levels from before vaccination to each subsequent time point|GMR of the geometric mean of SARS-CoV-2-specific WT serum neutralizing titers to the geometric mean of SARS CoV 2 (spike protein and RBD) specific binding antibody levels|Confirmed COVID-19 incidence","Biontech SE|Pfizer","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","7600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","C4591001|2020-002641-42","April 29, 2020","June 28, 2021","January 23, 2023","April 30, 2020",,"June 29, 2020","Diablo Clinical Research, Inc., Walnut Creek, California, United States|Research Centers of America, Hollywood, Florida, United States|Clinical Neuroscience Solutions, Inc, Orlando, Florida, United States|Meridian Clinical Research, LLC, Savannah, Georgia, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|Kentucky Pediatric/ Adult Research, Bardstown, Kentucky, United States|University of Maryland, Center for Vaccine Development and Global Health, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Investigational Pharmacy Service, Boston, Massachusetts, United States|Sundance Clinical Research, LLC, Saint Louis, Missouri, United States|Meridian Clinical Research, LLC, Norfolk, Nebraska, United States|Quality Clinical Research, Inc., Omaha, Nebraska, United States|NYU Langone Health, New York, New York, United States|Rochester Clinical Research, Inc., Rochester, New York, United States|Rochester Regional Health/Rochester General Hospital, Rochester, New York, United States|M3 Wake Research, Inc., Raleigh, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Aventiv Research Inc., Columbus, Ohio, United States|Benchmark Research, Austin, Texas, United States|Ventavia Research Group, LLC, Fort Worth, Texas, United States|Texas Center For Drug Development, Inc., Houston, Texas, United States|J. Lewis Research, Inc. / Foothill Family Clinic, Salt Lake City, Utah, United States|J. Lewis Research, Inc. / Foothill Family Clinic South, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04368728"
814,"NCT04415060","SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival","SAVE-ICU","Not yet recruiting","No Results Available","Covid19","Drug: Isoflurane Inhalant Product|Drug: Sevoflurane inhalant product","Hospital Mortality|Ventilator-Free Days|ICU-Free Days|Participant Quality of Life at 3 and 12 months after discharge|Median Daily Oxygenation|Adjunctive ARDS therapies|Hospital-Free Days|Disability|Cost Utility Analysis|Cost Effectiveness Analysis","Sunnybrook Health Sciences Centre","All","18 Years and older   (Adult, Older Adult)","Phase 3","752","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2149","June 15, 2020","June 15, 2022","June 15, 2022","June 4, 2020",,"June 26, 2020","University of Alberta Hospital, Edmonton, Alberta, Canada|London Health Sciences Centre - University Hospital, London, Ontario, Canada|London Health Sciences Centre - Victoria Hospital, London, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|University Health Network - Toronto General Hospital, Toronto, Ontario, Canada|Centre hospitalier de l'Université de Montréal, Montréal, Quebec, Canada|Universite de Sherbrooke, Sherbrooke, Quebec, Canada|University Health Network - Toronto Western Hopsital, Toronto, Canada",,"https://ClinicalTrials.gov/show/NCT04415060"
815,"NCT04422626","Data Analysis of the Cytokine Adsorption Treatment on Coronavirus Disease-19 (COVID-19) Patients With Respiratory Failure","CYTOAID","Not yet recruiting","No Results Available","SARS-CoV-2|COVID-19",,"Change in the partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) ratio after CytoSorb therapy|Change in inflammatory biomarker levels during treatment|change in organ function|length of stay in ICU|length of hospital stay|Duration of mechanical ventilation|Duration of vasopressor therapy|Duration of renal replacement therapy|Occurrence of critical illness polyneuropathy and/or myopathy|need for extracorporeal membrane oxygenation (ECMO)|cost calculation|device-related adverse and serious adverse events|In-hospital mortality","University of Pecs","All","18 Years and older   (Adult, Older Adult)",,"42","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20802-5/2020/EÜIG","July 1, 2020","July 1, 2022","December 1, 2022","June 9, 2020",,"June 11, 2020",,,"https://ClinicalTrials.gov/show/NCT04422626"
816,"NCT04428268","Chloroquine + Losartan Compared to Chloroquine Alone for the Treatment of COVID-19 Pneumonia",,"Recruiting","No Results Available","COVID-19 Pneumonia","Drug: Chloroquine Phosphate Tablets","Overall mortality|Clinical outcome assessment|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Time to negative SARS-CoV-2 test","Hospital Universitario Dr. Jose E. Gonzalez","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IF20-00003","March 10, 2020","June 10, 2020","August 30, 2020","June 11, 2020",,"June 16, 2020","Hospital Universitario José E. Gonzalez, Monterrey, Nuevo Leon, Mexico",,"https://ClinicalTrials.gov/show/NCT04428268"
817,"NCT04349410","The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol","FMTVDM","Enrolling by invitation","No Results Available","CoVid 19 Positive","Drug: Hydroxychloroquine, Azithromycin|Drug: Hydroxychloroquine, Doxycycline|Drug: Hydroxychloroquine, Clindamycin|Drug: Hydroxychloroquine, Clindamycin, Primaquine - low dose.|Drug: Hydroxychloroquine, Clindamycin, Primaquine - high dose.|Drug: Remdesivir|Drug: Tocilizumab|Drug: Methylprednisolone|Drug: Interferon-Alpha2B|Drug: Losartan|Drug: Convalescent Serum","Improvement in FMTVDM Measurement with nuclear imaging.|Ventilator status|Survival status","The Camelot Foundation","All","Child, Adult, Older Adult","Phase 2|Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","FMTVDM2020","April 11, 2020","October 11, 2020","November 11, 2020","April 16, 2020",,"April 17, 2020","FHHI-OI-Camelot; QME, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04349410"
818,"NCT04376996","Slovenian National COVID-19 Prevalence Study","SLO-COVID-19","Recruiting","No Results Available","COVID-19|SARS-CoV-2","Diagnostic Test: NO intervention planned due to the observational study design - only a diagnostic testing","Prevalence of SARS-CoV-2 RNA in nasopharyngeal samples|Prevalence of anti-SARS-CoV-2 antibodies in blood samples","University of Ljubljana","All","Child, Adult, Older Adult",,"3000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ULMF2020-COVID-19","April 20, 2020","October 2020","December 2020","May 6, 2020",,"May 7, 2020","University of Ljubljana, Ljubljana, Slovenia",,"https://ClinicalTrials.gov/show/NCT04376996"
819,"NCT04371029","Impact of Neck Inspiratory Muscle Activation During Sleep in ICU Patients After a COVID 19 ARDS","COVISLEEP","Recruiting","No Results Available","ARDS|COVID-19","Other: PSG","Proportion of patients with altered spleep|Sleep architecture at hospital discharge|Sleep monitoring during hospital stay after ICU discharge|Sleep quality|Sleep architecture at month-3|Cost of ICU hospitalization","University Hospital, Bordeaux","All","18 Years and older   (Adult, Older Adult)","Not Applicable","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","CHUBX 2020/14","April 28, 2020","September 28, 2020","December 28, 2020","May 1, 2020",,"June 12, 2020","Hopital Pellegrin, Bordeaux, France",,"https://ClinicalTrials.gov/show/NCT04371029"
820,"NCT04410562","Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy","COVID-Preg","Recruiting","No Results Available","Pregnancy Related|COVID|Covid-19","Drug: Hydroxychloroquine|Drug: Placebo","Number of PCR confirmed cases among pregnant women|Incidence of COVID-19 disease during pregnancy|Incidence of COVID-19-related admissions|Incidence of all-cause admissions|Incidence of all-cause outpatient attendances|Mean duration of symptoms-signs of COVID-19|Frequency and severity of adverse events|Incidence of preeclampsia|Incidence of gestational diabetes|Incidence of SARS-CoV-2 infections during pregnancy|Prevalence of intrauterine growth restriction|Maternal mortality rate|Proportion of neonates with SARS-CoV-2- intrauterine infection by PCR-confirmed SARS-CoV-2-infection in nasopharyngeal aspirate.|Proportion of neonates with clinical signs/symptoms of COVID-19|Prevalence of low birth weight (<10th centile according to local standards)|Prevalence of preterm birth (<37 weeks of gestational age)|Prevalence of embryo and foetal losses (miscarriages and stillbirths)|Frequency of congenital malformations|Proportion of adverse perinatal outcome|Neonatal morbidity|Neonatal mortality rate","Barcelona Institute for Global Health|Hospital Clinic of Barcelona|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|University Hospital of Torrejon|Fundación de investigación HM","Female","Child, Adult, Older Adult","Phase 3","714","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020-001587-29","May 13, 2020","May 13, 2021","August 1, 2021","June 1, 2020",,"June 1, 2020","Hospital Sant Creu i Sant Pau, Barcelona, Catalunya, Spain|Hospital Clínic Maternity, Barcelona, Catalunya, Spain|University hospital of Torrejón, Madrid, Spain|HM Puerta del Sur, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04410562"
821,"NCT04361032","Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia","TRONCHER","Not yet recruiting","No Results Available","COVID19|Intensive Care Unit","Drug: Tocilizumab Injection|Drug: Deferoxamine","the mortality rate","Abderrahmane Mami Hospital|Eshmoun Clinical Research Centre|Datametrix","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","260","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ECC2020-06","May 4, 2020","September 4, 2020","October 4, 2020","April 24, 2020",,"May 6, 2020","Eshmoun Clinical Research Centre/ Hôpital Abderrahmane Mami-Ariana, Ariana, Tunisia",,"https://ClinicalTrials.gov/show/NCT04361032"
822,"NCT04426084","Cardiovascular Risk Factors and Severe COVID-19. A Nationwide Registry-based Case-Control Study",,"Active, not recruiting","No Results Available","COVID-19","Other: Hypertension|Other: Diabetes type 2|Other: Obesity|Drug: Antihypertensive Agents|Drug: Statins (Cardiovascular Agents)","Severe Covid-19|Severe Covid-19 with pulmonary embolism|CRRT(Continuous Renal Replacement Therapy)|ECMO (Extracorporeal Membrane Oxygenation )|ICU Mortality","Karolinska Institutet","All","18 Years and older   (Adult, Older Adult)",,"22784","Other","Observational","Observational Model: Case-Control|Time Perspective: Other","4","March 1, 2020","May 11, 2020","December 31, 2022","June 11, 2020",,"June 11, 2020","Södersjukhuset, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT04426084"
823,"NCT04385199","Convalescent Plasma for Patients With COVID-19",,"Recruiting","No Results Available","Coronavirus Infection|Coronavirus|COVID","Biological: Convalescent plasma","Improvement in respiratory disease|ICU Length of Stay|Length of Stay|Ventilator days|Tolerability of convalescent plasma|Radiographic improvement","Henry Ford Health System","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13807","May 4, 2020","August 1, 2020","August 1, 2020","May 12, 2020",,"May 12, 2020","Henry Ford Hospital, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT04385199"
824,"NCT04374370","SARSCoV2 (COVID-19) Convalescent Plasma (CP) Expanded Access Protocol (EAP)",,"Available","No Results Available","COVID|SARSCoV2 Convalescent Plasma","Biological: SARSCoV2 Convalescent Plasma",,"AdventHealth","All","6 Years to 99 Years   (Child, Adult, Older Adult)",,,"Other","Expanded Access:Intermediate-size Population",,"1596191",,,,"May 5, 2020",,"May 5, 2020","AdventHealth Orlando, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04374370"
825,"NCT04375709","Quality of Life and Physical Performance After Novel Coronavirus Infection (COVID-19);",,"Recruiting","No Results Available","Covid-19 (New Coronavirus) Infection","Other: Physical exercise|Behavioral: Education sessions","Health-related quality of life; EuroQoL (EQ-5D-5L)|6-minute walk test|Jamar dynamometer|Hospital Anxiety and Depression Scale (HADS)|revised Impact of Event Scale (IES-R)|Mini-Nutritional Assessment (MNA)|Spirometry (bed-side)|Post-Covid Functional Scale (PCFS)|modified Medical Research Council Dyspnoea Scale (mMRC Dyspnoea)","Kantonsspital Winterthur KSW","All","18 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020_00899 / COV19_2020","March 15, 2020","June 30, 2021","August 31, 2021","May 5, 2020",,"May 12, 2020","Kantonsspital Winterthur, Winterthur, Zürich, Switzerland",,"https://ClinicalTrials.gov/show/NCT04375709"
826,"NCT04327531","Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey Study",,"Completed","No Results Available","COVID-19|Physician-Patient Relations","Behavioral: turkish physicians","Evaluation of covid-19 knowledge level of turkish physicians|what they think about the future","Kanuni Sultan Suleyman Training and Research Hospital","All","25 Years to 55 Years   (Adult)",,"200","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","turkishcovid19","March 26, 2020","May 22, 2020","May 28, 2020","March 31, 2020",,"June 5, 2020","Pinar Yalcin Bahat, Istanbul, İ̇stanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04327531"
827,"NCT04377464","COVID-19 - Quality of Life After Infection",,"Not yet recruiting","No Results Available","COVID-19|Quality of Life","Other: SF12, EQ-5D-5L and work status standardized quantitative assessments","Six-month SF-12v2(HK) Scores|Six-month EQ-5D-5L Scores|One-month SF-12v2(HK)|One-month EQ-5D-5L Scores|Three-month SF-12v2(HK) Scores|Three-month EQ-5D-5L Scores|One, Three and Six-month Return to Work Status","Chinese University of Hong Kong","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NTEC-2020-0227","May 5, 2020","April 30, 2021","April 30, 2022","May 6, 2020",,"May 6, 2020",,"""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT04377464/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT04377464/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04377464"
828,"NCT04391309","IC14 (Anti-CD14) Treatment in Patients With SARS-CoV-2 (COVID-19)",,"Not yet recruiting","No Results Available","SARS-CoV2","Biological: IC14|Other: Placebo","Acute respiratory failure|Time to clinical improvement|Invasive mechanical ventilation|Hospitalization|Sequential Organ Failure Assessment|Ordinal Scale|Time to clinical improvment|Time to recovery|Change in C-reactive protein|Adverse events|Serious adverse events","Implicit Bioscience|University of Washington","All","18 Years and older   (Adult, Older Adult)","Phase 2","300","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COV04","July 2020","July 2021","September 2021","May 18, 2020",,"June 24, 2020","University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04391309"
829,"NCT04425889","COVID-19 Antibodies Among Healthcare Workers",,"Completed","No Results Available","COVID-19|SARS-CoV 2","Diagnostic Test: COVID-19 IgG/IgM Rapid Test Cassette test (Healgen Scientific, Houston, Texas, USA)","Presence of antibody","Hospital Universitario Dr. Jose E. Gonzalez","All","18 Years to 99 Years   (Adult, Older Adult)",,"156","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","IF20-00008","May 5, 2020","May 30, 2020","June 1, 2020","June 11, 2020",,"June 12, 2020","Hospital Universitario José E. Gonzalez, Monterrey, Nuevo Leon, Mexico",,"https://ClinicalTrials.gov/show/NCT04425889"
830,"NCT04355364","Efficacy and Safety of Aerosolized Intra-tracheal Dornase Alfa Administration in Patients With COVID19-induced ARDS (COVIDORNASE)","COVIDORNASE","Recruiting","No Results Available","COVID-19|Acute Respiratory Distress Syndrome","Drug: Dornase Alfa Inhalation Solution [Pulmozyme]|Procedure: standard procedure","Efficacy of intratracheal administration: occurrence of at least one grade improvement","Fondation Ophtalmologique Adolphe de Rothschild|University Hospital, Strasbourg, France|Centre Hospitalier Régional Metz-Thionville","All","18 Years and older   (Adult, Older Adult)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CGE_2020_9","April 21, 2020","August 21, 2020","August 21, 2020","April 21, 2020",,"June 1, 2020","Hôpital Fondation A. de Rotschhild, Paris, France",,"https://ClinicalTrials.gov/show/NCT04355364"
831,"NCT04364802","COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients","PIIPPI","Recruiting","No Results Available","COVID-19|SARS-CoV 2","Drug: Povidone-Iodine Nasal Spray and Gargle","Percent of healthcare workers testing positive for COVID-19.|Percent of patients testing positive for COVID-9.|PVP-I Ease of Use|PVP-I Comfort","Alexandra Kejner|University of Kentucky","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","250","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","58748","April 29, 2020","May 2021","May 2021","April 28, 2020",,"May 14, 2020","University of Kentucky, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT04364802"
832,"NCT04409925","DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1)","DISCONNECT-1","Not yet recruiting","No Results Available","COVID-19 Infection","Drug: rhDNase I","Safety of inhaled rhDNase1 in non-ventilated COVID-19 patients by reporting of adverse events: rate of all adverse events, rate of serious adverse events, rate of grade 3/4/5 adverse events, drug-related adverse events.|Time to first study participant enrolment|Enrolment rate|Eligible patient consent rate|Completeness of drug delivery|Completeness of study-specific tests or procedures|Completeness of data collection|Hypoxia rate|Supplemental oxygen requirement type|Progression to mechanical ventilation rate|Duration of mechanical ventilation|Radiological progression|Renal dysfunction rate|Renal dysfunction extent|Time to hospital discharge or in-hospital mortality|Overall safety of health care workers and study personnel|Daily safety of health care workers and study","Exactis Innovation|Jewish General Hospital|Hamilton Health Sciences Corporation|McGill University Health Centre/Research Institute of the McGill University Health Centre|Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 1","25","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DISCONNECT-1","June 2020","August 2020","January 2021","June 1, 2020",,"June 17, 2020",,,"https://ClinicalTrials.gov/show/NCT04409925"
833,"NCT04325061","Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19","DEXA-COVID19","Recruiting","No Results Available","Acute Respiratory Distress Syndrome Caused by COVID-19","Drug: Dexamethasone","60-day mortality|Ventilator-free days","Dr. Negrin University Hospital|Li Ka Shing Knowledge Institute|Consorcio Centro de Investigación Biomédica en Red, M.P.","All","18 Years and older   (Adult, Older Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-001278-31","April 3, 2020","October 30, 2020","October 30, 2020","March 27, 2020",,"April 17, 2020","ICU, Hospital Universitari Mutua Terrassa, Terrassa, Barcelona, Spain|Hospital Universitario Dr. Negrin, Las Palmas de Gran Canaria, Las Palmas, Spain|Department of Anesthesia, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain|Intensive Care Unit, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain|AVI, Hospital Clinic, Barcelona, Spain|Cardiac ICU, Hospital Clinic, Barcelona, Spain|Department of Anesthesia, Hospital Clinic, Barcelona, Spain|Hepatic ICU, Hospital Clínic, Barcelona, Spain|UVIR, Hospital Clinic, Barcelona, Spain|Intensive Care Unit, Hospital General de Ciudad Real, Ciudad Real, Spain|Department of Anesthesia, Hospital Universitario La Princesa, Madrid, Spain|Intensive Care Unit, Hospital Universitario La Princesa, Madrid, Spain|Intensive Care Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Department of Anesthesia, Hospital Universitario La Paz, Madrid, Spain|Intensive Care Unit, Hospital Universitario La Paz, Madrid, Spain|Department of Anesthesia, Hospital Universitario Virgen de Arrixaca, Murcia, Spain|Intensive Care Unit, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Department of Anesthesia, Hospital Unversitario Montecelo, Pontevedra, Spain|Anesthesia, Hospital General Universitario de Valencia, Valencia, Spain|Department of Anesthesia, Hospital Clinico Universitario, Valencia, Spain|Intensive Care Unit, Hospital Clinico Universitario, Valencia, Spain|Department of Anesthesia, Hospital Clínico Universitario, Valladolid, Spain|Anesthesia, Hospital Universitario Río Hortega, Valladolid, Spain|Intensive Care Unit, Hospital Universitario Río Hortega, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT04325061"
834,"NCT04362137","Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)","RUXCOVID","Recruiting","No Results Available","Cytokine Storm (Covid-19)","Drug: Ruxolitinib|Drug: Placebo","Proportion of patients who die, develop respiratory failure [require mechanical ventilation] or require intensive care unit (ICU) care|Clinical status|Percentage of patients with at least two-point improvement from baseline in clinical status|Percentage of patients with at least one-point improvement from baseline in clinical status|Percentage of patients with at least one-point deterioration from baseline in clinical status|Time to improvement in clinical status|Mean change from baseline in the clinical status|Mortality rate|Proportion of patients requiring mechanical ventilation|Duration of hospitalization|Time to discharge or to a NEWS2 score of ≤2|Change from baseline in NEWS2 score|Change from baseline in SpO2/FiO2 ratio.|Proportion of patients with no oxygen therapy","Novartis Pharmaceuticals|Incyte Corporation|Novartis","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","402","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CINC424J12301|INCB 18424-368|2020-001662-11","March 31, 2020","October 22, 2020","October 23, 2020","April 24, 2020",,"June 26, 2020","Novartis Investigative Site, Aurora, Colorado, United States|Novartis Investigative Site, Stamford, Connecticut, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Newark, New Jersey, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Madison, Wisconsin, United States|Novartis Investigative Site, Aachen, Germany|Novartis Investigative Site, Lubeck, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Nuernberg, Germany|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Sestroretsk, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain|Novartis Investigative Site, Barcelona, Cataluna, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Blackpool, United Kingdom|Novartis Investigative Site, Harrow, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04362137"
835,"NCT04355533","Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19","PED-COVID","Not yet recruiting","No Results Available","COVID-19 Infection","Biological: serology test|Diagnostic Test: NG Biotech|Biological: nasopharyngeal swab|Biological: rectal swab|Biological: saliva sample","Seroconversion against SARS-CoV2 in children of the Parisian area|Protective immunity|Measure of Ab antiN and Ab anti-S1|Neutralization activity|Positive qPCR|correlation between different Ab and qPCR and neutralization activity|correlation of the NGBiotech rapid test with the classical serological result|correlation of the NGBiotech rapid test with qPCR results|duration of viral carriage in stool, saliva and or nasopharynx|correlation between antibody profile and viral clearance|Ab profile and memory of immunity|saliva biofluid characteristics of COVID-19 infected|correlation of LIPS, the NGBiotech rapid test with the classical serological result|Presence of COVID-19 Symptom|seroconversion against SARS-CoV2 in parents of the Parisian area|Intra-family correlation of serological results|Measure of Ab antiN and Ab anti-S1 and neutralization activity|correlation between different Ab and qPCR","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France|NG Biotech|Commissariat a l’energie atomique et aux energies alternatives|Institut Pasteur","All","up to 17 Years   (Child)","Not Applicable","1920","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","APHP200467|2020-A00999-30","June 2020","June 2020","September 2021","April 21, 2020",,"May 20, 2020","Hôpital necker Enfants-Malades, ¨Paris, France",,"https://ClinicalTrials.gov/show/NCT04355533"
836,"NCT04365959","The Prone Position in Covid-19 Affected Patients","PRON-COVID","Active, not recruiting","No Results Available","Sars-CoV2","Procedure: Prone position","Number of patients in whom the prone position caused an increase in oxygenation|The feasibility of prone position","University of Milano Bicocca","All","18 Years to 75 Years   (Adult, Older Adult)",,"56","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PRON-COVID","March 20, 2020","April 9, 2020","May 31, 2020","April 28, 2020",,"April 28, 2020","ASST Monza, Monza, MB, Italy",,"https://ClinicalTrials.gov/show/NCT04365959"
837,"NCT04333862","Assessment of Covid-19 Infection Rates in Healthcare Workers Using a Desynchronization Strategy","Covid-19","Recruiting","No Results Available","SARS-CoV-2",,"Fraction of healthcare workers infected with SARS-CoV-2|Fraction of healthcare workers with COVID-19|Number of patients infected in the hospital|Development of SARS-CoV2 specific antibody repertoire","University Hospital Inselspital, Berne","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-00563","March 19, 2020","June 30, 2020","December 31, 2021","April 3, 2020",,"April 3, 2020","Guido Beldi, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT04333862"
838,"NCT04273646","Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19",,"Not yet recruiting","No Results Available","2019 Novel Coronavirus Pneumonia|COVID-19","Biological: UC-MSCs|Drug: Placebo","Pneumonia severity index|Oxygenation index (PaO2/FiO2)|Side effects in the UC-MSCs treatment group|28-days survival|Sequential organ failure assessment|C-reactive protein|Procalcitonin|Lymphocyte count|CD3+, CD4+ and CD8+ T celll count|CD4+/CD8+ratio","Wuhan Union Hospital, China|Wuhan Hamilton Bio-technology Co., Ltd, China.","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","202001","April 20, 2020","June 30, 2020","February 15, 2022","February 18, 2020",,"April 14, 2020","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04273646"
839,"NCT04315896","Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial)","HYDRA","Recruiting","No Results Available","COVID-19|Severe Acute Respiratory Syndrome","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","All-cause hospital mortality|Length of hospital stay|Need of mechanical ventilation|Ventilator free days|Grade 3-4 adverse reaction","National Institute of Respiratory Diseases, Mexico|Sanofi","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","500","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HidroxycloroquinaCOVID19","April 14, 2020","October 31, 2020","March 22, 2021","March 20, 2020",,"April 17, 2020","Instituto Nacional de Enfermedades Respiratorias, ""Ismael Cosío Villegas"", Mexico, City, Mexico",,"https://ClinicalTrials.gov/show/NCT04315896"
840,"NCT04384250","Genetic Basis of COVID-19 Infection",,"Recruiting","No Results Available","Genetic Basis of COVID-19 Infection","Diagnostic Test: Whole Exome Sequencing","Mutations leading to increase susceptibility to SARS-COV-2 infection","Mansoura University","All","up to 50 Years   (Child, Adult)",,"50","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","RP:20.05.70","May 10, 2020","August 31, 2020","May 1, 2021","May 12, 2020",,"May 12, 2020","Mansoura University, Mansoura, Dakahlyia, Egypt",,"https://ClinicalTrials.gov/show/NCT04384250"
841,"NCT04408209","Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection",,"Recruiting","No Results Available","COVID-19 Infection","Procedure: Convalescent Plasma","Survival|Clinical improvement ie percentage of patients not fulfilling the criteria for severe disease","National and Kapodistrian University of Athens|Hellenic Society of Hematology","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","245-14-4-20","April 23, 2020","June 30, 2020","September 15, 2021","May 29, 2020",,"June 2, 2020","""Evangelismos"" General Hospital, Athens, Attiki, Greece|""Agios Savas"" Oncology Hospital, Athens, Attiki, Greece|""Alexandra"" General Hospital, Athens, Attiki, Greece|""Sotiria"" General Hospital, Athens, Attiki, Greece|Attikon"" University General Hospital, Athens, Chaidari, Greece|University General Hospital of Patras, Patra, Rio, Greece",,"https://ClinicalTrials.gov/show/NCT04408209"
842,"NCT04347369","A Retrospective Study of Neural Network Model to Dynamically Quantificate the Severity in COVID-19 Disease",,"Recruiting","No Results Available","COVID-19 Disease","Other: other","discrimination|Calibration|Net benefit","Xinqiao Hospital of Chongqing","All","18 Years to 80 Years   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","XQonc-015","January 17, 2020","April 30, 2020","May 31, 2020","April 15, 2020",,"April 15, 2020","Xinqiao Hospital of Chongqing, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT04347369"
843,"NCT04381858","Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia",,"Recruiting","No Results Available","COVID-19 Pneumonia","Drug: Plasma from COVID-19 convalescent patient|Drug: Human immunoglobulin","Mean hospitalization time|Mean Oxigenation index evolution|Rate of severe ARDS|Rate and time to dead|Mean time with invasive mechanical ventilation|Time to Viral PCR Negativization","Centenario Hospital Miguel Hidalgo","All","16 Years to 90 Years   (Child, Adult, Older Adult)","Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","2020-A-10","May 6, 2020","August 30, 2020","September 30, 2020","May 11, 2020",,"May 12, 2020","Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico",,"https://ClinicalTrials.gov/show/NCT04381858"
844,"NCT04410107","Lung Function, Exercise Capacity and Health-Related Quality of Life After Severe COVID-19",,"Recruiting","No Results Available","COVID-19|SARS-CoV-2 Infection","Diagnostic Test: Lung Function tests|Diagnostic Test: Exercise capacity|Diagnostic Test: Exercise physiology|Diagnostic Test: Health-related quality of life|Diagnostic Test: Respiratory symptoms, symptoms of anxiety and depression, and post-traumatic stress screening","Forced expiratory volume in the first second/forced vital capacity|Total lung capacity|Lung diffusion capacity for carbon monoxide|6-minute walk test distance|Short-form 36 questionnaire (SF-36)|Forced vital capacity|Residual volume/total lung capacity|Inspiratory capacity/total lung capacity|Airway resistance (Raw)|Resistance at 20Hz and 5Hz (R5-R20)|Reactance at 5Hz (X5)|Resonant frequency (Fres)|Reactance area (AХ)|Pulse oximetry (SpO2) at rest|Pulse oximetry (SpO2) during exercise|Respiratory symptoms adapted from American Thoracic Society Questionnaire|Oxygen uptake at peak exercise|Minute-ventilation/carbon dioxide output during exercise|Dyspnea during exercise|Inspiratory capacity during exercise|Beck Anxiety Inventory (BAI)|Beck Depression Inventory (BDI)|Post-traumatic stress symptoms questionnaire","Federal University of Rio Grande do Sul|Hospital de Clinicas de Porto Alegre|Conselho Nacional de Desenvolvimento Científico e Tecnológico|Hospital Moinhos de Vento|Federal University of Health Science of Porto Alegre|Universidade de Passo Fundo|Hospital Nossa Senhora da Conceicao","All","Child, Adult, Older Adult",,"134","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-0169","May 15, 2020","December 31, 2020","August 2, 2022","June 1, 2020",,"June 1, 2020","Universidade de Passo Fundo, Passo Fundo, Rio Grande Do Sul, Brazil|Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital de Clínicas de Porto Alegre/Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande Do Sul, Brazil|Univesidade de Ciências da Saúde de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Nossa Senhora da Conceição, Porto Alegre, Rio Grande Do Sul, Brazil",,"https://ClinicalTrials.gov/show/NCT04410107"
845,"NCT04390191","Early CPAP in COVID-19 Confirmed or Suspected Patients","PAP-COVID","Recruiting","No Results Available","COVID-19|COVID|Coronavirus","Device: Continuous Positive Airway Pressure","Efficacy Endpoint composite score|Time to ICU admission|Time to Intubation and mechanical ventilation|14 day and 28 day mortality|Conversion rate of COVID household members in CPAP vs control|Clinical COPD Questionnaire (CCQ)|Percentage of patients electing to continue CPAP for greater than 72 hours|Degree of improvement in oxygen saturation|Time to hospital admission or ED","Icahn School of Medicine at Mount Sinai|Itamar Medical LTD|Community Surgical Supply of Toms River, Inc|Philips Healthcare","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 20-0900","May 7, 2020","April 2021","May 2021","May 15, 2020",,"May 15, 2020","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04390191"
846,"NCT04346355","Efficacy of Early Administration of Tocilizumab in COVID-19 Patients",,"Terminated","No Results Available","COVID-19 Pneumonia","Drug: Tocilizumab","Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count","Azienda Unità Sanitaria Locale Reggio Emilia","All","18 Years and older   (Adult, Older Adult)","Phase 2","126","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RCT-TCZ-COVID-19|2020-001386-37","March 31, 2020","June 6, 2020","June 6, 2020","April 15, 2020",,"June 22, 2020","Ospedale di Guastalla, Guastalla, RE, Italy|Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, RE, Italy|Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy|Policlinico Sant'Orsola Malpighi, Bologna, Italy|ASST Cremona, Cremona, Italy|Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy|Azienda Ospedaliero Universitaria Ferrara, Ferrara, Italy|Azienda Ospedaliero Universitaria Careggi, Firenze, Italy|Ospedale Evangelico Internazionale di Genova, Genova, Italy|Azienda Sociosanitaria ASL 1 ,Imperia, Imperia, Italy|Azienda Sociosanitaria ASL 5 La Spezia, La Spezia, Italy|ASST Mantova - Ospedale Carlo Poma, Mantova, Italy|IRCCS Istituto Auxologico Italiano Milano, Milano, Italy|Azienda Ospedaliero-Universitaria ""Maggiore della Carità"" di Novara, Novara, Italy|Ospedali Riuniti Padova Sud - ULSS 6 Euganea, Padova, Italy|Azienda Ospedaliero-Universitaria Parma, Parma, Italy|Azienda Unità Sanitaria Locale di Piacenza, Piacenza, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|AO Ordine Mauriziano di Torino, Torino, Italy|ASST Bergamo Ovest -Treviglio, Treviglio, Italy|AULSS 2 Marca Trevigiana, Treviso, Italy|AULSS2 Marca Trevigiana - Ospedale Vittorio Veneto, Treviso, Italy|AULSS 3 Serenissima Ospedale ""Dell'Angelo"", Venezia, Italy|Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy|IRCCS Sacro Cuore Don Calabria, Verona, Italy",,"https://ClinicalTrials.gov/show/NCT04346355"
847,"NCT04359602","COVID-19 Recovered Volunteer Research Participant Pool Registry",,"Recruiting","No Results Available","Recovered From COVID-19",,"Serological testing of COVID patients|Immune response","University of California, Los Angeles","All","18 Years and older   (Adult, Older Adult)",,"10000","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","20-000625","April 8, 2020","April 20, 2022","April 20, 2042","April 24, 2020",,"May 4, 2020","Ronald Reagan UCLA Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04359602"
848,"NCT04305106","Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT","BEST-RCT","Recruiting","No Results Available","COVID-19 Pneumonia","Drug: Bevacizumab","The time from randomization to clinical improvement","Qilu Hospital of Shandong University|Renmin Hospital of Wuhan University|Ialy Moriggia Pelascini Gravedona Hospital S.p.A|Wuhan University|Jiangbei Union Hospital of Huazhong University of science and technology|Shandong Provincial Chest Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","QLEmer","March 17, 2020","June 30, 2020","July 31, 2020","March 12, 2020",,"March 26, 2020","Qilu Hospital of Shandong University, Jinan, Shandong, China",,"https://ClinicalTrials.gov/show/NCT04305106"
849,"NCT04315987","NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia","HOPE","Not yet recruiting","No Results Available","COVID-19 Pneumonia","Biological: NestaCell®|Biological: Placebo","Change in Clinical Condition|Rate of mortality within 10-days|Change of Clinical symptoms - respiratory rate|Hypoxia|PaO2 / FiO2 ratio|CD4+ and CD8+ T cell count|Changes of blood oxygen|Side effects in the treatment group|Complete blood count, cardiac, hepatic and renal profiles;","Azidus Brasil|Cellavita Pesquisa Científica Ltda|Hospital Vera Cruz","All","18 Years and older   (Adult, Older Adult)","Phase 2","90","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HOPE","June 2020","August 2020","August 2020","March 20, 2020",,"June 9, 2020","Hospital Vera Cruz, Campinas, São Paulo, Brazil|Hospital de Barueri, São Paulo, Brazil|IncCOR, São Paulo, Brazil|UNIFESP, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04315987"
850,"NCT04378777","Immunophenotyping Assessment in a COVID-19 Cohort","IMPACC","Enrolling by invitation","No Results Available","Coronavirus Disease 2019 (COVID-19)|SARS-CoV-2","Procedure: Biological sample collection|Procedure: Data Collection: Clinical Care Assessments","Mortality Rate Among COVID-19 Patients|Proportion of Patients with COVID-19 who Require Intensive Care Unit (ICU)-Level Care, Mechanical Ventilatory Support (MV), and/or Extracorporeal Membrane Oxygenation (ECMO) Over Time to Day 28|Proportion of Patients with COVID-19 who Develop Shock, Secondary Organ Failure, or Secondary Infection Over Time to Day 28|Mechanistic: Longitudinal Assessment of Viral Load by Semi-Quantitative Polymerase Chain Reaction (PCR) Over Time to Day 28|Mechanistic: Antibody Isotype/Subclass Classification and Functionality Over Time through Day 28 and at follow-up through month 12|Mechanistic: Longitudinal Assessment of Inflammatory Mediators as Collected Over Time to Day 28|Mechanistic: Longitudinal Assessment of Markers of Myocardial Injury Over Time to Day 28|Duration of Mechanical Ventilation in Patients with COVID-19 Over Time to Day 28|Proportion of Patients with COVID-19 with Requirement for New (Or Increased from Baseline if on Home Oxygen) Supplemental Oxygen Over Time to Day 28|Requirement for Extracorporeal Membrane Oxygenation (ECMO) in COVID-19 Patients with COVID-19 Over Time to Day 28|Mechanistic: Immune Cell Frequencies and Activation Status (CyTOF) in Blood and Endotracheal Aspirate over time Through Day 28 and In blood at Select Study Visits Through Month 12|Mechanistic: Gene Expression (Transcriptomics) in Blood|Mechanistic: Gene Expression (Transcriptomics) in Respiratory Epithelium|Mechanistic: Gene Expression (Transcriptomics) in Plasma Protein|Mechanistic: Gene expression (Transcriptomics) in Metabolic Profiling|Mechanistic: Circulating Immune Mediators Assessed by OLINK Methodology","National Institute of Allergy and Infectious Diseases (NIAID)|Benaroya Research Institute|Boston Children’s Hospital","All","18 Years and older   (Adult, Older Adult)",,"2000","NIH|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DAIT-COVID-19-002","May 1, 2020","December 2020","December 2021","May 7, 2020",,"May 14, 2020","University of California, Los Angeles: Department of Medicine, Los Angeles, California, United States|University of California San Francisco School of Medicine, San Francisco, California, United States|Stanford Medicine: Sean N. Parker Center for Allergy & Asthma Research, Stanford, California, United States|Yale School of Medicine, New Haven, Connecticut, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04378777"
851,"NCT04371107","Proactive Care of Ambulatory COVID19 Patients","AMBU-COVID","Not yet recruiting","No Results Available","Covid19|Azithromycin|Ambulatory","Other: consultation|Drug: Azithromycin","Length of symptom duration (in days) with azithromycin treatment","Centre Hospitalier Universitaire, Amiens","All","18 Years and older   (Adult, Older Adult)","Phase 3","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PI2020_843_0039","April 29, 2020","June 2020","July 2020","May 1, 2020",,"May 6, 2020","CHU Amiens, Amiens, France",,"https://ClinicalTrials.gov/show/NCT04371107"
852,"NCT04359667","Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab","UHID-COVID19","Not yet recruiting","No Results Available","COVID-19|Severe Pneumonia","Drug: Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]","serum interleukin-6 and soluble interleukin-6 receptor as biomarkers of clinical outcomes in patients with severe coronavirus disease (COVID-19) pneumonia treated with tocilizumab","University Hospital for Infectious Diseases, Croatia","All","18 Years and older   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","UHID-04","June 16, 2020","April 16, 2021","May 15, 2021","April 24, 2020",,"June 9, 2020","University Hospital for Infectious Diseases ""Dr Fran Mihaljevic"", Zagreb, Croatia",,"https://ClinicalTrials.gov/show/NCT04359667"
853,"NCT04368000","Prone Positioning in Awake Patients With COVID-19 Requiring Hospitalization","PAPR","Recruiting","No Results Available","Respiratory Failure|COVID-19","Behavioral: Intermittent prone positioning instructions|Behavioral: Usual care positioning with no instructions","Change in imputed partial pressure of oxygen over fraction of inspired oxygen (PaO2/FiO2) from peripheral capillary oxygen saturation over fraction of inspired oxygen (SpO2/FiO2)|Change in imputed PaO2/FiO2 from SpO2/FiO2|Proportion of participants requiring endotracheal intubation|Proportion of participants requiring mechanical ventilation|Proportion of participants transferred to intensive care for worsening respiratory failure|Proportion of participants who had escalated oxygen delivery needs|Average number of days hospitalized|Average number of ventilator-free days|Proportion of participants discharged from hospital on hospice|Proportion of participants with all-cause inpatient mortality","University of Utah","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB_00132123","April 29, 2020","December 2020","January 2021","April 29, 2020",,"May 20, 2020","University of Utah Health Sciences Center, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04368000"
854,"NCT04244591","Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure",,"Completed","No Results Available","COVID-19 Infections","Drug: methylprednisolone therapy|Other: Standard care","Lower Murray lung injury score|The difference of PaO2/FiO2 between two groups|Lower Sequential Organ Failure Assessment (SOFA) score|Mechanical ventilation support|Clearance of noval coronavirus|All-cause mortality","Peking Union Medical College Hospital|Zhongda Hospital|Zhongnan Hospital|Renmin Hospital of Wuhan University","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Glucocorticoid COVID-19","January 26, 2020","April 13, 2020","April 13, 2020","January 28, 2020",,"June 16, 2020","Medical ICU,Peking Union Medical College Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04244591"
855,"NCT04395482","Lung CT Scan Analysis of SARS-CoV2 Induced Lung Injury","TAC-COVID19","Recruiting","No Results Available","covid19","Other: Lung CT scan analysis in COVID-19 patients","A qualitative analysis of parenchymal lung damage induced by COVID-19|A quantitative analysis of parenchymal lung damage induced by COVID-19|The potential impact of parenchymal morphological CT scans in patients with severe moderate respiratory failure.|Automated segmentation of lung scans of patients with COVID-19 and ARDS.|Knowledge of chest CT features in COVID-19 patients and their detail through the use of machine learning and other quantitative techniques.|The ability within which the analysis of artificial intelligence that uses deep learning models can be used to predict clinical outcomes","University of Milano Bicocca","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","TAC-COVID19","April 15, 2020","June 15, 2020","October 15, 2020","May 20, 2020",,"May 26, 2020","Ospedale Papa Giovanni XXIII, Bergamo, Italy|Policlinico San Marco-San Donato group, Bergamo, Italy|Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy|ASST di Lecco Ospedale Alessandro Manzoni, Lecco, Italy|ASST Melegnano-Martesana, Ospedale Santa Maria delle Stelle, Melzo, Italy|ASST Monza, Monza, Italy|AUSL Romagna-Ospedale Infermi di Rimini, Rimini, Italy|Istituto per la Sicurezza Sociale-Ospedale della Repubblica di San Marino, San Marino, San Marino",,"https://ClinicalTrials.gov/show/NCT04395482"
856,"NCT04383444","Surveillance of Individuals Following SARS-CoV-2 Exposure",,"Recruiting","No Results Available","COVID-19",,"Results of SARS-CoV-2 RT- PCR testing, antibody assay, and culture|SARS-CoV-2 culture and RT-PCR results|Symptom checklist","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"1050","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","200117|20-I-0117","July 2, 2020","August 1, 2023","August 1, 2023","May 12, 2020",,"June 29, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04383444"
857,"NCT04424446","Saliva/Nares as Source of Detection for SARS-CoV-2 at NIH",,"Recruiting","No Results Available","COVID-19",,"Saliva and nasal swab SARSCoV-2 RT-PCR test results","National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"5000","NIH","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","200128|20-CC-0128","July 2, 2020","June 1, 2021","June 1, 2021","June 11, 2020",,"June 29, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04424446"
858,"NCT04335201","Defibrotide in COVID-19 Pneumonia","DEFI-VID19","Not yet recruiting","No Results Available","Patients With COVID-19 Pneumonia Will Allow to Detect an Absolute Reduction in the Rate of Respiratory-failure","Drug: Defibrotide Injection","to able to reduce the progression of acute respiratory failure|Adverse events|duration of hospitalization|systemic inflammation|overall survival","IRCCS San Raffaele","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DEFI-VID19","April 6, 2020","September 30, 2020","December 31, 2020","April 6, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04335201"
859,"NCT04354870","COVID-19 PrEP HCW HCQ Study",,"Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine (HCQ)","Frequency of seroconversion to SARS-CoV-2|Incidence of COVID-19 symptoms in the 4 weeks preceding seroconversion|Hospital admission rate|ICU admission rate|Mortality rate|Incidents of AEs or SAEs related to HCQ upon study termination time","NYU Langone Health","All","18 Years and older   (Adult, Older Adult)","Phase 2","350","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","s20-00390","April 3, 2020","August 1, 2020","September 1, 2020","April 21, 2020",,"April 22, 2020","NYU Langone Health, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04354870"
860,"NCT04320615","A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia","COVACTA","Active, not recruiting","No Results Available","COVID-19 Pneumonia","Drug: Tocilizumab (TCZ)|Drug: Placebo","Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Time to Recovery|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 3","450","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","WA42380|2020-001154-22","April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",,"June 29, 2020","University of California San Diego, La Jolla, California, United States|eStudySite, La Mesa, California, United States|David Geffen School of Medicine UCLA, Los Angeles, California, United States|Stanford University, Stanford, California, United States|Denver Health Medical Center, Denver, Colorado, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States|Baystate Health System, Springfield, Massachusetts, United States|Mayo Clinic - PPDS, Rochester, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital/Rutgers, New Brunswick, New Jersey, United States|James J Peters Veterans Administration Medical Center - NAVREF, Bronx, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic Foundation; Pulmonary, Allergy & Critical Care Medicine, Cleveland, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Baylor St. Luke's Medical Center, Houston, Texas, United States|Ben Taub General Hospital - HCHD, Houston, Texas, United States|Intermountain Medical Group, Saint George, Utah, United States|Intermountain LDS Hospital, Salt Lake City, Utah, United States|Evergreen Health Infectious Disease, Kirkland, Washington, United States|Swedish Hospital Medical Center, Seattle, Washington, United States|Hamilton General Hospital; Pharmacy, Hamilton, Ontario, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Clinical Research Institute of Montreal, Montreal, Quebec, Canada|Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Odense Universitetshospital, Odense C, Denmark|Sjællands Universitetshospital, Roskilde, Roskilde, Denmark|Centre Hospitalier Departemental de Vendee, La Roche Sur Yon, France|Centre Hospitalier et Universitaire de Limoges, Limoges, France|Hôpital de La Croix Rousse, Lyon, France|Hotel Dieu - Nantes, Nantes, France|Hopital de la Pitie Salpetriere, Paris, France|HOPITAL COCHIN university hospital, Paris, France|CHRU de Tours, Pharmacie, Tours, France|Universitatsklinikum Dusseldorf, Dusseldorf, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Uniklinik Köln, Köln, Germany|LMU Klinikum der Universitat Munchen, Munchen, Germany|Azienda Ospedaliera Dei Colli, Napoli, Campania, Italy|Istituto Nazionale Malattie Infettive Lazzaro Spallanzani IRCCS, Roma, Lazio, Italy|ASST Papa Giovanni XXIII; Dipartimento Interaziendale di Farmacia Clinica, Bergamo, Lombardia, Italy|ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco, Milano, Lombardia, Italy|Azienda Ospedaliera San Gerardo di Monza, Monza MI, Lombardia, Italy|Fondazione IRCCS Policlinico San Matteo di Pavia; S.S. Fisiopatologia Respiratoria, Pavia, Lombardia, Italy|Amphia Ziekenhuis, Breda, Netherlands|St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands|Erasmus MC, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario HM Sanchinarro-CIOCC, Madrid, Spain|Greater Glasgow and Clyde Health Board, Glasgow, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|University College Hospital, London, United Kingdom|Royal Free Hospital, London, United Kingdom|St George's Clinical Research Facility, London, United Kingdom|Imperial College London, London, United Kingdom|North Manchester General Hospital, Manchester, United Kingdom|Salford Royal Hospital, Salford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04320615"
861,"NCT04344730","Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 Pneumonia","COVIDICUS","Recruiting","No Results Available","Acute Hypoxemic Respiratory Failure|COVID-19","Drug: Dexamethasone injection|Drug: placebo|Procedure: conventional oxygen|Procedure: CPAP|Procedure: HFNO|Procedure: mechanical ventilation","The time-to-death from all causes|The time to need for mechanical ventilation (MV)|The viral load in the respiratory tract|Number of patient with at least one episode of healthcare-associated infections|Number of days alive without mechanical ventilation|Measure of SOFA score|Number of days alive without renal replacement therapy|Lengths of ICU-stay|Lengths of hospital-stay|Number of patients with severe hypoxemia,|Number of patients with cardiac arrest within 1 hour after intubation","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Not Applicable","550","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","APHP200388|2020-001457-43","April 10, 2020","December 31, 2020","December 31, 2020","April 14, 2020",,"April 14, 2020","Hopital Bichat - Aphp, Paris, France",,"https://ClinicalTrials.gov/show/NCT04344730"
862,"NCT04372186","A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia",,"Recruiting","No Results Available","COVID-19 Pneumonia","Drug: Placebo|Drug: Tocilizumab","Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","379","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ML42528","May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",,"June 26, 2020","Banner - University Medical Center Phoenix; In-Patient Pharmacy, Phoenix, Arizona, United States|Univ of AZ Coll of Med, Tucson, Arizona, United States|Scripps Mercy Hospital, Chula Vista, California, United States|El Centro Regional Medical Center, El Centro, California, United States|Harper University Hospital, Fountain Valley, California, United States|eStudySite, La Mesa, California, United States|Riverside University Health System-Medical Center, Moreno Valley, California, United States|Highland Hospital Oakland, Oakland, California, United States|St. Joseph'S Hospital, Orange, California, United States|Desert Regional Medical Center, Palm Springs, California, United States|San Leandro Hospital; Inpatient Pharmacy, San Leandro, California, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|UCHealth Greeley Hospital, Greeley, Colorado, United States|Medical Center of The Rockies, Loveland, Colorado, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Howard University, Washington, District of Columbia, United States|Suncoast Research Associates LLC - ERN - PPDS, Doral, Florida, United States|Miami Veterans Administration Healthcare System - NAVREF, Miami, Florida, United States|University of Miami Pulmonary, Miami, Florida, United States|Westchester General Hospital, Miami, Florida, United States|Larkin Community Hospital, South Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Columbus Regional Research Institute, Columbus, Georgia, United States|St. Lukes Boise Medical Center, Boise, Idaho, United States|Uni of Kansas Medical Center, Kansas City, Kansas, United States|Ochsner Clinic, New Orleans, Louisiana, United States|LSU-Shreveport, Shreveport, Louisiana, United States|Holy Cross Germantown Hospital, Germantown, Maryland, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Detroit Receiving Hospital, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Sinai Grace Hospital, Detroit, Michigan, United States|Optum Health Care, Las Vegas, Nevada, United States|St. Joseph'S Regional Medical Center, Paterson, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|St. Barnabas Hospital, Bronx, New York, United States|Kings County Hospital Center, Brooklyn, New York, United States|SUNY Downstate Medical Center., Brooklyn, New York, United States|Elmhurst Hospital Center, Elmhurst, New York, United States|Flushing Hospital, Flushing, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|NYC Health and Hospitals Queens, Jamaica, New York, United States|Harlem Hospital, New York, New York, United States|Canton-Potsdam Hospital, Potsdam, New York, United States|Novant Health Presbyterian Medical Center (Presbyterian Hospital), Charlotte, North Carolina, United States|Cape Fear Valley Medical Center, Fayetteville, North Carolina, United States|Novant Health Rowan Medical Center, Salisbury, North Carolina, United States|Novant Health Foryth Medical Center, Winston-Salem, North Carolina, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Sanford Health System, Sioux Falls, South Dakota, United States|JPS Health Network, Fort Worth, Texas, United States|Valley Baptist Medical Center, Harlingen, Texas, United States|Michael E Debakey VA Medical Center, Houston, Texas, United States|McAllen Medical Center, McAllen, Texas, United States|Crossroads Clinical Research, LLC, Victoria, Texas, United States|Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Aga Khan University Hospital, Nairobi, Kenya|Organismo Publico Descentralizado Hospital Juarez de Mexico, Ciudad De México, Mexico|Hospital General de Culiacan, Culiacan, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Mexico|Hospital Militar Central, Jesus Maria, Peru|Hospital Nacional Dos de Mayo, Lima, Peru|University of the Free State, Bloemfontein, South Africa|George Provincial Hospital, George, South Africa|Mzansi Ethical Research Centre, Middelburg, South Africa|Milpark Hospital, Parktown West, South Africa|University of Stellenbosch; Respiratory Research, Parow, South Africa|Phoenix Pharma, Port Elizabeth, South Africa",,"https://ClinicalTrials.gov/show/NCT04372186"
863,"NCT04332107","Azithromycin for COVID-19 Treatment in Outpatients Nationwide","ACTION","Recruiting","No Results Available","COVID-19|SARS-CoV-2","Drug: Azithromycin|Drug: Placebos","Hospitalization|Viral load|Mortality|Adverse events|Positive SARS-CoV-2 test - nasal swab|Positive SARS-CoV-2 test - saliva swab|Positive SARS-CoV-2 test - rectal swab|Genetic macrolide resistance determinants|COVID-19 symptoms|Number of emergency room visits|Number of household members with COVID-19 (confirmed or symptomatic)|Death","Thomas M. Lietman|Bill and Melinda Gates Foundation|Pfizer|Stanford University|University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Phase 3","2271","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20-30504","May 22, 2020","September 30, 2020","September 30, 2021","April 2, 2020",,"May 22, 2020","University of California San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT04332107"
864,"NCT04407130","Efficacy and Safety of Ivermectin and Doxycycline in Combination or IVE Alone in Patients With COVID-19 Infection.",,"Enrolling by invitation","No Results Available","COVID-19 Patients","Drug: Ivermectin + Doxycycline + Placebo|Drug: Ivermectin + Placebo|Drug: Placebo","Virological clearance|Remission of fever|Remission of cough|Patients requiring oxygen|Patients failing to maintain SpO2 >88% despite oxygenation|Number of days on oxygen support|Chest X-ray improvement|Duration of hospitalization|All causes of mortality","International Centre for Diarrhoeal Disease Research, Bangladesh","All","40 Years to 65 Years   (Adult, Older Adult)","Phase 2","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PR-20039","June 16, 2020","July 2020","July 2020","May 29, 2020",,"June 26, 2020","Icddr,B, Dhaka, Bangladesh",,"https://ClinicalTrials.gov/show/NCT04407130"
865,"NCT04445623","Prasugrel in Severe COVID-19 Pneumonia","PARTISAN","Not yet recruiting","No Results Available","COVID19|Thrombosis","Drug: Prasugrel Hydrochloride 10 MG Oral Tablet|Drug: Placebo","P/F ratio at day 7|Daily P/F ratio|Daily need for oxygen supply|Need for ICU|Death|MOF|Discharge|Clinical progression of the disease SOFA score|Clinical progression of the disease APACHE II|Venous thrombosis/ pulmonary embolism/thrombosis|Need for CT imaging|Daily Temperature|Daily blood pressure|Daily total blood count Hemoglobin|Daily total blood count Red Blood Cells|Daily total blood count Leukocytes|Daily total blood count Platelets|Daily indices of organ damage Liver|Indices of inflammation C-reactive protein|Indices of haemostasis PT|Daily progression at imaging (chest-X-ray)|Major bleeding|Total bleeding|Unexpected clinical or laboratory findings|Indices of inflammation D-dimer|Indices of inflammation Fibrinogen|Indices of inflammation IL-6|Indices of inflammation IL-1|Daily indices of organ damage kidney|Daily indices of organ damage heart|Haemostasis aPTT|Haemostasis VASP PRI|Haemostasis platelet-leukocytes aggregates","Azienda Ospedaliera Universitaria Integrata Verona|University of Milan","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","128","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","MGI-COVID-19-prasugrel","July 2020","October 2020","January 2021","June 24, 2020",,"June 26, 2020","Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy",,"https://ClinicalTrials.gov/show/NCT04445623"
866,"NCT04409509","Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID‑19)",,"Not yet recruiting","No Results Available","Coronavirus Disease 2019 (COVID‑19)","Biological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody|Drug: Placebo","The incidence of tracheal intubation or death prior to tracheal intubation|Proportion of subjects with death from all causes|Proportion of subjects intubated|Number and proportion of subjects with ≥ 2‑point improvement on National Institute of Allergy and Infectious Diseases (NIAID) Ordinal scale|Number and proportion of subjects within each of the categories of the NIAID|Proportion of subjects requiring continuous positive airway pressure (CPAP)|Proportion of subjects requiring bilevel positive airway pressure (BiPAP)|Proportion of subjects requiring high‑flow nasal cannula (HFNC)|Proportion of subjects requiring extracorporeal membrane oxygenation (ECMO)|Maximum change from baseline in Sequential Organ Failure Assessment (SOFA) score|Average SOFA score over the subject's duration of the study|Length of hospital stay|Number and proportion of subjects experiencing Adverse Events (AEs)|Number and proportion of subjects experiencing serious adverse events (SAEs)|Number and proportion of subjects with adverse events of special interest (AESIs)|Number and proportion of subjects with CSL312 induced anti‑CSL312 antibodies|Maximum plasma concentration (Cmax) of CSL312|Time to maximum plasma concentration (Tmax) of CSL312|Area under the plasma concentration‑time curve (AUC) of CSL312","CSL Behring","All","18 Years and older   (Adult, Older Adult)","Phase 2","124","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CSL312_COVID-19","June 2020","December 2020","December 2020","June 1, 2020",,"June 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04409509"
867,"NCT04370821","COVID-19 CHAMPS Study of Healthcare, First Responder and Service Workers","CHAMPS","Recruiting","No Results Available","Occupational Exposure to SARS-CoV-2|COVID-19",,"Sample Size of enrolled CHAMPS Study participants by demographic characteristics during the first two years of the study|Exposure to SARS-CoV-2 based on models computed from participant baseline data and community variables, if available.|Infectious disease and chronic disease incidence rates by demographic characteristics|Completeness of data by demographic characteristics.|Participation rates in ancillary and sub-studies within the CHAMPS registry.|Number of participants enrolled in randomized trials based on the CHAMPS registry","Villanova University","All","18 Years and older   (Adult, Older Adult)",,"20000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB FY2020-215","May 9, 2020","April 27, 2040","April 27, 2040","May 1, 2020",,"May 12, 2020","Villanova University, Villanova, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04370821"
868,"NCT04386616","A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia","COVASTIL","Recruiting","No Results Available","COVID-19 Pneumonia","Drug: MSTT1041A|Drug: MSTT1041A-matched Placebo|Drug: UTTR1147A|Drug: UTTR1147A-matched Placebo","Clinical Status, Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement, Defined as a National Early Warning Score 2 (NEWS2) of ≤2 Maintained for 24 hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal of Care (Whichever Occurs First)|Mortality Rate at Days 7, 14, 21, 28, and 60|Time to Hospital Discharge or ""Ready for Discharge""|Duration of Supplemental Oxygen|Duration of Hypoxemia|Percentage of Participants Alive and Free of Respiratory Failure|Incidence and Severity of Adverse Events, with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)|Change from Baseline in Respiratory Rate|Change from Baseline in Pulse Rate|Change from Baseline in Systolic Blood Pressure|Change from Baseline in Diastolic Blood Pressure|Change from Baseline in Body Temperature|Change from Baseline in Oxygen Saturation|Change from Baseline in RR, QRS, PR, QT, and QTcF Intervals, as Measured by Electrocardiogram (ECG)|Change from Baseline in Heart Rate, as Measured by Electrocardiogram (ECG)|Number of Participants with Clinical Laboratory Test Abnormalities in Hematology Parameters|Number of Participants with Clinical Laboratory Test Abnormalities in Blood Chemistry Parameters|Serum Concentration of UTTR1147A at Specified Timepoints|Serum Concentration of MSTT1041A at Specified Timepoints|Prevalence of Anti-Drug Antibodies (ADAs) at Baseline and Incidence of ADAs During the Study","Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GA42469","June 2, 2020","September 24, 2020","October 27, 2020","May 13, 2020",,"June 25, 2020","eStudySite - Chula Vista - PPDS, Chula Vista, California, United States|eStudySite, La Mesa, California, United States|MedPharmics, Metairie, Louisiana, United States|Southeast Louisiana Veterans Health Care System - NAVREF, New Orleans, Louisiana, United States|Henry Ford Health System, Detroit, Michigan, United States|St. Joseph'S Regional Medical Center, Paterson, New Jersey, United States|Lincoln Medical Mental Health Center, Bronx, New York, United States|Staten Island University Hospital; Department of Pharmacy, Staten Island, New York, United States|Mercy St. Vincent Medical Center, Toledo, Ohio, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Temple Uni Medical Center; Pulmonary & Critical Care Medicine, Philadelphia, Pennsylvania, United States|Parkland Health & Hospital System, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|MultiCare Institute for Research and Innovation; Clinic/Outpatient Facility, Tacoma, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04386616"
869,"NCT04444596","Conjunctival Swab vs Nasopharyngeal Swab in Patients With COVID-19",,"Recruiting","No Results Available","COVID-19|SARS-CoV 2","Diagnostic Test: Conjunctival swab and nasopharyngeal swab","SARS-CoV2 positive conjunctival swabs|Conjunctival swab vs nasopharyngeal swab","Medical University Innsbruck","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","1104/2020","June 17, 2020","March 31, 2021","March 31, 2021","June 23, 2020",,"June 23, 2020","Medical University Innsbruck, Innsbruck, Tirol, Austria",,"https://ClinicalTrials.gov/show/NCT04444596"
870,"NCT04363736","A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia","MARIPOSA","Recruiting","No Results Available","COVID-19 Pneumonia","Drug: Tociliuzumab","Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA42481","May 5, 2020","July 3, 2020","August 3, 2020","April 27, 2020",,"June 2, 2020","Mayo Clinic - Arizona, Phoenix, Arizona, United States|Univ of AZ Coll of Med, Tucson, Arizona, United States|St. Jude Medical Center, Fullerton, California, United States|LAC + USC Medical Center, Los Angeles, California, United States|USC Keck Medical Center of USC, Los Angeles, California, United States|Norwalk Hospital, Norwalk, Connecticut, United States|Medstar Georgetown University Hospital, Washington, District of Columbia, United States|University of Florida; Health Science Center, Jacksonville, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, United States|MedPharmics, Metairie, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Renown Institute for Heart & Vascular Health, Reno, Nevada, United States|St Joseph's Regional Medical Center, Wayne, New Jersey, United States|SUNY Downstate Medical Center., Brooklyn, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Vassar Brothers Medical Center, Poughkeepsie, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Mercy St. Vincent Medical Center, Toledo, Ohio, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Allegheny Health Network (Pittsburg PA), Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Houston Methodist Hospital, Houston, Texas, United States|Michael E. DeBakey VA Medical Center, Houston, Texas, United States|Houston Methodist Sugar Land Hospital, Sugar Land, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04363736"
871,"NCT04364893","Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19","BRACE-CORONA","Recruiting","No Results Available","Corona Virus Infection|COVID-19","Other: Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors","Median days alive and out of the hospital|Number of participants with adverse cardiovascular outcomes and new worsening heart failure|Cardiovascular biomarkers related to COVID-19","D'Or Institute for Research and Education|Brazilian Clinical Research Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","700","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRJ_2003","April 6, 2020","October 1, 2020","December 1, 2020","April 28, 2020",,"June 24, 2020","Idor, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04364893"
872,"NCT04346056","Retrospective Study on Severe Respiratory Illness to Access the Presence of COVID-19","Explore","Recruiting","No Results Available","Coronavirus Disease (COVID-19)|COVID-19",,"Exploring the presence of COVID-19","Ain Shams University","All","1 Year to 80 Years   (Child, Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","FMASU P17a/ 2020","April 14, 2020","October 1, 2020","December 1, 2020","April 15, 2020",,"April 20, 2020","Faculty of Medicine Ain Shams University, Cairo, Non-US, Egypt|Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt",,"https://ClinicalTrials.gov/show/NCT04346056"
873,"NCT04356560","COVID-19 Surveillance of Patients and Healthcare Workers in a Hospital Department",,"Enrolling by invitation","No Results Available","COVID-19","Diagnostic Test: COVID-19 test, polymerase chain reaction for SARS-CoV-2","Incidence of healthcare workers with SARS-CoV-2|Incidence of ENT patients with SARS-CoV-2|Development of SARS-CoV-2 antibodies among healthcare workers|Sensitivity and specificity of a COVID-19 screening symptom questionnaire among healthcare workers|SARS CoV-2 and bacterial super infections in upper respiratory airways","Rigshospitalet, Denmark","All","Child, Adult, Older Adult",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DT P-2020-353","March 23, 2020","September 30, 2020","December 31, 2020","April 22, 2020",,"April 24, 2020","Rigshospitalet University Hospital of Copenhagen, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT04356560"
874,"NCT04404244","Extraordinary Measures for Egyptian Children With Hemato-Oncological Disorders During COVID-19 Pandemic","PedCan-COVID","Recruiting","No Results Available","Coronavirus COVID-19",,"Incidence of COVID-19 among children with cancer|Families training","Fatma Soliman Elsayed Ebeid|Ain Shams University","All","up to 18 Years   (Child, Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","FMASU P25a/ 2020","January 1, 2020","January 1, 2021","June 1, 2021","May 27, 2020",,"May 27, 2020","Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt",,"https://ClinicalTrials.gov/show/NCT04404244"
875,"NCT04350710","Description of Respiratory Mechanics in Patients With SARS-CoV-2 Associated ARDS",,"Recruiting","No Results Available","Acute Respiratory Distress Syndrome|COVID","Other: PEEP trial","Recruitment-to Inflation ratio (R/I ratio)|PaO2/FiO2 (mmHg)|Lung volume recruited (VRec)|Plateau pressure (cm H2O)|Oesophagal pressure (cm H2O)|weight (Kg)|urine output (mL)|serum creatinine (Umo/L)|Mean arterial pressure (mmHg)|Peak Pressure (cm H2O)|PEEP total (cm H2O)|PEP Set (cm H2O)|Height (cm)|Airway pening pressure (cm H2O)|Expired volume in PEEP setted at 15 cmH2O (mL)|Expired volume in PEEP setted at 5 cmH2O (mL)","University Hospital, Angers","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2030/31","March 18, 2020","April 20, 2020","December 31, 2020","April 17, 2020",,"April 17, 2020","CHU, Angers, France",,"https://ClinicalTrials.gov/show/NCT04350710"
876,"NCT04409821","Tele-based Psychological Emotional Support for Informal CARegivers of COVID-19 Patients in Intensive Care","CO-CarES","Not yet recruiting","No Results Available","Posttraumatic Stress Disorder|Prolonged Grief Disorder|COVID","Behavioral: Tele-delivered psychological intervention","Recruitment rate|Completion rate|Peri-traumatic distress inventory (negative emotions)|Impact of Events Scale (6 item)|Prolonged Grief-13-scale|PROMIS Depression (8 item scale)|PROMIS Anxiety (8 item scale)|Perceived Stress Scale (4 item)","Rigshospitalet, Denmark","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","P-2020-544|0216-00030B","June 2020","February 2022","February 2022","June 1, 2020",,"June 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04409821"
877,"NCT04371640","Sirolimus in COVID-19 Phase 1","SirCO-1","Recruiting","No Results Available","SARS-CoV-2|Covid-19","Drug: Sirolimus 1 MG/ML|Drug: Placebo","Change in SARS-CoV-2 viral burden from baseline to day 7 of treatment|Change in SARS-CoV-2 viral burden at days 1-6|Rate of treatment emergent adverse events","Walter K. Kraft|Thomas Jefferson University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15680","May 2020","July 2020","August 2020","May 1, 2020",,"May 7, 2020","Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04371640"
878,"NCT04337359","Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness",,"Available","No Results Available","Severe/Very Severe COVID-19 Illness","Drug: Ruxolitinib",,"Novartis Pharmaceuticals|Novartis","All","6 Years and older   (Child, Adult, Older Adult)",,,"Industry","Expanded Access:Intermediate-size Population",,"CINC424A2001M",,,,"April 7, 2020",,"May 4, 2020",,,"https://ClinicalTrials.gov/show/NCT04337359"
879,"NCT04417257","Study of LAU-7b for the Treatment of COVID-19 Disease in Adults","RESOLUTION","Not yet recruiting","No Results Available","COVID-19 Disease","Drug: LAU-7b|Drug: Placebo oral capsule","Health status of the patient on the 7-point ordinal scale (World Health Organization) compared to placebo|The safety of LAU-7b therapy will be assessed through the monitoring of treatment emergent adverse events, compared to placebo|Rate of COVID-19 disease-related aggravation, depicted by a change from baseline in the ordinal scale score of at least one category, compared to placebo|Rate of COVID-19 disease-related transfer to intensive care unit, depicted by a change from baseline in the ordinal scale score to categories 5 or 6, compared to placebo|Rate of COVID-19 disease-related transfer to mechanical ventilation, depicted by a change from baseline in the ordinal scale score to category 6, compared to placebo|Rate of COVID-19 disease-related death, depicted by a change from baseline in the ordinal scale score to category 7|Health status of the patient on the 7-point ordinal scale (World Health Organization), compared to placebo|Mean change from baseline of the ordinal scale patient health status as a function of assessment time, compared to placebo|Time to an improvement of one category on the ordinal scale patient health status, compared to placebo|Time to recovery, defined here as the time to reach categories 2 or 1 on the ordinal scale patient health status (first occurrence if more than once), compared to placebo|Time to mechanical ventilation, defined here as time to reach category 6 on the ordinal scale patient health status, compared to placebo|Time to death, defined here as a tim to reach category 7 on the ordinal scale patient health status, censored to Day 29 if it happens later than Day 29, compared to placebo|Duration of hospitalization (days) within the study period Days 1-29, compared to placebo|Time to attain an undetectable viral load through oropharyngeal swabs done at specified times, compared to placebo|The change from baseline in the score obtained on the EQ-5D-5L quality-of-life survey","Laurent Pharmaceuticals Inc.","All","45 Years and older   (Adult, Older Adult)","Phase 2","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LAU-20-01","June 29, 2020","December 15, 2020","January 15, 2021","June 4, 2020",,"June 26, 2020","St-Paul's Hospital, Vancouver, British Columbia, Canada|Centre d'études cliniques CIUSS SLJ, Hôpital Chicoutimi, Chicoutimi, Quebec, Canada|CIUSSSS de l'Est-de-l'Ile-de-Montréal, Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada|Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada|McGill University Health Centre, Montréal, Quebec, Canada|CISSS Ds Laurentides, Saint-Jérôme, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04417257"
880,"NCT04273529","The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia",,"Not yet recruiting","No Results Available","COVID-19 Thalidomide","Drug: thalidomide|Drug: placebo","Time to Clinical recoveryTime to Clinical Recovery (TTCR)|All cause mortality|Frequency of respiratory progression|Time to defervescence","First Affiliated Hospital of Wenzhou Medical University|Second Affiliated Hospital of Wenzhou Medical University|Wenzhou Central Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20200214-COVID-19-M-T","February 20, 2020","May 30, 2020","June 30, 2020","February 18, 2020",,"February 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04273529"
881,"NCT04273581","The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19",,"Not yet recruiting","No Results Available","COVID-19 Thalidomide","Drug: placebo|Drug: Thalidomide","Time to Clinical Improvement (TTCI)|Clinical status|Time to Hospital Discharge OR NEWS2 (National Early Warning Score 2) of ≤ 2 maintained for 24 hours|All cause mortality|Duration (days) of mechanical ventilation|Duration (days) of extracorporeal membrane oxygenation|Duration (days) of supplemental oxygenation|Length of hospital stay (days)|Time to 2019-nCoV RT-PCR negativity in upper and lower respiratory tract specimens|Change (reduction) in 2019-nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve.|Frequency of serious adverse drug events|Serum TNF-α, IL-1β, IL-2, IL-6, IL-7, IL-10, GSCF, IP10#MCP1, MIP1α and other cytokine expression levels before and after treatment","First Affiliated Hospital of Wenzhou Medical University|Second Affiliated Hospital of Wenzhou Medical University|Wenzhou Central Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20200214-COVID-19-S-T","February 18, 2020","April 30, 2020","May 30, 2020","February 18, 2020",,"February 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04273581"
882,"NCT04379336","BCG Vaccination for Healthcare Workers in COVID-19 Pandemic",,"Recruiting","No Results Available","COVID-19|Sars-CoV2","Biological: Bacille Calmette-Guérin (BCG)|Other: Placebo Comparator","Incidence of HCWs hospitalized due to COVID-19 per arm|Incidence of SARS-CoV-2 infection per arm|Incidence of upper respiratory tract infections per arm|Days of unplanned absenteeism due to COVID-19 or any reason per arm|Incidence of hospitalization for any reason per arm|Incidence of intensive care unit admission per arm|Incidence of death per arm|Prevalence of latent TB infection|Incidence of active TB per arm|Compare the effect of latent TB on morbidity and mortality due to COVID-19 per arm|Incidence of treatment related adverse events","TASK Applied Science","All","18 Years and older   (Adult, Older Adult)","Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","TASK-008 BCG-CORONA","May 4, 2020","April 28, 2021","April 28, 2021","May 7, 2020",,"May 7, 2020","TASK Foundation, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT04379336"
883,"NCT04437706","Network-Targeted Strategies for Efficient Community SARS-CoV-2 (COVID-19) Sampling","Snowball","Not yet recruiting","No Results Available","COVID-19|SARS-CoV 2",,"Active Infection|Past Exposure","Duke University","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","Pro00105430","July 1, 2020","June 30, 2021","June 30, 2021","June 18, 2020",,"June 18, 2020","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04437706"
884,"NCT04409262","A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia","REMDACTA","Recruiting","No Results Available","COVID-19 Pneumonia","Drug: Remdesivir|Drug: Tocilizumab|Drug: Placebo","Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Day 28|Time to Clinical Improvement (TTCI) Defined as Time from Randomization to National Early Warning Score 2 (NEWS2) Score of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Days 7, 14, and 21|Proportion of Participants Requiring Initiation of Mechanical Ventilation Post-baseline|Ventilator-Free Days from Randomization to Day 28|Proportion of Participants Requiring Initiation of Intensive Care Unit (ICU) Care Post-baseline|Duration of ICU Stay in Days|Time to Clinical Failure, Defined as the Time from Randomization to the First Occurrence of Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate on Days 7, 14, 21, 28, and 60|Time to Recovery, Defined as Time from Randomization to the Time when a Category of 2, Non-ICU Hospital Ward (or ""Ready for Hospital Ward"") not Requiring Supplemental Oxygen, or Better is Observed|Time from Randomization to Hospital Discharge or ""Ready for Discharge"" (as Evidenced by Normal Body Temperature and Respiratory Rate, and Stable Oxygen Saturation on Ambient Air or </= 2L Supplemental Oxygen)|Duration of Supplemental Oxygen Use","Hoffmann-La Roche|Gilead Sciences","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","450","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","WA42511|2020-002275-34","June 16, 2020","July 31, 2020","July 31, 2020","June 1, 2020",,"June 18, 2020","Valleywise Health Medical Center, Phoenix, Arizona, United States|eStudySite - Chula Vista - PPDS, Chula Vista, California, United States|Hoag Hospital Irvine, Irvine, California, United States|Providence St. John's Health Center, Santa Monica, California, United States|Holy Cross Hospital Inc, Fort Lauderdale, Florida, United States|University of Miami Miller School of Medicine; Clinical Reseach Building, Miami, Florida, United States|St Luke's Health System; Rheumatology Research, Boise, Idaho, United States|Rush University Medical Center, Chicago, Illinois, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Louisiana State University Health Sciences Center/Ochsner, Shreveport, Louisiana, United States|University of Maryland School of Medicine, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|St. Michael'S Medical Center, Newark, New Jersey, United States|Wyckoff Heights Medical Center, Staten Island, New York, United States|Novant Health Clinical Research, Charlotte, North Carolina, United States|Cone Health Medical Group, Greensboro, North Carolina, United States|OhioHealth Research Institute, Columbus, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Allegheny Health Network (Pittsburg PA), Pittsburgh, Pennsylvania, United States|Baylor St. Luke's Medical Center, Houston, Texas, United States|Intermountain LDS Hospital, Salt Lake City, Utah, United States|The Providence Regional Medical Center Everett, Everett, Washington, United States|West Virginia University Hospital, Morgantown, West Virginia, United States|Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, MG, Brazil|Instituto de Pesquisa Clinica Evandro Chagas - IPEC FIOCRUZ, Rio de Janeiro, RJ, Brazil|Faculdade de Medicina do ABC - FMABC, Santo Andre, SP, Brazil|Instituto de Infectologia Emilio Ribas, Sao Paulo, SP, Brazil|Instituto do Coração - HCFMUSP, Sao Paulo, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT04409262"
885,"NCT04334044","Treatment of SARS Caused by COVID-19 With Ruxolitinib",,"Recruiting","No Results Available","COVID-19|Severe Acute Respiratory Syndrome Coronavirus 2","Drug: Ruxolitinib Oral Tablet","Recovery of Pneumonia|Response of C-reactive protein|Response of Ferritin|Response of D-dimer|Rate of ICU admission|Rate of mechanical ventilation|Overall Survival|Toxicity Rate","Grupo Cooperativo de Hemopatías Malignas","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HAL 345/2020","April 15, 2020","June 1, 2020","June 1, 2020","April 3, 2020",,"April 17, 2020","Grupo Cooperativo de Hemopatías Malignas, Huixquilucan, Estado De México, Mexico",,"https://ClinicalTrials.gov/show/NCT04334044"
886,"NCT04349618","Ultraprotective Ventilation Without Extracorporeal Circulation During COVID 19 Pneumonia","VT4COVID","Not yet recruiting","No Results Available","Acute Respiratory Distress Syndrome|COVID19|Sars-CoV2|Pneumonia","Other: PROTECTIVE VENTILATION|Other: ULTRAPROTECTIVE VENTILATION","A composite score based on all-cause mortality and the number of ventilator free-days (VFD)|All-cause mortality (intention to treat)|Ventilator-free days (VFD)|All-cause mortality with per protocol analysis|Time to successful extubation|Length of hospital stay|Respiratory parameters assessed daily from inclusion to weaning of deep sedation or 14 days whichever comes first|Daily sedation dose during the first 14 days of the study|Rate of use of rescue therapies|Incidence density rate of severe mixed acidosis|Incidence density rate of ventilator associated pneumonia|Incidence density rate of acute cor pulmonale|Incidence density rate of barotrauma|Incidence density rate of any serious adverse events|Cognitive impairment assessed by phone call using the Telephone Montreal Cognitive Assessment (T-MoCA) test|Quality of life assessed by the RAND 36-Item Health Survey (SF-36) score|Post-traumatic stress disorder assessed by the Impact of Event Scale - revised (IES-R) score by phone call|Cost-efficacy ratio of the innovative strategy compared to the reference strategy","Hospices Civils de Lyon","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","69HCL20_0322","April 14, 2020","July 14, 2021","April 14, 2022","April 16, 2020",,"April 16, 2020","Service de Médecine Intensive Réanimation CHU Gabriel Montpied, Clermont-Ferrand, France|Service de Médecine Intensive Réanimation Hôpital Michallon - CHU Grenoble Alpes, La Tronche, France|Service de Médecine Intensive Réanimation Hôpital Edouard Herriot Hospices Civils de Lyon, Lyon, France|Service de Réanimation Chirurgicale Hôpital Edouard Herriot Hospices Civils de Lyon, Lyon, France|Service de Médecine Intensive Réanimation Hôpital de la Croix Rousse Hospices Civils de Lyon, Lyon, France|Service de Réanimation Chirurgicale Hôpital de la Croix Rousse Hospices Civils de Lyon, Lyon, France|Service de réanimation Polyvalente Centre Hospitalier Saint Joseph-Saint Luc, Lyon, France|Service de Réanimation Clinique de la Sauvegarde, Lyon, France|Service de Réanimation Polyvalente Centre Hospitalier Lyon Sud Hospices Civils de Lyon, Pierre-Bénite, France|Service de Réanimation Centre hospitalier Annecy Genevois, Pringy, France|Service de Médecine Intensive Réanimation Hôpital Nord - CHU Saint-Etienne, Saint-Priest-en-Jarez, France",,"https://ClinicalTrials.gov/show/NCT04349618"
887,"NCT04386109","Neonatal Complications of Coronavirus Disease (COVID-19)",,"Recruiting","No Results Available","Neonatal COVID-19 Disease","Other: No intervention - exposure is to COVID-19","Incidence of neonatal COVID-19|Incidence of vertically transmitted COVID-19|Presentation and natural history of neonatal COVID-19|Presentation of neonates with COVID-19 positive mothers|Outcomes for neonates with COVID-19|Clinical treatment of neonatal COVID-19|Neonatal secondary impacts of maternal COVID-19","University of Oxford|Imperial College London|University of Leicester|University of Nottingham|University of Glasgow|University Hospital of Wales|Public Health England|St George's, University of London","All","up to 29 Days   (Child)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","14905","April 1, 2020","March 31, 2021","September 30, 2021","May 13, 2020",,"May 13, 2020","Imperial College, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04386109"
888,"NCT04365127","Progesterone for the Treatment of COVID-19 in Hospitalized Men",,"Recruiting","No Results Available","COVID-19|Sars-CoV2","Drug: Progesterone 100 MG","Change in clinical status of subjects at Day 15 based on the following 7-point ordinal scale|Change in clinical status of subjects assessed daily while hospitalized and on Day 29|Duration of supplemental oxygen, mechanical ventilation (if applicable), and hospitalization","Sara Ghandehari|IBSA Institut Biochimique SA|Cedars-Sinai Medical Center","Male","18 Years and older   (Adult, Older Adult)","Phase 1","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00000611","April 27, 2020","September 1, 2020","April 17, 2021","April 28, 2020",,"April 28, 2020","Cedars Sinai Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04365127"
889,"NCT04374032","Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection",,"Recruiting","No Results Available","COVID-19 Infection","Drug: metenkefalin + tridecactide|Drug: The standard of care","Time to onset of change in the patient's clinical condition|Safety and tolerability evaluation - treatment-related adverse events will be assessed by CTCAE|Length of in-hospital stay|Survival rate|Intubation rate|Proinflammatory markers levels","Bosnalijek D.D","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EN-COVCS-01","May 1, 2020","August 31, 2020","October 31, 2020","May 5, 2020",,"May 7, 2020","Clinical Center University of Sarajevo, Sarajevo, Sarajevo Canton, Bosnia and Herzegovina",,"https://ClinicalTrials.gov/show/NCT04374032"
890,"NCT04342221","Hydroxychloroquine for COVID-19","COV-HCQ","Recruiting","No Results Available","COVID-19, Hydroxychloroquine Sulfate","Drug: Hydroxychloroquine Sulfate|Drug: Placebo","Effect of HCQ on in vivo viral clearance","University Hospital Tuebingen|Robert Bosch Medical Center|Universitätsklinikum Hamburg-Eppendorf|Bernhard Nocht Institute for Tropical Medicine","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COV-HCQ|2020-001224-33","March 29, 2020","March 2021","February 2022","April 10, 2020",,"April 10, 2020","Institute for Tropical Medicine, Tübingen, Germany",,"https://ClinicalTrials.gov/show/NCT04342221"
891,"NCT04363333","Obstructive Sleep Apnea & Covid-19 Outcomes","OSACOVID-19","Recruiting","No Results Available","COVID|Obstructive Sleep Apnea|Pneumonia","Diagnostic Test: Polysomnography","The rate of clinical improvement|Clinical status","Koç University|Koc Healthcare Istanbul American Hospital, Marmara University Pendik Education and Research Hospital","All","18 Years and older   (Adult, Older Adult)",,"275","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020.140.IRB1.030","April 27, 2020","November 30, 2020","December 31, 2020","April 27, 2020",,"May 13, 2020","Koc University, Istanbul, Turkey|Koc Healthcare Istanbul American Hospital, İstanbul, Turkey|Marmara University Pendik Education and Research Hospital, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04363333"
892,"NCT04351711","Immunological Profiling of Patients With COVID-19 in Respiratory Distress","ACTICOV-2","Not yet recruiting","No Results Available","SARS-CoV-2|Covid-19","Other: Immunological profiling","Membrane expression of Human Leukocyte Antigen -DR isotype compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 38 compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of Programmed cell death 1 protein compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 45RA compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 27 (naïve/central memory/effector memory) compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of CD57 on T CD4+ and T CD8+ cells compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 27 on T CD4+ and T CD8+ cells compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 28 on T CD4+ and T CD8+ cells compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of Human Leukocyte Antigen -DR isotype on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 69 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 56 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 57 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 14 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 16 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)|Number of regulatory T cells (CD4+CD25hiCD127loFoxP3+).|Percentage of regulatory T cells (CD4+CD25hiCD127loFoxP3+).|Rate of circulating Immunoglobulin A compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Immunoglobulin G compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Immunoglobulin M compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Soluble cluster of differentiation 14 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Soluble cluster of differentiation 163 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Ultrasensitive C-Reactive Protein compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Soluble tumor necrosis factor alpha receptor type I compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating E-selectin (cluster of differentiation 62E) compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Granulocyte Macrophage Colony-Stimulating Factor compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating InterCellular Adhesion Molecule-1 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interferon alpha compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interferon beta compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interferon gamma compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-1 alpha compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-1 beta compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-4 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-6 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-8 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-10 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-12p70 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-13 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-17A compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Induced Protein 10 (C-X-C motif chemokine 10) compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Monocyte Chemoattractant Protein-1 (C-C Motif Chemokine Ligand 2) compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Macrophage inflammatory protein-1 alpha (C-C Motif Chemokine Ligand 3) compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Macrophage inflammatory protein-1 beta (C-C Motif Chemokine Ligand 4) compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating P-selectin compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of tumor necrosis factor alpha compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of tissue plasminogen activator compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of soluble form of endothelial protein C receptor compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of D-Dimers compared to normal values (based on 150 healthy volunteers previously sampled)|Compare the immune activation phenotype (defined in primary outcome) of patients affected by COVID-19 before any respiratory distress against that of 150 volunteers from the general population (data already existing).|Compare the immune activation phenotype (defined in primary outcome) of patients affected by COVID-19 with respiratory failure against versus those without respiratory failure|Mortality rate|Comparison of E-selectin levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Granulocyte Macrophage Colony-Stimulating Factor levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of InterCellular Adhesion Molecule levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interferon alpha levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interferon gamma levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-1alpha levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-1beta levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-4 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-6 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-8 (C-X-C motif ligand 8) levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-10 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-12p70 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-13 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-17A levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Induced Protein -10 (C-X-C motif chemokine 10) levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Monocyte Chemoattractant Protein-1 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Macrophage Inflammatory Protein-1alpha levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Macrophage Inflammatory Protein -1beta levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of P-Selectin levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Tumor necrosis factor alpha levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Identify inflammatory mediators over-produced by the PBMC of patients with COVID-19 before respiratory distress|Compare the inflammatory mediators over-produced by the peripheral blood mononuclear cells of patients with COVID-19 with versus without respiratory failure|Comparison of transcriptome from peripheral blood mononuclear cells from 12 patients with respiratory failure (from intensive care ward) and 10 without (normal hospitalization)","Centre Hospitalier Universitaire de Nīmes|Institute of Human Genetics, Montpellier","All","18 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","NIMAO/2020-01/PC-01","April 2020","October 2020","October 2020","April 17, 2020",,"April 17, 2020","CHU de Nimes, Nîmes, France",,"https://ClinicalTrials.gov/show/NCT04351711"
893,"NCT04359680","Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers",,"Recruiting","No Results Available","COVID-19|Viral Respiratory Illnesses","Drug: Nitazoxanide|Drug: Placebo|Dietary Supplement: Vitamin Super B-Complex","The proportion of subjects with symptomatic laboratory-confirmed COVID-19 identified after start of treatment and before the end of the 6-week treatment period.|The proportion of subjects with symptomatic laboratory-confirmed VRI identified after the start of treatment and before the end of the 6-week treatment period.","Romark Laboratories L.C.","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 3","800","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","RM08-3007","May 13, 2020","August 31, 2020","August 31, 2020","April 24, 2020",,"June 4, 2020","Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Integrative Clinical Trials LLC, Brooklyn, New York, United States|Centex Studies, Inc., Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04359680"
894,"NCT04283461","Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)",,"Recruiting","No Results Available","COVID-19|COVID-19 Immunisation","Biological: mRNA-1273","Frequency of solicited local reactogenicity adverse events (AEs)|Frequency of any medically-attended adverse events (MAAEs)|Frequency of any new-onset chronic medical conditions (NOCMCs)|Frequency of any serious adverse events (SAEs)|Frequency of any unsolicited adverse events (AEs)|Frequency of solicited systemic reactogenicity adverse events (AEs)|Grade of any unsolicited adverse events (AEs)|Grade of solicited local reactogenicity adverse events (AEs)|Grade of solicited systemic reactogenicity adverse events (AEs)|Geometric mean fold rise (GMFR) in IgG titer from baseline|Geometric mean titer (GMT) of antibody|Percentage of subjects who seroconverted","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","155","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","20-0003|1UM1AI148373-01","March 16, 2020","November 22, 2021","November 22, 2021","February 25, 2020",,"May 29, 2020","Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|National Institutes of Health - Clinical Center - Vaccine Research Center Clinical Trials Program, Bethesda, Maryland, United States|Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04283461"
895,"NCT04400929","Using GM-CSF as a Host Directed Therapeutic Against COVID-19",,"Not yet recruiting","No Results Available","COVID|Sars-CoV2|ARDS, Human","Drug: Sargramostim|Other: Normal Saline 0.9%","Measuring oxygenation","Singapore General Hospital","All","21 Years to 80 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SH-Leuk-01","June 2020","June 2021","June 2022","May 26, 2020",,"May 26, 2020",,,"https://ClinicalTrials.gov/show/NCT04400929"
896,"NCT04382651","Study of Efficacy and Safety of MAS825 in Patients With COVID-19","MAS-COVID","Recruiting","No Results Available","COVID-19 Pneumonia, Impaired Respiratory Function","Drug: MAS825|Drug: Matching placebo","APACHE II severity of disease score on Day 15 or on day of discharge (whichever is earlier)|Serum C-reactive protein (CRP levels)|Ferritin levels|Proportion of participants without the need for invasive mechanical ventilation|Proportion of participants with at least one level improvement in clinical status|Clinical status over time","Novartis Pharmaceuticals|Novartis","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CMAS825F12201","June 11, 2020","August 19, 2020","December 1, 2020","May 11, 2020",,"June 23, 2020","Novartis Investigative Site, Chula Vista, California, United States|Novartis Investigative Site, La Mesa, California, United States|Novartis Investigative Site, Mission Hills, California, United States|Novartis Investigative Site, Santa Monica, California, United States|Novartis Investigative Site, Torrance, California, United States|Novartis Investigative Site, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04382651"
897,"NCT04397666","RT-PCR on Conjunctival Sample for the Detection of SARS-CoV-2 in Patients With Covid-19","P20/09","Recruiting","No Results Available","Covid 19 , Conjunctivitus","Diagnostic Test: conjunctival RT PCR","the SARS-Cov-2 positivity rate in patients with Covid-19 with or without signs of conjunctivitis","Versailles Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","68","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","P20/09_COVEYES","May 15, 2020","September 15, 2020","November 15, 2020","May 21, 2020",,"May 21, 2020","Centre Hospitalier de versailles, Le Chesnay, France",,"https://ClinicalTrials.gov/show/NCT04397666"
898,"NCT04350476","COVID-19 Remote Monitoring",,"Not yet recruiting","No Results Available","COVID-19|Cardiac Arrhythmias","Diagnostic Test: VitalConnect Vital Sign Patch","Number of different arrhythmias|Temperature|Oxygen Saturation","Vivek Reddy|Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","GCO 20-0932","July 2020","April 2021","April 2021","April 17, 2020",,"May 13, 2020","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04350476"
899,"NCT04372017","Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection",,"Active, not recruiting","No Results Available","COVID-19|SARS-CoV 2","Drug: Hydroxychloroquine|Dietary Supplement: Vitamin D","Cohort A: Percentage of COVID-19 exposed healthcare workers treated with hydroxychloroquine with a positive COVID-19 test.|Cohort B: Percentage of COVID-19 exposed high-risk individuals treated with hydroxychloroquine with a positive COVID-19 test.","Sanford Health","All","18 Years and older   (Adult, Older Adult)","Phase 3","1","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","PEPCOH","May 14, 2020","June 4, 2020","June 4, 2021","May 1, 2020",,"June 9, 2020","Sanford Health, Sioux Falls, South Dakota, United States",,"https://ClinicalTrials.gov/show/NCT04372017"
900,"NCT04413955","Registry of Seraph®-100 Microbind® Affinity Blood Filter for COVID-19 Under EUA",,"Not yet recruiting","No Results Available","COVID-19|SARS-CoV 2","Device: Seraph®-100 Microbind® Affinity Blood Filter","Rate of known, expected, or unanticipated adverse device effects|Change in cardiovascular hemodynamic stability|Change in cardiovascular hemodynamic support|Change in pulmonary/respiratory status|Change in laboratory measures of cytokine reactions and/or viral sepsis: IL-6|Change in laboratory measures of cytokine reactions and/or viral sepsis: CRP|Change in laboratory measures of cytokine reactions and/or viral sepsis: Ferritin|Change in laboratory measures of cytokine reactions and/or viral sepsis: D-Dimer|Change in laboratory measures of cytokine reactions and/or viral sepsis: ALC","Children's Hospital Medical Center, Cincinnati|ExThera Medical Corporation","All","18 Years and older   (Adult, Older Adult)",,"100","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","001-Seraph®-100 for SARS-CoV-2","May 31, 2020","December 31, 2021","December 31, 2021","June 4, 2020",,"June 4, 2020",,,"https://ClinicalTrials.gov/show/NCT04413955"
901,"NCT04384471","Covid-19 Pandemic: Patients' Experience in T1D",,"Enrolling by invitation","No Results Available","Type1diabetes|Covid19","Other: Online survey","Self-reported acute diabetes complication|Self-reported hypoglycemia|Ability to get diabetes supplies and to access diabetes care|Concern about not having access to diabetes supplies and to access diabetes care|Impact of the pandemic situation on daily life activities|Impact on stress, anxiety and depression for adults participants|Impact on stress, anxiety and depression for children and adolescents","McGill University|Juvenile Diabetes Research Foundation|Canadian Institutes of Health Research (CIHR)","All","1 Year and older   (Child, Adult, Older Adult)",,"384","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","2021-1079","April 29, 2020","July 1, 2020","January 1, 2021","May 12, 2020",,"May 12, 2020","Institut de Recherches Cliniques de Montréal, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04384471"
902,"NCT04449380","Clinical Study for the Treatment With Interferon-ß-1a (IFNß-1a) of COVID-19 Patients","INTERCOP","Not yet recruiting","No Results Available","COVID-19 Virus Infection","Drug: Interferon-ß-1a|Combination Product: Standard of Care (SOC)","Time to negative conversion of SARS-CoV-2 nasopharyngeal swab|Improvement in clinical severity score (a)|Improvement in clinical severity score (b)|Incidence of new oxygen use, non-invasive ventilation, or high flow oxygen devices during the trial|Oxygenation free days in the first 28 days|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial|Number of patients transferred to Intensive Care Unit (ICU)|Mortality rate|Changes from baseline in pulmonary computed tomography (CT) imaging severity score|Duration of hospital stay expressed in days|Viral load measured on plasma with RT-PCR","IRCCS San Raffaele","All","18 Years and older   (Adult, Older Adult)","Phase 2","126","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INTERCOP","July 2020","February 2021","April 2021","June 26, 2020",,"June 26, 2020","IRCCS Ospedale San Raffaele, Milano, Italy",,"https://ClinicalTrials.gov/show/NCT04449380"
903,"NCT04407468","Awake Prone Positioning and Oxygen Therapy in Patients With COVID-19","APRONOX","Recruiting","No Results Available","COVID|ARDS|Pneumonia","Procedure: Prone position","analyze the relationship between the prone position and the need for orotracheal intubation.|the impact of the prone position on the partial oxygen saturation / inspired oxygen fraction index (SaO2 / FiO2).","Hospital General San Juan del Rio","All","18 Years and older   (Adult, Older Adult)",,"368","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","1178/SESEQ-HSGJR/08-05-20/UTI","May 1, 2020","July 30, 2020","July 30, 2020","May 29, 2020",,"May 29, 2020","Hospital Materno Celaya, Celaya, Guanajuato, Mexico|Hospital Santo Tomas, Querétaro City, Queretaro, Mexico|Hospital General San Juan del Rio, Querétaro City, Queretaro, Mexico|ISSSTE Hospital Regional Merida, Mérida, Yucatan, Mexico|Hospital General de Zona 48 San PEDRO Xalpa IMSS, Estado De México, Mexico|Hospital Fernando Quiroz Gutierrez, Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT04407468"
904,"NCT04363203","VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)","VA-REACH","Suspended","No Results Available","SARS-CoV-2|COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Placebo oral tablet","Days to resolution of cough, fever and shortness of breath|Days to resolution of all COVID-19 symptoms|All cause hospitalization|All cause mortality|COVID-19 specific mortality|COVID-19 specific hospitalization","Salomeh Keyhani MD|San Francisco VA Health Care System","All","216 Months and older   (Adult, Older Adult)","Phase 3","300","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20-30517","April 30, 2020","March 2021","August 2021","April 27, 2020",,"June 22, 2020","San Francisco VA, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT04363203"
905,"NCT04394793","Low Dose Radiation Therapy for Covid-19 Pneumonia",,"Recruiting","No Results Available","COVID-19|Pneumonia","Radiation: Low dose radiation therapy","Symptomatic improvement by National Early warning score (NEWS)|Length of hospital stay|Number of ICU admissions or deaths","All India Institute of Medical Sciences, New Delhi","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID-AIIMS","June 13, 2020","July 2020","August 2020","May 19, 2020",,"June 16, 2020","All India Institute of Medical Sciences, New Delhi, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT04394793"
906,"NCT04343781","National Survey of Symptoms of People Aged 70 and Overs Diagnosed With COVID-19","COVID19PUGG2","Completed","No Results Available","SARS-CoV-2|COVID-19","Other: observation","symptoms of COVID-19 in older patients","University Hospital, Angers","All","70 Years and older   (Older Adult)",,"353","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","ar20-0031v1","March 22, 2020","April 5, 2020","April 5, 2020","April 13, 2020",,"June 16, 2020","Angers University Hospital, Angers, France",,"https://ClinicalTrials.gov/show/NCT04343781"
907,"NCT04393558","Wearable Sensor to Monitor COVID-19 Like Signs and Symptoms",,"Recruiting","No Results Available","COVID-19|Healthy Control","Device: ADAM Sensor","Body temperature|Cough Frequency|Respiratory frequency|Heart Rate Instantaneous heart rate every 15 minutes.","Shirley Ryan AbilityLab","All","18 Years to 95 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","STU00212522","April 20, 2020","December 31, 2022","December 31, 2022","May 19, 2020",,"May 21, 2020","Shirley Ryan AbilityLab, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04393558"
908,"NCT04343248","Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)",,"Recruiting","No Results Available","COVID-19|Viral Respiratory Illnesses","Drug: Nitazoxanide|Drug: Placebo|Dietary Supplement: Vitamin Super B-Complex","Symptomatic laboratory-confirmed COVID-19|Symptomatic laboratory-confirmed VRI","Romark Laboratories L.C.","All","65 Years to 120 Years   (Older Adult)","Phase 3","800","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","RM08-3006","May 12, 2020","August 31, 2020","August 31, 2020","April 13, 2020",,"June 4, 2020","The Chappel Group Research, Kissimmee, Florida, United States|Clinical Trial Specialists, Inc., Acworth, Georgia, United States|Centex Studies, Inc., Lake Charles, Louisiana, United States|Centex Studies, Inc., Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04343248"
909,"NCT04353271","Trial of Hydroxychloroquine In Covid-19 Kinetics","THICK","Active, not recruiting","No Results Available","Covid 19|Corona Virus Infection","Drug: Hydroxychloroquine|Other: Placebo","Percentage of virus free subjects|Disease severity|Incidence of hospitalization|Incidence of Death|Incidence of confirmed SARS-CoV-2 Detection|Incidence of all-cause study medication discontinuation or withdrawal|Immunity to Covid-19","University of South Alabama","All","19 Years to 85 Years   (Adult, Older Adult)","Phase 2|Phase 3","58","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","[1582736-1]","April 17, 2020","July 1, 2020","December 1, 2020","April 20, 2020",,"April 28, 2020","University of South Alabama, Mobile, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT04353271"
910,"NCT04413838","Efficiency and Security of NIVOLUMAB Therapy in Obese Individuals With COVID-19(COrona VIrus Disease) Infection","NIVISCO","Not yet recruiting","No Results Available","Obesity, COVID-19 Infection","Drug: NIVOLUMAB|Other: Routine standard of care","Patient's clinical state|Readmission|Mortality|Oxygen flow needs|Requirement of oxygen|Discharge from hospital|Adverse events|Presence of nasopharyngeal SARS-CoV-2|nasopharyngeal SARS-CoV-2 viral charge|Number of total Lymphocytes T|Number of CD3+ Lymphocytes T(lymphocyte subpopulation of CD3+ T cells)|Number of CD4+ Lymphocytes T(lymphocyte subpopulation of CD4+ T cells)|Number of CD8+ Lymphocytes T(lymphocyte subpopulation of CD8+ T cells)|Interleukin 6 (IL-6)|Interleukin 10 (IL-10)|Tumor Necrosis Factor alpha (TNFα )|Interferon gamma (IFNγ)|Type I Interferon (type I IFN)|Tim3 expression|PD1 expression|PD-L1 expression|Human Leukocyte Antigen - DR isotype gene expression (HLA-DR expression)|Production of IFNγ by lymphocytes T|Production of granzyme B by lymphocytesT|Lipopolysaccharides (LPS)|LBP(LPS-Binding Protein)|sCD14|High Density Lipoproteins|Apolipoprotein","Hospices Civils de Lyon","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","69HCL20_0478","June 15, 2020","June 15, 2021","September 15, 2021","June 4, 2020",,"June 4, 2020","Hôpital Lyon Sud Service Endocrinologie, Diabète et Nutrition, Pierre-Bénite, France",,"https://ClinicalTrials.gov/show/NCT04413838"
911,"NCT04389554","D-dimer Levels in Pregnant With COVID-19",,"Completed","No Results Available","COVID-19|D-dimer","Other: Blood D-dimer assay","Compare D-dimer values of COVID-19 patients and healthy pregnant women","Kanuni Sultan Suleyman Training and Research Hospital","Female","18 Years to 45 Years   (Adult)",,"300","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","MTalmac","May 14, 2020","May 28, 2020","May 29, 2020","May 15, 2020",,"June 1, 2020","Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turgut Ozal, Turkey",,"https://ClinicalTrials.gov/show/NCT04389554"
912,"NCT04367805","COVID-19 Infection in Patients With Hepatocellular Carcinoma","COVID19-CHIEF","Recruiting","No Results Available","Hepatocellular Carcinoma|COVID-19","Diagnostic Test: nasopharyngeal Covid 19 RT-PCR","Incidence of COVID-19 infection in patients with hepatocellular carcinoma in France","Centre Hospitalier Universitaire, Amiens|Centre Hospitalier-Universitaire Bondy|University Hospital, Bordeaux|Centre Hospitalier-Universitaire CLICHY|Centre Hospitalier Général CORBEIL-ESSONNE|CHU CRETEIL|University Hospital, Grenoble|University Hospital, Lille|CHU LYON|Poitiers University Hospital|Rennes University Hospital|University Hospital, Rouen|University Hospital, Toulouse|CHU VILLEJUIF|Central Hospital, Nancy, France|Centre Hospitalier Universitaire de Nice|University Hospital, Montpellier","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PI2020_843_0042","April 27, 2020","October 2020","October 2020","April 29, 2020",,"April 29, 2020","CHU Amiens, Amiens, France",,"https://ClinicalTrials.gov/show/NCT04367805"
913,"NCT04405492","Evaluation of Rapid Diagnostic Solutions, Serological and Molecular Tests for COVID-19","ERap-COV","Not yet recruiting","No Results Available","SARS-CoV 2|COVID-19","Device: Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling.|Device: Capillary and salivary sampling","Clinical performance of several diagnostic tests : tests based either on detection of the virus SARS-CoV-2 or detection of human antibodies generated in response to infection|Sensitivity and specificity of immunological, antigenic, molecular and proteomic tests according to symptom duration, stage of the disease: asymptomatic, ambulatory, hospitalized, ventilated|Description of the incidence of infection among hospital caregivers, time to seroconversion according to clinical form, medium-term antibody persistence|Sensitivity and specificity of immunodiagnostic tests according to the sample used (serum and capillary blood) and according to the duration of the symptoms|Sensitivity and specificity of antigenic rapid tests, molecular tests, proteomic tests according to the sample used (salivary samples or nasopharyngeal swabs) and according to the duration of the symptoms|Suitability of rapid tests in view of its intended purpose for self-testing","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1210","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","APHP200556","May 25, 2020","March 25, 2021","March 25, 2021","May 28, 2020",,"May 28, 2020",,,"https://ClinicalTrials.gov/show/NCT04405492"
914,"NCT04252664","A Trial of Remdesivir in Adults With Mild and Moderate COVID-19",,"Suspended","No Results Available","COVID-19|SARS-CoV-2","Drug: Remdesivir|Drug: Remdesivir placebo","Time to Clinical recoveryTime to Clinical Recovery (TTCR)|All cause mortality|Frequency of respiratory progression|Time to defervescence (in those with fever at enrolment)|Time to cough reported as mild or absent (in those with cough at enrolment rated severe or moderate)|Time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnoea at enrolment rated as severe or moderate,)|Frequency of requirement for supplemental oxygen or non-invasive ventilation|Time to 2019-nCoV RT-PCR negative in upper respiratory tract specimen|Change (reduction) in 2019-nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve.|Frequency of requirement for mechanical ventilation|Frequency of serious adverse events","Capital Medical University|Chinese Academy of Medical Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 3","308","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAP-China remdesivir 1","February 12, 2020","April 10, 2020","April 27, 2020","February 5, 2020",,"April 15, 2020","Jin Yin-tan hospital, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04252664"
915,"NCT04362124","Performance Evaluation of BCG Vaccination in Healthcare Personnel to Reduce the Severity of SARS-COV-2 Infection",,"Not yet recruiting","No Results Available","COVID-19","Biological: vaccine BCG|Other: Placebo","Primary outcome|Secondary outcome","Universidad de Antioquia","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","PEC03_2020","April 2020","June 2021","November 2021","April 24, 2020",,"April 28, 2020","Program for Research and Control in Tropical Diseases - PECET, Medellín, Antioquia, Colombia",,"https://ClinicalTrials.gov/show/NCT04362124"
916,"NCT04348240","Transmissibility and Viral Load of SARS-CoV-2 in Oral Secretions",,"Recruiting","No Results Available","COVID-19",,"To determine SARS-CoV-2 viral load and infectivity in saliva that may contribute to asymptomatic transmission","National Institute of Dental and Craniofacial Research (NIDCR)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"60","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","200094|20-D-0094","April 16, 2020","July 1, 2020","July 1, 2020","April 16, 2020",,"May 21, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04348240"
917,"NCT04397614","Mobile Health Study and Enhanced Symptom Monitoring in COVID-19 Cancer Patients",,"Not yet recruiting","No Results Available","Sars-CoV2|Covid-19","Other: mHealth Assessments","Percentage of ecological momentary assessments completed|Percentage of satisfied mHealth app users|Proportion of manifestation of severe disease|Proportion of treatment-related toxicity|Proportion of hospitalization|Proportion of COVID-19 related mortality","University of Oklahoma","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-19 Mobile Health","June 2020","December 2021","December 2021","May 21, 2020",,"May 21, 2020","Stephenson Cancer Center, Oklahoma City, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT04397614"
918,"NCT04319731","A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure",,"Recruiting","No Results Available","SARS CoV-2 Infection","Biological: Human Amniotic Fluid","Ventilator Free Days|Duration of supplemental oxygen use|All cause mortality|Systemic inflammation","University of Utah","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","131618","March 20, 2020","March 20, 2021","March 20, 2021","March 24, 2020",,"April 17, 2020","University of Utah Health, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04319731"
919,"NCT04385017","Role of Inflammasomes in COVID-19 Disease","CoVInnate","Recruiting","No Results Available","COVID-19 by SARS-CoV-2 Infection","Other: COVID-19 patients","Level of activation of inflammasomes in monocytes and polymorphonuclear neutrophils during COVID-19|Genes nucleoside polymorphism analysis","Centre Hospitalier Universitaire de Nice","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","20-PP-07","May 11, 2020","June 12, 2021","June 12, 2021","May 12, 2020",,"May 12, 2020","Ch Cannes, Réanimation, Cannes, Alpes Maritimes, France|CHU de nice, Nice, Alpes-Maritimes, France",,"https://ClinicalTrials.gov/show/NCT04385017"
920,"NCT04340479","The Use of Ultrasound in Establishing COVID-19 Infection as Part of a Trauma Evaluation",,"Not yet recruiting","No Results Available","COVID|Trauma|Ultrasound","Diagnostic Test: Ultrasound lung imaging as part of FAST+ evaluation","Correlation of FAST+ pulmonary findings with active COVID infection|Description of additional ancillary findings of the FAST+ examination among infected and non-infected patients","University of Colorado, Denver","All","Child, Adult, Older Adult",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-0751","June 2020","May 2022","May 2022","April 9, 2020",,"June 4, 2020","Children's Hospital Colorado, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT04340479"
921,"NCT04329559","COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study",,"Recruiting","No Results Available","COVID-19|Liver Cirrhosis",,"All-cause mortality of COVID-19 patients with liver cirrhosis|Liver-related mortality of COVID-19 patients with liver cirrhosis|Risk factors associated with specific outcomes of COVID-19 patients with liver cirrhosis|Baseline characteristics of COVID-19 patients with liver cirrhosis","Hepatopancreatobiliary Surgery Institute of Gansu Province|Renmin Hospital of Wuhan University|LanZhou University|Minda Hospital Affiliated to Hubei University for Nationalities|Wuhan Union Hospital, China|The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture|Tianjin Second People's Hospital|Sixth People’s Hospital of Shenyang|Guangxi Zhuang Autonomous Region|Shenzhen Third People's Hospital|Ankang Central Hospital|Xingtai People's Hospital|Dalian Sixth People’s Hospital|The Central Hospital of Lishui City|The Affiliated Third Hospital of Jiangsu University|Suizhou Hospital, Hubei University of Medicine","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","CHESS2002","March 30, 2020","June 29, 2020","June 29, 2021","April 1, 2020",,"April 1, 2020","Dalian Sixth People's Hospital, Dalian, China|Minda Hospital Affiliated to Hubei University for Nationalities, Enshi, China|The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture, Enshi, China|The First Hospital of Lanzhou University, Lanzhou, China|The Central Hospital of Lishui City, Lishui, China|Guangxi Zhuang Autonomous Region, Nanning, China|The Sixth Peoples Hospital of Shenyang, Shenyang, China|Shenzhen Third People's Hospital, Shenzhen, China|Suizhou Hospital, Hubei University of Medicine, Suizhou, China|Tianjin Second People's Hospital, Tianjin, China|Ankang Central Hospital, Wuhan, China|Renmin Hospital of Wuhan University, Wuhan, China|Wuhan Union Hospital, Wuhan, China|Xingtai People's Hospital, Xingtai, China|The Affiliated Third Hospital of Jiangsu University, Zhenjiang, China",,"https://ClinicalTrials.gov/show/NCT04329559"
922,"NCT04426253","Identification of Genetic Factors Determining Disease Course in the New Type of Coronavirus Infection, COVID-19",,"Active, not recruiting","No Results Available","COVID-19|Sars-CoV2",,"Identification of genetic factors determining the course of the disease in case of COVID-19","Szeged University","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","COVID19_HUNGEN_001","June 5, 2020","December 31, 2020","July 31, 2021","June 11, 2020",,"June 11, 2020","University of Pécs 1st Department of Internal Medicine Intensive Care Unit, Pécs, Hungary|University of Pécs First Department of Internal Medicine, Pécs, Hungary|University of Pécs Infection Department of the Coronavirus Center, Pécs, Hungary|University of Pécs Institute of Laboratory Medicine, Pécs, Hungary|University of Pécs Szentágotahi Research Centre, Pécs, Hungary|University of Pécs Szentágothai Research Centre Genomics and Bioinformatics Core Facility, Pécs, Hungary|University of Szeged Szentágothai Research Centre Virology Research Group, Pécs, Hungary|University of Szeged Department of Anaesthesiology And Inthensive Therapy, Szeged, Hungary|University of Szeged Department of Dermatology and Allergology, Szeged, Hungary|University of Szeged Department of Medical Biology, Szeged, Hungary|University of Szeged Department of Paediatrics, Szeged, Hungary|University of Szeged First Department of Medicine, Szeged, Hungary|University of Szeged Institute of Clinical Microbiology, Szeged, Hungary|University of Szeged Institute of Medical Microbiology and Immunobiology, Szeged, Hungary",,"https://ClinicalTrials.gov/show/NCT04426253"
923,"NCT04405921","Hydroxychloroquine, Azithromycin in the Treatment of Covid-19","PACTT","Not yet recruiting","No Results Available","SARS-CoV-2 Pneumonia|COVID-19","Drug: Hydroxychloroquine 200 Mg Oral Tablet|Drug: Azithromycin 250 MG","Clinical recovery at day-14, from the start of treatment.|Viral Clearance via RT-PCR at day 5- 7-10 and day 14","Centre Hôpital Universitaire Farhat Hached","All","18 Years and older   (Adult, Older Adult)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","PACTT","July 2020","December 2020","March 2021","May 28, 2020",,"June 19, 2020","University Hospital Farhat Hached, Sousse, Tunisia",,"https://ClinicalTrials.gov/show/NCT04405921"
924,"NCT04346628","Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19",,"Not yet recruiting","No Results Available","Sars-CoV2|COVID-19","Drug: Favipiravir|Drug: Placebo|Other: Standard of care treatment","Time until cessation of oral shedding of SARS-CoV-2 virus|Sars-CoV-2 viral load|Count of participants with clinical worsening of COVID-19 disease|Count of participants with development of SARS-CoV-2 antibodies|Time until cessation of symptoms|Count of participant with absence of development of any symptoms|Cmax of favipiravir|Cmin of favipiravir","Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","56032","July 2020","July 2021","July 2021","April 15, 2020",,"June 29, 2020","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04346628"
925,"NCT04446065","Protection of Health Workers Against COVID-19","HERD","Not yet recruiting","No Results Available","COVID-19|SARS-CoV2","Drug: Previfenon®|Drug: Placebo","Event of clinical acute respiratory disease with a diagnosis of COVID-19 confirmed with rtPCR|Rate of positive cases for IgM and IgG anti-SARS-CoV-2|Composite outcome considering symptomatic and asymptomatic cases with positive rtPCR test|Hospitalization due to any acute respiratory infection|Event of upper and lower airway respiratory infection","MELISA Institute Genomics & Proteomics Research SpA|Universidad Austral","All","25 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","524","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","MEL109042020","July 30, 2020","October 30, 2020","November 30, 2020","June 24, 2020",,"June 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04446065"
926,"NCT04357535","Prognosis of Coronavirus Disease 2019 (COVID-19) Patients Receiving Receiving Antihypertensives",,"Recruiting","No Results Available","COVID-19","Drug: Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB)","Severity of COVID-19 Infection|Degree of severity of respiratory disease|Septic shock as defined by sepsis-3 criteria","Hakeam Abdulaziz Hakeam|Buraidah Central Hospital|King Khalid University Hospital|Princess Nourah Bint Abdulrahman University|King Faisal Specialist Hospital & Research Center","All","18 Years and older   (Adult, Older Adult)",,"226","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2210061","May 10, 2020","July 1, 2020","August 1, 2020","April 22, 2020",,"June 29, 2020","King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT04357535"
927,"NCT04403035","Comparison of the ID NOW and Accula Point-of-Care Assays for Detection of COVID-19",,"Recruiting","No Results Available","Covid-19","Diagnostic Test: ID NOW vs. Accula","Test characteristics","Ascension South East Michigan","All","18 Years to 95 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1599159","May 10, 2020","July 1, 2020","May 9, 2021","May 27, 2020",,"May 27, 2020","Ascension St. John Hospital, Detroit, Michigan, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT04403035/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT04403035/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04403035"
928,"NCT04318301","Hypertension in Patients Hospitalized With COVID-19","HT-COVID19","Completed","No Results Available","COVID-19|Hypertension",,"Rate of Death|the severity of pneumonia","Zhenhua Zen|Nanfang Hospital of Southern Medical University","All","18 Years to 100 Years   (Adult, Older Adult)",,"275","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","HT-COVID19","March 21, 2020","March 28, 2020","March 30, 2020","March 23, 2020",,"April 29, 2020","Hankou Hospital, Hankou, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04318301"
929,"NCT04358068","Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19",,"Active, not recruiting","No Results Available","COVID-19|SARS-CoV 2","Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin","Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset","National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ACTG A5395|38720","May 1, 2020","July 6, 2020","July 6, 2020","April 22, 2020",,"June 29, 2020","Alabama CRS, Birmingham, Alabama, United States|UCSD Antiviral Research Center CRS, San Diego, California, United States|Harbor-UCLA CRS, Torrance, California, United States|Whitman-Walker Health CRS, Washington, District of Columbia, United States|Northwestern University CRS, Chicago, Illinois, United States|Rush University CRS, Chicago, Illinois, United States|Greensboro CRS, Greensboro, North Carolina, United States|Cincinnati Clinical Research Site, Cincinnati, Ohio, United States|University of Pittsburgh CRS, Pittsburgh, Pennsylvania, United States|Trinity Health and Wellness Center CRS, Dallas, Texas, United States|University of Washington AIDS CRS, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04358068"
930,"NCT04318431","Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children","COVILLE","Active, not recruiting","No Results Available","Covid19","Diagnostic Test: Data collection and rhinopharyngeal swab","Proportion of asymptomatic children or children with mild respiratory symptoms|Confirmed Cov2-SARS cases by age|Confirmed Cov2-SARS cases by symptoms|Viral load|Other respiratory viruses|Sars-Cov2 IgM|Sars-Cov2 IgG","Centre Hospitalier Intercommunal Creteil|Association Clinique Thérapeutique Infantile du val de Marne","All","up to 15 Years   (Child)","Not Applicable","605","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","COVILLE|2020-A00724-35","April 14, 2020","May 12, 2020","June 2020","March 24, 2020",,"June 4, 2020","Cabinet du Dr Belaroussi, Boulogne, France|Cabinet du Dr Derkx, Champigny-sur-Marne, France|Cabinet du Dr Coicadan, Chennevières-sur-Marne, France|14 Av rené Samuel, Clamart, France|Cabinet du Dr Corrard, Combs-la-Ville, France|10 rue Delambre, Lagny-sur-Marne, France|157 Avenue du Général Leclerc, Maisons-Alfort, France|21 Grande Rue Charles de Gaulle, Nogent-sur-Marne, France|Cabinet du Dr Deberdt, Nogent-sur-Marne, France|Cabinet du Dr Wollner, Nogent-sur-Marne, France|4 allée des Norottes, Noisy-le-Grand, France|Cabinet du Dr D'acremont, Paris, France|146 Avenue Ledru Rollin, Paris, France|132 Boulevard du Montparnasse, Paris, France|Cabinet du Dr Romain, Paris, France|Cabinet du Dr Turberg-Romain, Paris, France|15 Quai Louis Blériot, Paris, France|Cabinet du Dr Michot, Paris, France|24 rue Volta, Puteaux, France|Cabinet du Dr Cohen, Saint-Maur-des-Fossés, France|Cabinet de Pédiatrie des Docteurs Ravilly et Bessa, Villejuif, France|13 Villa Beauséjour, Vincennes, France",,"https://ClinicalTrials.gov/show/NCT04318431"
931,"NCT04397172","Intensive Care Associated Complications and Outcome of Acute Respiratory Distress Syndrome Due to COVID-19",,"Recruiting","No Results Available","COVID|Corona Virus Infection|Sars-CoV2","Procedure: Study Arm","Short Form (36) Health Survey (SF-36)|Mortality|Modified Rankin Scale (mRS)|Duration of mechanical ventilation in days|Barthel Index|Beck's Depression Inventory II (BDI-II)|Essener Questionnaire for Coping with a Disease (EFK)|Number of patients with Critical Illness Myopathy","University Hospital Inselspital, Berne","All","18 Years to 80 Years   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-00730","April 9, 2020","April 2021","December 2021","May 21, 2020",,"May 22, 2020","Inselspital Bern, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT04397172"
932,"NCT04361526","Pilot Study on Cytokine Filtration in COVID-19 ARDS","CytokCOVID19","Recruiting","No Results Available","Coronavirus Infection|Acute Respiratory Distress Syndrome|COVID","Device: Cytokine Adsorption","Mechanical ventilation-free days|30-day mortality|length of ICU stay (days)|length of hospital stay|Duration of renal replacement and cathecolamines therapies|Need for extracorporeal membrane oxygenation (ECMO) support|multi-organ failure measured by the Sequential Organ Failure Assessment (SOFA) score","Manuel Castellà|Hospital Clinic of Barcelona","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HCB/2020/0464","April 17, 2020","July 2020","July 2020","April 24, 2020",,"April 24, 2020","Hospital Clínic de Barcelona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04361526"
933,"NCT04377815","Finding Out if COVID-19 Infection Can be pREdicted by ChAnges in Smell and/or Taste","FORECAST","Recruiting","No Results Available","COVID-19|Anosmia","Other: General Public cohort","Percentage of people reporting changes in smell/taste|mortality rate|Percentage of people with change in smell/taste before other symptoms|proportion of other COVID-19 linked symptoms in people with smell and/or taste change|Percentage of people with persistent changes in smell and/or taste|Percentage of hospitalisation|co-morbidities association|prevalence of changes in smell/taste|clinical outcomes","University College, London","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Other","132311|20/HRA/1879","April 23, 2020","August 30, 2020","December 23, 2020","May 6, 2020",,"May 6, 2020","University College London Hospital, London, United Kingdom|GP Practices, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04377815"
934,"NCT04280588","Fingolimod in COVID-19",,"Recruiting","No Results Available","Coronavirus Disease (COVID-19)","Drug: Fingolimod 0.5 mg","The change of pneumonia severity on X-ray images","First Affiliated Hospital of Fujian Medical University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MRCTA, ECFAH of FMU [2020]027","February 22, 2020","July 1, 2020","July 1, 2020","February 21, 2020",,"February 21, 2020","Wan-Jin Chen, Fuzhou, China",,"https://ClinicalTrials.gov/show/NCT04280588"
935,"NCT04402814","IgG/IgM Antibody Test in Patients Who Have Tested Negative or Positive for COVID-19 With Nasopharyngeal PCR Testing.",,"Recruiting","No Results Available","SARS-CoV 2","Diagnostic Test: Clungene rapid test cassette","IgG/IgM antibodies","Fadi Haddad, M.D.|Sharp HealthCare","All","18 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IgG/IgM COVID19|2005801","May 5, 2020","October 1, 2020","December 1, 2020","May 27, 2020",,"May 27, 2020","Fadi A. Haddad MD Inc., La Mesa, California, United States|Sharp Grossmont Hospital, La Mesa, California, United States|Sharp Memorial Hosptial, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT04402814"
936,"NCT04374084","Moxibustion Plus Cupping in Convalescent Patients With COVID-19",,"Recruiting","No Results Available","COVID-19|Convalescence","Other: Moxibustion plus Cupping","The change of the average VAS score from baseline to week 4|The change of the average VAS score from baseline to week 2, and week 8|The change of the severity VAS score from baseline to week 2, week 4 and week 8|The change of the average insomnia VAS score from baseline to week 2, week 4 and week 8|The change of the average VAS score of sweating, mental fatigue, anorexia and nervousness from baseline to week 2, week 4 and week 8|The change of the average times of diarrhea and complete spontaneous bowel movement to week 2, week 4 and week 8|The proportion of patients with 50%/75% improvement of clinical symptoms to week 2, week 4 and week 8|The change of the walking distance of six-minute-walking test from baseline to week 2, week 4 and week 8|The change of the lowest oxygen saturation of six-minute-walking test from baseline to week 2, week 4 and week 8|The proportion of patients in recovery of pulmonary function on week 2 and week 4|The proportion of patients whose lung CT return to normal on week 4|The change of the WHO QOL-BREF score from baseline to week 4 and week 8|The change of the SAS score from baseline to week 4 and week 8|The change of the SDS score from baseline to week 4 and week 8|The change of the blood CRP value from baseline to week 4|The change of the blood LYMPH# value from baseline to week 4|The change of the blood NEUT% value from baseline to week 4|The change of the average VAS score from baseline to week 4 in different age groups.|The change of the average VAS score from baseline to week 4 in different gender groups.|The change of the average VAS score from baseline to week 4 in different clinical classification of COVID-19.","Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Hubei Hospital of Traditional Chinese Medicine|Hubei Provincial Hospital of Integrated Chinese & Western Medicine|Wuhan Hospital of Traditional Chinese Medicine|The Third Hospital of Wuhan|Huangshi Hospital of Traditional Chinese Medicine|Yichang Hospital of Traditional Chinese Medicine|Ezhou Hospital of Traditional Chinese Medicine|The First Hospital of Hunan University of Chinese Medicine|The Hospital of Jiangxi University of Traditional Chinese Medicine|Shenzhen Bao'an Traditional Chinese Medicine Hospital Group","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2020YFC0845000","May 10, 2020","December 2021","December 2021","May 5, 2020",,"June 5, 2020","Hubei Province Hospital, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04374084"
937,"NCT04345315","Correlative Study on Cancer Patients and Healthcare Professionals Exposed to Infection by Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-Cov-2), COVID-19 Causative Agent.","CORSA","Recruiting","No Results Available","COVID-19|SARS-CoV-2","Other: serological test|Other: Rapid molecular test|Genetic: Next generation Sequencing (NGS) analysis|Other: serum chemistry analysis","epidemiology|Immunoglobulin G (IgG) and Immunoglobulin M (IgM) antibodies evaluation|methods comparison|correlation between biochemical and coagulative factors with SARS-CoV-2 positivity.|phylogenetic map|interactions between the virus and host cells","Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|AUSL Romagna","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Other","IRSTB113","March 27, 2020","March 2021","March 2022","April 14, 2020",,"April 15, 2020","UO Microbiologia,Centro Servizi Pievesestina, AUSL Romagna, Cesena, FC, Italy|Irst Irccs, Meldola, FC, Italy",,"https://ClinicalTrials.gov/show/NCT04345315"
938,"NCT04354259","Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19","ILIAD","Recruiting","No Results Available","Sars-CoV2|Covid-19","Drug: Peginterferon Lambda-1A|Other: placebo","Cohort A (Ambulatory) - Proportion swab negative at day 7 (Primary efficacy endpoint)|Cohort A (Ambulatory) - Treatment-emergent and treatment related serious adverse events (Primary Safety Endpoint)|Cohort B (Hospitalized) - Time to viral negativity (Primary Efficacy Endpoint)|Cohort B (Hospitalized) - treatment-emergent and treatment-related serious adverse events (Primary Safety Endpoint)|Cohort A (Ambulatory) - Symptom Resolution (Clinical Outcome #1)|Cohort A (Ambulatory) - Symptom severity scores (Clinical Outcome #2)|Cohort A (Ambulatory) - Hospitalization (Clinical Outcome #3)|Cohort A (Ambulatory) - Adverse and serious adverse events (Clinical Outcome #4)|Cohort A (Ambulatory) - Swab negative at day 3 (Virologic/Immunological Outcome #1)|Cohort A (Ambulatory) - Time RNA negativity (Virologic/Immunological Outcome #2)|Cohort A (Ambulatory) - Proportion viremic (Virologic/Immunological Outcome #3)|Cohort A (Ambulatory) - Proportion with antibodies (Virologic/Immunological Outcome #4)|Cohort A (Ambulatory) - Correlation with interferon lambda 4 genotype (Virologic/Immunological Outcome #5)|Cohort A (Ambulatory) - Symptoms in household contacts (Transmission Outcome #1)|Cohort A (Ambulatory) - COVID-19 in household contacts (Transmission Outcome #2)|Cohort B (Hospitalized) - ICU admission (Clinical Outcome #1)|Cohort B (Hospitalized) - Need for intubation (Clinical Outcome #2)|Cohort B (Hospitalized) - Length of hospital stay (Clinical Outcome #3)|Cohort B (Hospitalized) - Change in respiratory symptom score (Clinical Outcome #4)|Cohort B (Hospitalized) - Readmission to hospital (Clinical Outcome #5)|Cohort B (Hospitalized) - All-cause mortality (Clinical Outcome #6)|Cohort B (Hospitalized) - COVID-19-related mortality (Clinical Outcome #7)|Cohort B (Hospitalized) - Adverse (AEs) and Serious Adverse Events (SAEs) (Clinical Outcome #8)|Cohort B (Hospitalized) - Dose reduction or dose omission (Clinical Outcome #9)|Cohort B (Hospitalized) - Proportion negative swab. (Virologic/Immunological Outcome #1)|Cohort B (Hospitalized) - Proportion negative by day 14 (Virologic/Immunological Outcome) #2)|Cohort B (Hospitalized) - Time to negativity by rectal swab (Virologic/Immunological Outcome #3)|Cohort B (Hospitalized) - Correlation with interferon lambda 4 (IFNL4) genotype (Virologic/Immunological Outcome #4)|Cohort B (Hospitalized) - Proportion with Antibody (Virologic/Immunological Outcome #6)|Cohort B (Hospitalized) - Proportion with viremia (Virologic/Immunological Outcome #7)","University Health Network, Toronto","All","18 Years and older   (Adult, Older Adult)","Phase 2","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","JF-4-2020","May 13, 2020","August 1, 2020","November 30, 2020","April 21, 2020",,"May 18, 2020","Toronto General Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04354259"
939,"NCT04412538","Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19",,"Recruiting","No Results Available","COVID-19","Biological: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Biological: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Biological: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Biological: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Biological: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Biological: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Biological: Placebo on a 0- and 28-day schedule|Biological: Placebo on a 0- and 14-day schedule","Adverse reactions/events rate|Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule)|Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule)|Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule)|Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule)|Serious adverse events|Level of Neutralizing antibodies against SARS-CoV-2 Phase Ia (Day 0, 14 schedule)|Level of Neutralizing antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule)|Level of IgG antibodies against SARS-CoV-2 Phase Ia (Day 0, 14 schedule)|Level of IgG antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule)|Level of Neutralizing antibodies against SARS-CoV-2 Phase Ia (Day 0, 28 schedule)|Level of Neutralizing antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule)|Level of IgG antibodies against SARS-CoV-2 Phase Ia (Day 0, 28 schedule)|Level of IgG antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule)|Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase Ia (Day 0, 14 schedule)|Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase Ia (Day 0, 14 schedule)|Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase Ia (Day 0, 28 schedule)|Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase Ia (Day 0, 28 schedule)","Chinese Academy of Medical Sciences|West China Second University Hospital|Yunnan Center for Disease Control and Prevention","All","18 Years to 59 Years   (Adult)","Phase 1|Phase 2","942","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","20200401","May 15, 2020","September 2020","September 2021","June 2, 2020",,"June 4, 2020","West China Second University Hospital, Sichuan University / West China women's and children's Hospital, Chengdu, Sichuan, China",,"https://ClinicalTrials.gov/show/NCT04412538"
940,"NCT04370275","Accuracy of Lung Ultrasound in the Diagnosis of covid19 Pneumonia","POCUSars-CoV-2","Recruiting","No Results Available","COVID-19|Pneumonia, Viral",,"Negative Predictive Value of Lung Ultrasound in the diagnosis of COVID-19|Positive Predictive Value of Lung Ultrasound in the diagnosis of COVID-19|Sensitivity and Specificity of Lung Ultrasound in the diagnosis of COVID-19","Ospedale di Latisana","All","18 Years and older   (Adult, Older Adult)",,"235","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CEUR-2020-Os-086","April 23, 2020","May 23, 2020","May 31, 2020","April 30, 2020",,"April 30, 2020","SC Pronto Soccorso e Medicina d'Urgenza, Latisana, Udine, Italy",,"https://ClinicalTrials.gov/show/NCT04370275"
941,"NCT04363749","COVID-19 Infection: Exploration of Respiratory Control Center Abnormalities","CRC-COVID","Not yet recruiting","No Results Available","Covid19|Neurological Complication","Other: hypoxia : 14.3 and 12.7% FIO2, hypercapnia 7% CO2, inspiratory mechanical constraint","Intensity of the emotional response to hypoxic exposure (14.3 et 12.7% FIO2)|Perception of a hypoxic stimulus induced dyspnea (14.3 et 12.7% FIO2)|Perception of a hypercapnic stimulus induced dyspnea (7% CO2)|Perception of a inspiratory mechanical constraint induced dyspnea|brain MRI","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","APHP200476","April 27, 2020","April 27, 2021","November 27, 2021","April 27, 2020",,"April 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04363749"
942,"NCT04371432","Genetics of COVID-19 Susceptibility and Manifestations",,"Recruiting","No Results Available","COVID-19|Coronavirus 2019",,"Molecular etiology of host susceptibility to severe COVID-19|Mechanisms of disease","National Human Genome Research Institute (NHGRI)|National Institutes of Health Clinical Center (CC)","All","3 Years to 60 Years   (Child, Adult)",,"2500","NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","200090|20-HG-0090","July 2, 2020","June 1, 2025","June 1, 2025","May 1, 2020",,"June 29, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04371432"
943,"NCT04389944","Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19",,"Recruiting","No Results Available","Coronavirus Disease 2019 Infectious Disease (COVID-19 Infection)","Other: convalescent plasma application to SARS-CoV-2 infected patients","Serious adverse events in convalescent plasma treated patients|Virologic clearance in nasopharyngeal swab of convalescent plasma treated patients|Transfer to ICU|in-hospital death|Virologic clearance in plasma of convalescent plasma treated patients|Time to discharge from hospital after enrolment|Humoral immune response","University Hospital, Basel, Switzerland","All","18 Years and older   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Req-2020-00508; me20khanna2","March 31, 2020","June 30, 2020","June 30, 2020","May 15, 2020",,"May 15, 2020","Blutspendezentrum SRK beider Basel, University Hospital Basel, Basel, Switzerland",,"https://ClinicalTrials.gov/show/NCT04389944"
944,"NCT04381286","Transpulmonary Driving Pressure in ARDS COVID19 Patients","TRANSPULMONARY","Recruiting","No Results Available","Mechanical Ventilation|SARS-CoV-2|COVID-19",,"Duration of mechanical Ventilation|Number of Participants with during of Acute respiratory distress syndrom (SDRA)|Length of stay in intensive care unit|Mortality|number of patients with pulmonary complications|Number of Participants with pulmonary stress and strain","University Hospital, Montpellier","All","18 Years to 90 Years   (Adult, Older Adult)",,"40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RECHMPL20_0194","April 1, 2019","April 1, 2021","December 31, 2021","May 8, 2020",,"May 12, 2020","Uhmontpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04381286"
945,"NCT04411433","Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19",,"Recruiting","No Results Available","Sars-CoV2|COVID-19","Drug: Favipiravir (3200 mg + 1200 mg)|Drug: Favipiravir (3600 mg + 1600 mg)|Drug: Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine|Drug: Favipiravir (3200 mg + 1200 mg) combined with Azithromycin|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine combined with Azithromycin","Time to recovery (discharge)|Decrease in viral load|Adverse Event (AE), Serious Adverse Event (SAE) and discontinuation of treatment|Frequency of occurrence of lymphopenia from baseline|Frequency of occurrence of thrombocytopenia from baseline|Changes in alanine aminotransferase (ALT) levels from baseline|Changes in aspartate aminotransferase (AST) levels from baseline|Changes in C-reactive protein (CRP) levels from baseline|Changes in level of D-dimer levels from baseline|Changes in prothrombin time (PT) values from baseline|Changes in partial thromboplastin time (PTT) values from baseline|Changes in blood pressure from baseline|Changes in respiratory rate from baseline|Changes in pulse oxymetry from baseline|Changes in fever from baseline","Ministry of Health, Turkey|Hacettepe University, Faculty of Medicine|Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization|Umraniye Education and Research Hospital|SB Istanbul Education and Research Hospital|Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey|Tepecik Training and Research Hospital|Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine|Ankara University|Ankara City Hospital Bilkent|Ankara Training and Research Hospital|Ege University Hospital (Application and Research Center)|Kocaeli Derince Education and Research Hospital|Istanbul University, Istanbul Faculty of Medicine|Kayseri City Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID-19-FAV","May 8, 2020","July 30, 2020","July 30, 2020","June 2, 2020",,"June 2, 2020","Hacettepe University, School of Medicine, Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT04411433"
946,"NCT04400032","Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome - Vanguard","CIRCA-19","Not yet recruiting","No Results Available","Acute Respiratory Distress Syndrome|Covid19","Biological: Mesenchymal Stromal Cells","Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0|Number of Participants alive by Day 28|Number of Participants with ventilator-free Days by Day 28","Ottawa Hospital Research Institute|Stem Cell Network","All","18 Years and older   (Adult, Older Adult)","Phase 1","9","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20200243-01H","May 2020","January 2021","June 2021","May 22, 2020",,"May 22, 2020","The Ottawa Hospital, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04400032"
947,"NCT04435808","Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine","SARS-CoV-2 Infection|Symptomatic vs. Asymptomatic Infection with SARS-CoV-2|Occupational Health Exposure|Impact of Hydroxychloroquine use on Need for Hospitalization with SARS-CoV-2 Infection|Impact of Hydroxychloroquine use on Need for ICU Care with SARS-CoV-2 Infection|Adverse Effect Profile of Hydroxychloroquine|Seroconversion Following SARS-CoV-2 Infection|Metagenomic Next Generation Sequencing of SARS-CoV-2 Isolates","University of New Mexico","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","350","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","20-206","April 14, 2020","April 14, 2021","April 14, 2025","June 17, 2020",,"June 17, 2020","University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT04435808/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04435808"
948,"NCT04336332","Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19",,"Recruiting","No Results Available","SARS-CoV-2|COVID-19","Combination Product: Hydroxychloroquine Sulfate + Azithromycin|Drug: Hydroxychloroquine Sulfate","Changes in patients viral load|Second evaluation of changes in patients viral load|Symptom questionnaire|Fever assessment|Vital Signs - Body Temperature|Discharge|Recovery|Assessment of agent toxicity|Oropharynx swab sample collections|Blood Sample collections|Viral shedding assessment - nasopharyngeal secretions|Viral shedding assessment - serology|Cytokines in blood","Rutgers, The State University of New Jersey","All","18 Years and older   (Adult, Older Adult)","Phase 2","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","002011|Pro2020000712","April 1, 2020","April 30, 2021","April 30, 2021","April 7, 2020",,"May 8, 2020","Saint Barnabas Medical Center, Livingston, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Robert Wood Johnson University Hopsital, New Brunswick, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|The University Hospital, Newark, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04336332"
949,"NCT04352608","Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)",,"Recruiting","No Results Available","COVID-19","Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Biological: Two doses of placebo at the emergency vaccination schedule|Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Biological: Two doses of placebo at the routine vaccination schedule","Safety indexes of adverse reactions|Immunogenicity indexes of neutralizing-antibody seroconversion rates for the emergency vaccination schedule （day 0,14）|Immunogenicity indexes of neutralizing-antibody seroconversion rates for the routine vaccination schedule (day 0,28)|Occurrence of abnormal changes of laboratory safety examinations (hemoglobin,WBCs, platelets, ALT, AST, total bilirubin, creatinine, creatine phosphokinase, urine protein, urine sugar, urinary erythrocyte)|Safety indexes of serious adverse events (SAEs）|Immunogenicity indexes of neutralizing-antibody seroconversion rates|Immunogenicity indexes of IgG antibody seropositivity rates|Immunogenicity indexes IgM antibody seropositivity rates|Immunogenicity indexes of GMT of neutralizing-antibody|Immunogenicity indexes of GMR of neutralizing-antibody","Sinovac Research and Development Co., Ltd.|Sinovac Biotech Co., Ltd","All","18 Years to 59 Years   (Adult)","Phase 1|Phase 2","744","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PRO-nCOV-1001","April 16, 2020","August 13, 2020","December 13, 2020","April 20, 2020",,"April 28, 2020","Suining County Center for Disease Control and Prevention, Xuzhou, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT04352608"
950,"NCT04383574","Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19)",,"Not yet recruiting","No Results Available","COVID-19","Biological: Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|Other: Two doses of placebo at the schedule of day 0,28","Safety index-incidence of adverse reactions|Immunogenicity index-seroconversion rates of neutralizing antibody|Safety index-incidence of serious adverse events|Immunogenicity index-seropositive rates of neutralizing antibody|Immunogenicity index-geometric mean titer (GMT) of neutralizing antibody|Immunogenicity index-geometric mean ratio (GMR) of neutralizing antibody","Sinovac Research and Development Co., Ltd.|Sinovac Biotech Co., Ltd","All","60 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","422","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","PRO-nCOV-1002","May 20, 2020","July 20, 2020","July 20, 2020","May 12, 2020",,"May 12, 2020","Renqiu City Center for Disease Control and Prevention, Renqiu, Hebei, China",,"https://ClinicalTrials.gov/show/NCT04383574"
951,"NCT04379154","Analysis of Volatile Organic Compounds by Electronic Noses in Hospitalised Patients for an Infection by SARS-CoV-2 (COVID-19)","VOC-COVID","Recruiting","No Results Available","COVID-19","Device: Volatile Organic Compounds analysis","Profiles of volatile organic compounds (VOCs) in exhaled air between 2 health conditions|Profiles of volatil organic compounds (VOCs) in exhaled air on 1 health condition|Profiles of volatil organic compounds (VOCs) in exhaled air between 2 periods","Hopital Foch","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2020_0060","April 14, 2020","June 28, 2020","November 16, 2020","May 7, 2020",,"May 7, 2020","Hôpital Foch, Suresnes, France",,"https://ClinicalTrials.gov/show/NCT04379154"
952,"NCT04346017","Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome",,"Recruiting","No Results Available","COVID-19","Diagnostic Test: Cytokines dosage|Diagnostic Test: Complement dosage","IL6 concentration|IL6 concentration change from baseline value|Complement parameters|Complement parameters change from baseline values|Inflammatory cytokines baseline concentrations|Inflammatory cytokines change from baseline values|Concentration of markers of macrophage activation|Markers of macrophage activation change from baseline values","Francis Corazza|Brugmann University Hospital","All","Child, Adult, Older Adult","Not Applicable","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CHUB-IL6-COVID-19","March 20, 2020","December 2020","December 2020","April 15, 2020",,"April 15, 2020","CHU Brugmann, Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT04346017"
953,"NCT04331106","Survey of the Anxiety Associated With the COVID-19 Pandemic","CORA","Recruiting","No Results Available","Anxiety Related to the COVID-19 Pandemic","Diagnostic Test: Online Questionnaire","Characteristics of COVID-19-related anxiety|COVID-19-related anxiety symptoms|Self-efficacy and coping with COVID-19|Consequences of COVID-19 in the last three weeks.|General Illness Attitude|Media reporting|Ultra-brief screening scale for anxiety and depression|Change in characteristics of COVID-19-related anxiety|Change in COVID-19-related anxiety symptoms","Charite University, Berlin, Germany","All","18 Years and older   (Adult, Older Adult)",,"6000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EA1/071/20","March 27, 2020","September 2020","September 2021","April 2, 2020",,"April 13, 2020","Charité-Universitätsmedizin Berlin - Department of Psychiatry and Psychotherapy, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT04331106"
954,"NCT04344457","Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19","COVID-19","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Indomethacin|Drug: Zithromax Oral Product","Improvement of clinical status|Time of clinical recovery of fever|Time of clinical recovery of cough|Safety as determined by changes in QTC intervals measured by ECG|Safety as determined by presence of side effects|Time to improvement","Perseverance Research Center, LLC|Athena Medical Group","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","80","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HIZ-PRC-COVID-19","April 16, 2020","June 20, 2020","September 30, 2020","April 14, 2020",,"April 30, 2020","Perseverance Research Center, Scottsdale, Arizona, United States|Covidcraz 19, Llc, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT04344457"
955,"NCT04393961","At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study",,"Recruiting","No Results Available","COVID19|COVID-19|Coronavirus","Device: Premier Biotech COVID-19 IgG/IgM Rapid test Cassette","Does Participant Accurately Read Result|Acceptability and Usability of Tests|Social Distancing Behavior Change|COVID-19 Related Anxiety","ProofPilot|Radish Health|Sanesco","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","600","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","2458","April 5, 2020","July 29, 2020","August 29, 2020","May 19, 2020",,"May 19, 2020","ProofPilot Online App (https://p.proofpilot.com), New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04393961"
956,"NCT04368988","Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant",,"Recruiting","No Results Available","COVID-19","Biological: SARS-CoV-2 rS|Other: Matrix-M Adjuvant|Other: NSS Saline Placebo","Subjects with solicited AEs - Phase 1|Safety Laboratory Values (serum chemistry, hematology) - Phase 1|Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) - Phase 1","Novavax","All","18 Years to 59 Years   (Adult)","Phase 1","131","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","2019nCoV-101","May 25, 2020","December 31, 2020","July 31, 2021","April 30, 2020",,"May 27, 2020","Investigational Research Site 1, Herston, Queensland, Australia|Investigational Research Site 2, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT04368988"
957,"NCT04414124","A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19",,"Recruiting","No Results Available","Mild-to-moderate COVID-19","Other: KB109 + Self Supportive Care (SSC)|Other: Self Supportive Care (SSC) Alone","Number of patients experiencing study-product related treatment-emergent adverse events (TEAEs)|Change from baseline to end of intake in overall composite COVID-19 symptom score|Time to resolution of fever|Proportion of patients with decreased oxygen saturation|Effect of COVID-19 symptoms on physical activities|Proportion of patients requiring hospitalization","Kaleido Biosciences","All","18 Years and older   (Adult, Older Adult)","Not Applicable","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","K031-120","June 2020","October 2020","December 2020","June 4, 2020",,"June 4, 2020","Medical Center for Clinical Research, San Diego, California, United States|Mount Vernon Clinical Research, Atlanta, Georgia, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Wake Research - Clinical Research Center of Nevada, LLC, Las Vegas, Nevada, United States|Carolina Institute For Clinical Research, Fayetteville, North Carolina, United States|M3 Wake Research, Inc, Raleigh, North Carolina, United States|ClinSearch LLC, Chattanooga, Tennessee, United States|Global Medical Research, DeSoto, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04414124"
958,"NCT04406090","Endovascular Thrombectomy in COVID-19 Infected Patients","ET-COVID-19","Recruiting","No Results Available","Ischemic Stroke|Covid 19","Other: Mechanical Trombectomy","Intrahospital mortality|short-term morbidity|Angiographic success","University Hospital, Montpellier","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","RECHMPL20_0322","April 1, 2020","June 30, 2020","June 30, 2020","May 28, 2020",,"May 28, 2020","Uhmontpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04406090"
959,"NCT04420741","Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure","COMBAT-COVID","Recruiting","No Results Available","COVID-19|Respiratory Failure","Drug: Iloprost|Drug: Isotonic saline","Mechanical ventilation free days|28 and 90-day mortality|Modified Sequential Organ Failure Assessment (SOFA)|Vasopressor free days|Renal replacement free days|Serious adverse reactions (SARs)|Serious adverse events (SAEs)","Pär Johansson|Rigshospitalet, Denmark","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COMBAT-COVID-19|2020-001296-33","June 15, 2020","May 31, 2021","May 31, 2021","June 9, 2020",,"June 23, 2020","Dept. of Anaesthesia and Intensive Care, Bispebjerg Hospital, Copenhagen, Denmark|Dept. of Intensive Care, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark|Dept. of Intensive Care, Copenhagen University Hospital Herlev, Herlev, Denmark|Dept. of Anaesthesia and Intensive Care, Nordsjaelands Hospital, Hillerød, Denmark|Dept. of Anaesthesia and Intensive Care, Hvidovre Hospital, Hvidovre, Denmark",,"https://ClinicalTrials.gov/show/NCT04420741"
960,"NCT04351152","Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia",,"Recruiting","No Results Available","Coronavirus Disease 2019 (COVID-19) Pneumonia","Biological: Lenzilumab|Drug: Standard of Care","Incidence of invasive mechanical ventilation (IMV) and/or Mortality|Incidence of acute respiratory distress syndrome (ARDS)|Duration of Hospitalization|Duration of Intensive Care Unit (ICU) Stay|Ventilator-free Days|Incidence of Non-invasive Ventilation|Proportion of Participants Alive and Off Oxygen|Percentage of Participants Experiencing Adverse Events|Percentage of Participants Experiencing Serious Adverse Events","Humanigen, Inc.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","238","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","HGEN003-06","April 30, 2020","September 2020","September 2020","April 17, 2020",,"June 11, 2020","Mayo Clinic, Phoenix, Arizona, United States|Mayo Clinic, Jacksonville, Florida, United States|AdventHealth Orlando, Orlando, Florida, United States|Emory University, Atlanta, Georgia, United States|Mayo Clinic, Rochester, Minnesota, United States|Dartmouth-Hitchcock, Lebanon, New Hampshire, United States|Atrium Health, Charlotte, North Carolina, United States|Texas Health, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04351152"
961,"NCT04375735","London's Exogenous Surfactant Study for COVID19","LESSCOVID","Not yet recruiting","No Results Available","ARDS, Human|COVID-19","Drug: Bovine Lipid Extract Surfactant","Adverse events (patient) - Decrease in oxygenation|Adverse events (patient) - Decrease in hemodynamics|Adverse event (healthcare worker) - Circuit breach|Adverse event (healthcare worker) - COVID-19 symptoms|Change in oxygenation|Change in Lung compliance|Ventilated days|Length of ICU stay|Length of hospital stay|Mortality|G-CSF levels (serum inflammatory biomarker)|GM-CSF levels (serum inflammatory biomarker)|IFN gamma levels (serum inflammatory biomarker)|IL-1 beta levels (serum inflammatory biomarker)|IL-4 levels (serum inflammatory biomarker)|IL-6 levels (serum inflammatory biomarker)|IL-10 levels (serum inflammatory biomarker)|I levels (serum inflammatory biomarker)|MCP-1 levels (serum inflammatory biomarker)|TNF alpha levels (serum inflammatory biomarker)","Lawson Health Research Institute|London Health Sciences Centre","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9890","July 1, 2020","January 1, 2021","July 1, 2021","May 5, 2020",,"June 11, 2020",,,"https://ClinicalTrials.gov/show/NCT04375735"
962,"NCT04336384","Impact of Covid-19 in Congenital Heart Disease","COVID-CHD","Recruiting","No Results Available","Congenital Heart Disease|Covid-19",,"Prevalence of Covid-19 infection in the overall CHD population|Prevalence of Covid-19 infection per CHD sub-group|Cardiovascular complications|Other complications|Number of deaths","University Hospital, Montpellier|Pr. Jean-Benoît THAMBO, Bordeaux (président)|Dr. Céline GRUNENWALD GRONIER, Strasbourg|Dr. Sébastien HASCOET, Le Plessis-Robinson|Dr. Adeline BASQUIN, Rennes|Dr. Nicolas COMBES, Toulouse|Dr. Xavier IRIART, Bordeaux|Dr. Daniela LAUX, Paris|Dr. Magalie LADOUCEUR, Paris|Pr. BERTRAND LEOBON, Toulouse|Pr. Caroline OVAERT, Marseille|Dr. Karine WARIN-FRESSE, Nantes|Alexis BLANC, Montpellier|Pr. Roland HENAINE, Lyon|Hamouda ABASSI, Montpellier","All","Child, Adult, Older Adult",,"5000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RECHMPL20_0155","March 1, 2020","December 1, 2020","December 30, 2020","April 7, 2020",,"April 14, 2020","Uh Montpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04336384"
963,"NCT04405986","Exploring Brain Damages After COVID-19 Infection","BRAINCOV","Recruiting","No Results Available","SARS-CoV 2","Procedure: Auditory Evoked Potentials (AEP)|Procedure: Blink and Masseter Inhibitory Reflex","Latency of electrophysiological response|Delay of Muscle contraction|Delay of silent period|Duration of silent period|Inhibition rate","University Hospital, Bordeaux","All","18 Years and older   (Adult, Older Adult)","Not Applicable","38","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","CHUBX 2020/20","May 19, 2020","December 19, 2020","December 19, 2020","May 28, 2020",,"June 1, 2020","CHU de Bordeaux, Bordeaux, France",,"https://ClinicalTrials.gov/show/NCT04405986"
964,"NCT04344938","Covid 19 Pandemic. Emerging Legal and Ehical Disputes Over Patient Confidentiality",,"Not yet recruiting","No Results Available","Covid 19 Pandemic From Ethical View","Other: questionnair about Emerging Legal and Ehical Disputes Over Patient Confidentiality","Evaluate the ethical requirement of controlled disrupts of patients In case of infectious disease pandemic","Assiut University|Doaa M.EL Shehaby","All","18 Years to 60 Years   (Adult)",,"874","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","2020A10","April 2020","June 2020","July 2020","April 14, 2020",,"April 17, 2020",,,"https://ClinicalTrials.gov/show/NCT04344938"
965,"NCT04348305","Hydrocortisone for COVID-19 and Severe Hypoxia","COVID STEROID","Active, not recruiting","No Results Available","Covid-19|Hypoxia","Drug: Hydrocortisone|Drug: Sodium Chloride 9mg/mL","Days alive without life support at day 28|All-cause mortality at day 28|Days alive without life support at day 90|All-cause mortality at day 90|Number of participants with one or more serious adverse reactions|Days alive and out of hospital at day 90|All-cause mortality at 1 year after randomisation|Health-related quality of life at 1 year","Scandinavian Critical Care Trials Group|Rigshospitalet, Denmark|Copenhagen Trial Unit, Center for Clinical Intervention Research|University of Copenhagen|Aarhus University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 3","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RH-ITA-008|2020-001395-15","April 17, 2020","March 30, 2021","December 30, 2021","April 16, 2020",,"June 24, 2020","Aarhus University Hospital - Dept of Intensive care, Aarhus, Denmark|Rigshospitalet, Copenhagen, Denmark|Dept of Infectious diseases, Rigshospitalet, Copenhagen, Denmark|Herlev Hospital - Dept. of Intensive Care, Herlev, Denmark|North Zealand Hospital, Hillerød, Denmark|Hvidovre Hospital - Dept of Infectious diseases, Hvidovre, Denmark|Hvidovre Hospital - Dept of Intensive Care, Hvidovre, Denmark|Hvidovre Hospital - Dept of Pulmonary Medicine, Hvidovre, Denmark|Kolding Hospital, Kolding, Denmark|Køge Hospital, Køge, Denmark|Dept of Intensive Care, Odense University Hospital, Odense, Denmark|Roskilde Hospital, Roskilde, Denmark|Slagelse Hospital, Slagelse, Denmark|Viborg Hospital, Viborg, Denmark",,"https://ClinicalTrials.gov/show/NCT04348305"
966,"NCT04402866","TD-0903 for ALI Associated With COVID-19",,"Recruiting","No Results Available","Acute Lung Injury (ALI) Associated With COVID-19|Lung Inflammation Associated With COVID-19","Drug: TD-0903|Drug: Placebo","Part 2: SaO2/FiO2 ratio|Part 2: Ventilator-free Days (VFDs)|Part 2: Intensive Care Unit Free Days (ICU-free)|Part 2: AUC in SaO2/FiO2 ratio|Part 2: SaO2/FiO2 ratio > 315|Part 2: Subjects Discharged|Part 2: Hospital Discharge|Part 2: Mortality Rate|Part 2: Modified Borg Dyspnea Score|Part 2: Clinical Status Scale|Part 2: Vital Status","Theravance Biopharma","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","159","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","0188|2020-001807-18","June 24, 2020","October 2020","October 2020","May 27, 2020",,"June 26, 2020","Theravance Biopharma Investigational Site, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04402866"
967,"NCT04412668","Study to Evaluate the Safety and Efficacy of ATYR1923 In Patients With Severe Pneumonia Related to COVID-19",,"Recruiting","No Results Available","SARS-CoV-2 (COVID-19) Severe Pneumonia","Drug: ATYR1923 1 mg/kg|Drug: ATYR1923 3 mg/kg|Drug: Placebo","Incidence of treatment-emergent adverse events (TEAEs)|Time to normalization of oxygen saturation (SpO2) (>93% on room air sustained for at least 24 hours)|Duration of supplemental oxygen (O2) requirement|Number of days with fever (temperature >100.4ºF [38.0ºC])|Time to normalization of temperature (≤100.4ºF [38.0ºC])|Change from baseline in World Health Organization (WHO) Ordinal Scale score on Days 5, 7, 14, 28, and 60|Time to improvement from inpatient hospital admission based on at least a 1 point reduction in WHO Ordinal Scale score","aTyr Pharma, Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ATYR1923-C-003","June 12, 2020","October 31, 2020","October 31, 2020","June 2, 2020",,"June 18, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|aTyr Investigative Site, Washington, District of Columbia, United States|University of Iowa, Iowa City, Iowa, United States|aTyr Investigative Site, Vineland, New Jersey, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04412668"
968,"NCT04422678","The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia",,"Not yet recruiting","No Results Available","COVID-19","Drug: Imatinib Mesylate|Drug: Standard of Care","Primary endpoint: Disease Progression|Improvement in Hypoxic Index|Hospital Length of Stay|Days on invasive mechanical ventilation|Inflammatory Markers|Viral clearance|Radiological assessment|Safety of Imatinib","Alexandria University|Science, Technology & Innovation Funding Authority (STIFA), Egypt","All","18 Years and older   (Adult, Older Adult)","Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Alex CCM 2020/5","June 2020","September 2020","October 2020","June 9, 2020",,"June 9, 2020",,,"https://ClinicalTrials.gov/show/NCT04422678"
969,"NCT04368351","Bacteriotherapy in the Treatment of COVID-19","BACT-ovid","Active, not recruiting","No Results Available","COVID|Pneumonia|Diarrhea","Dietary Supplement: SivoMixx (200 billion)|Drug: Azithromycin|Drug: hydroxychloroquine","delta of time of disappearance of acute diarrhea|Delta in the number of patients requiring orotracheal intubation despite treatment|Delta of crude mortality|Delta of length of stay for patients in hospital","University of Roma La Sapienza","All","18 Years and older   (Adult, Older Adult)",,"70","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","DPHID-UniRoma05","March 1, 2020","June 30, 2020","July 31, 2020","April 29, 2020",,"May 4, 2020","Department of Public Heath and Infectious Diseases. University of Rome ""Sapienza"" (Italy), Rome, Italy",,"https://ClinicalTrials.gov/show/NCT04368351"
970,"NCT04344288","Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection","CORTI-Covid","Recruiting","No Results Available","Viral Pneumonia Human Coronavirus|COVID-19","Drug: Prednisone|Other: Control group","Number of patients with a theoretical respiratory indication for transfer to intensive care unit evaluated by a SpO2 <90% stabilized at rest and under not more than 5 L / min of supplemental oxygen using medium concentration mask.|disease severity assessed on a 7-level ordinal scale|number of patients with a supplemental oxygen use|radiological signs on chest imaging|number of patients transferred to intensive care unit|number of patients requiring invasive ventilation|Duration of oxygen therapy|number of adverse events induced by corticosteroid treatment|number of patients with infections other than SARS-CoV-2|number of deaths","Hospices Civils de Lyon","All","18 Years and older   (Adult, Older Adult)","Phase 2","304","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","69HCL20_0321|2020-001553-48","April 21, 2020","November 2020","November 2020","April 14, 2020",,"June 11, 2020","Hôpital Pneumologique et Cardiovasculaire Louis Pradel, Bron, France|Groupement Hospitalier Nord, Lyon, France|Groupement Hospitalier Nord, Lyon, France|Hôpital Edouard Herriot, Lyon, France|Hôpital St Joseph Saint Luc, Lyon, France|Hôpital St Joseph, Marseille, France|Centre hospitalier Lyon Sud, Pierre-Bénite, France|Centre hospitalier Lyon Sud, Pierre-Bénite, France|CHU St Etienne, Saint-Étienne, France|Clinique Charcot, Sainte-Foy-lès-Lyon, France|CHG Vienne, Vienne, France|Médipôle, Villeurbanne, France|Clinique des Portes du Sud, Vénissieux, France|CH Annecy-Genevois, Épagny, France",,"https://ClinicalTrials.gov/show/NCT04344288"
971,"NCT04444531","Clinical Improvement and COVID-19 Pneumonia",,"Completed","No Results Available","COVID-19 Pneumonia",,"Time to clinical improvement|Clinical improvement at day 14|Clinical improvement at day 28|Time to a 2-fold decrease of C-protein reactive from baseline|Time to a 2-fold decrease of ferritin from baseline|Time to a 2-fold decrease of Lactate Dehydrogenase from baseline|Time to a 2-fold decrease of D-dimer from baseline","Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta",,"Child, Adult, Older Adult",,"18","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID Networking group","March 20, 2020","May 19, 2020","May 26, 2020","June 23, 2020",,"June 23, 2020","Policlinic Ibiza Hospital, Ibiza, Spain",,"https://ClinicalTrials.gov/show/NCT04444531"
972,"NCT04334005","Vitamin D on Prevention and Treatment of COVID-19","COVITD-19","Not yet recruiting","No Results Available","Patients Infected With COVID-19","Dietary Supplement: Vitamin D","Composite of cumulative death (i.e. mortality) for all causes and for specific causes.|Necessity of invasive assisted ventilation|Necessity of non-invasive assisted ventilation|Intensive care unit admission|Post-anesthesia care unit admission|Hospital admission|Medical consultation|Home care and isolation time|Bed rest time|symptoms' duration (i.e. cough, fever, nasal congestion, gastrointestinal symptoms, fatigue, anosmia, ageusia, diarrhea or alternative signs of COVID-19)|Subjective perception of recovery","Universidad de Granada","All","40 Years to 70 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COVITD-19","April 10, 2020","June 30, 2020","June 30, 2020","April 3, 2020",,"April 7, 2020","Universidad de Granada, Granada, Andalucia, Spain|Medicine Faculty, Granada, Spain",,"https://ClinicalTrials.gov/show/NCT04334005"
973,"NCT03891420","A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19",,"Recruiting","No Results Available","COVID-19|Yellow Fever","Drug: Galidesivir|Drug: Placebo","number of subjects with treatment emergent adverse events and serious adverse events|number of subjects with change in laboratory parameters|exposure of galidesivir as measured by plasma concentrations|yellow fever virus (YFV) titer (Group A)|antiviral effect on SARS-CoV-2 in the respiratory tract - COVID-19 (Group B)|changes in clinical status using 8-point ordinal scale in COVID-19 (Group B)|changes from baseline and time to improvement using NEWS in COVID-19 (Group B)|mortality","BioCryst Pharmaceuticals|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Older Adult)","Phase 1","66","Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BCX4430-108|272201300017C-18-0-1|DMID18-0022","April 9, 2020","May 31, 2021","May 31, 2021","March 27, 2019",,"April 15, 2020","Clinical Research Unit and Department of Infectious and Parasitic Diseases Hospital das Clínicas, School of Medicine, USP, São Paulo, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT03891420"
974,"NCT04371510","Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Chronic Haemodialysis Patients","PredictCovid-D","Recruiting","No Results Available","COVID-19 by SARS-CoV-2 Infection","Other: blood sample","Predictive value of IL-6 contents of whole blood samples after ex vivo stimulation","Centre Hospitalier Universitaire de Nice","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","115","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","20-PP-08","April 22, 2020","October 22, 2020","February 22, 2021","May 1, 2020",,"May 1, 2020","CHU de nice, Nice, Alpes-Maritimes, France",,"https://ClinicalTrials.gov/show/NCT04371510"
975,"NCT04350099","Emotional Burden of Healthcare Professionals and Covid Infection 19","Emocovid","Not yet recruiting","No Results Available","Emotionnal Distress; COVID-19","Other: quetionnary","anxiety","University Hospital, Limoges","All","Child, Adult, Older Adult",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","87RI20_0015/Emocovid","April 15, 2020","December 15, 2020","June 15, 2021","April 16, 2020",,"April 16, 2020","CH Esquirol, Limoges, France|CHU de Limoges, Limoges, France",,"https://ClinicalTrials.gov/show/NCT04350099"
976,"NCT04420988","Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients",,"Available","No Results Available","COVID-19|SARS-CoV 2|SARS-CoV Infection","Biological: COVID-19 Convalescent Plasma",,"Rutgers, The State University of New Jersey|University Hospital - Newark, NJ","All","18 Years and older   (Adult, Older Adult)",,,"Other","Expanded Access:Individual Patients|Intermediate-size Population",,"Pro2020000746, Pro2020000911",,,,"June 9, 2020",,"June 9, 2020","Rutgers New Jersey Medical School, Newark, New Jersey, United States|University Hospital, Newark, New Jersey, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT04420988/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04420988"
977,"NCT04349241","Efficacy and Safety of Favipiravir in Management of COVID-19","FAV-001","Completed","No Results Available","Coronavirus Disease (COVID-19)","Drug: favipiravir|Drug: Standard of care therapy","Viral clearance|Clinical improvement|Radiological Improvement","Ain Shams University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FMASU P14 / 2020","April 18, 2020","June 1, 2020","June 20, 2020","April 16, 2020",,"June 25, 2020","Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt",,"https://ClinicalTrials.gov/show/NCT04349241"
978,"NCT04397523","Efficacy and Safety of COVID-19 Convalescent Plasma",,"Recruiting","No Results Available","Convalescent Plasma|COVID-19|SARS-CoV 2","Biological: anti-SARS-CoV-2 convalescent plasma","Duration of oxygenation and ventilation support|Hospital length of stay (LOS)|ICU admission|Ventilator free days|Incidence of serious adverse events|Type of respiratory support|Number of participants with different clinical outcomes including death, critical illness and recovery","Institute for Transfusion Medicine of RNM|University Clinic for Infectious Diseases, North Macedonia","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ITM05/2020MKD","April 30, 2020","April 29, 2021","April 29, 2021","May 21, 2020",,"May 22, 2020","Institute for Transfusion Medicine of RNM, Skopje, North Macedonia",,"https://ClinicalTrials.gov/show/NCT04397523"
979,"NCT04427878","Is Adipose Tissue a Reservoir for SARS-Cov2 Spread in Covid-19 Patients?","TA/SARS-Cov2","Not yet recruiting","No Results Available","Covid-19 Patients","Procedure: biopsies of subcutaneous adipose tissue","The presence of SARS-CoV2 in adipose tissue of Covid19 patients|The expression of inflammatory cytokines in adipose tissue of Covid19 patients","Centre Hospitalier Universitaire de Nice","All","18 Years and older   (Adult, Older Adult)","Not Applicable","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","20-PP-15","July 1, 2020","July 9, 2020","July 9, 2021","June 11, 2020",,"June 11, 2020","CHU de Nice, Nice, France",,"https://ClinicalTrials.gov/show/NCT04427878"
980,"NCT04405726","Prognostic Factors of COVID19","Covid-HUS","Recruiting","No Results Available","SARS-CoV-2",,"Clinical Presentation and Incidence of Covid-19 Infection in patients hospitalised in Strasbourg Hospital","University Hospital, Strasbourg, France","All","1 Year and older   (Child, Adult, Older Adult)",,"500","Other","Observational","Observational Model: Case-Only|Time Perspective: Other","7760","March 27, 2020","March 2022","March 2022","May 28, 2020",,"June 25, 2020","Service de Virologie - Hôpital Civil, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT04405726"
981,"NCT04303299","Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID-19 : A Randomized Control Trial","THDMS-COVID-19","Not yet recruiting","No Results Available","SARS-COV-2 Infections|COVID-19","Drug: Oral","SARS-CoV-2 eradication time|Number of patient with Death|Number of patient with Recovery adjusted by initial severity in each arm|Number of day With ventilator dependent adjusted by initial severity in each arm|Number of patient developed Acute Respiratory Distress Syndrome After treatment","Rajavithi Hospital","All","16 Years to 100 Years   (Child, Adult, Older Adult)","Phase 3","320","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TH-DMS-COVID19 study","July 15, 2020","December 31, 2020","March 30, 2021","March 11, 2020",,"June 16, 2020","Assistant Professor Subsai Kongsaengdao, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT04303299"
982,"NCT04393805","Heparins for Thromboprophylaxis in COVID-19 Patients: HETHICO Study in Veneto","HETHICO","Not yet recruiting","No Results Available","COVID-19|Hypercoagulability","Drug: Low Molecular Weight Heparin","Bleeding|Thrombosis|Mortality|Worsening|LOS","Quovadis Associazione|University of Padova","All","18 Years and older   (Adult, Older Adult)",,"877","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","HETHICO","June 2020","December 2020","December 2020","May 19, 2020",,"May 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04393805"
983,"NCT04423003","Endoscopic Interventions in Patients With COVID-19",,"Completed","No Results Available","Change; Endoscopy, COVID-19","Procedure: Endoscopic intervention","death in time of observation","University Hospital Tuebingen","All","Child, Adult, Older Adult",,"10","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","242/2020BO2","March 1, 2020","May 15, 2020","May 15, 2020","June 9, 2020",,"June 9, 2020","University Hospital of Tuebingen, Tuebingen, Germany",,"https://ClinicalTrials.gov/show/NCT04423003"
984,"NCT04432272","ANTIBODY-LEVEL BASED ANALYSIS OF COVID CONVALESCENT SERUM (ABACCuS)","ABACCuS","Not yet recruiting","No Results Available","COVID-19|Severe Acute Respiratory Syndrome (SARS)|Coronavirus Infections","Biological: COVID-19 convalescent plasma","Avoidance of intubation at 28 days (group A)|Mortality (group B)|Cardio-circulatory arrest|Patient Outcome at 28 days|Renal failure|Liver failure|Cytokine Storm|Respiratory support|Vasopressor medication support|Length of ICU length of stay|Intensive Care Unit (ICU) mortality|Hospital length of stay|Ventilator free days|Intubation duration|Readmission|Serum anti-SARS-CoV-2 IgG|SARS-CoV-2 RNA|Mortality (group A)|Time from Transfusion to end of ventilator support (group B)","William Beaumont Hospitals","All","18 Years and older   (Adult, Older Adult)","Phase 2","500","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-198","June 2020","June 2021","August 2021","June 16, 2020",,"June 16, 2020","William Beaumont Hospital, Royal Oak, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT04432272"
985,"NCT04352842","Echocardiographic Manifestation in Patient With COVID-19 （EARLY-MYO COVID-19）",,"Completed","No Results Available","Covid19|Echocardiography","Other: Echocardiography","Death","RenJi Hospital","All","18 Years and older   (Adult, Older Adult)",,"51","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID19-Echocardiography","January 21, 2020","April 8, 2020","April 8, 2020","April 20, 2020",,"May 19, 2020","Ren Ji Hospital Affliated to School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04352842"
986,"NCT04408248","AKI Biomarkers in Coronavirus(COVID)-19",,"Not yet recruiting","No Results Available","COVID|Acute Respiratory Failure|Acute Kidney Injury",,"Any stage of acute kidney injury|need for RRT in first 7 days|Mortality|Duration of mechanical ventilation|Duration of vasopressor support","Guy's and St Thomas' NHS Foundation Trust|University Hospital Muenster","All","18 Years and older   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","283675","July 1, 2020","May 31, 2021","June 30, 2021","May 29, 2020",,"June 19, 2020",,,"https://ClinicalTrials.gov/show/NCT04408248"
987,"NCT04405271","TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)",,"Not yet recruiting","No Results Available","Healthcare Workers|COVID-19|SARS-CoV 2","Drug: Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet|Drug: Placebo","COVID-19 incident cases|Number of asymptomatic SARS-CoV-2 (Covid-19) infections confirmed by serology|Severity of symptomatic COVID-19|Respiratory symptom duration in days|Relation between treatments and symptoms duration|Time course of specific IgM/IgG seroconversion","Hospital Italiano de Buenos Aires|Sociedad Argentina de Infectología (SADI) (Argentine Society of Infectious Diseases)","All","18 Years and older   (Adult, Older Adult)","Phase 3","1378","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","16052020","June 15, 2020","November 15, 2020","November 15, 2020","May 28, 2020",,"May 28, 2020","Sociedad Argentina de Infectología, A. J. Carranza 974, Ciudad Autonoma de Buenos Aires, Capital Federal, Argentina",,"https://ClinicalTrials.gov/show/NCT04405271"
988,"NCT04330521","Impact of the Coronavirus (COVID-19) on Patients With Cancer",,"Recruiting","No Results Available","Cancer|COVID-19",,"Number of participants who fill out the survey and participate in the semi-structured interviews.","Stanford University","All","18 Years to 99 Years   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","55596","April 8, 2020","May 2022","May 2022","April 1, 2020",,"June 29, 2020","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04330521"
989,"NCT04410549","Pulmonary Optical Coherence Tomography in COVID-19 Patients",,"Recruiting","No Results Available","Covid19|Pulmonary Embolism","Diagnostic Test: Optical Coherence Tomography (OCT)","optical coherence tomography pulmonary microthrombosis assessment in COVID-19 pneumonia patients|Pulmonary artery vessel anatomy characterization|Correlation between TTE pulmonary hypertension and right ventricular disfunction|Correlations with standard inflammatory, coagulation and tissue damage","IRCCS San Raffaele","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","OCT COVID","May 27, 2020","June 30, 2020","June 30, 2020","June 1, 2020",,"June 1, 2020","IRCCS San Raffaele, Milano, Italy","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT04410549/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT04410549"
990,"NCT04380727","Almitrine and COVID-19 Related Hypoxemia",,"Completed","No Results Available","COVID-19|Hypoxic Respiratory Failure",,"Changes from baseline PaO2 (mmHg)|Changes from baseline ScvO2 (%)","Central Hospital, Nancy, France","All","18 Years and older   (Adult, Older Adult)",,"17","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","COVID-19_CHRU NANCY_2020PI080","March 20, 2020","April 14, 2020","April 25, 2020","May 8, 2020",,"May 8, 2020","Centre Hospitalier Universitaire NANCY, Vandoeuvre-les-Nancy, France",,"https://ClinicalTrials.gov/show/NCT04380727"
991,"NCT04347408","Seroprevalence of SARS-Cov-2 Antibodies in Children",,"Recruiting","No Results Available","COVID|Corona Virus Infection","Diagnostic Test: Covid-19 Antibody testing (IgG and IgM)","Immunoglobulins (G and M) to SARS-Cov2 in plasma","Queen's University, Belfast|Belfast Health and Social Care Trust","All","2 Years to 15 Years   (Child)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","282617","May 6, 2020","December 13, 2020","December 13, 2020","April 15, 2020",,"June 16, 2020","Royal Belfast Hospital for Sick Children, Belfast, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|Royal Hospital for Children, Glasgow, United Kingdom|Public Health England, London, United Kingdom|Public Health England, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04347408"
992,"NCT04394208","Silymarin in COVID-19 Pneumonia","SCOPE","Not yet recruiting","No Results Available","COVID-19|Viral Pneumonia Human Coronavirus","Drug: Silymarin|Drug: Placebo","Time to clinical improvement|Clinical outcome|Duration of Mechanical Ventilation|Hospitalization|Virologic Response|Adverse events","Cairo University","All","18 Years and older   (Adult, Older Adult)","Phase 3","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","CairoU COVID-19 Study Group","June 1, 2020","August 30, 2020","September 30, 2020","May 19, 2020",,"May 19, 2020","Cairo University, Giza, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04394208"
993,"NCT04427267","Assessment of Thermal Condition of Health Workers Who Use Personal Protective Equipment From Biological Hazards During Their Work With COVID-19 Patients",,"Active, not recruiting","No Results Available","Thermal Condition of Health Workers Who Use Personal Protective Equipment From Biological Hazards During Their Work With COVID-19 Patients","Other: Personal protective equipment from biological hazard","Skin thermometry|Hygrometry under costume|Heart rate|Air thermometry|Air hygrometry","Federal State Budgetary Scientific Institution ""Izmerov Research Institute of Occupational Health""","All","18 Years to 45 Years   (Adult)",,"6","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","PPE-02","June 3, 2020","June 10, 2020","June 10, 2020","June 11, 2020",,"June 16, 2020","Federal State Budgetary Scientific Institution Izmerov Research Institute of Occupational Health, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04427267"
994,"NCT04357457","Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia","AIRVM-COVID","Not yet recruiting","No Results Available","Covid 19|Hypoxemic Respiratory Failure","Drug: Almitrine|Drug: Placebo","Rate of endotracheal intubation|28-day mortality|In-hospital mortality|Number of ventilator-free days|Number of days in the ICU|Number of days in the hospital|Discontinuation rate of the treatment","Assistance Publique - Hôpitaux de Paris|Centre Hospitalier de Chartres","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","212","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","APHP200461|2020-001909-22","May 2020","July 2020","July 2020","April 22, 2020",,"May 13, 2020","Hospital Pitié-Salpêtrière, Paris, France",,"https://ClinicalTrials.gov/show/NCT04357457"
995,"NCT04386044","Investigating the Role of Vitamin D in the Morbidity of COVID-19 Patients",,"Not yet recruiting","No Results Available","COVID-19|Vitamin D Deficiency",,"COVID-19 infection|Oxygen therapy for COVID-19|Discharge following COVID-19 hospitalisation|Death due to COVID-19","Tameside General Hospital","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Other|Time Perspective: Other","TGH1234","June 1, 2020","December 31, 2020","June 1, 2021","May 13, 2020",,"May 13, 2020","Tameside Hospital NHS Foundation Trust, Ashton-under-Lyne, Greater Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04386044"
996,"NCT04385095","Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection",,"Recruiting","No Results Available","SARS-CoV-2","Drug: Interferon beta 1a|Drug: Placebo","Ordinal Scale for Clinical Improvement|Progression to pneumonia|Time to clinical improvement|National Early Warning Score 2 (NEWS2) assessment of acute-illness severity|Changes in daily breathlessness, cough and sputum scale (BCSS)|Safety and tolerability - blood pressure II. Viral load|Safety and tolerability - heart rate II. Viral load|Safety and tolerability - temperature II. Viral load|Safety and tolerability - respiratory rate II. Viral load|Safety and tolerability - oxygen saturation II. Viral load|Safety and tolerability - adverse events II. Viral load|Safety and tolerability - concomitant medications II. Viral load","Synairgen Research Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 2","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SG016","March 16, 2020","August 31, 2020","May 31, 2021","May 12, 2020",,"May 12, 2020","Belfast City Hospital, Belfast, United Kingdom|Queen Elizabeth Hospital,, Birmingham, United Kingdom|Bradford Royal Infirmary, Bradford, United Kingdom|Hull and East Yorkshire NHS Trust, Castle Hill Hospital,, Hull, United Kingdom|Glenfield Hospital,, Leicester, United Kingdom|Wythenshawe Hospital, Manchester, United Kingdom|City Campus of Nottingham University, Nottingham, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|University Hospital Southampton Nhs Foundation Trust, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04385095"
997,"NCT04344951","Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial","HOPE","Recruiting","No Results Available","Pneumonia, Viral|Covid-19","Drug: UNIKINON (Chloroquine phosphate) 200mg tablets","50% reduction in symptom score for patients with lower respiratory tract infection|Lack of progression for patients with upper respiratory tract infection|Comparison of the primary endpoint with respective patients not receiving the treatment|Serious respiratory failure until day 14. This will be compared with respective patients not receiving the treatment.|Frequency of AEs and SAEs","Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.|Athens General Hospital Hippokrateio|Athens General Hospital of Thoracic Diseases SOTIRIA|General Hospital of Athens Sismanoglio|Divine Providence Hospital Pammakaristos|AHEPA University Hospital|University General Hospital of Ioannina|Corfu General Hospital Agia Irini","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","60","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","UNIKINON-01/HOPE","April 6, 2020","April 1, 2021","April 30, 2021","April 14, 2020",,"June 2, 2020","Divine Providence Hospital ""Pammakaristos"", Athens, Greece|Athens General Hospital ""Hippokrateio"", Athens, Greece|Athens General Hospital of Thoracic Diseases ""SOTIRIA"", 1st University Pulmonary Clinic, Athens, Greece|Athens General Hospital of Thoracic Diseases ""SOTIRIA"", 3rd University Pathology Clinic, Athens, Greece|Corfu General Hospital Agia Irini, Corfu, Greece|University General Hospital of Ioannina, Ioánnina, Greece|General Hospital of Athens ""Sismanoglio"", Maroúsi, Greece|University General Hospital of Thessaloniki AHEPA, Thessaloníki, Greece",,"https://ClinicalTrials.gov/show/NCT04344951"
998,"NCT04360876","Targeted Steroids for ARDS Due to COVID-19 Pneumonia: A Pilot Randomized Clinical Trial",,"Not yet recruiting","No Results Available","COVID-19|ARDS","Drug: Dexamethasone injection|Drug: Placebos","Ventilator Free Days (VFD) at Day 28|Clinical Status at day 14 as measured by World Health Organization (WHO) 7-point ordinal scale.|Clinical Status at day 28 as measured by WHO 7-point ordinal scale|In-Hospital Mortality at day 28|In-Hospital Mortality at day 90|Time to Mortality to day 28|ICU-free days to day 28|Hospital Length of Stay among survivors to day 90|Severity of ARDS to day 10|Days to resolution of fever|Change in C-Reactive Protein (CRP) level from baseline to day 10|Vasopressor-free days to day 28|Renal replacement-free days to day 28|Duration of mechanical ventilation to day 28|Oxygenation-free days to day 28|Incidence of New Mechanical Ventilation to day 28|Change in sequential organ failure assessment (SOFA) score from baseline to day 10|In-hospital adverse events to day 28|Discontinuation of study drug infusion","University of Colorado, Denver","All","18 Years and older   (Adult, Older Adult)","Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","20-0811","May 1, 2020","September 30, 2020","December 31, 2020","April 24, 2020",,"April 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04360876"
999,"NCT04350736","First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19",,"Recruiting","No Results Available","Acute Lung Injury (ALI) Associated With COVID-19|Inflammatory Lung Conditions Associated With COVID-19","Drug: TD-0903|Drug: Placebo","Safety and Tolerability of SAD of TD-0903: Adverse Events|Safety and Tolerability of MAD of TD-0903: Adverse Events|Pharmacokinetics (PK) of TD-0903 when given as a Single Ascending Dose (SAD): AUC|Pharmacokinetics (PK) of TD-0903 when given as a Single Ascending Dose (SAD): Cmax|Pharmacokinetics (PK) of TD-0903 when given as a Single Ascending Dose (SAD): Tmax|Pharmacokinetics (PK) of TD-0903 when given as a Multiple Ascending Dose (MAD): AUC|Pharmacokinetics (PK) of TD-0903 when given as a Multiple Ascending Dose (MAD): Cmax|Pharmacokinetics (PK) of TD-0903 when given as a Multiple Ascending Dose (MAD): Tmax","Theravance Biopharma","All","18 Years to 50 Years   (Adult)","Phase 1","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","0183|2020-000577-24","April 23, 2020","June 2020","June 2020","April 17, 2020",,"May 22, 2020","Theravance Biopharma Investigational Site, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04350736"
1000,"NCT04362176","Passive Immunity Trial of Nashville II for COVID-19","PassItOnII","Recruiting","No Results Available","COVID-19|Coronavirus|SARS-CoV-2","Biological: pathogen reduced SARS-CoV-2 convalescent plasma|Biological: Placebo","COVID Ordinal Outcomes Scale:Day 15|All-location, all-cause 14-day mortality|All-location, all-cause 28-day mortality|COVID Ordinal Outcomes Scale Day 3|COVID Ordinal Outcomes Scale Day 8|COVID Ordinal Outcomes Scale Day 29|Composite of death or receipt of ECMO through Day 28|Oxygen-free days through Day 28|Vasopressor-free days through Day 28|Ventilator-free days through Day 28|ICU-free days through Day 28|Hospital-free days through Day 28","Vanderbilt University Medical Center|Dolly Parton","All","18 Years and older   (Adult, Older Adult)","Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","200738","April 24, 2020","April 2021","April 2021","April 24, 2020",,"May 4, 2020","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04362176"
